{"b00d37721834cf495111376f4cfd68910186c44b": [["As the novel coronavirus has spread across the United States, infecting almost two million people and leading to over 110,000 deaths (as of June 9, 2020), over 96% of Americans have experienced orders to shelter in place (CDC 2020) .", [["deaths", "DISEASE", 126, 132], ["coronavirus", "ORGANISM", 13, 24], ["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["the novel coronavirus", "PROBLEM", 3, 24], ["coronavirus", "OBSERVATION", 13, 24]]], ["Shelter in place orders require that people stay in their homes as much as possible and leave home for only essential activities, such as grocery shopping, visiting the doctor, or working in an essential sector (U.S. Department of Homeland Security 2020).", [["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43]]], ["Although people are able to engage in outdoor activities, like walking or exercising, they are required to practice social distancing by maintaining a separation from others of at least 6 ft.", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["These new requirements came about very quickly and led to significant changes in the daily lives of almost all Americans.", [["new", "OBSERVATION_MODIFIER", 6, 9]]]], "079c584ccfa936df16a04090f490222f0cffe8ab": [["IntroductionInfluenza is a highly contagious airborne life-threatening viral infection causing recurrent outbreaks of humans responsible for respiratory diseases and death.", [["respiratory", "ANATOMY", 141, 152], ["Influenza", "DISEASE", 12, 21], ["viral infection", "DISEASE", 71, 86], ["respiratory diseases", "DISEASE", 141, 161], ["death", "DISEASE", 166, 171], ["humans", "ORGANISM", 118, 124], ["humans", "SPECIES", 118, 124], ["humans", "SPECIES", 118, 124], ["IntroductionInfluenza", "PROBLEM", 0, 21], ["threatening viral infection", "PROBLEM", 59, 86], ["respiratory diseases", "PROBLEM", 141, 161], ["death", "PROBLEM", 166, 171], ["viral infection", "OBSERVATION", 71, 86]]], ["It was estimated during 2017-2018 that there were 959,000 hospitalizations and 79,400 deaths (CDC 2018) alone in the United States related to influenza illness.", [["deaths", "DISEASE", 86, 92], ["influenza illness", "DISEASE", 142, 159], ["influenza illness", "PROBLEM", 142, 159], ["influenza", "OBSERVATION", 142, 151]]], ["Moreover, WHO estimates that 3-5 million people suffer from the disease every year with death rate ranging between 290,000 and 650,000 due to influenza epidemics (Influenza (Seasonal) 2018) worldwide (Sherman et al. 2019) .", [["death", "DISEASE", 88, 93], ["influenza", "DISEASE", 142, 151], ["Influenza", "DISEASE", 163, 172], ["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["the disease", "PROBLEM", 60, 71], ["death rate", "TEST", 88, 98], ["influenza epidemics", "PROBLEM", 142, 161], ["Influenza", "PROBLEM", 163, 172]]], ["Of note, previous epidemiological studies on pandemic A/H1N1 during the year 2009 clearly showed that the severity of influenza was not so high in individuals effected with HIV compared with HIV-negative patients (Martinez et al. 2011; Perez et al. 2010) .", [["influenza", "DISEASE", 118, 127], ["HIV-negative", "DISEASE", 191, 203], ["pandemic A/H1N1", "ORGANISM", 45, 60], ["HIV", "ORGANISM", 173, 176], ["HIV", "ORGANISM", 191, 194], ["patients", "ORGANISM", 204, 212], ["HIV", "SPECIES", 173, 176], ["HIV", "SPECIES", 191, 194], ["patients", "SPECIES", 204, 212], ["A/H1N1", "SPECIES", 54, 60], ["HIV", "SPECIES", 173, 176], ["HIV", "SPECIES", 191, 194], ["previous epidemiological studies", "TEST", 9, 41], ["H1N1", "PROBLEM", 56, 60], ["influenza", "PROBLEM", 118, 127], ["HIV", "PROBLEM", 173, 176], ["HIV", "TEST", 191, 194], ["influenza", "OBSERVATION", 118, 127]]], ["This clearly shows that influenza remains a major target for vaccine and antiviral treatment and prophylaxis.", [["influenza", "DISEASE", 24, 33], ["influenza", "PROBLEM", 24, 33], ["vaccine", "TREATMENT", 61, 68], ["antiviral treatment", "TREATMENT", 73, 92], ["prophylaxis", "TREATMENT", 97, 108], ["influenza", "OBSERVATION", 24, 33]]], ["One of the causes of the severity of the disease is due to influenza replication and transcription played by viral RNAdependent RNA polymerase (RdRp) which is composed of three subunits i.e., polymerase basic1 (PB1), polymerase basic 2 (PB2), and polymerase acidic (PA) (Fodor 2013; Resa-Infante et al. 2011) .", [["viral RNAdependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 109, 142], ["RdRp", "GENE_OR_GENE_PRODUCT", 144, 148], ["basic1", "GENE_OR_GENE_PRODUCT", 203, 209], ["PB1", "GENE_OR_GENE_PRODUCT", 211, 214], ["polymerase basic 2", "GENE_OR_GENE_PRODUCT", 217, 235], ["PB2", "GENE_OR_GENE_PRODUCT", 237, 240], ["PA", "GENE_OR_GENE_PRODUCT", 266, 268], ["viral RNAdependent RNA polymerase", "PROTEIN", 109, 142], ["RdRp", "PROTEIN", 144, 148], ["polymerase basic1", "PROTEIN", 192, 209], ["PB1", "PROTEIN", 211, 214], ["polymerase basic 2", "PROTEIN", 217, 235], ["PB2", "PROTEIN", 237, 240], ["the disease", "PROBLEM", 37, 48], ["influenza replication", "PROBLEM", 59, 80], ["transcription", "TREATMENT", 85, 98], ["viral RNAdependent RNA polymerase (RdRp", "PROBLEM", 109, 148], ["polymerase basic1", "TEST", 192, 209], ["polymerase basic", "TEST", 217, 233], ["PB2", "TEST", 237, 240], ["polymerase acidic", "TEST", 247, 264], ["disease", "OBSERVATION", 41, 48], ["due to", "UNCERTAINTY", 52, 58], ["influenza replication", "OBSERVATION", 59, 80]]], ["Both PB1 and the N-terminus of PB2 form a large central cavity for catalytic mechanism of influenza-A virus (IAV) viral replication (Hengrung et al. 2015; Pflug et al. 2014; Reich et al. 2014) .", [["PB1", "GENE_OR_GENE_PRODUCT", 5, 8], ["PB2", "GENE_OR_GENE_PRODUCT", 31, 34], ["influenza-A virus", "ORGANISM", 90, 107], ["IAV", "ORGANISM", 109, 112], ["PB1", "DNA", 5, 8], ["N-terminus", "PROTEIN", 17, 27], ["PB2", "PROTEIN", 31, 34], ["influenza-A virus", "SPECIES", 90, 107], ["influenza-A virus", "SPECIES", 90, 107], ["IAV", "SPECIES", 109, 112], ["a large central cavity", "PROBLEM", 40, 62], ["influenza", "PROBLEM", 90, 99], ["A virus (IAV) viral replication", "TREATMENT", 100, 131], ["PB2", "OBSERVATION", 31, 34], ["large", "OBSERVATION_MODIFIER", 42, 47], ["central cavity", "OBSERVATION", 48, 62], ["influenza", "OBSERVATION", 90, 99]]], ["The priming loop of (a \u03b2-hairpin structure) PB1 thumb domain protrudes into the central cavity and supports the sugar base of the first NTP during de nova initiation Appleby et al. 2015; Butcher et al. 2001; Tao et al. 2002) .", [["central cavity", "ANATOMY", 80, 94], ["NTP", "CHEMICAL", 136, 139], ["sugar", "CHEMICAL", 112, 117], ["sugar", "SIMPLE_CHEMICAL", 112, 117], ["\u03b2-hairpin structure", "PROTEIN", 23, 42], ["PB1 thumb domain", "PROTEIN", 44, 60], ["The priming loop of (a \u03b2-hairpin structure", "TREATMENT", 0, 42], ["loop", "OBSERVATION_MODIFIER", 12, 16], ["thumb", "ANATOMY", 48, 53], ["central", "ANATOMY_MODIFIER", 80, 87], ["cavity", "ANATOMY_MODIFIER", 88, 94]]], ["Moreover, primer-independent replication on the viral RNA (vRNA) template was also initiated by the priming loop (Te Velthuis et al. 2016) .", [["viral RNA (vRNA) template", "DNA", 48, 73], ["the viral RNA (vRNA) template", "TREATMENT", 44, 73]]], ["However, no drug exits presently in the market that blocks the entry of putative NTP and inhibits the initiation of vRNA priming loop occupying to the catalytic site of IAV RdRp.", [["NTP", "CHEMICAL", 81, 84], ["NTP", "CHEMICAL", 81, 84], ["NTP", "SIMPLE_CHEMICAL", 81, 84], ["IAV RdRp", "ORGANISM", 169, 177], ["catalytic site", "PROTEIN", 151, 165], ["IAV RdRp", "PROTEIN", 169, 177], ["drug exits", "PROBLEM", 12, 22], ["putative NTP", "TREATMENT", 72, 84], ["vRNA priming loop", "TREATMENT", 116, 133], ["IAV RdRp", "TREATMENT", 169, 177], ["no", "UNCERTAINTY", 9, 11], ["IAV RdRp", "OBSERVATION", 169, 177]]], ["Apart from the catalytic site, IAV RdRp contains multiple sites for potential antivirus drug development due to its high conservation among different strains (Babar et al. 2014) .IntroductionRecently, four different active sites of IAV RdRp were predicted computationally (Pagadala 2019) .", [["IAV RdRp", "ORGANISM", 31, 39], ["IAV RdRp", "ORGANISM", 232, 240], ["catalytic site", "PROTEIN", 15, 29], ["IAV RdRp", "PROTEIN", 31, 39], ["IAV RdRp", "PROTEIN", 232, 240], ["the catalytic site", "PROBLEM", 11, 29], ["IAV RdRp", "TREATMENT", 31, 39], ["multiple sites", "TREATMENT", 49, 63], ["potential antivirus drug development", "TREATMENT", 68, 104], ["IAV RdRp", "TREATMENT", 232, 240], ["catalytic site", "OBSERVATION", 15, 29], ["IAV RdRp", "OBSERVATION", 31, 39], ["multiple", "OBSERVATION_MODIFIER", 49, 57], ["antivirus", "OBSERVATION", 78, 87], ["different", "OBSERVATION_MODIFIER", 206, 215], ["active", "OBSERVATION_MODIFIER", 216, 222], ["sites", "OBSERVATION_MODIFIER", 223, 228], ["IAV RdRp", "OBSERVATION", 232, 240]]], ["At present, three major classes of drugs are under development for influenza: RNA synthesis inhibitors, cap-snatching inhibitors, and inhibitors targeting protein-protein interactions between the three polymerase subunits (e.g., PA-PB1, PB1-PB2).", [["influenza", "DISEASE", 67, 76], ["cap-snatching inhibitors", "SIMPLE_CHEMICAL", 104, 128], ["PA-PB1", "GENE_OR_GENE_PRODUCT", 229, 235], ["PB1-PB2", "GENE_OR_GENE_PRODUCT", 237, 244], ["polymerase subunits", "PROTEIN", 202, 221], ["PA", "PROTEIN", 229, 231], ["PB1", "PROTEIN", 232, 235], ["PB1", "PROTEIN", 237, 240], ["PB2", "PROTEIN", 241, 244], ["drugs", "TREATMENT", 35, 40], ["influenza", "PROBLEM", 67, 76], ["RNA synthesis inhibitors", "TREATMENT", 78, 102], ["cap-snatching inhibitors", "TREATMENT", 104, 128], ["inhibitors", "TREATMENT", 134, 144], ["protein-protein interactions", "TREATMENT", 155, 183], ["the three polymerase subunits", "TREATMENT", 192, 221], ["PA", "TEST", 229, 231], ["drugs", "OBSERVATION", 35, 40]]], ["Inhibition of IAV RNA synthesis during chain elongation is mainly inhibited by nucleoside mimicking's such as favipiravir (T-705), 2\u2032-deoxy-2\u2032-fluoroguanosine (Furuta et al. 2009; Tisdale et al. 1995) .", [["nucleoside", "CHEMICAL", 79, 89], ["favipiravir", "CHEMICAL", 110, 121], ["T-705", "CHEMICAL", 123, 128], ["2\u2032-deoxy-2\u2032-fluoroguanosine", "CHEMICAL", 131, 158], ["nucleoside", "CHEMICAL", 79, 89], ["favipiravir", "CHEMICAL", 110, 121], ["T-705", "CHEMICAL", 123, 128], ["2\u2032-deoxy-2\u2032-fluoroguanosine", "CHEMICAL", 131, 158], ["IAV", "ORGANISM", 14, 17], ["nucleoside", "SIMPLE_CHEMICAL", 79, 89], ["favipiravir", "SIMPLE_CHEMICAL", 110, 121], ["T-705", "SIMPLE_CHEMICAL", 123, 128], ["2\u2032-deoxy-2\u2032-fluoroguanosine", "SIMPLE_CHEMICAL", 131, 158], ["IAV RNA", "RNA", 14, 21], ["IAV", "SPECIES", 14, 17], ["IAV RNA synthesis", "TREATMENT", 14, 31], ["chain elongation", "PROBLEM", 39, 55], ["nucleoside mimicking's", "TREATMENT", 79, 101], ["deoxy", "TEST", 134, 139], ["IAV RNA", "OBSERVATION", 14, 21]]], ["On the other hand, the pyrazine carboxamide derivatives (T-1105 and T-1106) show different antiviral activity on the type of host cells used.", [["cells", "ANATOMY", 130, 135], ["pyrazine carboxamide", "CHEMICAL", 23, 43], ["T-1105 and T-1106", "CHEMICAL", 57, 74], ["pyrazine carboxamide", "CHEMICAL", 23, 43], ["pyrazine carboxamide derivatives", "SIMPLE_CHEMICAL", 23, 55], ["T-1105", "SIMPLE_CHEMICAL", 57, 63], ["T-1106", "SIMPLE_CHEMICAL", 68, 74], ["host cells", "CELL", 125, 135], ["host cells", "CELL_TYPE", 125, 135], ["the pyrazine carboxamide derivatives", "TREATMENT", 19, 55], ["different antiviral activity", "PROBLEM", 81, 109], ["host cells", "TREATMENT", 125, 135], ["antiviral activity", "OBSERVATION", 91, 109], ["host cells", "OBSERVATION", 125, 135]]], ["Both ribavirin and its amidine prodrug viramidine are converted to ribavirin monophosphate and acts on cellular enzyme inosine 5\u2032-monophosphate dehydrogenase leading to the inhibition of vRNA synthesis (Sidwell et al. 2005; Ghanem et al. 2007 ).", [["cellular", "ANATOMY", 103, 111], ["ribavirin", "CHEMICAL", 5, 14], ["amidine", "CHEMICAL", 23, 30], ["viramidine", "CHEMICAL", 39, 49], ["ribavirin monophosphate", "CHEMICAL", 67, 90], ["inosine 5\u2032-monophosphate", "CHEMICAL", 119, 143], ["ribavirin", "CHEMICAL", 5, 14], ["amidine", "CHEMICAL", 23, 30], ["viramidine", "CHEMICAL", 39, 49], ["ribavirin monophosphate", "CHEMICAL", 67, 90], ["inosine 5\u2032-monophosphate", "CHEMICAL", 119, 143], ["ribavirin", "SIMPLE_CHEMICAL", 5, 14], ["amidine", "SIMPLE_CHEMICAL", 23, 30], ["viramidine", "SIMPLE_CHEMICAL", 39, 49], ["ribavirin monophosphate", "SIMPLE_CHEMICAL", 67, 90], ["cellular", "CELL", 103, 111], ["inosine 5\u2032-monophosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 119, 157], ["cellular enzyme inosine 5\u2032-monophosphate dehydrogenase", "PROTEIN", 103, 157], ["ribavirin", "TREATMENT", 5, 14], ["its amidine prodrug viramidine", "TREATMENT", 19, 49], ["ribavirin monophosphate", "TREATMENT", 67, 90], ["cellular enzyme inosine", "TREATMENT", 103, 126], ["monophosphate dehydrogenase", "PROBLEM", 130, 157], ["vRNA synthesis", "TREATMENT", 187, 201], ["ribavirin", "OBSERVATION", 5, 14]]], ["In comparison with ribavirin, cytotoxicity of viramidine is lesser which lead to further evaluation as a possible anti-influenza viral therapy.", [["ribavirin", "CHEMICAL", 19, 28], ["viramidine", "CHEMICAL", 46, 56], ["ribavirin", "CHEMICAL", 19, 28], ["viramidine", "CHEMICAL", 46, 56], ["ribavirin", "SIMPLE_CHEMICAL", 19, 28], ["viramidine", "SIMPLE_CHEMICAL", 46, 56], ["ribavirin", "TREATMENT", 19, 28], ["viramidine", "TREATMENT", 46, 56], ["further evaluation", "TEST", 81, 99], ["anti-influenza viral therapy", "TREATMENT", 114, 142], ["possible", "UNCERTAINTY", 105, 113], ["anti-influenza viral therapy", "OBSERVATION", 114, 142]]], ["Unlike ribavirin, the influence of T-705 on cellular DNA or RNA synthesis was negative, indicating its high specificity and lesser cytotoxicity.", [["cellular", "ANATOMY", 44, 52], ["ribavirin", "CHEMICAL", 7, 16], ["T-705", "CHEMICAL", 35, 40], ["ribavirin", "CHEMICAL", 7, 16], ["ribavirin", "SIMPLE_CHEMICAL", 7, 16], ["T-705", "GENE_OR_GENE_PRODUCT", 35, 40], ["cellular DNA", "CELLULAR_COMPONENT", 44, 56], ["ribavirin", "TREATMENT", 7, 16], ["T", "TEST", 35, 36], ["cellular DNA", "TEST", 44, 56], ["RNA synthesis", "TEST", 60, 73], ["lesser cytotoxicity", "PROBLEM", 124, 143], ["ribavirin", "OBSERVATION", 7, 16], ["lesser", "OBSERVATION_MODIFIER", 124, 130], ["cytotoxicity", "OBSERVATION_MODIFIER", 131, 143]]], ["Recently, a set of compounds that were screened targeting IAV RNA synthesis revealed that 2\u2032F-2\u2032 dNTP nucleoside analogs inhibit cPol and vPol in a completely different way (Reich et al. 2017) .", [["dNTP", "CHEMICAL", 97, 101], ["nucleoside", "CHEMICAL", 102, 112], ["nucleoside", "CHEMICAL", 102, 112], ["IAV", "ORGANISM", 58, 61], ["2\u2032F-2\u2032 dNTP nucleoside analogs", "SIMPLE_CHEMICAL", 90, 120], ["cPol", "SIMPLE_CHEMICAL", 129, 133], ["vPol", "GENE_OR_GENE_PRODUCT", 138, 142], ["IAV RNA", "RNA", 58, 65], ["cPol and vPol", "PROTEIN", 129, 142], ["IAV", "SPECIES", 58, 61], ["IAV RNA synthesis", "TEST", 58, 75], ["dNTP nucleoside analogs", "TREATMENT", 97, 120], ["cPol", "TEST", 129, 133], ["vPol", "TREATMENT", 138, 142]]], ["A combination therapy of amantadine and oseltamivir as well as favirpiravir and oseltamivir in H5N1 infected mice has shown increased in drug efficacy (Ilyushina et al. 2007 ).", [["amantadine", "CHEMICAL", 25, 35], ["oseltamivir", "CHEMICAL", 40, 51], ["favirpiravir", "CHEMICAL", 63, 75], ["oseltamivir", "CHEMICAL", 80, 91], ["H5N1 infected", "DISEASE", 95, 108], ["amantadine", "CHEMICAL", 25, 35], ["oseltamivir", "CHEMICAL", 40, 51], ["favirpiravir", "CHEMICAL", 63, 75], ["oseltamivir", "CHEMICAL", 80, 91], ["amantadine", "SIMPLE_CHEMICAL", 25, 35], ["oseltamivir", "SIMPLE_CHEMICAL", 40, 51], ["favirpiravir", "SIMPLE_CHEMICAL", 63, 75], ["oseltamivir", "SIMPLE_CHEMICAL", 80, 91], ["H5N1", "ORGANISM", 95, 99], ["mice", "ORGANISM", 109, 113], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 109, 113], ["A combination therapy", "TREATMENT", 0, 21], ["amantadine", "TREATMENT", 25, 35], ["oseltamivir", "TREATMENT", 40, 51], ["favirpiravir", "TREATMENT", 63, 75], ["oseltamivir", "TREATMENT", 80, 91], ["H5N1 infected mice", "TREATMENT", 95, 113], ["increased", "OBSERVATION_MODIFIER", 124, 133]]], ["Although the combination of oseltamivir and ribavirin was shown effective, ribavirin has shown some undesirable toxic effects.", [["oseltamivir", "CHEMICAL", 28, 39], ["ribavirin", "CHEMICAL", 44, 53], ["ribavirin", "CHEMICAL", 75, 84], ["oseltamivir", "CHEMICAL", 28, 39], ["ribavirin", "CHEMICAL", 44, 53], ["ribavirin", "CHEMICAL", 75, 84], ["oseltamivir", "SIMPLE_CHEMICAL", 28, 39], ["ribavirin", "SIMPLE_CHEMICAL", 44, 53], ["ribavirin", "SIMPLE_CHEMICAL", 75, 84], ["oseltamivir", "TREATMENT", 28, 39], ["ribavirin", "TREATMENT", 44, 53], ["ribavirin", "TREATMENT", 75, 84], ["some undesirable toxic effects", "PROBLEM", 95, 125], ["undesirable", "OBSERVATION_MODIFIER", 100, 111], ["toxic effects", "OBSERVATION", 112, 125]]], ["Recently, combination therapy with three antiviral drugs (amantadine, ribavirin, and oseltamivir) has shown a strong effect on drug-resistant viruses including pH1N1 influenza in Korea (Kim et al. 2011) .", [["amantadine", "CHEMICAL", 58, 68], ["ribavirin", "CHEMICAL", 70, 79], ["oseltamivir", "CHEMICAL", 85, 96], ["pH1N1 influenza", "DISEASE", 160, 175], ["amantadine", "CHEMICAL", 58, 68], ["ribavirin", "CHEMICAL", 70, 79], ["oseltamivir", "CHEMICAL", 85, 96], ["amantadine", "SIMPLE_CHEMICAL", 58, 68], ["ribavirin", "SIMPLE_CHEMICAL", 70, 79], ["oseltamivir", "SIMPLE_CHEMICAL", 85, 96], ["pH1N1", "ORGANISM", 160, 165], ["pH1N1 influenza", "SPECIES", 160, 175], ["combination therapy", "TREATMENT", 10, 29], ["three antiviral drugs", "TREATMENT", 35, 56], ["amantadine", "TREATMENT", 58, 68], ["ribavirin", "TREATMENT", 70, 79], ["oseltamivir", "TREATMENT", 85, 96], ["drug-resistant viruses", "PROBLEM", 127, 149], ["pH1N1 influenza", "PROBLEM", 160, 175]]], ["In continuation, the TCDA therapy also showed similar pharmacokinetics compared with mono-drug therapy with increased safety in immune compromised patients (Kim et al. 2011; Seo et al. 2013) .IntroductionIn continuation of the previous publication of known molecules of anti-influenza nucleoside analogs that were approved for the treatment of influenza viral infection and their mechanism of binding, in the present study, (Sherman et al. 2019 ) the compound database of~800 nucleoside triphosphates that are commercially available was developed for molecular docking against the built homology model in three stages of replication mechanism I. In the presence of influenza-A vRNA; II.", [["TCDA", "CHEMICAL", 21, 25], ["nucleoside", "CHEMICAL", 285, 295], ["influenza viral infection", "DISEASE", 344, 369], ["nucleoside triphosphates", "CHEMICAL", 476, 500], ["TCDA", "CHEMICAL", 21, 25], ["nucleoside", "CHEMICAL", 285, 295], ["nucleoside triphosphates", "CHEMICAL", 476, 500], ["TCDA", "SIMPLE_CHEMICAL", 21, 25], ["mono-drug", "SIMPLE_CHEMICAL", 85, 94], ["patients", "ORGANISM", 147, 155], ["nucleoside analogs", "SIMPLE_CHEMICAL", 285, 303], ["influenza viral", "ORGANISM", 344, 359], ["nucleoside triphosphates", "SIMPLE_CHEMICAL", 476, 500], ["patients", "SPECIES", 147, 155], ["the TCDA therapy", "TREATMENT", 17, 33], ["similar pharmacokinetics", "PROBLEM", 46, 70], ["mono-drug therapy", "TREATMENT", 85, 102], ["anti-influenza nucleoside analogs", "TREATMENT", 270, 303], ["influenza viral infection", "PROBLEM", 344, 369], ["nucleoside triphosphates", "TREATMENT", 476, 500], ["influenza", "PROBLEM", 665, 674], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["influenza", "OBSERVATION", 665, 674]]], ["In the presence of Influenza-A vRNA with extended primer; and III.", [["Influenza-A", "SPECIES", 19, 30], ["Influenza", "PROBLEM", 19, 28], ["A vRNA", "PROBLEM", 29, 35], ["Influenza", "OBSERVATION", 19, 28]]], ["In the presence of influenza-B vRNA (Pagadala 2019) .", [["influenza-B vRNA", "ORGANISM", 19, 35], ["influenza", "PROBLEM", 19, 28], ["influenza", "OBSERVATION", 19, 28]]], ["Based on the docking studies, the top ranking 11 nucleoside triphosphates that bind commonly to the catalytic site in all the three stages with higher affinities and are predicted to inhibit the IAV viral replication were chosen and their ligand protein interactions were studied further.", [["nucleoside triphosphates", "CHEMICAL", 49, 73], ["nucleoside triphosphates", "CHEMICAL", 49, 73], ["nucleoside triphosphates", "SIMPLE_CHEMICAL", 49, 73], ["IAV viral", "ORGANISM", 195, 204], ["catalytic site", "PROTEIN", 100, 114], ["the docking studies", "TEST", 9, 28], ["the top ranking 11 nucleoside triphosphates", "TREATMENT", 30, 73], ["the IAV viral replication", "TREATMENT", 191, 216], ["IAV", "OBSERVATION_MODIFIER", 195, 198], ["viral replication", "OBSERVATION", 199, 216]]], ["In addition, the binding modes of 11 NTPs against IAV RdRp were predicted and their dihedral angles \u03a6 T C (2\u2032) -C (1\u2032) -N (1) -N (5)/C (6) and \u03a6 P O (5\u2032) -C (1\u2032) -N (1) -N (5)/C (6) that play an important role in ligand binding were analyzed.", [["NTPs", "CHEMICAL", 37, 41], ["NTPs", "CHEMICAL", 37, 41], ["C (2\u2032) -C (1\u2032) -N (1) -N", "CHEMICAL", 104, 128], ["C", "CHEMICAL", 133, 134], ["\u03a6 P O (5\u2032) -C (1\u2032) -N (1) -N", "CHEMICAL", 143, 171], ["NTPs", "SIMPLE_CHEMICAL", 37, 41], ["IAV RdRp", "ORGANISM", 50, 58], ["T C (2\u2032) -C (1\u2032) -N (1) -N (5)", "SIMPLE_CHEMICAL", 102, 132], ["C (6)", "SIMPLE_CHEMICAL", 133, 138], ["\u03a6 P O (5\u2032) -C (1\u2032) -N (1) -N (5)/C (6)", "SIMPLE_CHEMICAL", 143, 181], ["IAV RdRp", "PROTEIN", 50, 58], ["the binding modes of 11 NTPs", "TREATMENT", 13, 41], ["IAV RdRp", "TREATMENT", 50, 58], ["their dihedral angles", "TEST", 78, 99], ["T", "TEST", 102, 103], ["C", "TEST", 104, 105]]], ["Furthermore, 25% (IC 25 ), 50% (IC 50 ), and 95% (EC 95 ) effective concentrations of these 11 NTPs were calculated for IAV RdRp inhibition using trichloroacetic acid (TCA) precipitation assay (Pagadala 2019) .", [["NTPs", "CHEMICAL", 95, 99], ["trichloroacetic acid", "CHEMICAL", 146, 166], ["TCA", "CHEMICAL", 168, 171], ["NTPs", "CHEMICAL", 95, 99], ["trichloroacetic acid", "CHEMICAL", 146, 166], ["TCA", "CHEMICAL", 168, 171], ["IAV", "ORGANISM", 120, 123], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 146, 166], ["TCA", "SIMPLE_CHEMICAL", 168, 171], ["IAV", "SPECIES", 120, 123], ["EC", "TEST", 50, 52], ["these 11 NTPs", "TREATMENT", 86, 99], ["IAV RdRp inhibition", "TREATMENT", 120, 139], ["trichloroacetic acid (TCA)", "TREATMENT", 146, 172]]], ["Finally, LogIC 50 of the molecules that showed inhibition was correlated with \u0394G and their regression analysis R 2 was calculated.Molecular dockingThe database of~800 nucleoside triphosphates developed from different chemical companies were used for molecular docking using the same methodology that was published earlier with the homology model of A/PR/8/34/H1N1 polymerase in three different stages of replication mechanism; I: In the presence of influenza-A vRNA, II.", [["nucleoside triphosphates", "CHEMICAL", 167, 191], ["nucleoside triphosphates", "CHEMICAL", 167, 191], ["nucleoside triphosphates", "SIMPLE_CHEMICAL", 167, 191], ["A", "GENE_OR_GENE_PRODUCT", 349, 350], ["PR", "GENE_OR_GENE_PRODUCT", 351, 353], ["8/34", "GENE_OR_GENE_PRODUCT", 354, 358], ["LogIC 50", "PROTEIN", 9, 17], ["PR", "PROTEIN", 351, 353], ["8/34", "PROTEIN", 354, 358], ["H1N1 polymerase", "PROTEIN", 359, 374], ["A/PR/8/34/H1N1", "SPECIES", 349, 363], ["\u0394G", "TEST", 78, 80], ["their regression analysis", "TEST", 85, 110], ["The database", "TEST", 147, 159], ["nucleoside triphosphates", "TREATMENT", 167, 191], ["H1N1 polymerase", "PROBLEM", 359, 374], ["influenza", "PROBLEM", 449, 458], ["influenza", "OBSERVATION", 449, 458]]], ["In the presence of Influenza-A vRNA with extended primer, and III.", [["Influenza-A vRNA", "RNA", 19, 35], ["Influenza-A", "SPECIES", 19, 30], ["Influenza", "PROBLEM", 19, 28], ["A vRNA", "PROBLEM", 29, 35], ["Influenza", "OBSERVATION", 19, 28], ["vRNA", "OBSERVATION", 31, 35]]], ["In the presence of influenza-B vRNA using MOE (Chemical computing group, Montreal, Canada) (Pagadala 2019) .", [["influenza", "PROBLEM", 19, 28], ["influenza", "OBSERVATION", 19, 28]]], ["Initially, the ligand was optimized by energy minimization with TAFF forcefield until the energy gradient is below 0.001 Kcal/Mol (Clark et al. 1989) .", [["TAFF forcefield", "TREATMENT", 64, 79], ["the energy gradient", "TEST", 86, 105]]], ["Totally 1000 docking poses for each ligand were generated using implicit generalized born solvation model and ligand placement method \"Alpha PMI\" with London dG scoring function.", [["implicit generalized born solvation model", "TREATMENT", 64, 105], ["ligand placement method", "TREATMENT", 110, 133], ["Alpha PMI", "PROBLEM", 135, 144]]], ["At the end, global minimum of the ligand was predicted using the simulated annealing based on the Monte Carlo method (Metropolis et al. 1953) .", [["global", "OBSERVATION_MODIFIER", 12, 18], ["minimum", "OBSERVATION_MODIFIER", 19, 26]]], ["Finally, the affinity of the docking poses as the sum of the electrostatic, and Van der Waals energies were ranked with \u0394G (U total in kcal/Mol).", [["Van der Waals energies", "TREATMENT", 80, 102], ["\u0394G (U total in kcal/Mol", "TREATMENT", 120, 143]]], ["The reaction model cutoff between 8 and 10 \u00c5 as a dielectric function with the pocket radius of 6 \u00c5 was included in our docking studies.", [["The reaction model cutoff", "TEST", 0, 25], ["a dielectric function", "TEST", 48, 69], ["our docking studies", "TEST", 116, 135], ["pocket", "OBSERVATION_MODIFIER", 79, 85]]], ["In total, the 30 docking conformations were retained as a cutoff.TCA precipitation assayWe then investigated the effect of top ranking 11 compounds with higher MW and TPSA and bind to the catalytic site of RdRp inhibiting the incorporation of GTP into TCA-precipitable material with the A/PR/8/34 (PR8) strain (Table 1 and Fig. 1 ).", [["TCA", "CHEMICAL", 65, 68], ["TPSA", "CHEMICAL", 167, 171], ["GTP", "CHEMICAL", 243, 246], ["TCA", "CHEMICAL", 252, 255], ["TCA", "CHEMICAL", 65, 68], ["GTP", "CHEMICAL", 243, 246], ["TCA", "CHEMICAL", 252, 255], ["TCA", "SIMPLE_CHEMICAL", 65, 68], ["TPSA", "SIMPLE_CHEMICAL", 167, 171], ["RdRp", "GENE_OR_GENE_PRODUCT", 206, 210], ["GTP", "SIMPLE_CHEMICAL", 243, 246], ["TCA", "SIMPLE_CHEMICAL", 252, 255], ["8/34", "GENE_OR_GENE_PRODUCT", 292, 296], ["PR8", "ORGANISM", 298, 301], ["catalytic site", "PROTEIN", 188, 202], ["RdRp", "PROTEIN", 206, 210], ["PR", "PROTEIN", 289, 291], ["TCA precipitation", "TREATMENT", 65, 82], ["higher MW and TPSA", "TREATMENT", 153, 171], ["RdRp", "PROBLEM", 206, 210], ["GTP into TCA-precipitable material", "PROBLEM", 243, 277], ["RdRp", "OBSERVATION", 206, 210]]], ["The purified influenza virus A/PR/8/ 34/H1N1 obtained from Charles River (MD) was disrupted with 2.5% Triton N-101 and diluted 1:2 with 0.25% Triton N-101.", [["Triton N-101", "CHEMICAL", 102, 114], ["Triton N-101", "CHEMICAL", 142, 154], ["Triton N-101", "CHEMICAL", 102, 114], ["Triton N-101", "CHEMICAL", 142, 154], ["influenza virus A/PR/8/ 34/H1N1", "ORGANISM", 13, 44], ["Charles River", "ORGANISM", 59, 72], ["Triton N-101", "SIMPLE_CHEMICAL", 102, 114], ["Triton N-101", "SIMPLE_CHEMICAL", 142, 154], ["PR", "PROTEIN", 31, 33], ["influenza virus", "SPECIES", 13, 28], ["influenza virus A/PR/8/ 34/H1N1", "SPECIES", 13, 44], ["The purified influenza virus", "PROBLEM", 0, 28], ["influenza virus", "OBSERVATION", 13, 28]]], ["Disruption provided the source of influenza ribonucleoprotein (RNP) containing the IAV RdRp and template vRNA.", [["RNP", "CELLULAR_COMPONENT", 63, 66], ["IAV RdRp", "ORGANISM", 83, 91], ["influenza ribonucleoprotein", "PROTEIN", 34, 61], ["RNP", "PROTEIN", 63, 66], ["IAV RdRp and template vRNA", "RNA", 83, 109], ["influenza ribonucleoprotein", "PROBLEM", 34, 61], ["the IAV RdRp", "TREATMENT", 79, 91], ["template vRNA", "PROBLEM", 96, 109], ["IAV RdRp", "OBSERVATION", 83, 91], ["template vRNA", "OBSERVATION", 96, 109]]], ["Samples were stored on ice until use in the assay.", [["Samples", "ANATOMY", 0, 7], ["ice", "TREATMENT", 23, 26]]], ["Six serial half-log dilutions of the test drugs (twelve drugs) at concentrations of 0.001, 0.01, 0.1, 1, 10, and 100 \u03bcM and positive control 2\u2032Deoxy-2\u2032fluoroguanosine 5\u2032triphosphate (high tests of 100 \u00b5M) were tested in triplicate.", [["Deoxy-2\u2032fluoroguanosine 5\u2032triphosphate", "CHEMICAL", 143, 181], ["Deoxy-2\u2032fluoroguanosine 5\u2032triphosphate", "CHEMICAL", 143, 181], ["Deoxy-2\u2032fluoroguanosine 5\u2032triphosphate", "SIMPLE_CHEMICAL", 143, 181], ["the test drugs", "TREATMENT", 33, 47], ["twelve drugs", "TREATMENT", 49, 61], ["Deoxy", "TEST", 143, 148], ["2\u2032fluoroguanosine 5\u2032triphosphate", "TREATMENT", 149, 181]]], ["Each polymerase reaction contained the following: disrupted RNP, Tris-HCl, KCl, MgCl 2 , Dithiothreitol, 0.25% Triton N-101, [\u03b1-32 P] GTP, ATP, CTP, UTP, GTP, and Adenyl (3\u2032-5\u2032) Guanosine.", [["Tris-HCl", "CHEMICAL", 65, 73], ["KCl", "CHEMICAL", 75, 78], ["MgCl", "CHEMICAL", 80, 84], ["Dithiothreitol", "CHEMICAL", 89, 103], ["Triton N-101", "CHEMICAL", 111, 123], ["GTP", "CHEMICAL", 134, 137], ["ATP", "CHEMICAL", 139, 142], ["CTP", "CHEMICAL", 144, 147], ["UTP", "CHEMICAL", 149, 152], ["GTP", "CHEMICAL", 154, 157], ["Adenyl (3\u2032-5\u2032", "CHEMICAL", 163, 176], ["Guanosine", "CHEMICAL", 178, 187], ["Tris", "CHEMICAL", 65, 69], ["HCl", "CHEMICAL", 70, 73], ["KCl", "CHEMICAL", 75, 78], ["MgCl 2", "CHEMICAL", 80, 86], ["Dithiothreitol", "CHEMICAL", 89, 103], ["Triton N-101", "CHEMICAL", 111, 123], ["[\u03b1-32 P] GTP", "CHEMICAL", 125, 137], ["ATP", "CHEMICAL", 139, 142], ["CTP", "CHEMICAL", 144, 147], ["UTP", "CHEMICAL", 149, 152], ["GTP", "CHEMICAL", 154, 157], ["Adenyl (3\u2032-5\u2032) Guanosine", "CHEMICAL", 163, 187], ["Tris-HCl", "SIMPLE_CHEMICAL", 65, 73], ["KCl", "SIMPLE_CHEMICAL", 75, 78], ["MgCl 2", "SIMPLE_CHEMICAL", 80, 86], ["Dithiothreitol", "SIMPLE_CHEMICAL", 89, 103], ["Triton N-101", "SIMPLE_CHEMICAL", 111, 123], ["[\u03b1-32 P] GTP", "SIMPLE_CHEMICAL", 125, 137], ["ATP", "SIMPLE_CHEMICAL", 139, 142], ["CTP", "SIMPLE_CHEMICAL", 144, 147], ["UTP", "SIMPLE_CHEMICAL", 149, 152], ["GTP", "SIMPLE_CHEMICAL", 154, 157], ["Adenyl (3\u2032-5\u2032) Guanosine", "SIMPLE_CHEMICAL", 163, 187], ["RNP", "PROTEIN", 60, 63], ["Each polymerase reaction", "PROBLEM", 0, 24], ["Tris", "TEST", 65, 69], ["KCl", "TREATMENT", 75, 78], ["MgCl", "TEST", 80, 84], ["Dithiothreitol", "TEST", 89, 103], ["GTP", "TEST", 134, 137], ["ATP", "TEST", 139, 142], ["CTP", "TEST", 144, 147], ["UTP", "TEST", 149, 152], ["GTP", "TREATMENT", 154, 157], ["Adenyl (3\u2032", "TREATMENT", 163, 173], ["Guanosine", "TREATMENT", 178, 187]]], ["For testing the inhibitor, the reactions contained the inhibitor and the same was done for reactions containing the positive control.", [["testing the inhibitor", "TREATMENT", 4, 25], ["the reactions", "PROBLEM", 27, 40], ["the inhibitor", "TREATMENT", 51, 64], ["reactions", "PROBLEM", 91, 100], ["the positive control", "TREATMENT", 112, 132]]], ["The reaction was incubated at 30\u00b0C for 1 h, transferred onto glass-fiber filter plates and subsequent precipitation of nucleic acids with 10% TCA.", [["nucleic acids", "CHEMICAL", 119, 132], ["TCA", "CHEMICAL", 142, 145], ["TCA", "CHEMICAL", 142, 145], ["nucleic acids", "SIMPLE_CHEMICAL", 119, 132], ["TCA", "SIMPLE_CHEMICAL", 142, 145], ["The reaction", "PROBLEM", 0, 12], ["glass-fiber filter plates", "TREATMENT", 61, 86], ["nucleic acids", "TREATMENT", 119, 132], ["10% TCA", "TREATMENT", 138, 145], ["nucleic acids", "OBSERVATION", 119, 132]]], ["The filters were then washed with 5% TCA followed by 95% ethanol and air dried.", [["TCA", "CHEMICAL", 37, 40], ["ethanol", "CHEMICAL", 57, 64], ["TCA", "CHEMICAL", 37, 40], ["ethanol", "CHEMICAL", 57, 64], ["TCA", "SIMPLE_CHEMICAL", 37, 40], ["ethanol", "SIMPLE_CHEMICAL", 57, 64], ["The filters", "TREATMENT", 0, 11], ["5% TCA", "TREATMENT", 34, 40], ["filters", "OBSERVATION", 4, 11], ["air dried", "OBSERVATION", 69, 78]]], ["Once the filter has dried, incorporation of [\u03b1-32 P] GTP was measured using a scintillation counter (Micro beta).", [["[\u03b1-32 P] GTP", "CHEMICAL", 44, 56], ["[\u03b1-32 P] GTP", "CHEMICAL", 44, 56], ["[\u03b1-32 P] GTP", "SIMPLE_CHEMICAL", 44, 56], ["Micro beta", "PROTEIN", 101, 111], ["the filter", "TREATMENT", 5, 15], ["incorporation of [\u03b1-32 P] GTP", "TREATMENT", 27, 56], ["a scintillation counter (Micro beta)", "TREATMENT", 76, 112], ["filter", "OBSERVATION", 9, 15]]], ["Radioactivity was measured in a Micro beta liquid scintillation counter.", [["Radioactivity", "TEST", 0, 13], ["a Micro beta liquid scintillation counter", "TREATMENT", 30, 71]]], ["Negative control reactions were prepared by omitting RNP complexes, whereas, positive control reactions for polymerase inhibitors contained the specific inhibitor 2\u2032-deoxy-2\u2032-Fluoroguanosine 5\u2032-triphosphate.", [["2\u2032-deoxy-2\u2032-Fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 163, 206], ["2\u2032-deoxy-2\u2032-Fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 163, 206], ["2\u2032-deoxy-2\u2032-Fluoroguanosine 5\u2032-triphosphate", "SIMPLE_CHEMICAL", 163, 206], ["RNP complexes", "PROTEIN", 53, 66], ["positive control reactions", "PROBLEM", 77, 103], ["polymerase inhibitors", "TREATMENT", 108, 129], ["the specific inhibitor", "TREATMENT", 140, 162], ["deoxy", "TEST", 166, 171], ["Fluoroguanosine", "TREATMENT", 175, 190], ["triphosphate", "TREATMENT", 194, 206]]], ["Inhibition of viral polymerase activity was measured by IC 25 , IC 50 , and IC 95 in triplicate (Pagadala 2019) .ResultsBinding modes of 11 NTPs against the homology model of human A/PR/8/34/H1N1 RdRpStage-I: In the presence of influenza-A vRNAIn the docked complex, compound 1 binds to the catalytic site with both ribose sugar and cytidine nitrogen interacting with Ser 494 and Ala 648 of the priming loop through 2\u2032 and backbone oxygens.", [["NTPs", "CHEMICAL", 140, 144], ["ribose", "CHEMICAL", 316, 322], ["cytidine nitrogen", "CHEMICAL", 333, 350], ["Ser 494", "CHEMICAL", 368, 375], ["Ala 648", "CHEMICAL", 380, 387], ["NTPs", "CHEMICAL", 140, 144], ["ribose sugar", "CHEMICAL", 316, 328], ["cytidine", "CHEMICAL", 333, 341], ["nitrogen", "CHEMICAL", 342, 350], ["Ser", "CHEMICAL", 368, 371], ["Ala", "CHEMICAL", 380, 383], ["oxygens", "CHEMICAL", 432, 439], ["human", "ORGANISM", 175, 180], ["A/PR/8/34/H1N1", "ORGANISM", 181, 195], ["ribose sugar", "SIMPLE_CHEMICAL", 316, 328], ["cytidine nitrogen", "SIMPLE_CHEMICAL", 333, 350], ["Ser 494", "AMINO_ACID", 368, 375], ["Ala 648", "AMINO_ACID", 380, 387], ["backbone oxygens", "SIMPLE_CHEMICAL", 423, 439], ["viral polymerase", "PROTEIN", 14, 30], ["human A", "PROTEIN", 175, 182], ["PR", "PROTEIN", 183, 185], ["docked complex", "PROTEIN", 251, 265], ["catalytic site", "PROTEIN", 291, 305], ["human", "SPECIES", 175, 180], ["human A/PR/8/34/H1N1", "SPECIES", 175, 195], ["viral polymerase activity", "TEST", 14, 39], ["IC", "TEST", 56, 58], ["IC", "TEST", 64, 66], ["IC", "TEST", 76, 78], ["NTPs", "TREATMENT", 140, 144], ["influenza", "PROBLEM", 228, 237], ["both ribose sugar", "TREATMENT", 311, 328], ["cytidine nitrogen", "TREATMENT", 333, 350], ["Ala", "TEST", 380, 383], ["the priming loop", "TREATMENT", 391, 407], ["backbone oxygens", "TREATMENT", 423, 439], ["viral polymerase activity", "OBSERVATION", 14, 39], ["influenza", "OBSERVATION", 228, 237]]], ["The central 1H-indole ring and sulfonyl oxygen atoms contacts with Asn 42 and Leu 45 of PB2-N involved in interactions with the 3\u2032activator strand of vRNA once it enters the polymerase active site.", [["1H-indole", "CHEMICAL", 12, 21], ["oxygen", "CHEMICAL", 40, 46], ["Asn 42 and Leu 45 of PB2-N", "CHEMICAL", 67, 93], ["1H", "CHEMICAL", 12, 14], ["indole", "CHEMICAL", 15, 21], ["sulfonyl", "CHEMICAL", 31, 39], ["oxygen", "CHEMICAL", 40, 46], ["Asn", "CHEMICAL", 67, 70], ["Leu", "CHEMICAL", 78, 81], ["N", "CHEMICAL", 92, 93], ["1H-indole ring", "SIMPLE_CHEMICAL", 12, 26], ["sulfonyl oxygen atoms", "SIMPLE_CHEMICAL", 31, 52], ["Asn 42", "AMINO_ACID", 67, 73], ["Leu 45", "AMINO_ACID", 78, 84], ["vRNA", "CELLULAR_COMPONENT", 150, 154], ["PB2", "PROTEIN", 88, 91], ["3\u2032activator strand", "PROTEIN", 128, 146], ["polymerase active site", "PROTEIN", 174, 196], ["The central 1H-indole ring and sulfonyl oxygen atoms", "TREATMENT", 0, 52], ["the 3\u2032activator strand of vRNA", "TREATMENT", 124, 154], ["central", "ANATOMY_MODIFIER", 4, 11], ["indole ring", "OBSERVATION", 15, 26]]], ["However, the terminal 1H-indole ring contacts with Pro 641 of PB1 priming loop through ethyl carbon.", [["terminal 1H-indole", "CHEMICAL", 13, 31], ["Pro 641", "CHEMICAL", 51, 58], ["ethyl carbon", "CHEMICAL", 87, 99], ["1H", "CHEMICAL", 22, 24], ["indole", "CHEMICAL", 25, 31], ["Pro 641", "CHEMICAL", 51, 58], ["ethyl carbon", "CHEMICAL", 87, 99], ["ethyl carbon", "SIMPLE_CHEMICAL", 87, 99], ["PB1", "PROTEIN", 62, 65], ["PB1 priming loop through ethyl carbon", "TREATMENT", 62, 99]]], ["Also, the \u03b1 and \u03b3 phosphates contact with side chains of Asn 536 and Arg 142 at the end of the second tunnel (Fig. 2a) .", [["\u03b1 and \u03b3 phosphates", "CHEMICAL", 10, 28], ["Asn 536", "CHEMICAL", 57, 64], ["Arg 142", "CHEMICAL", 69, 76], ["phosphates", "CHEMICAL", 18, 28], ["Asn", "CHEMICAL", 57, 60], ["Arg 142", "CHEMICAL", 69, 76], ["\u03b1", "SIMPLE_CHEMICAL", 10, 11], ["Asn 536", "AMINO_ACID", 57, 64], ["Arg 142", "AMINO_ACID", 69, 76], ["Arg", "TEST", 69, 72]]], ["Due to its bigger size, compound 2, occupies more space towards the catalytic site showing interactions between cyanine and Met 646 of the priming loop.", [["cyanine", "CHEMICAL", 112, 119], ["Met 646", "CHEMICAL", 124, 131], ["cyanine", "CHEMICAL", 112, 119], ["Met", "CHEMICAL", 124, 127], ["cyanine", "SIMPLE_CHEMICAL", 112, 119], ["Met 646", "SIMPLE_CHEMICAL", 124, 131], ["catalytic site", "PROTEIN", 68, 82], ["cyanine", "TREATMENT", 112, 119], ["the priming loop", "TREATMENT", 135, 151], ["bigger", "OBSERVATION_MODIFIER", 11, 17], ["size", "OBSERVATION_MODIFIER", 18, 22]]], ["In addition, 7-Allyl also shows contact with Met 646 and 507 while the ribose sugar towards the exit channel makes contacts with Asn 504 , Glu 508 , and Asn 537 of PB1 in the central region of a typical right-handed RdRp fold.", [["Allyl", "CHEMICAL", 15, 20], ["Met 646", "CHEMICAL", 45, 52], ["ribose", "CHEMICAL", 71, 77], ["Asn 504", "CHEMICAL", 129, 136], ["Glu 508", "CHEMICAL", 139, 146], ["Asn 537", "CHEMICAL", 153, 160], ["7-Allyl", "CHEMICAL", 13, 20], ["Met", "CHEMICAL", 45, 48], ["ribose sugar", "CHEMICAL", 71, 83], ["Asn", "CHEMICAL", 129, 132], ["Glu", "CHEMICAL", 139, 142], ["Asn", "CHEMICAL", 153, 156], ["7-Allyl", "SIMPLE_CHEMICAL", 13, 20], ["Met 646", "SIMPLE_CHEMICAL", 45, 52], ["ribose sugar", "SIMPLE_CHEMICAL", 71, 83], ["Asn 504", "AMINO_ACID", 129, 136], ["Glu 508", "AMINO_ACID", 139, 146], ["Asn 537", "AMINO_ACID", 153, 160], ["PB1", "AMINO_ACID", 164, 167], ["exit channel", "PROTEIN", 96, 108], ["PB1", "PROTEIN", 164, 167], ["RdRp fold", "PROTEIN", 216, 225], ["the ribose sugar", "TEST", 67, 83], ["Glu", "TEST", 139, 142], ["PB1", "TREATMENT", 164, 167], ["central", "ANATOMY_MODIFIER", 175, 182], ["right", "ANATOMY_MODIFIER", 203, 208], ["RdRp fold", "OBSERVATION", 216, 225]]], ["The central sulfonyl at the C-terminal region contacts with Asn 42 , Pro 43 , and Ala 44 of PB2-N through backbone atoms (Fig. 2b ).", [["sulfonyl", "CHEMICAL", 12, 20], ["Asn 42 , Pro 43 , and Ala 44 of PB2-N", "CHEMICAL", 60, 97], ["sulfonyl", "CHEMICAL", 12, 20], ["C", "CHEMICAL", 28, 29], ["Asn", "CHEMICAL", 60, 63], ["Pro", "CHEMICAL", 69, 72], ["Ala", "CHEMICAL", 82, 85], ["PB2-N", "CHEMICAL", 92, 97], ["sulfonyl", "SIMPLE_CHEMICAL", 12, 20], ["Asn 42", "AMINO_ACID", 60, 66], ["Pro 43", "AMINO_ACID", 69, 75], ["C-terminal region", "PROTEIN", 28, 45], ["PB2", "PROTEIN", 92, 95], ["The central sulfonyl", "TREATMENT", 0, 20], ["Asn", "TEST", 60, 63], ["Pro", "TEST", 69, 72], ["Ala", "TEST", 82, 85], ["PB2", "TEST", 92, 95], ["central", "ANATOMY_MODIFIER", 4, 11]]], ["In comparison, the terminal 1H-indole ring of compound 3 shows H-Pi stack with Glu 232 and Arg 233 near the NTP tunnel placing the sulfonyl oxygens close to Mg ++ .", [["terminal 1H-indole", "CHEMICAL", 19, 37], ["H-Pi", "CHEMICAL", 63, 67], ["Glu 232", "CHEMICAL", 79, 86], ["Arg 233", "CHEMICAL", 91, 98], ["sulfonyl oxygens", "CHEMICAL", 131, 147], ["Mg", "CHEMICAL", 157, 159], ["1H", "CHEMICAL", 28, 30], ["indole", "CHEMICAL", 31, 37], ["Glu", "CHEMICAL", 79, 82], ["Arg", "CHEMICAL", 91, 94], ["NTP", "CHEMICAL", 108, 111], ["sulfonyl oxygens", "CHEMICAL", 131, 147], ["Mg ++", "CHEMICAL", 157, 162], ["H-Pi", "SIMPLE_CHEMICAL", 63, 67], ["Glu 232", "SIMPLE_CHEMICAL", 79, 86], ["Arg 233", "AMINO_ACID", 91, 98], ["sulfonyl oxygens", "SIMPLE_CHEMICAL", 131, 147], ["Mg ++", "SIMPLE_CHEMICAL", 157, 162], ["H-Pi stack", "TEST", 63, 73], ["Glu", "TEST", 79, 82], ["Arg", "TEST", 91, 94], ["the NTP tunnel", "TREATMENT", 104, 118], ["the sulfonyl oxygens", "TREATMENT", 127, 147], ["NTP tunnel", "OBSERVATION", 108, 118]]], ["In addition, the central 1H-indole ring and the attached sulfonyl oxygen also interacts with Met 646 and Ser 511 of PB1 central domain through H-Pi and hydrogen bond.", [["1H-indole", "CHEMICAL", 25, 34], ["sulfonyl", "CHEMICAL", 57, 65], ["oxygen", "CHEMICAL", 66, 72], ["Met 646", "CHEMICAL", 93, 100], ["H-Pi", "CHEMICAL", 143, 147], ["1H", "CHEMICAL", 25, 27], ["indole", "CHEMICAL", 28, 34], ["sulfonyl oxygen", "CHEMICAL", 57, 72], ["Met", "CHEMICAL", 93, 96], ["Ser", "CHEMICAL", 105, 108], ["H-Pi", "CHEMICAL", 143, 147], ["hydrogen", "CHEMICAL", 152, 160], ["sulfonyl oxygen", "SIMPLE_CHEMICAL", 57, 72], ["Met 646", "AMINO_ACID", 93, 100], ["Ser 511", "AMINO_ACID", 105, 112], ["H-Pi", "SIMPLE_CHEMICAL", 143, 147], ["PB1 central domain", "PROTEIN", 116, 134], ["the central 1H-indole ring", "TREATMENT", 13, 39], ["the attached sulfonyl oxygen", "TREATMENT", 44, 72], ["central", "ANATOMY_MODIFIER", 17, 24], ["indole ring", "OBSERVATION", 28, 39], ["hydrogen bond", "OBSERVATION", 152, 165]]], ["This orientation is further stabilized by additional contacts with Met 646 and Ala 648 of the priming loop through the central 5-5-propargylamino carbon and oxygen atoms.", [["Met 646", "CHEMICAL", 67, 74], ["Ala 648", "CHEMICAL", 79, 86], ["5-5-propargylamino carbon", "CHEMICAL", 127, 152], ["oxygen", "CHEMICAL", 157, 163], ["Met", "CHEMICAL", 67, 70], ["Ala", "CHEMICAL", 79, 82], ["5-5-propargylamino carbon", "CHEMICAL", 127, 152], ["oxygen", "CHEMICAL", 157, 163], ["Met 646", "SIMPLE_CHEMICAL", 67, 74], ["Ala 648", "AMINO_ACID", 79, 86], ["5-5-propargylamino carbon", "SIMPLE_CHEMICAL", 127, 152], ["oxygen atoms", "SIMPLE_CHEMICAL", 157, 169], ["Ala", "TEST", 79, 82], ["the priming loop", "TREATMENT", 90, 106], ["5-propargylamino carbon and oxygen atoms", "TREATMENT", 129, 169]]], ["Other than these interactions, the ribose sugar, \u03b1 and \u03b3 phosphates also interacts with Thr 493 , Asn 537 , and Asn 276 of PB1 central domain (Fig. 2c) .Stage-I: In the presence of influenza-A vRNAFurthermore, it was demonstrated that compound 4 occupies the binding pocket at the end of tunnel 2 with -phosphate and oxymethyl of ribose sugar makes contacts with PB2 linker Asn 138 and Arg 142 that leads to an Nterminal subdomain.", [["ribose", "CHEMICAL", 35, 41], ["\u03b1 and \u03b3 phosphates", "CHEMICAL", 49, 67], ["Asn 537", "CHEMICAL", 98, 105], ["phosphate", "CHEMICAL", 303, 312], ["oxymethyl of ribose", "CHEMICAL", 317, 336], ["Asn 138", "CHEMICAL", 374, 381], ["Arg 142", "CHEMICAL", 386, 393], ["ribose", "CHEMICAL", 35, 41], ["sugar", "CHEMICAL", 42, 47], ["\u03b1 and \u03b3 phosphates", "CHEMICAL", 49, 67], ["Thr", "CHEMICAL", 88, 91], ["Asn", "CHEMICAL", 98, 101], ["Asn", "CHEMICAL", 112, 115], ["phosphate", "CHEMICAL", 303, 312], ["oxymethyl", "CHEMICAL", 317, 326], ["ribose sugar", "CHEMICAL", 330, 342], ["Asn", "CHEMICAL", 374, 377], ["Arg 142", "CHEMICAL", 386, 393], ["ribose sugar", "SIMPLE_CHEMICAL", 35, 47], ["\u03b1", "SIMPLE_CHEMICAL", 49, 50], ["\u03b3 phosphates", "SIMPLE_CHEMICAL", 55, 67], ["Thr 493", "AMINO_ACID", 88, 95], ["Asn 537", "AMINO_ACID", 98, 105], ["Asn 276", "AMINO_ACID", 112, 119], ["-phosphate", "SIMPLE_CHEMICAL", 302, 312], ["oxymethyl of ribose sugar", "SIMPLE_CHEMICAL", 317, 342], ["PB2 linker", "SIMPLE_CHEMICAL", 363, 373], ["Asn 138", "AMINO_ACID", 374, 381], ["Arg 142", "AMINO_ACID", 386, 393], ["PB1 central domain", "PROTEIN", 123, 141], ["Fig. 2c", "PROTEIN", 143, 150], ["PB2", "PROTEIN", 363, 366], ["Nterminal subdomain", "PROTEIN", 411, 430], ["the ribose sugar", "TEST", 31, 47], ["Thr", "TEST", 88, 91], ["Asn", "TEST", 98, 101], ["Asn", "TEST", 112, 115], ["PB1 central domain", "TREATMENT", 123, 141], ["influenza", "PROBLEM", 181, 190], ["the binding pocket", "PROBLEM", 255, 273], ["phosphate and oxymethyl of ribose sugar", "TREATMENT", 303, 342], ["PB2 linker Asn", "TREATMENT", 363, 377], ["Arg", "TEST", 386, 389], ["influenza", "OBSERVATION", 181, 190], ["binding pocket", "OBSERVATION", 259, 273]]], ["The cytidine which is placed far away from the PB2 linker shows contacts with Val 502 of PB1 central domain.", [["cytidine", "CHEMICAL", 4, 12], ["Val 502", "CHEMICAL", 78, 85], ["cytidine", "CHEMICAL", 4, 12], ["Val", "CHEMICAL", 78, 81], ["cytidine", "SIMPLE_CHEMICAL", 4, 12], ["PB2 linker", "PROTEIN", 47, 57], ["Val 502", "PROTEIN", 78, 85], ["PB1 central domain", "PROTEIN", 89, 107], ["The cytidine", "TREATMENT", 0, 12], ["PB1 central domain", "TREATMENT", 89, 107]]], ["This allows 6-aminoally aliphatic chain to enter deeply into the pocket forming a U-shape, exposing desthiobiotin at the other end of the molecule to interact with Lys 670 of PB2 627 linker (Fig. 2d) .", [["6-aminoally aliphatic", "CHEMICAL", 12, 33], ["desthiobiotin", "CHEMICAL", 100, 113], ["Lys 670 of PB2 627", "CHEMICAL", 164, 182], ["6-aminoally", "CHEMICAL", 12, 23], ["desthiobiotin", "CHEMICAL", 100, 113], ["Lys", "CHEMICAL", 164, 167], ["desthiobiotin", "SIMPLE_CHEMICAL", 100, 113], ["desthiobiotin", "PROTEIN", 100, 113], ["Lys 670", "PROTEIN", 164, 171], ["PB2 627 linker", "PROTEIN", 175, 189], ["6-aminoally aliphatic chain", "TREATMENT", 12, 39], ["desthiobiotin", "TREATMENT", 100, 113], ["PB2 627 linker", "TREATMENT", 175, 189], ["pocket", "OBSERVATION_MODIFIER", 65, 71], ["U-shape", "OBSERVATION_MODIFIER", 82, 89]]], ["When desthiobiotin-6-Aminoallyl was replaced with N 4 -biotin-OBEA, compound 5 penetrates much deeper than compound 4 in the same binding site.", [["desthiobiotin-6-Aminoallyl", "CHEMICAL", 5, 31], ["N 4 -biotin-OBEA", "CHEMICAL", 50, 66], ["compound 5", "CHEMICAL", 68, 78], ["desthiobiotin-6-Aminoallyl", "CHEMICAL", 5, 31], ["N 4 -biotin-OBEA", "CHEMICAL", 50, 66], ["desthiobiotin-6-Aminoallyl", "SIMPLE_CHEMICAL", 5, 31], ["N 4 -biotin-OBEA", "SIMPLE_CHEMICAL", 50, 66], ["compound 5", "SIMPLE_CHEMICAL", 68, 78], ["desthiobiotin", "TEST", 5, 18], ["Aminoallyl", "TREATMENT", 21, 31], ["N", "TREATMENT", 50, 51], ["biotin", "TREATMENT", 55, 61]]], ["The sulfur atom of biotin contacts with Val 139 , Leu 668 , and Lys 670 of PB2-N subdomain and PB2 627 linkers, while the oxo group interact with Phe 501 of PB1 central domain.", [["sulfur", "CHEMICAL", 4, 10], ["biotin", "CHEMICAL", 19, 25], ["Val 139 , Leu 668", "CHEMICAL", 40, 57], ["Lys 670", "CHEMICAL", 64, 71], ["Phe 501", "CHEMICAL", 146, 153], ["sulfur", "CHEMICAL", 4, 10], ["biotin", "CHEMICAL", 19, 25], ["Val", "CHEMICAL", 40, 43], ["Leu", "CHEMICAL", 50, 53], ["Lys", "CHEMICAL", 64, 67], ["N", "CHEMICAL", 79, 80], ["oxo", "CHEMICAL", 122, 125], ["Phe", "CHEMICAL", 146, 149], ["sulfur atom", "SIMPLE_CHEMICAL", 4, 15], ["biotin", "SIMPLE_CHEMICAL", 19, 25], ["Val 139", "SIMPLE_CHEMICAL", 40, 47], ["Leu 668", "AMINO_ACID", 50, 57], ["Lys 670", "AMINO_ACID", 64, 71], ["PB2", "PROTEIN", 75, 78], ["N subdomain", "PROTEIN", 79, 90], ["PB2 627 linkers", "PROTEIN", 95, 110], ["oxo group", "PROTEIN", 122, 131], ["PB1 central domain", "PROTEIN", 157, 175], ["Leu", "TEST", 50, 53], ["Lys", "TEST", 64, 67], ["PB2", "TEST", 75, 78], ["PB2 627 linkers", "TREATMENT", 95, 110], ["Phe", "TEST", 146, 149], ["PB1 central domain", "PROBLEM", 157, 175]]], ["In addition, the OBEA aliphatic chain also shows contacts with Val 502 , Ala 503 , and Asn 536 through backbone carbon, and oxygen atoms.", [["OBEA aliphatic", "CHEMICAL", 17, 31], ["Val 502 , Ala 503 , and Asn 536", "CHEMICAL", 63, 94], ["oxygen", "CHEMICAL", 124, 130], ["OBEA", "CHEMICAL", 17, 21], ["Val", "CHEMICAL", 63, 66], ["Ala", "CHEMICAL", 73, 76], ["Asn", "CHEMICAL", 87, 90], ["carbon", "CHEMICAL", 112, 118], ["oxygen", "CHEMICAL", 124, 130], ["OBEA", "SIMPLE_CHEMICAL", 17, 21], ["Val 502", "SIMPLE_CHEMICAL", 63, 70], ["Ala 503", "AMINO_ACID", 73, 80], ["Asn 536", "AMINO_ACID", 87, 94], ["backbone carbon", "SIMPLE_CHEMICAL", 103, 118], ["oxygen atoms", "SIMPLE_CHEMICAL", 124, 136], ["OBEA aliphatic chain", "PROTEIN", 17, 37], ["the OBEA aliphatic chain", "TEST", 13, 37], ["backbone carbon", "TREATMENT", 103, 118], ["oxygen atoms", "TREATMENT", 124, 136]]], ["Moreover, the cytidine and ribose sugar along with \u03b1, \u03b2, and \u03b3 phosphates shows contacts with Ser 494 , Met 507 , Ala 648 , Gly 275 , Asn 276 , and Asn 536 of PB1 central and priming loop forming more or less a circular fold.", [["cytidine", "CHEMICAL", 14, 22], ["ribose", "CHEMICAL", 27, 33], ["\u03b1, \u03b2, and \u03b3 phosphates", "CHEMICAL", 51, 73], ["Asn 276", "CHEMICAL", 134, 141], ["Asn 536", "CHEMICAL", 148, 155], ["cytidine", "CHEMICAL", 14, 22], ["ribose sugar", "CHEMICAL", 27, 39], ["\u03b1, \u03b2, and \u03b3 phosphates", "CHEMICAL", 51, 73], ["Ser", "CHEMICAL", 94, 97], ["Met", "CHEMICAL", 104, 107], ["Ala", "CHEMICAL", 114, 117], ["Gly", "CHEMICAL", 124, 127], ["Asn", "CHEMICAL", 134, 137], ["Asn", "CHEMICAL", 148, 151], ["cytidine", "SIMPLE_CHEMICAL", 14, 22], ["ribose sugar", "SIMPLE_CHEMICAL", 27, 39], ["\u03b1, \u03b2", "SIMPLE_CHEMICAL", 51, 55], ["\u03b3 phosphates", "SIMPLE_CHEMICAL", 61, 73], ["Ser 494", "AMINO_ACID", 94, 101], ["Met 507", "AMINO_ACID", 104, 111], ["Ala 648", "AMINO_ACID", 114, 121], ["Gly 275", "AMINO_ACID", 124, 131], ["Asn 276", "AMINO_ACID", 134, 141], ["Asn 536", "AMINO_ACID", 148, 155], ["\u03b1, \u03b2, and \u03b3 phosphates", "PROTEIN", 51, 73], ["PB1", "PROTEIN", 159, 162], ["the cytidine and ribose sugar", "TEST", 10, 39], ["Ala", "TEST", 114, 117], ["Gly", "TEST", 124, 127], ["Asn", "TEST", 134, 137], ["Asn", "TEST", 148, 151], ["priming loop forming", "PROBLEM", 175, 195], ["circular fold", "OBSERVATION_MODIFIER", 211, 224]]], ["This shows that compound 5 binds with a greater number of contacts than compound 4 in the same binding site influencing both PB1 priming loop and PB2 linker domain involved in RNA catalysis (Fig. 2e) .Stage-I: In the presence of influenza-A vRNAAlong with the above, compound 6 also binds to the same binding site that was identified previously with compounds 4 and 5 with one end of adenosine moiety shows Pi stack with Gly 275 and the adenosine at the other end orients towards the PB2 627 linker domain without showing any contacts with IAV RdRp.", [["adenosine", "CHEMICAL", 384, 393], ["Pi", "CHEMICAL", 407, 409], ["Gly 275", "CHEMICAL", 421, 428], ["adenosine", "CHEMICAL", 437, 446], ["adenosine", "CHEMICAL", 384, 393], ["Gly", "CHEMICAL", 421, 424], ["adenosine", "CHEMICAL", 437, 446], ["adenosine moiety", "SIMPLE_CHEMICAL", 384, 400], ["Pi", "SIMPLE_CHEMICAL", 407, 409], ["Gly 275", "AMINO_ACID", 421, 428], ["adenosine", "SIMPLE_CHEMICAL", 437, 446], ["IAV RdRp", "ORGANISM", 540, 548], ["PB1 priming loop", "PROTEIN", 125, 141], ["PB2 linker domain", "PROTEIN", 146, 163], ["PB2 627 linker domain", "PROTEIN", 484, 505], ["IAV RdRp", "PROTEIN", 540, 548], ["compound 5 binds", "PROBLEM", 16, 32], ["PB1 priming loop", "TREATMENT", 125, 141], ["PB2 linker domain", "PROBLEM", 146, 163], ["RNA catalysis", "TREATMENT", 176, 189], ["influenza", "PROBLEM", 229, 238], ["adenosine moiety", "TREATMENT", 384, 400], ["the adenosine", "TREATMENT", 433, 446], ["IAV RdRp", "TREATMENT", 540, 548], ["compound", "OBSERVATION_MODIFIER", 16, 24], ["5 binds", "OBSERVATION_MODIFIER", 25, 32], ["greater", "OBSERVATION_MODIFIER", 40, 47], ["number", "OBSERVATION_MODIFIER", 48, 54], ["RNA catalysis", "OBSERVATION", 176, 189], ["influenza", "OBSERVATION", 229, 238], ["without showing", "UNCERTAINTY", 506, 521], ["IAV RdRp", "OBSERVATION", 540, 548]]], ["The terminal oxygens of both the \u03b1 and \u03b3 phosphates show interactions with Lys 279 and Ala 503 of PB1 central domain and Thr 238 of PB2-N-terminal domain keeping both the domains intact.", [["Lys 279", "CHEMICAL", 75, 82], ["Ala 503", "CHEMICAL", 87, 94], ["oxygens", "CHEMICAL", 13, 20], ["phosphates", "CHEMICAL", 41, 51], ["Lys", "CHEMICAL", 75, 78], ["Ala", "CHEMICAL", 87, 90], ["Thr", "CHEMICAL", 121, 124], ["N", "CHEMICAL", 136, 137], ["\u03b3 phosphates", "SIMPLE_CHEMICAL", 39, 51], ["Lys 279", "AMINO_ACID", 75, 82], ["Ala 503", "AMINO_ACID", 87, 94], ["Thr 238", "AMINO_ACID", 121, 128], ["PB1 central domain", "PROTEIN", 98, 116], ["Thr 238", "PROTEIN", 121, 128], ["PB2-N-terminal domain", "PROTEIN", 132, 153], ["the \u03b1 and \u03b3 phosphates", "TEST", 29, 51], ["Lys", "TEST", 75, 78], ["Ala", "TEST", 87, 90], ["PB1 central domain", "TEST", 98, 116], ["Thr", "TEST", 121, 124], ["PB2", "TEST", 132, 135], ["terminal domain", "TREATMENT", 138, 153], ["terminal", "OBSERVATION_MODIFIER", 4, 12], ["oxygens", "OBSERVATION_MODIFIER", 13, 20], ["domains", "OBSERVATION_MODIFIER", 171, 178], ["intact", "OBSERVATION", 179, 185]]], ["On the other hand, the ribose sugars of both the sides also show contacts with Asn 276 , Asn 536 , and Phe 501 of PB1 central domain through carbon, and oxygen atoms (Fig. 2f) .", [["ribose", "CHEMICAL", 23, 29], ["Asn 276", "CHEMICAL", 79, 86], ["Asn 536", "CHEMICAL", 89, 96], ["Phe", "CHEMICAL", 103, 106], ["oxygen", "CHEMICAL", 153, 159], ["ribose sugars", "CHEMICAL", 23, 36], ["Asn", "CHEMICAL", 79, 82], ["Asn", "CHEMICAL", 89, 92], ["Phe", "CHEMICAL", 103, 106], ["carbon", "CHEMICAL", 141, 147], ["oxygen", "CHEMICAL", 153, 159], ["ribose", "SIMPLE_CHEMICAL", 23, 29], ["Asn 276", "AMINO_ACID", 79, 86], ["Asn 536", "AMINO_ACID", 89, 96], ["Phe", "AMINO_ACID", 103, 106], ["carbon", "SIMPLE_CHEMICAL", 141, 147], ["oxygen atoms", "SIMPLE_CHEMICAL", 153, 165], ["PB1 central domain", "PROTEIN", 114, 132], ["the ribose sugars", "TEST", 19, 36], ["PB1 central domain through carbon", "TREATMENT", 114, 147], ["oxygen atoms", "TREATMENT", 153, 165]]], ["However, the benzyl ring of compound 7 shows H-Pi stacking with Met 507 with sulfonyl oxygen interacting with Phe 495 of the PB1 central domain.", [["benzyl", "CHEMICAL", 13, 19], ["H-Pi", "CHEMICAL", 45, 49], ["Met 507", "CHEMICAL", 64, 71], ["sulfonyl oxygen", "CHEMICAL", 77, 92], ["Phe 495", "CHEMICAL", 110, 117], ["benzyl", "CHEMICAL", 13, 19], ["Met 507", "CHEMICAL", 64, 71], ["sulfonyl oxygen", "CHEMICAL", 77, 92], ["Phe", "CHEMICAL", 110, 113], ["benzyl ring", "SIMPLE_CHEMICAL", 13, 24], ["compound 7", "SIMPLE_CHEMICAL", 28, 38], ["H-Pi", "SIMPLE_CHEMICAL", 45, 49], ["Met 507", "SIMPLE_CHEMICAL", 64, 71], ["sulfonyl oxygen", "SIMPLE_CHEMICAL", 77, 92], ["Phe 495", "AMINO_ACID", 110, 117], ["PB1 central domain", "PROTEIN", 125, 143], ["H-Pi stacking", "PROBLEM", 45, 58], ["sulfonyl oxygen", "TREATMENT", 77, 92], ["the PB1 central domain", "TREATMENT", 121, 143]]], ["Also, the ribose sugar interacts with Lys 279 and Val 502 of PB1 central domain through 2\u2032 oxygen and carbon.", [["ribose", "CHEMICAL", 10, 16], ["Lys 279", "CHEMICAL", 38, 45], ["Val 502", "CHEMICAL", 50, 57], ["oxygen", "CHEMICAL", 91, 97], ["carbon", "CHEMICAL", 102, 108], ["ribose sugar", "CHEMICAL", 10, 22], ["Lys", "CHEMICAL", 38, 41], ["Val", "CHEMICAL", 50, 53], ["oxygen", "CHEMICAL", 91, 97], ["carbon", "CHEMICAL", 102, 108], ["ribose sugar", "SIMPLE_CHEMICAL", 10, 22], ["Lys 279", "AMINO_ACID", 38, 45], ["Val 502", "AMINO_ACID", 50, 57], ["2\u2032 oxygen", "SIMPLE_CHEMICAL", 88, 97], ["carbon", "SIMPLE_CHEMICAL", 102, 108], ["PB1 central domain", "PROTEIN", 61, 79], ["PB1 central domain", "TREATMENT", 61, 79], ["2\u2032 oxygen", "TREATMENT", 88, 97], ["carbon", "TREATMENT", 102, 108]]], ["In addition, the 5\u2032-dimethoxytrityl group also contacts with Val 502 through phenyl carbon.", [["5\u2032-dimethoxytrityl", "CHEMICAL", 17, 35], ["Val 502", "CHEMICAL", 61, 68], ["phenyl carbon", "CHEMICAL", 77, 90], ["5\u2032-dimethoxytrityl", "CHEMICAL", 17, 35], ["Val 502", "CHEMICAL", 61, 68], ["phenyl carbon", "CHEMICAL", 77, 90], ["5\u2032-dimethoxytrityl", "SIMPLE_CHEMICAL", 17, 35], ["Val 502", "SIMPLE_CHEMICAL", 61, 68], ["phenyl carbon", "SIMPLE_CHEMICAL", 77, 90], ["phenyl carbon", "TREATMENT", 77, 90]]], ["In comparison, the adenosine ring forms H-Pi interactions with Asn 137 of PB2 near the entry channel.", [["adenosine", "CHEMICAL", 19, 28], ["H-Pi", "CHEMICAL", 40, 44], ["Asn 137", "CHEMICAL", 63, 70], ["adenosine", "CHEMICAL", 19, 28], ["H-Pi", "CHEMICAL", 40, 44], ["Asn", "CHEMICAL", 63, 66], ["adenosine ring", "SIMPLE_CHEMICAL", 19, 33], ["H-Pi", "SIMPLE_CHEMICAL", 40, 44], ["Asn 137", "AMINO_ACID", 63, 70], ["PB2", "PROTEIN", 74, 77], ["entry channel", "PROTEIN", 87, 100], ["the adenosine ring", "TREATMENT", 15, 33], ["entry channel", "OBSERVATION", 87, 100]]], ["In addition, the adenosine and ribose rings also to show contacts with Asp 671 and Gly 669 of PB2 linker domain through backbone and methyl carbons.", [["adenosine", "CHEMICAL", 17, 26], ["ribose", "CHEMICAL", 31, 37], ["Asp 671", "CHEMICAL", 71, 78], ["Gly 669", "CHEMICAL", 83, 90], ["methyl carbons", "CHEMICAL", 133, 147], ["adenosine", "CHEMICAL", 17, 26], ["ribose", "CHEMICAL", 31, 37], ["Asp", "CHEMICAL", 71, 74], ["Gly", "CHEMICAL", 83, 86], ["methyl carbons", "CHEMICAL", 133, 147], ["adenosine", "SIMPLE_CHEMICAL", 17, 26], ["ribose rings", "SIMPLE_CHEMICAL", 31, 43], ["Asp 671", "AMINO_ACID", 71, 78], ["Gly 669", "AMINO_ACID", 83, 90], ["methyl carbons", "SIMPLE_CHEMICAL", 133, 147], ["PB2 linker domain", "PROTEIN", 94, 111], ["the adenosine and ribose rings", "TREATMENT", 13, 43], ["Asp", "TEST", 71, 74], ["PB2 linker domain", "TREATMENT", 94, 111], ["backbone and methyl carbons", "TREATMENT", 120, 147], ["ribose rings", "OBSERVATION", 31, 43], ["methyl carbons", "OBSERVATION", 133, 147]]], ["Moreover, the attached \u03b1 and \u03b3 triphosphates also orient towards the linker domain showing contacts with Gly 500 of PB1 central domain and Lys 670 of PB2 627 linker through terminal oxygens (Fig. 2g) .", [["\u03b1 and \u03b3 triphosphates", "CHEMICAL", 23, 44], ["Lys 670 of PB2 627", "CHEMICAL", 139, 157], ["\u03b1 and \u03b3 triphosphates", "CHEMICAL", 23, 44], ["Gly", "CHEMICAL", 105, 108], ["Lys", "CHEMICAL", 139, 142], ["oxygens", "CHEMICAL", 182, 189], ["\u03b3 triphosphates", "SIMPLE_CHEMICAL", 29, 44], ["Lys 670", "AMINO_ACID", 139, 146], ["PB2 627 linker", "AMINO_ACID", 150, 164], ["terminal oxygens", "SIMPLE_CHEMICAL", 173, 189], ["linker domain", "PROTEIN", 69, 82], ["PB1 central domain", "PROTEIN", 116, 134], ["Lys 670", "PROTEIN", 139, 146], ["PB2 627 linker", "PROTEIN", 150, 164], ["the attached \u03b1 and \u03b3 triphosphates", "TREATMENT", 10, 44], ["PB1 central domain", "TREATMENT", 116, 134], ["Lys", "TREATMENT", 139, 142], ["PB2 627 linker through terminal oxygens", "TREATMENT", 150, 189], ["terminal", "OBSERVATION_MODIFIER", 173, 181], ["oxygens", "OBSERVATION_MODIFIER", 182, 189]]], ["However, both the anthraniloyl rings of compound 8 in 2\u2032 and 3\u2032 shows contacts with Val 502 Arg 142 both PB1 and PB2 domains through terminal chlorine.", [["anthraniloyl", "CHEMICAL", 18, 30], ["Val 502 Arg 142", "CHEMICAL", 84, 99], ["chlorine", "CHEMICAL", 142, 150], ["anthraniloyl", "CHEMICAL", 18, 30], ["Val", "CHEMICAL", 84, 87], ["Arg", "CHEMICAL", 92, 95], ["chlorine", "CHEMICAL", 142, 150], ["2\u2032", "SIMPLE_CHEMICAL", 54, 56], ["3\u2032", "SIMPLE_CHEMICAL", 61, 63], ["Val 502", "SIMPLE_CHEMICAL", 84, 91], ["Arg 142", "AMINO_ACID", 92, 99], ["terminal chlorine", "SIMPLE_CHEMICAL", 133, 150], ["PB1", "PROTEIN", 105, 108], ["PB2 domains", "PROTEIN", 113, 124], ["terminal chlorine", "TREATMENT", 133, 150], ["terminal chlorine", "OBSERVATION", 133, 150]]], ["Other than these contacts, oxo group of 2\u2032 ribose sugars also interact with Thr 238 of PB2 through a backbone carbon (Fig. 2h) .Stage-I: In the presence of influenza-A vRNAWhen compound 6 is replaced with guanosyl moiety limiting the number of phosphates to four allowing the compound 9 to occupy both the tunnels with a priming loop in between.", [["oxo group of 2\u2032 ribose", "CHEMICAL", 27, 49], ["Thr 238", "CHEMICAL", 76, 83], ["influenza", "DISEASE", 156, 165], ["phosphates", "CHEMICAL", 244, 254], ["oxo", "CHEMICAL", 27, 30], ["2\u2032 ribose sugars", "CHEMICAL", 40, 56], ["Thr", "CHEMICAL", 76, 79], ["carbon", "CHEMICAL", 110, 116], ["guanosyl", "CHEMICAL", 205, 213], ["phosphates", "CHEMICAL", 244, 254], ["oxo", "SIMPLE_CHEMICAL", 27, 30], ["2\u2032 ribose sugars", "SIMPLE_CHEMICAL", 40, 56], ["Thr 238", "AMINO_ACID", 76, 83], ["guanosyl moiety", "SIMPLE_CHEMICAL", 205, 220], ["phosphates", "SIMPLE_CHEMICAL", 244, 254], ["oxo group of 2\u2032 ribose sugars", "TREATMENT", 27, 56], ["Thr", "TREATMENT", 76, 79], ["PB2", "TREATMENT", 87, 90], ["a backbone carbon", "TREATMENT", 99, 116], ["influenza", "PROBLEM", 156, 165], ["A vRNAWhen compound", "TREATMENT", 166, 185], ["guanosyl moiety", "TREATMENT", 205, 220], ["phosphates", "TREATMENT", 244, 254], ["a priming loop", "TREATMENT", 319, 333], ["influenza", "OBSERVATION", 156, 165], ["tunnels", "OBSERVATION", 306, 313], ["priming loop", "OBSERVATION", 321, 333]]], ["The 5\u2032 adenosyl group is placed in tunnel 1 orienting towards the C-terminal domain of PB2 interacting with Asn 42 , Ala 44 , and Leu 45 while 5\u2032 guanosyl placed in tunnel 2 shows contacts with Ser 494 near to the exit channel.", [["Asn 42 , Ala 44 , and Leu", "CHEMICAL", 108, 133], ["5\u2032 guanosyl", "CHEMICAL", 143, 154], ["5\u2032 adenosyl", "CHEMICAL", 4, 15], ["C", "CHEMICAL", 66, 67], ["Asn", "CHEMICAL", 108, 111], ["Ala", "CHEMICAL", 117, 120], ["Leu", "CHEMICAL", 130, 133], ["5\u2032 guanosyl", "CHEMICAL", 143, 154], ["Ser", "CHEMICAL", 194, 197], ["5\u2032 adenosyl", "SIMPLE_CHEMICAL", 4, 15], ["PB2", "GENE_OR_GENE_PRODUCT", 87, 90], ["Asn 42", "AMINO_ACID", 108, 114], ["Ala 44", "AMINO_ACID", 117, 123], ["Leu 45", "AMINO_ACID", 130, 136], ["5\u2032 guanosyl", "SIMPLE_CHEMICAL", 143, 154], ["Ser 494", "AMINO_ACID", 194, 201], ["C-terminal domain", "PROTEIN", 66, 83], ["PB2", "PROTEIN", 87, 90], ["Ser 494", "PROTEIN", 194, 201], ["exit channel", "PROTEIN", 214, 226], ["The 5\u2032 adenosyl group", "TREATMENT", 0, 21], ["tunnel", "TREATMENT", 35, 41], ["Asn", "TEST", 108, 111], ["Ala", "TEST", 117, 120], ["Leu", "TEST", 130, 133], ["exit channel", "OBSERVATION", 214, 226]]], ["In addition, the \u03b1 and \u03b2 phosphates also contact with Ala 648 of the priming loop through terminal oxygens (Fig. 2i ).", [["\u03b1 and \u03b2 phosphates", "CHEMICAL", 17, 35], ["Ala 648", "CHEMICAL", 54, 61], ["phosphates", "CHEMICAL", 25, 35], ["Ala", "CHEMICAL", 54, 57], ["oxygens", "CHEMICAL", 99, 106], ["\u03b1", "GENE_OR_GENE_PRODUCT", 17, 18], ["\u03b2 phosphates", "SIMPLE_CHEMICAL", 23, 35], ["Ala 648", "AMINO_ACID", 54, 61], ["Ala", "TREATMENT", 54, 57], ["the priming loop through terminal oxygens", "TREATMENT", 65, 106], ["terminal", "OBSERVATION_MODIFIER", 90, 98], ["oxygens", "OBSERVATION_MODIFIER", 99, 106]]], ["The propionamide-N-allyl of compound 10 shows interactions with Arg 233 , Met 507 , and Met 646 of the PB1 priming loop through oxo, nitro, and carbon atoms, leaving the indole ring to move freely in the catalytic site of IAV RdRp.", [["propionamide-N-allyl", "CHEMICAL", 4, 24], ["Arg 233", "CHEMICAL", 64, 71], ["Met 507", "CHEMICAL", 74, 81], ["Met 646", "CHEMICAL", 88, 95], ["oxo, nitro, and carbon atoms", "CHEMICAL", 128, 156], ["indole", "CHEMICAL", 170, 176], ["propionamide-N-allyl", "CHEMICAL", 4, 24], ["Arg", "CHEMICAL", 64, 67], ["Met", "CHEMICAL", 74, 77], ["Met", "CHEMICAL", 88, 91], ["oxo", "CHEMICAL", 128, 131], ["nitro", "CHEMICAL", 133, 138], ["carbon", "CHEMICAL", 144, 150], ["indole", "CHEMICAL", 170, 176], ["propionamide-N-allyl", "SIMPLE_CHEMICAL", 4, 24], ["compound 10", "SIMPLE_CHEMICAL", 28, 39], ["Arg 233", "SIMPLE_CHEMICAL", 64, 71], ["Met", "AMINO_ACID", 74, 77], ["507", "AMINO_ACID", 78, 81], ["Met", "AMINO_ACID", 88, 91], ["646", "AMINO_ACID", 92, 95], ["oxo", "SIMPLE_CHEMICAL", 128, 131], ["nitro", "SIMPLE_CHEMICAL", 133, 138], ["carbon atoms", "SIMPLE_CHEMICAL", 144, 156], ["IAV RdRp", "ORGANISM", 222, 230], ["PB1", "PROTEIN", 103, 106], ["catalytic site", "PROTEIN", 204, 218], ["IAV RdRp", "PROTEIN", 222, 230], ["The propionamide-N-allyl of compound", "TREATMENT", 0, 36], ["the PB1 priming loop through oxo", "TREATMENT", 99, 131], ["nitro", "TREATMENT", 133, 138], ["carbon atoms", "TREATMENT", 144, 156], ["the indole ring", "TREATMENT", 166, 181], ["IAV RdRp", "TREATMENT", 222, 230], ["indole ring", "OBSERVATION", 170, 181], ["IAV RdRp", "OBSERVATION", 222, 230]]], ["Both the ribose sugar and \u03b1, \u03b2, and \u03b3 phosphates in tunnel 2 interacts with Gly 275 and Phe 495 , Lys 279 , Ala 503 , Asn 537 , and Phe 501 of PB1 through 3\u2032 and terminal oxygens ( (Fig. 2k) .Stage-I: In the presence of influenza-A vRNAThe bind modes of compounds 1-3 show that cyanine moiety is placed below the priming loop perpendicular to the tunnel 1 with the rest of the chain appears in parallel to the tunnel 2 almost showing a V-shape.", [["ribose", "CHEMICAL", 9, 15], ["\u03b1, \u03b2, and \u03b3 phosphates", "CHEMICAL", 26, 48], ["Gly 275", "CHEMICAL", 76, 83], ["Phe", "CHEMICAL", 88, 91], ["Lys 279", "CHEMICAL", 98, 105], ["Ala 503 , Asn 537", "CHEMICAL", 108, 125], ["Phe", "CHEMICAL", 132, 135], ["influenza", "DISEASE", 220, 229], ["cyanine", "CHEMICAL", 278, 285], ["ribose sugar", "CHEMICAL", 9, 21], ["\u03b1, \u03b2, and \u03b3 phosphates", "CHEMICAL", 26, 48], ["Gly", "CHEMICAL", 76, 79], ["Phe", "CHEMICAL", 88, 91], ["Lys", "CHEMICAL", 98, 101], ["Ala", "CHEMICAL", 108, 111], ["Asn", "CHEMICAL", 118, 121], ["Phe", "CHEMICAL", 132, 135], ["oxygens", "CHEMICAL", 171, 178], ["cyanine", "CHEMICAL", 278, 285], ["ribose sugar", "SIMPLE_CHEMICAL", 9, 21], ["\u03b1, \u03b2", "SIMPLE_CHEMICAL", 26, 30], ["\u03b3 phosphates", "SIMPLE_CHEMICAL", 36, 48], ["Gly 275", "AMINO_ACID", 76, 83], ["Phe 495", "AMINO_ACID", 88, 95], ["Lys 279", "AMINO_ACID", 98, 105], ["Ala 503", "AMINO_ACID", 108, 115], ["Asn 537", "AMINO_ACID", 118, 125], ["Phe 501", "AMINO_ACID", 132, 139], ["terminal oxygens", "SIMPLE_CHEMICAL", 162, 178], ["cyanine moiety", "SIMPLE_CHEMICAL", 278, 292], ["the ribose sugar", "TEST", 5, 21], ["Gly", "TEST", 76, 79], ["Phe", "TEST", 88, 91], ["Lys", "TEST", 98, 101], ["Ala", "TEST", 108, 111], ["Asn", "TEST", 118, 121], ["Phe", "TEST", 132, 135], ["PB1", "TEST", 143, 146], ["terminal oxygens", "TREATMENT", 162, 178], ["influenza", "PROBLEM", 220, 229], ["cyanine moiety", "TREATMENT", 278, 292], ["terminal", "OBSERVATION_MODIFIER", 162, 170], ["oxygens", "OBSERVATION_MODIFIER", 171, 178], ["influenza", "OBSERVATION", 220, 229], ["tunnel", "OBSERVATION", 410, 416], ["shape", "OBSERVATION_MODIFIER", 438, 443]]], ["This reveals that compounds 1 and 3 with cytidine moiety are more effective in binding to IAV RdRp than compound with uridine moiety.", [["cytidine", "CHEMICAL", 41, 49], ["uridine", "CHEMICAL", 118, 125], ["cytidine", "CHEMICAL", 41, 49], ["uridine", "CHEMICAL", 118, 125], ["3", "GENE_OR_GENE_PRODUCT", 34, 35], ["cytidine moiety", "SIMPLE_CHEMICAL", 41, 56], ["IAV RdRp", "ORGANISM", 90, 98], ["uridine moiety", "SIMPLE_CHEMICAL", 118, 132], ["IAV RdRp", "PROTEIN", 90, 98], ["cytidine moiety", "TREATMENT", 41, 56], ["IAV RdRp", "TREATMENT", 90, 98], ["uridine moiety", "TREATMENT", 118, 132], ["IAV RdRp", "OBSERVATION", 90, 98]]], ["These compounds follow the order in binding to IAV RdRp, compound 1 > compound 3 > compound 2.", [["IAV", "ORGANISM", 47, 50], ["compound 3", "SIMPLE_CHEMICAL", 70, 80], ["compound 2", "SIMPLE_CHEMICAL", 83, 93], ["IAV RdRp", "PROBLEM", 47, 55]]], ["In comparison, the binding orientation of compounds 4-6, 9, and compounds 10-11 shows linearity in the catalytic site interacting with PB1 priming loop.", [["compounds 4-6, 9, and compounds 10-11", "CHEMICAL", 42, 79], ["4-6", "SIMPLE_CHEMICAL", 52, 55], ["catalytic site", "PROTEIN", 103, 117], ["PB1", "PROTEIN", 135, 138], ["the binding orientation of compounds", "TEST", 15, 51], ["PB1 priming loop", "TREATMENT", 135, 151], ["loop", "OBSERVATION_MODIFIER", 147, 151]]], ["In case of compounds 4 and 5, both occupy tunnel 2 with biotin orienting towards the exit channel.", [["biotin", "CHEMICAL", 56, 62], ["biotin", "CHEMICAL", 56, 62], ["biotin", "SIMPLE_CHEMICAL", 56, 62], ["tunnel", "OBSERVATION", 42, 48]]], ["However, compound 4 is close to the PB2 linker domain while the same moiety stays nearer to PB1 priming loop.", [["PB2 linker domain", "PROTEIN", 36, 53], ["PB1", "PROTEIN", 92, 95], ["the PB2 linker domain", "TREATMENT", 32, 53], ["PB1 priming loop", "TREATMENT", 92, 108], ["loop", "OBSERVATION_MODIFIER", 104, 108]]], ["Surprisingly, compound 6 with Penta phosphate completely occupies tunnel 2 with respect to compound 9 having tetra phosphate which occupies tunnel 2 partially.", [["Penta phosphate", "CHEMICAL", 30, 45], ["compound 9", "CHEMICAL", 91, 101], ["tetra phosphate", "CHEMICAL", 109, 124], ["Penta phosphate", "CHEMICAL", 30, 45], ["tetra phosphate", "CHEMICAL", 109, 124], ["Penta phosphate", "SIMPLE_CHEMICAL", 30, 45], ["tetra phosphate", "SIMPLE_CHEMICAL", 109, 124], ["Penta phosphate", "TREATMENT", 30, 45], ["tetra phosphate", "TREATMENT", 109, 124], ["tunnel", "OBSERVATION", 66, 72], ["tunnel", "OBSERVATION", 140, 146]]], ["This may be due to the presence of guanosyl at one end in compound 10 instead of adenosyl at both the ends in compound 6.", [["guanosyl", "CHEMICAL", 35, 43], ["adenosyl", "CHEMICAL", 81, 89], ["guanosyl", "CHEMICAL", 35, 43], ["adenosyl", "CHEMICAL", 81, 89], ["guanosyl", "SIMPLE_CHEMICAL", 35, 43], ["adenosyl", "SIMPLE_CHEMICAL", 81, 89], ["guanosyl", "TREATMENT", 35, 43], ["adenosyl", "TREATMENT", 81, 89], ["may be due to", "UNCERTAINTY", 5, 18]]], ["Furthermore, comparison of compounds 10 and 11 clearly indicates that 2\u2032-deoxyuridine-5\u2032triphosphate of both these compounds in tunnel 2 are placed quite opposite to each other with 5-[(3-Indolyl) propionamide-N-allyl] of compound 10 is placed close to PB1 3a) .", [["2\u2032-deoxyuridine-5\u2032triphosphate", "CHEMICAL", 70, 100], ["5-[(3-Indolyl) propionamide-N-allyl", "CHEMICAL", 182, 217], ["2\u2032-deoxyuridine-5\u2032triphosphate", "CHEMICAL", 70, 100], ["5-[(3-Indolyl) propionamide-N-allyl]", "CHEMICAL", 182, 218], ["2\u2032-deoxyuridine-5\u2032triphosphate", "SIMPLE_CHEMICAL", 70, 100], ["5-[(3-Indolyl) propionamide-N-allyl", "SIMPLE_CHEMICAL", 182, 217], ["deoxyuridine", "TREATMENT", 73, 85], ["5\u2032triphosphate", "TREATMENT", 86, 100], ["tunnel 2", "TREATMENT", 128, 136], ["Indolyl) propionamide-N-allyl] of compound", "TREATMENT", 188, 230]]], ["Due to its bigger size, compound 2 occupies more space in the tunnel 2 just above the priming loop of PB1.", [["PB1", "GENE_OR_GENE_PRODUCT", 102, 105], ["PB1", "PROTEIN", 102, 105], ["the priming loop of PB1", "TREATMENT", 82, 105], ["bigger", "OBSERVATION_MODIFIER", 11, 17], ["size", "OBSERVATION_MODIFIER", 18, 22], ["compound", "OBSERVATION_MODIFIER", 24, 32], ["occupies", "OBSERVATION_MODIFIER", 35, 43], ["more", "OBSERVATION_MODIFIER", 44, 48], ["space", "OBSERVATION_MODIFIER", 49, 54], ["tunnel", "OBSERVATION", 62, 68], ["PB1", "ANATOMY", 102, 105]]], ["The oxygen atoms of uridine and ribose sugar shows contact with Phe 501 and Asn 536 of PB1 and Lys 140 of PB2 at the end of the tunnel 2.", [["oxygen", "CHEMICAL", 4, 10], ["uridine", "CHEMICAL", 20, 27], ["ribose", "CHEMICAL", 32, 38], ["Phe", "CHEMICAL", 64, 67], ["Asn 536", "CHEMICAL", 76, 83], ["Lys 140", "CHEMICAL", 95, 102], ["oxygen", "CHEMICAL", 4, 10], ["uridine", "CHEMICAL", 20, 27], ["ribose sugar", "CHEMICAL", 32, 44], ["Phe", "CHEMICAL", 64, 67], ["Asn", "CHEMICAL", 76, 79], ["Lys", "CHEMICAL", 95, 98], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["uridine", "SIMPLE_CHEMICAL", 20, 27], ["ribose sugar", "SIMPLE_CHEMICAL", 32, 44], ["Phe 501", "AMINO_ACID", 64, 71], ["Asn 536", "AMINO_ACID", 76, 83], ["Lys 140", "AMINO_ACID", 95, 102], ["The oxygen atoms of uridine", "TREATMENT", 0, 27], ["ribose sugar", "TEST", 32, 44], ["PB1", "TREATMENT", 87, 90], ["Lys", "TREATMENT", 95, 98], ["PB2", "TREATMENT", 106, 109], ["oxygen atoms", "OBSERVATION", 4, 16], ["tunnel", "OBSERVATION", 128, 134]]], ["In addition, the 7-Allyl group also shows contact with Asn 536 and Asn 276 of PB1 catalytic site above the priming loop.", [["Asn 536", "CHEMICAL", 55, 62], ["Asn 276", "CHEMICAL", 67, 74], ["7-Allyl", "CHEMICAL", 17, 24], ["Asn", "CHEMICAL", 55, 58], ["Asn", "CHEMICAL", 67, 70], ["7-Allyl", "SIMPLE_CHEMICAL", 17, 24], ["Asn 536", "AMINO_ACID", 55, 62], ["Asn 276", "AMINO_ACID", 67, 74], ["PB1 catalytic site", "PROTEIN", 78, 96], ["PB1 catalytic site", "TREATMENT", 78, 96], ["priming loop", "OBSERVATION", 107, 119]]], ["However, triphosphate orients towards the exit channel and makes contact with the positive changed lys 140 of PB2-N and Lys 670 of PB2 627 domains.", [["triphosphate", "CHEMICAL", 9, 21], ["triphosphate", "CHEMICAL", 9, 21], ["N", "CHEMICAL", 114, 115], ["Lys", "CHEMICAL", 120, 123], ["triphosphate", "SIMPLE_CHEMICAL", 9, 21], ["PB2", "PROTEIN", 110, 113], ["Lys 670", "PROTEIN", 120, 127], ["PB2 627 domains", "PROTEIN", 131, 146], ["PB2", "TEST", 110, 113], ["Lys", "TEST", 120, 123], ["PB2", "TEST", 131, 134]]], ["Both the sulfonyl groups attached to 1H-indole ring contacts with Ser 494 of PB1 central, Ala 648 and His 649 of PB1 priming loop and Arg 216 of PB2-N laying almost in parallel to the priming loop (Fig. 3b) .", [["sulfonyl", "CHEMICAL", 9, 17], ["1H-indole", "CHEMICAL", 37, 46], ["Ser 494", "CHEMICAL", 66, 73], ["Ala 648", "CHEMICAL", 90, 97], ["Arg 216", "CHEMICAL", 134, 141], ["sulfonyl", "CHEMICAL", 9, 17], ["1H", "CHEMICAL", 37, 39], ["indole", "CHEMICAL", 40, 46], ["Ser", "CHEMICAL", 66, 69], ["Ala", "CHEMICAL", 90, 93], ["His", "CHEMICAL", 102, 105], ["Arg", "CHEMICAL", 134, 137], ["sulfonyl", "SIMPLE_CHEMICAL", 9, 17], ["1H-indole", "SIMPLE_CHEMICAL", 37, 46], ["Ser 494", "AMINO_ACID", 66, 73], ["PB1", "AMINO_ACID", 77, 80], ["Ala 648", "AMINO_ACID", 90, 97], ["Arg 216", "AMINO_ACID", 134, 141], ["PB1", "PROTEIN", 113, 116], ["PB2", "PROTEIN", 145, 148], ["Ala", "TEST", 90, 93], ["PB1 priming loop", "TREATMENT", 113, 129], ["Arg", "TEST", 134, 137], ["PB2", "TEST", 145, 148]]], ["The cyanine group of compound 3 also lies in almost parallel to the priming loop of PB1 with a sulfonyl group attached at the two ends of the indole interacts with Met 507 and Asn 536 of PB1 central and Ala 648 of the PB1 priming loop.", [["cyanine", "CHEMICAL", 4, 11], ["sulfonyl", "CHEMICAL", 95, 103], ["indole", "CHEMICAL", 142, 148], ["Met 507", "CHEMICAL", 164, 171], ["Asn 536", "CHEMICAL", 176, 183], ["Ala 648", "CHEMICAL", 203, 210], ["cyanine", "CHEMICAL", 4, 11], ["sulfonyl", "CHEMICAL", 95, 103], ["indole", "CHEMICAL", 142, 148], ["Met", "CHEMICAL", 164, 167], ["Asn", "CHEMICAL", 176, 179], ["Ala", "CHEMICAL", 203, 206], ["cyanine", "SIMPLE_CHEMICAL", 4, 11], ["compound 3", "SIMPLE_CHEMICAL", 21, 31], ["indole", "SIMPLE_CHEMICAL", 142, 148], ["Met 507", "SIMPLE_CHEMICAL", 164, 171], ["Asn 536", "AMINO_ACID", 176, 183], ["PB1", "AMINO_ACID", 187, 190], ["Ala 648", "AMINO_ACID", 203, 210], ["PB1", "PROTEIN", 84, 87], ["Met 507", "PROTEIN", 164, 171], ["PB1", "PROTEIN", 187, 190], ["PB1 priming loop", "PROTEIN", 218, 234], ["a sulfonyl group", "TREATMENT", 93, 109], ["Ala", "TEST", 203, 206], ["the PB1 priming loop", "TREATMENT", 214, 234], ["indole interacts", "OBSERVATION", 142, 158]]], ["The 5-5-propargylamino and 2\u2032-deoxycytidine interacts with Asn 536 and Phe 496 while the terminal phosphates interaction with Lys 279 , Val 502 , and Val 503 of PB1 central domain at the end of the tunnel 2 (Fig. 3c) .", [["5-5-propargylamino and 2\u2032-deoxycytidine", "CHEMICAL", 4, 43], ["Asn 536", "CHEMICAL", 59, 66], ["Phe 496", "CHEMICAL", 71, 78], ["Lys 279", "CHEMICAL", 126, 133], ["5-5-propargylamino", "CHEMICAL", 4, 22], ["2\u2032-deoxycytidine", "CHEMICAL", 27, 43], ["Asn", "CHEMICAL", 59, 62], ["Phe", "CHEMICAL", 71, 74], ["phosphates", "CHEMICAL", 98, 108], ["Lys", "CHEMICAL", 126, 129], ["Val", "CHEMICAL", 136, 139], ["Val", "CHEMICAL", 150, 153], ["5-5-propargylamino", "SIMPLE_CHEMICAL", 4, 22], ["2\u2032-deoxycytidine", "SIMPLE_CHEMICAL", 27, 43], ["Asn 536", "AMINO_ACID", 59, 66], ["Phe 496", "AMINO_ACID", 71, 78], ["Lys 279", "AMINO_ACID", 126, 133], ["PB1 central domain", "PROTEIN", 161, 179], ["propargylamino", "TREATMENT", 8, 22], ["Phe", "TEST", 71, 74], ["Lys", "TEST", 126, 129], ["PB1 central domain", "TREATMENT", 161, 179], ["the tunnel", "TREATMENT", 194, 204]]], ["The \u03b3-phosphate of compound 4 penetrates deeper at the end of the tunnel 2 showing contacts with Asn 16 and Ser 594 of both PB1 central and PA-C through terminal oxygens.", [["\u03b3-phosphate of compound 4", "CHEMICAL", 4, 29], ["Asn 16 and Ser 594", "CHEMICAL", 97, 115], ["\u03b3-phosphate", "CHEMICAL", 4, 15], ["Asn", "CHEMICAL", 97, 100], ["Ser", "CHEMICAL", 108, 111], ["oxygens", "CHEMICAL", 162, 169], ["\u03b3-phosphate", "SIMPLE_CHEMICAL", 4, 15], ["compound 4", "SIMPLE_CHEMICAL", 19, 29], ["Asn 16", "AMINO_ACID", 97, 103], ["Ser 594", "AMINO_ACID", 108, 115], ["PA-C", "SIMPLE_CHEMICAL", 140, 144], ["terminal oxygens", "SIMPLE_CHEMICAL", 153, 169], ["Asn", "TEST", 97, 100], ["both PB1 central", "TREATMENT", 119, 135], ["PA-C through terminal oxygens", "TREATMENT", 140, 169], ["penetrates", "OBSERVATION_MODIFIER", 30, 40], ["terminal oxygens", "OBSERVATION", 153, 169]]], ["Both cytidine and desthiobiotin rings including the aminoallyl contacts with Gly 500 of PB1 central, Gln 138 and Arg 142 of PB2-N through oxo and nitro groups (Fig. 3d) .", [["cytidine", "CHEMICAL", 5, 13], ["desthiobiotin", "CHEMICAL", 18, 31], ["aminoallyl", "CHEMICAL", 52, 62], ["Gly 500", "CHEMICAL", 77, 84], ["Gln 138", "CHEMICAL", 101, 108], ["Arg 142 of PB2-N", "CHEMICAL", 113, 129], ["nitro", "CHEMICAL", 146, 151], ["cytidine", "CHEMICAL", 5, 13], ["desthiobiotin", "CHEMICAL", 18, 31], ["aminoallyl", "CHEMICAL", 52, 62], ["Gly", "CHEMICAL", 77, 80], ["Gln", "CHEMICAL", 101, 104], ["Arg", "CHEMICAL", 113, 116], ["PB2-N", "CHEMICAL", 124, 129], ["oxo", "CHEMICAL", 138, 141], ["nitro", "CHEMICAL", 146, 151], ["cytidine", "SIMPLE_CHEMICAL", 5, 13], ["desthiobiotin rings", "SIMPLE_CHEMICAL", 18, 37], ["Gln 138", "AMINO_ACID", 101, 108], ["Arg 142", "AMINO_ACID", 113, 120], ["PB2-N", "SIMPLE_CHEMICAL", 124, 129], ["oxo", "SIMPLE_CHEMICAL", 138, 141], ["Both cytidine and desthiobiotin rings", "TREATMENT", 0, 37], ["Gln", "TEST", 101, 104], ["Arg", "TEST", 113, 116], ["PB2", "TREATMENT", 124, 127], ["oxo and nitro groups", "TREATMENT", 138, 158], ["desthiobiotin rings", "OBSERVATION", 18, 37]]], ["Replacing desthiobiotin-6-Aminoallyl with N4-Biotin-OBEA allows compound 5 to also bind at the end of the tunnel 2 forming a circular structure.", [["desthiobiotin-6-Aminoallyl", "CHEMICAL", 10, 36], ["N4-Biotin-OBEA", "CHEMICAL", 42, 56], ["desthiobiotin-6-Aminoallyl", "CHEMICAL", 10, 36], ["N4-Biotin-OBEA", "CHEMICAL", 42, 56], ["desthiobiotin-6-Aminoallyl", "SIMPLE_CHEMICAL", 10, 36], ["N4-Biotin-OBEA", "SIMPLE_CHEMICAL", 42, 56], ["desthiobiotin", "TREATMENT", 10, 23], ["Aminoallyl", "TREATMENT", 26, 36], ["N4-Biotin", "TREATMENT", 42, 51], ["tunnel", "OBSERVATION", 106, 112], ["circular", "OBSERVATION_MODIFIER", 125, 133]]], ["The terminal biotin contacts with Lys 279 and Lys 140 of both PB1 Central and PB2-N, while the cytidine interacts with Asn 16 of PB1-N through oxo and nitrogen atoms.", [["biotin", "CHEMICAL", 13, 19], ["Lys 279", "CHEMICAL", 34, 41], ["Lys 140", "CHEMICAL", 46, 53], ["cytidine", "CHEMICAL", 95, 103], ["Asn 16 of PB1-N", "CHEMICAL", 119, 134], ["oxo", "CHEMICAL", 143, 146], ["nitrogen", "CHEMICAL", 151, 159], ["biotin", "CHEMICAL", 13, 19], ["Lys", "CHEMICAL", 34, 37], ["Lys", "CHEMICAL", 46, 49], ["PB2-N", "CHEMICAL", 78, 83], ["cytidine", "CHEMICAL", 95, 103], ["Asn", "CHEMICAL", 119, 122], ["PB1-N", "CHEMICAL", 129, 134], ["oxo", "CHEMICAL", 143, 146], ["nitrogen", "CHEMICAL", 151, 159], ["biotin", "SIMPLE_CHEMICAL", 13, 19], ["Lys 279", "AMINO_ACID", 34, 41], ["Lys 140", "AMINO_ACID", 46, 53], ["cytidine", "SIMPLE_CHEMICAL", 95, 103], ["PB1-N", "SIMPLE_CHEMICAL", 129, 134], ["oxo", "SIMPLE_CHEMICAL", 143, 146], ["nitrogen atoms", "SIMPLE_CHEMICAL", 151, 165], ["PB2", "PROTEIN", 78, 81], ["Lys", "TEST", 34, 37], ["Lys", "TEST", 46, 49], ["PB2", "TEST", 78, 81], ["the cytidine", "TREATMENT", 91, 103], ["Asn", "TEST", 119, 122], ["PB1-N through oxo and nitrogen atoms", "TREATMENT", 129, 165]]], ["In addition, the \u03b2 and \u03b3 triphosphate interacts with Ile 535 , Asp 538 of PB1 central, and Thr 238 of PB2-N through terminal oxygens (Fig. 3e) .Stage-I: In the presence of influenza-A vRNAIn comparison with compounds 4 and 5, compound 6 with two ends of adenosine interaction with Met 507 of PB1 central and Met 645 of PB2 627 domains.", [["\u03b2 and \u03b3 triphosphate", "CHEMICAL", 17, 37], ["Ile 535", "CHEMICAL", 53, 60], ["adenosine", "CHEMICAL", 254, 263], ["Met 507", "CHEMICAL", 281, 288], ["\u03b3 triphosphate", "CHEMICAL", 23, 37], ["Ile", "CHEMICAL", 53, 56], ["Asp", "CHEMICAL", 63, 66], ["Thr", "CHEMICAL", 91, 94], ["PB2-N", "CHEMICAL", 102, 107], ["oxygens", "CHEMICAL", 125, 132], ["adenosine", "CHEMICAL", 254, 263], ["Met", "CHEMICAL", 281, 284], ["\u03b2", "GENE_OR_GENE_PRODUCT", 17, 18], ["\u03b3 triphosphate", "SIMPLE_CHEMICAL", 23, 37], ["Ile 535", "AMINO_ACID", 53, 60], ["Asp 538", "AMINO_ACID", 63, 70], ["Thr 238", "AMINO_ACID", 91, 98], ["adenosine", "SIMPLE_CHEMICAL", 254, 263], ["Met", "GENE_OR_GENE_PRODUCT", 281, 284], ["Met", "GENE_OR_GENE_PRODUCT", 308, 311], ["\u03b2 and \u03b3 triphosphate", "PROTEIN", 17, 37], ["PB2", "PROTEIN", 102, 105], ["Met 645", "PROTEIN", 308, 315], ["PB2 627 domains", "PROTEIN", 319, 334], ["Asp", "TEST", 63, 66], ["PB1 central", "TEST", 74, 85], ["Thr", "TEST", 91, 94], ["PB2", "TEST", 102, 105], ["terminal oxygens", "TREATMENT", 116, 132], ["influenza", "PROBLEM", 172, 181], ["PB2", "TEST", 319, 322], ["terminal", "OBSERVATION_MODIFIER", 116, 124], ["oxygens", "OBSERVATION_MODIFIER", 125, 132], ["influenza", "OBSERVATION", 172, 181]]], ["The attached furanosyls also shows contacts with Asn 537 and Gly 500 of PB1 domains through 2\u2032 and 3\u2032 oxygens.", [["furanosyls", "CHEMICAL", 13, 23], ["Asn 537", "CHEMICAL", 49, 56], ["furanosyls", "CHEMICAL", 13, 23], ["Asn", "CHEMICAL", 49, 52], ["Gly", "CHEMICAL", 61, 64], ["oxygens", "CHEMICAL", 102, 109], ["furanosyls", "SIMPLE_CHEMICAL", 13, 23], ["Asn 537", "AMINO_ACID", 49, 56], ["Gly 500", "AMINO_ACID", 61, 68], ["2\u2032", "SIMPLE_CHEMICAL", 92, 94], ["3\u2032 oxygens", "SIMPLE_CHEMICAL", 99, 109], ["PB1 domains", "PROTEIN", 72, 83], ["PB1 domains", "TREATMENT", 72, 83], ["3\u2032 oxygens", "TREATMENT", 99, 109]]], ["In addition, the \u03b1, \u03b2, and \u03b5 triphosphates in-between shows contact with Asn 276 , Asn 536 , and Pro 219 of PB1 central and PB2-N with terminal oxygens (Fig. 3f) .", [["\u03b1, \u03b2, and \u03b5 triphosphates", "CHEMICAL", 17, 42], ["Asn 276", "CHEMICAL", 73, 80], ["Asn 536", "CHEMICAL", 83, 90], ["\u03b1, \u03b2, and \u03b5 triphosphates", "CHEMICAL", 17, 42], ["Asn", "CHEMICAL", 73, 76], ["Asn", "CHEMICAL", 83, 86], ["Pro", "CHEMICAL", 97, 100], ["PB2-N", "CHEMICAL", 124, 129], ["oxygens", "CHEMICAL", 144, 151], ["\u03b1", "GENE_OR_GENE_PRODUCT", 17, 18], ["\u03b2", "GENE_OR_GENE_PRODUCT", 20, 21], ["\u03b5 triphosphates", "SIMPLE_CHEMICAL", 27, 42], ["Asn 276", "SIMPLE_CHEMICAL", 73, 80], ["Asn 536", "AMINO_ACID", 83, 90], ["\u03b2", "PROTEIN", 20, 21], ["PB2", "PROTEIN", 124, 127], ["the \u03b1, \u03b2, and \u03b5 triphosphates", "TEST", 13, 42], ["Asn", "TEST", 83, 86], ["Pro", "TEST", 97, 100], ["PB1 central", "TREATMENT", 108, 119], ["PB2", "TEST", 124, 127], ["terminal oxygens (Fig.", "TREATMENT", 135, 157], ["terminal", "OBSERVATION_MODIFIER", 135, 143], ["oxygens", "OBSERVATION_MODIFIER", 144, 151]]], ["However, the sulfonyl group of compound 7 is placed just below to the tip of the priming loop interacting with Gly 650 of PB1 priming loop.", [["Gly 650", "CHEMICAL", 111, 118], ["sulfonyl", "CHEMICAL", 13, 21], ["Gly", "CHEMICAL", 111, 114], ["compound 7", "SIMPLE_CHEMICAL", 31, 41], ["Gly 650", "AMINO_ACID", 111, 118], ["PB1", "PROTEIN", 122, 125], ["PB1 priming loop", "TREATMENT", 122, 138], ["tip", "OBSERVATION_MODIFIER", 70, 73]]], ["The 5\u2032-dimethoxytrityl group also makes contact with Arg 126 through H-Pi stacking along with Met 646 of PB1 and Ly 41 of PB2-N near to the entry channel of tunnel 1.", [["5\u2032-dimethoxytrityl", "CHEMICAL", 4, 22], ["Arg 126", "CHEMICAL", 53, 60], ["H-Pi", "CHEMICAL", 69, 73], ["Met 646", "CHEMICAL", 94, 101], ["Ly 41 of PB2-N", "CHEMICAL", 113, 127], ["5\u2032-dimethoxytrityl", "CHEMICAL", 4, 22], ["Arg 126", "CHEMICAL", 53, 60], ["H-Pi", "CHEMICAL", 69, 73], ["Met", "CHEMICAL", 94, 97], ["Ly", "CHEMICAL", 113, 115], ["PB2-N", "CHEMICAL", 122, 127], ["5\u2032-dimethoxytrityl", "SIMPLE_CHEMICAL", 4, 22], ["Arg 126", "SIMPLE_CHEMICAL", 53, 60], ["H-Pi", "SIMPLE_CHEMICAL", 69, 73], ["Met", "AMINO_ACID", 94, 97], ["PB1", "PROTEIN", 105, 108], ["Ly 41", "PROTEIN", 113, 118], ["PB2", "PROTEIN", 122, 125], ["tunnel 1", "PROTEIN", 157, 165], ["PB1", "TEST", 105, 108], ["PB2", "TREATMENT", 122, 125], ["tunnel", "OBSERVATION", 157, 163]]], ["The N2-isobutyrylguanosine protrudes towards NTP tunnel showing no contacts with the viral enzyme (Fig. 3g) .", [["N2-isobutyrylguanosine", "CHEMICAL", 4, 26], ["NTP", "CHEMICAL", 45, 48], ["N2-isobutyrylguanosine", "CHEMICAL", 4, 26], ["NTP", "CHEMICAL", 45, 48], ["N2-isobutyrylguanosine", "SIMPLE_CHEMICAL", 4, 26], ["NTP", "SIMPLE_CHEMICAL", 45, 48], ["viral enzyme", "PROTEIN", 85, 97], ["The N2-isobutyrylguanosine protrudes", "TREATMENT", 0, 36], ["NTP tunnel", "TREATMENT", 45, 55], ["the viral enzyme", "TEST", 81, 97], ["NTP tunnel", "OBSERVATION", 45, 55], ["no", "UNCERTAINTY", 64, 66]]], ["In comparison, the compound 8 with 5-chloroanthraniloyl groups attached to 2\u2032 and 3\u2032 positions of ribose sugar make H-Pi interactions with Lys 140 and Arg 142 of PB2-N at the end of the second tunnel.", [["5-chloroanthraniloyl", "CHEMICAL", 35, 55], ["ribose", "CHEMICAL", 98, 104], ["H-Pi", "CHEMICAL", 116, 120], ["Lys 140", "CHEMICAL", 139, 146], ["Arg 142 of PB2-N", "CHEMICAL", 151, 167], ["5-chloroanthraniloyl", "CHEMICAL", 35, 55], ["ribose sugar", "CHEMICAL", 98, 110], ["H-Pi", "CHEMICAL", 116, 120], ["Lys", "CHEMICAL", 139, 142], ["Arg", "CHEMICAL", 151, 154], ["PB2-N", "CHEMICAL", 162, 167], ["5-chloroanthraniloyl groups", "SIMPLE_CHEMICAL", 35, 62], ["2\u2032", "SIMPLE_CHEMICAL", 75, 77], ["3\u2032 positions of ribose sugar", "SIMPLE_CHEMICAL", 82, 110], ["H-Pi", "SIMPLE_CHEMICAL", 116, 120], ["Lys 140", "SIMPLE_CHEMICAL", 139, 146], ["Arg 142", "AMINO_ACID", 151, 158], ["PB2", "PROTEIN", 162, 165], ["5-chloroanthraniloyl groups", "TREATMENT", 35, 62], ["ribose sugar", "TREATMENT", 98, 110], ["Lys", "TEST", 139, 142], ["PB2", "TREATMENT", 162, 165], ["N", "TREATMENT", 166, 167], ["second tunnel", "OBSERVATION", 186, 199]]], ["In addition, the adenosine and triphosphate groups attached to 1\u2032 and 4\u2032 positions also show contacts with Gln 138 and Thr 238 of PB2-N far away from the linker domain through H-Pi and weak hydrogen bonds (Fig. 3h) .", [["adenosine", "CHEMICAL", 17, 26], ["triphosphate", "CHEMICAL", 31, 43], ["Gln 138", "CHEMICAL", 107, 114], ["Thr", "CHEMICAL", 119, 122], ["Pi", "CHEMICAL", 178, 180], ["adenosine", "CHEMICAL", 17, 26], ["triphosphate", "CHEMICAL", 31, 43], ["Gln", "CHEMICAL", 107, 110], ["Thr", "CHEMICAL", 119, 122], ["PB2-N", "CHEMICAL", 130, 135], ["hydrogen", "CHEMICAL", 190, 198], ["adenosine", "SIMPLE_CHEMICAL", 17, 26], ["triphosphate", "SIMPLE_CHEMICAL", 31, 43], ["4\u2032 positions", "SIMPLE_CHEMICAL", 70, 82], ["Gln 138", "SIMPLE_CHEMICAL", 107, 114], ["Thr 238", "AMINO_ACID", 119, 126], ["H-Pi", "SIMPLE_CHEMICAL", 176, 180], ["PB2", "PROTEIN", 130, 133], ["linker domain", "PROTEIN", 154, 167], ["the adenosine and triphosphate groups", "TREATMENT", 13, 50], ["Gln", "TEST", 107, 110], ["PB2", "TEST", 130, 133], ["H-Pi", "TEST", 176, 180], ["weak hydrogen bonds", "PROBLEM", 185, 204], ["hydrogen bonds", "OBSERVATION", 190, 204]]], ["However, the two ends of adenosine and guanosyl moieties of compound 9 show H-Pi stack with Met 507 of PB1 central, Thr 238 of PB2-N, and Lys 670 of PB2 627 domains, while the attached furanosyls shows contact with Val 502 , Asn 504 , Met 507 of PB1, and Gly 669 of PB2 627 domains, respectively.", [["adenosine", "CHEMICAL", 25, 34], ["guanosyl", "CHEMICAL", 39, 47], ["compound 9", "CHEMICAL", 60, 70], ["H-Pi", "CHEMICAL", 76, 80], ["Met", "CHEMICAL", 92, 95], ["Lys 670", "CHEMICAL", 138, 145], ["furanosyls", "CHEMICAL", 185, 195], ["Val 502", "CHEMICAL", 215, 222], ["adenosine", "CHEMICAL", 25, 34], ["guanosyl", "CHEMICAL", 39, 47], ["H-Pi", "CHEMICAL", 76, 80], ["Met", "CHEMICAL", 92, 95], ["Thr", "CHEMICAL", 116, 119], ["PB2-N", "CHEMICAL", 127, 132], ["Lys", "CHEMICAL", 138, 141], ["furanosyls", "CHEMICAL", 185, 195], ["Val", "CHEMICAL", 215, 218], ["Asn", "CHEMICAL", 225, 228], ["Met", "CHEMICAL", 235, 238], ["Gly", "CHEMICAL", 255, 258], ["adenosine", "SIMPLE_CHEMICAL", 25, 34], ["guanosyl moieties", "SIMPLE_CHEMICAL", 39, 56], ["compound 9", "SIMPLE_CHEMICAL", 60, 70], ["H-Pi", "SIMPLE_CHEMICAL", 76, 80], ["Met", "AMINO_ACID", 92, 95], ["Thr 238", "AMINO_ACID", 116, 123], ["Lys 670", "AMINO_ACID", 138, 145], ["furanosyls", "SIMPLE_CHEMICAL", 185, 195], ["Asn 504", "AMINO_ACID", 225, 232], ["Met", "GENE_OR_GENE_PRODUCT", 235, 238], ["PB2", "PROTEIN", 127, 130], ["PB2 627 domains", "PROTEIN", 149, 164], ["PB1", "PROTEIN", 246, 249], ["PB2 627 domains", "PROTEIN", 266, 281], ["adenosine and guanosyl moieties", "TREATMENT", 25, 56], ["PB1 central", "TEST", 103, 114], ["Thr", "TEST", 116, 119], ["PB2", "TEST", 127, 130], ["Lys", "TEST", 138, 141], ["PB2", "TEST", 149, 152], ["the attached furanosyls", "TEST", 172, 195], ["Asn", "TEST", 225, 228], ["PB1", "TEST", 246, 249], ["Gly", "TEST", 255, 258], ["PB2", "TEST", 266, 269]]], ["In addition, the \u03b1 and \u03b3 phosphates also show contact with Lys 279 , Asn 504 , Asn 536 , and Asp 538 of PB1 central through terminal oxygens.", [["Lys 279", "CHEMICAL", 59, 66], ["Asn 504 , Asn 536", "CHEMICAL", 69, 86], ["Asp 538", "CHEMICAL", 93, 100], ["phosphates", "CHEMICAL", 25, 35], ["Lys", "CHEMICAL", 59, 62], ["Asn", "CHEMICAL", 69, 72], ["Asn", "CHEMICAL", 79, 82], ["Asp", "CHEMICAL", 93, 96], ["oxygens", "CHEMICAL", 133, 140], ["\u03b1", "GENE_OR_GENE_PRODUCT", 17, 18], ["\u03b3 phosphates", "SIMPLE_CHEMICAL", 23, 35], ["Lys 279", "AMINO_ACID", 59, 66], ["Asn 504", "AMINO_ACID", 69, 76], ["Asn 536", "AMINO_ACID", 79, 86], ["Asp 538", "AMINO_ACID", 93, 100], ["the \u03b1 and \u03b3 phosphates", "TEST", 13, 35], ["Lys", "TEST", 59, 62], ["Asn", "TEST", 69, 72], ["Asn", "TEST", 79, 82], ["Asp", "TEST", 93, 96], ["PB1 central through terminal oxygens", "TREATMENT", 104, 140], ["terminal oxygens", "OBSERVATION", 124, 140]]], ["In addition, adenine also interacts with Ala 648 of the priming loop through the amino group (Fig. 3i) .", [["adenine", "CHEMICAL", 13, 20], ["Ala 648", "CHEMICAL", 41, 48], ["adenine", "CHEMICAL", 13, 20], ["Ala", "CHEMICAL", 41, 44], ["amino", "CHEMICAL", 81, 86], ["adenine", "SIMPLE_CHEMICAL", 13, 20], ["Ala 648", "AMINO_ACID", 41, 48], ["Ala", "TREATMENT", 41, 44], ["the priming loop", "TREATMENT", 52, 68]]], ["The indole and uridine groups of compound 10 forms H-Pi stacking with Ala 139 and Arg 126 of PB1 central.", [["indole", "CHEMICAL", 4, 10], ["uridine", "CHEMICAL", 15, 22], ["H-Pi", "CHEMICAL", 51, 55], ["Ala 139", "CHEMICAL", 70, 77], ["Arg 126", "CHEMICAL", 82, 89], ["indole", "CHEMICAL", 4, 10], ["uridine", "CHEMICAL", 15, 22], ["H-Pi", "CHEMICAL", 51, 55], ["Ala", "CHEMICAL", 70, 73], ["Arg", "CHEMICAL", 82, 85], ["indole", "SIMPLE_CHEMICAL", 4, 10], ["uridine", "SIMPLE_CHEMICAL", 15, 22], ["compound 10", "SIMPLE_CHEMICAL", 33, 44], ["H-Pi", "SIMPLE_CHEMICAL", 51, 55], ["Ala 139", "AMINO_ACID", 70, 77], ["Arg 126", "AMINO_ACID", 82, 89], ["The indole and uridine groups", "TREATMENT", 0, 29], ["H-Pi stacking", "TEST", 51, 64], ["Ala", "TEST", 70, 73], ["Arg", "TEST", 82, 85]]], ["The propionamide-N-allyl shows contacts with the backbone atoms of Gly 125 and Gln 39 of both PB1 central and PB2-N through backbone nitrogen.", [["propionamide-N-allyl", "CHEMICAL", 4, 24], ["Gly 125", "CHEMICAL", 67, 74], ["Gln 39", "CHEMICAL", 79, 85], ["backbone nitrogen", "CHEMICAL", 124, 141], ["propionamide-N-allyl", "CHEMICAL", 4, 24], ["Gly", "CHEMICAL", 67, 70], ["Gln", "CHEMICAL", 79, 82], ["PB2-N", "CHEMICAL", 110, 115], ["nitrogen", "CHEMICAL", 133, 141], ["propionamide-N-allyl", "SIMPLE_CHEMICAL", 4, 24], ["Gly 125", "AMINO_ACID", 67, 74], ["Gln 39", "AMINO_ACID", 79, 85], ["PB2-N", "SIMPLE_CHEMICAL", 110, 115], ["PB2", "PROTEIN", 110, 113], ["The propionamide", "TREATMENT", 0, 16], ["both PB1 central and PB2", "TREATMENT", 89, 113], ["backbone nitrogen", "TREATMENT", 124, 141]]], ["In addition, both the sugar, and the base which occupies in tunnel 1 contacts with Lys 229 , Asp 230 , and Ala 231 of PB1 central and Lys 41 of PB2-N with both stronger and weaker hydrogen bonds.", [["Lys 229", "CHEMICAL", 83, 90], ["Asp 230", "CHEMICAL", 93, 100], ["Ala 231", "CHEMICAL", 107, 114], ["Lys 41 of PB2-N", "CHEMICAL", 134, 149], ["sugar", "CHEMICAL", 22, 27], ["Lys", "CHEMICAL", 83, 86], ["Asp", "CHEMICAL", 93, 96], ["Ala", "CHEMICAL", 107, 110], ["Lys", "CHEMICAL", 134, 137], ["PB2-N", "CHEMICAL", 144, 149], ["hydrogen", "CHEMICAL", 180, 188], ["sugar", "SIMPLE_CHEMICAL", 22, 27], ["Lys 229", "AMINO_ACID", 83, 90], ["Asp 230", "AMINO_ACID", 93, 100], ["Ala 231", "AMINO_ACID", 107, 114], ["Lys 41", "AMINO_ACID", 134, 140], ["Lys", "TEST", 83, 86], ["Asp", "TEST", 93, 96], ["Ala", "TEST", 107, 110], ["PB1 central", "TEST", 118, 129], ["Lys", "TEST", 134, 137], ["PB2", "TEST", 144, 147], ["both", "ANATOMY_MODIFIER", 13, 17], ["sugar", "OBSERVATION_MODIFIER", 22, 27], ["base", "ANATOMY_MODIFIER", 37, 41], ["hydrogen bonds", "OBSERVATION", 180, 194]]], ["The attached 5\u2032triphosphate also shows contacts with Ala 231 of PB1 central and with Lys 41 and Asn 42 of PB2-N domain (Fig. 2j) .", [["5\u2032triphosphate", "CHEMICAL", 13, 27], ["Ala 231", "CHEMICAL", 53, 60], ["5\u2032triphosphate", "CHEMICAL", 13, 27], ["Ala", "CHEMICAL", 53, 56], ["Lys", "CHEMICAL", 85, 88], ["Asn", "CHEMICAL", 96, 99], ["5\u2032triphosphate", "SIMPLE_CHEMICAL", 13, 27], ["Ala 231", "AMINO_ACID", 53, 60], ["Lys 41", "AMINO_ACID", 85, 91], ["Asn 42", "AMINO_ACID", 96, 102], ["PB2", "PROTEIN", 106, 109], ["N domain", "PROTEIN", 110, 118], ["Ala", "TREATMENT", 53, 56], ["PB1 central", "TREATMENT", 64, 75], ["Lys", "TEST", 85, 88], ["Asn", "TEST", 96, 99], ["PB2", "TEST", 106, 109]]], ["Furthermore, compound 11 also binds similar to compound 10 in perpendicular to the catalytic site.", [["compound 11", "CHEMICAL", 13, 24], ["catalytic site", "PROTEIN", 83, 97], ["compound 11 also binds", "PROBLEM", 13, 35], ["catalytic site", "OBSERVATION", 83, 97]]], ["Biotin-16-5-aminoallyl interacts with Leu 122 , Thr 128 and Ala 139 and Met 646 of PB1 central while 2\u2032-deoxyuridine shows H-Pi stacking with Met 645 of the priming loop.", [["Biotin-16-5-aminoallyl", "CHEMICAL", 0, 22], ["Leu 122", "CHEMICAL", 38, 45], ["Ala 139", "CHEMICAL", 60, 67], ["Met 646", "CHEMICAL", 72, 79], ["2\u2032-deoxyuridine", "CHEMICAL", 101, 116], ["H-Pi", "CHEMICAL", 123, 127], ["Met 645", "CHEMICAL", 142, 149], ["Biotin-16-5-aminoallyl", "CHEMICAL", 0, 22], ["Leu", "CHEMICAL", 38, 41], ["Thr", "CHEMICAL", 48, 51], ["Ala", "CHEMICAL", 60, 63], ["Met", "CHEMICAL", 72, 75], ["2\u2032-deoxyuridine", "CHEMICAL", 101, 116], ["Met", "CHEMICAL", 142, 145], ["Biotin-16-5-aminoallyl", "SIMPLE_CHEMICAL", 0, 22], ["Leu 122", "SIMPLE_CHEMICAL", 38, 45], ["Thr 128", "AMINO_ACID", 48, 55], ["Ala 139", "AMINO_ACID", 60, 67], ["Met", "AMINO_ACID", 72, 75], ["646", "AMINO_ACID", 76, 79], ["2\u2032-deoxyuridine", "SIMPLE_CHEMICAL", 101, 116], ["H-Pi", "SIMPLE_CHEMICAL", 123, 127], ["Met 645", "AMINO_ACID", 142, 149], ["Met 645", "PROTEIN", 142, 149], ["Biotin", "TEST", 0, 6], ["Thr", "TEST", 48, 51], ["Ala", "TEST", 60, 63], ["PB1 central", "TEST", 83, 94], ["deoxyuridine", "TREATMENT", 104, 116], ["H-Pi stacking", "PROBLEM", 123, 136], ["the priming loop", "TREATMENT", 153, 169]]], ["This binding clearly shows that Biotin-16-5-aminoallyl orient away from the catalytic site with triphosphate projecting into the entry channel (Fig. 3k) .Stage-I: In the presence of influenza-A vRNAThe binding orientations of these compounds reveal that compound 1 occupy tunnel 1 while compounds 2 and 3 Fig. 3 Ligand protein interaction of top 11 compounds represented in codes 3-AA-CTP (a), 7-AA-CTP (b), cyanine-5-dCTP (c), Desthiobion-6-dCTP (d), N4-Biotin-dCTP (e) Penta phosphate (f), 5\u2032-DMT-2\u2032-Ts-N2-Biotin-Ibu-G (g), Bis-Cl-ANT-ATP (h), Tetra phosphate (i), 5\u2032-Indoyl-AA-dUTP (j), and Biotin-16-dUTP (k) with the homology model of IAV RdRp from A/PR/8/34/H1N1 strain in the presence of Flu A Primer occupied tunnel 2 above the priming loop with cyanine moiety placing in perpendicular to the tunnels 1 and 2 forming a V-shape.", [["Biotin-16-5-aminoallyl", "CHEMICAL", 32, 54], ["triphosphate", "CHEMICAL", 96, 108], ["CTP", "CHEMICAL", 385, 388], ["CTP", "CHEMICAL", 399, 402], ["cyanine-5-dCTP", "CHEMICAL", 408, 422], ["Desthiobion-6-dCTP", "CHEMICAL", 428, 446], ["dCTP", "CHEMICAL", 462, 466], ["Penta phosphate", "CHEMICAL", 471, 486], ["DMT", "CHEMICAL", 495, 498], ["Bis-Cl", "CHEMICAL", 526, 532], ["ATP", "CHEMICAL", 537, 540], ["Tetra phosphate", "CHEMICAL", 546, 561], ["5\u2032-Indoyl-AA-dUTP", "CHEMICAL", 567, 584], ["Biotin-16-dUTP", "CHEMICAL", 594, 608], ["Flu", "CHEMICAL", 695, 698], ["cyanine", "CHEMICAL", 754, 761], ["Biotin-16-5-aminoallyl", "CHEMICAL", 32, 54], ["triphosphate", "CHEMICAL", 96, 108], ["3-AA-CTP", "CHEMICAL", 380, 388], ["7-AA-CTP", "CHEMICAL", 394, 402], ["cyanine-5-dCTP", "CHEMICAL", 408, 422], ["Desthiobion-6-dCTP", "CHEMICAL", 428, 446], ["N4-Biotin-dCTP", "CHEMICAL", 452, 466], ["Penta phosphate", "CHEMICAL", 471, 486], ["5\u2032-DMT-2\u2032-Ts-N2-Biotin-Ibu-G", "CHEMICAL", 492, 520], ["Bis-Cl-ANT-ATP", "CHEMICAL", 526, 540], ["Tetra phosphate", "CHEMICAL", 546, 561], ["5\u2032-Indoyl-AA-dUTP", "CHEMICAL", 567, 584], ["Biotin", "CHEMICAL", 594, 600], ["dUTP", "CHEMICAL", 604, 608], ["Flu A", "CHEMICAL", 695, 700], ["cyanine", "CHEMICAL", 754, 761], ["Biotin-16-5-aminoallyl", "SIMPLE_CHEMICAL", 32, 54], ["triphosphate", "SIMPLE_CHEMICAL", 96, 108], ["3-AA-CTP", "SIMPLE_CHEMICAL", 380, 388], ["7-AA-CTP (b)", "SIMPLE_CHEMICAL", 394, 406], ["cyanine-5-dCTP (c)", "SIMPLE_CHEMICAL", 408, 426], ["Desthiobion-6-dCTP (d)", "SIMPLE_CHEMICAL", 428, 450], ["N4-Biotin-dCTP (e) Penta phosphate (f)", "SIMPLE_CHEMICAL", 452, 490], ["5\u2032-DMT-2\u2032-Ts-N2-Biotin-Ibu-G (g)", "SIMPLE_CHEMICAL", 492, 524], ["Bis-Cl-ANT-ATP", "SIMPLE_CHEMICAL", 526, 540], ["Tetra phosphate (i)", "SIMPLE_CHEMICAL", 546, 565], ["5\u2032-Indoyl-AA-dUTP (j)", "SIMPLE_CHEMICAL", 567, 588], ["Biotin-16-dUTP", "SIMPLE_CHEMICAL", 594, 608], ["IAV RdRp", "ORGANISM", 640, 648], ["A/PR/8/34/H1N1", "ORGANISM", 654, 668], ["cyanine moiety", "SIMPLE_CHEMICAL", 754, 768], ["catalytic site", "PROTEIN", 76, 90], ["entry channel", "PROTEIN", 129, 142], ["IAV RdRp", "PROTEIN", 640, 648], ["PR", "PROTEIN", 656, 658], ["IAV RdRp", "SPECIES", 640, 648], ["A/PR/8/34/H1N1 strain", "SPECIES", 654, 675], ["Biotin", "TEST", 32, 38], ["triphosphate", "TREATMENT", 96, 108], ["influenza", "PROBLEM", 182, 191], ["these compounds", "TEST", 226, 241], ["AA", "TEST", 396, 398], ["cyanine", "TEST", 408, 415], ["Desthiobion", "TEST", 428, 439], ["Biotin", "TEST", 455, 461], ["Penta phosphate", "TEST", 471, 486], ["DMT", "TEST", 495, 498], ["2\u2032-Ts", "TEST", 499, 504], ["Biotin", "TEST", 508, 514], ["Ibu", "TEST", 515, 518], ["Bis-Cl", "TEST", 526, 532], ["Tetra phosphate", "TEST", 546, 561], ["Indoyl", "TEST", 570, 576], ["Biotin", "TEST", 594, 600], ["IAV RdRp", "PROBLEM", 640, 648], ["A/PR", "TEST", 654, 658], ["H1N1 strain", "PROBLEM", 664, 675], ["Flu A Primer occupied tunnel", "TREATMENT", 695, 723], ["cyanine moiety", "TREATMENT", 754, 768], ["influenza", "OBSERVATION", 182, 191], ["IAV RdRp", "OBSERVATION", 640, 648], ["H1N1", "OBSERVATION", 664, 668], ["Flu", "OBSERVATION", 695, 698], ["tunnel", "OBSERVATION", 717, 723], ["cyanine moiety", "OBSERVATION", 754, 768], ["tunnels", "OBSERVATION", 801, 808], ["shape", "OBSERVATION_MODIFIER", 829, 834]]], ["This proves that compound with cytidine base is more effective against polymerase inhibition than compound with uridine base.", [["cytidine", "CHEMICAL", 31, 39], ["uridine", "CHEMICAL", 112, 119], ["cytidine", "CHEMICAL", 31, 39], ["uridine", "CHEMICAL", 112, 119], ["cytidine", "SIMPLE_CHEMICAL", 31, 39], ["uridine", "SIMPLE_CHEMICAL", 112, 119], ["cytidine base", "TREATMENT", 31, 44], ["polymerase inhibition", "PROBLEM", 71, 92], ["uridine base", "TREATMENT", 112, 124]]], ["The order of compounds inhibiting RdRp is as follows, compound 3 > compound 2 > compound 1.", [["RdRp", "ORGANISM", 34, 38], ["compound 2 > compound 1", "SIMPLE_CHEMICAL", 67, 90], ["compounds inhibiting RdRp", "TREATMENT", 13, 38]]], ["Surprisingly, compound 4 also forms a Vshape while compound 5 shows circular form binding close to the PB2 linker domain with triphosphates is on the opposite sides.", [["compound 5", "CHEMICAL", 51, 61], ["triphosphates", "CHEMICAL", 126, 139], ["triphosphates", "CHEMICAL", 126, 139], ["triphosphates", "SIMPLE_CHEMICAL", 126, 139], ["PB2 linker domain", "PROTEIN", 103, 120], ["circular form binding", "PROBLEM", 68, 89], ["triphosphates", "TREATMENT", 126, 139]]], ["In comparison, the binding orientation of compounds 6 and 9 shows linearity above the catalytic site in the tunnel 2 interacting with a priming loop of PB1.", [["compounds 6 and 9", "CHEMICAL", 42, 59], ["catalytic site", "PROTEIN", 86, 100], ["PB1", "PROTEIN", 152, 155], ["a priming loop of PB1", "TREATMENT", 134, 155], ["catalytic", "OBSERVATION_MODIFIER", 86, 95], ["site", "OBSERVATION_MODIFIER", 96, 100], ["tunnel", "OBSERVATION", 108, 114]]], ["The other linear shape compounds 10 and 11 binds away from tunnel 1 with 2\u2032-deoxyuridine-5\u2032-triphosphate placing in tunnel 1 close to NTP tunnel.", [["2\u2032-deoxyuridine-5\u2032-triphosphate", "CHEMICAL", 73, 104], ["2\u2032-deoxyuridine-5\u2032-triphosphate", "CHEMICAL", 73, 104], ["NTP", "CHEMICAL", 134, 137], ["2\u2032-deoxyuridine-5\u2032-triphosphate", "SIMPLE_CHEMICAL", 73, 104], ["The other linear shape compounds", "PROBLEM", 0, 32], ["tunnel", "TEST", 59, 65], ["deoxyuridine", "TREATMENT", 76, 88], ["triphosphate", "TREATMENT", 92, 104], ["tunnel", "TREATMENT", 116, 122], ["NTP tunnel", "TREATMENT", 134, 144], ["linear", "OBSERVATION_MODIFIER", 10, 16], ["shape", "OBSERVATION_MODIFIER", 17, 22], ["compounds", "OBSERVATION_MODIFIER", 23, 32], ["NTP tunnel", "OBSERVATION", 134, 144]]], ["However, compound 8 mostly occupies tunnel 2 near to the PB2 linker domain.", [["PB2 linker domain", "PROTEIN", 57, 74], ["tunnel", "OBSERVATION", 36, 42], ["PB2", "ANATOMY", 57, 60], ["linker domain", "OBSERVATION", 61, 74]]], ["Compared with dicyclic group of compound 8, a tricyclic group of compound 7 binds in tunnel 1 below the PB1 priming loop with 5\u2032-dimethoxytrityl orients towards the 3\u2032end of the primer and 2\u2032-tosyl-N2-isobutyryl-guanosine towards motif-B involved in stabilizing the base pair between the incoming NTP and the primer template.Stage-I: In the presence of influenza-A vRNAThese docking studies also show that the residues Arg 126 , Lys 279 , Gly 410 , Phe 495 , Phe 501 , Val 502 , Asn 532 , Asn 536 , Met 646 , and Ala 652 from PB1; Asn 41 , Asn 137 , Lys 140 , and Arg 142 from PB2 act as common pharmacophores of these compounds preventing the activity of A/PR/8/34/H1N1 influenza-A polymerase in the presence of capped primer.Stage-III: In the presence of influenza-B vRNAWhen influenza-A vRNA was replaced with influenza-B vRNA, both the nitrogenous base and the ribose sugar of compound 1 interacts with Asn 504 and Asn 537 through C 60 and O 91 atoms.", [["5\u2032-dimethoxytrityl", "CHEMICAL", 126, 144], ["2\u2032-tosyl-N2-isobutyryl-guanosine", "CHEMICAL", 189, 221], ["NTP", "CHEMICAL", 297, 300], ["Asn 41 , Asn 137 , Lys 140", "CHEMICAL", 531, 557], ["Arg 142", "CHEMICAL", 564, 571], ["ribose", "CHEMICAL", 865, 871], ["Asn 504", "CHEMICAL", 907, 914], ["Asn 537", "CHEMICAL", 919, 926], ["dicyclic", "CHEMICAL", 14, 22], ["5\u2032-dimethoxytrityl", "CHEMICAL", 126, 144], ["2\u2032-tosyl-N2-isobutyryl-guanosine", "CHEMICAL", 189, 221], ["NTP", "CHEMICAL", 297, 300], ["Arg", "CHEMICAL", 419, 422], ["Lys", "CHEMICAL", 429, 432], ["Gly", "CHEMICAL", 439, 442], ["Phe", "CHEMICAL", 449, 452], ["Phe", "CHEMICAL", 459, 462], ["Val", "CHEMICAL", 469, 472], ["Asn", "CHEMICAL", 479, 482], ["Asn", "CHEMICAL", 489, 492], ["Met", "CHEMICAL", 499, 502], ["Ala", "CHEMICAL", 513, 516], ["Asn", "CHEMICAL", 531, 534], ["Asn", "CHEMICAL", 540, 543], ["Lys", "CHEMICAL", 550, 553], ["Arg 142", "CHEMICAL", 564, 571], ["ribose sugar", "CHEMICAL", 865, 877], ["Asn", "CHEMICAL", 907, 910], ["Asn", "CHEMICAL", 919, 922], ["C", "CHEMICAL", 935, 936], ["O", "CHEMICAL", 944, 945], ["compound 7", "SIMPLE_CHEMICAL", 65, 75], ["5\u2032-dimethoxytrityl", "SIMPLE_CHEMICAL", 126, 144], ["2\u2032-tosyl-N2-isobutyryl-guanosine", "SIMPLE_CHEMICAL", 189, 221], ["motif-B", "SIMPLE_CHEMICAL", 230, 237], ["NTP", "SIMPLE_CHEMICAL", 297, 300], ["Arg 126", "AMINO_ACID", 419, 426], ["Lys 279", "AMINO_ACID", 429, 436], ["Gly 410", "AMINO_ACID", 439, 446], ["Phe 495", "AMINO_ACID", 449, 456], ["Phe 501", "AMINO_ACID", 459, 466], ["Val 502", "AMINO_ACID", 469, 476], ["Asn 532", "AMINO_ACID", 479, 486], ["Asn 536", "AMINO_ACID", 489, 496], ["Met 646", "AMINO_ACID", 499, 506], ["Ala 652", "AMINO_ACID", 513, 520], ["Asn 41", "AMINO_ACID", 531, 537], ["Asn 137", "AMINO_ACID", 540, 547], ["Lys 140", "AMINO_ACID", 550, 557], ["Arg 142", "AMINO_ACID", 564, 571], ["PB2", "GENE_OR_GENE_PRODUCT", 577, 580], ["A/PR/8/34", "ORGANISM", 656, 665], ["H1N1 influenza-A polymerase", "ORGANISM", 666, 693], ["influenza-B vRNAWhen influenza-A vRNA", "ORGANISM", 757, 794], ["influenza-B vRNA", "ORGANISM", 813, 829], ["ribose sugar", "SIMPLE_CHEMICAL", 865, 877], ["Asn 504", "SIMPLE_CHEMICAL", 907, 914], ["Asn 537", "AMINO_ACID", 919, 926], ["C 60", "SIMPLE_CHEMICAL", 935, 939], ["O 91 atoms", "SIMPLE_CHEMICAL", 944, 954], ["PB1", "PROTEIN", 104, 107], ["primer template", "DNA", 309, 324], ["PR", "PROTEIN", 658, 660], ["8/34", "PROTEIN", 661, 665], ["H1N1 influenza-A polymerase", "PROTEIN", 666, 693], ["H1N1 influenza", "SPECIES", 666, 680], ["A/PR/8/34/H1N1 influenza-A", "SPECIES", 656, 682], ["a tricyclic group of compound 7 binds in tunnel", "TREATMENT", 44, 91], ["the PB1 priming loop", "TREATMENT", 100, 120], ["dimethoxytrityl", "TREATMENT", 129, 144], ["the primer", "TREATMENT", 174, 184], ["isobutyryl", "TREATMENT", 201, 211], ["guanosine", "TREATMENT", 212, 221], ["the incoming NTP", "TREATMENT", 284, 300], ["the primer template", "TREATMENT", 305, 324], ["influenza", "PROBLEM", 353, 362], ["A vRNAThese docking studies", "TEST", 363, 390], ["the residues Arg", "TEST", 406, 422], ["Lys", "TEST", 429, 432], ["Gly", "TEST", 439, 442], ["Phe", "TEST", 449, 452], ["Phe", "TEST", 459, 462], ["Val", "TEST", 469, 472], ["Asn", "TEST", 479, 482], ["Asn", "TEST", 489, 492], ["Met", "TEST", 499, 502], ["Ala", "TEST", 513, 516], ["PB1", "TEST", 526, 529], ["Asn", "TEST", 531, 534], ["Asn", "TEST", 540, 543], ["Lys", "TEST", 550, 553], ["Arg", "TEST", 564, 567], ["PB2 act", "TEST", 577, 584], ["these compounds", "PROBLEM", 613, 628], ["A/PR", "TEST", 656, 660], ["H1N1 influenza", "PROBLEM", 666, 680], ["A polymerase", "PROBLEM", 681, 693], ["capped primer", "PROBLEM", 713, 726], ["influenza", "PROBLEM", 757, 766], ["influenza", "PROBLEM", 778, 787], ["A vRNA", "TREATMENT", 788, 794], ["influenza", "PROBLEM", 813, 822], ["B vRNA", "PROBLEM", 823, 829], ["base", "ANATOMY_MODIFIER", 266, 270], ["influenza", "OBSERVATION", 353, 362], ["capped primer", "OBSERVATION", 713, 726], ["influenza", "OBSERVATION", 757, 766], ["nitrogenous", "ANATOMY_MODIFIER", 840, 851], ["base", "ANATOMY_MODIFIER", 852, 856]]], ["The 5\u2032 triphosphate contacts with Asn 276 and Lys 279 at the exit channel of the RdRp through terminal oxygens.", [["5\u2032 triphosphate", "CHEMICAL", 4, 19], ["Asn 276", "CHEMICAL", 34, 41], ["Lys 279", "CHEMICAL", 46, 53], ["5\u2032 triphosphate", "CHEMICAL", 4, 19], ["Asn", "CHEMICAL", 34, 37], ["Lys", "CHEMICAL", 46, 49], ["oxygens", "CHEMICAL", 103, 110], ["5\u2032 triphosphate", "SIMPLE_CHEMICAL", 4, 19], ["Asn 276", "AMINO_ACID", 34, 41], ["Lys 279", "AMINO_ACID", 46, 53], ["RdRp", "PROTEIN", 81, 85], ["Lys", "TEST", 46, 49], ["terminal oxygens", "TREATMENT", 94, 110], ["terminal", "OBSERVATION_MODIFIER", 94, 102], ["oxygens", "OBSERVATION_MODIFIER", 103, 110]]], ["The 1H-indole interacts with positively charged Lys 576 and Arg 583 of PB1 central domain through sulfonyl oxygens 124,125&133 .", [["1H-indole", "CHEMICAL", 4, 13], ["Lys 576", "CHEMICAL", 48, 55], ["Arg 583", "CHEMICAL", 60, 67], ["sulfonyl oxygens", "CHEMICAL", 98, 114], ["1H-indole", "CHEMICAL", 4, 13], ["Lys", "CHEMICAL", 48, 51], ["Arg", "CHEMICAL", 60, 63], ["sulfonyl oxygens", "CHEMICAL", 98, 114], ["1H-indole", "SIMPLE_CHEMICAL", 4, 13], ["Lys 576", "AMINO_ACID", 48, 55], ["Arg 583", "AMINO_ACID", 60, 67], ["sulfonyl oxygens", "SIMPLE_CHEMICAL", 98, 114], ["PB1 central domain", "PROTEIN", 71, 89], ["Arg", "TEST", 60, 63], ["sulfonyl oxygens", "TEST", 98, 114]]], ["In addition, the cytidine ring also forms, contacts with Arg 233 and Ala 648 at the NTP tunnel and PB1 priming loop though terminal oxygen and amino nitrogen (Fig. 4a) .", [["cytidine", "CHEMICAL", 17, 25], ["Arg 233", "CHEMICAL", 57, 64], ["Ala 648", "CHEMICAL", 69, 76], ["NTP", "CHEMICAL", 84, 87], ["oxygen", "CHEMICAL", 132, 138], ["amino nitrogen", "CHEMICAL", 143, 157], ["cytidine", "CHEMICAL", 17, 25], ["Arg", "CHEMICAL", 57, 60], ["Ala", "CHEMICAL", 69, 72], ["NTP", "CHEMICAL", 84, 87], ["oxygen", "CHEMICAL", 132, 138], ["amino nitrogen", "CHEMICAL", 143, 157], ["cytidine", "SIMPLE_CHEMICAL", 17, 25], ["Arg 233", "AMINO_ACID", 57, 64], ["Ala 648", "AMINO_ACID", 69, 76], ["oxygen", "SIMPLE_CHEMICAL", 132, 138], ["amino nitrogen", "SIMPLE_CHEMICAL", 143, 157], ["PB1", "PROTEIN", 99, 102], ["the cytidine ring", "TREATMENT", 13, 30], ["Ala", "TEST", 69, 72], ["the NTP tunnel", "TREATMENT", 80, 94], ["PB1 priming loop", "TREATMENT", 99, 115], ["terminal oxygen", "TREATMENT", 123, 138], ["amino nitrogen", "TREATMENT", 143, 157], ["cytidine ring", "OBSERVATION", 17, 30], ["tunnel", "OBSERVATION", 88, 94], ["terminal", "OBSERVATION_MODIFIER", 123, 131], ["oxygen", "OBSERVATION_MODIFIER", 132, 138]]], ["Also, the uridine base O 100 in compound 2 shows contact with Ala 648 at the tip of the priming loop while the 3\u2032carbon of ribose sugar along with triphosphate forms a Uturn in tunnel 2 interacting with Gly 275 and Asn 537 of PB1 central.", [["uridine", "CHEMICAL", 10, 17], ["O 100", "CHEMICAL", 23, 28], ["compound 2", "CHEMICAL", 32, 42], ["Ala 648", "CHEMICAL", 62, 69], ["ribose", "CHEMICAL", 123, 129], ["triphosphate", "CHEMICAL", 147, 159], ["Gly 275", "CHEMICAL", 203, 210], ["Asn 537", "CHEMICAL", 215, 222], ["uridine", "CHEMICAL", 10, 17], ["O 100", "CHEMICAL", 23, 28], ["Ala", "CHEMICAL", 62, 65], ["3\u2032carbon", "CHEMICAL", 111, 119], ["ribose sugar", "CHEMICAL", 123, 135], ["triphosphate", "CHEMICAL", 147, 159], ["Gly", "CHEMICAL", 203, 206], ["Asn", "CHEMICAL", 215, 218], ["uridine base O 100", "SIMPLE_CHEMICAL", 10, 28], ["Ala 648", "AMINO_ACID", 62, 69], ["ribose sugar", "SIMPLE_CHEMICAL", 123, 135], ["triphosphate", "SIMPLE_CHEMICAL", 147, 159], ["Gly 275", "AMINO_ACID", 203, 210], ["Asn 537", "AMINO_ACID", 215, 222], ["the uridine base O", "TEST", 6, 24], ["Ala", "TREATMENT", 62, 65], ["ribose sugar", "TEST", 123, 135], ["triphosphate forms", "TREATMENT", 147, 165], ["PB1 central", "TREATMENT", 226, 237]]], ["The terminal 1H-indole ring points towards the 3\u2032 activation strand of the vRNA interacting with Asn 42 and Pro 43 of PB2-N through sulfonyl oxygens.", [["terminal 1H-indole", "CHEMICAL", 4, 22], ["Asn 42", "CHEMICAL", 97, 103], ["Pro 43 of PB2-N", "CHEMICAL", 108, 123], ["sulfonyl oxygens", "CHEMICAL", 132, 148], ["1H", "CHEMICAL", 13, 15], ["indole", "CHEMICAL", 16, 22], ["Asn", "CHEMICAL", 97, 100], ["Pro", "CHEMICAL", 108, 111], ["PB2-N", "CHEMICAL", 118, 123], ["sulfonyl oxygens", "CHEMICAL", 132, 148], ["vRNA", "CELLULAR_COMPONENT", 75, 79], ["Asn 42", "SIMPLE_CHEMICAL", 97, 103], ["PB2-N", "SIMPLE_CHEMICAL", 118, 123], ["sulfonyl oxygens", "SIMPLE_CHEMICAL", 132, 148], ["The terminal 1H-indole ring", "TREATMENT", 0, 27], ["Asn", "TEST", 97, 100], ["Pro", "TEST", 108, 111], ["PB2", "TEST", 118, 121], ["sulfonyl oxygens", "TREATMENT", 132, 148], ["terminal", "OBSERVATION_MODIFIER", 4, 12], ["indole ring", "OBSERVATION", 16, 27], ["vRNA", "OBSERVATION", 75, 79]]], ["In addition, the 7-Aminoally also shows contacts with Pro 647 and Met 646 of the PB1 priming loop (Fig. 4b) .", [["Pro 647", "CHEMICAL", 54, 61], ["Met 646", "CHEMICAL", 66, 73], ["Pro 647", "CHEMICAL", 54, 61], ["Met", "CHEMICAL", 66, 69], ["Pro 647", "SIMPLE_CHEMICAL", 54, 61], ["Met 646", "AMINO_ACID", 66, 73], ["Pro 647", "PROTEIN", 54, 61], ["PB1 priming loop", "PROTEIN", 81, 97], ["the PB1 priming loop", "TREATMENT", 77, 97]]], ["The compound 3 cyanine lies below the PB1 priming loop with central 1H-indole ring interacting with Met 645 and Met 646 of PB1 priming loop while the terminal IH-indole ring contacts with positively charged Ly 235 and Arg 239 of PB2 222-246 loop through sulfonyl oxygens.", [["compound 3 cyanine", "CHEMICAL", 4, 22], ["1H-indole", "CHEMICAL", 68, 77], ["Met 645", "CHEMICAL", 100, 107], ["Met 646", "CHEMICAL", 112, 119], ["IH-indole", "CHEMICAL", 159, 168], ["Ly", "CHEMICAL", 207, 209], ["Arg 239 of PB2 222-246", "CHEMICAL", 218, 240], ["sulfonyl oxygens", "CHEMICAL", 254, 270], ["cyanine", "CHEMICAL", 15, 22], ["1H-indole", "CHEMICAL", 68, 77], ["Met", "CHEMICAL", 100, 103], ["Met", "CHEMICAL", 112, 115], ["IH-indole", "CHEMICAL", 159, 168], ["Ly", "CHEMICAL", 207, 209], ["Arg", "CHEMICAL", 218, 221], ["sulfonyl oxygens", "CHEMICAL", 254, 270], ["compound 3 cyanine", "SIMPLE_CHEMICAL", 4, 22], ["1H-indole ring", "SIMPLE_CHEMICAL", 68, 82], ["Met 645", "SIMPLE_CHEMICAL", 100, 107], ["Met 646", "AMINO_ACID", 112, 119], ["Ly 235", "SIMPLE_CHEMICAL", 207, 213], ["Arg 239", "AMINO_ACID", 218, 225], ["sulfonyl oxygens", "SIMPLE_CHEMICAL", 254, 270], ["PB1 priming loop", "PROTEIN", 38, 54], ["PB1", "PROTEIN", 123, 126], ["The compound 3 cyanine", "TREATMENT", 0, 22], ["the PB1 priming loop", "TREATMENT", 34, 54], ["central 1H-indole ring", "TREATMENT", 60, 82], ["PB1 priming loop", "TREATMENT", 123, 139], ["Arg", "TEST", 218, 221], ["PB2", "TEST", 229, 232], ["loop through sulfonyl oxygens", "TREATMENT", 241, 270], ["terminal", "OBSERVATION_MODIFIER", 150, 158], ["IH", "OBSERVATION_MODIFIER", 159, 161], ["indole ring", "OBSERVATION", 162, 173]]], ["The 5-5-propargylamino lies perpendicular to the priming loop showing contacts with Met 507 , Glu 508 , and Met 645 of PB1 central domain.", [["5-5-propargylamino", "CHEMICAL", 4, 22], ["Met 507", "CHEMICAL", 84, 91], ["Glu 508", "CHEMICAL", 94, 101], ["Met 645", "CHEMICAL", 108, 115], ["5-5-propargylamino", "CHEMICAL", 4, 22], ["Met", "CHEMICAL", 84, 87], ["Glu", "CHEMICAL", 94, 97], ["Met", "CHEMICAL", 108, 111], ["5-5-propargylamino", "SIMPLE_CHEMICAL", 4, 22], ["Met 507", "AMINO_ACID", 84, 91], ["Glu 508", "AMINO_ACID", 94, 101], ["Met 645", "AMINO_ACID", 108, 115], ["5-5-propargylamino", "DNA", 4, 22], ["Met 507", "PROTEIN", 84, 91], ["PB1 central domain", "PROTEIN", 119, 137], ["Glu", "TEST", 94, 97], ["PB1 central domain", "TREATMENT", 119, 137]]], ["This orientation of 2\u2032-deoxycytidine-5\u2032-triphosphate towards the exit channel allows to interact with Gly 275 , Asn 276 , and Asn 536 of PB1 and Arg 142 of PB2 central (Fig. 4c) .", [["2\u2032-deoxycytidine-5\u2032-triphosphate", "CHEMICAL", 20, 52], ["Asn 276", "CHEMICAL", 112, 119], ["Asn 536", "CHEMICAL", 126, 133], ["2\u2032-deoxycytidine-5\u2032-triphosphate", "CHEMICAL", 20, 52], ["Gly", "CHEMICAL", 102, 105], ["Asn", "CHEMICAL", 112, 115], ["Asn", "CHEMICAL", 126, 129], ["Arg", "CHEMICAL", 145, 148], ["2\u2032-deoxycytidine-5\u2032-triphosphate", "SIMPLE_CHEMICAL", 20, 52], ["Gly 275", "AMINO_ACID", 102, 109], ["Asn 276", "AMINO_ACID", 112, 119], ["Asn 536", "AMINO_ACID", 126, 133], ["PB1", "AMINO_ACID", 137, 140], ["Arg 142", "AMINO_ACID", 145, 152], ["exit channel", "PROTEIN", 65, 77], ["PB1", "PROTEIN", 137, 140], ["This orientation", "TEST", 0, 16], ["deoxycytidine", "TREATMENT", 23, 36], ["triphosphate", "TREATMENT", 40, 52], ["PB1", "TREATMENT", 137, 140], ["Arg", "TEST", 145, 148], ["PB2 central (Fig.", "TREATMENT", 156, 173]]], ["The \u03b1 and \u03b2 phosphates of compound 4 contacts with Gly 275 and Asn 537 and the attached ribofuranosyl interacts with Val 502 and Asn 536 of PB1 central.", [["\u03b1 and \u03b2 phosphates", "CHEMICAL", 4, 22], ["Gly 275", "CHEMICAL", 51, 58], ["Asn 537", "CHEMICAL", 63, 70], ["ribofuranosyl", "CHEMICAL", 88, 101], ["Val 502", "CHEMICAL", 117, 124], ["Asn 536", "CHEMICAL", 129, 136], ["phosphates", "CHEMICAL", 12, 22], ["Gly", "CHEMICAL", 51, 54], ["Asn", "CHEMICAL", 63, 66], ["ribofuranosyl", "CHEMICAL", 88, 101], ["Val", "CHEMICAL", 117, 120], ["Asn", "CHEMICAL", 129, 132], ["\u03b1", "GENE_OR_GENE_PRODUCT", 4, 5], ["\u03b2 phosphates", "SIMPLE_CHEMICAL", 10, 22], ["Gly 275", "AMINO_ACID", 51, 58], ["Asn 537", "AMINO_ACID", 63, 70], ["ribofuranosyl", "SIMPLE_CHEMICAL", 88, 101], ["Val 502", "AMINO_ACID", 117, 124], ["Asn 536", "AMINO_ACID", 129, 136], ["PB1 central", "TREATMENT", 140, 151]]], ["Moreover, both the oxo and nitro group of cytidine base also shows contacts with Phe 501 and Asn 536 of PB1 central and Pro 219 of PB2-N2 at the end of the tunnel 2 through H-Pi interaction.", [["oxo", "CHEMICAL", 19, 22], ["nitro", "CHEMICAL", 27, 32], ["cytidine", "CHEMICAL", 42, 50], ["Phe", "CHEMICAL", 81, 84], ["Asn 536", "CHEMICAL", 93, 100], ["Pro 219 of PB2-N2", "CHEMICAL", 120, 137], ["oxo", "CHEMICAL", 19, 22], ["nitro", "CHEMICAL", 27, 32], ["cytidine", "CHEMICAL", 42, 50], ["Phe", "CHEMICAL", 81, 84], ["Asn", "CHEMICAL", 93, 96], ["PB2-N2", "CHEMICAL", 131, 137], ["oxo", "SIMPLE_CHEMICAL", 19, 22], ["nitro", "SIMPLE_CHEMICAL", 27, 32], ["cytidine", "SIMPLE_CHEMICAL", 42, 50], ["Phe 501", "AMINO_ACID", 81, 88], ["Asn 536", "AMINO_ACID", 93, 100], ["H-Pi", "GENE_OR_GENE_PRODUCT", 173, 177], ["PB2", "PROTEIN", 131, 134], ["nitro group of cytidine base", "TREATMENT", 27, 55], ["PB1 central", "TREATMENT", 104, 115], ["PB2", "TREATMENT", 131, 134], ["N2", "TREATMENT", 135, 137], ["tunnel", "OBSERVATION", 156, 162]]], ["In addition, the desthiobiotin also shows interaction with Lys 140 of the PB2-N through oxo group (Fig. 4d) .", [["desthiobiotin", "CHEMICAL", 17, 30], ["Lys 140", "CHEMICAL", 59, 66], ["oxo", "CHEMICAL", 88, 91], ["desthiobiotin", "CHEMICAL", 17, 30], ["Lys", "CHEMICAL", 59, 62], ["oxo", "CHEMICAL", 88, 91], ["desthiobiotin", "SIMPLE_CHEMICAL", 17, 30], ["oxo", "SIMPLE_CHEMICAL", 88, 91], ["PB2", "PROTEIN", 74, 77], ["Lys", "TEST", 59, 62], ["the PB2", "TREATMENT", 70, 77]]], ["The compound 5 also binds at the end of the tunnel 2 with the terminal ends of biotin and cytidine contacts with Lys 279 of PB2-N and Ala 643 of the priming loop through oxo groups.", [["compound 5", "CHEMICAL", 4, 14], ["biotin", "CHEMICAL", 79, 85], ["cytidine", "CHEMICAL", 90, 98], ["Lys 279 of PB2-N", "CHEMICAL", 113, 129], ["Ala 643", "CHEMICAL", 134, 141], ["oxo", "CHEMICAL", 170, 173], ["biotin", "CHEMICAL", 79, 85], ["cytidine", "CHEMICAL", 90, 98], ["Lys", "CHEMICAL", 113, 116], ["N", "CHEMICAL", 128, 129], ["Ala", "CHEMICAL", 134, 137], ["oxo", "CHEMICAL", 170, 173], ["biotin", "SIMPLE_CHEMICAL", 79, 85], ["cytidine", "SIMPLE_CHEMICAL", 90, 98], ["Lys 279", "AMINO_ACID", 113, 120], ["Ala 643", "AMINO_ACID", 134, 141], ["PB2", "PROTEIN", 124, 127], ["the tunnel", "TREATMENT", 40, 50], ["the terminal ends of biotin", "TREATMENT", 58, 85], ["PB2", "TEST", 124, 127], ["Ala", "TREATMENT", 134, 137], ["the priming loop through oxo groups", "TREATMENT", 145, 180], ["tunnel", "OBSERVATION", 44, 50]]], ["In addition, cytidine and furan contacts with Phe 505 , Glu 505 , and Ala 648 through nitrogen and 2\u2032 carbon while the \u03b1 and \u03b3 triphosphate interacts with Gly 275 and Asn 537 through terminal oxygens (Fig. 4e) .Stage-III: In the presence of influenza-B vRNAIn comparison with compounds 4 and 5, compound 6 occupies both tunnel 1 and tunnel 2 almost in parallel to the catalytic site of RdRp.", [["cytidine", "CHEMICAL", 13, 21], ["furan", "CHEMICAL", 26, 31], ["Phe 505", "CHEMICAL", 46, 53], ["Glu 505", "CHEMICAL", 56, 63], ["Ala 648", "CHEMICAL", 70, 77], ["nitrogen and 2\u2032 carbon", "CHEMICAL", 86, 108], ["\u03b1 and \u03b3 triphosphate", "CHEMICAL", 119, 139], ["Gly 275", "CHEMICAL", 155, 162], ["Asn 537", "CHEMICAL", 167, 174], ["compounds 4 and 5, compound 6", "CHEMICAL", 276, 305], ["cytidine", "CHEMICAL", 13, 21], ["furan", "CHEMICAL", 26, 31], ["Phe", "CHEMICAL", 46, 49], ["Glu", "CHEMICAL", 56, 59], ["Ala", "CHEMICAL", 70, 73], ["nitrogen", "CHEMICAL", 86, 94], ["2\u2032 carbon", "CHEMICAL", 99, 108], ["\u03b3 triphosphate", "CHEMICAL", 125, 139], ["Gly", "CHEMICAL", 155, 158], ["Asn", "CHEMICAL", 167, 170], ["oxygens", "CHEMICAL", 192, 199], ["cytidine", "SIMPLE_CHEMICAL", 13, 21], ["furan", "SIMPLE_CHEMICAL", 26, 31], ["Phe 505", "SIMPLE_CHEMICAL", 46, 53], ["Glu 505", "AMINO_ACID", 56, 63], ["Ala 648", "AMINO_ACID", 70, 77], ["nitrogen", "SIMPLE_CHEMICAL", 86, 94], ["2\u2032 carbon", "SIMPLE_CHEMICAL", 99, 108], ["\u03b1", "SIMPLE_CHEMICAL", 119, 120], ["\u03b3 triphosphate", "SIMPLE_CHEMICAL", 125, 139], ["Gly 275", "AMINO_ACID", 155, 162], ["Asn 537", "AMINO_ACID", 167, 174], ["RdRp", "GENE_OR_GENE_PRODUCT", 386, 390], ["catalytic site", "PROTEIN", 368, 382], ["RdRp", "PROTEIN", 386, 390], ["cytidine", "TREATMENT", 13, 21], ["Phe", "TEST", 46, 49], ["Glu", "TEST", 56, 59], ["Ala", "TEST", 70, 73], ["nitrogen", "TREATMENT", 86, 94], ["carbon", "TREATMENT", 102, 108], ["terminal oxygens", "TREATMENT", 183, 199], ["influenza", "PROBLEM", 241, 250], ["tunnel", "TREATMENT", 333, 339], ["influenza", "OBSERVATION", 241, 250], ["tunnel", "OBSERVATION", 320, 326], ["tunnel", "OBSERVATION", 333, 339], ["RdRp", "OBSERVATION", 386, 390]]], ["One end of adenosine moiety contacts along with the attached ribose sugar shows interactions with Val 644 , Met 645 , and Met 646 of PB1 priming loop while the other end of adenosine orients towards the exit channel contacting with Ala 503 of the PB1 central.", [["adenosine", "CHEMICAL", 11, 20], ["ribose", "CHEMICAL", 61, 67], ["Val 644", "CHEMICAL", 98, 105], ["Met 645", "CHEMICAL", 108, 115], ["Met 646", "CHEMICAL", 122, 129], ["adenosine", "CHEMICAL", 173, 182], ["Ala 503", "CHEMICAL", 232, 239], ["adenosine", "CHEMICAL", 11, 20], ["ribose sugar", "CHEMICAL", 61, 73], ["Val", "CHEMICAL", 98, 101], ["Met", "CHEMICAL", 108, 111], ["Met", "CHEMICAL", 122, 125], ["adenosine", "CHEMICAL", 173, 182], ["Ala", "CHEMICAL", 232, 235], ["adenosine", "SIMPLE_CHEMICAL", 11, 20], ["ribose sugar", "SIMPLE_CHEMICAL", 61, 73], ["Val 644", "AMINO_ACID", 98, 105], ["Met", "AMINO_ACID", 108, 111], ["645", "AMINO_ACID", 112, 115], ["Met", "AMINO_ACID", 122, 125], ["646", "AMINO_ACID", 126, 129], ["adenosine", "SIMPLE_CHEMICAL", 173, 182], ["Ala 503", "AMINO_ACID", 232, 239], ["PB1", "PROTEIN", 133, 136], ["exit channel", "PROTEIN", 203, 215], ["PB1", "PROTEIN", 247, 250], ["adenosine moiety", "TREATMENT", 11, 27], ["the attached ribose sugar", "TEST", 48, 73], ["PB1 priming loop", "TREATMENT", 133, 149], ["adenosine", "TREATMENT", 173, 182], ["the PB1 central", "TREATMENT", 243, 258], ["adenosine moiety", "OBSERVATION", 11, 27]]], ["The phosphate groups in between also interacting with Glu 508 of the PB1 along with Pro 647 and Ala 648 of the priming loop (Fig. 4f) .", [["phosphate", "CHEMICAL", 4, 13], ["Glu", "CHEMICAL", 54, 57], ["Pro 647", "CHEMICAL", 84, 91], ["Ala 648", "CHEMICAL", 96, 103], ["phosphate", "CHEMICAL", 4, 13], ["Glu", "CHEMICAL", 54, 57], ["Pro 647", "CHEMICAL", 84, 91], ["Ala", "CHEMICAL", 96, 99], ["phosphate", "SIMPLE_CHEMICAL", 4, 13], ["Glu 508", "AMINO_ACID", 54, 61], ["Pro 647", "SIMPLE_CHEMICAL", 84, 91], ["Ala 648", "AMINO_ACID", 96, 103], ["PB1", "PROTEIN", 69, 72], ["The phosphate groups", "TREATMENT", 0, 20], ["the PB1", "TREATMENT", 65, 72], ["Ala", "TEST", 96, 99], ["the priming loop", "TREATMENT", 107, 123]]], ["However, compound 7 is placed below the exit channel with 2\u2032-tosyl showing contacts with Ala 503 and Asn 504 and the ribose sugar interacting with Lys 279 and Phe 495 with another two hydrogen bonds.", [["2\u2032-tosyl", "CHEMICAL", 58, 66], ["Ala 503", "CHEMICAL", 89, 96], ["Asn 504", "CHEMICAL", 101, 108], ["ribose", "CHEMICAL", 117, 123], ["Lys 279", "CHEMICAL", 147, 154], ["Phe 495", "CHEMICAL", 159, 166], ["2\u2032-tosyl", "CHEMICAL", 58, 66], ["Ala", "CHEMICAL", 89, 92], ["Asn", "CHEMICAL", 101, 104], ["ribose sugar", "CHEMICAL", 117, 129], ["Lys", "CHEMICAL", 147, 150], ["Phe", "CHEMICAL", 159, 162], ["hydrogen", "CHEMICAL", 184, 192], ["2\u2032-tosyl", "SIMPLE_CHEMICAL", 58, 66], ["Ala 503", "AMINO_ACID", 89, 96], ["Asn 504", "AMINO_ACID", 101, 108], ["ribose sugar", "SIMPLE_CHEMICAL", 117, 129], ["Lys 279", "AMINO_ACID", 147, 154], ["Phe 495", "AMINO_ACID", 159, 166], ["the ribose sugar", "TEST", 113, 129], ["Lys", "TEST", 147, 150], ["Phe", "TEST", 159, 162], ["hydrogen bonds", "OBSERVATION", 184, 198]]], ["The 5\u2032-dimethoxytrityl group also makes contact with Ile 535 and Asn 536 below the exit channel Fig. 4g .", [["5\u2032-dimethoxytrityl", "CHEMICAL", 4, 22], ["Ile 535", "CHEMICAL", 53, 60], ["Asn 536", "CHEMICAL", 65, 72], ["5\u2032-dimethoxytrityl", "CHEMICAL", 4, 22], ["Ile", "CHEMICAL", 53, 56], ["Asn", "CHEMICAL", 65, 68], ["5\u2032-dimethoxytrityl", "SIMPLE_CHEMICAL", 4, 22], ["Ile 535", "SIMPLE_CHEMICAL", 53, 60], ["Asn 536", "AMINO_ACID", 65, 72]]], ["Similarly, the 5-chloroanthraniloyl makes contact with Asn 536 of PB1 below the exit channel of RdRp.", [["5-chloroanthraniloyl", "CHEMICAL", 15, 35], ["Asn 536", "CHEMICAL", 55, 62], ["5-chloroanthraniloyl", "CHEMICAL", 15, 35], ["Asn", "CHEMICAL", 55, 58], ["5-chloroanthraniloyl", "SIMPLE_CHEMICAL", 15, 35], ["Asn 536", "AMINO_ACID", 55, 62], ["PB1", "AMINO_ACID", 66, 69], ["PB1", "PROTEIN", 66, 69], ["exit channel", "PROTEIN", 80, 92], ["RdRp", "PROTEIN", 96, 100], ["PB1", "TREATMENT", 66, 69]]], ["In addition, the adenosine and triphosphate groups also show contacts with Ser 601 of PA-C, Gly 500 of PB1, and Gly 669 of PB2 627 linker (Fig. 4h ).", [["adenosine", "CHEMICAL", 17, 26], ["triphosphate", "CHEMICAL", 31, 43], ["Ser 601", "CHEMICAL", 75, 82], ["Gly 669 of PB2 627", "CHEMICAL", 112, 130], ["adenosine", "CHEMICAL", 17, 26], ["triphosphate", "CHEMICAL", 31, 43], ["Ser", "CHEMICAL", 75, 78], ["Gly", "CHEMICAL", 92, 95], ["Gly", "CHEMICAL", 112, 115], ["adenosine", "SIMPLE_CHEMICAL", 17, 26], ["triphosphate", "SIMPLE_CHEMICAL", 31, 43], ["Ser 601", "AMINO_ACID", 75, 82], ["PA-C", "SIMPLE_CHEMICAL", 86, 90], ["Gly", "AMINO_ACID", 92, 95], ["Gly 669", "AMINO_ACID", 112, 119], ["PB1", "PROTEIN", 103, 106], ["PB2 627 linker", "PROTEIN", 123, 137], ["the adenosine and triphosphate groups", "TREATMENT", 13, 50], ["PA", "TEST", 86, 88], ["PB1", "TEST", 103, 106], ["Gly", "TEST", 112, 115], ["PB2", "TEST", 123, 126]]], ["In comparison with compound 6, the compound 9 with adenosyl at one end orients towards the priming loop of PB1 while the other end with guanosyl orients very close to Leu 668 of PB2 linker domain.", [["compound 9", "CHEMICAL", 35, 45], ["adenosyl", "CHEMICAL", 51, 59], ["Leu 668", "CHEMICAL", 167, 174], ["adenosyl", "CHEMICAL", 51, 59], ["guanosyl", "CHEMICAL", 136, 144], ["Leu", "CHEMICAL", 167, 170], ["adenosyl", "SIMPLE_CHEMICAL", 51, 59], ["Leu 668", "AMINO_ACID", 167, 174], ["PB1", "PROTEIN", 107, 110], ["Leu 668", "PROTEIN", 167, 174], ["PB2 linker domain", "PROTEIN", 178, 195], ["the priming loop of PB1", "TREATMENT", 87, 110], ["PB2 linker domain", "TREATMENT", 178, 195], ["PB2 linker", "OBSERVATION", 178, 188]]], ["The 2\u2032ribose sugar of guanosyl shows contacts with Arg 142 of PB2-N2 subdomain, while the 2\u2032ribose sugar of adenosyl contacts with Gly 275 of PB1 at the exit channel.", [["guanosyl", "CHEMICAL", 22, 30], ["Arg 142", "CHEMICAL", 51, 58], ["adenosyl", "CHEMICAL", 108, 116], ["Gly 275", "CHEMICAL", 131, 138], ["2\u2032ribose sugar", "CHEMICAL", 4, 18], ["guanosyl", "CHEMICAL", 22, 30], ["Arg", "CHEMICAL", 51, 54], ["N2", "CHEMICAL", 66, 68], ["sugar", "CHEMICAL", 99, 104], ["adenosyl", "CHEMICAL", 108, 116], ["Gly", "CHEMICAL", 131, 134], ["2\u2032ribose sugar", "SIMPLE_CHEMICAL", 4, 18], ["guanosyl", "SIMPLE_CHEMICAL", 22, 30], ["Arg 142", "AMINO_ACID", 51, 58], ["Gly 275", "AMINO_ACID", 131, 138], ["PB1", "AMINO_ACID", 142, 145], ["PB2", "PROTEIN", 62, 65], ["N2 subdomain", "PROTEIN", 66, 78], ["PB1", "PROTEIN", 142, 145], ["exit channel", "PROTEIN", 153, 165], ["PB2", "TEST", 62, 65], ["N2 subdomain", "OBSERVATION", 66, 78]]], ["In addition, the phosphate groups also show contacts with Lys 279 , Val 502 , and Ala 503 of PB1 central fold through terminal oxygens (Fig. 4i) .", [["phosphate", "CHEMICAL", 17, 26], ["Lys 279", "CHEMICAL", 58, 65], ["Val 502", "CHEMICAL", 68, 75], ["phosphate", "CHEMICAL", 17, 26], ["Lys", "CHEMICAL", 58, 61], ["Val", "CHEMICAL", 68, 71], ["Ala", "CHEMICAL", 82, 85], ["oxygens", "CHEMICAL", 127, 134], ["phosphate", "SIMPLE_CHEMICAL", 17, 26], ["Lys 279", "AMINO_ACID", 58, 65], ["Val 502", "AMINO_ACID", 68, 75], ["Ala 503", "AMINO_ACID", 82, 89], ["the phosphate groups", "TEST", 13, 33], ["Lys", "TEST", 58, 61], ["Ala", "TEST", 82, 85], ["PB1 central fold through terminal oxygens", "TREATMENT", 93, 134], ["terminal", "OBSERVATION_MODIFIER", 118, 126], ["oxygens", "OBSERVATION_MODIFIER", 127, 134]]], ["The indole and propionamide-Nallyl of 5- propionamide-N-allyl] of compound 10 contacts with Glu 508 and Thr 493 of PB1 central while uridine base interacts with Ala 648 of the priming loop.", [["indole", "CHEMICAL", 4, 10], ["propionamide", "CHEMICAL", 15, 27], ["Nallyl", "CHEMICAL", 28, 34], ["5- propionamide-N-allyl", "CHEMICAL", 38, 61], ["Glu 508", "CHEMICAL", 92, 99], ["Thr 493", "CHEMICAL", 104, 111], ["uridine", "CHEMICAL", 133, 140], ["Ala 648", "CHEMICAL", 161, 168], ["indole", "CHEMICAL", 4, 10], ["propionamide", "CHEMICAL", 15, 27], ["Nallyl", "CHEMICAL", 28, 34], ["5- propionamide", "CHEMICAL", 38, 53], ["N-allyl", "CHEMICAL", 54, 61], ["Glu", "CHEMICAL", 92, 95], ["Thr", "CHEMICAL", 104, 107], ["uridine", "CHEMICAL", 133, 140], ["Ala", "CHEMICAL", 161, 164], ["indole", "SIMPLE_CHEMICAL", 4, 10], ["propionamide-Nallyl", "SIMPLE_CHEMICAL", 15, 34], ["5- propionamide-N-allyl", "SIMPLE_CHEMICAL", 38, 61], ["Glu 508", "SIMPLE_CHEMICAL", 92, 99], ["Thr 493", "AMINO_ACID", 104, 111], ["PB1", "AMINO_ACID", 115, 118], ["uridine", "SIMPLE_CHEMICAL", 133, 140], ["Ala 648", "AMINO_ACID", 161, 168], ["The indole", "TREATMENT", 0, 10], ["propionamide", "TREATMENT", 15, 27], ["Nallyl", "TREATMENT", 28, 34], ["Glu", "TEST", 92, 95], ["PB1 central while uridine base", "TREATMENT", 115, 145], ["Ala", "TREATMENT", 161, 164], ["the priming loop", "TREATMENT", 172, 188]]], ["In addition, the 2\u2032-deoxyuridine which occupies in tunnel 1 shows contacts with Pro 510 of PB1 central and the attached 5\u2032-triphosphate shows contacts with Ser 515 of PB1, Pro 43 , Ala 44 , and Asn 42 of PB2_C domain (Fig. 4j) .", [["2\u2032-deoxyuridine", "CHEMICAL", 17, 32], ["Pro 510", "CHEMICAL", 80, 87], ["5\u2032-triphosphate", "CHEMICAL", 120, 135], ["2\u2032-deoxyuridine", "CHEMICAL", 17, 32], ["5\u2032-triphosphate", "CHEMICAL", 120, 135], ["Ser", "CHEMICAL", 156, 159], ["Pro", "CHEMICAL", 172, 175], ["Ala", "CHEMICAL", 181, 184], ["Asn", "CHEMICAL", 194, 197], ["2\u2032-deoxyuridine", "SIMPLE_CHEMICAL", 17, 32], ["5\u2032-triphosphate", "SIMPLE_CHEMICAL", 120, 135], ["Ser 515", "AMINO_ACID", 156, 163], ["PB1", "AMINO_ACID", 167, 170], ["Ala 44", "AMINO_ACID", 181, 187], ["Asn", "AMINO_ACID", 194, 197], ["PB1", "PROTEIN", 91, 94], ["PB1", "PROTEIN", 167, 170], ["PB2_C domain", "PROTEIN", 204, 216], ["the 2\u2032-deoxyuridine", "TREATMENT", 13, 32], ["PB1 central", "TREATMENT", 91, 102], ["Pro", "TEST", 172, 175], ["Ala", "TEST", 181, 184], ["PB2_C domain", "TREATMENT", 204, 216]]], ["However, compound 11 interacts with Lys 279 , Phe 501 , Glu 508 , and Gly 125 of PB1 and Met 646 of the priming loop while 2\u2032-deoxyuridine-5\u2032-triphosphate shows contacts with Arg 233 , Gly 513 , and Ser 515 of PB1 and Asn 42 of PB2 at the Cterminal end of RdRP (Fig. 4k) .Stage-III: In the presence of influenza-B vRNAThe predicted V-shape orientations for compounds 1, 2, and 3 shows that cyanine moiety is placed almost in parallel to the PB1 priming loop while the rest of the molecule projects towards the exit channel in parallel to the catalytic site of RdRp polymerase.", [["Lys 279", "CHEMICAL", 36, 43], ["Phe", "CHEMICAL", 46, 49], ["Glu", "CHEMICAL", 56, 59], ["Met 646", "CHEMICAL", 89, 96], ["2\u2032-deoxyuridine-5\u2032-triphosphate", "CHEMICAL", 123, 154], ["cyanine", "CHEMICAL", 390, 397], ["Lys", "CHEMICAL", 36, 39], ["Phe", "CHEMICAL", 46, 49], ["Glu", "CHEMICAL", 56, 59], ["Gly", "CHEMICAL", 70, 73], ["Met", "CHEMICAL", 89, 92], ["2\u2032-deoxyuridine-5\u2032-triphosphate", "CHEMICAL", 123, 154], ["Arg", "CHEMICAL", 175, 178], ["Gly", "CHEMICAL", 185, 188], ["Ser", "CHEMICAL", 199, 202], ["Asn", "CHEMICAL", 218, 221], ["cyanine", "CHEMICAL", 390, 397], ["Lys 279", "AMINO_ACID", 36, 43], ["Phe 501", "AMINO_ACID", 46, 53], ["Glu 508", "AMINO_ACID", 56, 63], ["Gly 125", "AMINO_ACID", 70, 77], ["PB1", "AMINO_ACID", 81, 84], ["Met", "AMINO_ACID", 89, 92], ["646", "AMINO_ACID", 93, 96], ["2\u2032-deoxyuridine-5\u2032-triphosphate", "SIMPLE_CHEMICAL", 123, 154], ["Arg 233", "AMINO_ACID", 175, 182], ["Gly 513", "AMINO_ACID", 185, 192], ["Ser 515", "AMINO_ACID", 199, 206], ["PB1", "AMINO_ACID", 210, 213], ["Asn 42", "AMINO_ACID", 218, 224], ["cyanine moiety", "SIMPLE_CHEMICAL", 390, 404], ["RdRp polymerase", "GENE_OR_GENE_PRODUCT", 560, 575], ["PB1", "PROTEIN", 81, 84], ["PB1", "PROTEIN", 210, 213], ["PB2", "PROTEIN", 228, 231], ["Cterminal end", "PROTEIN", 239, 252], ["RdRP", "PROTEIN", 256, 260], ["PB1 priming loop", "PROTEIN", 441, 457], ["exit channel", "PROTEIN", 510, 522], ["catalytic site", "PROTEIN", 542, 556], ["RdRp polymerase", "PROTEIN", 560, 575], ["Lys", "TEST", 36, 39], ["Phe", "TEST", 46, 49], ["Glu", "TEST", 56, 59], ["Gly", "TEST", 70, 73], ["PB1", "TEST", 81, 84], ["Met", "TEST", 89, 92], ["the priming loop", "TEST", 100, 116], ["deoxyuridine", "TEST", 126, 138], ["Arg", "TEST", 175, 178], ["Gly", "TEST", 185, 188], ["PB1", "TEST", 210, 213], ["Asn", "TEST", 218, 221], ["PB2", "TREATMENT", 228, 231], ["influenza", "PROBLEM", 302, 311], ["cyanine moiety", "TREATMENT", 390, 404], ["influenza", "OBSERVATION", 302, 311], ["cyanine moiety", "OBSERVATION", 390, 404], ["loop", "OBSERVATION", 453, 457], ["exit channel", "OBSERVATION", 510, 522], ["RdRp polymerase", "OBSERVATION", 560, 575]]], ["This reveals that compounds 1 and 3 with cytidine moiety binds with higher affinity compared with compound with uridine moiety.", [["cytidine", "CHEMICAL", 41, 49], ["uridine", "CHEMICAL", 112, 119], ["cytidine", "CHEMICAL", 41, 49], ["uridine", "CHEMICAL", 112, 119], ["3", "GENE_OR_GENE_PRODUCT", 34, 35], ["cytidine moiety", "SIMPLE_CHEMICAL", 41, 56], ["uridine moiety", "SIMPLE_CHEMICAL", 112, 126], ["cytidine moiety binds", "TREATMENT", 41, 62], ["higher affinity", "PROBLEM", 68, 83], ["uridine moiety", "TREATMENT", 112, 126]]], ["These compounds inhibiting RdRp are as follows, compound 1 > compound 3 > compound 2.", [["RdRp", "ORGANISM", 27, 31], ["compound 3", "SIMPLE_CHEMICAL", 61, 71], ["compound 2", "SIMPLE_CHEMICAL", 74, 84], ["These compounds inhibiting RdRp", "PROBLEM", 0, 31]]], ["The orientation of binding shows that desthiobiotin-6-aminoallyl appears in parallel to the catalytic site of RdRp in tunnel 2 with triphosphate orientation towards the priming loop while the orientation of compound 5 appears in circular with triphosphate pointing towards the exit channel.", [["desthiobiotin-6-aminoallyl", "CHEMICAL", 38, 64], ["triphosphate", "CHEMICAL", 132, 144], ["triphosphate", "CHEMICAL", 243, 255], ["desthiobiotin-6-aminoallyl", "CHEMICAL", 38, 64], ["triphosphate", "CHEMICAL", 132, 144], ["triphosphate", "CHEMICAL", 243, 255], ["desthiobiotin-6-aminoallyl", "SIMPLE_CHEMICAL", 38, 64], ["triphosphate", "SIMPLE_CHEMICAL", 132, 144], ["triphosphate", "SIMPLE_CHEMICAL", 243, 255], ["catalytic site", "PROTEIN", 92, 106], ["RdRp", "PROTEIN", 110, 114], ["exit channel", "PROTEIN", 277, 289], ["desthiobiotin", "TEST", 38, 51], ["triphosphate orientation", "TREATMENT", 132, 156], ["the priming loop", "TREATMENT", 165, 181], ["triphosphate", "TREATMENT", 243, 255], ["RdRp", "OBSERVATION", 110, 114], ["priming loop", "OBSERVATION", 169, 181], ["exit channel", "OBSERVATION", 277, 289]]], ["In comparison, the binding orientations of compounds 6 and 9 shows linearity above and below the catalytic site.", [["compounds 6 and 9", "CHEMICAL", 43, 60], ["catalytic site", "PROTEIN", 97, 111], ["catalytic site", "OBSERVATION", 97, 111]]], ["In these orientations, it was carefully observed that the phosphate groups of compound 6 primarily interact with the priming loop which is not seen with compound 9.", [["phosphate", "CHEMICAL", 58, 67], ["compound 6", "CHEMICAL", 78, 88], ["phosphate", "CHEMICAL", 58, 67], ["phosphate", "SIMPLE_CHEMICAL", 58, 67], ["compound 6", "SIMPLE_CHEMICAL", 78, 88], ["the phosphate groups of compound", "PROBLEM", 54, 86], ["the priming loop", "TREATMENT", 113, 129], ["not seen", "UNCERTAINTY", 139, 147]]], ["The other linear shape compounds 10 and 11 binds below the priming loop occupying both tunnels 1 and 2 with triphosphates towards the entry channel.", [["triphosphates", "CHEMICAL", 108, 121], ["triphosphates", "CHEMICAL", 108, 121], ["triphosphates", "SIMPLE_CHEMICAL", 108, 121], ["entry channel", "PROTEIN", 134, 147], ["the priming loop occupying both tunnels", "TREATMENT", 55, 94], ["triphosphates", "TREATMENT", 108, 121], ["linear", "OBSERVATION_MODIFIER", 10, 16], ["shape", "OBSERVATION_MODIFIER", 17, 22], ["loop", "OBSERVATION_MODIFIER", 67, 71], ["tunnels", "OBSERVATION", 87, 94], ["entry channel", "OBSERVATION", 134, 147]]], ["However, compounds 7 and 8 mostly occupy tunnel 2 nearer to the PB2 linker domain.", [["PB2 linker domain", "PROTEIN", 64, 81], ["tunnel", "OBSERVATION", 41, 47], ["PB2 linker", "OBSERVATION", 64, 74]]], ["The predicted orientation shows that bulky groups of 5\u2032-dimethoxytrityl and 5-chloroanthraniloyl orients towards the catalytic site while compound 7 (isobutyryl-guanosine) and compound 8 (adenosine-5\u2032-O-triphosphate) orients towards the exit channel and the linker domain.", [["5\u2032-dimethoxytrityl", "CHEMICAL", 53, 71], ["5-chloroanthraniloyl", "CHEMICAL", 76, 96], ["isobutyryl-guanosine", "CHEMICAL", 150, 170], ["adenosine", "CHEMICAL", 188, 197], ["-5\u2032-O-triphosphate", "CHEMICAL", 197, 215], ["5\u2032-dimethoxytrityl", "CHEMICAL", 53, 71], ["5-chloroanthraniloyl", "CHEMICAL", 76, 96], ["isobutyryl-guanosine)", "CHEMICAL", 150, 171], ["adenosine-5\u2032-O-triphosphate", "CHEMICAL", 188, 215], ["5\u2032-dimethoxytrityl", "SIMPLE_CHEMICAL", 53, 71], ["5-chloroanthraniloyl", "SIMPLE_CHEMICAL", 76, 96], ["compound 7", "SIMPLE_CHEMICAL", 138, 148], ["isobutyryl-guanosine", "SIMPLE_CHEMICAL", 150, 170], ["compound 8", "SIMPLE_CHEMICAL", 176, 186], ["adenosine-5\u2032-O-triphosphate", "SIMPLE_CHEMICAL", 188, 215], ["catalytic site", "PROTEIN", 117, 131], ["exit channel", "PROTEIN", 237, 249], ["linker domain", "PROTEIN", 258, 271], ["dimethoxytrityl", "TREATMENT", 56, 71], ["isobutyryl", "TEST", 150, 160], ["compound", "TEST", 176, 184], ["adenosine", "TEST", 188, 197], ["5\u2032-O-triphosphate)", "TREATMENT", 198, 216], ["bulky", "OBSERVATION_MODIFIER", 37, 42]]], ["These two binding conformations clearly indicate that compound 8 is far away from the catalytic site and PB2 linker domain compared with compound 7 which is close to the catalytic site interacting with PB1 priming loop.Stage-III: In the presence of influenza-B vRNAThe docking results of these compounds show that the residues Arg 125 , Glu 126 , Ala 651 , and Ser 652 from PA; Thr 39 , Ala 231 , Ala 503 , Pro 510 , and Met 646 from PB1 and Arg 17 , Glu 18 , Gln 39 , and Lys 41 from PB2 act as common pharmacophores of these compounds preventing the activity of A/PR/8/34/H1N1 influenza-A polymerase after the translocation of 3\u2032end of the vRNA into the catalytic site.Stage-III: In the presence of influenza-B vRNAThe activity of the compounds against IAV replication using TCA precipitation assay Further experimental studies using TCA precipitation assay showed that compound 1 inhibited polymerase activity with an IC 25 an IC 50 of 0.03 and 1.69 \u03bcM with higher rates of inhibition between 0.1 and 1 \u00b5M compared with other concentrations used in the study (Fig. 5a) .", [["Glu", "CHEMICAL", 337, 340], ["Glu", "CHEMICAL", 451, 454], ["Gln 39 , and Lys 41", "CHEMICAL", 460, 479], ["TCA", "CHEMICAL", 777, 780], ["TCA", "CHEMICAL", 836, 839], ["Arg", "CHEMICAL", 327, 330], ["Glu", "CHEMICAL", 337, 340], ["Ala", "CHEMICAL", 347, 350], ["Ser", "CHEMICAL", 361, 364], ["Thr", "CHEMICAL", 378, 381], ["Ala", "CHEMICAL", 387, 390], ["Ala", "CHEMICAL", 397, 400], ["Pro", "CHEMICAL", 407, 410], ["Met", "CHEMICAL", 421, 424], ["Arg", "CHEMICAL", 442, 445], ["Glu", "CHEMICAL", 451, 454], ["Gln", "CHEMICAL", 460, 463], ["Lys", "CHEMICAL", 473, 476], ["TCA", "CHEMICAL", 777, 780], ["TCA", "CHEMICAL", 836, 839], ["Arg 125", "AMINO_ACID", 327, 334], ["Glu 126", "AMINO_ACID", 337, 344], ["Ala 651", "AMINO_ACID", 347, 354], ["Ser 652", "AMINO_ACID", 361, 368], ["PA", "GENE_OR_GENE_PRODUCT", 374, 376], ["Thr 39", "AMINO_ACID", 378, 384], ["Ala 231", "AMINO_ACID", 387, 394], ["Ala 503", "AMINO_ACID", 397, 404], ["Pro 510", "AMINO_ACID", 407, 414], ["Met 646", "GENE_OR_GENE_PRODUCT", 421, 428], ["PB1", "GENE_OR_GENE_PRODUCT", 434, 437], ["Arg 17", "AMINO_ACID", 442, 448], ["Glu 18", "AMINO_ACID", 451, 457], ["Gln 39", "AMINO_ACID", 460, 466], ["Lys 41", "AMINO_ACID", 473, 479], ["PB2", "GENE_OR_GENE_PRODUCT", 485, 488], ["A/PR/8/34/H1N1 influenza-A polymerase", "ORGANISM", 564, 601], ["influenza-B vRNAThe", "ORGANISM", 701, 720], ["IAV", "ORGANISM", 755, 758], ["TCA", "SIMPLE_CHEMICAL", 777, 780], ["TCA", "SIMPLE_CHEMICAL", 836, 839], ["catalytic site", "PROTEIN", 86, 100], ["PB2 linker domain", "PROTEIN", 105, 122], ["catalytic site", "PROTEIN", 170, 184], ["PB1 priming loop", "PROTEIN", 202, 218], ["PR", "PROTEIN", 566, 568], ["8/34", "PROTEIN", 569, 573], ["H1N1 influenza-A polymerase", "PROTEIN", 574, 601], ["3\u2032end", "PROTEIN", 629, 634], ["catalytic site", "DNA", 656, 670], ["H1N1 influenza", "SPECIES", 574, 588], ["A/PR/8/34/H1N1 influenza-A", "SPECIES", 564, 590], ["IAV", "SPECIES", 755, 758], ["PB2 linker domain", "PROBLEM", 105, 122], ["PB1 priming loop", "TREATMENT", 202, 218], ["influenza", "PROBLEM", 249, 258], ["these compounds", "TEST", 288, 303], ["the residues Arg", "TEST", 314, 330], ["Glu", "TEST", 337, 340], ["Ala", "TEST", 347, 350], ["Ser", "TEST", 361, 364], ["PA", "TEST", 374, 376], ["Thr", "TEST", 378, 381], ["Ala", "TEST", 387, 390], ["Ala", "TEST", 397, 400], ["Pro", "TEST", 407, 410], ["Met", "TEST", 421, 424], ["PB1", "TEST", 434, 437], ["Arg", "TEST", 442, 445], ["Glu", "TEST", 451, 454], ["Gln", "TEST", 460, 463], ["Lys", "TEST", 473, 476], ["PB2 act", "TEST", 485, 492], ["A/PR", "TEST", 564, 568], ["H1N1 influenza", "PROBLEM", 574, 588], ["A polymerase", "PROBLEM", 589, 601], ["influenza", "PROBLEM", 701, 710], ["IAV replication", "TREATMENT", 755, 770], ["TCA precipitation", "TREATMENT", 777, 794], ["Further experimental studies", "TEST", 801, 829], ["TCA precipitation assay", "TEST", 836, 859], ["compound 1 inhibited polymerase activity", "PROBLEM", 872, 912], ["an IC", "TEST", 918, 923], ["the study", "TEST", 1052, 1061], ["PB2 linker", "OBSERVATION", 105, 115], ["influenza", "OBSERVATION", 249, 258], ["vRNA", "OBSERVATION", 642, 646], ["catalytic site", "OBSERVATION", 656, 670], ["influenza", "OBSERVATION", 701, 710]]], ["5b) and 3 (Fig. 5c) weakly inhibited polymerase activities, having an IC 25 and IC 50 of 0.8 and 3.58 and 0.6 and 2.13 \u03bcM, whereas compounds 4 (Fig. 5d) and 8 (Fig. 5h) had a significant effect on Flu A polymerase activity with an IC 25 and IC 50 of 0.06 and 0.21 and 0.27 and 0.68 \u03bcM, respectively.", [["Flu", "CHEMICAL", 197, 200], ["Flu A", "CHEMICAL", 197, 202], ["Flu A polymerase", "GENE_OR_GENE_PRODUCT", 197, 213], ["Flu A polymerase", "PROTEIN", 197, 213], ["weakly inhibited polymerase activities", "PROBLEM", 20, 58], ["an IC", "TEST", 67, 72], ["IC", "TEST", 80, 82], ["a significant effect", "PROBLEM", 173, 193], ["an IC", "TEST", 228, 233], ["IC", "TEST", 241, 243]]], ["However, compounds 5 (Fig. 5e) and 6 ( Fig. 5f ) had a very large effect on polymerase inhibition with an IC 25 and IC 50 of 0.02 and 0.09 and 0.03 and 0.09 \u03bcM.", [["a very large effect on polymerase inhibition", "PROBLEM", 53, 97], ["an IC", "TREATMENT", 103, 108], ["very", "OBSERVATION_MODIFIER", 55, 59], ["large", "OBSERVATION_MODIFIER", 60, 65], ["effect", "OBSERVATION", 66, 72]]], ["Thus, compounds 5 and 6 displays broadspectrum antiviral activity against Flu A virus with IC 50 at the same concentration of 0.09 \u00b5M.", [["compounds 5 and 6", "CHEMICAL", 6, 23], ["Flu A", "CHEMICAL", 74, 79], ["Flu A virus", "ORGANISM", 74, 85], ["Flu A virus", "SPECIES", 74, 85], ["broadspectrum antiviral activity", "TREATMENT", 33, 65], ["Flu A virus", "TREATMENT", 74, 85], ["IC", "TREATMENT", 91, 93], ["antiviral activity", "OBSERVATION", 47, 65]]], ["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate, a known inhibitor of Flu A polymerase exhibited a 50% (IC 50 ) effective concentration at 1.2 \u03bcM.", [["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 0, 43], ["Flu A", "CHEMICAL", 66, 71], ["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 0, 43], ["Flu A", "CHEMICAL", 66, 71], ["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "SIMPLE_CHEMICAL", 0, 43], ["Flu A polymerase", "GENE_OR_GENE_PRODUCT", 66, 82], ["Flu A polymerase", "PROTEIN", 66, 82], ["deoxy", "TEST", 3, 8], ["fluoroguanosine", "TREATMENT", 12, 27], ["triphosphate", "TREATMENT", 31, 43], ["a known inhibitor", "TREATMENT", 45, 62], ["Flu A polymerase", "TEST", 66, 82]]], ["However, for compound 6, the higher rate of polymerase inhibition was seen completely at a very low concentration between 0.01 and 0.1 \u00b5M compared with all other compounds used in the study.", [["the higher rate of polymerase inhibition", "TREATMENT", 25, 65], ["the study", "TEST", 180, 189]]], ["Moreover, all these eight NTPs show 95% (EC 95 ) of viral polymerase inhibition greater than 100 \u00b5M.", [["NTPs", "CHEMICAL", 26, 30], ["NTPs", "CHEMICAL", 26, 30], ["viral polymerase", "PROTEIN", 52, 68], ["NTPs", "TEST", 26, 30], ["EC", "TEST", 41, 43], ["viral polymerase inhibition", "TEST", 52, 79]]], ["However, no significant effect of compounds 8-11 (Fig. 5i-k) was observed against the activity of the influenza polymerase even at higher concentration of 100 \u03bcM.Stage-III: In the presence of influenza-B vRNAA regression analysis of logIC 50 with the docked scores, \u0394G for the compounds 1-7 including the positive control 2\u2032deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate in the presence of influenza-A vRNA (Stage-I) ( Table 2) , influenza-A vRNA with extended primer (Stage-II) ( Table 3) and influenza-B vRNA (Stage-III) (Table 4 ), were carried out and their scatter plots was drawn.", [["compounds 8-11", "CHEMICAL", 34, 48], ["2\u2032deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 322, 364], ["2\u2032deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 322, 364], ["2\u2032deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "SIMPLE_CHEMICAL", 322, 364], ["influenza polymerase", "PROTEIN", 102, 122], ["logIC 50", "DNA", 233, 241], ["significant effect of compounds", "PROBLEM", 12, 43], ["the influenza polymerase", "PROBLEM", 98, 122], ["influenza", "PROBLEM", 192, 201], ["the compounds", "TEST", 273, 286], ["deoxy", "TEST", 324, 329], ["fluoroguanosine", "TREATMENT", 333, 348], ["triphosphate", "TREATMENT", 352, 364], ["influenza", "PROBLEM", 384, 393], ["A vRNA", "PROBLEM", 394, 400], ["influenza", "PROBLEM", 424, 433], ["A vRNA", "PROBLEM", 434, 440], ["extended primer", "TEST", 446, 461], ["influenza", "PROBLEM", 488, 497], ["their scatter plots", "TEST", 550, 569], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["effect", "OBSERVATION_MODIFIER", 24, 30], ["influenza", "OBSERVATION", 192, 201], ["influenza", "OBSERVATION", 384, 393]]], ["It was found that these compounds showed a positive correlation with an R 2 value of 0.21, and 0.20 in Stage-I and Stage-III and a negative correlation of 0.001 in Stage-II.", [["an R 2 value", "TEST", 69, 81], ["negative", "OBSERVATION", 131, 139]]], ["However, the best correlation was obtained with an R 2 value of 0.73 and 0.57 (Fig. 6) when \u0394G for the positive control 2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032triphosphate were removed from Stage-I and Stage-III.", [["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032triphosphate", "CHEMICAL", 120, 162], ["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032triphosphate", "CHEMICAL", 120, 162], ["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032triphosphate", "SIMPLE_CHEMICAL", 120, 162], ["an R 2 value", "TEST", 48, 60], ["\u0394G", "TEST", 92, 94], ["deoxy", "TEST", 123, 128], ["fluoroguanosine 5\u2032triphosphate", "TREATMENT", 132, 162]]], ["However, no change in R 2 value was seen in Stage-II even after removing the \u0394G for the positive control.DiscussionHere we report the identification of 11 NTPs that binds to the homology model of A/PR/8/34/H1N1 influenza virus RNA polymerase with higher affinities.", [["NTPs", "CHEMICAL", 155, 159], ["NTPs", "CHEMICAL", 155, 159], ["R 2", "GENE_OR_GENE_PRODUCT", 22, 25], ["A/PR/8/34/H1N1 influenza virus", "ORGANISM", 196, 226], ["PR", "PROTEIN", 198, 200], ["H1N1 influenza virus RNA polymerase", "PROTEIN", 206, 241], ["H1N1 influenza virus", "SPECIES", 206, 226], ["A/PR/8/34/H1N1 influenza virus", "SPECIES", 196, 226], ["change in R 2 value", "PROBLEM", 12, 31], ["the \u0394G", "TREATMENT", 73, 79], ["the positive control", "TREATMENT", 84, 104], ["A/PR", "TEST", 196, 200], ["H1N1 influenza virus RNA polymerase", "PROBLEM", 206, 241], ["higher affinities", "PROBLEM", 247, 264], ["no", "UNCERTAINTY", 9, 11], ["change", "OBSERVATION_MODIFIER", 12, 18], ["positive control", "OBSERVATION", 88, 104]]], ["The docking studies in the Stage-I and III confirm that all these linear and Vshaped compounds 1-3 except compound 11 with influenza-A vRNA commonly binds to the catalytic site around the priming loop of PB1 domain.", [["influenza-A vRNA", "ORGANISM", 123, 139], ["catalytic site", "DNA", 162, 176], ["PB1 domain", "PROTEIN", 204, 214], ["The docking studies", "TEST", 0, 19], ["Vshaped compounds", "TEST", 77, 94], ["influenza", "PROBLEM", 123, 132], ["A vRNA commonly binds", "PROBLEM", 133, 154], ["linear", "OBSERVATION_MODIFIER", 66, 72]]], ["However, compounds 10 and 11 occupies the catalytic site while the rest of the molecules bind to tunnel 2 in the presence of capped primer from \u02786 polymerase.", [["\u02786 polymerase", "GENE_OR_GENE_PRODUCT", 144, 157], ["catalytic site", "PROTEIN", 42, 56], ["\u02786 polymerase", "PROTEIN", 144, 157], ["capped primer", "TREATMENT", 125, 138], ["capped primer", "OBSERVATION", 125, 138]]], ["Both the cyclic compounds 7 and 8 along bind near to the exit channel below the linker domain in Stage-III, although compound 7 binds to catalytic site in Stage-I.", [["Stage-III", "GENE_OR_GENE_PRODUCT", 97, 106], ["exit channel", "PROTEIN", 57, 69], ["linker domain", "PROTEIN", 80, 93], ["Stage-III", "PROTEIN", 97, 106], ["catalytic site", "PROTEIN", 137, 151], ["compound 7 binds to catalytic site", "PROBLEM", 117, 151], ["cyclic compounds", "OBSERVATION", 9, 25]]], ["Previous studies also shown that the known compound AZT-TP bind near to the exit channel below the linker domain (Pagadala 2019) .", [["AZT", "CHEMICAL", 52, 55], ["TP", "CHEMICAL", 56, 58], ["AZT-TP", "CHEMICAL", 52, 58], ["AZT-TP", "GENE_OR_GENE_PRODUCT", 52, 58], ["exit channel", "PROTEIN", 76, 88], ["linker domain", "PROTEIN", 99, 112], ["Pagadala 2019", "PROTEIN", 114, 127], ["Previous studies", "TEST", 0, 16], ["the known compound AZT-TP bind", "PROBLEM", 33, 63], ["compound", "OBSERVATION_MODIFIER", 43, 51], ["AZT", "OBSERVATION", 52, 55], ["exit channel", "OBSERVATION", 76, 88], ["linker", "OBSERVATION_MODIFIER", 99, 105]]], ["Further, the results obtained using regression analysis with R 2 = 0.73 shows that binding Ligand protein interactions show that the compounds 1-3 in Stage-I primarily interact with PB2-N, residue nearby motif-II and motif-IV, and the PB1 priming loop that plays an important role in stabilizing the ligand-target interaction.", [["1-3", "GENE_OR_GENE_PRODUCT", 143, 146], ["Stage-I", "GENE_OR_GENE_PRODUCT", 150, 157], ["motif-IV", "GENE_OR_GENE_PRODUCT", 217, 225], ["PB2", "PROTEIN", 182, 185], ["N", "PROTEIN", 186, 187], ["motif-IV", "PROTEIN", 217, 225], ["PB1 priming loop", "PROTEIN", 235, 251], ["regression analysis", "TEST", 36, 55], ["R", "TEST", 61, 62], ["binding Ligand protein interactions", "TEST", 83, 118], ["the compounds", "TEST", 129, 142], ["PB2", "TREATMENT", 182, 185], ["motif-IV", "TREATMENT", 217, 225], ["the PB1 priming loop", "TREATMENT", 231, 251]]], ["In particular, Met 646 , Pro 647 , and Ala 648 of the priming loop of PB1 are the key residues stabilizing the compounds 1 and 3 scaffolds within the catalytic site of the IAV RdRp.", [["Met 646", "CHEMICAL", 15, 22], ["Pro 647", "CHEMICAL", 25, 32], ["Ala 648", "CHEMICAL", 39, 46], ["Met", "CHEMICAL", 15, 18], ["Pro 647", "CHEMICAL", 25, 32], ["Ala", "CHEMICAL", 39, 42], ["Met 646", "GENE_OR_GENE_PRODUCT", 15, 22], ["Pro 647", "SIMPLE_CHEMICAL", 25, 32], ["Ala 648", "AMINO_ACID", 39, 46], ["PB1", "GENE_OR_GENE_PRODUCT", 70, 73], ["IAV RdRp", "ORGANISM", 172, 180], ["PB1", "PROTEIN", 70, 73], ["compounds 1 and 3 scaffolds", "DNA", 111, 138], ["catalytic site", "PROTEIN", 150, 164], ["IAV RdRp", "PROTEIN", 172, 180], ["IAV RdRp", "SPECIES", 172, 180], ["Pro", "TEST", 25, 28], ["Ala", "TEST", 39, 42], ["the priming loop of PB1", "TREATMENT", 50, 73], ["key residues", "OBSERVATION", 82, 94], ["compounds", "OBSERVATION_MODIFIER", 111, 120], ["IAV RdRp", "OBSERVATION", 172, 180]]], ["This binding orientation in turn shields Asp 445 and Asp 446 essential for polymerase activity of influenza virus within the catalytic site (Zamyatkin et al. 2008 ).", [["Asp 445", "CHEMICAL", 41, 48], ["Asp 446", "CHEMICAL", 53, 60], ["Asp", "CHEMICAL", 41, 44], ["Asp", "CHEMICAL", 53, 56], ["Asp 445", "AMINO_ACID", 41, 48], ["Asp 446", "AMINO_ACID", 53, 60], ["influenza virus", "ORGANISM", 98, 113], ["catalytic site", "PROTEIN", 125, 139], ["influenza virus", "SPECIES", 98, 113], ["influenza virus", "SPECIES", 98, 113], ["Asp", "TEST", 41, 44], ["Asp", "TEST", 53, 56], ["polymerase activity", "PROBLEM", 75, 94], ["influenza virus", "PROBLEM", 98, 113], ["influenza virus", "OBSERVATION", 98, 113]]], ["These two residues coordinate the metal ions involved in the catalysis.", [["metal ions", "SIMPLE_CHEMICAL", 34, 44], ["the metal ions", "TREATMENT", 30, 44], ["the catalysis", "TREATMENT", 57, 70], ["metal ions", "OBSERVATION", 34, 44]]], ["When either of these Asp-Asp residues were (Biswas and Nayak 1994) .", [["Asp-Asp", "CHEMICAL", 21, 28], ["Asp", "CHEMICAL", 21, 24], ["Asp", "CHEMICAL", 25, 28], ["these Asp", "TEST", 15, 24], ["Asp residues", "PROBLEM", 25, 37]]], ["The Asp 446 may deprotonate the 3\u2032hydroxy group of the priming NTP by acting as a general base and helps the \u03b1-phosphate of the NTP to be incorporated into the activator strand.", [["Asp 446", "CHEMICAL", 4, 11], ["NTP", "CHEMICAL", 63, 66], ["\u03b1-phosphate", "CHEMICAL", 109, 120], ["NTP", "CHEMICAL", 128, 131], ["Asp", "CHEMICAL", 4, 7], ["3\u2032hydroxy", "CHEMICAL", 32, 41], ["NTP", "CHEMICAL", 63, 66], ["\u03b1-phosphate", "CHEMICAL", 109, 120], ["NTP", "CHEMICAL", 128, 131], ["Asp 446", "SIMPLE_CHEMICAL", 4, 11], ["NTP", "SIMPLE_CHEMICAL", 63, 66], ["\u03b1-phosphate", "SIMPLE_CHEMICAL", 109, 120], ["NTP", "SIMPLE_CHEMICAL", 128, 131], ["The Asp", "TEST", 0, 7], ["the priming NTP", "TREATMENT", 51, 66], ["the NTP", "TREATMENT", 124, 131]]], ["The suitable geometry for the reaction to happen is provided by His 649 of the priming loop.", [["His 649", "CHEMICAL", 64, 71], ["His", "CHEMICAL", 64, 67], ["the reaction", "PROBLEM", 26, 38], ["the priming loop", "TREATMENT", 75, 91]]], ["Mutational analysis of His 649 A and Pro 647 A individually, impair terminal de novo initiation on a vRNA promoter with P 651 A having the strongest effect (Te Velthuis et al. 2016) .", [["Pro 647 A", "GENE_OR_GENE_PRODUCT", 37, 46], ["vRNA promoter", "DNA", 101, 114], ["P 651 A", "DNA", 120, 127], ["Mutational analysis", "TEST", 0, 19], ["a vRNA promoter", "TREATMENT", 99, 114]]], ["To coordinate with the catalytic magnesium ion, the conformational change of Asp 446 side chain with 3.5 \u00c5 is required to allow the polymerase to initiate polymerization.", [["magnesium", "CHEMICAL", 33, 42], ["Asp 446", "CHEMICAL", 77, 84], ["magnesium", "CHEMICAL", 33, 42], ["Asp", "CHEMICAL", 77, 80], ["magnesium", "SIMPLE_CHEMICAL", 33, 42], ["Asp 446", "AMINO_ACID", 77, 84], ["the catalytic magnesium ion", "TREATMENT", 19, 46], ["Asp 446 side chain", "TREATMENT", 77, 95], ["the polymerase", "TREATMENT", 128, 142], ["polymerization", "TREATMENT", 155, 169]]], ["Apart from these interactions, compounds 1 and 3 have the ability to disturb the structural stability of priming loop by interacting with nearby residues Pro 647 and Ala 648 of PB1 central domain.", [["Ala 648", "CHEMICAL", 166, 173], ["Pro 647", "CHEMICAL", 154, 161], ["Ala", "CHEMICAL", 166, 169], ["3", "GENE_OR_GENE_PRODUCT", 47, 48], ["Pro 647", "AMINO_ACID", 154, 161], ["Ala 648", "AMINO_ACID", 166, 173], ["PB1 central domain", "PROTEIN", 177, 195], ["PB1 central domain", "TREATMENT", 177, 195]]], ["However, compound 2 may disturb the structural stability of PB2-N required for subunit binding to PB1-C by interacting with Asn 42 and Ala 44 of PB2-N.", [["Asn 42", "CHEMICAL", 124, 130], ["Asn", "CHEMICAL", 124, 127], ["Ala", "CHEMICAL", 135, 138], ["PB2-N", "GENE_OR_GENE_PRODUCT", 60, 65], ["PB1-C", "SIMPLE_CHEMICAL", 98, 103], ["Asn 42", "AMINO_ACID", 124, 130], ["Ala 44", "AMINO_ACID", 135, 141], ["PB2", "PROTEIN", 60, 63], ["N", "PROTEIN", 64, 65], ["PB1", "PROTEIN", 98, 101], ["PB2", "PROTEIN", 145, 148], ["stability", "OBSERVATION_MODIFIER", 47, 56]]], ["Structural analysis has shown that N-terminus of PB1 established a crucial high-affinity interaction with Cterminal domain of the PA protein (Reuther et al. 2011 ).", [["PB1", "GENE_OR_GENE_PRODUCT", 49, 52], ["PA", "GENE_OR_GENE_PRODUCT", 130, 132], ["PB1", "PROTEIN", 49, 52], ["Cterminal domain", "PROTEIN", 106, 122], ["PA protein", "PROTEIN", 130, 140], ["Structural analysis", "TEST", 0, 19], ["N-terminus of PB1", "TREATMENT", 35, 52]]], ["Based on the binding modes, it might be speculated that compounds 1-3 may induce some structural changes of motifs-II and IV involved in the formation of catalytic mechanism and putative NTP tunnel formation.", [["NTP", "CHEMICAL", 187, 190], ["NTP", "CHEMICAL", 187, 190], ["1-3", "GENE_OR_GENE_PRODUCT", 66, 69], ["motifs-II", "GENE_OR_GENE_PRODUCT", 108, 117], ["NTP tunnel", "MULTI-TISSUE_STRUCTURE", 187, 197], ["some structural changes of motifs", "PROBLEM", 81, 114], ["IV", "TREATMENT", 122, 124], ["catalytic mechanism", "PROBLEM", 154, 173], ["putative NTP tunnel formation", "TREATMENT", 178, 207], ["NTP tunnel", "OBSERVATION", 187, 197]]], ["Mutational analysis of Lys 481 of motif-IV to Gln and Arg caused a drastic reduction in catalytic activity of PB1 ranging from 1 to 7% compared with wild-type which shows the importance of this amino acid in the viral replicase transcriptase activity of PB1 (Biswas and Nayak 1994) .", [["Lys 481 of motif-IV", "CHEMICAL", 23, 42], ["Gln", "CHEMICAL", 46, 49], ["Arg", "CHEMICAL", 54, 57], ["amino acid", "CHEMICAL", 194, 204], ["Lys", "CHEMICAL", 23, 26], ["Gln", "CHEMICAL", 46, 49], ["Arg", "CHEMICAL", 54, 57], ["amino acid", "CHEMICAL", 194, 204], ["Lys 481", "AMINO_ACID", 23, 30], ["Gln", "AMINO_ACID", 46, 49], ["Arg", "AMINO_ACID", 54, 57], ["amino acid", "AMINO_ACID", 194, 204], ["PB1", "PROTEIN", 110, 113], ["viral replicase transcriptase", "PROTEIN", 212, 241], ["Mutational analysis", "TEST", 0, 19], ["Lys", "TEST", 23, 26], ["motif-IV to Gln", "TREATMENT", 34, 49], ["a drastic reduction", "TREATMENT", 65, 84], ["PB1", "TEST", 110, 113], ["this amino acid", "TREATMENT", 189, 204], ["the viral replicase transcriptase activity of PB1", "TREATMENT", 208, 257], ["drastic", "OBSERVATION_MODIFIER", 67, 74], ["reduction", "OBSERVATION_MODIFIER", 75, 84], ["catalytic activity", "OBSERVATION", 88, 106]]], ["The conserved residues of motif D, Lys 480 and Lys 481 involved in NTP binding is further stabilized by contacts with PA helix \u03b120 (656-663) and the PA peptide 671-684 ).", [["Lys 481", "CHEMICAL", 47, 54], ["NTP", "CHEMICAL", 67, 70], ["Lys", "CHEMICAL", 35, 38], ["Lys", "CHEMICAL", 47, 50], ["Lys 480", "AMINO_ACID", 35, 42], ["Lys 481", "AMINO_ACID", 47, 54], ["NTP", "SIMPLE_CHEMICAL", 67, 70], ["PA helix \u03b120", "GENE_OR_GENE_PRODUCT", 118, 130], ["Lys", "TEST", 47, 50], ["PA helix", "TEST", 118, 126], ["the PA peptide", "TEST", 145, 159]]], ["Thus, our compounds 1-3 interferes in stacking interactions between His 649 , P 651 with the incoming NTP by binding to the catalytic site and inhibit the activity of the viral polymerase.", [["His 649 , P 651", "CHEMICAL", 68, 83], ["NTP", "CHEMICAL", 102, 105], ["His", "CHEMICAL", 68, 71], ["NTP", "CHEMICAL", 102, 105], ["1-3", "GENE_OR_GENE_PRODUCT", 20, 23], ["NTP", "SIMPLE_CHEMICAL", 102, 105], ["catalytic site", "PROTEIN", 124, 138], ["viral polymerase", "PROTEIN", 171, 187], ["the incoming NTP", "TREATMENT", 89, 105], ["the viral polymerase", "PROBLEM", 167, 187], ["viral polymerase", "OBSERVATION", 171, 187]]], ["Furthermore, binding mode analysis revealed that compounds 4, 5, and 6 may disturb the structural stability of motif-IV by interacting the nearby residues mainly with Phe 501 and Val 502 of PB1 central.", [["compounds 4, 5, and 6", "CHEMICAL", 49, 70], ["Phe", "CHEMICAL", 167, 170], ["Phe", "CHEMICAL", 167, 170], ["Val", "CHEMICAL", 179, 182], ["motif-IV", "GENE_OR_GENE_PRODUCT", 111, 119], ["Phe 501", "AMINO_ACID", 167, 174], ["motif-IV", "PROTEIN", 111, 119], ["PB1", "PROTEIN", 190, 193], ["binding mode analysis", "TEST", 13, 34], ["motif-IV", "TREATMENT", 111, 119], ["Phe", "TEST", 167, 170], ["PB1 central", "TREATMENT", 190, 201]]], ["More likely PB1 Phe 501 plays a main role in IAV RdRp inhibition of these compounds 4, 5, and 6 in tunnel 2 above the PB1 priming loop.", [["Phe 501", "CHEMICAL", 16, 23], ["Phe", "CHEMICAL", 16, 19], ["PB1", "GENE_OR_GENE_PRODUCT", 12, 15], ["Phe 501", "AMINO_ACID", 16, 23], ["IAV RdRp", "ORGANISM", 45, 53], ["PB1", "DNA", 12, 15], ["PB1", "PROTEIN", 118, 121], ["PB1", "SPECIES", 12, 15], ["IAV", "SPECIES", 45, 48], ["tunnel", "TREATMENT", 99, 105], ["the PB1 priming loop", "TREATMENT", 114, 134], ["main", "OBSERVATION_MODIFIER", 32, 36], ["IAV RdRp", "OBSERVATION", 45, 53], ["compounds", "OBSERVATION_MODIFIER", 74, 83], ["loop", "OBSERVATION", 130, 134]]], ["However, this residue acts as an electron donor for compound 5 inhibition, while the same residue acts as an electron acceptor for IAV RdRp inhibition by compounds 4 and 6.", [["electron", "SIMPLE_CHEMICAL", 109, 117], ["an electron donor", "TREATMENT", 30, 47], ["compound 5 inhibition", "TREATMENT", 52, 73], ["an electron acceptor", "TREATMENT", 106, 126], ["IAV RdRp inhibition", "TREATMENT", 131, 150]]], ["Plausibly, the side chains of Arg 142 , Lys 279 , and Lys 670 create a favorable environment with a positive electrostatic potential for the binding of these compounds with high potency in TCA precipitation assay.", [["Arg 142", "CHEMICAL", 30, 37], ["Lys 279", "CHEMICAL", 40, 47], ["Lys 670", "CHEMICAL", 54, 61], ["TCA", "CHEMICAL", 189, 192], ["Arg", "CHEMICAL", 30, 33], ["Lys", "CHEMICAL", 40, 43], ["Lys", "CHEMICAL", 54, 57], ["TCA", "CHEMICAL", 189, 192], ["Arg 142", "SIMPLE_CHEMICAL", 30, 37], ["Lys 279", "AMINO_ACID", 40, 47], ["Lys 670", "AMINO_ACID", 54, 61], ["TCA", "SIMPLE_CHEMICAL", 189, 192], ["Arg", "TEST", 30, 33], ["Lys", "TEST", 40, 43], ["Lys", "TEST", 54, 57], ["high potency in TCA precipitation assay", "PROBLEM", 173, 212]]], ["In addition, compounds 4 and 5 might be associated with less conformational changes of PB2 linker domain by tight binding with Lys 670 of PB2 627 domain.", [["Lys 670", "CHEMICAL", 127, 134], ["Lys", "CHEMICAL", 127, 130], ["5", "ORGANISM", 29, 30], ["Lys 670", "AMINO_ACID", 127, 134], ["PB2 linker domain", "PROTEIN", 87, 104], ["Lys 670", "PROTEIN", 127, 134], ["PB2 627 domain", "PROTEIN", 138, 152], ["less conformational changes of PB2 linker domain", "PROBLEM", 56, 104], ["Lys", "TEST", 127, 130], ["PB2", "TEST", 138, 141]]], ["This contact may show the impact on the viral genome transcription and replication by influenza polymerase.", [["viral genome", "DNA", 40, 52], ["influenza polymerase", "PROTEIN", 86, 106], ["the viral genome transcription", "TREATMENT", 36, 66], ["influenza polymerase", "PROBLEM", 86, 106]]], ["These results also reveal that compounds with 2\u2032deoxycytidine-5\u2032triphosphate and diadenosine Penta phosphate are more potent than other molecules used in the study with 0.09 and 0.21 \u00b5M.", [["2\u2032deoxycytidine-5\u2032triphosphate", "CHEMICAL", 46, 76], ["diadenosine", "CHEMICAL", 81, 92], ["Penta phosphate", "CHEMICAL", 93, 108], ["2\u2032deoxycytidine-5\u2032triphosphate", "CHEMICAL", 46, 76], ["diadenosine Penta phosphate", "CHEMICAL", 81, 108], ["2\u2032deoxycytidine-5\u2032triphosphate", "SIMPLE_CHEMICAL", 46, 76], ["diadenosine Penta phosphate", "SIMPLE_CHEMICAL", 81, 108], ["2\u2032deoxycytidine", "TREATMENT", 46, 61], ["5\u2032triphosphate", "TREATMENT", 62, 76], ["diadenosine Penta phosphate", "TREATMENT", 81, 108], ["the study", "TEST", 154, 163]]], ["This may be due to inhibition of influenza virus RNA polymerase by incorporating in place of CTP and ATP.", [["CTP", "CHEMICAL", 93, 96], ["ATP", "CHEMICAL", 101, 104], ["CTP", "CHEMICAL", 93, 96], ["ATP", "CHEMICAL", 101, 104], ["influenza virus", "ORGANISM", 33, 48], ["CTP", "SIMPLE_CHEMICAL", 93, 96], ["ATP", "SIMPLE_CHEMICAL", 101, 104], ["influenza virus RNA polymerase", "PROTEIN", 33, 63], ["influenza virus", "SPECIES", 33, 48], ["influenza virus", "SPECIES", 33, 48], ["influenza virus RNA polymerase", "PROBLEM", 33, 63], ["CTP", "TEST", 93, 96], ["ATP", "TEST", 101, 104], ["may be due to", "UNCERTAINTY", 5, 18], ["influenza", "OBSERVATION", 33, 42]]], ["Previously, McGeoch and Kitron showed that IAV RdRp was stimulated by GpG and GpC (McGeoch and Kitron 1975) .", [["IAV RdRp", "ORGANISM", 43, 51], ["GpG", "SIMPLE_CHEMICAL", 70, 73], ["GpC", "SIMPLE_CHEMICAL", 78, 81], ["McGeoch", "PROTEIN", 12, 19], ["Kitron", "PROTEIN", 24, 30], ["IAV RdRp", "PROTEIN", 43, 51], ["GpG", "PROTEIN", 70, 73], ["IAV", "SPECIES", 43, 46], ["McGeoch", "TEST", 12, 19], ["Kitron", "TREATMENT", 24, 30], ["IAV RdRp", "TREATMENT", 43, 51], ["GpC", "TEST", 78, 81], ["IAV RdRp", "OBSERVATION", 43, 51]]], ["Later, plotch and krug had reported that initiation of IAV RdRp cRNA can be stimulated by ApG and GpG dinucleotides which are incorporated at the 5\u2032end of the cRNA (Plotch and Krug 1977) .", [["dinucleotides", "CHEMICAL", 102, 115], ["IAV RdRp", "ORGANISM", 55, 63], ["ApG", "SIMPLE_CHEMICAL", 90, 93], ["IAV RdRp cRNA", "RNA", 55, 68], ["IAV", "SPECIES", 55, 58], ["IAV RdRp cRNA", "TREATMENT", 55, 68], ["ApG and GpG dinucleotides", "TREATMENT", 90, 115], ["IAV RdRp", "OBSERVATION", 55, 63], ["GpG dinucleotides", "OBSERVATION", 98, 115]]], ["This enhancement of IAV RdRp by GpC and ApG is abolished by compounds 4, 5, and 6 more likely by compounds 5 and 6 than compound 4 in the series.", [["ApG", "CHEMICAL", 40, 43], ["IAV RdRp", "ORGANISM", 20, 28], ["GpC", "GENE_OR_GENE_PRODUCT", 32, 35], ["ApG", "GENE_OR_GENE_PRODUCT", 40, 43], ["IAV RdRp", "PROTEIN", 20, 28], ["GpC", "PROTEIN", 32, 35], ["ApG", "PROTEIN", 40, 43], ["IAV", "SPECIES", 20, 23], ["IAV RdRp", "TREATMENT", 20, 28], ["GpC", "PROBLEM", 32, 35], ["ApG", "TREATMENT", 40, 43], ["IAV RdRp", "OBSERVATION", 20, 28], ["GpC", "OBSERVATION_MODIFIER", 32, 35], ["compounds", "OBSERVATION_MODIFIER", 60, 69], ["compounds", "OBSERVATION", 97, 106]]], ["Even though, the binding site of compounds 7 and 8 is the same at the end of the tunnel 2, compound 7 may have a different mechanism of action by donating electrons to Gly 275 of linker that leads to the PB2-N2 subdomain and induce conformational changes of PA endonuclease.DiscussionBy determining the IC 50 profiles for each of these seven compounds tested experimentally, it was proved that compounds 1-7 and AZT-TP that was published previously were competitively inhibiting the incorporation of GTP into viral RNA of influenza polymerase (Pagadala 2019) .", [["Gly 275", "CHEMICAL", 168, 175], ["compounds 1-7", "CHEMICAL", 394, 407], ["AZT", "CHEMICAL", 412, 415], ["GTP", "CHEMICAL", 500, 503], ["Gly", "CHEMICAL", 168, 171], ["N2", "CHEMICAL", 208, 210], ["AZT-TP", "CHEMICAL", 412, 418], ["GTP", "CHEMICAL", 500, 503], ["Gly 275", "AMINO_ACID", 168, 175], ["PA endonuclease", "GENE_OR_GENE_PRODUCT", 258, 273], ["1-7", "SIMPLE_CHEMICAL", 404, 407], ["AZT-TP", "SIMPLE_CHEMICAL", 412, 418], ["GTP", "SIMPLE_CHEMICAL", 500, 503], ["PB2", "PROTEIN", 204, 207], ["N2 subdomain", "PROTEIN", 208, 220], ["PA endonuclease", "PROTEIN", 258, 273], ["viral RNA", "RNA", 509, 518], ["influenza polymerase", "PROTEIN", 522, 542], ["conformational changes of PA endonuclease", "PROBLEM", 232, 273], ["AZT-TP", "TREATMENT", 412, 418], ["GTP into viral RNA of influenza polymerase", "PROBLEM", 500, 542], ["compounds", "OBSERVATION", 33, 42], ["tunnel", "OBSERVATION", 81, 87], ["N2 subdomain", "OBSERVATION", 208, 220]]], ["This is in good correlation between our docking studies showing that these compounds bind to catalytic and linker domains and prevent the activity of influenza RdRp similar to positive control 2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate.", [["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 193, 236], ["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 193, 236], ["influenza RdRp", "ORGANISM", 150, 164], ["2\u2032-deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "SIMPLE_CHEMICAL", 193, 236], ["catalytic and linker domains", "PROTEIN", 93, 121], ["influenza RdRp", "PROTEIN", 150, 164], ["our docking studies", "TEST", 36, 55], ["catalytic and linker domains", "TREATMENT", 93, 121], ["influenza RdRp", "PROBLEM", 150, 164], ["deoxy", "TEST", 196, 201], ["fluoroguanosine", "TREATMENT", 205, 220], ["triphosphate", "TREATMENT", 224, 236]]], ["This also implies that compounds 1-3 may disturb the initiation of replication by inhibiting the incoming NTPs and compounds 4-7 may terminate viral elongation by adding the next correct nucleotide.", [["compounds 1-3", "CHEMICAL", 23, 36], ["NTPs", "CHEMICAL", 106, 110], ["nucleotide", "CHEMICAL", 187, 197], ["NTPs", "CHEMICAL", 106, 110], ["nucleotide", "CHEMICAL", 187, 197], ["1-3", "GENE_OR_GENE_PRODUCT", 33, 36], ["NTPs", "SIMPLE_CHEMICAL", 106, 110], ["replication", "TREATMENT", 67, 78], ["the incoming NTPs", "TREATMENT", 93, 110], ["viral elongation", "PROBLEM", 143, 159], ["viral elongation", "OBSERVATION", 143, 159]]], ["The results also suggest that the compounds 1-7 after binding to the catalytic site and exit channel inhibit the nucleophilic attack of the 3\u2032-OH on the \u03b1-phosphorous of the incoming NTP.", [["3\u2032-OH", "CHEMICAL", 140, 145], ["NTP", "CHEMICAL", 183, 186], ["3\u2032-OH", "CHEMICAL", 140, 145], ["\u03b1-phosphorous", "CHEMICAL", 153, 166], ["NTP", "CHEMICAL", 183, 186], ["3\u2032-OH", "SIMPLE_CHEMICAL", 140, 145], ["\u03b1-phosphorous", "SIMPLE_CHEMICAL", 153, 166], ["NTP", "SIMPLE_CHEMICAL", 183, 186], ["catalytic site", "PROTEIN", 69, 83], ["the compounds", "PROBLEM", 30, 43], ["nucleophilic attack", "OBSERVATION", 113, 132]]], ["For all the compounds 4, 5, 6, and 7 that demonstrated inhibitory activities, the IC 50 values were less than onefold better compared with IC 50 of 1.66 \u03bcM of the known compound 2\u2032deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate.", [["2\u2032deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 178, 220], ["2\u2032deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "CHEMICAL", 178, 220], ["2\u2032deoxy-2\u2032-fluoroguanosine 5\u2032-triphosphate", "SIMPLE_CHEMICAL", 178, 220], ["the IC 50 values", "TEST", 78, 94], ["IC", "TEST", 139, 141], ["deoxy", "TEST", 180, 185], ["fluoroguanosine", "TREATMENT", 189, 204]]], ["Even though compounds 8-11 did not inhibit viral replication in TCA precipitation assay, they all bound to the influenza catalytic site.", [["compounds 8-11", "CHEMICAL", 12, 26], ["TCA", "CHEMICAL", 64, 67], ["TCA", "CHEMICAL", 64, 67], ["TCA", "SIMPLE_CHEMICAL", 64, 67], ["influenza catalytic site", "DNA", 111, 135], ["TCA precipitation assay", "TEST", 64, 87], ["the influenza catalytic site", "PROBLEM", 107, 135], ["influenza", "OBSERVATION", 111, 120]]], ["Similar to compounds 1-7, these molecules might not exhibit anti-influenza activity, perhaps due to premature degradation or they may bind away from the catalytic site as explained in Stage-II and III.", [["1-7", "SIMPLE_CHEMICAL", 21, 24], ["Stage-II", "GENE_OR_GENE_PRODUCT", 184, 192], ["catalytic site", "PROTEIN", 153, 167], ["anti-influenza activity", "PROBLEM", 60, 83], ["premature degradation", "PROBLEM", 100, 121], ["might not exhibit", "UNCERTAINTY", 42, 59], ["anti-influenza activity", "OBSERVATION", 60, 83]]], ["Structural analysis of these compounds indicates that both indole ring and sulfonyl groups of V-shaped compounds 1-3 might play a major role in binding to the catalytic site of the viral polymerase.", [["indole", "CHEMICAL", 59, 65], ["sulfonyl", "CHEMICAL", 75, 83], ["indole", "CHEMICAL", 59, 65], ["sulfonyl", "CHEMICAL", 75, 83], ["indole ring", "SIMPLE_CHEMICAL", 59, 70], ["sulfonyl", "SIMPLE_CHEMICAL", 75, 83], ["1-3", "GENE_OR_GENE_PRODUCT", 113, 116], ["catalytic site", "PROTEIN", 159, 173], ["viral polymerase", "PROTEIN", 181, 197], ["Structural analysis", "TEST", 0, 19], ["these compounds", "PROBLEM", 23, 38], ["both indole ring", "TREATMENT", 54, 70], ["V-shaped compounds", "TREATMENT", 94, 112], ["indole ring", "OBSERVATION", 59, 70], ["shaped", "OBSERVATION_MODIFIER", 96, 102], ["compounds", "OBSERVATION", 103, 112], ["viral polymerase", "OBSERVATION", 181, 197]]], ["Previously, it was also shown that the effect of viral inhibition was high with compound A3 that contains an indole ring when compared with its derivate A3 that lack the indole ring.", [["indole", "CHEMICAL", 109, 115], ["indole", "CHEMICAL", 170, 176], ["indole", "CHEMICAL", 109, 115], ["indole", "CHEMICAL", 170, 176], ["indole ring", "SIMPLE_CHEMICAL", 170, 181], ["viral inhibition", "PROBLEM", 49, 65], ["compound A3", "PROBLEM", 80, 91], ["an indole ring", "TREATMENT", 106, 120], ["the indole ring", "TREATMENT", 166, 181], ["indole ring", "OBSERVATION", 109, 120], ["indole ring", "OBSERVATION", 170, 181]]], ["On the other hand, the high IC 50 of linear chain compounds 4 and 5 shows that high flexibility of desthiobiotin and N4-biotin might play an important role in destabilizing PB2 linker of the viral polymerase.", [["desthiobiotin", "CHEMICAL", 99, 112], ["N4-biotin", "CHEMICAL", 117, 126], ["desthiobiotin", "CHEMICAL", 99, 112], ["N4-biotin", "CHEMICAL", 117, 126], ["desthiobiotin", "SIMPLE_CHEMICAL", 99, 112], ["N4-biotin", "SIMPLE_CHEMICAL", 117, 126], ["PB2 linker", "PROTEIN", 173, 183], ["viral polymerase", "PROTEIN", 191, 207], ["linear chain compounds", "TEST", 37, 59], ["desthiobiotin and N4-biotin", "TREATMENT", 99, 126], ["destabilizing PB2 linker", "TREATMENT", 159, 183], ["the viral polymerase", "PROBLEM", 187, 207], ["high", "OBSERVATION_MODIFIER", 79, 83], ["viral polymerase", "OBSERVATION", 191, 207]]], ["In addition, destiobiotin may form destiobiotin-GTP complex through conjugation while N4-biotin may form N4-biotin-\u03b5-Lys 670 affecting the viral replication in TCA precipitation assay.", [["destiobiotin", "CHEMICAL", 13, 25], ["destiobiotin", "CHEMICAL", 35, 47], ["GTP", "CHEMICAL", 48, 51], ["N4-biotin", "CHEMICAL", 86, 95], ["N4-biotin-\u03b5-Lys 670", "CHEMICAL", 105, 124], ["TCA", "CHEMICAL", 160, 163], ["destiobiotin", "CHEMICAL", 13, 25], ["destiobiotin", "CHEMICAL", 35, 47], ["GTP", "CHEMICAL", 48, 51], ["N4-biotin", "CHEMICAL", 86, 95], ["N4-biotin-\u03b5-Lys 670", "CHEMICAL", 105, 124], ["TCA", "CHEMICAL", 160, 163], ["destiobiotin", "SIMPLE_CHEMICAL", 13, 25], ["destiobiotin", "SIMPLE_CHEMICAL", 35, 47], ["GTP", "SIMPLE_CHEMICAL", 48, 51], ["N4-biotin", "SIMPLE_CHEMICAL", 86, 95], ["N4-biotin-\u03b5-Lys 670", "SIMPLE_CHEMICAL", 105, 124], ["TCA", "SIMPLE_CHEMICAL", 160, 163], ["destiobiotin", "PROTEIN", 35, 47], ["GTP complex", "PROTEIN", 48, 59], ["destiobiotin", "TREATMENT", 13, 25], ["destiobiotin", "TREATMENT", 35, 47], ["GTP complex through conjugation", "PROBLEM", 48, 79], ["N4-biotin", "TREATMENT", 86, 95], ["the viral replication", "TREATMENT", 135, 156], ["TCA precipitation assay", "TEST", 160, 183], ["viral replication", "OBSERVATION", 139, 156]]], ["However, the high IC 50 of linear chain compound 6 may be due the presence of di-adenosine that leads to an increase in prolongation of transcription elongation competing with the natural substrates.", [["di-adenosine", "CHEMICAL", 78, 90], ["di-adenosine", "CHEMICAL", 78, 90], ["di-adenosine", "SIMPLE_CHEMICAL", 78, 90], ["di-adenosine", "PROBLEM", 78, 90], ["transcription elongation", "PROBLEM", 136, 160], ["high", "OBSERVATION_MODIFIER", 13, 17], ["linear", "OBSERVATION_MODIFIER", 27, 33], ["chain", "OBSERVATION_MODIFIER", 34, 39], ["may be due", "UNCERTAINTY", 51, 61], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["prolongation", "OBSERVATION_MODIFIER", 120, 132], ["transcription elongation", "OBSERVATION", 136, 160], ["natural substrates", "OBSERVATION", 180, 198]]], ["Considering the binding orientation, it clearly appears that a \u03c0-stacking between Phe 495 and 2\u2032-tosyl-N2-isobutyryl-guanosine of compound 7 may play an additional role in the inhibition of viral polymerase activity with an IC 50 of 0.68 \u00b5M.", [["Phe 495", "CHEMICAL", 82, 89], ["2\u2032-tosyl-N2-isobutyryl-guanosine", "CHEMICAL", 94, 126], ["Phe", "CHEMICAL", 82, 85], ["2\u2032-tosyl-N2-isobutyryl-guanosine", "CHEMICAL", 94, 126], ["Phe 495", "SIMPLE_CHEMICAL", 82, 89], ["2\u2032-tosyl-N2-isobutyryl-guanosine", "SIMPLE_CHEMICAL", 94, 126], ["compound 7", "SIMPLE_CHEMICAL", 130, 140], ["viral polymerase", "PROTEIN", 190, 206], ["Phe", "TEST", 82, 85], ["isobutyryl", "TREATMENT", 106, 116], ["guanosine of compound", "TREATMENT", 117, 138], ["viral polymerase activity", "PROBLEM", 190, 215], ["an IC", "TREATMENT", 221, 226]]], ["These docking combing through experimental studies clearly indicate that linear chain molecules inhibit polymerase activity with lower IC 50 compared with V-shaped and cyclic compounds used in the study.", [["experimental studies", "TEST", 30, 50], ["linear chain molecules", "PROBLEM", 73, 95], ["polymerase activity", "TEST", 104, 123], ["V-shaped and cyclic compounds", "PROBLEM", 155, 184], ["the study", "TEST", 193, 202], ["linear", "OBSERVATION_MODIFIER", 73, 79], ["chain", "OBSERVATION_MODIFIER", 80, 85]]], ["Conceivably, the pharmacophores of these compounds could be useful to screen chemical libraries of nucleoside molecules to identify novel anti-influenza drugs that bind to the catalytic site and still satisfy Lipinski's rule of five.", [["nucleoside", "CHEMICAL", 99, 109], ["nucleoside", "CHEMICAL", 99, 109], ["nucleoside molecules", "SIMPLE_CHEMICAL", 99, 119], ["catalytic site", "PROTEIN", 176, 190], ["nucleoside molecules", "TREATMENT", 99, 119], ["novel anti-influenza drugs", "TREATMENT", 132, 158]]], ["Thus, these findings clearly reveal that these compounds have the strong potential as therapeutic leads for further drug development to treat patients infected with influenza virus.ConclusionIn this study, we have successfully combined docking and experimental study to identify eight NTPs that bind to the catalytic site of IAV RdRp from A/PR/8/34/H1N1 strain.", [["influenza virus", "DISEASE", 165, 180], ["NTPs", "CHEMICAL", 285, 289], ["NTPs", "CHEMICAL", 285, 289], ["patients", "ORGANISM", 142, 150], ["influenza virus", "ORGANISM", 165, 180], ["IAV RdRp", "ORGANISM", 325, 333], ["A/PR/8/34/H1N1 strain", "ORGANISM", 339, 360], ["catalytic site", "PROTEIN", 307, 321], ["IAV RdRp", "PROTEIN", 325, 333], ["PR", "PROTEIN", 341, 343], ["patients", "SPECIES", 142, 150], ["A/PR/8/34/H1N1 strain", "SPECIES", 339, 360], ["further drug development", "TREATMENT", 108, 132], ["influenza virus", "PROBLEM", 165, 180], ["this study", "TEST", 194, 204], ["experimental study", "TEST", 248, 266], ["eight NTPs", "TREATMENT", 279, 289], ["H1N1 strain", "PROBLEM", 349, 360], ["influenza virus", "OBSERVATION", 165, 180], ["IAV RdRp", "OBSERVATION", 325, 333], ["H1N1", "OBSERVATION", 349, 353]]], ["Docking studies indicated that linear shape compounds 4, 5, and 6 may induce conformational changes of PB1 motif-IV and PB2 linker domain with an IC 50 of 0.21 and 0.09 \u00b5M.", [["4, 5, and 6", "CHEMICAL", 54, 65], ["PB1 motif-IV", "GENE_OR_GENE_PRODUCT", 103, 115], ["PB1 motif-IV", "PROTEIN", 103, 115], ["PB2 linker domain", "PROTEIN", 120, 137], ["Docking studies", "TEST", 0, 15], ["PB1 motif-IV and PB2 linker domain", "TREATMENT", 103, 137], ["an IC", "TREATMENT", 143, 148], ["linear", "OBSERVATION_MODIFIER", 31, 37], ["shape", "OBSERVATION_MODIFIER", 38, 43]]], ["Whereas, V-shaped compounds 1, 2, and 3 destabilize the PB1 priming loop involved in initiation of viral replication showing an IC 50 of 1.69, 3.58, and 2.13 \u00b5M.", [["3", "GENE_OR_GENE_PRODUCT", 38, 39], ["PB1", "DNA", 56, 59], ["V-shaped compounds", "PROBLEM", 9, 27], ["the PB1 priming loop", "TREATMENT", 52, 72], ["viral replication", "TREATMENT", 99, 116], ["an IC", "TEST", 125, 130], ["shaped", "OBSERVATION_MODIFIER", 11, 17], ["compounds", "OBSERVATION", 18, 27]]], ["However, cyclic compound 8 even though binds nearer to motif-IV of PB1 central domain showed a moderate inhibition with an IC 50 of 0.68 \u00b5M.", [["cyclic compound 8", "CHEMICAL", 9, 26], ["motif-IV", "PROTEIN", 55, 63], ["PB1 central domain", "PROTEIN", 67, 85], ["cyclic compound 8", "PROBLEM", 9, 26], ["IV of PB1 central domain", "TEST", 61, 85], ["a moderate inhibition", "PROBLEM", 93, 114], ["an IC", "TEST", 120, 125], ["moderate", "OBSERVATION_MODIFIER", 95, 103]]], ["This in turn indicates that the known compound 3\u2032azido-3\u2032-deoxy-thymidine-5\u2032-triphosphate binds to the viral promoter while the positive control 2\u2032deoxy-2\u2032fluoroguanosine triphosphate binds near to the exit channel inhibiting the transcriptional activity of viral polymerase with the same IC 50 of 1.12 \u00b5M (Pagadala 2019) .", [["3\u2032azido-3\u2032-deoxy-thymidine-5\u2032-triphosphate", "CHEMICAL", 47, 89], ["2\u2032deoxy-2\u2032fluoroguanosine triphosphate", "CHEMICAL", 145, 183], ["3\u2032azido-3\u2032-deoxy-thymidine-5\u2032-triphosphate", "CHEMICAL", 47, 89], ["2\u2032deoxy-2\u2032fluoroguanosine triphosphate", "CHEMICAL", 145, 183], ["3\u2032azido-3\u2032-deoxy-thymidine-5\u2032-triphosphate", "SIMPLE_CHEMICAL", 47, 89], ["2\u2032deoxy-2\u2032fluoroguanosine triphosphate", "SIMPLE_CHEMICAL", 145, 183], ["viral promoter", "DNA", 103, 117], ["viral polymerase", "PROTEIN", 258, 274], ["deoxy-thymidine", "TREATMENT", 58, 73], ["triphosphate binds", "TREATMENT", 77, 95], ["the viral promoter", "TREATMENT", 99, 117], ["deoxy", "TEST", 147, 152], ["fluoroguanosine triphosphate binds", "TREATMENT", 155, 189], ["viral polymerase", "PROBLEM", 258, 274], ["viral promoter", "OBSERVATION", 103, 117], ["transcriptional activity", "OBSERVATION", 230, 254]]], ["A good correlation between the \u0394G and IC 50 values with an R 2 = 0.73 indicate that these molecules bind to the catalytic site inhibiting the incorporation of natural NTPs for replication initiation and elongation of IAV RdRp.", [["NTPs", "CHEMICAL", 167, 171], ["NTPs", "CHEMICAL", 167, 171], ["NTPs", "SIMPLE_CHEMICAL", 167, 171], ["IAV RdRp", "ORGANISM", 217, 225], ["catalytic site", "PROTEIN", 112, 126], ["IAV RdRp", "PROTEIN", 217, 225], ["IAV RdRp", "SPECIES", 217, 225], ["these molecules bind", "PROBLEM", 84, 104], ["natural NTPs", "TREATMENT", 159, 171], ["replication initiation", "TREATMENT", 176, 198], ["elongation of IAV RdRp", "TREATMENT", 203, 225], ["good", "OBSERVATION_MODIFIER", 2, 6], ["natural NTPs", "OBSERVATION", 159, 171], ["IAV RdRp", "OBSERVATION", 217, 225]]], ["The compounds 5 and 6 exhibit significant antiviral effect inhibiting the viral replication with lower IC 50 of 0.09 \u00b5M compared with other compounds used in the study.", [["compounds 5 and 6", "CHEMICAL", 4, 21], ["significant antiviral effect", "PROBLEM", 30, 58], ["the viral replication", "TREATMENT", 70, 91], ["lower IC", "TREATMENT", 97, 105], ["the study", "TEST", 158, 167], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["antiviral effect", "OBSERVATION", 42, 58], ["viral replication", "OBSERVATION", 74, 91]]], ["Thus, this study clearly demonstrates the importance of catalytic site below and above the priming loop for the development of effective anti-influenza drugs.", [["catalytic site", "PROTEIN", 56, 70], ["this study", "TEST", 6, 16], ["the priming loop", "TREATMENT", 87, 103], ["effective anti-influenza drugs", "TREATMENT", 127, 157], ["effective", "OBSERVATION_MODIFIER", 127, 136], ["anti-influenza drugs", "OBSERVATION", 137, 157]]], ["The evaluation of these compounds in further experimental studies will pay the way to develop small molecule therapeutic that can inhibit the IAV viral replication binding to the catalytic site and satisfy Lipinski's rule of five.Compliance with ethical standardsConflict of interest The authors declare that they have no conflict of interest.Compliance with ethical standardsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [["IAV viral", "ORGANISM", 142, 151], ["catalytic site", "DNA", 179, 193], ["The evaluation", "TEST", 0, 14], ["these compounds", "PROBLEM", 18, 33], ["further experimental studies", "TEST", 37, 65], ["small molecule therapeutic", "PROBLEM", 94, 120], ["the IAV viral replication binding", "PROBLEM", 138, 171], ["ethical standards", "TREATMENT", 246, 263], ["ethical standards", "TREATMENT", 359, 376]]]], "60cfb43ca9b8d54f5b8cb4ab264d8d628c7c227b": [["IntroductionIt has been suggested that annual epidemics of different viral infections can interfere with each other, but clear trends over long time periods and underlying mechanisms are not known.", [["viral infections", "DISEASE", 69, 85], ["different viral infections", "PROBLEM", 59, 85], ["viral", "OBSERVATION_MODIFIER", 69, 74], ["infections", "OBSERVATION", 75, 85]]], ["[1] [2] [3] [4] A few population-level studies in Europe were based on observations in one respiratory season only (the 2009 H1N1 pandemic) in which the annually recurring influenza epidemic occurred relatively early.", [["influenza", "DISEASE", 172, 181], ["[1] [2] [3] [4] A", "SIMPLE_CHEMICAL", 0, 17], ["A few population", "TEST", 16, 32], ["level studies", "TEST", 33, 46], ["the annually recurring influenza epidemic", "PROBLEM", 149, 190], ["influenza", "OBSERVATION", 172, 181]]], ["With the occurrence of several early influenza A seasons in recent years, an exploration of longer time trends of different viruses was considered useful to gain more insight in the suggested relationship between circulating viruses.", [["an exploration", "TEST", 74, 88], ["different viruses", "PROBLEM", 114, 131], ["circulating viruses", "PROBLEM", 213, 232], ["several", "OBSERVATION_MODIFIER", 23, 30], ["early", "OBSERVATION_MODIFIER", 31, 36], ["influenza", "OBSERVATION", 37, 46], ["viruses", "OBSERVATION", 124, 131], ["viruses", "OBSERVATION", 225, 232]]], ["Understanding viral shifts and potential drivers thereof is relevant for further understanding whether certain viruses might promote or inhibit (pandemic) influenza spread and whether influenza vaccination could potentially affect trends in other respiratory viruses.IntroductionIn Europe, influenza epidemics generally occur in winter, with the official start of the epidemic when influenza-like illness (ILI) incidence in primary care sentinel surveillance exceeds an epidemic threshold (in combination with influenza A virus detection in clinical specimens collected from a subset of those ILI patients).", [["specimens", "ANATOMY", 550, 559], ["influenza", "DISEASE", 155, 164], ["influenza", "DISEASE", 184, 193], ["respiratory viruses", "DISEASE", 247, 266], ["influenza epidemics", "DISEASE", 290, 309], ["influenza-like illness", "DISEASE", 382, 404], ["ILI", "DISEASE", 406, 409], ["ILI", "DISEASE", 593, 596], ["influenza A virus", "ORGANISM", 510, 527], ["patients", "ORGANISM", 597, 605], ["influenza A virus", "SPECIES", 510, 527], ["patients", "SPECIES", 597, 605], ["influenza A virus", "SPECIES", 510, 527], ["certain viruses", "PROBLEM", 103, 118], ["inhibit (pandemic) influenza spread", "PROBLEM", 136, 171], ["influenza vaccination", "PROBLEM", 184, 205], ["other respiratory viruses", "PROBLEM", 241, 266], ["influenza epidemics", "PROBLEM", 290, 309], ["influenza", "PROBLEM", 382, 391], ["an epidemic threshold", "PROBLEM", 467, 488], ["influenza A virus detection", "PROBLEM", 510, 537], ["clinical specimens", "TEST", 541, 559], ["viral shifts", "OBSERVATION", 14, 26], ["respiratory viruses", "OBSERVATION", 247, 266]]], ["5 In the Netherlands, the influenza epidemic threshold has been calculated at an ILI incidence of 5\u00c11/10 000 for minimally two consecutive weeks which is usually not exceeded before the turn of the year, [5] [6] [7] [8] but the timing of the first exceedance (i.e., start of the epidemic) can vary between November and March (based on data from 1970 to 2006).", [["influenza", "DISEASE", 26, 35], ["the influenza epidemic threshold", "PROBLEM", 22, 54]]], ["9 An extremely early influenza season was the 2009/2010 season when the influenza A (H1N1)pdm09 pandemic strain appeared and the ILI epidemic threshold was reached by early October (week 41).", [["influenza", "DISEASE", 21, 30], ["influenza", "DISEASE", 72, 81], ["influenza A (H1N1)pdm09", "ORGANISM", 72, 95], ["influenza A (H1N1", "SPECIES", 72, 89], ["An extremely early influenza season", "PROBLEM", 2, 37], ["the influenza A (H1N1)pdm09 pandemic strain", "PROBLEM", 68, 111], ["early", "OBSERVATION_MODIFIER", 15, 20], ["influenza", "OBSERVATION", 21, 30]]], ["Such early occurrence may affect the circulation of other seasonal pathogens, and theories on possible interference between outbreaks of different respiratory viruses have been postulated to be a possible cause of delays in expected seasonal outbreaks of other respiratory viruses.", [["respiratory viruses", "DISEASE", 147, 166], ["respiratory viruses", "DISEASE", 261, 280], ["other seasonal pathogens", "PROBLEM", 52, 76], ["different respiratory viruses", "PROBLEM", 137, 166], ["other respiratory viruses", "PROBLEM", 255, 280], ["respiratory viruses", "OBSERVATION", 147, 166], ["respiratory viruses", "OBSERVATION", 261, 280]]], ["1-3 While those earlier population-level studies focused mainly on the possible interaction between influenza A virus and rhinovirus circulation, there may also be a relationship between influenza A and other prevalent viruses.", [["influenza A virus", "DISEASE", 100, 117], ["influenza A", "DISEASE", 187, 198], ["influenza A virus", "ORGANISM", 100, 117], ["rhinovirus", "ORGANISM", 122, 132], ["influenza A", "ORGANISM", 187, 198], ["influenza A virus", "SPECIES", 100, 117], ["influenza A virus", "SPECIES", 100, 117], ["influenza A", "SPECIES", 187, 198], ["level studies", "TEST", 35, 48], ["influenza A virus and rhinovirus circulation", "PROBLEM", 100, 144], ["influenza A", "PROBLEM", 187, 198]]], ["Therefore, we investigated trends in several common viruses for which laboratory data were available from national surveillance in the Netherlands for a longer time period of up to 10 years including both respiratory and enteral viruses.Laboratory dataWe investigated trends in the reporting of common infectious respiratory and enteral viruses for which laboratory data were available for the 10- The data were available from the \"Weekly Virological Records System\" of the Dutch Working Group on Clinical Virology giving the number of positive laboratory diagnoses by year and week, but not providing data on the denominator nor on age or gender of the patient.", [["respiratory", "ANATOMY", 205, 216], ["respiratory", "ANATOMY", 313, 324], ["respiratory and enteral viruses", "DISEASE", 205, 236], ["infectious respiratory and enteral viruses", "DISEASE", 302, 344], ["patient", "ORGANISM", 654, 661], ["patient", "SPECIES", 654, 661], ["several common viruses", "PROBLEM", 37, 59], ["laboratory data", "TEST", 70, 85], ["national surveillance", "TEST", 106, 127], ["both respiratory and enteral viruses", "PROBLEM", 200, 236], ["Laboratory dataWe", "TEST", 237, 254], ["common infectious respiratory and enteral viruses", "PROBLEM", 295, 344], ["laboratory data", "TEST", 355, 370], ["respiratory", "ANATOMY", 205, 216], ["enteral viruses", "OBSERVATION", 221, 236], ["common", "OBSERVATION_MODIFIER", 295, 301], ["infectious", "OBSERVATION", 302, 312], ["enteral viruses", "OBSERVATION", 329, 344]]], ["Submitting laboratories are associated with either hospitals or regional laboratories to which both GPs and hospitals submit samples.", [["Submitting laboratories", "TEST", 0, 23], ["regional laboratories", "TEST", 64, 85], ["hospitals submit samples", "TEST", 108, 132]]], ["The estimated proportion of all positive diagnostics captured by this national surveillance varies between the monitored pathogens and was estimated between 38% (for rotavirus) and 73% (for influenza virus) in a 2002 study of five pathogens.", [["influenza virus", "DISEASE", 190, 205], ["influenza virus", "ORGANISM", 190, 205], ["influenza virus", "SPECIES", 190, 205], ["rotavirus", "SPECIES", 166, 175], ["this national surveillance", "TEST", 65, 91], ["the monitored pathogens", "PROBLEM", 107, 130], ["rotavirus", "TEST", 166, 175], ["influenza virus", "PROBLEM", 190, 205], ["a 2002 study", "TEST", 210, 222], ["five pathogens", "PROBLEM", 226, 240], ["proportion", "OBSERVATION_MODIFIER", 14, 24], ["all", "OBSERVATION_MODIFIER", 28, 31], ["positive", "OBSERVATION", 32, 40]]], ["10 The types of tests used can differ between the submitting laboratories and over time.", [["tests", "TEST", 16, 21]]], ["Respiratory viruses were detected in throat swabs mainly by PCR-based methods in respiratory specimens from patients with respiratory disease symptoms.", [["throat swabs", "ANATOMY", 37, 49], ["respiratory specimens", "ANATOMY", 81, 102], ["respiratory", "ANATOMY", 122, 133], ["respiratory disease", "DISEASE", 122, 141], ["throat swabs", "ORGANISM_SUBSTANCE", 37, 49], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["Respiratory viruses", "PROBLEM", 0, 19], ["throat swabs", "TEST", 37, 49], ["PCR", "TEST", 60, 63], ["respiratory specimens", "TEST", 81, 102], ["respiratory disease symptoms", "PROBLEM", 122, 150], ["viruses", "OBSERVATION", 12, 19], ["respiratory", "ANATOMY", 81, 92]]], ["Enteric viruses were detected in fecal samples by EIA-based methods (rotavirus, norovirus) and by PCR-based methods (norovirus).", [["fecal samples", "ANATOMY", 33, 46], ["fecal samples", "ORGANISM_SUBSTANCE", 33, 46], ["rotavirus", "ORGANISM", 69, 78], ["norovirus", "ORGANISM", 117, 126], ["rotavirus", "SPECIES", 69, 78], ["Enteric viruses", "PROBLEM", 0, 15], ["fecal samples", "TEST", 33, 46], ["EIA", "TEST", 50, 53], ["rotavirus", "PROBLEM", 69, 78], ["norovirus", "PROBLEM", 80, 89], ["PCR", "TEST", 98, 101], ["viruses", "OBSERVATION", 8, 15]]], ["Enterovirus was detected mainly by PCR and in the early years also by culturing, in throat swabs, CNF, and in fecal specimens collected from patients suspected for an enterovirus infection.", [["throat swabs", "ANATOMY", 84, 96], ["fecal specimens", "ANATOMY", 110, 125], ["enterovirus infection", "DISEASE", 167, 188], ["Enterovirus", "ORGANISM", 0, 11], ["throat", "ORGANISM_SUBDIVISION", 84, 90], ["swabs", "ORGANISM_SUBSTANCE", 91, 96], ["CNF", "CANCER", 98, 101], ["fecal specimens", "ORGANISM_SUBSTANCE", 110, 125], ["patients", "ORGANISM", 141, 149], ["enterovirus", "ORGANISM", 167, 178], ["patients", "SPECIES", 141, 149], ["Enterovirus", "PROBLEM", 0, 11], ["PCR", "TEST", 35, 38], ["culturing", "TEST", 70, 79], ["throat swabs", "TEST", 84, 96], ["CNF", "TEST", 98, 101], ["fecal specimens", "TEST", 110, 125], ["an enterovirus infection", "PROBLEM", 164, 188], ["throat", "ANATOMY", 84, 90], ["fecal", "ANATOMY", 110, 115], ["enterovirus infection", "OBSERVATION", 167, 188]]], ["Cross-reaction between rhinovirus and enterovirus PCRs for throat swab samples cannot be excluded completely.", [["throat swab samples", "ANATOMY", 59, 78], ["rhinovirus", "ORGANISM", 23, 33], ["enterovirus", "ORGANISM", 38, 49], ["Cross-reaction", "TEST", 0, 14], ["rhinovirus", "PROBLEM", 23, 33], ["enterovirus PCRs", "TEST", 38, 54], ["throat swab samples", "TEST", 59, 78], ["rhinovirus", "OBSERVATION", 23, 33], ["not be excluded", "UNCERTAINTY", 82, 97]]], ["When collected from patients suspected for enterovirus infection, typing of enteroviruses indicated that this was a minority.", [["enterovirus infection", "DISEASE", 43, 64], ["enteroviruses", "DISEASE", 76, 89], ["patients", "ORGANISM", 20, 28], ["enterovirus", "ORGANISM", 43, 54], ["enteroviruses", "ORGANISM", 76, 89], ["patients", "SPECIES", 20, 28], ["enterovirus infection", "PROBLEM", 43, 64], ["enteroviruses", "PROBLEM", 76, 89], ["suspected for", "UNCERTAINTY", 29, 42], ["infection", "OBSERVATION", 55, 64]]], ["When collected from patients with respiratory symptoms, enteroviruses might be misidentified as rhinovirus, as occurred during enterovirus D68 outbreaks.", [["respiratory", "ANATOMY", 34, 45], ["respiratory symptoms", "DISEASE", 34, 54], ["enteroviruses", "DISEASE", 56, 69], ["rhinovirus", "DISEASE", 96, 106], ["patients", "ORGANISM", 20, 28], ["enteroviruses", "ORGANISM", 56, 69], ["rhinovirus", "ORGANISM", 96, 106], ["enterovirus D68", "ORGANISM", 127, 142], ["patients", "SPECIES", 20, 28], ["enterovirus D68", "SPECIES", 127, 142], ["respiratory symptoms", "PROBLEM", 34, 54], ["enteroviruses", "PROBLEM", 56, 69], ["rhinovirus", "PROBLEM", 96, 106], ["rhinovirus", "OBSERVATION", 96, 106]]], ["11Selection of years with early and late influenza A epidemicsTo determine whether an influenza A season occurred relatively early, we used both the influenza sentinel surveillance data and the laboratory data from the Weekly Virological Records system.", [["early and late influenza A epidemics", "PROBLEM", 26, 62], ["an influenza", "PROBLEM", 83, 95], ["the influenza sentinel surveillance data", "TEST", 145, 185], ["the laboratory data", "TEST", 190, 209], ["influenza", "OBSERVATION", 41, 50], ["influenza", "OBSERVATION", 86, 95]]], ["As general practitioner (GP) influenza sentinel surveillance is the current gold standard for influenza surveillance in the Netherlands (with an epidemic threshold), early influenza A seasons were first identified using published dates of the influenza epidemics.", [["influenza", "DISEASE", 94, 103], ["influenza", "DISEASE", 243, 252], ["influenza sentinel surveillance", "TEST", 29, 60], ["influenza surveillance", "TEST", 94, 116], ["early influenza A seasons", "PROBLEM", 166, 191], ["the influenza epidemics", "PROBLEM", 239, 262], ["influenza epidemics", "OBSERVATION", 243, 262]]], ["We combined this information with visual inspection (as there is no threshold available) of trends in influenza A laboratory diagnoses reported in the Weekly Virological Records System for confirmation of the early ILI epidemics and for identification of any additional early influenza A seasons according to those laboratory data.", [["ILI", "DISEASE", 215, 218], ["visual inspection", "TEST", 34, 51], ["influenza", "PROBLEM", 102, 111], ["the early ILI epidemics", "PROBLEM", 205, 228], ["those laboratory data", "TEST", 309, 330]]], ["A pre-defined cutoff point for the identification of early influenza seasons is not available.", [["influenza", "DISEASE", 59, 68], ["A pre-defined cutoff point", "TEST", 0, 26], ["early influenza seasons", "PROBLEM", 53, 76]]], ["Using the published ILI epidemic periods, we identified two relatively early influenza A seasons wherein influenza epidemics started before the turn of the year (i.e., before week 1): the 2003/2004 season (epidemic starting in week 49 lasting to week 4) and the 2009/2010 season (epidemic starting in week 41 lasting to week 51).", [["influenza epidemics", "DISEASE", 105, 124], ["influenza epidemics", "PROBLEM", 105, 124], ["relatively", "OBSERVATION_MODIFIER", 60, 70], ["early", "OBSERVATION_MODIFIER", 71, 76], ["influenza", "OBSERVATION", 77, 86]]], ["12, 13 These two early epidemics were also confirmed by visible early increases in influenza laboratory data reported in the Weekly Virological Records System ( Figure 1 ).", [["visible early increases in influenza laboratory data", "PROBLEM", 56, 108], ["early", "OBSERVATION_MODIFIER", 17, 22], ["epidemics", "OBSERVATION", 23, 32], ["visible", "OBSERVATION_MODIFIER", 56, 63], ["early", "OBSERVATION_MODIFIER", 64, 69], ["increases", "OBSERVATION_MODIFIER", 70, 79]]], ["After visual inspection of the laboratory data, the 2010/2011 season was additionally selected as an early season as influenza A diagnoses were clearly on the rise before week 1 ( Figure 1 ).", [["visual inspection", "TEST", 6, 23], ["the laboratory data", "TEST", 27, 46], ["influenza", "PROBLEM", 117, 126]]], ["While the influenza epidemic in the 2008/2009 season did not start early (week 1) 8 according to the ILI sentinel surveillance system, in the laboratory surveillance data this season seemed neither clearly early nor clearly late and was therefore excluded (influenza A laboratory diagnoses in this season are represented in Appendix 1).Presentation of virus trendsAs most of the viruses under study peak in winter, we defined year-long seasons running from July to June rather than using calendar years (January to December).", [["influenza", "DISEASE", 10, 19], ["the influenza epidemic", "PROBLEM", 6, 28], ["influenza", "PROBLEM", 257, 266], ["virus trends", "PROBLEM", 352, 364], ["virus", "OBSERVATION", 352, 357], ["viruses", "OBSERVATION", 379, 386]]], ["For comparability between the seasons, we presented the number of detected viruses per week as a percentage of the total number of detections during the study period per each respective virus.", [["the study", "TEST", 149, 158]]], ["Due to the intensified testing that occurred during the A (H1N1)pdm09 pandemic, the total number of influenza A virus laboratory diagnoses in the pandemic season was 13\u00c11 times higher than the average number of influenza A virus laboratory diagnoses in the 2003-2012 seasons, excluding the pandemic season.", [["A (H1N1)pdm09", "ORGANISM", 56, 69], ["influenza A virus", "ORGANISM", 100, 117], ["influenza A virus", "ORGANISM", 211, 228], ["influenza A virus", "SPECIES", 100, 117], ["influenza A virus", "SPECIES", 211, 228], ["influenza A virus", "SPECIES", 100, 117], ["influenza A virus", "SPECIES", 211, 228], ["the intensified testing", "TEST", 7, 30], ["pandemic", "PROBLEM", 70, 78], ["influenza A virus laboratory diagnoses", "PROBLEM", 100, 138], ["influenza", "PROBLEM", 211, 220]]], ["To facilitate the inclusion of such a high peak into the presented graphs, the number of influenza A virus laboratory diagnoses during the 2009/ 2010 season was scaled down (reduced by a factor 13\u00c11, changing the height but not the shape of the epidemic in that year).", [["influenza A virus", "ORGANISM", 89, 106], ["factor 13\u00c11", "PROTEIN", 187, 198], ["influenza A virus", "SPECIES", 89, 106], ["influenza A virus", "SPECIES", 89, 106], ["influenza", "PROBLEM", 89, 98]]], ["As the number of influenza B virus laboratory diagnoses was very low during the pandemic, such downscaling was not performed for the influenza B virus laboratory diagnoses.", [["influenza B", "DISEASE", 17, 28], ["influenza B", "DISEASE", 133, 144], ["influenza B virus", "ORGANISM", 17, 34], ["influenza B virus", "ORGANISM", 133, 150], ["influenza B virus", "SPECIES", 17, 34], ["influenza B virus", "SPECIES", 133, 150], ["influenza B virus", "SPECIES", 17, 34], ["influenza B virus", "SPECIES", 133, 150], ["influenza B virus laboratory diagnoses", "PROBLEM", 17, 55], ["the pandemic", "PROBLEM", 76, 88], ["the influenza B virus laboratory diagnoses", "PROBLEM", 129, 171]]], ["Correlation coefficients between different viruses were calculated using Spearman's rank correlations for non-normally distributed data.", [["Correlation coefficients between different viruses", "PROBLEM", 0, 50], ["Spearman's rank correlations", "TEST", 73, 101]]], ["We also shifted the time series forwards and backwards in time (\u00c010 to +10 weeks) and compared whether the time shift with maximal correlation differed between early and late influenza seasons.Virus seasonality and relative timingThe highest numbers of laboratory reports were available for RSV and the lowest for influenza B (20 282 and 1309 reported diagnoses during the total study period, Table 1 ).", [["influenza", "DISEASE", 175, 184], ["influenza B", "DISEASE", 314, 325], ["Virus", "ORGANISM", 193, 198], ["RSV", "ORGANISM", 291, 294], ["RSV", "SPECIES", 291, 294], ["Virus seasonality", "PROBLEM", 193, 210], ["RSV", "PROBLEM", 291, 294], ["influenza B", "PROBLEM", 314, 325]]], ["Time series of all considered pathogens are shown in Figure 1 .", [["pathogens", "PROBLEM", 30, 39]]], ["Almost all of the included respiratory viruses (influenza A and B virus, RSV, coronavirus) except rhinovirus showed very clear seasonality in their reporting over time.", [["respiratory viruses", "DISEASE", 27, 46], ["influenza A and B virus", "DISEASE", 48, 71], ["rhinovirus", "DISEASE", 98, 108], ["respiratory viruses", "ORGANISM", 27, 46], ["influenza A and B virus", "ORGANISM", 48, 71], ["RSV", "ORGANISM", 73, 76], ["coronavirus", "ORGANISM", 78, 89], ["rhinovirus", "ORGANISM", 98, 108], ["B virus", "SPECIES", 64, 71], ["coronavirus", "SPECIES", 78, 89], ["B virus", "SPECIES", 64, 71], ["RSV", "SPECIES", 73, 76], ["respiratory viruses", "PROBLEM", 27, 46], ["influenza A and B virus", "PROBLEM", 48, 71], ["RSV", "PROBLEM", 73, 76], ["coronavirus", "PROBLEM", 78, 89], ["rhinovirus", "PROBLEM", 98, 108], ["respiratory viruses", "OBSERVATION", 27, 46]]], ["The numbers increase, peak, and are elevated during winter season (December-February) or occasionally in very early spring (March-April) ( Figure 1 and Appendix 2A-D).", [["numbers", "OBSERVATION_MODIFIER", 4, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["peak", "OBSERVATION_MODIFIER", 22, 26], ["elevated", "OBSERVATION_MODIFIER", 36, 44]]], ["However, while influenza B virus diagnoses also displayed such winter seasonality, outbreaks did not occur each winter (five of the ten observed years showed clear influenza B epidemics, while the other 5 years showed very low levels or even near-absence).", [["influenza B", "DISEASE", 15, 26], ["influenza B virus", "ORGANISM", 15, 32], ["influenza B virus", "SPECIES", 15, 32], ["influenza B virus", "SPECIES", 15, 32], ["influenza B virus diagnoses", "PROBLEM", 15, 42], ["clear influenza B epidemics", "PROBLEM", 158, 185], ["very low levels", "PROBLEM", 218, 233]]], ["In our data, rhinovirus levels showed less clear seasonality than the other respiratory viruses.", [["rhinovirus", "ORGANISM", 13, 23], ["rhinovirus levels", "TEST", 13, 30], ["less clear", "OBSERVATION_MODIFIER", 38, 48], ["respiratory viruses", "OBSERVATION", 76, 95]]], ["They tended to be elevated over broad periods ( Figure 1 ) and seemed to be present year-round with less pronounced elevations during autumn/winter/spring.", [["less pronounced elevations", "PROBLEM", 100, 126], ["elevated", "OBSERVATION", 18, 26], ["less pronounced", "OBSERVATION_MODIFIER", 100, 115], ["elevations", "OBSERVATION_MODIFIER", 116, 126]]], ["Generally, RSV van Asten et al. epidemics preceded influenza A virus epidemics, which in turn preceded influenza B epidemics (in the years that influenza B epidemics occurred).", [["influenza A virus epidemics", "DISEASE", 51, 78], ["influenza B epidemics", "DISEASE", 103, 124], ["influenza B", "DISEASE", 144, 155], ["RSV", "ORGANISM", 11, 14], ["influenza A virus", "ORGANISM", 51, 68], ["influenza B", "ORGANISM", 103, 114], ["influenza A virus", "SPECIES", 51, 68], ["RSV", "SPECIES", 11, 14], ["influenza A virus", "SPECIES", 51, 68], ["epidemics", "PROBLEM", 32, 41], ["influenza A virus epidemics", "PROBLEM", 51, 78], ["influenza B epidemics", "PROBLEM", 103, 124], ["influenza B epidemics", "PROBLEM", 144, 165]]], ["Increases in coronavirus also usually preceded increases in influenza A (but not in the 2009/2010 season).", [["coronavirus", "ORGANISM", 13, 24], ["Increases in coronavirus", "PROBLEM", 0, 24], ["influenza A", "PROBLEM", 60, 71], ["coronavirus", "OBSERVATION", 13, 24], ["increases", "OBSERVATION_MODIFIER", 47, 56], ["influenza", "OBSERVATION", 60, 69]]], ["The timing of rhinovirus levels relative to influenza A virus in laboratory diagnoses was less clear (due to seemingly year-round presence of rhinoviruses in specimens submitted for laboratory diagnoses).", [["specimens", "ANATOMY", 158, 167], ["rhinoviruses", "DISEASE", 142, 154], ["rhinovirus", "ORGANISM", 14, 24], ["influenza A virus", "ORGANISM", 44, 61], ["rhinoviruses", "ORGANISM", 142, 154], ["specimens", "CANCER", 158, 167], ["influenza A virus", "SPECIES", 44, 61], ["influenza A virus", "SPECIES", 44, 61], ["rhinovirus levels", "PROBLEM", 14, 31], ["influenza A virus", "PROBLEM", 44, 61], ["rhinoviruses", "PROBLEM", 142, 154], ["rhinoviruses", "OBSERVATION", 142, 154]]], ["The two gastrointestinal viruses in the study (norovirus and rotavirus) both also presented with winter seasonality, often with norovirus preceding rotavirus epidemics ( Figure 1 and Appendix 2C).", [["gastrointestinal", "ANATOMY", 8, 24], ["gastrointestinal viruses", "DISEASE", 8, 32], ["norovirus and rotavirus", "DISEASE", 47, 70], ["norovirus", "DISEASE", 128, 137], ["rotavirus epidemics", "DISEASE", 148, 167], ["gastrointestinal viruses", "ORGANISM", 8, 32], ["norovirus", "ORGANISM", 47, 56], ["rotavirus", "ORGANISM", 61, 70], ["rotavirus", "SPECIES", 61, 70], ["The two gastrointestinal viruses", "PROBLEM", 0, 32], ["the study", "TEST", 36, 45], ["norovirus", "PROBLEM", 47, 56], ["rotavirus", "PROBLEM", 61, 70], ["norovirus", "PROBLEM", 128, 137], ["rotavirus epidemics", "PROBLEM", 148, 167], ["gastrointestinal", "ANATOMY", 8, 24], ["viruses", "OBSERVATION", 25, 32]]], ["Norovirus and influenza A virus epidemics usually overlapped, but the norovirus epidemics had broader peaks, and numbers tended to start increasing earlier than influenza A virus diagnoses levels and decreased after the disappearance of influenza A virus.", [["Norovirus", "DISEASE", 0, 9], ["influenza A virus epidemics", "DISEASE", 14, 41], ["norovirus", "DISEASE", 70, 79], ["influenza A virus", "DISEASE", 237, 254], ["Norovirus", "ORGANISM", 0, 9], ["influenza A virus", "ORGANISM", 14, 31], ["influenza A virus", "ORGANISM", 161, 178], ["influenza A virus", "ORGANISM", 237, 254], ["influenza A virus", "SPECIES", 14, 31], ["influenza A virus", "SPECIES", 161, 178], ["influenza A virus", "SPECIES", 237, 254], ["influenza A virus", "SPECIES", 14, 31], ["influenza A virus", "SPECIES", 161, 178], ["influenza A virus", "SPECIES", 237, 254], ["Norovirus", "PROBLEM", 0, 9], ["influenza A virus epidemics", "PROBLEM", 14, 41], ["the norovirus epidemics", "PROBLEM", 66, 89], ["influenza A virus diagnoses levels", "PROBLEM", 161, 195], ["influenza A virus", "PROBLEM", 237, 254], ["norovirus", "OBSERVATION", 70, 79], ["influenza", "OBSERVATION", 237, 246]]], ["Also, rotavirus outbreaks usually occurred before influenza A outbreaks started.Virus seasonality and relative timingEnteroviruses, of which there are many types, can cause respiratory illness, but they also cause other illness.", [["respiratory", "ANATOMY", 173, 184], ["rotavirus outbreaks", "DISEASE", 6, 25], ["respiratory illness", "DISEASE", 173, 192], ["rotavirus", "ORGANISM", 6, 15], ["Virus", "ORGANISM", 80, 85], ["rotavirus", "SPECIES", 6, 15], ["rotavirus outbreaks", "PROBLEM", 6, 25], ["influenza", "PROBLEM", 50, 59], ["Virus seasonality", "PROBLEM", 80, 97], ["relative timingEnteroviruses", "PROBLEM", 102, 130], ["respiratory illness", "PROBLEM", 173, 192], ["relative timing", "OBSERVATION_MODIFIER", 102, 117], ["Enteroviruses", "OBSERVATION", 117, 130]]], ["14 Enterovirus data were sparse until 2005, but in the 2006-2012 time period, enterovirus levels generally peak in summer (June-August).Description of viruses during early occurrence of influenza A virusVisually, we assessed whether seasons with early influenza A virus epidemics (as reported in the Weekly Virological Records System) coincided with shifts in the reporting of other common pathogens or shifts in temperature and humidity trends.", [["influenza A virusVisually", "DISEASE", 186, 211], ["influenza A virus epidemics", "DISEASE", 252, 279], ["enterovirus", "ORGANISM", 78, 89], ["influenza A virus", "ORGANISM", 252, 269], ["influenza A virus", "SPECIES", 252, 269], ["influenza A virus", "SPECIES", 252, 269], ["Enterovirus data", "TEST", 3, 19], ["enterovirus levels", "TEST", 78, 96], ["viruses", "PROBLEM", 151, 158], ["influenza", "PROBLEM", 186, 195], ["early influenza A virus epidemics", "PROBLEM", 246, 279], ["other common pathogens", "PROBLEM", 377, 399], ["shifts in temperature", "PROBLEM", 403, 424], ["viruses", "OBSERVATION", 151, 158], ["influenza", "OBSERVATION", 186, 195]]], ["Occurrence of seasons with relatively early influenza A virus circulation compared to seasons with later circulation of influenza A virus is shown in Figure 2 (early seasons in color, late seasons in gray).", [["influenza A virus", "DISEASE", 120, 137], ["influenza A virus", "ORGANISM", 44, 61], ["influenza A virus", "ORGANISM", 120, 137], ["influenza A virus", "SPECIES", 44, 61], ["influenza A virus", "SPECIES", 120, 137], ["influenza A virus", "SPECIES", 44, 61], ["influenza A virus", "SPECIES", 120, 137], ["relatively early influenza A virus circulation", "PROBLEM", 27, 73], ["influenza A virus", "PROBLEM", 120, 137], ["early", "OBSERVATION_MODIFIER", 38, 43], ["influenza", "OBSERVATION", 44, 53], ["influenza", "OBSERVATION", 120, 129]]], ["For the other viruses, the same grouping was made (based on early and late influenza seasons), with their trend during early influenza A seasons also given in color (Correlation between influenza A and other viruses at different time shiftsThe correlation coefficients between influenza and other viruses were stratified by timing of the occurrence of the influenza epidemic (early versus late, Table 3 ).", [["influenza A", "DISEASE", 186, 197], ["influenza", "DISEASE", 277, 286], ["influenza", "DISEASE", 356, 365], ["influenza A", "SPECIES", 186, 197], ["the other viruses", "PROBLEM", 4, 21], ["early and late influenza seasons", "PROBLEM", 60, 92], ["early influenza A seasons", "PROBLEM", 119, 144], ["influenza", "PROBLEM", 186, 195], ["other viruses", "PROBLEM", 202, 215], ["influenza", "PROBLEM", 277, 286], ["other viruses", "PROBLEM", 291, 304], ["the influenza epidemic", "PROBLEM", 352, 374], ["viruses", "OBSERVATION", 14, 21]]], ["As the different viruses might differ in the timing of their occurrence relative to influenza A occurrence, the correlation coefficients were calculated at different time lags (shifted between 10 weeks earlier up to 10 weeks later) to determine the time shift with the maximum correlation with influenza A. When comparing seasons with early versus later occurrence of influenza epidemics, the maximum correlation coefficient was observed at different lags for all viruses.", [["influenza", "DISEASE", 368, 377], ["the different viruses", "PROBLEM", 3, 24], ["influenza", "PROBLEM", 84, 93], ["the correlation coefficients", "TEST", 108, 136], ["influenza", "PROBLEM", 294, 303], ["influenza epidemics", "PROBLEM", 368, 387], ["all viruses", "PROBLEM", 460, 471], ["different", "OBSERVATION_MODIFIER", 7, 16], ["viruses", "OBSERVATION", 17, 24], ["influenza", "OBSERVATION", 368, 377], ["viruses", "OBSERVATION", 464, 471]]], ["This difference in time lag relative to influenza A occurrence was smallest for influenza B, indicating that influenza B circulation relative to influenza A tends to occur at a more stable delay than for the other viruses.", [["influenza", "DISEASE", 40, 49], ["influenza B", "DISEASE", 80, 91], ["influenza B", "DISEASE", 109, 120], ["influenza B", "ORGANISM", 80, 91], ["influenza B", "ORGANISM", 109, 120], ["time lag", "PROBLEM", 19, 27], ["influenza", "PROBLEM", 40, 49], ["influenza B", "PROBLEM", 80, 91], ["influenza B circulation", "PROBLEM", 109, 132], ["influenza A", "PROBLEM", 145, 156], ["the other viruses", "PROBLEM", 204, 221], ["influenza", "OBSERVATION", 40, 49]]], ["This suggests that changes in timing of influenza A circulation will be accompanied by changes in timing of influenza B circulation.", [["influenza B", "ORGANISM", 108, 119], ["influenza A circulation", "PROBLEM", 40, 63], ["influenza B circulation", "PROBLEM", 108, 131]]], ["However, such an overall correlation coefficient (calculated over multiple seasons combined) obscured the visual observation that in van Asten et al.Correlation between influenza A and other viruses at different time shiftstwo of the three early influenza seasons, influenza B virus was almost absent (Figure 2 ).DiscussionViruses that showed a shifted trend of reporting during years with early influenza A epidemics were of respiratory nature with clear winter seasonality and with epidemics occurring relatively close in time to influenza A virus epidemics.", [["influenza A and other viruses", "DISEASE", 169, 198], ["influenza", "DISEASE", 246, 255], ["influenza B", "DISEASE", 265, 276], ["influenza A epidemics", "DISEASE", 396, 417], ["influenza A virus epidemics", "DISEASE", 532, 559], ["influenza A", "ORGANISM", 169, 180], ["influenza B virus", "ORGANISM", 265, 282], ["influenza A virus", "ORGANISM", 532, 549], ["influenza B virus", "SPECIES", 265, 282], ["influenza A virus", "SPECIES", 532, 549], ["influenza A", "SPECIES", 169, 180], ["influenza B virus", "SPECIES", 265, 282], ["influenza A virus", "SPECIES", 532, 549], ["the visual observation", "TEST", 102, 124], ["influenza", "PROBLEM", 169, 178], ["other viruses", "PROBLEM", 185, 198], ["the three early influenza seasons", "PROBLEM", 230, 263], ["influenza B virus", "PROBLEM", 265, 282], ["early influenza A epidemics", "PROBLEM", 390, 417], ["epidemics", "PROBLEM", 484, 493], ["influenza A virus epidemics", "PROBLEM", 532, 559]]], ["Although per individual virus the shifts were not consistently of the same type or direction, generally said, in years when influenza A hit early, RSV tended to be delayed, coronavirus outbreaks tended to be intensified, and influenza B virus tended not to circulate at all.", [["coronavirus", "DISEASE", 173, 184], ["influenza B", "DISEASE", 225, 236], ["RSV", "ORGANISM", 147, 150], ["coronavirus", "ORGANISM", 173, 184], ["influenza B virus", "ORGANISM", 225, 242], ["influenza B virus", "SPECIES", 225, 242], ["RSV", "SPECIES", 147, 150], ["influenza B virus", "SPECIES", 225, 242], ["influenza", "PROBLEM", 124, 133], ["RSV", "PROBLEM", 147, 150], ["coronavirus outbreaks", "PROBLEM", 173, 194], ["influenza B virus", "PROBLEM", 225, 242], ["virus", "OBSERVATION", 24, 29]]], ["Viruses that act on other organ systems (enteral) seemed not to be affected by the timing of influenza A outbreaks.", [["organ", "ANATOMY", 26, 31], ["organ", "ORGAN", 26, 31], ["Viruses", "PROBLEM", 0, 7], ["influenza", "PROBLEM", 93, 102], ["influenza", "OBSERVATION", 93, 102]]], ["In our data, rhinovirus showed little seasonality, but rather year-round presence, and therefore, no association with timing of influenza A could be observed.DiscussionChanges in seasonal patterns of respiratory pathogen laboratory reports have been observed in other, shorter, studies.", [["influenza", "DISEASE", 128, 137], ["rhinovirus", "ORGANISM", 13, 23], ["rhinovirus", "PROBLEM", 13, 23], ["little seasonality", "PROBLEM", 31, 49], ["influenza A", "PROBLEM", 128, 139]]], ["In Hong Kong, after the early occurring A(H1N1) pdm09 pandemic, increases were observed in adenovirus and parainfluenza virus detections, while the usual RSV summer peak disappeared in data from hospitals and clinics.", [["A(H1N1) pdm09", "ORGANISM", 40, 53], ["adenovirus", "ORGANISM", 91, 101], ["parainfluenza virus", "ORGANISM", 106, 125], ["RSV", "ORGANISM", 154, 157], ["parainfluenza", "SPECIES", 106, 119], ["adenovirus", "SPECIES", 91, 101], ["parainfluenza virus", "SPECIES", 106, 125], ["RSV", "SPECIES", 154, 157], ["A(H1N1) pdm09 pandemic", "PROBLEM", 40, 62], ["adenovirus", "PROBLEM", 91, 101], ["parainfluenza virus detections", "PROBLEM", 106, 136], ["parainfluenza virus", "OBSERVATION", 106, 125]]], ["15 Rhinovirus and coronavirus were not included.", [["coronavirus", "ORGANISM", 18, 29], ["Rhinovirus", "PROBLEM", 3, 13], ["coronavirus", "PROBLEM", 18, 29], ["Rhinovirus", "OBSERVATION", 3, 13], ["coronavirus", "OBSERVATION", 18, 29]]], ["In another study in Beijing, all respiratory virus epidemics, except rhinovirus, were delayed after the pandemic influenza epidemic (data came from fever clinics which screen patients prior to being assigned to a specific hospital department).", [["respiratory virus epidemics", "DISEASE", 33, 60], ["influenza", "DISEASE", 113, 122], ["fever", "DISEASE", 148, 153], ["rhinovirus", "ORGANISM", 69, 79], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 175, 183], ["another study", "TEST", 3, 16], ["all respiratory virus epidemics", "PROBLEM", 29, 60], ["rhinovirus", "PROBLEM", 69, 79], ["the pandemic influenza epidemic", "PROBLEM", 100, 131], ["fever", "PROBLEM", 148, 153], ["respiratory virus", "ANATOMY", 33, 50]]], ["16 However, both regions have different climates from the Netherlands (and from each other) complicating comparisons.", [["both", "ANATOMY_MODIFIER", 12, 16], ["regions", "ANATOMY_MODIFIER", 17, 24], ["different", "OBSERVATION_MODIFIER", 30, 39], ["climates", "OBSERVATION", 40, 48]]], ["Other European observations have also been reported regarding the effect of rhinovirus on influenza virus circulation.", [["rhinovirus", "ORGANISM", 76, 86], ["influenza virus", "ORGANISM", 90, 105], ["influenza virus", "SPECIES", 90, 105], ["influenza virus", "SPECIES", 90, 105], ["rhinovirus", "PROBLEM", 76, 86], ["influenza virus circulation", "PROBLEM", 90, 117], ["rhinovirus", "OBSERVATION", 76, 86]]], ["While those reports hypothesize on viral interference between influenza virus and rhinovirus circulation (with rhinovirus delaying influenza spread), 1-3,17 we (like the Beijing study 16 ) did not observe clear-cut trends in rhinovirus reports in our laboratory diagnoses data.", [["influenza virus and rhinovirus circulation", "DISEASE", 62, 104], ["influenza", "DISEASE", 131, 140], ["influenza virus", "ORGANISM", 62, 77], ["rhinovirus", "ORGANISM", 82, 92], ["rhinovirus", "ORGANISM", 225, 235], ["influenza virus and rhinovirus", "SPECIES", 62, 92], ["influenza virus", "SPECIES", 62, 77], ["viral interference", "PROBLEM", 35, 53], ["influenza virus", "PROBLEM", 62, 77], ["rhinovirus circulation", "PROBLEM", 82, 104], ["rhinovirus delaying influenza spread", "PROBLEM", 111, 147], ["the Beijing study", "TEST", 166, 183], ["rhinovirus", "PROBLEM", 225, 235]]], ["The relationship previously reported between rhinovirus and influenza virus might perhaps be age specific because in one study, the reduced likelihood of A(H1N1)pdm09 detection in rhinovirus-positive samples 3 was observed in a pediatric population, as was the reduced likelihood of detecting eight viruses in rhinovirus-positive samples in another study in children, 17 while our data were not age specific and we did not have such information on concurrent infections.DiscussionBesides the reported possible interaction between rhinovirus and influenza A virus, much less is known about interaction between and with other (respiratory and nonrespiratory) viruses.", [["samples", "ANATOMY", 200, 207], ["samples", "ANATOMY", 330, 337], ["rhinovirus and influenza virus", "DISEASE", 45, 75], ["infections", "DISEASE", 459, 469], ["rhinovirus and influenza A virus", "DISEASE", 530, 562], ["respiratory and nonrespiratory) viruses", "DISEASE", 625, 664], ["rhinovirus", "ORGANISM", 45, 55], ["influenza virus", "ORGANISM", 60, 75], ["A(H1N1)pdm09", "ORGANISM", 154, 166], ["rhinovirus", "ORGANISM", 180, 190], ["rhinovirus", "ORGANISM", 310, 320], ["children", "ORGANISM", 358, 366], ["rhinovirus", "ORGANISM", 530, 540], ["influenza A virus", "ORGANISM", 545, 562], ["influenza virus", "SPECIES", 60, 75], ["children", "SPECIES", 358, 366], ["influenza A virus", "SPECIES", 545, 562], ["influenza virus", "SPECIES", 60, 75], ["influenza A virus", "SPECIES", 545, 562], ["rhinovirus", "PROBLEM", 45, 55], ["influenza virus", "PROBLEM", 60, 75], ["one study", "TEST", 117, 126], ["A(H1N1)pdm09 detection", "PROBLEM", 154, 176], ["rhinovirus", "PROBLEM", 180, 190], ["positive samples", "PROBLEM", 191, 207], ["eight viruses in rhinovirus", "PROBLEM", 293, 320], ["concurrent infections", "PROBLEM", 448, 469], ["rhinovirus", "PROBLEM", 530, 540], ["influenza A virus", "PROBLEM", 545, 562], ["other (respiratory and nonrespiratory) viruses", "PROBLEM", 618, 664], ["viruses", "OBSERVATION", 299, 306], ["infections", "OBSERVATION", 459, 469], ["possible", "UNCERTAINTY", 501, 509], ["rhinovirus", "OBSERVATION", 530, 540]]], ["Our data suggest that respiratory viruses may impact each other's seasonality (in this study focused on the relationship between influenza A virus and other respiratory viruses), albeit through unknown mechanisms, as also hinted at by the Beijing and Hong Kong data.", [["respiratory viruses", "DISEASE", 22, 41], ["influenza A virus", "DISEASE", 129, 146], ["respiratory viruses", "DISEASE", 157, 176], ["influenza A virus", "ORGANISM", 129, 146], ["influenza A virus", "SPECIES", 129, 146], ["influenza A virus", "SPECIES", 129, 146], ["Our data", "TEST", 0, 8], ["respiratory viruses", "PROBLEM", 22, 41], ["this study", "TEST", 82, 92], ["influenza A virus", "PROBLEM", 129, 146], ["other respiratory viruses", "PROBLEM", 151, 176], ["respiratory viruses", "OBSERVATION", 22, 41], ["respiratory viruses", "OBSERVATION", 157, 176]]], ["15, 16 Virtually all research suggesting interaction between respiratory viruses in human populations has focused on observational (ecological) studies such as ours, most including only one or a few seasons of data while our study included a 10-year period.", [["respiratory viruses", "DISEASE", 61, 80], ["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["interaction between respiratory viruses in human populations", "PROBLEM", 41, 101], ["our study", "TEST", 221, 230], ["respiratory viruses", "OBSERVATION", 61, 80]]], ["Only one prospective cohort study has been published (based on one season) which showed rhinovirus and coronavirus to interrupt the A(H1N1)pdm09 pandemic.", [["rhinovirus and coronavirus", "DISEASE", 88, 114], ["rhinovirus", "ORGANISM", 88, 98], ["coronavirus", "ORGANISM", 103, 114], ["A(H1N1)pdm09", "ORGANISM", 132, 144], ["one prospective cohort study", "TEST", 5, 33], ["rhinovirus", "PROBLEM", 88, 98], ["coronavirus", "PROBLEM", 103, 114], ["pandemic", "PROBLEM", 145, 153], ["rhinovirus", "OBSERVATION", 88, 98]]], ["18 Our results could not confirm their finding of coronavirus inhibiting influenza A virus circulation, but we observed more coronavirus laboratory reports when influenza A virus circulated early.", [["coronavirus", "DISEASE", 50, 61], ["influenza A virus", "DISEASE", 161, 178], ["coronavirus", "ORGANISM", 50, 61], ["influenza A virus", "ORGANISM", 73, 90], ["influenza A virus", "ORGANISM", 161, 178], ["influenza A virus", "SPECIES", 73, 90], ["influenza A virus", "SPECIES", 161, 178], ["influenza A virus", "SPECIES", 73, 90], ["influenza A virus", "SPECIES", 161, 178], ["coronavirus inhibiting influenza A virus circulation", "PROBLEM", 50, 102], ["influenza A virus", "PROBLEM", 161, 178]]], ["In contrast to most of the other studies, we could investigate whether patterns recurred due to our longer study period.", [["the other studies", "TEST", 23, 40]]], ["This revealed that coronavirus laboratory reporting was more intense in 2009/2010 when it did not overlap with influenza A virus circulation.", [["coronavirus", "ORGANISM", 19, 30], ["influenza A virus", "ORGANISM", 111, 128], ["influenza A virus", "SPECIES", 111, 128], ["influenza A virus", "SPECIES", 111, 128], ["coronavirus laboratory", "TEST", 19, 41], ["influenza A virus circulation", "PROBLEM", 111, 140], ["coronavirus", "OBSERVATION", 19, 30], ["influenza", "OBSERVATION", 111, 120]]], ["However, it was also more intense in the early influenza A year thereafter (2010/2011) when it actually completely overlapped with the influenza A epidemic hinting that direct biological inhibition of either virus by the other might be unlikely and thus apparent interaction reported by others may have depended on indirect factors or may be spurious.", [["influenza", "DISEASE", 47, 56], ["influenza", "DISEASE", 135, 144], ["the influenza", "PROBLEM", 131, 144], ["more intense", "OBSERVATION_MODIFIER", 21, 33], ["may be", "UNCERTAINTY", 335, 341], ["spurious", "OBSERVATION", 342, 350]]], ["These variations by year in our data illustrate how results from shorter observational studies have to be interpreted with caution, especially when they focus only on 1 year or one season.", [["shorter observational studies", "TEST", 65, 94]]], ["However, also in our longer study we have to remain cautious; to refute biological inhibition between coronavirus and influenza, it would be helpful to know whether the coronavirus and influenza virus specimens were from the same age group.DiscussionUnfortunately, as in other observational studies, surveillance artifacts could not be ruled out for any of the viruses in our study.", [["specimens", "ANATOMY", 201, 210], ["coronavirus and influenza", "DISEASE", 102, 127], ["coronavirus", "ORGANISM", 102, 113], ["coronavirus", "ORGANISM", 169, 180], ["influenza virus specimens", "ORGANISM", 185, 210], ["coronavirus", "SPECIES", 169, 180], ["influenza virus", "SPECIES", 185, 200], ["coronavirus", "PROBLEM", 102, 113], ["influenza", "PROBLEM", 118, 127], ["the coronavirus and influenza virus specimens", "PROBLEM", 165, 210], ["other observational studies", "TEST", 271, 298], ["surveillance artifacts", "TEST", 300, 322], ["the viruses", "PROBLEM", 357, 368], ["our study", "TEST", 372, 381], ["viruses", "OBSERVATION", 361, 368]]], ["These artifacts concern increases and decreases in laboratory testing over time that may not necessarily be related to changes in virus circulation in the population.", [["These artifacts", "PROBLEM", 0, 15], ["laboratory testing", "TEST", 51, 69], ["changes in virus circulation", "PROBLEM", 119, 147], ["artifacts", "OBSERVATION", 6, 15], ["increases", "OBSERVATION_MODIFIER", 24, 33], ["decreases", "OBSERVATION_MODIFIER", 38, 47], ["may not necessarily be related to", "UNCERTAINTY", 85, 118], ["virus", "OBSERVATION", 130, 135]]], ["Like previous studies, we did not have information on issues potentially underlying such changes, such as shifts in laboratory testing policy, availability and use of new diagnostic tools, variations in testing intensity due to previous or new outbreaks, and possible outsourcing of certain tests.", [["previous studies", "TEST", 5, 21], ["laboratory testing", "TEST", 116, 134], ["new diagnostic tools", "TEST", 167, 187], ["variations in testing intensity", "TEST", 189, 220], ["previous or new outbreaks", "PROBLEM", 228, 253], ["certain tests", "TEST", 283, 296]]], ["If certain age groups are more likely to be hospitalized (such as infants with RSV infection) and/or to be sampled than other age groups and thus overrepresented in the laboratory data, our observed trends might not be representative for the total population if virus circulation trends actually differ between age groups.", [["RSV infection", "DISEASE", 79, 92], ["infants", "ORGANISM", 66, 73], ["RSV", "ORGANISM", 79, 82], ["infants", "SPECIES", 66, 73], ["RSV", "SPECIES", 79, 82], ["RSV infection", "PROBLEM", 79, 92], ["the total population", "TREATMENT", 238, 258], ["virus circulation", "PROBLEM", 262, 279]]], ["Future ecological analyses should preferably include age-specific data as this may further clarify the true occurrence of shifted20seasonality.", [["Future ecological analyses", "TEST", 0, 26], ["shifted20seasonality", "PROBLEM", 122, 142]]], ["Comparison between the different studies (including ours) is also made difficult by unknowns other than age, such as illness severity and influenza vaccination status.", [["illness", "DISEASE", 117, 124], ["influenza", "DISEASE", 138, 147], ["the different studies", "TEST", 19, 40], ["illness severity", "PROBLEM", 117, 133], ["influenza vaccination status", "PROBLEM", 138, 166]]], ["As other ecological-type studies have suggested, also our observed shifts in the occurrence of influenza B virus, RSV, and coronavirus during early influenza A seasons suggest that viral interaction might play a role in the occurrence of virus epidemics.", [["influenza B", "DISEASE", 95, 106], ["coronavirus", "DISEASE", 123, 134], ["influenza B virus", "ORGANISM", 95, 112], ["RSV", "ORGANISM", 114, 117], ["coronavirus", "ORGANISM", 123, 134], ["early influenza A", "ORGANISM", 142, 159], ["influenza B virus", "SPECIES", 95, 112], ["coronavirus", "SPECIES", 123, 134], ["influenza B virus", "SPECIES", 95, 112], ["RSV", "SPECIES", 114, 117], ["type studies", "TEST", 20, 32], ["influenza B virus", "PROBLEM", 95, 112], ["RSV", "PROBLEM", 114, 117], ["coronavirus", "PROBLEM", 123, 134], ["early influenza", "PROBLEM", 142, 157], ["viral interaction", "PROBLEM", 181, 198], ["virus epidemics", "PROBLEM", 238, 253], ["influenza", "OBSERVATION", 95, 104]]], ["[1] [2] [3] 17 With our data, the precise direction of potential interactions is not clear, that is, which virus(es) impacts which.", [["our data", "TEST", 20, 28]]], ["There are several types of virus-virus interactions, described in a review by Da Palma, 19 ranging from (i) direct virus-virus interactions (e.g., when nucleic acids or proteins of one virus physically interact with the genes or gene products of a coinfecting virus); (ii) indirect interactions resulting from alterations in the host environment; to (iii) immunological interactions.", [["nucleic acids", "CHEMICAL", 152, 165], ["virus-virus", "ORGANISM", 27, 38], ["virus-virus", "SPECIES", 27, 38], ["virus-virus", "SPECIES", 115, 126], ["virus-virus interactions", "PROBLEM", 27, 51], ["Da Palma", "TEST", 78, 86], ["direct virus-virus interactions", "PROBLEM", 108, 139], ["nucleic acids", "TREATMENT", 152, 165], ["one virus", "PROBLEM", 181, 190], ["a coinfecting virus", "PROBLEM", 246, 265], ["several", "OBSERVATION_MODIFIER", 10, 17], ["virus", "OBSERVATION", 27, 32]]], ["However, with the current data we cannot determine whether the viruses impacted each other biologically.", [["the viruses", "PROBLEM", 59, 70], ["viruses", "OBSERVATION", 63, 70]]], ["Further, there are other issues that can impact the timing and magnitude of seasonal epidemics such as environmental, social, and behavioral phenomena that may also be the potential drivers of observed shifts in reporting patterns instead of viral inter-action (alone).", [["seasonal epidemics", "PROBLEM", 76, 94], ["behavioral phenomena", "PROBLEM", 130, 150]]], ["20 To further attempt to disentangle these issues, future ecological studies should preferably include age-specific virological data over multiple seasons and better yet, cohort studies could be performed that (i) address the order of infection by different viruses (by serial sampling of subjects during the study period regardless of symptoms) as proposed by others; 17, 21 (ii) include persons from the same household as was done by Pascalis et al.; 18 and (iii) include multiple years and thus multiple seasons per virus.20There are several examples highlighting the importance of understanding drivers of viral shifts.", [["infection", "DISEASE", 235, 244], ["persons", "ORGANISM", 389, 396], ["persons", "SPECIES", 389, 396], ["future ecological studies", "TEST", 51, 76], ["cohort studies", "TEST", 171, 185], ["infection", "PROBLEM", 235, 244], ["different viruses", "PROBLEM", 248, 265], ["the study", "TEST", 305, 314], ["symptoms", "PROBLEM", 336, 344], ["viral shifts", "PROBLEM", 610, 622], ["infection", "OBSERVATION", 235, 244], ["viral shifts", "OBSERVATION", 610, 622]]], ["As suggested by Greer et al., further studies are relevant in light of the discussion whether rhinovirus promotes (pandemic) influenza spread through coughing and sneezing 22 or whether it may paradoxically provide natural protection due to inhibition of influenza infection in those already infected with rhinovirus.", [["influenza", "DISEASE", 125, 134], ["coughing", "DISEASE", 150, 158], ["sneezing", "DISEASE", 163, 171], ["influenza infection", "DISEASE", 255, 274], ["rhinovirus", "DISEASE", 306, 316], ["rhinovirus", "ORGANISM", 94, 104], ["influenza", "ORGANISM", 255, 264], ["rhinovirus", "ORGANISM", 306, 316], ["further studies", "TEST", 30, 45], ["rhinovirus promotes", "PROBLEM", 94, 113], ["influenza", "PROBLEM", 125, 134], ["coughing", "PROBLEM", 150, 158], ["sneezing", "PROBLEM", 163, 171], ["natural protection", "TREATMENT", 215, 233], ["influenza infection", "PROBLEM", 255, 274], ["rhinovirus", "PROBLEM", 306, 316], ["influenza", "OBSERVATION", 255, 264], ["rhinovirus", "OBSERVATION", 306, 316]]], ["17 Further studies may also provide input to the question whether influenza vaccination can render persons more susceptible to other respiratory viruses due to the lack of temporary nonspecific immunity induced by actual influenza infection.", [["influenza", "DISEASE", 66, 75], ["respiratory viruses", "DISEASE", 133, 152], ["influenza infection", "DISEASE", 221, 240], ["influenza", "ORGANISM", 66, 75], ["persons", "ORGANISM", 99, 106], ["persons", "SPECIES", 99, 106], ["Further studies", "TEST", 3, 18], ["influenza vaccination", "TREATMENT", 66, 87], ["other respiratory viruses", "PROBLEM", 127, 152], ["temporary nonspecific immunity", "PROBLEM", 172, 202], ["actual influenza infection", "PROBLEM", 214, 240]]], ["23 Canadian and Australian researchers hypothesize that through this same mechanism of induced temporary non-specific Table 3 .", [["Australian researchers", "TREATMENT", 16, 38]]], ["Correlation coefficients between number of weekly laboratory diagnoses of influenza A and weekly counts of other pathogens at different time lags (10 weeks later to 10 weeks earlier)*20*Bolded numbers indicate the largest correlation coefficient (with a negative correlation for enterovirus due to opposite seasonality with influenza A virus). immunity, the circulation of a seasonal influenza strain preceding a pandemic strain might decrease the susceptibility to that ensuing pandemic strain.", [["influenza", "DISEASE", 74, 83], ["enterovirus", "DISEASE", 279, 290], ["influenza A virus", "DISEASE", 324, 341], ["influenza", "DISEASE", 384, 393], ["influenza A virus", "ORGANISM", 324, 341], ["influenza A virus", "SPECIES", 324, 341], ["influenza A virus", "SPECIES", 324, 341], ["influenza", "PROBLEM", 74, 83], ["other pathogens", "PROBLEM", 107, 122], ["enterovirus", "PROBLEM", 279, 290], ["influenza A virus", "PROBLEM", 324, 341], ["a seasonal influenza strain", "PROBLEM", 373, 400], ["a pandemic strain", "PROBLEM", 411, 428], ["ensuing pandemic strain", "PROBLEM", 471, 494]]], ["24 Not evaluated in our study but possibly also playing a role in virus shifts or virus-virus interactions is the variation in the circulation of influenza A subtypes from year to year.", [["virus-virus", "ORGANISM", 82, 93], ["our study", "TEST", 20, 29], ["virus shifts", "PROBLEM", 66, 78], ["virus", "PROBLEM", 82, 87], ["virus interactions", "PROBLEM", 88, 106], ["influenza", "PROBLEM", 146, 155]]], ["Evaluation of such an effect might require evaluation of longer time series as the first general impression from our data was that there was no clear consistent association with subtype as the three early influenza years were not all dominated by the same influenza A type ( Studying the association of climatic factors (an example of environmental phenomena potentially affecting virus circulation) with influenza [26] [27] [28] was beyond the scope of this study, although covering the timespan of the study, a visual assessment of temperature and humidity trends showed no clear visual association between early influenza occurrence and early occurrence of low temperatures or low humidity.", [["influenza", "DISEASE", 205, 214], ["influenza", "DISEASE", 405, 414], ["influenza", "DISEASE", 615, 624], ["climatic factors", "PROTEIN", 303, 319], ["Evaluation", "TEST", 0, 10], ["evaluation", "TEST", 43, 53], ["climatic factors", "PROBLEM", 303, 319], ["environmental phenomena", "PROBLEM", 335, 358], ["influenza", "PROBLEM", 405, 414], ["this study", "TEST", 454, 464], ["the study", "TEST", 500, 509], ["a visual assessment", "TEST", 511, 530], ["humidity trends", "TEST", 550, 565], ["early influenza occurrence", "PROBLEM", 609, 635], ["low temperatures", "PROBLEM", 660, 676], ["low humidity", "PROBLEM", 680, 692], ["low temperatures", "OBSERVATION_MODIFIER", 660, 676], ["low humidity", "OBSERVATION_MODIFIER", 680, 692]]], ["Although two of the three early ILI seasons (2009/2010, 2010/ 2011) seem to have longer and colder cold spells (average weekly temperatures below 0\u00b0C) that also occur earlier in the winter season than in the other years, the first mentioned season (the 2009/2010 pandemic year) actually showed the cold spell occurring after the influenza season instead of at the beginning or during the influenza season (Appendix 2E).20Unlike earlier studies, we included several non-respiratory pathogens, for which the results showed no shifts in trends, and therefore, interaction with influenza A virus seems unlikely.", [["ILI", "DISEASE", 32, 35], ["influenza", "DISEASE", 329, 338], ["influenza A virus", "DISEASE", 574, 591], ["influenza A virus", "ORGANISM", 574, 591], ["influenza A virus", "SPECIES", 574, 591], ["influenza A virus", "SPECIES", 574, 591], ["colder cold spells", "PROBLEM", 92, 110], ["the cold spell", "PROBLEM", 294, 308], ["the influenza season", "PROBLEM", 325, 345], ["several non-respiratory pathogens", "PROBLEM", 457, 490], ["shifts in trends", "PROBLEM", 524, 540], ["influenza A virus", "PROBLEM", 574, 591]]], ["As norovirus, rotavirus, and enterovirus affect other organ systems, direct interaction may not be expected.", [["organ", "ANATOMY", 54, 59], ["norovirus", "DISEASE", 3, 12], ["rotavirus", "ORGANISM", 14, 23], ["enterovirus", "ORGANISM", 29, 40], ["organ", "ORGAN", 54, 59], ["rotavirus", "SPECIES", 14, 23], ["norovirus", "PROBLEM", 3, 12], ["rotavirus", "PROBLEM", 14, 23], ["enterovirus affect other organ systems", "PROBLEM", 29, 67], ["norovirus", "OBSERVATION", 3, 12]]], ["However, sporadic examples do not rule out such unexpected interactions as others have suggested that live polio vaccine (against an enteral virus) might prevent otitis media 29 (a respiratory infection), and decrease infantile diarrhea mortality 30 (gastro-intestinal mortality).", [["respiratory", "ANATOMY", 181, 192], ["intestinal", "ANATOMY", 258, 268], ["otitis", "DISEASE", 162, 168], ["respiratory infection", "DISEASE", 181, 202], ["infantile diarrhea", "DISEASE", 218, 236], ["intestinal", "ORGAN", 258, 268], ["live polio vaccine", "TREATMENT", 102, 120], ["an enteral virus", "TREATMENT", 130, 146], ["otitis media", "PROBLEM", 162, 174], ["a respiratory infection", "PROBLEM", 179, 202], ["infantile diarrhea mortality", "PROBLEM", 218, 246], ["respiratory", "ANATOMY", 181, 192], ["infection", "OBSERVATION", 193, 202], ["intestinal", "ANATOMY", 258, 268]]], ["Another issue is that, like others, we investigated shifts in virus circulation within the same seasons.", [["shifts in virus circulation", "PROBLEM", 52, 79]]], ["Whether early occurrence of influenza A may affect the circulation of seasonal pathogens in seasons thereafter is not known.20In conclusion, when influenza hit early we observed shifts in patterns of several respiratory pathogens that occur close in time with influenza A. Further research is needed to understand whether this was caused by (in)direct biological interaction between viruses or other underlying mechanisms such as human behavior and environmental factors or whether these observed shifts were just random occurrences.", [["influenza", "DISEASE", 28, 37], ["respiratory pathogens", "DISEASE", 208, 229], ["human", "ORGANISM", 430, 435], ["human", "SPECIES", 430, 435], ["human", "SPECIES", 430, 435], ["influenza", "PROBLEM", 28, 37], ["seasonal pathogens", "PROBLEM", 70, 88], ["influenza", "PROBLEM", 146, 155], ["several respiratory pathogens", "PROBLEM", 200, 229], ["influenza", "PROBLEM", 260, 269], ["direct biological interaction between viruses", "PROBLEM", 345, 390], ["human behavior", "PROBLEM", 430, 444], ["influenza", "OBSERVATION", 28, 37], ["several", "OBSERVATION_MODIFIER", 200, 207], ["respiratory pathogens", "OBSERVATION", 208, 229]]], ["Understanding these phenomena is of value in understand-ing or predicting the timing and magnitude of viral epidemics, providing knowledge which can be used for early warning and the allocation of healthcare resources.", [["viral epidemics", "PROBLEM", 102, 117]]]], "9039f0cd4aef64d178d99bd07eb72f0573bf13bf": [["IntroductionBioisosterism is a powerful concept that has found widespread application in drug design and continues to be an important tactical element in contemporary medicinal chemistry practices [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .", [["IntroductionBioisosterism", "DISEASE", 0, 25], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "CHEMICAL", 197, 232], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 197, 237]]], ["Bioisosterism, which evolved from the concept of shape isosterism exhibited by simple structural elements, was originally recognized by Langmuir almost a century ago, and the first experiments that demonstrated the potential of bioisosterism in a practical setting were reported in 1932 and 1933 [1, [11] [12] [13] .", [["Bioisosterism", "DISEASE", 0, 13], ["[11] [12] [13]", "SIMPLE_CHEMICAL", 300, 314], ["Bioisosterism", "PROBLEM", 0, 13], ["shape isosterism", "PROBLEM", 49, 65], ["simple structural elements", "PROBLEM", 79, 105], ["bioisosterism", "PROBLEM", 228, 241], ["shape", "OBSERVATION_MODIFIER", 49, 54], ["simple", "OBSERVATION_MODIFIER", 79, 85], ["structural elements", "OBSERVATION", 86, 105]]], ["In a series of experiments, Erlenmeyer and his colleagues showed that antibodies recognizing ortho-substituted tyrosine moieties in synthetic antigens, derived by reaction with diazonium ions, were not able to distinguish between a phenyl and thiophene ring or O, NH, and CH 2 in a linker element [12, 13] .", [["ortho", "CHEMICAL", 93, 98], ["tyrosine", "CHEMICAL", 111, 119], ["diazonium", "CHEMICAL", 177, 186], ["phenyl", "CHEMICAL", 232, 238], ["thiophene", "CHEMICAL", 243, 252], ["NH", "CHEMICAL", 264, 266], ["tyrosine", "CHEMICAL", 111, 119], ["diazonium", "CHEMICAL", 177, 186], ["phenyl", "CHEMICAL", 232, 238], ["thiophene", "CHEMICAL", 243, 252], ["O", "CHEMICAL", 261, 262], ["NH", "CHEMICAL", 264, 266], ["CH 2", "CHEMICAL", 272, 276], ["ortho-substituted tyrosine moieties", "SIMPLE_CHEMICAL", 93, 128], ["diazonium ions", "SIMPLE_CHEMICAL", 177, 191], ["phenyl", "SIMPLE_CHEMICAL", 232, 238], ["thiophene ring", "SIMPLE_CHEMICAL", 243, 257], ["O, NH", "SIMPLE_CHEMICAL", 261, 266], ["synthetic antigens", "PROTEIN", 132, 150], ["antibodies", "TEST", 70, 80], ["ortho-substituted tyrosine moieties", "TREATMENT", 93, 128], ["diazonium ions", "TREATMENT", 177, 191], ["a phenyl and thiophene ring", "TREATMENT", 230, 257]]], ["The description of this phenomenon as bioisosterism is attributed to Harris Friedman who introduced the term in 1951 to define compounds demonstrating similar biological activities [14] .", [["bioisosterism", "DISEASE", 38, 51], ["this phenomenon", "PROBLEM", 19, 34]]], ["However, Friedman recognized that bioisosterism and isosterism were distinct concepts, an observation that anticipated contemporary drug design principles in which the utility of bioisosteres is frequently dependent on context and relies upon a less than exact structural or physicochemical mimicry for the manifestation of biological effect.", [["bioisosterism and isosterism", "PROBLEM", 34, 62], ["contemporary drug design principles", "TREATMENT", 119, 154], ["bioisosteres", "TREATMENT", 179, 191]]], ["The thoughtful deployment of a bioisostere offers potential value in drug design campaigns by providing an opportunity to probe the effect of steric size and shape, the modulation of dipole and electronic properties, lipophilicity and polarity, or pK a on a biological response, which may be functional mimicry or antagonism of a biological regulator [1, 2, 10] .", [["steric size and shape", "PROBLEM", 142, 163], ["size", "OBSERVATION_MODIFIER", 149, 153], ["shape", "OBSERVATION_MODIFIER", 158, 163]]], ["In addition to affecting potency and function, isosteres have demonstrated utility in addressing problems associated with pharmacokinetic and pharmaceutical properties, specificity, toxicity, and metabolic activation pathways in vivo in addition to being a source of novel intellectual property [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .", [["toxicity", "DISEASE", 182, 190], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 295, 335], ["pharmacokinetic and pharmaceutical properties", "PROBLEM", 122, 167], ["toxicity", "PROBLEM", 182, 190]]], ["This chapter will summarize some of the more interesting tactical applications of bioisosteres in drug design where problems of the type commonly encountered by medicinal chemists have inspired innovative solutions that offer useful instruction.", [["bioisosteres", "SIMPLE_CHEMICAL", 82, 94]]], ["The vignettes are organized based on a specific property or problem under examination rather than the perhaps more traditional approach of cataloguing based on functional group mimicry.Introduction2 Bioisosteres Designed to Enhance Drug Potency and SelectivityFluorine as an Isostere of HydrogenFluorine has emerged as a remarkable element in drug design, and its applications continue to provide interesting effects on biological activity that can often be somewhat surprising, leading to its broad deployment by the medicinal chemistry community which, in turn, has promoted a deeper understanding of its properties [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .", [["Fluorine", "CHEMICAL", 260, 268], ["HydrogenFluorine", "CHEMICAL", 287, 303], ["Fluorine", "CHEMICAL", 260, 268], ["HydrogenFluorine", "CHEMICAL", 287, 303], ["[15] [16] [17] [18] [19] [20] [21] [22] [23]", "CHEMICAL", 618, 662], ["Fluorine", "SIMPLE_CHEMICAL", 260, 268], ["HydrogenFluorine", "SIMPLE_CHEMICAL", 287, 303], ["[15] [16] [17] [18] [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 618, 667], ["examination", "TEST", 74, 85], ["cataloguing", "TREATMENT", 139, 150], ["Introduction2 Bioisosteres", "TREATMENT", 185, 211], ["Fluorine", "TREATMENT", 260, 268], ["an Isostere of HydrogenFluorine", "TREATMENT", 272, 303], ["its applications", "TREATMENT", 360, 376]]], ["The strategic introduction of fluorine to replace a hydrogen atom can markedly influence potency [25] [26] [27] [28] [29] [30] .", [["fluorine", "CHEMICAL", 30, 38], ["hydrogen atom", "CHEMICAL", 52, 65], ["fluorine", "CHEMICAL", 30, 38], ["hydrogen", "CHEMICAL", 52, 60], ["fluorine", "SIMPLE_CHEMICAL", 30, 38], ["hydrogen atom", "SIMPLE_CHEMICAL", 52, 65], ["[25] [26] [27] [28] [29] [30]", "SIMPLE_CHEMICAL", 97, 126], ["fluorine", "TREATMENT", 30, 38], ["a hydrogen atom", "TREATMENT", 50, 65]]], ["For example, the L-nucleoside analogue emtricitabine (2, FTC) is the 5-fluoro analogue of lamivudine (1, 3TC) and is consistently the more potent HIV-1 inhibitor in cell culture by four-to tenfold, which is reflected in the inhibition of HIV-1 reverse transcriptase by the respective triphosphate derivatives [25] [26] [27] .", [["cell culture", "ANATOMY", 165, 177], ["L-nucleoside", "CHEMICAL", 17, 29], ["emtricitabine", "CHEMICAL", 39, 52], ["2, FTC", "CHEMICAL", 54, 60], ["5-fluoro", "CHEMICAL", 69, 77], ["lamivudine", "CHEMICAL", 90, 100], ["1, 3TC", "CHEMICAL", 102, 108], ["triphosphate", "CHEMICAL", 284, 296], ["L-nucleoside", "CHEMICAL", 17, 29], ["emtricitabine", "CHEMICAL", 39, 52], ["2, FTC", "CHEMICAL", 54, 60], ["5-fluoro", "CHEMICAL", 69, 77], ["lamivudine", "CHEMICAL", 90, 100], ["1, 3TC", "CHEMICAL", 102, 108], ["triphosphate", "CHEMICAL", 284, 296], ["L-nucleoside", "SIMPLE_CHEMICAL", 17, 29], ["emtricitabine", "SIMPLE_CHEMICAL", 39, 52], ["2", "SIMPLE_CHEMICAL", 54, 55], ["FTC", "SIMPLE_CHEMICAL", 57, 60], ["5-fluoro", "SIMPLE_CHEMICAL", 69, 77], ["lamivudine", "SIMPLE_CHEMICAL", 90, 100], ["1, 3TC", "SIMPLE_CHEMICAL", 102, 108], ["HIV-1", "ORGANISM", 146, 151], ["cell culture", "CELL", 165, 177], ["HIV-1 reverse transcriptase", "GENE_OR_GENE_PRODUCT", 238, 265], ["triphosphate derivatives [25] [26] [27]", "SIMPLE_CHEMICAL", 284, 323], ["HIV-1 reverse transcriptase", "PROTEIN", 238, 265], ["HIV-1", "SPECIES", 238, 243], ["HIV-1", "SPECIES", 146, 151], ["HIV-1", "SPECIES", 238, 243], ["the L-nucleoside analogue emtricitabine (2, FTC)", "TREATMENT", 13, 61], ["the 5-fluoro analogue", "TREATMENT", 65, 86], ["lamivudine", "TREATMENT", 90, 100], ["3TC", "TREATMENT", 105, 108], ["cell culture", "TEST", 165, 177], ["HIV-1 reverse transcriptase", "TREATMENT", 238, 265], ["the respective triphosphate derivatives", "TREATMENT", 269, 308]]], ["The F atom ortho to the piperazine and morpholine in the antibacterial agents, the quinolone-based DNA gyrase inhibitor 3 and the protein synthesis inhibitor linezolid 4, respectively, is of importance to both potency and efficacy in vivo while in indole-based HIV-1 attachment inhibitors, the 4-F substituent installed in 6 enhanced the potency of prototype 5 by more than 50-fold [15, 16, [28] [29] [30] .", [["piperazine", "CHEMICAL", 24, 34], ["morpholine", "CHEMICAL", 39, 49], ["quinolone", "CHEMICAL", 83, 92], ["linezolid", "CHEMICAL", 158, 167], ["indole", "CHEMICAL", 248, 254], ["4-F substituent", "CHEMICAL", 294, 309], ["F", "CHEMICAL", 4, 5], ["piperazine", "CHEMICAL", 24, 34], ["morpholine", "CHEMICAL", 39, 49], ["quinolone", "CHEMICAL", 83, 92], ["linezolid", "CHEMICAL", 158, 167], ["indole", "CHEMICAL", 248, 254], ["4-F", "CHEMICAL", 294, 297], ["F atom ortho", "SIMPLE_CHEMICAL", 4, 16], ["piperazine", "SIMPLE_CHEMICAL", 24, 34], ["morpholine", "SIMPLE_CHEMICAL", 39, 49], ["quinolone", "SIMPLE_CHEMICAL", 83, 92], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["linezolid 4", "SIMPLE_CHEMICAL", 158, 169], ["indole", "SIMPLE_CHEMICAL", 248, 254], ["HIV-1", "ORGANISM", 261, 266], ["4-F substituent", "SIMPLE_CHEMICAL", 294, 309], ["[28] [29] [30]", "SIMPLE_CHEMICAL", 391, 405], ["HIV-1", "SPECIES", 261, 266], ["HIV-1", "SPECIES", 261, 266], ["the piperazine", "TREATMENT", 20, 34], ["morpholine", "TREATMENT", 39, 49], ["the antibacterial agents", "TREATMENT", 53, 77], ["the quinolone", "TREATMENT", 79, 92], ["based DNA gyrase inhibitor", "TREATMENT", 93, 119], ["the protein synthesis inhibitor linezolid", "TREATMENT", 126, 167], ["HIV-1 attachment inhibitors", "TREATMENT", 261, 288], ["the 4-F substituent", "TREATMENT", 290, 309]]], ["In a series of \u03b3-secretase inhibitors that reduced A\u03b2 protein production in a cellbased assay, the modest potency associated with the parent molecule 7 (evaluated in racemic form) was markedly improved by complete fluorination at C-5 although in this particular example gem-dimethyl substitution at C-5 also improved biological activity [31] .", [["C-5", "CHEMICAL", 230, 233], ["gem-dimethyl", "CHEMICAL", 270, 282], ["C-5", "CHEMICAL", 299, 302], ["gem-dimethyl", "CHEMICAL", 270, 282], ["\u03b3-secretase", "GENE_OR_GENE_PRODUCT", 15, 26], ["A\u03b2", "SIMPLE_CHEMICAL", 51, 53], ["C-5", "SIMPLE_CHEMICAL", 230, 233], ["gem-dimethyl", "SIMPLE_CHEMICAL", 270, 282], ["C-5", "SIMPLE_CHEMICAL", 299, 302], ["A\u03b2 protein", "PROTEIN", 51, 61], ["\u03b3-secretase inhibitors", "TREATMENT", 15, 37], ["reduced A\u03b2 protein production", "PROBLEM", 43, 72], ["a cellbased assay", "TEST", 76, 93], ["dimethyl substitution", "TREATMENT", 274, 295], ["improved", "OBSERVATION_MODIFIER", 193, 201]]], ["The introduction of a F atom at the para-position of the benzylated imide 10 enhanced thrombin inhibitory activity by over fivefold along with selectivity over the related serine protease trypsin by fourfold with 11 exhibiting a 67-fold preference for the coagulation cascade enzyme [17, 32] .", [["benzylated imide", "CHEMICAL", 57, 73], ["F", "CHEMICAL", 22, 23], ["benzylated imide", "CHEMICAL", 57, 73], ["serine", "CHEMICAL", 172, 178], ["F atom", "SIMPLE_CHEMICAL", 22, 28], ["benzylated imide 10", "SIMPLE_CHEMICAL", 57, 76], ["thrombin", "GENE_OR_GENE_PRODUCT", 86, 94], ["trypsin", "GENE_OR_GENE_PRODUCT", 188, 195], ["thrombin", "PROTEIN", 86, 94], ["serine protease", "PROTEIN", 172, 187], ["trypsin", "PROTEIN", 188, 195], ["coagulation cascade enzyme", "PROTEIN", 256, 282], ["a F atom", "TREATMENT", 20, 28], ["the benzylated imide", "TREATMENT", 53, 73], ["enhanced thrombin inhibitory activity", "TREATMENT", 77, 114], ["the related serine protease trypsin", "TREATMENT", 160, 195], ["the coagulation cascade enzyme", "TEST", 252, 282]]], ["An X-ray crystallographic structure of 11 bound to thrombin provided an understanding of the structure-activity relationship (SAR) observation with the F substituent proximal (2.4 \u00c5) to the backbone C \u03b1 -H atom of Asn 98 and aligned to establish an interaction with the C atom of the backbone amide C\u00bcO of Asn 98 at a distance of 3.5 \u00c5 and an angle of 96 to the plane of the C\u00bcO (Fig. 1) [17, 18, 32] .", [["\u03b1 -H", "CHEMICAL", 201, 205], ["Asn 98", "CHEMICAL", 214, 220], ["Asn 98", "CHEMICAL", 306, 312], ["F", "CHEMICAL", 152, 153], ["C \u03b1 -H", "CHEMICAL", 199, 205], ["Asn", "CHEMICAL", 214, 217], ["C", "CHEMICAL", 270, 271], ["amide", "CHEMICAL", 293, 298], ["C", "CHEMICAL", 299, 300], ["O", "CHEMICAL", 301, 302], ["Asn", "CHEMICAL", 306, 309], ["C\u00bcO", "CHEMICAL", 375, 378], ["thrombin", "GENE_OR_GENE_PRODUCT", 51, 59], ["Asn 98", "AMINO_ACID", 214, 220], ["Asn 98", "AMINO_ACID", 306, 312], ["C\u00bcO", "SIMPLE_CHEMICAL", 375, 378], ["thrombin", "PROTEIN", 51, 59], ["An X-ray crystallographic structure", "TEST", 0, 35], ["thrombin", "TEST", 51, 59], ["the F substituent proximal", "TREATMENT", 148, 174], ["the backbone C", "TEST", 186, 200], ["Asn", "TEST", 306, 309]]], ["The F to C\u00bcO carbon interaction is the one with broader occurrence, and although this interaction is considered to be energetically modest, it appears to be sufficient to differentiate the potency between 10 and 11 by playing a supporting role to the primary interactions between the enzyme and the inhibitor [33] .", [["C", "CHEMICAL", 9, 10], ["O", "CHEMICAL", 11, 12], ["carbon", "CHEMICAL", 13, 19], ["C\u00bcO carbon", "SIMPLE_CHEMICAL", 9, 19], ["enzyme", "PROTEIN", 284, 290], ["the enzyme", "TEST", 280, 290]]], ["In an analogous matched pair study, the thrombin inhibitory activity of the amidine 12 is embellished sixfold by F substitution to afford 13, with an X-ray crystallographic co-crystal structure suggestive of a H-bonding or electrostatic interaction between the F atom and backbone NH of Gly 216 which are 3.47 \u00c5 apart, close to the upper distance limit for a H-bond [16] .", [["amidine", "CHEMICAL", 76, 83], ["H", "CHEMICAL", 210, 211], ["Gly 216", "CHEMICAL", 287, 294], ["amidine", "CHEMICAL", 76, 83], ["H", "CHEMICAL", 210, 211], ["F", "CHEMICAL", 261, 262], ["NH", "CHEMICAL", 281, 283], ["Gly", "CHEMICAL", 287, 290], ["H", "CHEMICAL", 359, 360], ["thrombin", "GENE_OR_GENE_PRODUCT", 40, 48], ["amidine 12", "SIMPLE_CHEMICAL", 76, 86], ["F atom", "SIMPLE_CHEMICAL", 261, 267], ["Gly 216", "AMINO_ACID", 287, 294], ["thrombin", "PROTEIN", 40, 48], ["H", "PROTEIN", 359, 360], ["an analogous matched pair study", "TEST", 3, 34], ["the amidine", "TREATMENT", 72, 83], ["an X-ray crystallographic co-crystal structure", "TEST", 147, 193], ["electrostatic interaction", "PROBLEM", 223, 248], ["upper", "ANATOMY_MODIFIER", 332, 337]]], ["The importance of this interaction was underscored from a comparison with the co-crystal of 12 and thrombin in which the aromatic ring adopted a significantly different conformation to that of 13 [16] .Carboxylic Acid Isosteres to Improve PotencyCarboxylic acid isosteres are a familiar part of the medicinal chemistry landscape and have been deployed to address a number of challenges in drug design, including positively influencing potency.", [["Carboxylic Acid", "CHEMICAL", 202, 217], ["PotencyCarboxylic acid", "CHEMICAL", 239, 261], ["Carboxylic Acid", "CHEMICAL", 202, 217], ["PotencyCarboxylic acid", "CHEMICAL", 239, 261], ["thrombin", "GENE_OR_GENE_PRODUCT", 99, 107], ["Carboxylic Acid Isosteres", "SIMPLE_CHEMICAL", 202, 227], ["PotencyCarboxylic acid isosteres", "SIMPLE_CHEMICAL", 239, 271], ["thrombin", "PROTEIN", 99, 107], ["thrombin", "TREATMENT", 99, 107], ["Carboxylic Acid Isosteres", "TREATMENT", 202, 227], ["PotencyCarboxylic acid isosteres", "PROBLEM", 239, 271], ["aromatic ring", "OBSERVATION", 121, 134]]], ["A particularly compelling example that illustrates the importance of carefully selecting the optimal isostere is provided by the SARs that subtended the discovery of the potent angiotensin II receptor antagonist losartan (15) and its analogues 14 and 16-20 [34] [35] [36] [37] [38] .", [["angiotensin II", "CHEMICAL", 177, 191], ["losartan", "CHEMICAL", 212, 220], ["losartan", "CHEMICAL", 212, 220], ["angiotensin II receptor", "GENE_OR_GENE_PRODUCT", 177, 200], ["losartan", "SIMPLE_CHEMICAL", 212, 220], ["16-20 [34] [35] [36] [37] [38]", "SIMPLE_CHEMICAL", 251, 281], ["angiotensin II receptor", "PROTEIN", 177, 200], ["the potent angiotensin II receptor antagonist losartan", "TREATMENT", 166, 220], ["its analogues", "TEST", 230, 243]]], ["A key insight was that the tetrazole moiety in 15 enhances potency over the carboxylic acid analogue EXP-7711 (14) by tenfold, attributed to the topological geometry in which the 2H isomer depicted projects the acidic NH or negative charge 1.5 \u00c5 further from the aryl ring than does the carboxylic acid moiety [34, 39, 40] .", [["tetrazole", "CHEMICAL", 27, 36], ["carboxylic acid", "CHEMICAL", 76, 91], ["EXP-7711", "CHEMICAL", 101, 109], ["aryl", "CHEMICAL", 263, 267], ["carboxylic acid", "CHEMICAL", 287, 302], ["tetrazole", "CHEMICAL", 27, 36], ["carboxylic acid", "CHEMICAL", 76, 91], ["EXP-7711", "CHEMICAL", 101, 109], ["2H", "CHEMICAL", 179, 181], ["NH", "CHEMICAL", 218, 220], ["aryl", "CHEMICAL", 263, 267], ["carboxylic acid", "CHEMICAL", 287, 302], ["tetrazole", "SIMPLE_CHEMICAL", 27, 36], ["carboxylic acid", "SIMPLE_CHEMICAL", 76, 91], ["EXP-7711", "SIMPLE_CHEMICAL", 101, 109], ["carboxylic acid", "SIMPLE_CHEMICAL", 287, 302], ["acidic NH", "PROTEIN", 211, 220], ["the tetrazole moiety", "TREATMENT", 23, 43], ["the carboxylic acid analogue EXP", "TEST", 72, 104], ["the carboxylic acid moiety", "TEST", 283, 309]]], ["Interestingly, as summarized by the comparison presented in Table 1 , the position of the carboxylic acid moiety on the phenyl ring exerts minimal effect on potency, with 14 and 18 similarly active, while the ortho-tetrazole isomer 19 is over 50-fold more potent than the meta-substituted analogue 20 [38] .", [["carboxylic acid", "CHEMICAL", 90, 105], ["phenyl", "CHEMICAL", 120, 126], ["ortho-tetrazole", "CHEMICAL", 209, 224], ["carboxylic acid", "CHEMICAL", 90, 105], ["phenyl", "CHEMICAL", 120, 126], ["ortho-tetrazole", "CHEMICAL", 209, 224], ["carboxylic acid", "SIMPLE_CHEMICAL", 90, 105], ["phenyl ring", "SIMPLE_CHEMICAL", 120, 131], ["ortho-tetrazole isomer 19", "SIMPLE_CHEMICAL", 209, 234], ["the carboxylic acid moiety", "TREATMENT", 86, 112], ["the phenyl ring", "TREATMENT", 116, 131], ["the ortho-tetrazole isomer", "TREATMENT", 205, 231], ["minimal", "OBSERVATION_MODIFIER", 139, 146], ["effect", "OBSERVATION_MODIFIER", 147, 153]]], ["The carboxylic acid and tetrazole moieties are considered to bind in the same pocket in the angiotensin II receptor and interact with Lys 199 [41] .", [["carboxylic acid", "CHEMICAL", 4, 19], ["tetrazole", "CHEMICAL", 24, 33], ["angiotensin II", "CHEMICAL", 92, 106], ["Lys 199", "CHEMICAL", 134, 141], ["carboxylic acid", "CHEMICAL", 4, 19], ["tetrazole", "CHEMICAL", 24, 33], ["Lys", "CHEMICAL", 134, 137], ["carboxylic acid", "SIMPLE_CHEMICAL", 4, 19], ["tetrazole moieties", "SIMPLE_CHEMICAL", 24, 42], ["angiotensin II receptor", "GENE_OR_GENE_PRODUCT", 92, 115], ["angiotensin II receptor", "PROTEIN", 92, 115], ["The carboxylic acid and tetrazole moieties", "TREATMENT", 0, 42]]], ["However, this interaction does not appear to depend on the formation of a classic salt bridge since mutation of Lys 199 to Gln exerted only a modest twofold effect on the binding of losartan (15) and a fivefold effect on the binding of EXP-7711 (14) , data that are more consistent with a H-bonding interaction between drug and protein [41] .", [["Lys 199", "CHEMICAL", 112, 119], ["Gln", "CHEMICAL", 123, 126], ["losartan", "CHEMICAL", 182, 190], ["EXP-7711", "CHEMICAL", 236, 244], ["H", "CHEMICAL", 289, 290], ["Lys", "CHEMICAL", 112, 115], ["Gln", "CHEMICAL", 123, 126], ["losartan", "CHEMICAL", 182, 190], ["EXP-7711", "CHEMICAL", 236, 244], ["H", "CHEMICAL", 289, 290], ["Lys 199", "AMINO_ACID", 112, 119], ["Gln", "AMINO_ACID", 123, 126], ["losartan", "SIMPLE_CHEMICAL", 182, 190], ["a classic salt bridge", "TREATMENT", 72, 93], ["mutation of Lys", "PROBLEM", 100, 115], ["losartan", "TREATMENT", 182, 190], ["EXP", "TEST", 236, 239]]], ["The poor activity of 20 may be a consequence of increased steric bulk compared to the carboxylic acid analogue 18.", [["carboxylic acid", "CHEMICAL", 86, 101], ["carboxylic acid", "CHEMICAL", 86, 101], ["carboxylic acid", "SIMPLE_CHEMICAL", 86, 101], ["increased steric bulk", "PROBLEM", 48, 69], ["the carboxylic acid analogue", "TEST", 82, 110], ["poor activity", "OBSERVATION_MODIFIER", 4, 17], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["steric bulk", "OBSERVATION", 58, 69]]], ["The importance of topology and the associated geometric implications are also apparent in acylsulfonamide-based angiotensin II antagonists where this functionality functions suitably as an acid surrogate.", [["acylsulfonamide", "CHEMICAL", 90, 105], ["angiotensin II", "CHEMICAL", 112, 126], ["acylsulfonamide", "CHEMICAL", 90, 105], ["acylsulfonamide", "SIMPLE_CHEMICAL", 90, 105], ["angiotensin II antagonists", "GENE_OR_GENE_PRODUCT", 112, 138], ["angiotensin II antagonists", "TREATMENT", 112, 138], ["an acid surrogate", "TEST", 186, 203]]], ["The CONHSO 2 Ph moiety of 16 is a 20-fold less potent ligand than the topologically reversed SO 2 NHCOPh isomer 17, an observation that is consistent with the longer C-S bond in 17 more effectively mimicking the topology of the tetrazole 15 by projecting the charge further from the biphenyl core than 16, which more closely resembles the carboxylic acid 14 [34, 38, 42] .Carboxylic Acid Isosteres to Improve PotencyThe discovery of the macrocyclic hepatitis C virus (HCV) NS3 protease inhibitor BILN-2061 (21) represented a milestone in HCV drug design by providing proof-of-concept for this mechanistic approach to the control of viremia in infected subjects.", [["CONHSO 2 Ph", "CHEMICAL", 4, 15], ["tetrazole", "CHEMICAL", 228, 237], ["biphenyl", "CHEMICAL", 283, 291], ["carboxylic acid", "CHEMICAL", 339, 354], ["Carboxylic Acid", "CHEMICAL", 372, 387], ["hepatitis C", "DISEASE", 449, 460], ["BILN-2061", "CHEMICAL", 496, 505], ["viremia", "DISEASE", 632, 639], ["CONHSO 2 Ph", "CHEMICAL", 4, 15], ["SO 2 NHCOPh", "CHEMICAL", 93, 104], ["C-S", "CHEMICAL", 166, 169], ["tetrazole", "CHEMICAL", 228, 237], ["biphenyl", "CHEMICAL", 283, 291], ["carboxylic acid", "CHEMICAL", 339, 354], ["Carboxylic Acid", "CHEMICAL", 372, 387], ["BILN-2061", "CHEMICAL", 496, 505], ["tetrazole 15", "SIMPLE_CHEMICAL", 228, 240], ["carboxylic acid", "SIMPLE_CHEMICAL", 339, 354], ["Carboxylic Acid Isosteres", "SIMPLE_CHEMICAL", 372, 397], ["hepatitis C virus", "ORGANISM", 449, 466], ["HCV", "ORGANISM", 468, 471], ["HCV", "ORGANISM", 538, 541], ["macrocyclic hepatitis C virus (HCV) NS3 protease", "PROTEIN", 437, 485], ["hepatitis C virus", "SPECIES", 449, 466], ["hepatitis C virus", "SPECIES", 449, 466], ["HCV", "SPECIES", 468, 471], ["HCV", "SPECIES", 538, 541], ["The CONHSO", "TEST", 0, 10], ["Ph moiety", "TEST", 13, 22], ["the tetrazole", "TREATMENT", 224, 237], ["the carboxylic acid", "TEST", 335, 354], ["Carboxylic Acid Isosteres", "TREATMENT", 372, 397], ["the macrocyclic hepatitis C virus (HCV) NS3 protease inhibitor BILN", "TREATMENT", 433, 500], ["HCV drug design", "TREATMENT", 538, 553], ["this mechanistic approach", "TREATMENT", 588, 613], ["viremia in infected subjects", "PROBLEM", 632, 660], ["consistent with", "UNCERTAINTY", 139, 154], ["macrocyclic hepatitis", "OBSERVATION", 437, 458], ["viremia", "OBSERVATION", 632, 639]]], ["The disclosure of this series of tripeptide-based inhibitor stimulated considerable interest in further structural optimization, an endeavor that became of particular importance in the context of overcoming the cardiotoxicity that resulted in termination of this pioneering molecule [43] [44] [45] .", [["cardiotoxicity", "DISEASE", 211, 225], ["tripeptide", "CHEMICAL", 33, 43], ["tripeptide", "SIMPLE_CHEMICAL", 33, 43], ["[43] [44] [45]", "SIMPLE_CHEMICAL", 283, 297], ["tripeptide-based inhibitor", "TREATMENT", 33, 59], ["the cardiotoxicity", "PROBLEM", 207, 225]]], ["The conversion of the carboxyl terminus to an acylsulfonamide, particularly the cyclopropyl acylsulfonamide moiety, afforded compounds with increased potency as a consequence of the cyclopropyl ring complementing the P1 0 pocket and the sulfone oxygen atoms engaging the protein via H-bonding interactions with the catalytic elements of the enzyme.", [["acylsulfonamide", "CHEMICAL", 46, 61], ["cyclopropyl acylsulfonamide", "CHEMICAL", 80, 107], ["cyclopropyl", "CHEMICAL", 182, 193], ["oxygen", "CHEMICAL", 245, 251], ["H", "CHEMICAL", 283, 284], ["carboxyl", "CHEMICAL", 22, 30], ["acylsulfonamide", "CHEMICAL", 46, 61], ["cyclopropyl acylsulfonamide", "CHEMICAL", 80, 107], ["cyclopropyl", "CHEMICAL", 182, 193], ["sulfone", "CHEMICAL", 237, 244], ["oxygen", "CHEMICAL", 245, 251], ["H", "CHEMICAL", 283, 284], ["acylsulfonamide", "SIMPLE_CHEMICAL", 46, 61], ["cyclopropyl acylsulfonamide moiety", "SIMPLE_CHEMICAL", 80, 114], ["cyclopropyl ring", "SIMPLE_CHEMICAL", 182, 198], ["sulfone oxygen atoms", "SIMPLE_CHEMICAL", 237, 257], ["carboxyl terminus", "PROTEIN", 22, 39], ["P1 0 pocket", "PROTEIN", 217, 228], ["catalytic elements", "PROTEIN", 315, 333], ["enzyme", "PROTEIN", 341, 347], ["the carboxyl terminus", "TREATMENT", 18, 39], ["an acylsulfonamide", "TREATMENT", 43, 61], ["the cyclopropyl acylsulfonamide moiety", "TREATMENT", 76, 114], ["the cyclopropyl ring", "TREATMENT", 178, 198], ["the P1 0 pocket", "TREATMENT", 213, 228], ["the sulfone oxygen atoms", "TREATMENT", 233, 257], ["the enzyme", "TEST", 337, 347]]], ["The significant advantage conferred by this structural modification can be readily assessed by comparing the potency of the matched pairs of acyclic inhibitors 22 and 23 and the P4-P2* macrocycles 24 and 25 [46] [47] [48] [49] .", [["25 [46] [47] [48] [49]", "SIMPLE_CHEMICAL", 204, 226], ["acyclic inhibitors", "TEST", 141, 159], ["the P4-P2* macrocycles", "TEST", 174, 196], ["significant", "OBSERVATION_MODIFIER", 4, 15]]], ["The optimization of inhibitors of the anti-apoptotic B-cell lymphoma 2 proteins Bcl-2, Bcl-x L , and Bcl-w, for which the fragment leads biphenyl carboxylic acid 26 and phenol 27 were identified using a nuclear magnetic resonance (NMR) screen, involved tethering of the two molecules which bound weakly to proximal pockets in the Bcl-x L protein [50] [51] [52] .", [["biphenyl carboxylic acid", "CHEMICAL", 137, 161], ["phenol", "CHEMICAL", 169, 175], ["biphenyl carboxylic acid", "CHEMICAL", 137, 161], ["phenol", "CHEMICAL", 169, 175], ["B-cell lymphoma 2", "GENE_OR_GENE_PRODUCT", 53, 70], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 80, 85], ["Bcl-x L", "GENE_OR_GENE_PRODUCT", 87, 94], ["Bcl-w", "GENE_OR_GENE_PRODUCT", 101, 106], ["biphenyl carboxylic acid 26", "SIMPLE_CHEMICAL", 137, 164], ["phenol 27", "SIMPLE_CHEMICAL", 169, 178], ["Bcl-x L", "GENE_OR_GENE_PRODUCT", 330, 337], ["anti-apoptotic B-cell lymphoma 2 proteins", "PROTEIN", 38, 79], ["Bcl-2", "PROTEIN", 80, 85], ["Bcl-x L", "PROTEIN", 87, 94], ["Bcl-w", "PROTEIN", 101, 106], ["Bcl", "PROTEIN", 330, 333], ["inhibitors", "TREATMENT", 20, 30], ["the anti-apoptotic B-cell lymphoma", "TEST", 34, 68], ["Bcl", "TEST", 80, 83], ["Bcl", "TEST", 87, 90], ["Bcl", "TEST", 101, 104], ["biphenyl carboxylic acid", "TEST", 137, 161], ["a nuclear magnetic resonance", "TEST", 201, 229], ["the Bcl-x L protein", "TEST", 326, 345], ["cell lymphoma", "OBSERVATION", 55, 68], ["Bcl", "ANATOMY", 101, 104]]], ["Initial attempts to link acid 26 to phenol 27 focused on substituting at the C atom ortho to the carboxylic acid moiety of 26, a topology that was probed based on an analysis of NMR data [50, 51] .", [["phenol 27", "CHEMICAL", 36, 45], ["carboxylic acid", "CHEMICAL", 97, 112], ["phenol", "CHEMICAL", 36, 42], ["C", "CHEMICAL", 77, 78], ["carboxylic acid", "CHEMICAL", 97, 112], ["phenol 27", "SIMPLE_CHEMICAL", 36, 45], ["carboxylic acid", "SIMPLE_CHEMICAL", 97, 112], ["phenol", "TREATMENT", 36, 42], ["the carboxylic acid moiety", "TEST", 93, 119], ["an analysis", "TEST", 163, 174], ["NMR data", "TEST", 178, 186]]], ["However, this approach was not initially successful in identifying hybrid molecules with increased affinity, attributed to poor geometric vectors that gave suboptimal binding.", [["hybrid molecules", "PROBLEM", 67, 83], ["increased affinity", "PROBLEM", 89, 107], ["poor geometric vectors", "PROBLEM", 123, 145], ["suboptimal binding", "PROBLEM", 156, 174]]], ["An acylsulfonamide was conceived to offer an improved vector while preserving the acidic moiety, of importance as a complement to Arg 139 of the Bcl protein, and a library of 120 molecules were prepared after establishing that the simple methyl acylsulfonamide exhibited comparable affinity for Bcl as 26 [51] .", [["acylsulfonamide", "CHEMICAL", 3, 18], ["Arg 139", "CHEMICAL", 130, 137], ["methyl acylsulfonamide", "CHEMICAL", 238, 260], ["acylsulfonamide", "CHEMICAL", 3, 18], ["Arg", "CHEMICAL", 130, 133], ["methyl acylsulfonamide", "CHEMICAL", 238, 260], ["acylsulfonamide", "SIMPLE_CHEMICAL", 3, 18], ["Bcl", "GENE_OR_GENE_PRODUCT", 145, 148], ["methyl acylsulfonamide", "SIMPLE_CHEMICAL", 238, 260], ["Arg 139", "PROTEIN", 130, 137], ["Bcl protein", "PROTEIN", 145, 156], ["An acylsulfonamide", "TREATMENT", 0, 18], ["the Bcl protein", "TEST", 141, 156], ["the simple methyl acylsulfonamide", "TREATMENT", 227, 260], ["Bcl", "TEST", 295, 298]]], ["The acylsulfonamide 28 emerged from that exercise with further optimization to navitoclax (ABT-263, 30) proceeding via the intermediacy of compound 29 [50] [51] [52] .Applications of Heterocycles as Isosteres and Isosterism Between HeterocyclesHeterocycles find widespread application in drug design as important scaffolds for deploying functionality or as critical pharmacophoric elements that interact intimately with target proteins, a cue taken from Mother Nature who takes significant advantage of heterocycles.", [["acylsulfonamide", "CHEMICAL", 4, 19], ["navitoclax", "CHEMICAL", 79, 89], ["ABT-263", "CHEMICAL", 91, 98], ["Heterocycles", "CHEMICAL", 183, 195], ["acylsulfonamide", "CHEMICAL", 4, 19], ["navitoclax", "CHEMICAL", 79, 89], ["ABT-263", "CHEMICAL", 91, 98], ["Heterocycles", "CHEMICAL", 183, 195], ["HeterocyclesHeterocycles", "CHEMICAL", 232, 256], ["heterocycles", "CHEMICAL", 503, 515], ["acylsulfonamide 28", "SIMPLE_CHEMICAL", 4, 22], ["navitoclax", "SIMPLE_CHEMICAL", 79, 89], ["ABT-263", "SIMPLE_CHEMICAL", 91, 98], ["compound 29 [50] [51] [52]", "SIMPLE_CHEMICAL", 139, 165], ["Heterocycles", "SIMPLE_CHEMICAL", 183, 195], ["Isosteres", "SIMPLE_CHEMICAL", 199, 208], ["Isosterism", "SIMPLE_CHEMICAL", 213, 223], ["HeterocyclesHeterocycles", "SIMPLE_CHEMICAL", 232, 256], ["target proteins", "PROTEIN", 420, 435], ["The acylsulfonamide", "TREATMENT", 0, 19], ["navitoclax", "TREATMENT", 79, 89], ["ABT", "TEST", 91, 94], ["Heterocycles as Isosteres", "TREATMENT", 183, 208], ["Isosterism", "TREATMENT", 213, 223], ["HeterocyclesHeterocycles", "TREATMENT", 232, 256], ["drug design", "TREATMENT", 288, 299], ["important scaffolds", "TREATMENT", 303, 322], ["heterocycles", "TREATMENT", 503, 515], ["pharmacophoric elements", "OBSERVATION", 366, 389]]], ["The immense utility of heterocycles resides in their typically facile synthetic accessibility combined with the versatility to project a range of vectors while the electronic properties of the ring can readily be modulated by the introduction of additional heteroatoms and substituent selection.", [["heterocycles", "CHEMICAL", 23, 35], ["heterocycles", "TREATMENT", 23, 35], ["additional heteroatoms", "TREATMENT", 246, 268], ["substituent selection", "TREATMENT", 273, 294], ["substituent selection", "OBSERVATION", 273, 294]]], ["Aspects of heterocycles that are of importance to the medicinal chemist revolve around their ability to act as H-bond donors or acceptors, to influence the properties of substituents by withdrawing or donating charge and to engage in \u03c0-\u03c0 and dipole-dipole interactions.", [["heterocycles", "CHEMICAL", 11, 23], ["H", "CHEMICAL", 111, 112], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 234, 237], ["heterocycles", "TREATMENT", 11, 23], ["acceptors", "TREATMENT", 128, 137], ["heterocycles", "OBSERVATION", 11, 23]]], ["Thus, the careful selection of a heterocycle for a specific application is frequently of considerable importance and there are many examples where the effects of substitution by rings offering a similar silhouette can be quite subtle in nature and not always well understood.", [["a heterocycle", "TREATMENT", 31, 44], ["a specific application", "TREATMENT", 49, 71], ["substitution by rings", "TREATMENT", 162, 183]]], ["The H-bonding potential of a wide range of functionality, designated pK BHX , has been determined based on the association of 4-fluorophenol with an acceptor in CCl 4 monitored at room temperature by the shift in the infrared stretching frequency of the OH bond [53] [54] [55] .", [["H", "CHEMICAL", 4, 5], ["BHX", "CHEMICAL", 72, 75], ["4-fluorophenol", "CHEMICAL", 126, 140], ["CCl 4", "CHEMICAL", 161, 166], ["H", "CHEMICAL", 4, 5], ["BHX", "CHEMICAL", 72, 75], ["4-fluorophenol", "CHEMICAL", 126, 140], ["CCl 4", "CHEMICAL", 161, 166], ["OH", "CHEMICAL", 254, 256], ["pK BHX", "SIMPLE_CHEMICAL", 69, 75], ["4-fluorophenol", "SIMPLE_CHEMICAL", 126, 140], ["CCl 4", "SIMPLE_CHEMICAL", 161, 166], ["an acceptor in CCl", "TREATMENT", 146, 164]]], ["On this scale, a stronger H-bond acceptor is associated with a higher pK BHX value that shows dependence on several physical properties, including the position of the acceptor atom in the periodic table, polarizability, field and inductive/resonance effects, electronic resonance, and steric effects associated with substituents and their interaction with the acceptor atom.", [["H", "CHEMICAL", 26, 27], ["BHX", "PROTEIN", 73, 76], ["a higher pK BHX value", "PROBLEM", 61, 82], ["the acceptor atom", "TREATMENT", 163, 180], ["inductive/resonance effects", "PROBLEM", 230, 257], ["electronic resonance", "TEST", 259, 279], ["steric effects", "PROBLEM", 285, 299], ["substituents", "TREATMENT", 316, 328], ["the acceptor atom", "TREATMENT", 356, 373]]], ["A particularly important aspect of H-bonding potential is that across a range of functionality it is not quantitatively related to basicity (pK BH + or pKa) and there are several examples where a H-bonding interaction occurs preferentially at an atom of low basicity in the presence of a more basic acceptor [56] [57] [58] [59] [60] [61] [62] .", [["H", "CHEMICAL", 196, 197], ["H", "CHEMICAL", 35, 36], ["H", "CHEMICAL", 196, 197], ["[56] [57] [58] [59] [60] [61] [62]", "CHEMICAL", 308, 342], ["[56] [57] [58] [59] [60] [61] [62]", "SIMPLE_CHEMICAL", 308, 342], ["pKa", "PROBLEM", 152, 155], ["low basicity", "OBSERVATION_MODIFIER", 254, 266]]], ["For example, nicotine (31) protonates initially on the pyrrolidine nitrogen atom in H 2 O, but H-bonding with 4-fluorophenol in CCl 4 occurs primarily at the pyridine nitrogen atom.", [["nicotine", "CHEMICAL", 13, 21], ["pyrrolidine nitrogen", "CHEMICAL", 55, 75], ["H 2 O", "CHEMICAL", 84, 89], ["H", "CHEMICAL", 95, 96], ["4-fluorophenol", "CHEMICAL", 110, 124], ["CCl 4", "CHEMICAL", 128, 133], ["pyridine nitrogen", "CHEMICAL", 158, 175], ["nicotine", "CHEMICAL", 13, 21], ["pyrrolidine", "CHEMICAL", 55, 66], ["nitrogen", "CHEMICAL", 67, 75], ["H 2 O", "CHEMICAL", 84, 89], ["H", "CHEMICAL", 95, 96], ["4-fluorophenol", "CHEMICAL", 110, 124], ["CCl 4", "CHEMICAL", 128, 133], ["pyridine", "CHEMICAL", 158, 166], ["nitrogen", "CHEMICAL", 167, 175], ["nicotine (31)", "SIMPLE_CHEMICAL", 13, 26], ["pyrrolidine nitrogen atom", "SIMPLE_CHEMICAL", 55, 80], ["H 2 O", "SIMPLE_CHEMICAL", 84, 89], ["H-bonding", "SIMPLE_CHEMICAL", 95, 104], ["4-fluorophenol", "SIMPLE_CHEMICAL", 110, 124], ["CCl 4", "SIMPLE_CHEMICAL", 128, 133], ["pyridine nitrogen atom", "SIMPLE_CHEMICAL", 158, 180], ["nicotine", "TREATMENT", 13, 21], ["the pyrrolidine nitrogen atom", "TREATMENT", 51, 80], ["fluorophenol in CCl", "TREATMENT", 112, 131], ["the pyridine nitrogen atom", "TREATMENT", 154, 180]]], ["For cotinine (32) , the amide carbonyl is the primary site for H-bonding, which contrasts with basicity since the amide exhibits a pK BH + value of \u00c00.71 compared to 5.20 for the pyridine nitrogen atom where protonation occurs [56] [57] [58] [59] [60] [61] [62] .", [["cotinine", "CHEMICAL", 4, 12], ["amide carbonyl", "CHEMICAL", 24, 38], ["H", "CHEMICAL", 63, 64], ["pyridine nitrogen", "CHEMICAL", 179, 196], ["cotinine", "CHEMICAL", 4, 12], ["amide carbonyl", "CHEMICAL", 24, 38], ["H", "CHEMICAL", 63, 64], ["amide", "CHEMICAL", 114, 119], ["pyridine", "CHEMICAL", 179, 187], ["nitrogen", "CHEMICAL", 188, 196], ["cotinine (32)", "SIMPLE_CHEMICAL", 4, 17], ["amide carbonyl", "SIMPLE_CHEMICAL", 24, 38], ["amide", "SIMPLE_CHEMICAL", 114, 119], ["pyridine nitrogen atom", "SIMPLE_CHEMICAL", 179, 201], ["[56] [57] [58] [59] [60] [61] [62]", "SIMPLE_CHEMICAL", 227, 261], ["cotinine", "TEST", 4, 12], ["the amide carbonyl", "TREATMENT", 20, 38], ["a pK BH", "TEST", 129, 136], ["the pyridine nitrogen atom", "TEST", 175, 201]]], ["Table 2 presents a comparison of pK HBX and pK BH + (pKa) values for some common 5-and 6-membered ring heterocycles where within a homologous series there is some correlation between H-bonding potential (pK BH + ) and pK a values although isoxazole and pyridazine are notable exceptions.", [["isoxazole", "CHEMICAL", 239, 248], ["pyridazine", "CHEMICAL", 253, 263], ["heterocycles", "CHEMICAL", 103, 115], ["H-", "CHEMICAL", 183, 185], ["isoxazole", "CHEMICAL", 239, 248], ["pyridazine", "CHEMICAL", 253, 263], ["pK HBX", "SIMPLE_CHEMICAL", 33, 39], ["6-membered ring heterocycles", "SIMPLE_CHEMICAL", 87, 115], ["isoxazole", "SIMPLE_CHEMICAL", 239, 248], ["pyridazine", "SIMPLE_CHEMICAL", 253, 263], ["pK HBX", "TEST", 33, 39], ["pK BH", "TEST", 44, 49], ["pKa) values", "TEST", 53, 64], ["6-membered ring heterocycles", "TREATMENT", 87, 115], ["K BH", "TEST", 205, 209], ["pK a values", "TEST", 218, 229], ["isoxazole", "TREATMENT", 239, 248], ["pyridazine", "TREATMENT", 253, 263]]], ["In the case of pyridazine, a heterocycle that has been proposed to be a privileged scaffold in medicinal chemistry, the high H-bonding potential for this poorly basic molecule is attributed to the \u03b1-effect in which unfavorable lone pair-lone pair interactions are relieved by one of the N atoms engaging in a H-bonding interaction, as depicted in Fig. 2 [63, 64] .Applications of Heterocycles as Isosteres and Isosterism Between HeterocyclesThe topological deployment of an oxazole heterocycle influenced the potency of blood platelet aggregation inhibition associated with the non-prostanoid prostacyclin (PGI 2 ) mimetics 33 and 34 [65] [66] [67] [68] .", [["blood platelet", "ANATOMY", 520, 534], ["pyridazine", "CHEMICAL", 15, 25], ["heterocycle", "CHEMICAL", 29, 40], ["H", "CHEMICAL", 309, 310], ["oxazole", "CHEMICAL", 474, 481], ["platelet aggregation", "DISEASE", 526, 546], ["prostacyclin", "CHEMICAL", 593, 605], ["pyridazine", "CHEMICAL", 15, 25], ["H", "CHEMICAL", 125, 126], ["N", "CHEMICAL", 287, 288], ["H", "CHEMICAL", 309, 310], ["Heterocycles", "CHEMICAL", 380, 392], ["oxazole", "CHEMICAL", 474, 481], ["prostacyclin", "CHEMICAL", 593, 605], ["pyridazine", "SIMPLE_CHEMICAL", 15, 25], ["Heterocycles", "SIMPLE_CHEMICAL", 380, 392], ["Isosterism", "SIMPLE_CHEMICAL", 410, 420], ["oxazole heterocycle", "SIMPLE_CHEMICAL", 474, 493], ["blood", "ORGANISM_SUBSTANCE", 520, 525], ["platelet", "CELL", 526, 534], ["non-prostanoid prostacyclin", "SIMPLE_CHEMICAL", 578, 605], ["PGI 2", "SIMPLE_CHEMICAL", 607, 612], ["[65] [66] [67] [68]", "SIMPLE_CHEMICAL", 634, 653], ["pyridazine", "TREATMENT", 15, 25], ["a heterocycle", "TREATMENT", 27, 40], ["medicinal chemistry", "TEST", 95, 114], ["this poorly basic molecule", "PROBLEM", 149, 175], ["Heterocycles as Isosteres", "TREATMENT", 380, 405], ["Isosterism", "TREATMENT", 410, 420], ["Heterocycles", "TREATMENT", 429, 441], ["an oxazole heterocycle", "TREATMENT", 471, 493], ["blood platelet aggregation inhibition", "PROBLEM", 520, 557], ["the non-prostanoid prostacyclin (PGI", "TREATMENT", 574, 610], ["mimetics", "TEST", 615, 623]]], ["The oxazole 33 is fivefold more potent than the isomer 34 which, in turn, is comparable to the cis-olefin 35 [65] [66] [67] [68] .", [["oxazole", "CHEMICAL", 4, 11], ["cis-olefin", "CHEMICAL", 95, 105], ["oxazole 33", "CHEMICAL", 4, 14], ["cis-olefin", "CHEMICAL", 95, 105], ["oxazole 33", "SIMPLE_CHEMICAL", 4, 14], ["cis-olefin 35 [65] [66] [67] [68]", "SIMPLE_CHEMICAL", 95, 128], ["The oxazole", "TREATMENT", 0, 11]]], ["These data were interpreted in the context of the nitrogen atom of the central oxazole The metal binding properties of azole rings were explored in the context of inhibitors of HIV-1 integrase and conducted with a chemotype in which the binding topology of the fluorobenzyl substituent controlled the presentation of the heteroatom to one of the catalytic magnesium atoms [73] [74] [75] [76] [77] .", [["nitrogen", "CHEMICAL", 50, 58], ["oxazole", "CHEMICAL", 79, 86], ["azole", "CHEMICAL", 119, 124], ["fluorobenzyl", "CHEMICAL", 261, 273], ["magnesium", "CHEMICAL", 356, 365], ["nitrogen", "CHEMICAL", 50, 58], ["oxazole", "CHEMICAL", 79, 86], ["azole", "CHEMICAL", 119, 124], ["fluorobenzyl", "CHEMICAL", 261, 273], ["magnesium", "CHEMICAL", 356, 365], ["[73] [74] [75] [76]", "CHEMICAL", 372, 391], ["oxazole", "SIMPLE_CHEMICAL", 79, 86], ["azole rings", "SIMPLE_CHEMICAL", 119, 130], ["HIV-1", "ORGANISM", 177, 182], ["fluorobenzyl substituent", "SIMPLE_CHEMICAL", 261, 285], ["magnesium atoms [73] [74] [75] [76] [77]", "SIMPLE_CHEMICAL", 356, 396], ["HIV-1", "SPECIES", 177, 182], ["HIV-1", "SPECIES", 177, 182], ["These data", "TEST", 0, 10], ["the nitrogen atom", "TREATMENT", 46, 63], ["the central oxazole", "TREATMENT", 67, 86], ["The metal binding properties of azole rings", "TREATMENT", 87, 130], ["inhibitors", "TREATMENT", 163, 173], ["HIV", "PROBLEM", 177, 180], ["a chemotype", "PROBLEM", 212, 223], ["the fluorobenzyl substituent", "TREATMENT", 257, 285], ["the heteroatom", "TREATMENT", 317, 331], ["the catalytic magnesium atoms", "TEST", 342, 371], ["central oxazole", "OBSERVATION", 71, 86]]], ["As depicted in Fig. 4 , the positioning of the fluorobenzyl moieties in 41 and 42 dominates the binding conformation thereby dictating which azole heteroatom is presented to the active site metal atom, providing a sensitive assessment of metal binding potential, with SARs summarized in Table 3 [73] [74] [75] [76] [77] .", [["fluorobenzyl", "CHEMICAL", 47, 59], ["azole", "CHEMICAL", 141, 146], ["fluorobenzyl", "CHEMICAL", 47, 59], ["azole", "CHEMICAL", 141, 146], ["fluorobenzyl moieties", "SIMPLE_CHEMICAL", 47, 68], ["azole heteroatom", "SIMPLE_CHEMICAL", 141, 157], ["metal atom", "SIMPLE_CHEMICAL", 190, 200], ["3 [73] [74] [75] [76] [77]", "SIMPLE_CHEMICAL", 293, 319], ["the fluorobenzyl moieties", "TREATMENT", 43, 68], ["azole heteroatom", "TREATMENT", 141, 157], ["a sensitive assessment", "TEST", 212, 234], ["Fig", "OBSERVATION", 15, 18]]], ["The importance of Mg 2+ coordination potential and its impact on potency is most evident in the comparison between the two 1,2,4-oxadiazoles 47 and 48 in which the O atom of 48 is an ineffective metal coordinator, an observation that is concordant with heteroatom H-bonding potential and was recapitulated in a series of 1,6-naphthyridine derivatives [73] [74] [75] .", [["Mg", "CHEMICAL", 18, 20], ["1,2,4-oxadiazoles", "CHEMICAL", 123, 140], ["1,6-naphthyridine", "CHEMICAL", 321, 338], ["Mg 2+", "CHEMICAL", 18, 23], ["1,2,4-oxadiazoles", "CHEMICAL", 123, 140], ["O", "CHEMICAL", 164, 165], ["H", "CHEMICAL", 264, 265], ["1,6-naphthyridine", "CHEMICAL", 321, 338], ["Mg 2+", "SIMPLE_CHEMICAL", 18, 23], ["1,2,4-oxadiazoles", "SIMPLE_CHEMICAL", 123, 140], ["O atom", "SIMPLE_CHEMICAL", 164, 170], ["1,6-naphthyridine derivatives [73] [74] [75]", "SIMPLE_CHEMICAL", 321, 365], ["Mg", "TREATMENT", 18, 20], ["oxadiazoles", "TREATMENT", 129, 140], ["an observation", "TEST", 214, 228], ["naphthyridine derivatives", "TREATMENT", 325, 350]]], ["Interestingly, in the pyrido[1,2-a]pyrimidine series, the thiazole 44 was selected as the basis for further optimization while in the 1,6-naphthyridine chemotype, the 1,3,4oxadiazole ring that performs only modestly in this series (refer to compound 46) was the most effective amide surrogate studied, presumably reflecting subtle differences in binding between the two structural classes [75] [76] [77] .Applications of Heterocycles as Isosteres and Isosterism Between HeterocyclesThe electron-withdrawing properties of heterocyclic rings have been exploited as an important element in drug design with two aspects prominent: the acidifying effect of a heterocycle on a NH substituent, which enhances H-bonding donor properties and confers carboxylic acid mimicry in the case of sulfonamide antibacterial agents, and, secondly, the electron-withdrawing properties of a heterocycle ring that has been used to advantage in the design of mechanism-based inhibitors of serinetype proteases and hydrolases [78] [79] [80] [81] .", [["pyrido[1,2-a]pyrimidine", "CHEMICAL", 22, 45], ["thiazole", "CHEMICAL", 58, 66], ["1,6-naphthyridine", "CHEMICAL", 134, 151], ["1,3,4oxadiazole", "CHEMICAL", 167, 182], ["Heterocycles", "CHEMICAL", 421, 433], ["Heterocycles", "CHEMICAL", 470, 482], ["NH", "CHEMICAL", 671, 673], ["H", "CHEMICAL", 702, 703], ["carboxylic acid", "CHEMICAL", 741, 756], ["sulfonamide", "CHEMICAL", 780, 791], ["pyrido[1,2-a]pyrimidine", "CHEMICAL", 22, 45], ["thiazole", "CHEMICAL", 58, 66], ["1,6-naphthyridine", "CHEMICAL", 134, 151], ["1,3,4oxadiazole", "CHEMICAL", 167, 182], ["amide", "CHEMICAL", 277, 282], ["Heterocycles", "CHEMICAL", 421, 433], ["NH", "CHEMICAL", 671, 673], ["H", "CHEMICAL", 702, 703], ["carboxylic acid", "CHEMICAL", 741, 756], ["sulfonamide", "CHEMICAL", 780, 791], ["pyrido[1,2-a]pyrimidine", "SIMPLE_CHEMICAL", 22, 45], ["thiazole 44", "SIMPLE_CHEMICAL", 58, 69], ["1,6-naphthyridine chemotype", "SIMPLE_CHEMICAL", 134, 161], ["1,3,4oxadiazole ring", "SIMPLE_CHEMICAL", 167, 187], ["Heterocycles", "SIMPLE_CHEMICAL", 421, 433], ["Isosteres", "SIMPLE_CHEMICAL", 437, 446], ["Isosterism", "SIMPLE_CHEMICAL", 451, 461], ["Heterocycles", "SIMPLE_CHEMICAL", 470, 482], ["heterocyclic rings", "SIMPLE_CHEMICAL", 521, 539], ["NH substituent", "SIMPLE_CHEMICAL", 671, 685], ["carboxylic acid", "SIMPLE_CHEMICAL", 741, 756], ["sulfonamide antibacterial agents", "SIMPLE_CHEMICAL", 780, 812], ["serinetype proteases", "SIMPLE_CHEMICAL", 966, 986], ["hydrolases [78] [79] [80] [81]", "SIMPLE_CHEMICAL", 991, 1021], ["serinetype proteases", "PROTEIN", 966, 986], ["a]pyrimidine series", "TREATMENT", 33, 52], ["the thiazole", "TREATMENT", 54, 66], ["further optimization", "TEST", 100, 120], ["the 1,3,4oxadiazole ring", "TREATMENT", 163, 187], ["subtle differences in binding", "PROBLEM", 324, 353], ["Heterocycles as Isosteres", "TREATMENT", 421, 446], ["Isosterism", "TREATMENT", 451, 461], ["HeterocyclesThe electron", "TREATMENT", 470, 494], ["heterocyclic rings", "TREATMENT", 521, 539], ["a NH substituent", "TREATMENT", 669, 685], ["H-bonding donor properties", "TREATMENT", 702, 728], ["carboxylic acid mimicry", "TREATMENT", 741, 764], ["sulfonamide antibacterial agents", "TREATMENT", 780, 812], ["a heterocycle ring", "TREATMENT", 868, 886], ["serinetype proteases", "TEST", 966, 986], ["hydrolases", "TEST", 991, 1001], ["heterocyclic rings", "OBSERVATION", 521, 539]]], ["The site of attachment of substituents on a heterocyclic ring has been shown to be of importance to potency in all of these settings, interpretable based on the quantification of electron withdrawal.", [["electron", "SIMPLE_CHEMICAL", 179, 187], ["a heterocyclic ring", "TREATMENT", 42, 61], ["electron withdrawal", "PROBLEM", 179, 198], ["substituents", "OBSERVATION_MODIFIER", 26, 38], ["electron withdrawal", "OBSERVATION", 179, 198]]], ["A scale of electron withdrawal has been formulated as the concept of charge demand, defined as the fraction of \u03c0-charge transferred from a negatively charged trigonal carbon atom to the adjacent X group, typically measured by 13 C-NMR chemical shifts of trigonal benzylic carbanions, as depicted in Fig. 5 [82] [83] [84] [85] .", [["trigonal carbon", "CHEMICAL", 158, 173], ["C", "CHEMICAL", 229, 230], ["trigonal benzylic carbanions", "CHEMICAL", 254, 282], ["electron", "SIMPLE_CHEMICAL", 11, 19], ["trigonal benzylic carbanions", "SIMPLE_CHEMICAL", 254, 282], ["5 [82] [83] [84] [85]", "SIMPLE_CHEMICAL", 304, 325], ["X group", "PROTEIN", 195, 202], ["electron withdrawal", "PROBLEM", 11, 30], ["charge demand", "PROBLEM", 69, 82], ["a negatively charged trigonal carbon atom", "TREATMENT", 137, 178], ["trigonal benzylic carbanions", "TREATMENT", 254, 282], ["carbon atom", "OBSERVATION", 167, 178]]], ["The resonance electronwithdrawing capacity of common functional groups and a selection of heterocycles is summarized in Table 4 , data that reveals interesting trends and emphasizes the importance of carefully selecting specific heterocycles for a particular application.Applications of Heterocycles as Isosteres and Isosterism Between HeterocyclesAn important aspect associated with the design of serine protease inhibitors has focused on substrate mimetics that present the enzyme with an electrophilic carbonyl element.", [["heterocycles", "CHEMICAL", 90, 102], ["Heterocycles", "CHEMICAL", 287, 299], ["serine", "CHEMICAL", 398, 404], ["carbonyl", "CHEMICAL", 505, 513], ["Heterocycles", "SIMPLE_CHEMICAL", 287, 299], ["serine", "AMINO_ACID", 398, 404], ["a selection of heterocycles", "TREATMENT", 75, 102], ["specific heterocycles", "TREATMENT", 220, 241], ["a particular application", "TREATMENT", 246, 270], ["Heterocycles as Isosteres", "TREATMENT", 287, 312], ["Isosterism", "TREATMENT", 317, 327], ["Heterocycles", "TREATMENT", 336, 348], ["serine protease inhibitors", "TREATMENT", 398, 424], ["substrate mimetics", "TREATMENT", 440, 458], ["the enzyme", "TEST", 472, 482], ["an electrophilic carbonyl element", "TREATMENT", 488, 521], ["electrophilic", "OBSERVATION", 491, 504], ["carbonyl element", "OBSERVATION", 505, 521]]], ["This acts as a decoy for the scissile amide bond that reacts with the catalytic serine hydroxyl to form a stable but unproductive tetrahedral intermediate [79] .", [["hydroxyl", "CHEMICAL", 87, 95], ["scissile amide", "CHEMICAL", 29, 43], ["serine hydroxyl", "CHEMICAL", 80, 95], ["serine", "AMINO_ACID", 80, 86], ["hydroxyl", "SIMPLE_CHEMICAL", 87, 95], ["a decoy for the scissile amide bond", "TREATMENT", 13, 48], ["the catalytic serine hydroxyl", "TREATMENT", 66, 95], ["stable", "OBSERVATION_MODIFIER", 106, 112]]], ["The equilibrium in favor of the adduct is a function of the electrophilicity of the C\u00bcO moiety, with peptidic aldehydes an early vehicle that established the viability of this concept but which was subsequently refined by deploying trifluoromethyl ketones and \u03b1-ketoamides.", [["aldehydes", "CHEMICAL", 110, 119], ["trifluoromethyl ketones", "CHEMICAL", 232, 255], ["\u03b1-ketoamides", "CHEMICAL", 260, 272], ["C\u00bcO", "CHEMICAL", 84, 87], ["aldehydes", "CHEMICAL", 110, 119], ["trifluoromethyl ketones", "CHEMICAL", 232, 255], ["\u03b1-ketoamides", "CHEMICAL", 260, 272], ["C\u00bcO moiety", "SIMPLE_CHEMICAL", 84, 94], ["peptidic aldehydes", "SIMPLE_CHEMICAL", 101, 119], ["trifluoromethyl ketones", "SIMPLE_CHEMICAL", 232, 255], ["\u03b1-ketoamides", "SIMPLE_CHEMICAL", 260, 272], ["the C\u00bcO moiety", "PROBLEM", 80, 94], ["peptidic aldehydes", "PROBLEM", 101, 119], ["trifluoromethyl ketones", "TEST", 232, 255], ["\u03b1-ketoamides", "TREATMENT", 260, 272], ["equilibrium", "OBSERVATION_MODIFIER", 4, 15], ["adduct", "OBSERVATION", 32, 38]]], ["Trifluoromethyl ketones provide an additional example of the beneficial effect on potency of replacing H with F since the corresponding methyl ketones are typically inactive [86] . \u03b1-Ketoamides are particularly interesting in inhibitor optimization because they provide an opportunity for the incorporation of structural elements designed to interact more extensively with the S 0 pockets of an enzyme [87] .", [["Trifluoromethyl ketones", "CHEMICAL", 0, 23], ["H", "CHEMICAL", 103, 104], ["methyl ketones", "CHEMICAL", 136, 150], ["\u03b1-Ketoamides", "CHEMICAL", 181, 193], ["Trifluoromethyl ketones", "CHEMICAL", 0, 23], ["H", "CHEMICAL", 103, 104], ["methyl ketones", "CHEMICAL", 136, 150], ["\u03b1-Ketoamides", "CHEMICAL", 181, 193], ["Trifluoromethyl ketones", "SIMPLE_CHEMICAL", 0, 23], ["methyl ketones", "SIMPLE_CHEMICAL", 136, 150], ["\u03b1-Ketoamides", "SIMPLE_CHEMICAL", 181, 193], ["S 0 pockets", "PROTEIN", 377, 388], ["Trifluoromethyl ketones", "TEST", 0, 23], ["the corresponding methyl ketones", "TEST", 118, 150], ["\u03b1-Ketoamides", "TREATMENT", 181, 193], ["inhibitor optimization", "TREATMENT", 226, 248], ["an enzyme", "TEST", 392, 401]]], ["This design concept was further explored in the context of human neutrophil elastase (HNE) inhibitors that focused on tripeptidic, mechanism-based inhibitors that incorporated heterocycles as the carbonyl-activating element [88] [89] [90] [91] [92] [93] [94] . \u03b1-Ketoamides were included in this study for purpose of comparison and inhibitory potency was found to correlate nicely with Table 5 [89] .", [["HNE", "CHEMICAL", 86, 89], ["carbonyl", "CHEMICAL", 196, 204], ["\u03b1-Ketoamides", "CHEMICAL", 261, 273], ["heterocycles", "CHEMICAL", 176, 188], ["carbonyl", "CHEMICAL", 196, 204], ["\u03b1-Ketoamides", "CHEMICAL", 261, 273], ["human", "ORGANISM", 59, 64], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 65, 84], ["HNE", "SIMPLE_CHEMICAL", 86, 89], ["tripeptidic", "SIMPLE_CHEMICAL", 118, 129], ["carbonyl", "SIMPLE_CHEMICAL", 196, 204], ["[88] [89] [90] [91] [92] [93] [94]", "SIMPLE_CHEMICAL", 224, 258], ["\u03b1-Ketoamides", "SIMPLE_CHEMICAL", 261, 273], ["human neutrophil elastase", "PROTEIN", 59, 84], ["HNE", "PROTEIN", 86, 89], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["human neutrophil elastase (HNE) inhibitors", "TREATMENT", 59, 101], ["tripeptidic", "TREATMENT", 118, 129], ["mechanism-based inhibitors", "TREATMENT", 131, 157], ["\u03b1-Ketoamides", "TREATMENT", 261, 273], ["this study", "TEST", 291, 301]]], ["In addition to providing the potential for unique interactions with enzyme and the ability to probe interactions with S 0 sites, the heterocycle moiety was also considered to offer the potential to sterically interfere with reductive metabolism of the carbonyl moiety [88] [89] [90] 94] .", [["carbonyl", "CHEMICAL", 252, 260], ["carbonyl moiety [88] [89] [90] 94", "SIMPLE_CHEMICAL", 252, 285], ["enzyme", "PROTEIN", 68, 74], ["S 0 sites", "DNA", 118, 127], ["enzyme", "TREATMENT", 68, 74], ["the heterocycle moiety", "TREATMENT", 129, 151]]], ["Studies with a matched pair of oxadiazole derivatives found that HNE inhibitory activity was sensitive to the topology of the heterocycle, a structure-activity relationship clearly rooted in the electron-withdrawing properties of the heterocycle [91, 92] .", [["oxadiazole", "CHEMICAL", 31, 41], ["HNE", "CHEMICAL", 65, 68], ["oxadiazole", "CHEMICAL", 31, 41], ["oxadiazole derivatives", "SIMPLE_CHEMICAL", 31, 53], ["HNE", "SIMPLE_CHEMICAL", 65, 68], ["electron", "SIMPLE_CHEMICAL", 195, 203], ["Studies", "TEST", 0, 7], ["a matched pair of oxadiazole derivatives", "TREATMENT", 13, 53], ["HNE inhibitory activity", "PROBLEM", 65, 88], ["the heterocycle", "TEST", 230, 245]]], ["The 1,3,4-oxadiazole 51 is a potent inhibitor of HNE with a K i \u00bc 0.025 nM, but the isomeric 1,2,4-oxadiazole 52 is 20-fold weaker, with a K i \u00bc 0.49 nM [90] .", [["1,3,4-oxadiazole", "CHEMICAL", 4, 20], ["HNE", "CHEMICAL", 49, 52], ["K", "CHEMICAL", 60, 61], ["1,2,4-oxadiazole", "CHEMICAL", 93, 109], ["K", "CHEMICAL", 139, 140], ["1,3,4-oxadiazole 51", "CHEMICAL", 4, 23], ["HNE", "CHEMICAL", 49, 52], ["1,2,4-oxadiazole", "CHEMICAL", 93, 109], ["1,3,4-oxadiazole 51", "SIMPLE_CHEMICAL", 4, 23], ["HNE", "SIMPLE_CHEMICAL", 49, 52], ["1,2,4-oxadiazole 52", "SIMPLE_CHEMICAL", 93, 112], ["oxadiazole", "TREATMENT", 10, 20], ["a potent inhibitor of HNE", "TREATMENT", 27, 52], ["a K i", "TEST", 58, 63], ["oxadiazole", "TREATMENT", 99, 109], ["a K i", "TEST", 137, 142]]], ["In these inhibitors, the electron-withdrawing effect of the 1,3,4-oxadiazole moiety is similar to an oxazole, whereas the 1,2,4-oxadiazole ring performs more like an imidazole (Table 4 ).", [["1,3,4-oxadiazole", "CHEMICAL", 60, 76], ["oxazole", "CHEMICAL", 101, 108], ["1,2,4-oxadiazole", "CHEMICAL", 122, 138], ["imidazole", "CHEMICAL", 166, 175], ["1,3,4-oxadiazole", "CHEMICAL", 60, 76], ["oxazole", "CHEMICAL", 101, 108], ["1,2,4-oxadiazole", "CHEMICAL", 122, 138], ["imidazole", "CHEMICAL", 166, 175], ["electron", "SIMPLE_CHEMICAL", 25, 33], ["1,3,4-oxadiazole moiety", "SIMPLE_CHEMICAL", 60, 83], ["oxazole", "SIMPLE_CHEMICAL", 101, 108], ["1,2,4-oxadiazole ring", "SIMPLE_CHEMICAL", 122, 143], ["imidazole", "SIMPLE_CHEMICAL", 166, 175], ["the electron", "TEST", 21, 33], ["the 1,3,4-oxadiazole moiety", "TREATMENT", 56, 83], ["an oxazole", "TREATMENT", 98, 108], ["the 1,2,4-oxadiazole ring", "TREATMENT", 118, 143], ["an imidazole (Table", "TREATMENT", 163, 182]]], ["Based on this result, the 1,3,4-oxadiazole moiety was adopted as the carbonyl-activating moiety in more advanced SAR studies that ultimately led to the identification of ONO-6818 (53) as an orally bioavailable, non-peptidic inhibitor of HNE that was advanced into clinical trials [92] .", [["orally", "ANATOMY", 190, 196], ["1,3,4-oxadiazole", "CHEMICAL", 26, 42], ["ONO-6818", "CHEMICAL", 170, 178], ["HNE", "CHEMICAL", 237, 240], ["1,3,4-oxadiazole", "CHEMICAL", 26, 42], ["carbonyl", "CHEMICAL", 69, 77], ["ONO-6818", "CHEMICAL", 170, 178], ["1,3,4-oxadiazole moiety", "SIMPLE_CHEMICAL", 26, 49], ["carbonyl", "SIMPLE_CHEMICAL", 69, 77], ["ONO-6818", "SIMPLE_CHEMICAL", 170, 178], ["HNE", "SIMPLE_CHEMICAL", 237, 240], ["the 1,3,4-oxadiazole moiety", "TREATMENT", 22, 49], ["the carbonyl-activating moiety", "TREATMENT", 65, 95], ["advanced SAR studies", "TEST", 104, 124], ["non-peptidic inhibitor of HNE", "TREATMENT", 211, 240]]], ["The basic design principles were confirmed by an X-ray crystallographic analysis of a benzoxazole-based HNE inhibitor bound to the enzyme which revealed that the catalytic serine hydroxyl had reacted with the activated carbonyl moiety as anticipated to afford a tetrahedral intermediate [88] .", [["benzoxazole", "CHEMICAL", 86, 97], ["HNE", "CHEMICAL", 104, 107], ["hydroxyl", "CHEMICAL", 179, 187], ["benzoxazole", "CHEMICAL", 86, 97], ["serine hydroxyl", "CHEMICAL", 172, 187], ["carbonyl", "CHEMICAL", 219, 227], ["benzoxazole", "SIMPLE_CHEMICAL", 86, 97], ["HNE", "SIMPLE_CHEMICAL", 104, 107], ["serine hydroxyl", "SIMPLE_CHEMICAL", 172, 187], ["an X-ray crystallographic analysis", "TEST", 46, 80], ["a benzoxazole-based HNE inhibitor", "TREATMENT", 84, 117], ["the enzyme", "TEST", 127, 137], ["the catalytic serine hydroxyl", "PROBLEM", 158, 187], ["the activated carbonyl moiety", "TREATMENT", 205, 234]]], ["In addition, the benzoxazole nitrogen atom engaged the NH of the imidazole of His 57 , the residue that is part of the catalytic triad, in a H-bonding interaction, as summarized in Fig. 6 [88] .Applications of Heterocycles as Isosteres and Isosterism Between Heterocycles2-Keto-oxazole derivatives have featured prominently in the design of inhibitors of fatty acid amide hydrolase (FAAH), a serine hydrolase responsible for degrading endogenous lipid amides, including anandamide and related fatty acid amides that have been identified as neuronal modulators [80, 81, [95] [96] [97] [98] [99] [100] [101] [102] [103] .", [["neuronal", "ANATOMY", 540, 548], ["benzoxazole nitrogen", "CHEMICAL", 17, 37], ["imidazole", "CHEMICAL", 65, 74], ["His 57", "CHEMICAL", 78, 84], ["H", "CHEMICAL", 141, 142], ["Heterocycles", "CHEMICAL", 210, 222], ["Heterocycles2-Keto-oxazole", "CHEMICAL", 259, 285], ["fatty acid amide", "CHEMICAL", 355, 371], ["anandamide", "CHEMICAL", 470, 480], ["fatty acid amides", "CHEMICAL", 493, 510], ["benzoxazole", "CHEMICAL", 17, 28], ["nitrogen", "CHEMICAL", 29, 37], ["NH", "CHEMICAL", 55, 57], ["imidazole", "CHEMICAL", 65, 74], ["His", "CHEMICAL", 78, 81], ["H", "CHEMICAL", 141, 142], ["Heterocycles", "CHEMICAL", 210, 222], ["Heterocycles2-Keto-oxazole", "CHEMICAL", 259, 285], ["fatty acid amide", "CHEMICAL", 355, 371], ["serine", "CHEMICAL", 392, 398], ["amides", "CHEMICAL", 452, 458], ["anandamide", "CHEMICAL", 470, 480], ["fatty acid amides", "CHEMICAL", 493, 510], ["benzoxazole nitrogen atom", "SIMPLE_CHEMICAL", 17, 42], ["His 57", "SIMPLE_CHEMICAL", 78, 84], ["Heterocycles", "SIMPLE_CHEMICAL", 210, 222], ["Isosteres", "SIMPLE_CHEMICAL", 226, 235], ["Isosterism", "SIMPLE_CHEMICAL", 240, 250], ["Heterocycles2-Keto-oxazole derivatives", "SIMPLE_CHEMICAL", 259, 297], ["fatty acid amide hydrolase", "GENE_OR_GENE_PRODUCT", 355, 381], ["FAAH", "GENE_OR_GENE_PRODUCT", 383, 387], ["serine", "AMINO_ACID", 392, 398], ["lipid amides", "SIMPLE_CHEMICAL", 446, 458], ["anandamide", "SIMPLE_CHEMICAL", 470, 480], ["fatty acid amides", "SIMPLE_CHEMICAL", 493, 510], ["neuronal", "CELL", 540, 548], ["[95] [96] [97] [98] [99] [100] [101] [102] [103]", "SIMPLE_CHEMICAL", 569, 617], ["catalytic triad", "PROTEIN", 119, 134], ["fatty acid amide hydrolase", "PROTEIN", 355, 381], ["FAAH", "PROTEIN", 383, 387], ["serine hydrolase", "PROTEIN", 392, 408], ["the benzoxazole nitrogen atom", "TREATMENT", 13, 42], ["the imidazole", "TREATMENT", 61, 74], ["the residue", "PROBLEM", 87, 98], ["Heterocycles as Isosteres", "TREATMENT", 210, 235], ["Isosterism", "TREATMENT", 240, 250], ["Heterocycles2", "TREATMENT", 259, 272], ["Keto-oxazole derivatives", "TREATMENT", 273, 297], ["fatty acid amide hydrolase (FAAH)", "PROBLEM", 355, 388], ["a serine hydrolase", "TEST", 390, 408], ["anandamide", "TREATMENT", 470, 480], ["fatty acid amides", "TEST", 493, 510], ["neuronal modulators", "TEST", 540, 559]]], ["The electronic properties of the oxazole heterocycle were influenced by electron-donating and electron-withdrawing substituents introduced at C-5 of the ring that indirectly influenced the electrophilicity of the carbonyl moiety designed to react with the enzyme serine hydroxyl; a survey that provided the structure-potency relationships is compiled in Table 6 .", [["oxazole", "CHEMICAL", 33, 40], ["C-5", "CHEMICAL", 142, 145], ["hydroxyl", "CHEMICAL", 270, 278], ["oxazole", "CHEMICAL", 33, 40], ["carbonyl", "CHEMICAL", 213, 221], ["serine hydroxyl", "CHEMICAL", 263, 278], ["oxazole heterocycle", "SIMPLE_CHEMICAL", 33, 52], ["electron", "SIMPLE_CHEMICAL", 72, 80], ["electron", "SIMPLE_CHEMICAL", 94, 102], ["C-5", "SIMPLE_CHEMICAL", 142, 145], ["carbonyl moiety", "SIMPLE_CHEMICAL", 213, 228], ["serine hydroxyl", "SIMPLE_CHEMICAL", 263, 278], ["the oxazole heterocycle", "TREATMENT", 29, 52], ["substituents", "TREATMENT", 115, 127], ["the enzyme serine hydroxyl", "TREATMENT", 252, 278], ["a survey", "TEST", 280, 288], ["oxazole heterocycle", "OBSERVATION", 33, 52], ["carbonyl moiety", "OBSERVATION", 213, 228]]], ["FAAH inhibitory activity was found to correlate with the Hammett \u03c3 constant associated with the substituent, with the plot of the data allowing the conclusion that the 5-CO 2 H derivative bound as the anion while the 5-CHO and 5-CO.CF 3 analogues bound as their hydrated forms [82, [94] [95] [96] 104] .Applications of Heterocycles as Isosteres and Isosterism Between HeterocyclesA particularly striking example of the importance of correctly deploying a heterocycle based on its electronic and H-bonding properties that relates closely to biological potency is illustrated by the series of 3 non-peptidic heteroaryl nitriles compiled in Table 7 that have been explored as inhibitors of the cysteine proteases cathepsins K and S [105] .", [["5-CO 2 H", "CHEMICAL", 168, 176], ["5-CHO", "CHEMICAL", 217, 222], ["5-CO.CF", "CHEMICAL", 227, 234], ["Heterocycles", "CHEMICAL", 319, 331], ["H", "CHEMICAL", 495, 496], ["heteroaryl nitriles", "CHEMICAL", 606, 625], ["K", "CHEMICAL", 721, 722], ["5-CO 2 H", "CHEMICAL", 168, 176], ["5-CHO", "CHEMICAL", 217, 222], ["5-CO.CF", "CHEMICAL", 227, 234], ["Heterocycles", "CHEMICAL", 319, 331], ["H", "CHEMICAL", 495, 496], ["heteroaryl nitriles", "CHEMICAL", 606, 625], ["cysteine", "CHEMICAL", 691, 699], ["FAAH", "GENE_OR_GENE_PRODUCT", 0, 4], ["5-CO 2 H derivative", "SIMPLE_CHEMICAL", 168, 187], ["anion", "SIMPLE_CHEMICAL", 201, 206], ["5-CHO", "SIMPLE_CHEMICAL", 217, 222], ["5-CO.CF 3 analogues", "SIMPLE_CHEMICAL", 227, 246], ["[94] [95] [96] 104", "SIMPLE_CHEMICAL", 282, 300], ["Heterocycles", "SIMPLE_CHEMICAL", 319, 331], ["Isosteres", "SIMPLE_CHEMICAL", 335, 344], ["Isosterism", "SIMPLE_CHEMICAL", 349, 359], ["H", "SIMPLE_CHEMICAL", 495, 496], ["non-peptidic heteroaryl nitriles", "SIMPLE_CHEMICAL", 593, 625], ["cathepsins K", "GENE_OR_GENE_PRODUCT", 710, 722], ["cysteine proteases", "PROTEIN", 691, 709], ["cathepsins K", "PROTEIN", 710, 722], ["FAAH inhibitory activity", "PROBLEM", 0, 24], ["their hydrated forms", "TEST", 256, 276], ["Heterocycles as Isosteres", "TREATMENT", 319, 344], ["Isosterism", "TREATMENT", 349, 359], ["Heterocycles", "TREATMENT", 368, 380], ["a heterocycle", "TREATMENT", 453, 466], ["its electronic and H-bonding properties", "TREATMENT", 476, 515], ["3 non-peptidic heteroaryl nitriles", "TREATMENT", 591, 625], ["the cysteine proteases", "TEST", 687, 709], ["K", "TEST", 721, 722]]], ["These compounds depend on the electron-withdrawing properties of the heterocycle to activate the nitrile moiety toward addition of the catalytic cysteine thiol of the enzyme to form a stable, covalent but reversible imino thioether-based complex.", [["thiol", "CHEMICAL", 154, 159], ["imino thioether", "CHEMICAL", 216, 231], ["nitrile", "CHEMICAL", 97, 104], ["cysteine thiol", "CHEMICAL", 145, 159], ["imino thioether", "CHEMICAL", 216, 231], ["electron", "SIMPLE_CHEMICAL", 30, 38], ["nitrile moiety", "SIMPLE_CHEMICAL", 97, 111], ["imino thioether", "SIMPLE_CHEMICAL", 216, 231], ["the electron", "TEST", 26, 38], ["the heterocycle", "TREATMENT", 65, 80], ["the nitrile moiety", "TREATMENT", 93, 111], ["the catalytic cysteine thiol", "TREATMENT", 131, 159], ["the enzyme", "TEST", 163, 173], ["reversible imino thioether-based complex", "PROBLEM", 205, 245], ["stable", "OBSERVATION", 184, 190], ["reversible", "OBSERVATION_MODIFIER", 205, 215], ["imino thioether", "OBSERVATION", 216, 231], ["complex", "OBSERVATION_MODIFIER", 238, 245]]], ["The 2-cyanopyrimidine 54 is a potent and effective inhibitor of both cathepsins, but the high charge demand at this site (0.43, Table 4 ) is such that the nitrile moiety is indiscriminately reactive and forms adducts with thiols of microsomal proteins.", [["2-cyanopyrimidine", "CHEMICAL", 4, 21], ["nitrile", "CHEMICAL", 155, 162], ["thiols", "CHEMICAL", 222, 228], ["2-cyanopyrimidine", "CHEMICAL", 4, 21], ["nitrile", "CHEMICAL", 155, 162], ["thiols", "CHEMICAL", 222, 228], ["2-cyanopyrimidine 54", "SIMPLE_CHEMICAL", 4, 24], ["cathepsins", "GENE_OR_GENE_PRODUCT", 69, 79], ["nitrile moiety", "SIMPLE_CHEMICAL", 155, 169], ["thiols", "SIMPLE_CHEMICAL", 222, 228], ["microsomal proteins", "GENE_OR_GENE_PRODUCT", 232, 251], ["cathepsins", "PROTEIN", 69, 79], ["microsomal proteins", "PROTEIN", 232, 251], ["cyanopyrimidine", "TREATMENT", 6, 21], ["both cathepsins", "TREATMENT", 64, 79], ["the high charge demand", "PROBLEM", 85, 107], ["the nitrile moiety", "PROBLEM", 151, 169], ["microsomal proteins", "PROBLEM", 232, 251], ["reactive", "OBSERVATION_MODIFIER", 190, 198]]], ["The isomeric 2-cyanopyridines 55 and 56 are of lower intrinsic electrophilicity based on the reduced charge demand (0.41, Table 4 ) which would be expected to translate into weaker enzyme inhibition.", [["2-cyanopyridines", "CHEMICAL", 13, 29], ["2-cyanopyridines", "CHEMICAL", 13, 29], ["2-cyanopyridines", "SIMPLE_CHEMICAL", 13, 29], ["The isomeric", "TEST", 0, 12], ["cyanopyridines", "TEST", 15, 29], ["lower intrinsic electrophilicity", "PROBLEM", 47, 79], ["the reduced charge demand", "TREATMENT", 89, 114], ["electrophilicity", "OBSERVATION", 63, 79]]], ["However, 55 and 56 exhibited markedly different protease inhibition profiles that provided unique insights into drug-target interactions.", [["protease", "PROTEIN", 48, 56], ["markedly different protease inhibition profiles", "PROBLEM", 29, 76]]], ["Pyridine 55 is 44-and 127-fold less potent toward cathepsins S and K, respectively, while the isomer 56 is inactive toward both cysteine proteases [105] .", [["Pyridine", "CHEMICAL", 0, 8], ["Pyridine 55", "CHEMICAL", 0, 11], ["cysteine", "CHEMICAL", 128, 136], ["Pyridine 55", "SIMPLE_CHEMICAL", 0, 11], ["cathepsins S", "GENE_OR_GENE_PRODUCT", 50, 62], ["K", "GENE_OR_GENE_PRODUCT", 67, 68], ["cathepsins S and K", "PROTEIN", 50, 68], ["cysteine proteases", "PROTEIN", 128, 146], ["Pyridine", "TREATMENT", 0, 8], ["cathepsins S", "TEST", 50, 62], ["K", "TEST", 67, 68]]], ["This observation was attributed to the concept that the pyrimidine N-3 is involved in cysteine thiol activation by acting as a general base to engage the thiol H atom, thereby catalyzing addition to the nitrile moiety, as depicted in Fig. 7 .", [["pyrimidine", "CHEMICAL", 56, 66], ["N-3", "CHEMICAL", 67, 70], ["cysteine thiol", "CHEMICAL", 86, 100], ["thiol H", "CHEMICAL", 154, 161], ["pyrimidine", "CHEMICAL", 56, 66], ["cysteine thiol", "CHEMICAL", 86, 100], ["thiol", "CHEMICAL", 154, 159], ["H", "CHEMICAL", 160, 161], ["nitrile", "CHEMICAL", 203, 210], ["pyrimidine N-3", "SIMPLE_CHEMICAL", 56, 70], ["cysteine", "AMINO_ACID", 86, 94], ["thiol", "SIMPLE_CHEMICAL", 95, 100], ["thiol H atom", "SIMPLE_CHEMICAL", 154, 166], ["nitrile moiety", "SIMPLE_CHEMICAL", 203, 217], ["the pyrimidine N-3", "TREATMENT", 52, 70], ["cysteine thiol activation", "TREATMENT", 86, 111], ["the nitrile moiety", "TREATMENT", 199, 217]]], ["Replacing the pyrimidine N-3 atom with a C-H, as in pyridine 56, not only removes this function but also introduces a negative steric interaction between the ring CH and the cysteine SH [105] .", [["pyrimidine N-3 atom", "CHEMICAL", 14, 33], ["C-H", "CHEMICAL", 41, 44], ["pyridine", "CHEMICAL", 52, 60], ["cysteine", "CHEMICAL", 174, 182], ["pyrimidine", "CHEMICAL", 14, 24], ["C-H", "CHEMICAL", 41, 44], ["pyridine", "CHEMICAL", 52, 60], ["CH", "CHEMICAL", 163, 165], ["cysteine", "CHEMICAL", 174, 182], ["SH", "CHEMICAL", 183, 185], ["pyrimidine N-3 atom", "SIMPLE_CHEMICAL", 14, 33], ["C-H", "SIMPLE_CHEMICAL", 41, 44], ["pyridine 56", "SIMPLE_CHEMICAL", 52, 63], ["the pyrimidine N", "TREATMENT", 10, 26], ["a C-H", "TREATMENT", 39, 44], ["pyridine", "TREATMENT", 52, 60]]], ["In a study inspired by observations of the marked potency differences between the two oxazole-based factor Xa inhibitors 57 and 58, which represent a matched pair differing only by the topology of the oxazole rings, dipole-dipole interactions between the heterocycle ring and an amide moiety of the protein were analyzed [106, 107] .", [["oxazole", "CHEMICAL", 86, 93], ["oxazole", "CHEMICAL", 201, 208], ["oxazole", "CHEMICAL", 86, 93], ["oxazole", "CHEMICAL", 201, 208], ["amide", "CHEMICAL", 279, 284], ["oxazole", "SIMPLE_CHEMICAL", 86, 93], ["Xa", "GENE_OR_GENE_PRODUCT", 107, 109], ["oxazole rings", "SIMPLE_CHEMICAL", 201, 214], ["a study", "TEST", 3, 10], ["the two oxazole", "TREATMENT", 78, 93], ["factor Xa inhibitors", "TREATMENT", 100, 120], ["the oxazole rings", "TREATMENT", 197, 214], ["dipole-dipole interactions", "TREATMENT", 216, 242], ["the heterocycle ring", "TREATMENT", 251, 271], ["an amide moiety", "TREATMENT", 276, 291], ["the protein", "TEST", 295, 306], ["marked", "OBSERVATION_MODIFIER", 43, 49], ["potency", "OBSERVATION_MODIFIER", 50, 57], ["oxazole rings", "OBSERVATION", 201, 214]]], ["The oxazoles 57 and 58 differed in potency by over tenfold while the isoxazole 59 was the most potent with a K i \u00bc 9 nM.", [["oxazoles 57 and 58", "CHEMICAL", 4, 22], ["isoxazole", "CHEMICAL", 69, 78], ["K", "CHEMICAL", 109, 110], ["oxazoles", "CHEMICAL", 4, 12], ["isoxazole 59", "CHEMICAL", 69, 81], ["oxazoles", "SIMPLE_CHEMICAL", 4, 12], ["58", "SIMPLE_CHEMICAL", 20, 22], ["isoxazole 59", "SIMPLE_CHEMICAL", 69, 81], ["The oxazoles", "TREATMENT", 0, 12], ["the isoxazole", "TREATMENT", 65, 78], ["a K i", "TEST", 107, 112]]], ["X-ray co-crystal data indicated that these inhibitors were not engaging the enzyme via a H-bond donor-acceptor interaction, but the heterocycle rings were noted to be close to the amide bond between Cys 191 and Gln 192 with the planes of each almost parallel, leading to the suggestion of a dipole-dipole interaction, as illustrated in Fig. 8 .", [["H", "CHEMICAL", 89, 90], ["Cys 191", "CHEMICAL", 199, 206], ["Gln 192", "CHEMICAL", 211, 218], ["H", "CHEMICAL", 89, 90], ["amide", "CHEMICAL", 180, 185], ["Cys", "CHEMICAL", 199, 202], ["Gln", "CHEMICAL", 211, 214], ["Cys 191", "AMINO_ACID", 199, 206], ["Gln 192", "AMINO_ACID", 211, 218], ["X-ray co-crystal data", "TEST", 0, 21], ["these inhibitors", "PROBLEM", 37, 53], ["the enzyme", "TEST", 72, 82], ["a H-bond donor-acceptor interaction", "TREATMENT", 87, 122], ["the heterocycle rings", "TREATMENT", 128, 149], ["Cys", "TEST", 199, 202], ["Gln", "TEST", 211, 214], ["a dipole-dipole interaction", "TREATMENT", 289, 316]]], ["Indeed, potency was shown to correlate with a favorable dipole-dipole interaction in the more active compound 57 that is mismatched in the less active isomer 58 (Fig. 9 ).", [["a favorable dipole-dipole interaction", "PROBLEM", 44, 81], ["dipole interaction", "OBSERVATION", 63, 81], ["more active", "OBSERVATION_MODIFIER", 89, 100]]], ["The experimental dipole moment for oxazole is 1.7 D and for isoxazole is 3.0 D and gas phase calculations indicate that under optimal conditions the interaction energies between these heterocycles and N-methylacetamide, which has a dipole moment of 3.7 D, are \u00c02.74 kcal/mol for oxazole and \u00c02.95 kcal/mol for isoxazole.", [["oxazole", "CHEMICAL", 35, 42], ["isoxazole", "CHEMICAL", 60, 69], ["heterocycles", "CHEMICAL", 184, 196], ["N-methylacetamide", "CHEMICAL", 201, 218], ["oxazole", "CHEMICAL", 279, 286], ["isoxazole", "CHEMICAL", 310, 319], ["oxazole", "CHEMICAL", 35, 42], ["isoxazole", "CHEMICAL", 60, 69], ["heterocycles", "CHEMICAL", 184, 196], ["N-methylacetamide", "CHEMICAL", 201, 218], ["oxazole", "CHEMICAL", 279, 286], ["isoxazole", "CHEMICAL", 310, 319], ["oxazole", "SIMPLE_CHEMICAL", 35, 42], ["isoxazole", "SIMPLE_CHEMICAL", 60, 69], ["N-methylacetamide", "SIMPLE_CHEMICAL", 201, 218], ["oxazole", "SIMPLE_CHEMICAL", 279, 286], ["\u00c02.95 kcal/mol", "SIMPLE_CHEMICAL", 291, 305], ["isoxazole", "SIMPLE_CHEMICAL", 310, 319], ["oxazole", "TREATMENT", 35, 42], ["isoxazole", "TREATMENT", 60, 69], ["gas phase calculations", "TEST", 83, 105], ["these heterocycles", "TREATMENT", 178, 196], ["methylacetamide", "TREATMENT", 203, 218], ["oxazole", "TREATMENT", 279, 286], ["isoxazole", "TREATMENT", 310, 319]]], ["Although the energies in an aqueous environment are expected to be lower based on solvation issues, these differences are sufficient to explain the differences in potency observed with the azoles 57-59.", [["azoles 57-59", "CHEMICAL", 189, 201], ["azoles", "CHEMICAL", 189, 195], ["the azoles", "TEST", 185, 195]]], ["A plot of the calculated energies versus dipole moment for a series of heterocycles interacting with N-methylacetamide exhibited a good correlation, R 2 \u00bc 0.84, while for benzene, pyrazine, and triazine, heterocyclic rings without a dipole moment, the interacting energies increase as the ring becomes more electron deficient.", [["heterocycles", "CHEMICAL", 71, 83], ["N-methylacetamide", "CHEMICAL", 101, 118], ["benzene", "CHEMICAL", 171, 178], ["pyrazine", "CHEMICAL", 180, 188], ["triazine", "CHEMICAL", 194, 202], ["heterocycles", "CHEMICAL", 71, 83], ["N-methylacetamide", "CHEMICAL", 101, 118], ["benzene", "CHEMICAL", 171, 178], ["pyrazine", "CHEMICAL", 180, 188], ["triazine", "CHEMICAL", 194, 202], ["N-methylacetamide", "SIMPLE_CHEMICAL", 101, 118], ["benzene", "SIMPLE_CHEMICAL", 171, 178], ["pyrazine", "SIMPLE_CHEMICAL", 180, 188], ["triazine, heterocyclic rings", "SIMPLE_CHEMICAL", 194, 222], ["electron", "SIMPLE_CHEMICAL", 307, 315], ["the calculated energies versus dipole moment", "TREATMENT", 10, 54], ["a series of heterocycles", "TREATMENT", 59, 83], ["methylacetamide", "TREATMENT", 103, 118], ["benzene", "TREATMENT", 171, 178], ["pyrazine", "TREATMENT", 180, 188], ["triazine", "TREATMENT", 194, 202], ["heterocyclic rings", "TREATMENT", 204, 222], ["a dipole moment", "TREATMENT", 231, 246], ["the interacting energies", "PROBLEM", 248, 272]]], ["These studies suggested that potency can be optimized by the careful deployment of heterocycle rings in a fashion that aligns dipole moments in an antiparallel orientation compared to proximal amide moieties in a target protein.", [["amide", "CHEMICAL", 193, 198], ["target protein", "PROTEIN", 213, 227], ["These studies", "TEST", 0, 13], ["heterocycle rings", "TREATMENT", 83, 100], ["proximal amide moieties", "TREATMENT", 184, 207], ["heterocycle rings", "OBSERVATION", 83, 100]]], ["This effect can be enhanced by decreasing the \u03c0-electron density of the heteroarene in order to improve heteroarene-amide \u03c0 interactions.Isosteres of Drug and Water MoleculesDisplacing a water molecule that mediates protein-ligand binding by introducing an appropriate structural element into the ligand to produce an isostere of the ligandwater complex can provide significant enhancements in potency by establishing new H-bonding interactions directly between the protein and ligand [108] .", [["heteroarene", "CHEMICAL", 72, 83], ["heteroarene-amide", "CHEMICAL", 104, 121], ["heteroarene", "CHEMICAL", 72, 83], ["heteroarene-amide \u03c0", "CHEMICAL", 104, 123], ["H", "CHEMICAL", 422, 423], ["\u03c0-electron", "SIMPLE_CHEMICAL", 46, 56], ["heteroarene", "SIMPLE_CHEMICAL", 72, 83], ["heteroarene-amide \u03c0", "SIMPLE_CHEMICAL", 104, 123], ["Drug", "SIMPLE_CHEMICAL", 150, 154], ["ligandwater complex", "PROTEIN", 334, 353], ["the heteroarene", "TREATMENT", 68, 83], ["Isosteres of Drug", "TREATMENT", 137, 154], ["Water Molecules", "TREATMENT", 159, 174], ["a water molecule", "TREATMENT", 185, 201], ["enhanced", "OBSERVATION_MODIFIER", 19, 27], ["decreasing", "OBSERVATION_MODIFIER", 31, 41]]], ["The increased potency arises from both increasing the enthalpic contribution to the thermodynamic signature of the association and taking advantage of the entropic energy gain that arises from releasing the bound water molecule into bulk solvent [108] .", [["The increased potency", "PROBLEM", 0, 21], ["the entropic energy gain", "PROBLEM", 151, 175], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["potency", "OBSERVATION_MODIFIER", 14, 21], ["both", "OBSERVATION_MODIFIER", 34, 38], ["increasing", "OBSERVATION_MODIFIER", 39, 49], ["enthalpic", "OBSERVATION", 54, 63], ["thermodynamic signature", "OBSERVATION", 84, 107], ["entropic energy", "OBSERVATION", 155, 170]]], ["Although this can be a challenging enterprise since success depends on several factors, including the specific topology of the ligand-water-protein complex and the ability to effectively mimic the key interactions, several examples have been described where this approach has been used to considerable advantage [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] .", [["[109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119]", "SIMPLE_CHEMICAL", 312, 377], ["ligand-water-protein complex", "PROTEIN", 127, 155]]], ["The design of a series of cyclic urea-based inhibitors of human immunodeficiency virus-1 (HIV-1) protease provides a particularly compelling pioneering example of the concept that in this case is based on displacing the water molecule that mediates the interaction between the NHs of the 2 flap residues Ile 50 /Ile 50' and the P2/P2 0 carbonyl O atoms of linear peptidomimetic inhibitors represented by 60, as depicted in Fig. 10 [109] [110] [111] .", [["cyclic urea", "CHEMICAL", 26, 37], ["human immunodeficiency virus", "DISEASE", 58, 86], ["Ile 50 /Ile", "CHEMICAL", 304, 315], ["cyclic urea", "CHEMICAL", 26, 37], ["Ile", "CHEMICAL", 304, 307], ["Ile", "CHEMICAL", 312, 315], ["carbonyl", "CHEMICAL", 336, 344], ["O", "CHEMICAL", 345, 346], ["cyclic urea", "SIMPLE_CHEMICAL", 26, 37], ["human immunodeficiency virus-1", "ORGANISM", 58, 88], ["HIV-1", "ORGANISM", 90, 95], ["protease", "PROTEIN", 97, 105], ["P2", "PROTEIN", 328, 330], ["human immunodeficiency virus-1", "SPECIES", 58, 88], ["HIV-1", "SPECIES", 90, 95], ["human immunodeficiency virus-1", "SPECIES", 58, 88], ["HIV-1", "SPECIES", 90, 95], ["cyclic urea-based inhibitors", "TREATMENT", 26, 54], ["human immunodeficiency virus", "PROBLEM", 58, 86], ["protease", "TREATMENT", 97, 105], ["the water molecule", "PROBLEM", 216, 234], ["the 2 flap residues Ile", "TREATMENT", 284, 307], ["the P2/P2 0 carbonyl O atoms", "TREATMENT", 324, 352], ["linear peptidomimetic inhibitors", "TREATMENT", 356, 388]]], ["A series of cyclic ureas exemplified by 61 were conceived based on the premise that the urea carbonyl moiety would displace the water molecule and establish H-bonds directly with the flap residues.", [["cyclic ureas", "CHEMICAL", 12, 24], ["urea carbonyl", "CHEMICAL", 88, 101], ["H", "CHEMICAL", 157, 158], ["cyclic ureas", "CHEMICAL", 12, 24], ["urea carbonyl", "CHEMICAL", 88, 101], ["H", "CHEMICAL", 157, 158], ["cyclic ureas", "SIMPLE_CHEMICAL", 12, 24], ["urea carbonyl moiety", "SIMPLE_CHEMICAL", 88, 108], ["cyclic ureas", "TEST", 12, 24], ["the urea carbonyl moiety", "TREATMENT", 84, 108], ["the water molecule", "TREATMENT", 124, 142], ["the flap residues", "TREATMENT", 179, 196], ["flap residues", "OBSERVATION", 183, 196]]], ["As an additional benefit, the conformational constraint provided by the cyclic template would preorganize the inhibitor for recognition by the protease, providing an additional entropic advantage [109] [110] [111] .", [["protease", "PROTEIN", 143, 151], ["the conformational constraint", "TREATMENT", 26, 55], ["the cyclic template", "TREATMENT", 68, 87], ["the inhibitor", "TREATMENT", 106, 119], ["an additional entropic advantage", "TREATMENT", 163, 195]]], ["The urea 62 was identified from the initial phase of these studies as a potent HIV-1 protease inhibitor, K i \u00bc 0.27 nM, that demonstrated antiviral activity in cell culture, EC 90 \u00bc 57 nM [109] .", [["cell culture", "ANATOMY", 160, 172], ["EC", "ANATOMY", 174, 176], ["urea", "CHEMICAL", 4, 8], ["K", "CHEMICAL", 105, 106], ["urea 62", "CHEMICAL", 4, 11], ["urea 62", "SIMPLE_CHEMICAL", 4, 11], ["HIV-1", "ORGANISM", 79, 84], ["K i \u00bc", "SIMPLE_CHEMICAL", 105, 110], ["cell culture", "CELL", 160, 172], ["EC", "CELL", 174, 176], ["EC 90", "CELL_LINE", 174, 179], ["HIV-1", "SPECIES", 79, 84], ["HIV-1", "SPECIES", 79, 84], ["The urea", "TEST", 0, 8], ["these studies", "TEST", 53, 66], ["a potent HIV", "TEST", 70, 82], ["K i", "TEST", 105, 108], ["antiviral activity", "PROBLEM", 138, 156], ["cell culture", "TEST", 160, 172], ["EC", "TEST", 174, 176], ["nM", "TEST", 185, 187], ["antiviral activity", "OBSERVATION", 138, 156]]], ["Poly(ADP-ribose) polymerase-1 (PARP-1) is a DNA repair enzyme and inhibitors are potentially useful when combined with specific anticancer therapeutic Fig. 11b .", [["anticancer", "ANATOMY", 128, 138], ["Poly(ADP-ribose", "CHEMICAL", 0, 15], ["Poly(ADP-ribose)", "CHEMICAL", 0, 16], ["Poly(ADP-ribose) polymerase-1", "GENE_OR_GENE_PRODUCT", 0, 29], ["PARP-1", "GENE_OR_GENE_PRODUCT", 31, 37], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["anticancer", "CANCER", 128, 138], ["Poly(ADP-ribose) polymerase-1 (PARP-1", "PROTEIN", 0, 37], ["DNA repair enzyme", "PROTEIN", 44, 61], ["Poly(ADP-ribose) polymerase", "TEST", 0, 27], ["PARP", "TEST", 31, 35], ["a DNA repair enzyme", "TREATMENT", 42, 61], ["inhibitors", "TREATMENT", 66, 76]]], ["Interestingly, the potency-enhancing effect of introducing the oxime moiety was muted in a series of compounds that incorporated a C-6 aryl substituent [113] [114] [115] .", [["oxime", "CHEMICAL", 63, 68], ["C-6 aryl", "CHEMICAL", 131, 139], ["oxime", "CHEMICAL", 63, 68], ["C-6 aryl", "CHEMICAL", 131, 139], ["oxime moiety", "SIMPLE_CHEMICAL", 63, 75], ["C-6 aryl substituent [113] [114] [115]", "SIMPLE_CHEMICAL", 131, 169], ["the oxime moiety", "PROBLEM", 59, 75], ["a C-6 aryl substituent", "TEST", 129, 151], ["enhancing", "OBSERVATION_MODIFIER", 27, 36], ["effect", "OBSERVATION_MODIFIER", 37, 43]]], ["The enzyme scytalone dehydratase catalyzes two steps in melanin biosynthesis in Magnaporthe grisea, a plant fungal pathogen [116] .", [["scytalone", "CHEMICAL", 11, 20], ["melanin", "CHEMICAL", 56, 63], ["scytalone", "CHEMICAL", 11, 20], ["scytalone dehydratase", "GENE_OR_GENE_PRODUCT", 11, 32], ["melanin", "SIMPLE_CHEMICAL", 56, 63], ["Magnaporthe grisea", "ORGANISM", 80, 98], ["enzyme scytalone dehydratase", "PROTEIN", 4, 32], ["Magnaporthe grisea", "SPECIES", 80, 98], ["Magnaporthe grisea", "SPECIES", 80, 98], ["The enzyme scytalone dehydratase", "TEST", 0, 32], ["melanin biosynthesis", "TREATMENT", 56, 76], ["Magnaporthe grisea", "PROBLEM", 80, 98], ["a plant fungal pathogen", "PROBLEM", 100, 123], ["melanin biosynthesis", "OBSERVATION", 56, 76], ["Magnaporthe grisea", "OBSERVATION", 80, 98], ["fungal pathogen", "OBSERVATION", 108, 123]]], ["The benzotriazine 68 is a potent scytalone dehydratase inhibitor and modeling of the analogue 72 in the active site of the enzyme (Fig. 12a ) recognized its isosteric relationship with the salicylamide 71 which had been co-crystallized with the enzyme.", [["benzotriazine", "CHEMICAL", 4, 17], ["scytalone", "CHEMICAL", 33, 42], ["salicylamide", "CHEMICAL", 189, 201], ["benzotriazine 68", "CHEMICAL", 4, 20], ["scytalone", "CHEMICAL", 33, 42], ["salicylamide 71", "CHEMICAL", 189, 204], ["benzotriazine 68", "SIMPLE_CHEMICAL", 4, 20], ["scytalone", "SIMPLE_CHEMICAL", 33, 42], ["salicylamide 71", "SIMPLE_CHEMICAL", 189, 204], ["enzyme", "PROTEIN", 123, 129], ["enzyme", "PROTEIN", 245, 251], ["The benzotriazine", "TREATMENT", 0, 17], ["a potent scytalone dehydratase inhibitor", "TREATMENT", 24, 64], ["the enzyme", "TEST", 119, 129], ["the salicylamide", "TREATMENT", 185, 201], ["the enzyme", "TEST", 241, 251]]], ["A water molecule that played a critical role in mediating the interaction between the inhibitor and two enzyme residues, Tyr 30 and Tyr 50 , by H-bonding to the benzotriazine moiety of 68 and the amide carbonyl of 72 was viewed as an opportunity for optimization of the scaffold.", [["Tyr", "CHEMICAL", 121, 124], ["Tyr", "CHEMICAL", 132, 135], ["benzotriazine", "CHEMICAL", 161, 174], ["Tyr", "CHEMICAL", 121, 124], ["Tyr", "CHEMICAL", 132, 135], ["H-", "CHEMICAL", 144, 146], ["benzotriazine", "CHEMICAL", 161, 174], ["amide carbonyl", "CHEMICAL", 196, 210], ["Tyr 30", "SIMPLE_CHEMICAL", 121, 127], ["Tyr 50", "SIMPLE_CHEMICAL", 132, 138], ["H-bonding", "SIMPLE_CHEMICAL", 144, 153], ["benzotriazine moiety", "SIMPLE_CHEMICAL", 161, 181], ["amide carbonyl", "SIMPLE_CHEMICAL", 196, 210], ["A water molecule", "PROBLEM", 0, 16], ["the inhibitor", "TREATMENT", 82, 95], ["two enzyme residues", "TEST", 100, 119], ["Tyr", "TEST", 121, 124], ["the benzotriazine moiety", "TEST", 157, 181], ["the amide carbonyl", "TEST", 192, 210], ["optimization of the scaffold", "TREATMENT", 250, 278], ["water molecule", "OBSERVATION", 2, 16]]], ["The removal of the key benzotriazine nitrogen atom that accepted a H-bond from the water molecule afforded the much weaker inhibitor cinnoline 69, but the introduction of a nitrile moiety at the 3-position of the heterocycle provided a molecule, 70, that is over 18,000-fold more potent than the progenitor [116] .", [["benzotriazine nitrogen", "CHEMICAL", 23, 45], ["H", "CHEMICAL", 67, 68], ["cinnoline 69", "CHEMICAL", 133, 145], ["nitrile", "CHEMICAL", 173, 180], ["benzotriazine", "CHEMICAL", 23, 36], ["nitrogen", "CHEMICAL", 37, 45], ["H", "CHEMICAL", 67, 68], ["cinnoline 69", "CHEMICAL", 133, 145], ["nitrile", "CHEMICAL", 173, 180], ["benzotriazine nitrogen atom", "SIMPLE_CHEMICAL", 23, 50], ["cinnoline 69", "SIMPLE_CHEMICAL", 133, 145], ["nitrile moiety", "SIMPLE_CHEMICAL", 173, 187], ["The removal", "TREATMENT", 0, 11], ["the key benzotriazine nitrogen atom", "TREATMENT", 15, 50], ["a H-bond from the water molecule", "TREATMENT", 65, 97], ["a nitrile moiety", "TREATMENT", 171, 187]]], ["The remarkable increase in potency for the addition of just two atoms represents a highly ligand-efficient modification that was also observed with an analogous quinazoline/quinoline matched pair [116, 121] .", [["quinazoline", "CHEMICAL", 161, 172], ["quinoline", "CHEMICAL", 173, 182], ["quinazoline", "CHEMICAL", 161, 172], ["quinoline", "CHEMICAL", 173, 182], ["quinazoline", "SIMPLE_CHEMICAL", 161, 172], ["quinoline", "SIMPLE_CHEMICAL", 173, 182], ["an analogous quinazoline/quinoline matched pair", "TREATMENT", 148, 195], ["remarkable", "OBSERVATION_MODIFIER", 4, 14], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["potency", "OBSERVATION_MODIFIER", 27, 34]]], ["An X-ray co-crystal structure of 70 bound to the enzyme confirmed the modeling hypothesis and validated the design principle, as summarized in Fig. 12b [116] .", [["An X-ray co-crystal structure", "TEST", 0, 29], ["the enzyme", "TEST", 45, 55], ["the modeling hypothesis", "PROBLEM", 66, 89]]], ["A similar strategy was adopted to enhance the potency of the triazine-based p38\u03b1 MAP kinase inhibitor 73, K i \u00bc 3.7 nM, in which the key N atom of the triazine heterocycle was replaced by C-CN in order to displace a bound water molecule observed in an X-ray co-crystal structure [117] .", [["triazine", "CHEMICAL", 61, 69], ["K", "CHEMICAL", 106, 107], ["triazine heterocycle", "CHEMICAL", 151, 171], ["triazine", "CHEMICAL", 61, 69], ["N", "CHEMICAL", 137, 138], ["triazine", "CHEMICAL", 151, 159], ["C-CN", "CHEMICAL", 188, 192], ["triazine", "SIMPLE_CHEMICAL", 61, 69], ["p38", "GENE_OR_GENE_PRODUCT", 76, 79], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 81, 91], ["triazine heterocycle", "SIMPLE_CHEMICAL", 151, 171], ["C-CN", "SIMPLE_CHEMICAL", 188, 192], ["p38\u03b1", "PROTEIN", 76, 80], ["CN", "PROTEIN", 190, 192], ["X", "PROTEIN", 252, 253], ["the triazine", "TREATMENT", 57, 69], ["MAP kinase inhibitor", "TEST", 81, 101], ["K i", "TEST", 106, 109], ["the triazine heterocycle", "TREATMENT", 147, 171], ["a bound water molecule", "PROBLEM", 214, 236], ["an X-ray co-crystal structure", "TEST", 249, 278]]], ["This rationalization led to the design of the cyanopyrimidine 74 which, with a K i \u00bc 0.057 nM, conferred a 60-fold enhancement of potency.", [["cyanopyrimidine", "CHEMICAL", 46, 61], ["K", "CHEMICAL", 79, 80], ["cyanopyrimidine", "CHEMICAL", 46, 61], ["cyanopyrimidine 74", "SIMPLE_CHEMICAL", 46, 64], ["the cyanopyrimidine", "TREATMENT", 42, 61], ["a K i", "TEST", 77, 82], ["60-fold", "OBSERVATION_MODIFIER", 107, 114], ["enhancement", "OBSERVATION", 115, 126], ["potency", "OBSERVATION_MODIFIER", 130, 137]]], ["X-ray crystallographic data obtained with a closely analogous compound demonstrated that the cyano moiety engaged the NH of Met 109 in a H-bonding interaction, displacing the water molecule interfacing Met 109 with the triazine N of 73, as hypothesized during the design exercise.", [["cyano", "CHEMICAL", 93, 98], ["Met 109", "CHEMICAL", 124, 131], ["H", "CHEMICAL", 137, 138], ["Met 109", "CHEMICAL", 202, 209], ["triazine", "CHEMICAL", 219, 227], ["cyano", "CHEMICAL", 93, 98], ["NH", "CHEMICAL", 118, 120], ["Met", "CHEMICAL", 124, 127], ["H", "CHEMICAL", 137, 138], ["Met", "CHEMICAL", 202, 205], ["triazine N", "CHEMICAL", 219, 229], ["cyano moiety", "SIMPLE_CHEMICAL", 93, 105], ["Met 109", "SIMPLE_CHEMICAL", 124, 131], ["Met 109", "SIMPLE_CHEMICAL", 202, 209], ["triazine N", "SIMPLE_CHEMICAL", 219, 229], ["X-ray crystallographic data", "TEST", 0, 27], ["a closely analogous compound", "PROBLEM", 42, 70], ["the cyano moiety", "PROBLEM", 89, 105], ["the triazine N", "TEST", 215, 229]]], ["The displacement of a water molecule mediating the interaction between a series of heat shock protein 90 (Hsp90) inhibitors and the protein by the introduction of a strategically deployed cyano substituent contributed significantly to potency [119] .", [["cyano", "CHEMICAL", 188, 193], ["cyano", "CHEMICAL", 188, 193], ["heat shock protein 90", "GENE_OR_GENE_PRODUCT", 83, 104], ["Hsp90", "GENE_OR_GENE_PRODUCT", 106, 111], ["cyano substituent", "SIMPLE_CHEMICAL", 188, 205], ["heat shock protein 90", "PROTEIN", 83, 104], ["Hsp90", "PROTEIN", 106, 111], ["heat shock protein", "TREATMENT", 83, 101], ["Hsp", "TEST", 106, 109], ["the protein", "TEST", 128, 139], ["a strategically deployed cyano substituent", "TREATMENT", 163, 205], ["displacement", "OBSERVATION_MODIFIER", 4, 16], ["water molecule", "OBSERVATION", 22, 36]]], ["The pyrrolopyrimidine 75 was designed from the fragment screening lead 77 but was devoid of significant potency based on the results of a fluorescence polarization assay.", [["pyrrolopyrimidine", "CHEMICAL", 4, 21], ["pyrrolopyrimidine", "CHEMICAL", 4, 21], ["pyrrolopyrimidine 75", "SIMPLE_CHEMICAL", 4, 24], ["The pyrrolopyrimidine", "TREATMENT", 0, 21], ["the fragment screening lead", "TEST", 43, 70], ["a fluorescence polarization assay", "TEST", 136, 169]]], ["This was attributed to the loss of a key H-bond between the imidazole 306 N.A. Meanwell nitrogen atom of 77 and a water molecule that interfaced with Asn 51 of Hsp90 and another water molecule in the active site.", [["imidazole", "CHEMICAL", 60, 69], ["Meanwell nitrogen", "CHEMICAL", 79, 96], ["Asn 51", "CHEMICAL", 150, 156], ["H", "CHEMICAL", 41, 42], ["imidazole", "CHEMICAL", 60, 69], ["nitrogen", "CHEMICAL", 88, 96], ["Asn", "CHEMICAL", 150, 153], ["Hsp90", "GENE_OR_GENE_PRODUCT", 160, 165], ["Hsp90", "PROTEIN", 160, 165], ["the imidazole", "TREATMENT", 56, 69], ["nitrogen atom", "TEST", 88, 101], ["a water molecule", "PROBLEM", 112, 128], ["Asn", "TREATMENT", 150, 153], ["Hsp90", "TREATMENT", 160, 165], ["another water molecule in the active site", "PROBLEM", 170, 211], ["active site", "OBSERVATION", 200, 211]]], ["The introduction of the 3-cyano moiety to 75 gave the significantly more potent Hsp90 inhibitor 76 with the nitrile nitrogen atom engaging Asn 51 directly, displacing the water molecule.", [["3-cyano", "CHEMICAL", 24, 31], ["nitrile nitrogen", "CHEMICAL", 108, 124], ["Asn 51", "CHEMICAL", 139, 145], ["3-cyano", "CHEMICAL", 24, 31], ["nitrile", "CHEMICAL", 108, 115], ["nitrogen", "CHEMICAL", 116, 124], ["Asn", "CHEMICAL", 139, 142], ["3-cyano moiety", "SIMPLE_CHEMICAL", 24, 38], ["Hsp90", "GENE_OR_GENE_PRODUCT", 80, 85], ["nitrile nitrogen atom", "SIMPLE_CHEMICAL", 108, 129], ["Asn 51", "SIMPLE_CHEMICAL", 139, 145], ["the 3-cyano moiety", "TREATMENT", 20, 38], ["potent Hsp90 inhibitor", "TREATMENT", 73, 95], ["the nitrile nitrogen atom", "TREATMENT", 104, 129], ["water molecule", "OBSERVATION", 171, 185]]], ["Further optimization afforded the more potent 78 that engaged the Hsp90 protein principally via the interactions summarized in Fig. 13 [119] .", [["Hsp90", "GENE_OR_GENE_PRODUCT", 66, 71], ["Hsp90 protein", "PROTEIN", 66, 79], ["the Hsp90 protein", "TREATMENT", 62, 79]]], ["One of the difficulties associated with displacing bound water molecules is illustrated by observations with a series of human prostaglandin D2 synthase (hH-PGDS) inhibitors based on the prototype 79, IC 50 \u00bc 2.34 nM [120] .", [["prostaglandin D2", "CHEMICAL", 127, 143], ["prostaglandin D2", "CHEMICAL", 127, 143], ["human", "ORGANISM", 121, 126], ["prostaglandin D2 synthase", "GENE_OR_GENE_PRODUCT", 127, 152], ["hH-PGDS", "GENE_OR_GENE_PRODUCT", 154, 161], ["human prostaglandin D2 synthase", "PROTEIN", 121, 152], ["hH", "PROTEIN", 154, 156], ["PGDS", "PROTEIN", 157, 161], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["displacing bound water molecules", "PROBLEM", 40, 72], ["human prostaglandin D2 synthase", "TREATMENT", 121, 152], ["hH-PGDS) inhibitors", "TREATMENT", 154, 173], ["IC", "TEST", 201, 203]]], ["In the X-ray co-crystallographic structure of 79 with the enzyme, the isoquinoline nitrogen was observed to engage the hydrogen atom of a water molecule that interacted with Thr 159 and Leu 199 of hH-PGDS, leading to a study of the effect of incorporation of structural elements designed to displace the bridging water.", [["isoquinoline nitrogen", "CHEMICAL", 70, 91], ["Thr", "CHEMICAL", 174, 177], ["Leu 199", "CHEMICAL", 186, 193], ["hH-PGDS", "CHEMICAL", 197, 204], ["isoquinoline", "CHEMICAL", 70, 82], ["nitrogen", "CHEMICAL", 83, 91], ["hydrogen", "CHEMICAL", 119, 127], ["Thr", "CHEMICAL", 174, 177], ["Leu", "CHEMICAL", 186, 189], ["hH-PGDS", "CHEMICAL", 197, 204], ["isoquinoline", "SIMPLE_CHEMICAL", 70, 82], ["Thr 159", "AMINO_ACID", 174, 181], ["Leu 199", "AMINO_ACID", 186, 193], ["hH-PGDS", "SIMPLE_CHEMICAL", 197, 204], ["the X-ray co-crystallographic structure", "TEST", 3, 42], ["the enzyme", "TEST", 54, 64], ["the isoquinoline nitrogen", "TREATMENT", 66, 91], ["Thr", "TEST", 174, 177], ["Leu", "TEST", 186, 189], ["a study", "TEST", 217, 224], ["structural elements", "PROBLEM", 259, 278], ["bridging", "OBSERVATION", 304, 312]]], ["The hydroxymethylated naphthalene derivative 80 and its amine analogue 81 were synthesized and confirmed by X-ray studies to perform as anticipated, displacing the water molecule and directly engaging Thr 159 and Leu 199 with the full complement of interactions.", [["naphthalene", "CHEMICAL", 22, 33], ["amine", "CHEMICAL", 56, 61], ["Leu 199", "CHEMICAL", 213, 220], ["hydroxymethylated naphthalene", "CHEMICAL", 4, 33], ["amine", "CHEMICAL", 56, 61], ["Thr", "CHEMICAL", 201, 204], ["Leu", "CHEMICAL", 213, 216], ["hydroxymethylated naphthalene derivative 80", "SIMPLE_CHEMICAL", 4, 47], ["amine analogue 81", "SIMPLE_CHEMICAL", 56, 73], ["Thr 159", "AMINO_ACID", 201, 208], ["Leu 199", "AMINO_ACID", 213, 220], ["Thr 159", "PROTEIN", 201, 208], ["The hydroxymethylated naphthalene derivative", "TREATMENT", 0, 44], ["its amine analogue", "TREATMENT", 52, 70], ["X-ray studies", "TEST", 108, 121], ["Leu", "TEST", 213, 216]]], ["However, the potency of these compounds was significantly diminished compared to 79 with IC 50 s of 1,480 nM for 80 and 845 nM for 81, representing 360-and 630-fold differences, respectively [120] .", [["significantly diminished", "PROBLEM", 44, 68], ["IC", "TEST", 89, 91], ["diminished", "OBSERVATION_MODIFIER", 58, 68]]], ["A potential explanation was suggested based on a closer analysis of the crystal structures which revealed that the topographical disposition of the hydroxyl and amino moieties of 80 and 81 was close to the plane of the naphthalene ring (21 and 27 , respectively), an energetically unfavorable arrangement that incurs allylic 1,3 strain [10, 122] .", [["hydroxyl", "CHEMICAL", 148, 156], ["amino moieties", "CHEMICAL", 161, 175], ["naphthalene", "CHEMICAL", 219, 230], ["hydroxyl", "CHEMICAL", 148, 156], ["amino", "CHEMICAL", 161, 166], ["naphthalene", "CHEMICAL", 219, 230], ["hydroxyl", "SIMPLE_CHEMICAL", 148, 156], ["amino", "AMINO_ACID", 161, 166], ["a closer analysis", "TEST", 47, 64], ["the hydroxyl and amino moieties", "TEST", 144, 175], ["the naphthalene ring", "TEST", 215, 235], ["naphthalene ring", "OBSERVATION", 219, 235]]], ["In addition, the dihedral angle between the phenyl and naphthalene rings was~20 less than the 117 observed for 79, data that taken together suggested that the increased energy associated with the imposed conformational constraints outweighed the entropic gains associated with displacing the water molecule [120] .Isosteres of Drug and Water Molecules3 Bioisosteres to Modulate ConformationFluorine as a Hydrogen IsostereThe properties of fluorine make it an intriguing and useful isostere of a hydrogen atom, particularly in the context of alkanes where its unique properties have only recently begun to be examined in detail and more fully appreciated [16] [17] [18] [19] [20] [21] [123] [124] [125] .", [["phenyl", "CHEMICAL", 44, 50], ["naphthalene", "CHEMICAL", 55, 66], ["Fluorine", "CHEMICAL", 390, 398], ["Hydrogen Isostere", "CHEMICAL", 404, 421], ["fluorine", "CHEMICAL", 439, 447], ["alkanes", "CHEMICAL", 541, 548], ["phenyl", "CHEMICAL", 44, 50], ["naphthalene", "CHEMICAL", 55, 66], ["Fluorine", "CHEMICAL", 390, 398], ["Hydrogen", "CHEMICAL", 404, 412], ["fluorine", "CHEMICAL", 439, 447], ["hydrogen", "CHEMICAL", 495, 503], ["alkanes", "CHEMICAL", 541, 548], ["[16] [17] [18] [19] [20] [21] [123] [124] [125]", "CHEMICAL", 654, 701], ["phenyl", "SIMPLE_CHEMICAL", 44, 50], ["naphthalene rings", "SIMPLE_CHEMICAL", 55, 72], ["Drug", "SIMPLE_CHEMICAL", 327, 331], ["Fluorine", "SIMPLE_CHEMICAL", 390, 398], ["fluorine", "SIMPLE_CHEMICAL", 439, 447], ["hydrogen atom", "SIMPLE_CHEMICAL", 495, 508], ["alkanes", "SIMPLE_CHEMICAL", 541, 548], ["[16] [17] [18] [19] [20] [21] [123] [124] [125]", "SIMPLE_CHEMICAL", 654, 701], ["the dihedral angle", "TEST", 13, 31], ["the phenyl and naphthalene rings", "TEST", 40, 72], ["the increased energy", "PROBLEM", 155, 175], ["Isosteres of Drug", "TREATMENT", 314, 331], ["Water Molecules3 Bioisosteres", "TREATMENT", 336, 365], ["Modulate ConformationFluorine", "TREATMENT", 369, 398], ["a Hydrogen Isostere", "TREATMENT", 402, 421], ["fluorine", "TREATMENT", 439, 447], ["a hydrogen atom", "TREATMENT", 493, 508], ["phenyl", "ANATOMY_MODIFIER", 44, 50], ["naphthalene rings", "OBSERVATION", 55, 72], ["Hydrogen Isostere", "OBSERVATION", 404, 421], ["hydrogen atom", "OBSERVATION", 495, 508], ["alkanes", "OBSERVATION", 541, 548]]], ["Fluorine is the most electronegative of the atoms that forms covalent bonds with carbon and the polarization associated with the C-F bond affords a strong dipole moment, 1.85 D for CH 3 F, that interacts with proximal functionality to influence conformational preferences in a fashion that can be exploited in drug design.", [["Fluorine", "CHEMICAL", 0, 8], ["carbon", "CHEMICAL", 81, 87], ["Fluorine", "CHEMICAL", 0, 8], ["carbon", "CHEMICAL", 81, 87], ["C-F", "CHEMICAL", 129, 132], ["CH 3 F", "CHEMICAL", 181, 187], ["Fluorine", "SIMPLE_CHEMICAL", 0, 8], ["carbon", "SIMPLE_CHEMICAL", 81, 87], ["C-F bond", "SIMPLE_CHEMICAL", 129, 137], ["CH 3 F", "SIMPLE_CHEMICAL", 181, 187], ["Fluorine", "TREATMENT", 0, 8], ["carbon", "TREATMENT", 81, 87], ["most electronegative", "OBSERVATION_MODIFIER", 16, 36], ["covalent bonds", "OBSERVATION", 61, 75]]], ["These effects, the strength of which are dependent on the identity of the interacting substituent, are based on several underlying principles that include dipole-dipole interactions, attractive electrostatic effects, repulsion between fluorine and electronegative atoms, p orbital repulsion, and a hyperconjugative effect between an adjacent C-H bond and the low-lying C-F \u03c3* orbital [21, [124] [125] [126] .", [["fluorine", "CHEMICAL", 235, 243], ["fluorine", "CHEMICAL", 235, 243], ["C-H", "CHEMICAL", 342, 345], ["C-F", "CHEMICAL", 369, 372], ["fluorine", "SIMPLE_CHEMICAL", 235, 243], ["C-H", "SIMPLE_CHEMICAL", 342, 345], ["the interacting substituent", "PROBLEM", 70, 97], ["dipole-dipole interactions", "PROBLEM", 155, 181], ["attractive electrostatic effects", "PROBLEM", 183, 215], ["repulsion between fluorine and electronegative atoms", "PROBLEM", 217, 269], ["orbital repulsion", "TEST", 273, 290], ["a hyperconjugative effect", "PROBLEM", 296, 321], ["an adjacent C-H bond", "TEST", 330, 350], ["orbital", "ANATOMY", 273, 280], ["repulsion", "OBSERVATION", 281, 290], ["orbital", "ANATOMY", 376, 383]]], ["Density functional theory (DFT) calculations have provided a relative ranking of the interaction energies between a fluorine atom and several elements and functional groups, with interactions with amine, alcohol, amide, and fluorine substituents of sufficient strength to be of practical utility in drug design exercises, data that are summarized in Table 9 [124-126].Fluorine as a Hydrogen Isostere1,2-Difluoroalkanes prefer a gauche conformation between the two fluorine atoms that is favored by 0.8 kcal/mol based upon a hyperconjugative interaction between an adjacent C-H bond donating into the low-lying C-F \u03c3* orbital ( Fig. 14a) [126, 127] .", [["fluorine", "CHEMICAL", 116, 124], ["amine", "CHEMICAL", 197, 202], ["alcohol", "CHEMICAL", 204, 211], ["fluorine", "CHEMICAL", 224, 232], ["Fluorine", "CHEMICAL", 368, 376], ["Hydrogen Isostere1,2-Difluoroalkanes", "CHEMICAL", 382, 418], ["fluorine", "CHEMICAL", 464, 472], ["fluorine", "CHEMICAL", 116, 124], ["amine", "CHEMICAL", 197, 202], ["alcohol", "CHEMICAL", 204, 211], ["amide", "CHEMICAL", 213, 218], ["fluorine", "CHEMICAL", 224, 232], ["Fluorine", "CHEMICAL", 368, 376], ["Hydrogen Isostere1,2-Difluoroalkanes", "CHEMICAL", 382, 418], ["fluorine", "CHEMICAL", 464, 472], ["C-H", "CHEMICAL", 573, 576], ["C-F", "CHEMICAL", 610, 613], ["fluorine atom", "SIMPLE_CHEMICAL", 116, 129], ["amine", "SIMPLE_CHEMICAL", 197, 202], ["alcohol", "SIMPLE_CHEMICAL", 204, 211], ["amide", "SIMPLE_CHEMICAL", 213, 218], ["fluorine substituents", "SIMPLE_CHEMICAL", 224, 245], ["Fluorine", "SIMPLE_CHEMICAL", 368, 376], ["Hydrogen Isostere1,2-Difluoroalkanes", "SIMPLE_CHEMICAL", 382, 418], ["fluorine atoms", "SIMPLE_CHEMICAL", 464, 478], ["C-H", "SIMPLE_CHEMICAL", 573, 576], ["Density functional theory (DFT) calculations", "PROBLEM", 0, 44], ["a fluorine atom", "TREATMENT", 114, 129], ["amide", "TREATMENT", 213, 218], ["fluorine substituents", "TREATMENT", 224, 245], ["Fluorine", "TREATMENT", 368, 376], ["a Hydrogen Isostere1", "TREATMENT", 380, 400], ["Difluoroalkanes", "TREATMENT", 403, 418], ["a gauche conformation", "TREATMENT", 426, 447], ["the two fluorine atoms", "TREATMENT", 456, 478], ["a hyperconjugative interaction", "PROBLEM", 522, 552], ["an adjacent C-H bond donating", "TREATMENT", 561, 590], ["orbital", "ANATOMY", 617, 624]]], ["For 1,3-difluoroalkanes, the conformational preference depicted in Fig. 14b is favored by dipole-dipole interactions between the C-F bonds that is estimated to amount to a difference of 3.3 kcal/mol [128] .", [["1,3-difluoroalkanes", "CHEMICAL", 4, 23], ["1,3-difluoroalkanes", "CHEMICAL", 4, 23], ["C-F", "CHEMICAL", 129, 132], ["1,3-difluoroalkanes", "SIMPLE_CHEMICAL", 4, 23], ["Fig. 14b", "SIMPLE_CHEMICAL", 67, 75], ["C-F bonds", "SIMPLE_CHEMICAL", 129, 138], ["difluoroalkanes", "TREATMENT", 8, 23], ["the C-F bonds", "TREATMENT", 125, 138]]], ["However, while these interactions have been shown to influence the conformational preferences of structurally simple fluoroalkane derivatives, they have yet to be fully exploited in drug design [126] [127] [128] [129] [130] .Fluorine as a Hydrogen IsostereThe conformation of an \u03b1-fluoro amide is influenced by the preference for the dipoles of the C-F and C\u00bcO moieties to align in an antiparallel fashion that in secondary amides can be reinforced by an electrostatic interaction between the electronegative F atom and amide NH [21, [131] [132] [133] [134] [135] [136] .", [["fluoroalkane", "CHEMICAL", 117, 129], ["Fluorine", "CHEMICAL", 225, 233], ["Hydrogen Isostere", "CHEMICAL", 239, 256], ["\u03b1-fluoro amide", "CHEMICAL", 279, 293], ["amide NH", "CHEMICAL", 520, 528], ["fluoroalkane", "CHEMICAL", 117, 129], ["Fluorine", "CHEMICAL", 225, 233], ["Hydrogen", "CHEMICAL", 239, 247], ["\u03b1-fluoro amide", "CHEMICAL", 279, 293], ["C-F", "CHEMICAL", 349, 352], ["C\u00bcO", "CHEMICAL", 357, 360], ["amides", "CHEMICAL", 424, 430], ["F", "CHEMICAL", 509, 510], ["amide", "CHEMICAL", 520, 525], ["NH", "CHEMICAL", 526, 528], ["fluoroalkane derivatives", "SIMPLE_CHEMICAL", 117, 141], ["[126] [127] [128] [129] [130]", "SIMPLE_CHEMICAL", 194, 223], ["Fluorine", "SIMPLE_CHEMICAL", 225, 233], ["\u03b1-fluoro amide", "SIMPLE_CHEMICAL", 279, 293], ["C-F", "SIMPLE_CHEMICAL", 349, 352], ["C\u00bcO moieties", "SIMPLE_CHEMICAL", 357, 369], ["secondary amides", "SIMPLE_CHEMICAL", 414, 430], ["F atom", "SIMPLE_CHEMICAL", 509, 515], ["amide NH [21, [131] [132] [133] [134] [135] [136]", "SIMPLE_CHEMICAL", 520, 569], ["C-F and C\u00bcO moieties", "PROTEIN", 349, 369], ["structurally simple fluoroalkane derivatives", "TREATMENT", 97, 141], ["Fluorine", "TREATMENT", 225, 233], ["a Hydrogen Isostere", "TREATMENT", 237, 256], ["an \u03b1-fluoro amide", "TREATMENT", 276, 293], ["the C-F and C\u00bcO moieties", "TREATMENT", 345, 369], ["Hydrogen Isostere", "OBSERVATION", 239, 256]]], ["An interesting illustration of the utility of this effect is provided by the biological evaluation of the enantiomers of 83, the \u03b1-fluorinated derivative of the vanilloid receptor agonist capsaicin (82) [136] .", [["capsaicin", "CHEMICAL", 188, 197], ["capsaicin", "CHEMICAL", 188, 197], ["capsaicin", "SIMPLE_CHEMICAL", 188, 197], ["the biological evaluation", "TEST", 73, 98], ["the vanilloid receptor agonist capsaicin", "TREATMENT", 157, 197]]], ["The trans conformer in which the C-F and C\u00bcO dipoles are aligned in the same plane in an antiparallel fashion is calculated to be 6 kcal/mol more stable than the gauche conformer and 8 kcal/mol more stable than the cis conformer based on ab initio calculations, attributed to a favorable dipole alignment and an electrostatic interaction between the F and NH atoms, as depicted in Fig. 15 [131] [132] [133] [134] [135] [136] .", [["C", "CHEMICAL", 33, 34], ["F", "CHEMICAL", 35, 36], ["C", "CHEMICAL", 41, 42], ["O", "CHEMICAL", 43, 44], ["F", "CHEMICAL", 350, 351], ["NH", "CHEMICAL", 356, 358], ["C-F", "SIMPLE_CHEMICAL", 33, 36], ["C\u00bcO dipoles", "SIMPLE_CHEMICAL", 41, 52], ["NH atoms", "SIMPLE_CHEMICAL", 356, 364], ["[131] [132] [133] [134] [135] [136]", "SIMPLE_CHEMICAL", 389, 424], ["C-F and C\u00bcO dipoles", "PROTEIN", 33, 52], ["F and NH atoms", "PROTEIN", 350, 364], ["the C-F and C\u00bcO dipoles", "TREATMENT", 29, 52], ["the gauche conformer", "TREATMENT", 158, 178], ["ab initio calculations", "TEST", 238, 260], ["a favorable dipole alignment", "PROBLEM", 276, 304], ["favorable", "OBSERVATION_MODIFIER", 278, 287], ["dipole alignment", "OBSERVATION", 288, 304]]], ["This conformational preference provided a potentially useful probe of the shape of the receptor based on the stereo-differentiation of the (R)-and (S)-enantiomers of 83 should the alkyl side chains project orthogonally to the plane of the amide moiety in the bound state, as depicted by the hashed bonds.", [["alkyl", "CHEMICAL", 180, 185], ["amide", "CHEMICAL", 239, 244], ["(R)-", "SIMPLE_CHEMICAL", 139, 143], ["(S)-enantiomers", "SIMPLE_CHEMICAL", 147, 162], ["alkyl side chains", "SIMPLE_CHEMICAL", 180, 197], ["the alkyl side chains", "TREATMENT", 176, 197]]], ["However, the TRPVI receptor failed to discriminate between the two enantiomers of 83, leading to the conclusion that the bound conformation of 82 is that in which the alkyl side chain vector projects in a plane similar to that of the amide moiety which for (R)-and (S)-83 would be disposed in the parallel fashion depicted [136] .", [["alkyl", "CHEMICAL", 167, 172], ["amide", "CHEMICAL", 234, 239], ["TRPVI receptor", "GENE_OR_GENE_PRODUCT", 13, 27], ["(S)-83", "SIMPLE_CHEMICAL", 265, 271], ["TRPVI receptor", "PROTEIN", 13, 27], ["the TRPVI receptor", "TEST", 9, 27], ["the alkyl side chain vector", "TREATMENT", 163, 190], ["the amide moiety", "TREATMENT", 230, 246]]], ["A fluorine atom deployed \u03b2to the nitrogen atom of an amide also influences conformational preferences by favoring a gauche arrangement between these functionalities, a phenomenon established by X-ray crystallographic and NMR studies in the context of a series of \u03b2-peptide derivatives [126, 134, 135, [137] [138] [139] .", [["fluorine atom", "CHEMICAL", 2, 15], ["\u03b2to the nitrogen", "CHEMICAL", 25, 41], ["\u03b2-peptide", "CHEMICAL", 263, 272], ["fluorine", "CHEMICAL", 2, 10], ["\u03b2to", "CHEMICAL", 25, 28], ["nitrogen", "CHEMICAL", 33, 41], ["amide", "CHEMICAL", 53, 58], ["\u03b2-peptide", "CHEMICAL", 263, 272], ["fluorine atom", "SIMPLE_CHEMICAL", 2, 15], ["\u03b2to", "SIMPLE_CHEMICAL", 25, 28], ["amide", "SIMPLE_CHEMICAL", 53, 58], ["\u03b2-peptide derivatives", "SIMPLE_CHEMICAL", 263, 284], ["A fluorine atom", "TREATMENT", 0, 15], ["the nitrogen atom", "TREATMENT", 29, 46], ["a gauche arrangement", "TREATMENT", 114, 134], ["NMR studies", "TEST", 221, 232]]], ["For the difluoro succinamide esters 85 (threo) and 87 (erythreo) and the corresponding acids 84 (threo) and 86 (erythreo), solid-state structures revealed that all 4 molecules adopted a conformation that satisfied a vicinal F-F gauche interaction, a phenomenon that extended to solution based on an analysis 3 J HF and 3 J HH coupling constants in the NMR spectra [134, 135] .", [["difluoro succinamide esters", "CHEMICAL", 8, 35], ["threo", "CHEMICAL", 40, 45], ["erythreo", "CHEMICAL", 55, 63], ["difluoro succinamide esters", "CHEMICAL", 8, 35], ["erythreo", "CHEMICAL", 55, 63], ["erythreo", "CHEMICAL", 112, 120], ["F-F", "CHEMICAL", 224, 227], ["difluoro succinamide esters", "SIMPLE_CHEMICAL", 8, 35], ["erythreo", "SIMPLE_CHEMICAL", 55, 63], ["F-F", "SIMPLE_CHEMICAL", 224, 227], ["the difluoro succinamide esters", "TEST", 4, 35], ["the corresponding acids", "TEST", 69, 92], ["a phenomenon", "PROBLEM", 248, 260], ["an analysis", "TEST", 296, 307], ["3 J HH coupling constants", "PROBLEM", 319, 344]]], ["In the case of the threo isomers 84 and 85, this conformational preference places the amide carbonyl moieties in an anti-periplanar arrangement while for the erythreo isomers, the amide carbonyls are disposed gauche [134, 135] .Fluorine as a Hydrogen IsostereFor the GPR119 agonist 88, EC 50 \u00bc 868 nM with intrinsic activity of 111% in a cAMP assay, isosteric replacement of the pro-(S) H atom \u03b2to the amine moiety resulted in 89, a compound with tenfold enhanced potency, EC 50 \u00bc 80 nM, and similar intrinsic agonistic properties, measured as 107% [140] .", [["amide carbonyl", "CHEMICAL", 86, 100], ["amide carbonyls", "CHEMICAL", 180, 195], ["Fluorine", "CHEMICAL", 228, 236], ["Hydrogen", "CHEMICAL", 242, 250], ["cAMP", "CHEMICAL", 338, 342], ["amine", "CHEMICAL", 402, 407], ["amide carbonyl", "CHEMICAL", 86, 100], ["erythreo", "CHEMICAL", 158, 166], ["amide carbonyls", "CHEMICAL", 180, 195], ["Fluorine", "CHEMICAL", 228, 236], ["Hydrogen", "CHEMICAL", 242, 250], ["cAMP", "CHEMICAL", 338, 342], ["pro-(S) H", "CHEMICAL", 379, 388], ["amine", "CHEMICAL", 402, 407], ["amide carbonyl moieties", "SIMPLE_CHEMICAL", 86, 109], ["erythreo isomers", "SIMPLE_CHEMICAL", 158, 174], ["amide carbonyls", "SIMPLE_CHEMICAL", 180, 195], ["Fluorine", "SIMPLE_CHEMICAL", 228, 236], ["Hydrogen", "SIMPLE_CHEMICAL", 242, 250], ["GPR119", "SIMPLE_CHEMICAL", 267, 273], ["EC", "CELL", 286, 288], ["cAMP", "SIMPLE_CHEMICAL", 338, 342], ["amine moiety", "SIMPLE_CHEMICAL", 402, 414], ["EC", "CELL", 473, 475], ["pro-(S) H atom \u03b2to", "PROTEIN", 379, 397], ["the threo isomers", "TEST", 15, 32], ["the amide carbonyl moieties", "TREATMENT", 82, 109], ["an anti-periplanar arrangement", "TREATMENT", 113, 143], ["the erythreo isomers", "TREATMENT", 154, 174], ["the amide carbonyls", "TREATMENT", 176, 195], ["Fluorine", "TREATMENT", 228, 236], ["EC", "TEST", 286, 288], ["intrinsic activity", "TEST", 306, 324], ["a cAMP assay", "TEST", 336, 348], ["isosteric replacement of the pro", "TREATMENT", 350, 382], ["the amine moiety", "TEST", 398, 414], ["EC", "TEST", 473, 475], ["agonistic properties", "OBSERVATION", 510, 530]]], ["The F atom was introduced based on an appreciation of its potential to influence conformational preferences, a hypothesis confirmed by NMR analysis which revealed a population of the conformation in which the F and NH atoms are gauche amounting to 75% in CDCl 3 solution [140] .Fluorine as a Hydrogen IsostereThe gauche interaction between a fluorine atom and an amide influences the conformational preference of proline with the 4-(R)-F and 4-(S)-F derivatives 90 and 91, respectively, favoring complementary conformers [124] .", [["Fluorine", "CHEMICAL", 278, 286], ["Hydrogen Isostere", "CHEMICAL", 292, 309], ["fluorine", "CHEMICAL", 342, 350], ["proline", "CHEMICAL", 413, 420], ["F", "CHEMICAL", 4, 5], ["F", "CHEMICAL", 209, 210], ["NH", "CHEMICAL", 215, 217], ["CDCl 3", "CHEMICAL", 255, 261], ["Fluorine", "CHEMICAL", 278, 286], ["Hydrogen", "CHEMICAL", 292, 300], ["fluorine", "CHEMICAL", 342, 350], ["amide", "CHEMICAL", 363, 368], ["proline", "CHEMICAL", 413, 420], ["4-(R)-F", "CHEMICAL", 430, 437], ["4-(S)-F", "CHEMICAL", 442, 449], ["F atom", "SIMPLE_CHEMICAL", 4, 10], ["NH atoms", "SIMPLE_CHEMICAL", 215, 223], ["Fluorine", "SIMPLE_CHEMICAL", 278, 286], ["fluorine atom", "SIMPLE_CHEMICAL", 342, 355], ["proline", "AMINO_ACID", 413, 420], ["4-(R)-F", "SIMPLE_CHEMICAL", 430, 437], ["4-(S)-F derivatives", "SIMPLE_CHEMICAL", 442, 461], ["NMR analysis", "TEST", 135, 147], ["Fluorine", "TREATMENT", 278, 286], ["a Hydrogen Isostere", "TREATMENT", 290, 309], ["a fluorine atom", "TREATMENT", 340, 355], ["Hydrogen Isostere", "OBSERVATION", 292, 309], ["gauche", "OBSERVATION", 313, 319]]], ["The incorporation of (R)-and (S)-4-F-Pro into collagen fibrils markedly affects the properties of the polymer in a fashion that has provided insight into the stabilizing effects of the 4-(R)-hydroxyproline that occurs naturally in collagen [124, [141] [142] [143] [144] [145] [146] .", [["4-(R)-hydroxyproline", "CHEMICAL", 185, 205], ["(R)-and (S)-4-F-Pro", "CHEMICAL", 21, 40], ["4-(R)-hydroxyproline", "CHEMICAL", 185, 205], ["(R)", "SIMPLE_CHEMICAL", 21, 24], ["(S)-4-F-Pro", "SIMPLE_CHEMICAL", 29, 40], ["collagen fibrils", "GENE_OR_GENE_PRODUCT", 46, 62], ["4-(R)-hydroxyproline", "SIMPLE_CHEMICAL", 185, 205], ["collagen [124, [141] [142] [143] [144] [145] [146]", "SIMPLE_CHEMICAL", 231, 281], ["collagen fibrils", "PROTEIN", 46, 62], ["collagen", "PROTEIN", 231, 239], ["collagen fibrils", "PROBLEM", 46, 62], ["hydroxyproline", "TREATMENT", 191, 205]]], ["These studies have led to the suggestion that the stabilizing effect of 4-(R)-hydroxyproline on collagen, which is manifested as favoring a tightly wound helix structure, is the result of an inductive effect rather than a H-bonding interaction of the 4-OH substituent.", [["wound", "ANATOMY", 148, 153], ["4-(R)-hydroxyproline", "CHEMICAL", 72, 92], ["H", "CHEMICAL", 222, 223], ["4-OH", "CHEMICAL", 251, 255], ["4-(R)-hydroxyproline", "CHEMICAL", 72, 92], ["H", "CHEMICAL", 222, 223], ["4-OH", "CHEMICAL", 251, 255], ["4-(R)-hydroxyproline", "SIMPLE_CHEMICAL", 72, 92], ["collagen", "GENE_OR_GENE_PRODUCT", 96, 104], ["4-OH substituent", "SIMPLE_CHEMICAL", 251, 267], ["collagen", "PROTEIN", 96, 104], ["These studies", "TEST", 0, 13], ["hydroxyproline on collagen", "TREATMENT", 78, 104], ["a tightly wound helix structure", "PROBLEM", 138, 169], ["an inductive effect", "PROBLEM", 188, 207], ["wound helix", "OBSERVATION", 148, 159]]], ["The C \u03b3 -endo conformation of proline is preferred by a modest 0.41 kcal/mol, leading to a 2:1 population of this conformer at room temperature while 4-(R)-hydroxyproline favors the C \u03b3 -exo conformer by a calculated 0.48 kcal/ mol ( Fig. 16 ) [147] .", [["proline", "CHEMICAL", 30, 37], ["4-(R)-hydroxyproline", "CHEMICAL", 150, 170], ["proline", "CHEMICAL", 30, 37], ["4-(R)-hydroxyproline", "CHEMICAL", 150, 170], ["C", "CHEMICAL", 182, 183], ["proline", "AMINO_ACID", 30, 37], ["4-(R)-hydroxyproline", "SIMPLE_CHEMICAL", 150, 170], ["C \u03b3 -exo conformer", "SIMPLE_CHEMICAL", 182, 200], ["C \u03b3", "PROTEIN", 4, 7], ["C \u03b3", "PROTEIN", 182, 185], ["endo conformation of proline", "TREATMENT", 9, 37]]], ["For 4-(S)-F proline (91), the C \u03b3 -endo conformation is favored by 0.61 kcal/mol, attributed to stabilization by the gauche effect between fluorine and the amide moiety which leads to the F atom adopting an axial disposition, an arrangement that is observed in the single-crystal X-ray structure ( Fig. 16 ) [147, 148] .", [["4-(S)-F proline", "CHEMICAL", 4, 19], ["fluorine", "CHEMICAL", 139, 147], ["4-(S)-F proline", "CHEMICAL", 4, 19], ["C", "CHEMICAL", 30, 31], ["fluorine", "CHEMICAL", 139, 147], ["amide", "CHEMICAL", 156, 161], ["F", "CHEMICAL", 188, 189], ["4-(S)-F proline (91)", "SIMPLE_CHEMICAL", 4, 24], ["fluorine", "SIMPLE_CHEMICAL", 139, 147], ["F atom", "SIMPLE_CHEMICAL", 188, 194], ["X", "PROTEIN", 280, 281], ["the C \u03b3 -endo conformation", "TREATMENT", 26, 52], ["fluorine and the amide moiety", "TREATMENT", 139, 168]]], ["In contrast, 4-(R)-fluoroproline (92) prefers the C \u03b3 -exo conformation by 0.85 kcal/mol, with the gauche effect between the F and amide moieties favoring an equatorial disposition of the F atom [147] .", [["4-(R)-fluoroproline", "CHEMICAL", 13, 32], ["4-(R)-fluoroproline", "CHEMICAL", 13, 32], ["C", "CHEMICAL", 50, 51], ["F", "CHEMICAL", 125, 126], ["amide", "CHEMICAL", 131, 136], ["F", "CHEMICAL", 188, 189], ["4-(R)-fluoroproline (92)", "SIMPLE_CHEMICAL", 13, 37], ["amide moieties", "SIMPLE_CHEMICAL", 131, 145], ["fluoroproline", "TREATMENT", 19, 32], ["the C \u03b3 -exo conformation", "TREATMENT", 46, 71], ["the gauche effect between the F and amide moieties", "TREATMENT", 95, 145], ["equatorial", "OBSERVATION_MODIFIER", 158, 168]]], ["The C \u03b3 -exo conformation mimics that preferred by 4-(R)-hydroxyproline and provides an explanation for the structural similarity of collagen fragments that incorporate either 4-(R)hydroxy-or 4-(R)-fluoroproline [149] .", [["4-(R)-hydroxyproline", "CHEMICAL", 51, 71], ["4-(R)hydroxy-or 4-(R)-fluoroproline", "CHEMICAL", 176, 211], ["4-(R)-hydroxyproline", "CHEMICAL", 51, 71], ["4-(R)hydroxy-or 4-(R)-fluoroproline", "CHEMICAL", 176, 211], ["4-(R)-hydroxyproline", "SIMPLE_CHEMICAL", 51, 71], ["collagen", "GENE_OR_GENE_PRODUCT", 133, 141], ["4-(R)hydroxy-or 4-(R)-fluoroproline [149]", "SIMPLE_CHEMICAL", 176, 217], ["C \u03b3", "PROTEIN", 4, 7], ["collagen fragments", "PROTEIN", 133, 151], ["hydroxyproline", "TREATMENT", 57, 71], ["collagen fragments", "PROBLEM", 133, 151], ["hydroxy", "TEST", 181, 188], ["fluoroproline", "TREATMENT", 198, 211]]], ["3-Fluoroproline also exhibits conformational bias as illustrated by studies with the diastereomeric esters 92 and 93 [150] .", [["3-Fluoroproline", "CHEMICAL", 0, 15], ["3-Fluoroproline", "CHEMICAL", 0, 15], ["esters", "CHEMICAL", 100, 106], ["3-Fluoroproline", "SIMPLE_CHEMICAL", 0, 15], ["Fluoroproline", "TREATMENT", 2, 15], ["the diastereomeric esters", "TEST", 81, 106]]], ["Both of these compounds crystallize with a trans configuration between the amide and ester moieties, as depicted in the structures of 92 and 93, but the proline rings adopt quite different conformations.", [["ester", "CHEMICAL", 85, 90], ["proline", "CHEMICAL", 153, 160], ["amide", "CHEMICAL", 75, 80], ["ester", "CHEMICAL", 85, 90], ["proline", "CHEMICAL", 153, 160], ["amide", "SIMPLE_CHEMICAL", 75, 80], ["ester moieties", "SIMPLE_CHEMICAL", 85, 99], ["proline rings", "SIMPLE_CHEMICAL", 153, 166], ["the amide and ester moieties", "TREATMENT", 71, 99], ["the proline rings", "TREATMENT", 149, 166], ["compounds crystallize", "OBSERVATION", 14, 35]]], ["In each case, the F atom is axially disposed, favored by a stabilizing gauche interaction with the amide moiety such that the pyrrolidine ring of the (R)-isomer 92 adopts the C \u03b3 -exo conformation while, in contrast, the (S)-isomer 93 favors the C \u03b3 -endo arrangement [150] .", [["pyrrolidine", "CHEMICAL", 126, 137], ["F", "CHEMICAL", 18, 19], ["amide", "CHEMICAL", 99, 104], ["pyrrolidine", "CHEMICAL", 126, 137], ["C", "CHEMICAL", 175, 176], ["(S)-isomer 93", "CHEMICAL", 221, 234], ["C", "CHEMICAL", 246, 247], ["F atom", "SIMPLE_CHEMICAL", 18, 24], ["pyrrolidine ring", "SIMPLE_CHEMICAL", 126, 142], ["(R)-isomer 92", "SIMPLE_CHEMICAL", 150, 163], ["(S)-isomer 93", "SIMPLE_CHEMICAL", 221, 234], ["C \u03b3", "PROTEIN", 175, 178], ["C \u03b3", "PROTEIN", 246, 249], ["the amide moiety", "TREATMENT", 95, 111], ["the pyrrolidine ring", "TREATMENT", 122, 142]]], ["In solution, the C \u03b3 -endo conformation of 93 dominated based on the 1 Hz coupling constant between the \u03b1and \u03b2-protons in the 1 H-NMR spectrum, an observation supported by calculations that indicate that this conformation should be preferred by a ratio of 97:3.", [["C", "CHEMICAL", 17, 18], ["\u03b1and \u03b2-protons", "CHEMICAL", 104, 118], ["H", "CHEMICAL", 128, 129], ["\u03b1and \u03b2-protons", "SIMPLE_CHEMICAL", 104, 118], ["C \u03b3", "PROTEIN", 17, 20], ["\u03b1and \u03b2-protons", "PROTEIN", 104, 118], ["the C \u03b3", "TEST", 13, 20], ["endo conformation", "TEST", 22, 39], ["an observation", "TEST", 144, 158]]], ["For the 3-(R)-isomer 92, unfavorable steric and electronic repulsive effects between the F atom and ester moiety led to a preference for the C \u03b3 -exo conformation, populated to the extent of 69%.", [["3-(R)-isomer 92", "CHEMICAL", 8, 23], ["ester", "CHEMICAL", 100, 105], ["3-(R)-isomer 92", "CHEMICAL", 8, 23], ["F", "CHEMICAL", 89, 90], ["ester", "CHEMICAL", 100, 105], ["C", "CHEMICAL", 141, 142], ["3-(R)-isomer 92", "SIMPLE_CHEMICAL", 8, 23], ["F atom", "SIMPLE_CHEMICAL", 89, 95], ["ester moiety", "SIMPLE_CHEMICAL", 100, 112], ["C \u03b3", "PROTEIN", 141, 144], ["the F atom and ester moiety", "TREATMENT", 85, 112], ["unfavorable steric", "OBSERVATION_MODIFIER", 25, 43], ["electronic repulsive", "OBSERVATION", 48, 68]]], ["Notably, the conformational preferences of each of these 2 proline derivatives were expressed when they were incorporated into short peptide sequences [145, 150, 151] .", [["proline", "CHEMICAL", 59, 66], ["proline", "CHEMICAL", 59, 66], ["2 proline derivatives", "SIMPLE_CHEMICAL", 57, 78], ["these 2 proline derivatives", "TREATMENT", 51, 78], ["short peptide sequences", "TEST", 127, 150]]], ["Ac Ac \u03b2-Amino fluoroalkanes exhibit conformational bias based on gauche interactions between the amine and F moieties, the energetics of which depend on the protonation state [21, 124, 152] .", [["Ac Ac \u03b2-Amino fluoroalkanes", "CHEMICAL", 0, 27], ["amine", "CHEMICAL", 97, 102], ["Ac Ac \u03b2-Amino fluoroalkanes", "CHEMICAL", 0, 27], ["amine", "CHEMICAL", 97, 102], ["F", "CHEMICAL", 107, 108], ["Ac Ac \u03b2-Amino fluoroalkanes", "SIMPLE_CHEMICAL", 0, 27], ["amine", "SIMPLE_CHEMICAL", 97, 102], ["F moieties", "SIMPLE_CHEMICAL", 107, 117], ["Ac Ac", "TREATMENT", 0, 5], ["Amino fluoroalkanes", "TREATMENT", 8, 27], ["conformational bias", "PROBLEM", 36, 55], ["gauche interactions", "TREATMENT", 65, 84]]], ["In the unprotonated form, a gauche relationship between the NH 2 and F of 2-fluoroethylamine is weakly favored by an energy estimated to be~1 kcal/mol, an interaction considered to be a bridging H-bond.", [["NH 2 and F of 2-fluoroethylamine", "CHEMICAL", 60, 92], ["NH", "CHEMICAL", 60, 62], ["F", "CHEMICAL", 69, 70], ["2-fluoroethylamine", "CHEMICAL", 74, 92], ["H", "CHEMICAL", 195, 196], ["F of 2-fluoroethylamine", "SIMPLE_CHEMICAL", 69, 92], ["fluoroethylamine", "TREATMENT", 76, 92]]], ["However, protonation results in a much stronger preference for a gauche relationship between the F atom and the charged amine that is estimated to be 5.8 kcal/mol and attributed to a favorable electrostatic (charge-dipole) interaction between the charged amine and the electronegative F atom [21, 124, 152] .", [["amine", "CHEMICAL", 120, 125], ["amine", "CHEMICAL", 255, 260], ["F", "CHEMICAL", 97, 98], ["amine", "CHEMICAL", 120, 125], ["amine", "CHEMICAL", 255, 260], ["F", "CHEMICAL", 285, 286], ["F atom", "SIMPLE_CHEMICAL", 97, 103], ["amine", "SIMPLE_CHEMICAL", 120, 125], ["amine", "SIMPLE_CHEMICAL", 255, 260], ["a favorable electrostatic (charge-dipole", "TREATMENT", 181, 221]]], ["These energetic preferences are such that cyclic amines experience considerable conformational bias, exemplified most effectively by the analysis of the protonated form of 3-fluoro-N-methyl-piperidine (94) as summarized in Fig. 17 [153] [154] [155] .", [["cyclic amines", "CHEMICAL", 42, 55], ["3-fluoro-N-methyl-piperidine", "CHEMICAL", 172, 200], ["cyclic amines", "CHEMICAL", 42, 55], ["3-fluoro-N-methyl-piperidine", "CHEMICAL", 172, 200], ["cyclic amines", "SIMPLE_CHEMICAL", 42, 55], ["3-fluoro-N-methyl-piperidine (94)", "SIMPLE_CHEMICAL", 172, 205], ["cyclic amines experience considerable conformational bias", "PROBLEM", 42, 99], ["3-fluoro", "TREATMENT", 172, 180], ["methyl-piperidine", "TREATMENT", 183, 200]]], ["Despite experiencing steric compression, the ring F atom of 94 overwhelmingly prefers an axial disposition, with conformer A in Fig. 17 representing the global minimum and favored to the extent of 95-96%, The Influence of Bioisosteres in Drug Design: Tactical Applications to. . . stabilized by an electrostatic interaction between the F and NH + moieties [155] .", [["F", "CHEMICAL", 50, 51], ["F", "CHEMICAL", 336, 337], ["NH +", "CHEMICAL", 342, 346], ["steric compression", "PROBLEM", 21, 39], ["Tactical Applications", "TREATMENT", 251, 272], ["steric compression", "OBSERVATION", 21, 39]]], ["Conformer D contributes only 4-5% of the population at equilibrium, with a productive electrostatic effect compensating for unfavorable diaxial interactions between the F and CH 3 moieties.Fluorine as a Hydrogen IsostereThe synthesis and evaluation of the two fluorinated enantiomers 96 and 97 of \u03b3-aminobutyric acid (GABA, 95) provided some insight into the conformation of the neurotransmitter when bound to cognate receptors or that recognized by the aminotransferase (Fig. 18) [156, 157] .", [["Fluorine", "CHEMICAL", 189, 197], ["Hydrogen Isostere", "CHEMICAL", 203, 220], ["enantiomers 96 and 97 of \u03b3-aminobutyric acid", "CHEMICAL", 272, 316], ["GABA", "CHEMICAL", 318, 322], ["F", "CHEMICAL", 169, 170], ["CH", "CHEMICAL", 175, 177], ["Fluorine", "CHEMICAL", 189, 197], ["Hydrogen", "CHEMICAL", 203, 211], ["\u03b3-aminobutyric acid", "CHEMICAL", 297, 316], ["GABA", "CHEMICAL", 318, 322], ["Fluorine", "SIMPLE_CHEMICAL", 189, 197], ["\u03b3-aminobutyric acid", "SIMPLE_CHEMICAL", 297, 316], ["GABA", "SIMPLE_CHEMICAL", 318, 322], ["aminotransferase", "SIMPLE_CHEMICAL", 454, 470], ["F and CH 3 moieties", "PROTEIN", 169, 188], ["cognate receptors", "PROTEIN", 410, 427], ["aminotransferase", "PROTEIN", 454, 470], ["a productive electrostatic effect", "PROBLEM", 73, 106], ["unfavorable diaxial interactions", "PROBLEM", 124, 156], ["Fluorine", "TREATMENT", 189, 197], ["a Hydrogen Isostere", "TREATMENT", 201, 220], ["The synthesis", "TEST", 220, 233], ["evaluation", "TEST", 238, 248], ["the two fluorinated enantiomers", "TEST", 252, 283], ["\u03b3-aminobutyric acid (GABA", "TEST", 297, 322], ["Hydrogen Isostere", "OBSERVATION", 203, 220]]], ["Fluorination of GABA (95) increases the acidity of the carboxylic acid moiety and decreases the basicity of the amine but preserves the zwitterionic nature of the molecule at neutral pH.", [["GABA", "CHEMICAL", 16, 20], ["carboxylic acid", "CHEMICAL", 55, 70], ["amine", "CHEMICAL", 112, 117], ["GABA", "CHEMICAL", 16, 20], ["carboxylic acid", "CHEMICAL", 55, 70], ["amine", "CHEMICAL", 112, 117], ["GABA (95)", "SIMPLE_CHEMICAL", 16, 25], ["carboxylic acid", "SIMPLE_CHEMICAL", 55, 70], ["amine", "SIMPLE_CHEMICAL", 112, 117], ["Fluorination of GABA", "TREATMENT", 0, 20], ["the carboxylic acid moiety", "TREATMENT", 51, 77], ["the basicity of the amine", "TREATMENT", 92, 117]]], ["NMR analysis indicated that all molecules adopted an extended conformation in solution but with 96 and 97 further preferring an arrangement in which a favorable gauche interaction occurs between the fluorine and the NH 3 + moiety [156] .", [["fluorine", "CHEMICAL", 199, 207], ["NH", "CHEMICAL", 216, 218], ["fluorine", "CHEMICAL", 199, 207], ["NH 3 +", "CHEMICAL", 216, 222], ["fluorine", "SIMPLE_CHEMICAL", 199, 207], ["NH 3 +", "SIMPLE_CHEMICAL", 216, 222], ["NMR analysis", "TEST", 0, 12], ["all molecules", "PROBLEM", 28, 41], ["an extended conformation in solution", "TREATMENT", 50, 86], ["a favorable gauche interaction", "PROBLEM", 149, 179]]], ["The available conformations for each of the enantiomers 96 and 97 are captured in Fig. 18 with those that are disfavored based on the absence of a gauche effect noted [156] .", [["the enantiomers", "TEST", 40, 55], ["a gauche effect", "PROBLEM", 145, 160]]], ["Both 96 and 97 activated the cloned human GABA A receptor with comparable potency, although both were significantly less potent than the natural neurotransmitter 95, results that are consistent with the bound form of the neurotransmitter being the extended conformation represented by B in Fig. 18 that is accessible to all three compounds [156, 157] .", [["GABA", "CHEMICAL", 42, 46], ["GABA", "CHEMICAL", 42, 46], ["human", "ORGANISM", 36, 41], ["GABA A receptor", "GENE_OR_GENE_PRODUCT", 42, 57], ["B", "CELL", 285, 286], ["human GABA A receptor", "PROTEIN", 36, 57], ["B", "PROTEIN", 285, 286], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["consistent with", "UNCERTAINTY", 183, 198]]], ["However, GABA aminotransferase was able to differentiate 96 and 97, catalyzing elimination of HF from the latter with 20-fold higher efficiency than for 96, an observation that suggested that the enzyme recognizes a conformation in which the NH 3 + and CH 2 CO 2 -moieties are disposed in a gauche arrangement, as represented by conformation C in Fig. 18 [156, 157] .", [["GABA", "CHEMICAL", 9, 13], ["GABA", "CHEMICAL", 9, 13], ["NH 3 +", "CHEMICAL", 242, 248], ["CH", "CHEMICAL", 253, 255], ["CO", "CHEMICAL", 258, 260], ["GABA aminotransferase", "GENE_OR_GENE_PRODUCT", 9, 30], ["NH 3 +", "SIMPLE_CHEMICAL", 242, 248], ["CO 2 -moieties", "SIMPLE_CHEMICAL", 258, 272], ["GABA aminotransferase", "PROTEIN", 9, 30], ["enzyme", "PROTEIN", 196, 202], ["GABA aminotransferase", "TEST", 9, 30], ["HF", "PROBLEM", 94, 96], ["an observation", "TEST", 157, 171], ["the enzyme", "TEST", 192, 202], ["gauche arrangement", "OBSERVATION", 291, 309]]], ["Both fluorinated derivatives were agonists at \u03c11 and \u03c12 GABA C receptors, with the (R)-isomer 97 tenfold weaker and the (S)-isomer 96 20-fold weaker than the natural ligand 95 [158] .", [["GABA", "CHEMICAL", 56, 60], ["GABA", "CHEMICAL", 56, 60], ["fluorinated derivatives", "SIMPLE_CHEMICAL", 5, 28], ["\u03c11", "SIMPLE_CHEMICAL", 46, 48], ["GABA C receptors", "GENE_OR_GENE_PRODUCT", 56, 72], ["\u03c11 and \u03c12 GABA C receptors", "PROTEIN", 46, 72], ["Both fluorinated derivatives", "TREATMENT", 0, 28]]], ["This was attributed to weaker electrostatic interactions due to the reduced basicity of the amine, observations that taken together suggested that GABA (95) binds to the GABA C receptor in the folded orientation represented by conformation C in Fig. 18 [158] .Fluorine as a Hydrogen IsostereIn an analogous fashion, the bound conformation of N-methyl-D-aspartate (99), an agonist mimetic of glutamic acid (Glu, 98), at recombinant GluN2A and GluN2B receptors expressed in Xenopus laevis oocytes was probed through the synthesis Fig. 17 Conformational preference of N-methyl-3-fluoropiperidine (94) in its protonated form and evaluation of (2S,3S)-3F-NMDA (100) and (2S,3R)-3F-NMDA (101), the available conformations of which are depicted in Fig. 19 [159] .", [["oocytes", "ANATOMY", 487, 494], ["amine", "CHEMICAL", 92, 97], ["GABA", "CHEMICAL", 147, 151], ["GABA", "CHEMICAL", 170, 174], ["Fluorine", "CHEMICAL", 260, 268], ["Hydrogen", "CHEMICAL", 274, 282], ["N-methyl-D-aspartate", "CHEMICAL", 342, 362], ["glutamic acid", "CHEMICAL", 391, 404], ["Glu", "CHEMICAL", 406, 409], ["N-methyl-3-fluoropiperidine", "CHEMICAL", 565, 592], ["NMDA", "CHEMICAL", 650, 654], ["NMDA", "CHEMICAL", 676, 680], ["amine", "CHEMICAL", 92, 97], ["GABA", "CHEMICAL", 147, 151], ["GABA", "CHEMICAL", 170, 174], ["Fluorine", "CHEMICAL", 260, 268], ["Hydrogen", "CHEMICAL", 274, 282], ["N-methyl-D-aspartate", "CHEMICAL", 342, 362], ["glutamic acid", "CHEMICAL", 391, 404], ["Glu", "CHEMICAL", 406, 409], ["N-methyl-3-fluoropiperidine", "CHEMICAL", 565, 592], ["(2S,3S)-3F-NMDA", "CHEMICAL", 639, 654], ["(2S,3R)-3F-NMDA", "CHEMICAL", 665, 680], ["amine", "SIMPLE_CHEMICAL", 92, 97], ["GABA (95)", "GENE_OR_GENE_PRODUCT", 147, 156], ["GABA C receptor", "GENE_OR_GENE_PRODUCT", 170, 185], ["Fluorine", "SIMPLE_CHEMICAL", 260, 268], ["Hydrogen IsostereIn", "SIMPLE_CHEMICAL", 274, 293], ["N-methyl-D-aspartate (99)", "SIMPLE_CHEMICAL", 342, 367], ["glutamic acid", "SIMPLE_CHEMICAL", 391, 404], ["Glu", "AMINO_ACID", 406, 409], ["GluN2A", "GENE_OR_GENE_PRODUCT", 431, 437], ["GluN2B receptors", "GENE_OR_GENE_PRODUCT", 442, 458], ["Xenopus laevis", "ORGANISM", 472, 486], ["oocytes", "ORGANISM", 487, 494], ["N-methyl-3-fluoropiperidine (94)", "SIMPLE_CHEMICAL", 565, 597], ["(2S,3S)-3F-NMDA (100)", "SIMPLE_CHEMICAL", 639, 660], ["(2S,3R)-3F-NMDA", "SIMPLE_CHEMICAL", 665, 680], ["GABA C receptor", "PROTEIN", 170, 185], ["GluN2A", "PROTEIN", 431, 437], ["GluN2B receptors", "PROTEIN", 442, 458], ["Xenopus laevis", "SPECIES", 472, 486], ["Xenopus laevis", "SPECIES", 472, 486], ["weaker electrostatic interactions", "PROBLEM", 23, 56], ["Fluorine", "TREATMENT", 260, 268], ["a Hydrogen IsostereIn", "TREATMENT", 272, 293], ["D-aspartate", "TEST", 351, 362], ["glutamic acid", "TEST", 391, 404], ["Glu", "TEST", 406, 409], ["recombinant GluN2A", "TREATMENT", 419, 437], ["GluN2B receptors", "TREATMENT", 442, 458], ["Xenopus laevis oocytes", "TREATMENT", 472, 494], ["the synthesis Fig", "TREATMENT", 514, 531], ["N-methyl", "TREATMENT", 565, 573], ["fluoropiperidine", "TREATMENT", 576, 592], ["evaluation", "TEST", 625, 635], ["weaker", "OBSERVATION_MODIFIER", 23, 29], ["electrostatic", "OBSERVATION", 30, 43], ["Xenopus laevis oocytes", "OBSERVATION", 472, 494]]], ["1 H-and 19 F-NMR spectral data were consistent with 100 adopting conformation A in solution while DFT calculations suggested that 101 would prefer the conformation represented by B in Fig. 19 , which was observed in the single-crystal X-ray structure.", [["H", "CHEMICAL", 2, 3], ["B", "PROTEIN", 179, 180], ["NMR spectral data", "TEST", 13, 30], ["DFT calculations", "TEST", 98, 114]]], ["(2S,3R)-3F-NMDA (101) exhibited no significant effect in the biological assays while (2S,3S)-3F-NMDA (98) induced currents in oocytes expressing either GluN2A or GluN2B receptors, although the maximal responses were less than that observed with NMDA (99) [159] .", [["oocytes", "ANATOMY", 126, 133], ["2S,3R)-3F-", "CHEMICAL", 1, 11], ["NMDA", "CHEMICAL", 11, 15], ["2S,3S)-3F-NMDA", "CHEMICAL", 86, 100], ["NMDA", "CHEMICAL", 245, 249], ["(2S,3R)-3F-NMDA", "CHEMICAL", 0, 15], ["(2S,3S)-3F-NMDA", "CHEMICAL", 85, 100], ["NMDA", "CHEMICAL", 245, 249], ["2S,3R)-3F-NMDA (101)", "SIMPLE_CHEMICAL", 1, 21], ["2S,3S)-3F-NMDA (98)", "SIMPLE_CHEMICAL", 86, 105], ["oocytes", "CELL", 126, 133], ["GluN2A", "GENE_OR_GENE_PRODUCT", 152, 158], ["GluN2B", "GENE_OR_GENE_PRODUCT", 162, 168], ["NMDA", "SIMPLE_CHEMICAL", 245, 249], ["oocytes", "CELL_TYPE", 126, 133], ["GluN2A", "PROTEIN", 152, 158], ["GluN2B receptors", "PROTEIN", 162, 178], ["significant effect", "PROBLEM", 35, 53], ["the biological assays", "TEST", 57, 78], ["NMDA", "TEST", 96, 100], ["GluN2B receptors", "TEST", 162, 178], ["the maximal responses", "TEST", 189, 210], ["NMDA", "TEST", 245, 249], ["no", "UNCERTAINTY", 32, 34], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["effect", "OBSERVATION", 47, 53]]], ["These observations are consistent with only (2S,3S)-3F-NMDA (100) being able to adopt a conformation that mimics the receptor-bound form of NMDA (99), designated as A in Fig. 19 , results that concur with the X-ray crystallographic structure of NMDA (99) bound to the GluN2D receptor that is highly homologous to GluN2A and GluN2B.Fluorine as a Hydrogen Isostere\u03b2-Fluoroethanol derivatives do not exhibit a strong conformational preference in the absence of an intramolecular interaction between the F and OH moieties which stabilizes a gauche arrangement by approximately 2 kcal/mol [152, 160, 161] .", [["2S,3S)-3F-", "CHEMICAL", 45, 55], ["NMDA", "CHEMICAL", 55, 59], ["NMDA", "CHEMICAL", 140, 144], ["NMDA", "CHEMICAL", 245, 249], ["Fluorine", "CHEMICAL", 331, 339], ["Hydrogen Isostere\u03b2-Fluoroethanol", "CHEMICAL", 345, 377], ["(2S,3S)-3F-NMDA", "CHEMICAL", 44, 59], ["NMDA", "CHEMICAL", 140, 144], ["NMDA", "CHEMICAL", 245, 249], ["Fluorine", "CHEMICAL", 331, 339], ["Hydrogen Isostere\u03b2-Fluoroethanol", "CHEMICAL", 345, 377], ["F", "CHEMICAL", 500, 501], ["OH", "CHEMICAL", 506, 508], ["2S,3S)-3F-NMDA", "SIMPLE_CHEMICAL", 45, 59], ["NMDA", "SIMPLE_CHEMICAL", 140, 144], ["NMDA (99)", "GENE_OR_GENE_PRODUCT", 245, 254], ["GluN2D receptor", "GENE_OR_GENE_PRODUCT", 268, 283], ["GluN2A", "GENE_OR_GENE_PRODUCT", 313, 319], ["GluN2B", "GENE_OR_GENE_PRODUCT", 324, 330], ["Fluorine", "SIMPLE_CHEMICAL", 331, 339], ["Hydrogen Isostere\u03b2-Fluoroethanol derivatives", "SIMPLE_CHEMICAL", 345, 389], ["OH moieties", "SIMPLE_CHEMICAL", 506, 517], ["GluN2D receptor", "PROTEIN", 268, 283], ["GluN2A", "PROTEIN", 313, 319], ["GluN2B", "PROTEIN", 324, 330], ["3F-NMDA", "TREATMENT", 52, 59], ["NMDA", "TEST", 140, 144], ["the X-ray", "TEST", 205, 214], ["NMDA", "TEST", 245, 249], ["the GluN2D receptor", "TREATMENT", 264, 283], ["Fluorine", "TREATMENT", 331, 339], ["a Hydrogen Isostere\u03b2-Fluoroethanol derivatives", "TREATMENT", 343, 389], ["an intramolecular interaction", "PROBLEM", 458, 487], ["the F and OH moieties", "TREATMENT", 496, 517], ["a gauche arrangement", "TREATMENT", 535, 555], ["consistent with", "UNCERTAINTY", 23, 38], ["intramolecular", "OBSERVATION", 461, 475]]], ["However, this effect is significantly reinforced by protonation of the alcohol which stabilizes the gauche conformer by an energy estimated at~7 kcal/mol and which has been attributed to the combination of a stereoelectronic effect and an intramolecular H-bonding-type interaction.", [["alcohol", "CHEMICAL", 71, 78], ["H", "CHEMICAL", 254, 255], ["alcohol", "CHEMICAL", 71, 78], ["H", "CHEMICAL", 254, 255], ["alcohol", "SIMPLE_CHEMICAL", 71, 78], ["a stereoelectronic effect", "PROBLEM", 206, 231], ["stereoelectronic effect", "OBSERVATION", 208, 231]]], ["The HIV-1 protease inhibitor indinavir (102) and its epimer 103 presented an interesting opportunity to probe the consequences of introducing F-OH interactions on conformational disposition, probed with the congeners 104-107, that could readily be equated with enzyme inhibitory activity, measured as the K i values that are summarized in Fig. 20 [162] .", [["indinavir", "CHEMICAL", 29, 38], ["F-OH", "CHEMICAL", 142, 146], ["indinavir", "CHEMICAL", 29, 38], ["-OH", "CHEMICAL", 143, 146], ["HIV-1", "ORGANISM", 4, 9], ["indinavir", "SIMPLE_CHEMICAL", 29, 38], ["F-OH", "SIMPLE_CHEMICAL", 142, 146], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 4, 9], ["The HIV", "TEST", 0, 7], ["1 protease inhibitor indinavir", "TREATMENT", 8, 38], ["its epimer", "TEST", 49, 59], ["the congeners", "TEST", 203, 216], ["the K i values", "TEST", 301, 315]]], ["In addition to influencing conformation, it was anticipated that the introduction of a F atom to indinavir (102) would affect the acidity of the OH, potentially introduce steric interactions between drug and target, and also affect solvation.", [["indinavir", "CHEMICAL", 97, 106], ["OH", "CHEMICAL", 145, 147], ["F", "CHEMICAL", 87, 88], ["indinavir", "CHEMICAL", 97, 106], ["OH", "CHEMICAL", 145, 147], ["F atom", "SIMPLE_CHEMICAL", 87, 93], ["indinavir", "SIMPLE_CHEMICAL", 97, 106], ["OH", "SIMPLE_CHEMICAL", 145, 147], ["a F atom to indinavir", "TREATMENT", 85, 106]]], ["In the indinavir series, the syn,syn analogue 104 exhibits potency comparable to the prototype 102 while the anti,anti isomer 106 is tenfold less active.", [["indinavir", "CHEMICAL", 7, 16], ["indinavir", "CHEMICAL", 7, 16], ["indinavir", "SIMPLE_CHEMICAL", 7, 16], ["syn analogue 104", "SIMPLE_CHEMICAL", 33, 49], ["the indinavir series", "TEST", 3, 23], ["the prototype", "TEST", 81, 94], ["the anti,anti isomer", "TEST", 105, 125]]], ["The syn,anti epi-indinavir derivative 107 is eightfold more potent than progenitor 103, but the anti,syn diastereomer 105 with a K i of 5,900 nM is substantially (36-fold) less active [162] .", [["progenitor 103", "ANATOMY", 72, 86], ["epi-indinavir", "CHEMICAL", 13, 26], ["K", "CHEMICAL", 129, 130], ["epi-indinavir", "CHEMICAL", 13, 26], ["epi-indinavir derivative 107", "SIMPLE_CHEMICAL", 13, 41], ["progenitor 103", "CELL", 72, 86], ["syn diastereomer 105", "SIMPLE_CHEMICAL", 101, 121], ["The syn", "TREATMENT", 0, 7], ["anti epi-indinavir derivative", "TREATMENT", 8, 37], ["the anti,syn diastereomer", "TEST", 92, 117], ["a K i", "TEST", 127, 132]]], ["The 2 most potent fluorinated compounds syn,syn (104) and syn,anti (107)The Conformation of Substituted Phenyl and Heteroaryl Derivatives and IsosterismThe topographical preferences of substituted aryl and heteroaryl rings are dependent upon both ring structure and the identity of the substituent atom [10, 163] .", [["Phenyl", "CHEMICAL", 104, 110], ["Heteroaryl", "CHEMICAL", 115, 125], ["Isosterism", "CHEMICAL", 142, 152], ["aryl", "CHEMICAL", 197, 201], ["heteroaryl", "CHEMICAL", 206, 216], ["Phenyl", "CHEMICAL", 104, 110], ["Heteroaryl", "CHEMICAL", 115, 125], ["Isosterism", "CHEMICAL", 142, 152], ["aryl", "CHEMICAL", 197, 201], ["heteroaryl", "CHEMICAL", 206, 216], ["fluorinated compounds syn", "SIMPLE_CHEMICAL", 18, 43], ["syn (104)", "SIMPLE_CHEMICAL", 44, 53], ["syn", "SIMPLE_CHEMICAL", 58, 61], ["anti (107)", "SIMPLE_CHEMICAL", 62, 72], ["Substituted Phenyl", "SIMPLE_CHEMICAL", 92, 110], ["Heteroaryl Derivatives", "SIMPLE_CHEMICAL", 115, 137], ["Isosterism", "SIMPLE_CHEMICAL", 142, 152], ["aryl", "SIMPLE_CHEMICAL", 197, 201], ["heteroaryl rings", "SIMPLE_CHEMICAL", 206, 222], ["Substituted Phenyl and Heteroaryl Derivatives", "TREATMENT", 92, 137], ["Isosterism", "TREATMENT", 142, 152], ["substituted aryl and heteroaryl rings", "TREATMENT", 185, 222], ["substituted aryl", "OBSERVATION", 185, 201], ["heteroaryl rings", "OBSERVATION", 206, 222], ["both", "OBSERVATION_MODIFIER", 242, 246], ["ring structure", "OBSERVATION", 247, 261], ["substituent atom", "OBSERVATION", 286, 302]]], ["An illustration of the effect of substituent identity on biological activity is illustrated by the structure-activity relationships associated with the three non-prostanoid prostacyclin agonists 108-110 compiled in Table 10 which reveal a significant limitation on one of the simplest of the classic isosteric relationships, that between O and CH 2 [10, 65, 66] .", [["prostacyclin", "CHEMICAL", 173, 185], ["prostacyclin", "CHEMICAL", 173, 185], ["O", "CHEMICAL", 338, 339], ["CH", "CHEMICAL", 344, 346], ["prostacyclin", "SIMPLE_CHEMICAL", 173, 185], ["substituent identity", "PROBLEM", 33, 53], ["the three non-prostanoid prostacyclin agonists", "TEST", 148, 194], ["a significant limitation", "PROBLEM", 237, 261], ["significant", "OBSERVATION_MODIFIER", 239, 250], ["limitation", "OBSERVATION", 251, 261], ["isosteric relationships", "OBSERVATION", 300, 323]]], ["The results have been interpreted based on the conformational preferences captured in Fig. 21 with the ether 108 and cinnamate 110 considered to be more potent based on the facility with which they are able to adopt an overall coplanar configuration with the phenyl ring, which contrasts with 109 in which the alkyl side chain projects orthogonally to the plane of the aromatic ring as a consequence of allylic 1,3-strain [10, 65, 66, 122, 163] .The Conformation of Substituted Phenyl and Heteroaryl Derivatives and IsosterismFor the HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) 111, replacing the OCH 2 moiety with a CH 2 linker afforded 112 which largely preserved antiviral activity, suggesting that in this context there is an isosteric relationship between the OCH 2 and CH 2 moieties [164] .", [["cinnamate", "CHEMICAL", 117, 126], ["alkyl", "CHEMICAL", 310, 315], ["Phenyl", "CHEMICAL", 478, 484], ["Heteroaryl", "CHEMICAL", 489, 499], ["IsosterismFor", "CHEMICAL", 516, 529], ["NNRTI) 111", "CHEMICAL", 588, 598], ["CH 2 linker", "CHEMICAL", 634, 645], ["ether", "CHEMICAL", 103, 108], ["cinnamate", "CHEMICAL", 117, 126], ["phenyl", "CHEMICAL", 259, 265], ["Phenyl", "CHEMICAL", 478, 484], ["Heteroaryl", "CHEMICAL", 489, 499], ["CH 2", "CHEMICAL", 634, 638], ["OCH 2", "CHEMICAL", 782, 787], ["CH 2", "CHEMICAL", 792, 796], ["ether 108", "SIMPLE_CHEMICAL", 103, 112], ["cinnamate 110", "SIMPLE_CHEMICAL", 117, 130], ["phenyl ring", "SIMPLE_CHEMICAL", 259, 270], ["allylic 1,3-strain", "SIMPLE_CHEMICAL", 403, 421], ["Phenyl", "SIMPLE_CHEMICAL", 478, 484], ["Heteroaryl Derivatives", "SIMPLE_CHEMICAL", 489, 511], ["IsosterismFor", "SIMPLE_CHEMICAL", 516, 529], ["HIV-1", "ORGANISM", 534, 539], ["non-nucleoside reverse transcriptase", "GENE_OR_GENE_PRODUCT", 540, 576], ["OCH 2 moiety", "SIMPLE_CHEMICAL", 614, 626], ["HIV-1", "SPECIES", 534, 539], ["HIV-1", "SPECIES", 534, 539], ["the phenyl ring", "TREATMENT", 255, 270], ["the alkyl side chain", "TREATMENT", 306, 326], ["Substituted Phenyl and Heteroaryl Derivatives", "TREATMENT", 466, 511], ["IsosterismFor", "TREATMENT", 516, 529], ["the HIV", "TREATMENT", 530, 537], ["non-nucleoside reverse transcriptase inhibitor (NNRTI)", "TREATMENT", 540, 594], ["the OCH 2 moiety", "TREATMENT", 610, 626], ["a CH 2 linker afforded", "TREATMENT", 632, 654], ["phenyl ring", "OBSERVATION", 259, 270], ["aromatic ring", "OBSERVATION", 369, 382], ["preserved", "OBSERVATION", 673, 682], ["antiviral activity", "OBSERVATION", 683, 701], ["isosteric relationship", "OBSERVATION", 747, 769]]], ["This thesis was supported by the good alignment of the key elements of 112 when docked over the X-ray crystallographic structure of 111 bound to the enzyme and reflects the specific orientation of 111 in the enzyme in which the plane of the chlorophenyl and azaindazole rings approach orthogonality.", [["chlorophenyl", "CHEMICAL", 241, 253], ["azaindazole", "CHEMICAL", 258, 269], ["chlorophenyl", "CHEMICAL", 241, 253], ["azaindazole", "CHEMICAL", 258, 269], ["chlorophenyl", "SIMPLE_CHEMICAL", 241, 253], ["azaindazole rings", "SIMPLE_CHEMICAL", 258, 275], ["enzyme", "PROTEIN", 149, 155], ["enzyme", "PROTEIN", 208, 214], ["the X-ray crystallographic structure", "TEST", 92, 128], ["the enzyme", "TEST", 145, 155], ["the enzyme", "TEST", 204, 214], ["the chlorophenyl", "TREATMENT", 237, 253], ["azaindazole rings approach orthogonality", "TREATMENT", 258, 298], ["good", "OBSERVATION_MODIFIER", 33, 37], ["alignment", "OBSERVATION_MODIFIER", 38, 47]]], ["The conformational preference for arylmethyl ethers that are devoid of ortho substitution is one in which the MeO moiety is close to coplanarity with the phenyl ring and is rationalized on the basis of a rehybridization of the substituent to maximize electronic overlap between the oxygen lone pair and the \u03c0 system [163] .", [["arylmethyl ethers", "CHEMICAL", 34, 51], ["MeO", "CHEMICAL", 110, 113], ["phenyl", "CHEMICAL", 154, 160], ["oxygen", "CHEMICAL", 282, 288], ["arylmethyl ethers", "CHEMICAL", 34, 51], ["MeO", "CHEMICAL", 110, 113], ["phenyl", "CHEMICAL", 154, 160], ["oxygen", "CHEMICAL", 282, 288], ["arylmethyl ethers", "SIMPLE_CHEMICAL", 34, 51], ["MeO", "SIMPLE_CHEMICAL", 110, 113], ["phenyl ring", "SIMPLE_CHEMICAL", 154, 165], ["oxygen", "SIMPLE_CHEMICAL", 282, 288], ["arylmethyl ethers", "TREATMENT", 34, 51], ["ortho substitution", "TREATMENT", 71, 89], ["the MeO moiety", "TREATMENT", 106, 120], ["the phenyl ring", "TREATMENT", 150, 165], ["a rehybridization of the substituent", "TREATMENT", 202, 238], ["the oxygen lone pair", "TREATMENT", 278, 298]]], ["However, in trifluoromethoxy-and difluoromethoxy-substituted benzenes, the substituent behaves more like an alkyl moiety, projecting orthogonally to the plane of the aromatic ring [165] [166] [167] [168] [169] .", [["trifluoromethoxy-and difluoromethoxy-substituted benzenes", "CHEMICAL", 12, 69], ["alkyl", "CHEMICAL", 108, 113], ["trifluoromethoxy-and difluoromethoxy-substituted benzenes", "CHEMICAL", 12, 69], ["trifluoromethoxy-", "SIMPLE_CHEMICAL", 12, 29], ["difluoromethoxy-substituted benzenes", "SIMPLE_CHEMICAL", 33, 69], ["alkyl moiety", "SIMPLE_CHEMICAL", 108, 120], ["[165] [166] [167] [168] [169]", "SIMPLE_CHEMICAL", 180, 209], ["trifluoromethoxy", "TEST", 12, 28], ["an alkyl moiety", "TREATMENT", 105, 120], ["alkyl moiety", "OBSERVATION", 108, 120], ["aromatic ring", "OBSERVATION", 166, 179]]], ["This conformation is calculated to be energetically favored by~0.5 kcal/mol over the coplanar topography, which contrasts with the 3 kcal/mol preference for planarity calculated for anisole.", [["anisole", "CHEMICAL", 182, 189], ["anisole", "CHEMICAL", 182, 189], ["anisole", "SIMPLE_CHEMICAL", 182, 189], ["the coplanar topography", "TEST", 81, 104], ["the 3 kcal/mol preference", "TREATMENT", 127, 152]]], ["An example where this effect appears to be manifested, at least in part, is provided by the cholesteryl ester transfer protein inhibitor 113, IC 50 \u00bc 1.6 \u03bcM, which is eightfold less potent than the fluorinated analogue 114, IC 50 \u00bc 0.2 \u03bcM, a structure-activity relationship attributed to both the effect of steric presentation of the substituent and a favorable drug-protein interaction [16, 166] .", [["cholesteryl ester", "CHEMICAL", 92, 109], ["cholesteryl ester", "CHEMICAL", 92, 109], ["cholesteryl ester", "SIMPLE_CHEMICAL", 92, 109], ["the cholesteryl ester transfer protein inhibitor", "TREATMENT", 88, 136], ["IC", "TEST", 142, 144], ["the fluorinated analogue", "TEST", 194, 218], ["IC", "TEST", 224, 226], ["the substituent", "PROBLEM", 330, 345], ["less potent", "OBSERVATION_MODIFIER", 177, 188]]], ["In this example, ab initio calculations indicate that while the ethoxy moiety in 113 is more stable when coplanar with the phenyl ring, the substituent in 114 prefers a vector that is closer to perpendicular.", [["ethoxy", "CHEMICAL", 64, 70], ["ethoxy", "CHEMICAL", 64, 70], ["phenyl", "CHEMICAL", 123, 129], ["ethoxy moiety", "SIMPLE_CHEMICAL", 64, 77], ["phenyl ring", "SIMPLE_CHEMICAL", 123, 134], ["ab initio calculations", "TEST", 17, 39], ["the ethoxy moiety", "TEST", 60, 77], ["the phenyl ring", "TREATMENT", 119, 134], ["stable", "OBSERVATION_MODIFIER", 93, 99]]], ["Heteroaryl ethers, in which the substituent is attached to a carbon atom adjacent to a heteroatom, exhibit a topological preference based on lone pairlone pair repulsive interactions, the energetics of which can be considerable and of both significance and utility in drug design [170] [171] [172] [173] [174] .", [["Heteroaryl ethers", "CHEMICAL", 0, 17], ["Heteroaryl ethers", "CHEMICAL", 0, 17], ["carbon", "CHEMICAL", 61, 67], ["Heteroaryl ethers", "SIMPLE_CHEMICAL", 0, 17], ["Heteroaryl ethers", "TREATMENT", 0, 17], ["a carbon atom", "TREATMENT", 59, 72], ["a heteroatom", "TREATMENT", 85, 97], ["lone pairlone pair repulsive interactions", "TREATMENT", 141, 182], ["heteroatom", "OBSERVATION", 87, 97]]], ["The conformational preferences for a series of methoxy-substituted 5-and 6-membered heterocycles based on DFT calculations are summarized in Fig. 22 and reveal that, with the exception of furan and thiophene, the equilibrium is significantly biased for all cases examined [170] .", [["methoxy", "CHEMICAL", 47, 54], ["furan", "CHEMICAL", 188, 193], ["thiophene", "CHEMICAL", 198, 207], ["methoxy", "CHEMICAL", 47, 54], ["furan", "CHEMICAL", 188, 193], ["thiophene", "CHEMICAL", 198, 207], ["methoxy-substituted 5-and 6-membered heterocycles", "SIMPLE_CHEMICAL", 47, 96], ["furan", "SIMPLE_CHEMICAL", 188, 193], ["thiophene", "SIMPLE_CHEMICAL", 198, 207], ["a series of methoxy", "TREATMENT", 35, 54], ["6-membered heterocycles", "TREATMENT", 73, 96], ["DFT calculations", "TEST", 106, 122], ["furan", "TREATMENT", 188, 193], ["thiophene", "TREATMENT", 198, 207]]], ["This preference was used as a design principle to good effect in the identification of the factor Xa inhibitor ZK-807834 (117), a compound that has its origin in the 2,7-dibenzylidenecycloheptanone 115 [171] [172] [173] .", [["ZK-807834", "CHEMICAL", 111, 120], ["2,7-dibenzylidenecycloheptanone", "CHEMICAL", 166, 197], ["ZK-807834", "CHEMICAL", 111, 120], ["2,7-dibenzylidenecycloheptanone", "CHEMICAL", 166, 197], ["Xa", "GENE_OR_GENE_PRODUCT", 98, 100], ["ZK-807834 (117)", "SIMPLE_CHEMICAL", 111, 126], ["2,7-dibenzylidenecycloheptanone 115 [171] [172] [173]", "SIMPLE_CHEMICAL", 166, 219], ["the factor Xa inhibitor", "TEST", 87, 110], ["ZK", "TEST", 111, 113]]], ["The progenitor 115 gave a cause for concern based on the potential for photochemically induced olefin isomerization, prompting conception of the pyridine ether chemotype represented by 116 which was designed based on the conformational analysis summarized in Fig. 23 .", [["olefin", "CHEMICAL", 95, 101], ["pyridine ether", "CHEMICAL", 145, 159], ["olefin", "CHEMICAL", 95, 101], ["pyridine ether", "CHEMICAL", 145, 159], ["progenitor 115", "CELL", 4, 18], ["olefin", "SIMPLE_CHEMICAL", 95, 101], ["pyridine ether chemotype", "SIMPLE_CHEMICAL", 145, 169], ["photochemically induced olefin isomerization", "TREATMENT", 71, 115], ["the pyridine ether chemotype", "TEST", 141, 169], ["the conformational analysis", "TEST", 217, 244], ["olefin isomerization", "OBSERVATION", 95, 115]]], ["ZK-807834 (117) is a potent factor Xa inhibitor, K i \u00bc 0.11 nM, and an X-ray co-crystal structure confirmed the predicted topology for the acyclic amidine-substituted phenyl ether although the ring with the cyclic amidine moiety adopted the less stable conformation [173] .", [["ZK-807834", "CHEMICAL", 0, 9], ["K", "CHEMICAL", 49, 50], ["amidine-substituted phenyl ether", "CHEMICAL", 147, 179], ["amidine", "CHEMICAL", 214, 221], ["ZK-807834", "CHEMICAL", 0, 9], ["acyclic amidine-substituted phenyl ether", "CHEMICAL", 139, 179], ["cyclic amidine", "CHEMICAL", 207, 221], ["ZK-807834", "SIMPLE_CHEMICAL", 0, 9], ["Xa", "GENE_OR_GENE_PRODUCT", 35, 37], ["acyclic amidine-substituted phenyl ether", "SIMPLE_CHEMICAL", 139, 179], ["cyclic amidine moiety", "SIMPLE_CHEMICAL", 207, 228], ["ZK", "TEST", 0, 2], ["a potent factor Xa inhibitor", "PROBLEM", 19, 47], ["K i", "TEST", 49, 52], ["nM", "TEST", 60, 62], ["an X-ray co-crystal structure", "TEST", 68, 97], ["the acyclic amidine", "TREATMENT", 135, 154], ["substituted phenyl ether", "TREATMENT", 155, 179], ["the ring", "TREATMENT", 189, 197], ["the cyclic amidine moiety", "TREATMENT", 203, 228]]], ["Two more recent examples where this phenomenon may be operative are provided by the corticotropin-releasing factor (CRF) antagonist 119, which has potential for the treatment of depression and anxiety, and the GPR119 agonist 121 that promotes postprandial insulin secretion and may be useful for the treatment of diabetes [174, 175] .", [["depression", "DISEASE", 178, 188], ["anxiety", "DISEASE", 193, 200], ["diabetes", "DISEASE", 313, 321], ["corticotropin-releasing factor", "GENE_OR_GENE_PRODUCT", 84, 114], ["CRF", "GENE_OR_GENE_PRODUCT", 116, 119], ["insulin", "GENE_OR_GENE_PRODUCT", 256, 263], ["corticotropin-releasing factor", "PROTEIN", 84, 114], ["this phenomenon", "PROBLEM", 31, 46], ["the corticotropin", "TEST", 80, 97], ["antagonist", "TEST", 121, 131], ["depression", "PROBLEM", 178, 188], ["anxiety", "PROBLEM", 193, 200], ["the GPR119 agonist", "TEST", 206, 224], ["postprandial insulin secretion", "PROBLEM", 243, 273], ["diabetes", "PROBLEM", 313, 321], ["depression", "OBSERVATION", 178, 188]]], ["In both cases, a heteroaryl phenyl ether is employed to mimic the topology inherent to a fused heterocyclic ring system, the pyrrolo In both examples, the favorable effect of the nonbonded lone pair-lone pair interactions may be augmented by intramolecular steric effects afforded by the heteroaryl CH 3 substituent that is manifested as allylic 1,3-strain [174, 175] .", [["heteroaryl phenyl ether", "CHEMICAL", 17, 40], ["pyrrolo", "CHEMICAL", 125, 132], ["heteroaryl CH 3 substituent", "CHEMICAL", 288, 315], ["heteroaryl phenyl ether", "CHEMICAL", 17, 40], ["pyrrolo", "CHEMICAL", 125, 132], ["heteroaryl CH 3", "CHEMICAL", 288, 303], ["heteroaryl phenyl ether", "SIMPLE_CHEMICAL", 17, 40], ["pyrrolo", "SIMPLE_CHEMICAL", 125, 132], ["heteroaryl CH 3 substituent", "SIMPLE_CHEMICAL", 288, 315], ["1,3-strain [174, 175]", "SIMPLE_CHEMICAL", 346, 367], ["a heteroaryl phenyl ether", "TREATMENT", 15, 40], ["a fused heterocyclic ring system", "TREATMENT", 87, 119], ["intramolecular steric effects", "PROBLEM", 242, 271], ["the heteroaryl CH", "TREATMENT", 284, 301], ["favorable", "OBSERVATION_MODIFIER", 155, 164], ["intramolecular steric", "OBSERVATION", 242, 263]]], ["The conformational bias provided by an alkyl substituent bound to a phenyl ring has been used to advantage in the design of the factor Xa inhibitor 123 (Table 11) which is based on the biphenyl prototype 122, in which improved physical properties (lower molecular weight and cLogP) were sought [176] .", [["alkyl substituent", "CHEMICAL", 39, 56], ["phenyl", "CHEMICAL", 68, 74], ["biphenyl", "CHEMICAL", 185, 193], ["phenyl", "CHEMICAL", 68, 74], ["biphenyl", "CHEMICAL", 185, 193], ["phenyl ring", "SIMPLE_CHEMICAL", 68, 79], ["Xa", "GENE_OR_GENE_PRODUCT", 135, 137], ["an alkyl substituent bound", "PROBLEM", 36, 62], ["a phenyl ring", "TREATMENT", 66, 79], ["the factor Xa inhibitor", "TREATMENT", 124, 147], ["the biphenyl prototype", "TEST", 181, 203]]], ["In this example, a cyclopropyl substituent was designed to replace the phenyl ring distal from the methoxyphenyl moiety that engages the enzyme S1 sub-pocket.", [["cyclopropyl", "CHEMICAL", 19, 30], ["methoxyphenyl", "CHEMICAL", 99, 112], ["cyclopropyl", "CHEMICAL", 19, 30], ["phenyl", "CHEMICAL", 71, 77], ["methoxyphenyl", "CHEMICAL", 99, 112], ["cyclopropyl substituent", "SIMPLE_CHEMICAL", 19, 42], ["methoxyphenyl moiety", "SIMPLE_CHEMICAL", 99, 119], ["enzyme S1 sub-pocket", "PROTEIN", 137, 157], ["a cyclopropyl substituent", "TREATMENT", 17, 42], ["the phenyl ring distal", "TREATMENT", 67, 89], ["the methoxyphenyl moiety", "TREATMENT", 95, 119], ["pocket", "OBSERVATION_MODIFIER", 151, 157]]], ["A careful analysis of phenylcyclopropane conformation indicated that for compounds with a benzylic H atom, the cyclopropane ring adopts a conformation designated as bisected (conformation A in Fig. 24 ) that is stabilized by electronic effects associated with overlap of the cyclopropyl carbon-carbon bond orbitals with the \u03c0 system.", [["phenylcyclopropane", "CHEMICAL", 22, 40], ["benzylic H", "CHEMICAL", 90, 100], ["cyclopropane", "CHEMICAL", 111, 123], ["cyclopropyl carbon-carbon", "CHEMICAL", 275, 300], ["phenylcyclopropane", "CHEMICAL", 22, 40], ["benzylic H", "CHEMICAL", 90, 100], ["cyclopropane", "CHEMICAL", 111, 123], ["cyclopropyl carbon-carbon", "CHEMICAL", 275, 300], ["phenylcyclopropane", "SIMPLE_CHEMICAL", 22, 40], ["benzylic H atom", "SIMPLE_CHEMICAL", 90, 105], ["cyclopropane ring", "SIMPLE_CHEMICAL", 111, 128], ["cyclopropyl carbon-carbon bond orbitals", "SIMPLE_CHEMICAL", 275, 314], ["A careful analysis", "TEST", 0, 18], ["phenylcyclopropane conformation", "TREATMENT", 22, 53], ["a benzylic H atom", "TREATMENT", 88, 105], ["the cyclopropane ring", "TREATMENT", 107, 128], ["the cyclopropyl carbon-carbon bond orbitals", "TREATMENT", 271, 314]]], ["However, the introduction of a benzylic substituent alters the preference to favor a perpendicular conformation (conformation B in Fig. 24 ), 0.7 kcal/mol more stable for CH 3 , that would more effectively mimic that of the biphenyl moiety of 122 and project the dimethylamine into the enzyme S4 pocket.", [["biphenyl", "CHEMICAL", 224, 232], ["dimethylamine", "CHEMICAL", 263, 276], ["CH 3", "CHEMICAL", 171, 175], ["biphenyl", "CHEMICAL", 224, 232], ["dimethylamine", "CHEMICAL", 263, 276], ["dimethylamine", "SIMPLE_CHEMICAL", 263, 276], ["conformation B", "PROTEIN", 113, 127], ["enzyme S4 pocket", "PROTEIN", 286, 302], ["a benzylic substituent alters", "TREATMENT", 29, 58], ["a perpendicular conformation", "PROBLEM", 83, 111], ["the biphenyl moiety", "TEST", 220, 239], ["S4 pocket", "OBSERVATION", 293, 302]]], ["Reduction to practice revealed that the phenylcyclopropane 123 is close to an order of magnitude more potent than 122, attributed to optimized hydrophobic interactions with the S4 pocket and slightly reduced strain in the bound geometry, as summarized in Table 11 [176] .", [["phenylcyclopropane 123", "CHEMICAL", 40, 62], ["phenylcyclopropane 123", "CHEMICAL", 40, 62], ["phenylcyclopropane 123", "SIMPLE_CHEMICAL", 40, 62], ["the phenylcyclopropane", "TREATMENT", 36, 58], ["the S4 pocket", "PROBLEM", 173, 186], ["slightly reduced strain in the bound geometry", "PROBLEM", 191, 236], ["hydrophobic interactions", "OBSERVATION", 143, 167], ["S4 pocket", "OBSERVATION", 177, 186], ["slightly", "OBSERVATION_MODIFIER", 191, 199], ["reduced", "OBSERVATION_MODIFIER", 200, 207], ["strain", "OBSERVATION_MODIFIER", 208, 214]]], ["In addition, the phenylcyclopropane 123 exhibits a reduced cLogP (1 log 10 ) and a lower molecular weight that, when combined with the improved potency, affords significant improvements in ligand efficiency (LE), ligand-lipophilicity efficiency (LLE), lipophilicity-corrected ligand efficiency (LELP), and Fsp 3 , the ratio of sp 3 C atoms to the total number of C atoms, all factors that are believed to be associated with increased drug durability in development [121, [177] [178] [179] [180] [181] [182] .", [["phenylcyclopropane 123", "CHEMICAL", 17, 39], ["phenylcyclopropane 123", "CHEMICAL", 17, 39], ["C", "CHEMICAL", 332, 333], ["C", "CHEMICAL", 363, 364], ["phenylcyclopropane 123", "SIMPLE_CHEMICAL", 17, 39], ["Fsp 3", "GENE_OR_GENE_PRODUCT", 306, 311], ["C atoms", "SIMPLE_CHEMICAL", 363, 370], ["the phenylcyclopropane", "TEST", 13, 35], ["a reduced cLogP", "PROBLEM", 49, 64], ["a lower molecular weight", "PROBLEM", 81, 105], ["lipophilicity", "TEST", 252, 265], ["corrected ligand efficiency", "PROBLEM", 266, 293], ["LELP", "TEST", 295, 299], ["Fsp", "TEST", 306, 309], ["increased drug durability", "PROBLEM", 424, 449], ["ligand efficiency", "OBSERVATION", 189, 206], ["lipophilicity efficiency", "OBSERVATION", 220, 244], ["LLE", "ANATOMY", 246, 249], ["ligand efficiency", "OBSERVATION", 276, 293], ["increased", "OBSERVATION_MODIFIER", 424, 433], ["drug durability", "OBSERVATION", 434, 449]]], ["The bicyclo[1.1.1]pentane moiety is another isostere that mimics the conformation of a phenyl ring while simultaneously reducing lipophilicity and increasing Fsp 3 .", [["bicyclo[1.1.1]pentane", "CHEMICAL", 4, 25], ["bicyclo[1.1.1]pentane", "CHEMICAL", 4, 25], ["phenyl", "CHEMICAL", 87, 93], ["Fsp 3", "CHEMICAL", 158, 163], ["bicyclo[1.1.1]pentane", "SIMPLE_CHEMICAL", 4, 25], ["isostere", "SIMPLE_CHEMICAL", 44, 52], ["phenyl ring", "SIMPLE_CHEMICAL", 87, 98], ["Fsp 3", "GENE_OR_GENE_PRODUCT", 158, 163], ["The bicyclo[1.1.1]pentane moiety", "TREATMENT", 0, 32], ["a phenyl ring", "TREATMENT", 85, 98], ["simultaneously reducing lipophilicity", "PROBLEM", 105, 142], ["increasing Fsp", "PROBLEM", 147, 161], ["phenyl ring", "OBSERVATION", 87, 98]]], ["This moiety originally demonstrated value in the context of the glutamate antagonists 124-126 but more recently has found utility in inhibitors of the amyloid precursor protein processing enzyme \u03b3-secretase 127 and 128 [183] [184] [185] [186] .", [["glutamate", "CHEMICAL", 64, 73], ["124-126", "CHEMICAL", 86, 93], ["glutamate", "CHEMICAL", 64, 73], ["glutamate", "SIMPLE_CHEMICAL", 64, 73], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 151, 176], ["amyloid precursor protein", "PROTEIN", 151, 176], ["the glutamate antagonists", "TEST", 60, 85], ["the amyloid precursor", "TEST", 147, 168], ["enzyme \u03b3-secretase", "TEST", 188, 206]]], ["The presentation of the two key vectors by the bicyclo[1.1.1]pentane ring faithfully reproduces that of the para-substituents of a phenyl ring, but the dimensions are such that the distance between the substituents is~1 \u00c5 shorter, as captured in Fig. 25 [186] .", [["bicyclo[1.1.1]pentane", "CHEMICAL", 47, 68], ["phenyl", "CHEMICAL", 131, 137], ["bicyclo[1.1.1]pentane", "CHEMICAL", 47, 68], ["phenyl", "CHEMICAL", 131, 137], ["bicyclo[1.1.1]pentane", "SIMPLE_CHEMICAL", 47, 68], ["phenyl ring", "SIMPLE_CHEMICAL", 131, 142], ["the bicyclo[1.1.1]pentane ring", "TREATMENT", 43, 73], ["a phenyl ring", "TREATMENT", 129, 142], ["phenyl ring", "OBSERVATION", 131, 142], ["substituents", "OBSERVATION_MODIFIER", 202, 214]]], ["In the case of the glutamate antagonist 125, a mimic of 124, this could readily be compensated by deploying the larger tetrazole as a carboxylic acid isostere, although the result was less than impressive [183] [184] [185] .", [["glutamate", "CHEMICAL", 19, 28], ["tetrazole", "CHEMICAL", 119, 128], ["carboxylic acid", "CHEMICAL", 134, 149], ["glutamate", "CHEMICAL", 19, 28], ["tetrazole", "CHEMICAL", 119, 128], ["carboxylic acid", "CHEMICAL", 134, 149], ["glutamate", "SIMPLE_CHEMICAL", 19, 28], ["tetrazole", "SIMPLE_CHEMICAL", 119, 128], ["carboxylic acid", "SIMPLE_CHEMICAL", 134, 149], ["the glutamate antagonist", "TEST", 15, 39], ["the larger tetrazole", "TREATMENT", 108, 128], ["a carboxylic acid isostere", "TEST", 132, 158]]], ["However, the propellane-based \u03b3-secretase inhibitor 128 is an effective mimic of the phenyl analogue 127 without resort to additional structural adjustment and this compound offers improved solubility, membrane permeability, and metabolic stability in HLM than the progenitor, data summarized in Table 12 [186] .", [["membrane", "ANATOMY", 202, 210], ["progenitor", "ANATOMY", 265, 275], ["propellane", "CHEMICAL", 13, 23], ["\u03b3-secretase inhibitor 128", "CHEMICAL", 30, 55], ["propellane", "CHEMICAL", 13, 23], ["phenyl", "CHEMICAL", 85, 91], ["propellane", "SIMPLE_CHEMICAL", 13, 23], ["\u03b3-secretase", "SIMPLE_CHEMICAL", 30, 41], ["phenyl analogue 127", "SIMPLE_CHEMICAL", 85, 104], ["membrane", "CELLULAR_COMPONENT", 202, 210], ["progenitor", "CELL", 265, 275], ["the propellane-based \u03b3-secretase inhibitor", "TEST", 9, 51], ["the phenyl analogue", "TEST", 81, 100], ["membrane permeability", "TEST", 202, 223], ["metabolic stability", "OBSERVATION", 229, 248]]], ["Moreover, 128 is less lipophilic, ElogD \u00bc 3.8 compared to 4.7 for 127, LLE increases from 4.76 to 6.55, and the introduction of five additional sp 3 carbon atoms more than doubles Fsp 3 from 0.25 to 0.53 [186] .", [["ElogD", "CHEMICAL", 34, 39], ["carbon", "CHEMICAL", 149, 155], ["Fsp 3", "CHEMICAL", 180, 185], ["ElogD", "TEST", 34, 39], ["LLE", "TEST", 71, 74], ["five additional sp 3 carbon atoms", "TREATMENT", 128, 161], ["doubles Fsp", "TEST", 172, 183], ["less lipophilic", "OBSERVATION_MODIFIER", 17, 32], ["LLE", "ANATOMY", 71, 74]]], ["HOIsosteres to Modulate Permeability and P-Glycoprotein RecognitionThe substitution of a H atom ortho to the anilide NH by a fluorine in the two closely related series of factor Xa inhibitors 129-132 and 133-135 resulted in improved Caco-2 cell permeability, as summarized in Table 13 [187, 188] .", [["Caco-2 cell", "ANATOMY", 233, 244], ["H", "CHEMICAL", 89, 90], ["anilide NH", "CHEMICAL", 109, 119], ["fluorine", "CHEMICAL", 125, 133], ["129-132 and 133-135", "CHEMICAL", 192, 211], ["H", "CHEMICAL", 89, 90], ["anilide NH", "CHEMICAL", 109, 119], ["fluorine", "CHEMICAL", 125, 133], ["HOIsosteres", "SIMPLE_CHEMICAL", 0, 11], ["H atom ortho", "SIMPLE_CHEMICAL", 89, 101], ["anilide NH", "SIMPLE_CHEMICAL", 109, 119], ["fluorine", "SIMPLE_CHEMICAL", 125, 133], ["factor Xa inhibitors 129-132", "SIMPLE_CHEMICAL", 171, 199], ["133-135", "SIMPLE_CHEMICAL", 204, 211], ["Caco-2 cell", "CELL", 233, 244], ["a H atom ortho", "TREATMENT", 87, 101], ["a fluorine", "TREATMENT", 123, 133], ["factor Xa inhibitors", "TEST", 171, 191], ["cell permeability", "OBSERVATION", 240, 257]]], ["The observed increase in permeability for 130, 132, and 134 compared to the corresponding unsubstituted analogues 129, 131, and 133, respectively, may be due to an effective masking of the H-bond donor properties of the anilide NH by association with the electronegative F atom in an electrostatic interaction [133, 189, 190] .", [["anilide", "CHEMICAL", 220, 227], ["H", "CHEMICAL", 189, 190], ["anilide NH", "CHEMICAL", 220, 230], ["F", "CHEMICAL", 271, 272], ["anilide NH", "SIMPLE_CHEMICAL", 220, 230], ["F atom", "SIMPLE_CHEMICAL", 271, 277], ["the corresponding unsubstituted analogues", "TEST", 72, 113], ["the H-bond donor properties", "TREATMENT", 185, 212], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["permeability", "OBSERVATION_MODIFIER", 25, 37], ["may be due to", "UNCERTAINTY", 147, 160], ["effective", "OBSERVATION", 164, 173]]], ["In contrast, an ortho nitrile substituent in the aminobenzisoxazole chemotype afforded a compound 135 with significantly reduced permeability, presumably a function of increased acidity and H-bond donor capacity of the NH while geometrical constraints prevent the linear cyanide moiety from establishing an intramolecular H-bond.", [["ortho nitrile", "CHEMICAL", 16, 29], ["aminobenzisoxazole", "CHEMICAL", 49, 67], ["H", "CHEMICAL", 190, 191], ["cyanide", "CHEMICAL", 271, 278], ["ortho nitrile", "CHEMICAL", 16, 29], ["aminobenzisoxazole", "CHEMICAL", 49, 67], ["H", "CHEMICAL", 190, 191], ["NH", "CHEMICAL", 219, 221], ["cyanide", "CHEMICAL", 271, 278], ["H", "CHEMICAL", 322, 323], ["ortho nitrile substituent", "SIMPLE_CHEMICAL", 16, 41], ["aminobenzisoxazole chemotype", "SIMPLE_CHEMICAL", 49, 77], ["NH", "SIMPLE_CHEMICAL", 219, 221], ["cyanide moiety", "SIMPLE_CHEMICAL", 271, 285], ["an ortho nitrile substituent", "TREATMENT", 13, 41], ["the aminobenzisoxazole chemotype", "TREATMENT", 45, 77], ["significantly reduced permeability", "PROBLEM", 107, 141], ["increased acidity", "PROBLEM", 168, 185], ["H-bond donor capacity of the NH", "TREATMENT", 190, 221], ["the linear cyanide moiety", "TREATMENT", 260, 285], ["increased", "OBSERVATION_MODIFIER", 168, 177], ["acidity", "OBSERVATION", 178, 185]]], ["The presence of a fluorine atom capable of engaging an amide or sulfonamide N-H in an electrostatic interaction has emerged as a common structural motif, particularly in kinase inhibitors, and may contribute to improved oral exposure, as illustrated by the matched pair comparisons between 136 and 137 and 138 and 139 that are compiled in Table 14 [191, 192] .Isosteres to Modulate Permeability and P-Glycoprotein RecognitionIntramolecular H-bond capture by a pendent F atom was exploited to reduce P-glycoprotein (P-gp)-mediated brain efflux in a series of \u03b2-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors [193] [194] [195] .", [["oral", "ANATOMY", 220, 224], ["brain", "ANATOMY", 530, 535], ["fluorine", "CHEMICAL", 18, 26], ["sulfonamide", "CHEMICAL", 64, 75], ["N-H", "CHEMICAL", 76, 79], ["fluorine", "CHEMICAL", 18, 26], ["amide", "CHEMICAL", 55, 60], ["sulfonamide", "CHEMICAL", 64, 75], ["N-H", "CHEMICAL", 76, 79], ["H", "CHEMICAL", 440, 441], ["F", "CHEMICAL", 468, 469], ["fluorine atom", "SIMPLE_CHEMICAL", 18, 31], ["sulfonamide N-H", "SIMPLE_CHEMICAL", 64, 79], ["oral", "ORGANISM_SUBDIVISION", 220, 224], ["Isosteres", "SIMPLE_CHEMICAL", 360, 369], ["F atom", "SIMPLE_CHEMICAL", 468, 474], ["brain", "ORGAN", 530, 535], ["amyloid precursor protein cleaving enzyme", "GENE_OR_GENE_PRODUCT", 565, 606], ["BACE1", "GENE_OR_GENE_PRODUCT", 608, 613], ["P-glycoprotein (P-gp", "PROTEIN", 499, 519], ["\u03b2-site amyloid precursor protein cleaving enzyme", "PROTEIN", 558, 606], ["BACE1", "PROTEIN", 608, 613], ["a fluorine atom", "TREATMENT", 16, 31], ["engaging an amide", "TREATMENT", 43, 60], ["sulfonamide", "TREATMENT", 64, 75], ["a common structural motif", "PROBLEM", 127, 152], ["kinase inhibitors", "TREATMENT", 170, 187], ["Isosteres", "TREATMENT", 360, 369], ["a pendent F atom", "TREATMENT", 458, 474], ["mediated brain efflux", "PROBLEM", 521, 542], ["a series of \u03b2-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors", "TREATMENT", 546, 625], ["brain", "ANATOMY", 530, 535], ["efflux", "OBSERVATION", 536, 542]]], ["The prototype BACE1 inhibitor 140 presented in Table 15 exhibited a large efflux ratio in cell lines expressing human or rat P-gp while analogues 141 and 142 show improved permeability properties, attributed to an intramolecular interaction between the F atom in the amide cap moiety and the NH, consistent with P-gp substrate recognition that relies upon protein-drug H-bonding [193] [194] [195] [196] [197] .Isosteres to Modulate Permeability and P-Glycoprotein RecognitionA similar tactical approach provided a solution to improved membrane in the series of CNS-penetrant bradykinin B1 antagonists 143-146 compiled in Table 16 which were explored as potential agents for the relief of pain [198] .", [["cell lines", "ANATOMY", 90, 100], ["membrane", "ANATOMY", 535, 543], ["analogues 141 and 142", "CHEMICAL", 136, 157], ["bradykinin", "CHEMICAL", 575, 585], ["143-146", "CHEMICAL", 601, 608], ["pain", "DISEASE", 688, 692], ["F", "CHEMICAL", 253, 254], ["amide", "CHEMICAL", 267, 272], ["NH", "CHEMICAL", 292, 294], ["BACE1", "GENE_OR_GENE_PRODUCT", 14, 19], ["cell lines", "CELL", 90, 100], ["human", "ORGANISM", 112, 117], ["rat", "ORGANISM", 121, 124], ["P-gp", "GENE_OR_GENE_PRODUCT", 125, 129], ["F atom", "SIMPLE_CHEMICAL", 253, 259], ["NH", "SIMPLE_CHEMICAL", 292, 294], ["H-bonding [193] [194] [195] [196] [197]", "SIMPLE_CHEMICAL", 369, 408], ["Isosteres", "SIMPLE_CHEMICAL", 410, 419], ["membrane", "CELLULAR_COMPONENT", 535, 543], ["CNS", "ANATOMICAL_SYSTEM", 561, 564], ["bradykinin B1", "SIMPLE_CHEMICAL", 575, 588], ["BACE1", "PROTEIN", 14, 19], ["cell lines", "CELL_LINE", 90, 100], ["human or rat P-gp", "PROTEIN", 112, 129], ["P", "PROTEIN", 312, 313], ["human", "SPECIES", 112, 117], ["rat", "SPECIES", 121, 124], ["human", "SPECIES", 112, 117], ["The prototype BACE1 inhibitor", "TREATMENT", 0, 29], ["a large efflux ratio", "PROBLEM", 66, 86], ["cell lines", "TREATMENT", 90, 100], ["analogues", "TEST", 136, 145], ["improved permeability properties", "PROBLEM", 163, 195], ["an intramolecular interaction", "PROBLEM", 211, 240], ["the amide cap moiety", "TREATMENT", 263, 283], ["Isosteres", "TREATMENT", 410, 419], ["Modulate Permeability", "TREATMENT", 423, 444], ["P-Glycoprotein RecognitionA", "TREATMENT", 449, 476], ["a solution", "TREATMENT", 512, 522], ["CNS-penetrant bradykinin B1 antagonists", "TREATMENT", 561, 600], ["pain", "PROBLEM", 688, 692], ["large", "OBSERVATION_MODIFIER", 68, 73], ["efflux ratio", "OBSERVATION", 74, 86], ["cell lines", "OBSERVATION", 90, 100], ["intramolecular", "OBSERVATION", 214, 228], ["Permeability", "OBSERVATION_MODIFIER", 432, 444], ["CNS", "ANATOMY", 561, 564]]], ["The introduction of F atoms into the amide moiety resulted in improved passive permeability and reduced P-gp efflux ratios, attributed to a reduction in the strength of the carbonyl marked with an asterisk (*) to act as a H-bond acceptor [198] .", [["F atoms", "CHEMICAL", 20, 27], ["carbonyl", "CHEMICAL", 173, 181], ["F", "CHEMICAL", 20, 21], ["amide", "CHEMICAL", 37, 42], ["carbonyl", "CHEMICAL", 173, 181], ["H", "CHEMICAL", 222, 223], ["F atoms", "SIMPLE_CHEMICAL", 20, 27], ["carbonyl", "SIMPLE_CHEMICAL", 173, 181], ["The introduction of F atoms into the amide moiety", "TREATMENT", 0, 49], ["improved passive permeability", "PROBLEM", 62, 91], ["reduced P-gp efflux ratios", "PROBLEM", 96, 122], ["a reduction", "PROBLEM", 138, 149], ["improved", "OBSERVATION_MODIFIER", 62, 70], ["passive permeability", "OBSERVATION", 71, 91], ["reduced", "OBSERVATION_MODIFIER", 96, 103], ["reduction", "OBSERVATION_MODIFIER", 140, 149]]], ["However, an intramolecular interaction between the F atoms and the NH may also be contributory.Isosteres to Modulate Permeability and P-Glycoprotein RecognitionThe alternative topology depicted in Fig. 26 offers the potential for a similar electrostatic interaction between the ortho-F atom and the benzamide NH and this structural element is also prevalent in drug design [133, 189] .", [["ortho-F atom", "CHEMICAL", 278, 290], ["benzamide", "CHEMICAL", 299, 308], ["F", "CHEMICAL", 51, 52], ["NH", "CHEMICAL", 67, 69], ["ortho-F", "CHEMICAL", 278, 285], ["benzamide", "CHEMICAL", 299, 308], ["NH", "CHEMICAL", 309, 311], ["F atoms", "SIMPLE_CHEMICAL", 51, 58], ["Isosteres", "SIMPLE_CHEMICAL", 95, 104], ["ortho-F atom", "SIMPLE_CHEMICAL", 278, 290], ["benzamide NH", "SIMPLE_CHEMICAL", 299, 311], ["Isosteres", "TREATMENT", 95, 104], ["the benzamide NH", "TREATMENT", 295, 311], ["intramolecular", "OBSERVATION", 12, 26], ["may also be", "UNCERTAINTY", 70, 81], ["Permeability", "OBSERVATION_MODIFIER", 117, 129]]], ["The potent tachykinin hNK 2 receptor antagonist 147 (Table 17 ) exhibited poor membrane permeability across a confluent Caco-2 cell layer, attributed to the polar amide NH moiety which was critical for potency and could not be modified by methylation or replaced by an isostere [199] .", [["membrane", "ANATOMY", 79, 87], ["Caco-2 cell layer", "ANATOMY", 120, 137], ["tachykinin", "CHEMICAL", 11, 21], ["NH", "CHEMICAL", 169, 171], ["amide", "CHEMICAL", 163, 168], ["NH", "CHEMICAL", 169, 171], ["tachykinin hNK 2", "GENE_OR_GENE_PRODUCT", 11, 27], ["membrane", "CELLULAR_COMPONENT", 79, 87], ["Caco-2 cell layer", "CELL", 120, 137], ["polar amide NH moiety", "SIMPLE_CHEMICAL", 157, 178], ["The potent tachykinin hNK", "TEST", 0, 25], ["receptor antagonist", "TEST", 28, 47], ["poor membrane permeability", "PROBLEM", 74, 100], ["a confluent Caco-2 cell layer", "PROBLEM", 108, 137], ["the polar amide NH moiety", "TREATMENT", 153, 178], ["membrane permeability", "OBSERVATION", 79, 100], ["confluent", "OBSERVATION_MODIFIER", 110, 119], ["cell layer", "OBSERVATION", 127, 137]]], ["A halogen atom was introduced ortho to the amide carbonyl moiety to establish an intramolecular interaction with the NH, described as a H-bond with the fluoro derivative 149, that resulted in improved permeability across a parallel artificial membrane (PAMPA) or a Caco-2 cell layer while a Cl substituent (148) was less effective but still superior to H. In this context, the ortho-F substituent in 149 performed somewhat similarly to the nitrogen atom of pyridine 151 which offers a more conventional H-bonding opportunity and markedly improved permeability in both assays compared to the analogous phenyl derivative 150 [199] .", [["membrane", "ANATOMY", 243, 251], ["Caco-2 cell layer", "ANATOMY", 265, 282], ["NH", "CHEMICAL", 117, 119], ["H", "CHEMICAL", 136, 137], ["fluoro derivative 149", "CHEMICAL", 152, 173], ["Cl", "CHEMICAL", 291, 293], ["ortho-F substituent", "CHEMICAL", 377, 396], ["pyridine 151", "CHEMICAL", 457, 469], ["halogen", "CHEMICAL", 2, 9], ["amide carbonyl", "CHEMICAL", 43, 57], ["NH", "CHEMICAL", 117, 119], ["H", "CHEMICAL", 136, 137], ["fluoro", "CHEMICAL", 152, 158], ["Cl", "CHEMICAL", 291, 293], ["ortho-F", "CHEMICAL", 377, 384], ["nitrogen", "CHEMICAL", 440, 448], ["pyridine", "CHEMICAL", 457, 465], ["H", "CHEMICAL", 503, 504], ["phenyl", "CHEMICAL", 601, 607], ["halogen atom", "SIMPLE_CHEMICAL", 2, 14], ["ortho", "SIMPLE_CHEMICAL", 30, 35], ["amide carbonyl moiety", "SIMPLE_CHEMICAL", 43, 64], ["NH", "SIMPLE_CHEMICAL", 117, 119], ["fluoro derivative 149", "SIMPLE_CHEMICAL", 152, 173], ["membrane", "CELLULAR_COMPONENT", 243, 251], ["PAMPA", "SIMPLE_CHEMICAL", 253, 258], ["Cl substituent", "SIMPLE_CHEMICAL", 291, 305], ["ortho-F substituent", "SIMPLE_CHEMICAL", 377, 396], ["pyridine 151", "SIMPLE_CHEMICAL", 457, 469], ["A halogen atom", "TREATMENT", 0, 14], ["the amide carbonyl moiety", "TREATMENT", 39, 64], ["the fluoro derivative", "TEST", 148, 169], ["a Caco-2 cell layer", "PROBLEM", 263, 282], ["a Cl substituent", "TEST", 289, 305], ["the ortho-F substituent", "TEST", 373, 396], ["the nitrogen atom of pyridine", "TREATMENT", 436, 465], ["the analogous phenyl derivative", "TREATMENT", 587, 618], ["intramolecular", "OBSERVATION", 81, 95], ["improved", "OBSERVATION_MODIFIER", 192, 200], ["permeability", "OBSERVATION", 201, 213], ["improved", "OBSERVATION_MODIFIER", 538, 546], ["permeability", "OBSERVATION_MODIFIER", 547, 559]]], ["The ortho-F atom in the antiandrogen enzalutamide (152) , which was approved for the treatment of castration-resistant prostate cancer by the FDA in August 2012, may contribute to its excellent pharmacokinetic profile [200, 201] .", [["prostate cancer", "ANATOMY", 119, 134], ["ortho-F atom", "CHEMICAL", 4, 16], ["enzalutamide", "CHEMICAL", 37, 49], ["prostate cancer", "DISEASE", 119, 134], ["ortho-F", "CHEMICAL", 4, 11], ["enzalutamide", "CHEMICAL", 37, 49], ["ortho-F atom", "SIMPLE_CHEMICAL", 4, 16], ["antiandrogen", "SIMPLE_CHEMICAL", 24, 36], ["enzalutamide", "SIMPLE_CHEMICAL", 37, 49], ["prostate cancer", "CANCER", 119, 134], ["the antiandrogen enzalutamide", "TREATMENT", 20, 49], ["castration", "TREATMENT", 98, 108], ["resistant prostate cancer", "PROBLEM", 109, 134], ["resistant", "OBSERVATION_MODIFIER", 109, 118], ["prostate", "ANATOMY", 119, 127], ["cancer", "OBSERVATION", 128, 134]]], ["A similar motif is presented by ZD-9331 (153), a fluorinated methotrexate analogue which exhibits activity toward ovarian cancer cells resistant to classical thymidylate synthase inhibitors [202, 203] .", [["ovarian cancer cells", "ANATOMY", 114, 134], ["ZD-9331", "CHEMICAL", 32, 39], ["methotrexate", "CHEMICAL", 61, 73], ["ovarian cancer", "DISEASE", 114, 128], ["thymidylate", "CHEMICAL", 158, 169], ["ZD-9331", "CHEMICAL", 32, 39], ["methotrexate", "CHEMICAL", 61, 73], ["ZD-9331", "SIMPLE_CHEMICAL", 32, 39], ["methotrexate", "SIMPLE_CHEMICAL", 61, 73], ["ovarian cancer cells", "CELL", 114, 134], ["thymidylate synthase", "GENE_OR_GENE_PRODUCT", 158, 178], ["ovarian cancer cells", "CELL_TYPE", 114, 134], ["classical thymidylate synthase", "PROTEIN", 148, 178], ["ZD", "TEST", 32, 34], ["a fluorinated methotrexate analogue", "TREATMENT", 47, 82], ["ovarian cancer cells", "PROBLEM", 114, 134], ["classical thymidylate synthase inhibitors", "TREATMENT", 148, 189], ["ovarian", "ANATOMY", 114, 121], ["cancer", "OBSERVATION", 122, 128]]], ["Fig. 26 The orthofluorinated benzamide motifIsosteres to Modulate Permeability and P-Glycoprotein RecognitionThe Influence of Bioisosteres in Drug Design: Tactical Applications to. . .", [["benzamide", "CHEMICAL", 29, 38], ["orthofluorinated benzamide motifIsosteres", "CHEMICAL", 12, 53], ["orthofluorinated benzamide motifIsosteres", "SIMPLE_CHEMICAL", 12, 53], ["The orthofluorinated benzamide motifIsosteres", "TREATMENT", 8, 53], ["Modulate Permeability", "TREATMENT", 57, 78], ["Tactical Applications", "TREATMENT", 155, 176]]], ["Another productive F-NH relationship that exerts a beneficial effect on Caco-2 permeability and efflux ratio is provided by the series of cyclic benzamidine-based BACE1 inhibitors 154-157 (compiled in Table 18 ) [204] .", [["cyclic benzamidine", "CHEMICAL", 138, 156], ["154-157", "CHEMICAL", 180, 187], ["F-NH", "CHEMICAL", 19, 23], ["cyclic benzamidine", "CHEMICAL", 138, 156], ["F-NH", "SIMPLE_CHEMICAL", 19, 23], ["Caco-2", "GENE_OR_GENE_PRODUCT", 72, 78], ["cyclic benzamidine", "SIMPLE_CHEMICAL", 138, 156], ["BACE1", "GENE_OR_GENE_PRODUCT", 163, 168], ["BACE1", "PROTEIN", 163, 168], ["Caco", "TEST", 72, 76], ["efflux ratio", "TEST", 96, 108], ["cyclic benzamidine", "TREATMENT", 138, 156], ["BACE1 inhibitors", "TEST", 163, 179], ["productive", "OBSERVATION_MODIFIER", 8, 18]]], ["The prototype compound 154 exhibited significant basicity, poor membrane permeability, and a high efflux ratio predictive of the molecule being a P-glycoprotein substrate which was anticipated to further contribute to reduced brain exposure.", [["membrane", "ANATOMY", 64, 72], ["brain", "ANATOMY", 226, 231], ["compound 154", "CHEMICAL", 14, 26], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["brain", "ORGAN", 226, 231], ["P-glycoprotein substrate", "PROTEIN", 146, 170], ["The prototype compound", "TEST", 0, 22], ["significant basicity", "PROBLEM", 37, 57], ["poor membrane permeability", "PROBLEM", 59, 85], ["a high efflux ratio", "PROBLEM", 91, 110], ["the molecule", "PROBLEM", 125, 137], ["a P-glycoprotein substrate", "PROBLEM", 144, 170], ["reduced brain exposure", "PROBLEM", 218, 240], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["basicity", "OBSERVATION", 49, 57], ["poor membrane permeability", "OBSERVATION", 59, 85], ["high efflux", "OBSERVATION", 93, 104], ["reduced brain exposure", "OBSERVATION", 218, 240]]], ["A key step toward solving the problem was the introduction of a fluorine atom ortho to the amidine moiety to afford 155, a compound with a pK a that is reduced by 1.3 units that exhibits improved Caco-2 permeability and a reduced efflux ratio while preserving BACE1 inhibitory activity.", [["fluorine", "CHEMICAL", 64, 72], ["amidine", "CHEMICAL", 91, 98], ["fluorine", "CHEMICAL", 64, 72], ["amidine", "CHEMICAL", 91, 98], ["fluorine atom ortho", "SIMPLE_CHEMICAL", 64, 83], ["amidine moiety", "SIMPLE_CHEMICAL", 91, 105], ["Caco-2", "SIMPLE_CHEMICAL", 196, 202], ["BACE1", "GENE_OR_GENE_PRODUCT", 260, 265], ["BACE1", "PROTEIN", 260, 265], ["a fluorine atom ortho", "TREATMENT", 62, 83], ["the amidine moiety", "TREATMENT", 87, 105], ["a reduced efflux ratio", "PROBLEM", 220, 242], ["improved", "OBSERVATION_MODIFIER", 187, 195], ["Caco", "OBSERVATION", 196, 200], ["reduced", "OBSERVATION_MODIFIER", 222, 229], ["efflux ratio", "OBSERVATION", 230, 242]]], ["A similar effect was observed between the matched pairs 156 and 157 in which the F atom is believed to form a weak H-bond with the NH while calculations indicated that the solvation energy of the fluorinated derivative is less negative than for the H analogue, electronic and steric effects that shield the polar nitrogen atom which thus presents less than 2 H-bond donors to the environment [204] .Isosteres of Guanidines and AmidinesThe high basicity associated with guanidine and amidine moieties limits the fraction of the more permeable unprotonated form that exists at physiological pH, providing an understanding for the generally poor permeability associated with molecules incorporating these structural elements [205, 206] .", [["H", "CHEMICAL", 249, 250], ["Guanidines", "CHEMICAL", 412, 422], ["Amidines", "CHEMICAL", 427, 435], ["guanidine", "CHEMICAL", 469, 478], ["amidine", "CHEMICAL", 483, 490], ["F", "CHEMICAL", 81, 82], ["H", "CHEMICAL", 115, 116], ["NH", "CHEMICAL", 131, 133], ["H", "CHEMICAL", 249, 250], ["nitrogen", "CHEMICAL", 313, 321], ["H", "CHEMICAL", 359, 360], ["Guanidines", "CHEMICAL", 412, 422], ["Amidines", "CHEMICAL", 427, 435], ["guanidine", "CHEMICAL", 469, 478], ["amidine", "CHEMICAL", 483, 490], ["Guanidines", "SIMPLE_CHEMICAL", 412, 422], ["Amidines", "SIMPLE_CHEMICAL", 427, 435], ["guanidine", "SIMPLE_CHEMICAL", 469, 478], ["amidine moieties", "SIMPLE_CHEMICAL", 483, 499], ["the H analogue", "PROBLEM", 245, 259], ["electronic and steric effects", "TREATMENT", 261, 290], ["the polar nitrogen atom", "PROBLEM", 303, 326], ["Guanidines", "TREATMENT", 412, 422], ["Amidines", "TREATMENT", 427, 435], ["guanidine and amidine moieties", "TREATMENT", 469, 499], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["effect", "OBSERVATION", 10, 16], ["high basicity", "OBSERVATION_MODIFIER", 439, 452]]], ["The prevalence of arginine as the P1 moiety of substrates of the serine protease enzymes that constitute the coagulation cascade has catalyzed the identification of guanidine and amidine surrogates as part of the effort to identify potent, selective, and orally bioavailable inhibitors that offer potential as antithrombotic agents [207] [208] [209] [210] .", [["arginine", "CHEMICAL", 18, 26], ["guanidine", "CHEMICAL", 165, 174], ["amidine", "CHEMICAL", 179, 186], ["arginine", "CHEMICAL", 18, 26], ["serine", "CHEMICAL", 65, 71], ["guanidine", "CHEMICAL", 165, 174], ["amidine", "CHEMICAL", 179, 186], ["arginine", "AMINO_ACID", 18, 26], ["guanidine", "SIMPLE_CHEMICAL", 165, 174], ["amidine", "SIMPLE_CHEMICAL", 179, 186], ["serine protease enzymes", "PROTEIN", 65, 88], ["arginine", "TREATMENT", 18, 26], ["the serine protease enzymes", "TREATMENT", 61, 88], ["the coagulation cascade", "TEST", 105, 128], ["guanidine", "TREATMENT", 165, 174], ["amidine surrogates", "TREATMENT", 179, 197], ["orally bioavailable inhibitors", "TREATMENT", 255, 285], ["antithrombotic agents", "TREATMENT", 310, 331]]], ["The pK a of a substituted guanidine moiety can be reduced significantly from the typical 13-14 range by modification to an acylguanidine, pK a~8 , or an oxyguanidine, pK a~7 -7.5, both of which represent isosteric replacements of a methylene moiety.", [["guanidine", "CHEMICAL", 26, 35], ["acylguanidine", "CHEMICAL", 123, 136], ["oxyguanidine", "CHEMICAL", 153, 165], ["methylene", "CHEMICAL", 232, 241], ["guanidine", "CHEMICAL", 26, 35], ["acylguanidine", "CHEMICAL", 123, 136], ["oxyguanidine", "CHEMICAL", 153, 165], ["methylene", "CHEMICAL", 232, 241], ["guanidine moiety", "SIMPLE_CHEMICAL", 26, 42], ["acylguanidine", "SIMPLE_CHEMICAL", 123, 136], ["oxyguanidine", "SIMPLE_CHEMICAL", 153, 165], ["methylene moiety", "SIMPLE_CHEMICAL", 232, 248], ["a substituted guanidine moiety", "TREATMENT", 12, 42], ["an acylguanidine", "TREATMENT", 120, 136], ["an oxyguanidine", "TEST", 150, 165], ["pK", "TEST", 167, 169], ["isosteric replacements", "TREATMENT", 204, 226], ["a methylene moiety", "TREATMENT", 230, 248], ["isosteric replacements", "OBSERVATION", 204, 226], ["methylene moiety", "OBSERVATION", 232, 248]]], ["However, these modifications have the potential to significantly affect molecular recognition that may be manifested as a reduction in potency, depending on the circumstance under study.", [["a reduction in potency", "PROBLEM", 120, 142], ["may be", "UNCERTAINTY", 99, 105], ["reduction", "OBSERVATION_MODIFIER", 122, 131]]], ["Nevertheless, acylguanidines have been successfully deployed in a series of histamine H 2 agonists and NPY Y2 antagonists while an oxyguanidine moiety has proven to be an effective surrogate of arginine in thrombin inhibitors, with RWJ-671818 (158) a representative compound that was advanced into phase 1 clinical trials [211] [212] [213] [214] [215] [216] [217] [218] .", [["acylguanidines", "CHEMICAL", 14, 28], ["histamine", "CHEMICAL", 76, 85], ["oxyguanidine", "CHEMICAL", 131, 143], ["arginine", "CHEMICAL", 194, 202], ["RWJ-671818", "CHEMICAL", 232, 242], ["acylguanidines", "CHEMICAL", 14, 28], ["histamine", "CHEMICAL", 76, 85], ["oxyguanidine", "CHEMICAL", 131, 143], ["arginine", "CHEMICAL", 194, 202], ["RWJ-671818", "CHEMICAL", 232, 242], ["[211] [212] [213] [214] [215] [216] [217]", "CHEMICAL", 322, 363], ["acylguanidines", "SIMPLE_CHEMICAL", 14, 28], ["histamine H 2 agonists", "GENE_OR_GENE_PRODUCT", 76, 98], ["NPY Y2 antagonists", "GENE_OR_GENE_PRODUCT", 103, 121], ["oxyguanidine moiety", "SIMPLE_CHEMICAL", 131, 150], ["arginine", "SIMPLE_CHEMICAL", 194, 202], ["thrombin", "GENE_OR_GENE_PRODUCT", 206, 214], ["RWJ-671818", "SIMPLE_CHEMICAL", 232, 242], ["[211] [212] [213] [214] [215] [216] [217] [218]", "SIMPLE_CHEMICAL", 322, 369], ["thrombin", "PROTEIN", 206, 214], ["acylguanidines", "TREATMENT", 14, 28], ["histamine H 2 agonists", "TREATMENT", 76, 98], ["NPY Y2 antagonists", "TREATMENT", 103, 121], ["an oxyguanidine moiety", "TREATMENT", 128, 150], ["arginine in thrombin inhibitors", "TREATMENT", 194, 225], ["RWJ", "TEST", 232, 235]]], ["An extensive survey of benzamidine mimetics was conducted using the potent factor Xa inhibitor SN429 (159), K i \u00bc 13 pM, as the basis for assessing the effect of this kind of structural variation on potency and oral bioavailability (Fig. 27 ) [219] .", [["oral", "ANATOMY", 211, 215], ["benzamidine", "CHEMICAL", 23, 34], ["SN429", "CHEMICAL", 95, 100], ["K", "CHEMICAL", 108, 109], ["benzamidine", "CHEMICAL", 23, 34], ["SN429", "CHEMICAL", 95, 100], ["benzamidine", "SIMPLE_CHEMICAL", 23, 34], ["Xa", "GENE_OR_GENE_PRODUCT", 82, 84], ["oral", "ORGANISM_SUBDIVISION", 211, 215], ["benzamidine mimetics", "TREATMENT", 23, 43], ["the potent factor Xa inhibitor", "TREATMENT", 64, 94]]], ["The study identified several neutral substituents that functioned as useful and effective amidine surrogates in this context, including the 3-chlorophenyl analogue which demonstrated a K i of 37 nM, potency similar to that of the 3-aminophenyl derivative, which displays a K i of 63 nM.", [["amidine", "CHEMICAL", 90, 97], ["3-chlorophenyl", "CHEMICAL", 140, 154], ["K", "CHEMICAL", 185, 186], ["3-aminophenyl", "CHEMICAL", 230, 243], ["K", "CHEMICAL", 273, 274], ["amidine", "CHEMICAL", 90, 97], ["3-chlorophenyl", "CHEMICAL", 140, 154], ["3-aminophenyl", "CHEMICAL", 230, 243], ["amidine", "SIMPLE_CHEMICAL", 90, 97], ["3-chlorophenyl analogue", "SIMPLE_CHEMICAL", 140, 163], ["3-aminophenyl derivative", "SIMPLE_CHEMICAL", 230, 254], ["The study", "TEST", 0, 9], ["several neutral substituents", "PROBLEM", 21, 49], ["effective amidine surrogates", "TREATMENT", 80, 108], ["a K i", "TEST", 183, 188], ["a K i", "TEST", 271, 276], ["neutral substituents", "OBSERVATION", 29, 49]]], ["However, both of these compounds are tenfold weaker than the more basic 3-aminomethyl compound, which exhibits a K i of 2.7 nM, and are significantly less potent than the prototype 159.", [["3-aminomethyl compound", "CHEMICAL", 72, 94], ["K", "CHEMICAL", 113, 114], ["3-aminomethyl", "CHEMICAL", 72, 85], ["3-aminomethyl compound", "SIMPLE_CHEMICAL", 72, 94], ["tenfold weaker", "PROBLEM", 37, 51], ["a K i", "TEST", 111, 116], ["compounds", "OBSERVATION", 23, 32], ["tenfold", "OBSERVATION_MODIFIER", 37, 44], ["weaker", "OBSERVATION_MODIFIER", 45, 51], ["significantly", "OBSERVATION_MODIFIER", 136, 149], ["less potent", "OBSERVATION_MODIFIER", 150, 161]]], ["However, the 4-methoxy analogue represented an acceptable compromise between potency (K i \u00bc 11 nM) and pharmacokinetic properties and it is this P1 moiety that is found in the factor Xa inhibitor apixaban (160) which received marketing approval from the FDA in December 2012 as an agent for reducing the risk of blood clots and stroke in subjects experiencing atrial fibrillation that is not related to a heart valve problem [207, 220] .Isosteres of Phosphates and PhosphonatesPhosphates and phosphonates are highly acidic elements, and the low pK a associated with these moieties provides a significant limit to membrane permeability and, hence, oral bioavailability [221] [222] [223] .", [["blood clots", "ANATOMY", 312, 323], ["atrial", "ANATOMY", 360, 366], ["heart", "ANATOMY", 405, 410], ["membrane", "ANATOMY", 613, 621], ["oral", "ANATOMY", 647, 651], ["4-methoxy", "CHEMICAL", 13, 22], ["K", "CHEMICAL", 86, 87], ["apixaban", "CHEMICAL", 196, 204], ["blood clots", "DISEASE", 312, 323], ["stroke", "DISEASE", 328, 334], ["atrial fibrillation", "DISEASE", 360, 379], ["heart valve problem", "DISEASE", 405, 424], ["Phosphates", "CHEMICAL", 450, 460], ["Phosphates", "CHEMICAL", 477, 487], ["phosphonates", "CHEMICAL", 492, 504], ["4-methoxy", "CHEMICAL", 13, 22], ["apixaban", "CHEMICAL", 196, 204], ["Phosphates", "CHEMICAL", 450, 460], ["Phosphonates", "CHEMICAL", 465, 477], ["Phosphates", "CHEMICAL", 477, 487], ["phosphonates", "CHEMICAL", 492, 504], ["4-methoxy", "SIMPLE_CHEMICAL", 13, 22], ["Xa", "GENE_OR_GENE_PRODUCT", 183, 185], ["apixaban", "SIMPLE_CHEMICAL", 196, 204], ["blood", "ORGANISM_SUBSTANCE", 312, 317], ["clots", "ORGANISM_SUBSTANCE", 318, 323], ["atrial", "MULTI-TISSUE_STRUCTURE", 360, 366], ["heart", "ORGAN", 405, 410], ["Phosphates", "SIMPLE_CHEMICAL", 450, 460], ["PhosphonatesPhosphates", "SIMPLE_CHEMICAL", 465, 487], ["phosphonates", "SIMPLE_CHEMICAL", 492, 504], ["membrane", "CELLULAR_COMPONENT", 613, 621], ["oral", "ORGANISM_SUBDIVISION", 647, 651], ["pharmacokinetic properties", "TEST", 103, 129], ["this P1 moiety", "PROBLEM", 140, 154], ["the factor Xa inhibitor apixaban", "TREATMENT", 172, 204], ["an agent", "TREATMENT", 278, 286], ["blood clots", "PROBLEM", 312, 323], ["stroke", "PROBLEM", 328, 334], ["atrial fibrillation", "PROBLEM", 360, 379], ["a heart valve problem", "PROBLEM", 403, 424], ["Isosteres of Phosphates", "TREATMENT", 437, 460], ["PhosphonatesPhosphates", "TREATMENT", 465, 487], ["phosphonates", "TREATMENT", 492, 504], ["highly acidic elements", "PROBLEM", 509, 531], ["the low pK", "PROBLEM", 537, 547], ["these moieties", "PROBLEM", 566, 580], ["acceptable", "OBSERVATION_MODIFIER", 47, 57], ["compromise", "OBSERVATION", 58, 68], ["blood", "ANATOMY", 312, 317], ["clots", "OBSERVATION", 318, 323], ["atrial", "ANATOMY", 360, 366], ["fibrillation", "OBSERVATION", 367, 379], ["heart valve", "ANATOMY", 405, 416], ["acidic elements", "OBSERVATION", 516, 531], ["low pK", "OBSERVATION_MODIFIER", 541, 547], ["significant", "OBSERVATION_MODIFIER", 592, 603], ["limit to membrane permeability", "OBSERVATION_MODIFIER", 604, 634]]], ["Monofluoro-and difluoromethylenebisphosphonic acids have been developed as useful chemically and enzymatically stable phosphate isosteres, but these rely upon preserving the inherently high acidity of the prototype and are not useful in the design of orally bioavailable drug candidates without resort to prodrug technology, which has been the most widely applied and successful tactic to deliver this kind of polar structural element [224] [225] [226] [227] [228] [229] .", [["Monofluoro-and difluoromethylenebisphosphonic acids", "CHEMICAL", 0, 51], ["phosphate", "CHEMICAL", 118, 127], ["Monofluoro-and difluoromethylenebisphosphonic acids", "CHEMICAL", 0, 51], ["phosphate", "CHEMICAL", 118, 127], ["[224] [225] [226] [227] [228] [229]", "CHEMICAL", 435, 470], ["Monofluoro", "SIMPLE_CHEMICAL", 0, 10], ["difluoromethylenebisphosphonic acids", "SIMPLE_CHEMICAL", 15, 51], ["phosphate isosteres", "SIMPLE_CHEMICAL", 118, 137], ["[224] [225] [226] [227] [228] [229]", "SIMPLE_CHEMICAL", 435, 470], ["Monofluoro", "TEST", 0, 10], ["difluoromethylenebisphosphonic acids", "TREATMENT", 15, 51], ["enzymatically stable phosphate isosteres", "PROBLEM", 97, 137], ["prodrug technology", "TREATMENT", 305, 323], ["stable", "OBSERVATION_MODIFIER", 111, 117], ["phosphate isosteres", "OBSERVATION", 118, 137]]], ["Phosphate and phosphonate isosteres have been of particular interest in the design of nucleoside and nucleotide antiviral and anticancer agents and phosphatase inhibitors for which the design principles are based on substrate mimicry [230, 231] .", [["anticancer", "ANATOMY", 126, 136], ["Phosphate", "CHEMICAL", 0, 9], ["phosphonate", "CHEMICAL", 14, 25], ["nucleoside", "CHEMICAL", 86, 96], ["nucleotide", "CHEMICAL", 101, 111], ["Phosphate", "CHEMICAL", 0, 9], ["phosphonate", "CHEMICAL", 14, 25], ["nucleoside", "CHEMICAL", 86, 96], ["nucleotide", "CHEMICAL", 101, 111], ["Phosphate", "SIMPLE_CHEMICAL", 0, 9], ["phosphonate isosteres", "SIMPLE_CHEMICAL", 14, 35], ["nucleoside", "SIMPLE_CHEMICAL", 86, 96], ["nucleotide", "SIMPLE_CHEMICAL", 101, 111], ["anticancer", "CANCER", 126, 136], ["Phosphate and phosphonate isosteres", "TREATMENT", 0, 35], ["nucleoside", "TREATMENT", 86, 96], ["nucleotide antiviral", "TREATMENT", 101, 121], ["anticancer agents", "TREATMENT", 126, 143], ["phosphatase inhibitors", "TREATMENT", 148, 170]]], ["However, the most notable success in the design of phosphate mimics has been accomplished in the arena of inhibitors of the strand transfer reaction catalyzed by HIV-1 integrase where the seminal identification of \u03b1,\u03b3-diketo acids as phosphate transfer transition state mimics inspired the design of a wide range isosteres, summarized in Fig. 28 , that are compatible with oral bioavailability [232] [233] [234] [235] [236] [237] .Isosteres of Phosphates and PhosphonatesThe HIV-1 integrase inhibitors raltegravir (161) , elvitegravir (162) , and dolutegravir (163) have been licensed for marketing by the FDA for the treatment of HIV-1 infection [232] [233] [234] [235] [236] [237] .Isosteres to Modulate Basicity/Acidity and SolubilityThe presence of a basic amine in a molecule can be associated with several problems including compound promiscuity, inhibition of the human ether a go-go-related gene type 1 (hERG) cardiac potassium channel, phospholipidosis, and recognition by P-glycoprotein [121, [238] [239] [240] [241] [242] [243] [244] [245] [246] .", [["seminal", "ANATOMY", 188, 195], ["oral", "ANATOMY", 373, 377], ["phosphate", "CHEMICAL", 51, 60], ["\u03b1,\u03b3-diketo acids", "CHEMICAL", 214, 230], ["phosphate", "CHEMICAL", 234, 243], ["Phosphates", "CHEMICAL", 444, 454], ["Phosphonates", "CHEMICAL", 459, 471], ["raltegravir", "CHEMICAL", 502, 513], ["elvitegravir", "CHEMICAL", 522, 534], ["dolutegravir", "CHEMICAL", 547, 559], ["HIV-1 infection", "DISEASE", 631, 646], ["amine", "CHEMICAL", 761, 766], ["potassium", "CHEMICAL", 926, 935], ["phosphate", "CHEMICAL", 51, 60], ["\u03b1,\u03b3-diketo acids", "CHEMICAL", 214, 230], ["phosphate", "CHEMICAL", 234, 243], ["Phosphates", "CHEMICAL", 444, 454], ["Phosphonates", "CHEMICAL", 459, 471], ["raltegravir", "CHEMICAL", 502, 513], ["elvitegravir", "CHEMICAL", 522, 534], ["dolutegravir", "CHEMICAL", 547, 559], ["amine", "CHEMICAL", 761, 766], ["ether", "CHEMICAL", 877, 882], ["potassium", "CHEMICAL", 926, 935], ["phosphate", "SIMPLE_CHEMICAL", 51, 60], ["HIV-1", "ORGANISM", 162, 167], ["seminal", "ORGANISM_SUBSTANCE", 188, 195], ["\u03b1", "SIMPLE_CHEMICAL", 214, 215], ["\u03b3-diketo acids", "SIMPLE_CHEMICAL", 216, 230], ["phosphate", "SIMPLE_CHEMICAL", 234, 243], ["oral", "ORGANISM_SUBDIVISION", 373, 377], ["Phosphates", "SIMPLE_CHEMICAL", 444, 454], ["Phosphonates", "SIMPLE_CHEMICAL", 459, 471], ["HIV-1", "ORGANISM", 475, 480], ["raltegravir", "SIMPLE_CHEMICAL", 502, 513], ["elvitegravir", "SIMPLE_CHEMICAL", 522, 534], ["dolutegravir", "SIMPLE_CHEMICAL", 547, 559], ["HIV-1", "ORGANISM", 631, 636], ["Acidity", "SIMPLE_CHEMICAL", 715, 722], ["amine", "SIMPLE_CHEMICAL", 761, 766], ["human", "ORGANISM", 871, 876], ["ether", "SIMPLE_CHEMICAL", 877, 882], ["go-go-related gene type 1", "GENE_OR_GENE_PRODUCT", 885, 910], ["hERG", "GENE_OR_GENE_PRODUCT", 912, 916], ["go-go-related gene type 1 (hERG) cardiac potassium channel", "PROTEIN", 885, 943], ["P", "PROTEIN", 982, 983], ["glycoprotein", "PROTEIN", 984, 996], ["HIV-1", "SPECIES", 162, 167], ["HIV-1", "SPECIES", 475, 480], ["HIV-1", "SPECIES", 631, 636], ["human", "SPECIES", 871, 876], ["HIV-1", "SPECIES", 162, 167], ["HIV-1", "SPECIES", 475, 480], ["HIV-1", "SPECIES", 631, 636], ["human", "SPECIES", 871, 876], ["phosphate mimics", "TREATMENT", 51, 67], ["inhibitors", "TREATMENT", 106, 116], ["the strand transfer reaction", "TREATMENT", 120, 148], ["the seminal identification", "TEST", 184, 210], ["\u03b3-diketo acids", "TREATMENT", 216, 230], ["a wide range isosteres", "TREATMENT", 300, 322], ["Isosteres of Phosphates", "TREATMENT", 431, 454], ["Phosphonates", "TREATMENT", 459, 471], ["The HIV-1 integrase inhibitors raltegravir", "TREATMENT", 471, 513], ["elvitegravir", "TEST", 522, 534], ["dolutegravir", "TREATMENT", 547, 559], ["HIV-1 infection", "PROBLEM", 631, 646], ["Isosteres", "TREATMENT", 684, 693], ["Modulate Basicity/Acidity", "TREATMENT", 697, 722], ["Solubility", "TREATMENT", 727, 737], ["a basic amine in a molecule", "PROBLEM", 753, 780], ["several problems", "PROBLEM", 804, 820], ["cardiac potassium channel", "TEST", 918, 943], ["phospholipidosis", "TEST", 945, 961], ["notable", "OBSERVATION_MODIFIER", 18, 25], ["success", "OBSERVATION", 26, 33], ["Basicity", "OBSERVATION_MODIFIER", 706, 714], ["Acidity", "OBSERVATION_MODIFIER", 715, 722], ["Solubility", "OBSERVATION_MODIFIER", 727, 737]]], ["The basicity of an amine can readily be modulated by the introduction of proximal electron-withdrawing substituents or functionality, with the highly electronegative fluorine the most notable and one of the most widely utilized based on its metabolic stability and modest steric volume [247] .", [["amine", "CHEMICAL", 19, 24], ["fluorine", "CHEMICAL", 166, 174], ["amine", "CHEMICAL", 19, 24], ["fluorine", "CHEMICAL", 166, 174], ["amine", "SIMPLE_CHEMICAL", 19, 24], ["electron", "SIMPLE_CHEMICAL", 82, 90], ["fluorine", "SIMPLE_CHEMICAL", 166, 174], ["proximal electron-withdrawing substituents", "TREATMENT", 73, 115], ["the highly electronegative fluorine", "PROBLEM", 139, 174], ["modest steric volume", "TEST", 265, 285], ["basicity", "OBSERVATION_MODIFIER", 4, 12], ["electronegative fluorine", "OBSERVATION", 150, 174], ["metabolic stability", "OBSERVATION", 241, 260], ["modest", "OBSERVATION_MODIFIER", 265, 271], ["steric volume", "OBSERVATION", 272, 285]]], ["The pK a s of fluorinated ethylamines are summarized in Table 19 where the data indicate that the effect of introducing a F atom is additive in nature which allows the change in pK a to be estimated with reasonable accuracy for aliphatic amines.", [["aliphatic amines", "CHEMICAL", 228, 244], ["ethylamines", "CHEMICAL", 26, 37], ["F", "CHEMICAL", 122, 123], ["aliphatic amines", "CHEMICAL", 228, 244], ["fluorinated ethylamines", "SIMPLE_CHEMICAL", 14, 37], ["F atom", "SIMPLE_CHEMICAL", 122, 128], ["aliphatic amines", "SIMPLE_CHEMICAL", 228, 244], ["fluorinated ethylamines", "TREATMENT", 14, 37], ["a F atom", "TREATMENT", 120, 128], ["aliphatic amines", "TREATMENT", 228, 244]]], ["Each fluorine atom introduced to a C atom \u03b2to the amine reduces the pK a by 1.7 units, an effect that is dependent on \u03c3-transmission and therefore declines with increasing distance such that the effect at the \u03b3-C is reduced to a shift of \u00c00.7 units while a F at the \u03b4-C reduces pK a by 0.3 units, data that is reflected in Table 19 .", [["fluorine atom", "CHEMICAL", 5, 18], ["amine", "CHEMICAL", 50, 55], ["fluorine", "CHEMICAL", 5, 13], ["C", "CHEMICAL", 35, 36], ["\u03b2to", "CHEMICAL", 42, 45], ["amine", "CHEMICAL", 50, 55], ["\u03b3-C", "CHEMICAL", 209, 212], ["fluorine atom", "SIMPLE_CHEMICAL", 5, 18], ["C atom \u03b2to", "SIMPLE_CHEMICAL", 35, 45], ["amine", "SIMPLE_CHEMICAL", 50, 55], ["\u03b3-C", "SIMPLE_CHEMICAL", 209, 212], ["\u03b4-C", "SIMPLE_CHEMICAL", 266, 269], ["\u03b3-C", "PROTEIN", 209, 212], ["\u03b4-C", "PROTEIN", 266, 269], ["Each fluorine atom", "TREATMENT", 0, 18], ["a C atom \u03b2to the amine", "TREATMENT", 33, 55], ["dependent", "OBSERVATION_MODIFIER", 105, 114]]], ["An insightful example of the application of the effect of F to reduce amine basicity is provided by the design of inhibitors of the motor protein kinesin spindle protein (KSP) explored as a potential therapy for the treatment of taxane-refractory solid tumors [248] .", [["solid tumors", "ANATOMY", 247, 259], ["amine", "CHEMICAL", 70, 75], ["taxane", "CHEMICAL", 229, 235], ["tumors", "DISEASE", 253, 259], ["amine", "CHEMICAL", 70, 75], ["taxane", "CHEMICAL", 229, 235], ["amine", "SIMPLE_CHEMICAL", 70, 75], ["kinesin spindle protein", "GENE_OR_GENE_PRODUCT", 146, 169], ["taxane", "SIMPLE_CHEMICAL", 229, 235], ["solid tumors", "CANCER", 247, 259], ["motor protein kinesin spindle protein", "PROTEIN", 132, 169], ["KSP", "PROTEIN", 171, 174], ["reduce amine basicity", "TREATMENT", 63, 84], ["inhibitors", "TREATMENT", 114, 124], ["a potential therapy", "TREATMENT", 188, 207], ["the treatment of taxane", "TREATMENT", 212, 235], ["refractory solid tumors", "PROBLEM", 236, 259], ["refractory", "OBSERVATION_MODIFIER", 236, 246], ["solid tumors", "OBSERVATION", 247, 259]]], ["The efficacy of this series of compounds was restricted by P-gp efflux which was determined experimentally to be minimized by adjusting the pK a of the amine to a range between 6.5 and 8.0.", [["amine", "CHEMICAL", 152, 157], ["amine", "CHEMICAL", 152, 157], ["amine", "SIMPLE_CHEMICAL", 152, 157], ["P-gp efflux", "PROBLEM", 59, 70]]], ["The N-cyclopropyl derivative 164 represented an initial solution to this problem but was associated with timedependent cytochrome P450 inhibition, a known liability of this structural element [249] .", [["N-cyclopropyl derivative 164", "CHEMICAL", 4, 32], ["N-cyclopropyl", "CHEMICAL", 4, 17], ["N-cyclopropyl derivative 164", "SIMPLE_CHEMICAL", 4, 32], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 119, 134], ["cytochrome P450", "PROTEIN", 119, 134], ["The N-cyclopropyl derivative", "TREATMENT", 0, 28], ["an initial solution", "TREATMENT", 45, 64], ["timedependent cytochrome P450 inhibition", "TREATMENT", 105, 145]]], ["The \u03b2-fluoroethyl derivative 165 also satisfied the pK a requirement but was found to be N-dealkylated in vitro and in vivo to release fluoroacetaldehyde which was oxidized to fluoroacetic acid, a toxin that is metabolized in vivo to a potent inhibitor of aconitase, an enzyme in the tricarboxylic acid cycle [139, 250] .", [["\u03b2-fluoroethyl derivative 165", "CHEMICAL", 4, 32], ["N-dealkylated", "CHEMICAL", 89, 102], ["fluoroacetaldehyde", "CHEMICAL", 135, 153], ["fluoroacetic acid", "CHEMICAL", 176, 193], ["tricarboxylic acid", "CHEMICAL", 284, 302], ["\u03b2-fluoroethyl", "CHEMICAL", 4, 17], ["N", "CHEMICAL", 89, 90], ["fluoroacetaldehyde", "CHEMICAL", 135, 153], ["fluoroacetic acid", "CHEMICAL", 176, 193], ["tricarboxylic acid", "CHEMICAL", 284, 302], ["\u03b2-fluoroethyl derivative 165", "SIMPLE_CHEMICAL", 4, 32], ["fluoroacetaldehyde", "SIMPLE_CHEMICAL", 135, 153], ["fluoroacetic acid", "SIMPLE_CHEMICAL", 176, 193], ["aconitase", "GENE_OR_GENE_PRODUCT", 256, 265], ["tricarboxylic acid", "SIMPLE_CHEMICAL", 284, 302], ["aconitase", "PROTEIN", 256, 265], ["The \u03b2-fluoroethyl derivative", "TREATMENT", 0, 28], ["vitro", "TREATMENT", 106, 111], ["fluoroacetaldehyde", "TREATMENT", 135, 153], ["fluoroacetic acid", "TREATMENT", 176, 193], ["a toxin", "TEST", 195, 202], ["a potent inhibitor of aconitase", "TREATMENT", 234, 265], ["an enzyme", "TEST", 267, 276], ["the tricarboxylic acid cycle", "TEST", 280, 308]]], ["This problem was solved by deploying the fluorine atom in the piperidine ring \u03b2to the amine, an arrangement that produced the cis derivative 166, in which the F atom is axially disposed as confirmed by single-crystal X-ray analysis, and the trans analogue 167, where the F atom adopts an equatorial disposition.", [["fluorine", "CHEMICAL", 41, 49], ["piperidine", "CHEMICAL", 62, 72], ["amine", "CHEMICAL", 86, 91], ["fluorine", "CHEMICAL", 41, 49], ["piperidine", "CHEMICAL", 62, 72], ["\u03b2to", "CHEMICAL", 78, 81], ["amine", "CHEMICAL", 86, 91], ["F", "CHEMICAL", 159, 160], ["F", "CHEMICAL", 271, 272], ["fluorine atom", "SIMPLE_CHEMICAL", 41, 54], ["piperidine ring \u03b2to", "SIMPLE_CHEMICAL", 62, 81], ["amine", "SIMPLE_CHEMICAL", 86, 91], ["cis derivative 166", "SIMPLE_CHEMICAL", 126, 144], ["F atom", "SIMPLE_CHEMICAL", 159, 165], ["F atom", "SIMPLE_CHEMICAL", 271, 277], ["the fluorine atom", "TREATMENT", 37, 54], ["the piperidine ring", "TREATMENT", 58, 77], ["single-crystal X-ray analysis", "TEST", 202, 231], ["equatorial disposition", "OBSERVATION", 288, 310]]], ["The effect of this structural modification on the basicity of the piperidine was dependent on the stereochemical disposition of the F atom with the pK a of 167 determined to be 6.6 while 168 was more basic with a pK a of 7.6 and it was this compound, designated as MK-0371, that was selected for clinical evaluation [248] .", [["piperidine", "CHEMICAL", 66, 76], ["MK-0371", "CHEMICAL", 265, 272], ["piperidine", "CHEMICAL", 66, 76], ["F", "CHEMICAL", 132, 133], ["MK-0371", "CHEMICAL", 265, 272], ["piperidine", "SIMPLE_CHEMICAL", 66, 76], ["F atom", "SIMPLE_CHEMICAL", 132, 138], ["MK-0371", "SIMPLE_CHEMICAL", 265, 272], ["this structural modification", "PROBLEM", 14, 42], ["the piperidine", "TREATMENT", 62, 76], ["the pK a", "TEST", 144, 152], ["a pK a", "TEST", 211, 217], ["clinical evaluation", "TEST", 296, 315]]], ["The electron-withdrawing properties of the CF 3 and CHF 2 deployed \u03b2to an amine reduce basicity to an extent that these functionalities have found application as amide mimics, an isosteric relationship furthered by the similarity of dipoles and the geometry of the N-C-CF 3 and N-C-CF 2 , which approximates the 120 associated with an amide moiety, as illustrated in Fig. 29 [251] [252] [253] [254] .", [["\u03b2to", "CHEMICAL", 67, 70], ["amine", "CHEMICAL", 74, 79], ["CF 3", "CHEMICAL", 43, 47], ["\u03b2to", "CHEMICAL", 67, 70], ["amine", "CHEMICAL", 74, 79], ["amide", "CHEMICAL", 162, 167], ["N-C-CF", "CHEMICAL", 265, 271], ["N-C-CF", "CHEMICAL", 278, 284], ["amide", "CHEMICAL", 335, 340], ["electron", "SIMPLE_CHEMICAL", 4, 12], ["\u03b2to", "SIMPLE_CHEMICAL", 67, 70], ["amine", "SIMPLE_CHEMICAL", 74, 79], ["N-C-CF 3", "SIMPLE_CHEMICAL", 265, 273], ["N-C-CF 2", "SIMPLE_CHEMICAL", 278, 286], ["C-CF 2", "PROTEIN", 280, 286], ["The electron", "TEST", 0, 12], ["the CF 3", "PROBLEM", 39, 47], ["CHF", "PROBLEM", 52, 55], ["the N", "TEST", 261, 266], ["CF", "TEST", 269, 271], ["C-CF", "TEST", 280, 284], ["an amide moiety", "TREATMENT", 332, 347], ["CHF", "OBSERVATION", 52, 55]]], ["Although this bioisostere was originally conceived to replace the amide bonds of peptide derivatives, it has begun to find a similar application in drug design, with the most prominent example being the cathepsin K inhibitor odanacatib (170) which has completed phase 3 clinical trials for the treatment of osteoporosis.", [["cathepsin K", "CHEMICAL", 203, 214], ["odanacatib", "CHEMICAL", 225, 235], ["osteoporosis", "DISEASE", 307, 319], ["amide", "CHEMICAL", 66, 71], ["odanacatib", "CHEMICAL", 225, 235], ["bioisostere", "SIMPLE_CHEMICAL", 14, 25], ["peptide derivatives", "SIMPLE_CHEMICAL", 81, 100], ["cathepsin K", "GENE_OR_GENE_PRODUCT", 203, 214], ["odanacatib", "SIMPLE_CHEMICAL", 225, 235], ["the amide bonds of peptide derivatives", "TREATMENT", 62, 100], ["the cathepsin K inhibitor odanacatib", "TREATMENT", 199, 235], ["the treatment", "TREATMENT", 290, 303], ["osteoporosis", "PROBLEM", 307, 319], ["most prominent", "OBSERVATION_MODIFIER", 170, 184], ["osteoporosis", "OBSERVATION", 307, 319]]], ["Cathepsin K is a lysosomal cysteine protease in osteoclasts that is responsible for bone degradation during remodeling and inhibitors prevent bone resorption.", [["lysosomal", "ANATOMY", 17, 26], ["osteoclasts", "ANATOMY", 48, 59], ["bone", "ANATOMY", 84, 88], ["bone", "ANATOMY", 142, 146], ["cysteine", "CHEMICAL", 27, 35], ["Cathepsin K", "GENE_OR_GENE_PRODUCT", 0, 11], ["osteoclasts", "CELL", 48, 59], ["bone", "TISSUE", 84, 88], ["bone", "TISSUE", 142, 146], ["Cathepsin K", "PROTEIN", 0, 11], ["lysosomal cysteine protease", "PROTEIN", 17, 44], ["osteoclasts", "CELL_TYPE", 48, 59], ["Cathepsin K", "TEST", 0, 11], ["a lysosomal cysteine protease in osteoclasts", "PROBLEM", 15, 59], ["bone degradation", "PROBLEM", 84, 100], ["remodeling and inhibitors", "TREATMENT", 108, 133], ["bone resorption", "PROBLEM", 142, 157], ["lysosomal cysteine protease", "OBSERVATION", 17, 44], ["osteoclasts", "OBSERVATION", 48, 59], ["responsible for", "UNCERTAINTY", 68, 83], ["bone", "ANATOMY", 142, 146], ["resorption", "OBSERVATION", 147, 157]]], ["L-006235 (168) , in which the nitrile moiety is presented to the enzyme as an electrophile to react reversibly with the catalytic cysteine thiol, emerged as a refined cathepsin K inhibitor that exhibited good pharmacokinetic properties.", [["L-006235", "CHEMICAL", 0, 8], ["nitrile", "CHEMICAL", 30, 37], ["thiol", "CHEMICAL", 139, 144], ["L-006235", "CHEMICAL", 0, 8], ["nitrile", "CHEMICAL", 30, 37], ["cysteine thiol", "CHEMICAL", 130, 144], ["L-006235", "SIMPLE_CHEMICAL", 0, 8], ["cysteine thiol", "SIMPLE_CHEMICAL", 130, 144], ["cathepsin K", "GENE_OR_GENE_PRODUCT", 167, 178], ["the catalytic cysteine thiol", "TREATMENT", 116, 144], ["a refined cathepsin K inhibitor", "TREATMENT", 157, 188], ["good", "OBSERVATION_MODIFIER", 204, 208], ["pharmacokinetic properties", "OBSERVATION", 209, 235]]], ["However, this compound has poor selectivity for cathepsin K versus the analogues enzymes cathepsin B, L, and S due to its strongly basic nature, which promoted accumulation in the acidic The Influence of Bioisosteres in Drug Design: Tactical Applications to. . . environment of lysosomes [255] .", [["lysosomes", "ANATOMY", 278, 287], ["K", "CHEMICAL", 58, 59], ["cathepsin K", "GENE_OR_GENE_PRODUCT", 48, 59], ["cathepsin B", "GENE_OR_GENE_PRODUCT", 89, 100], ["lysosomes", "CELLULAR_COMPONENT", 278, 287], ["cathepsin K", "PROTEIN", 48, 59], ["cathepsin B, L, and S", "PROTEIN", 89, 110], ["cathepsin K", "TEST", 48, 59], ["the analogues enzymes", "TEST", 67, 88], ["cathepsin", "TEST", 89, 98], ["Tactical Applications", "TREATMENT", 233, 254], ["acidic", "OBSERVATION_MODIFIER", 180, 186]]], ["L-873724 (169) offered good enzyme inhibitory selectivity but poor PK, with further optimization leading to odanacatib (170) which solved both problems by installing a F atom in the Ile residue to block hydroxylation while the cyclopropyl moiety reduced the propensity for amide hydrolysis [255, 256] .", [["L-873724", "CHEMICAL", 0, 8], ["odanacatib", "CHEMICAL", 108, 118], ["Ile", "CHEMICAL", 182, 185], ["cyclopropyl", "CHEMICAL", 227, 238], ["L-873724", "CHEMICAL", 0, 8], ["odanacatib", "CHEMICAL", 108, 118], ["F", "CHEMICAL", 168, 169], ["Ile", "CHEMICAL", 182, 185], ["cyclopropyl", "CHEMICAL", 227, 238], ["amide", "CHEMICAL", 273, 278], ["L-873724", "SIMPLE_CHEMICAL", 0, 8], ["PK", "GENE_OR_GENE_PRODUCT", 67, 69], ["odanacatib", "SIMPLE_CHEMICAL", 108, 118], ["cyclopropyl moiety", "SIMPLE_CHEMICAL", 227, 245], ["amide", "SIMPLE_CHEMICAL", 273, 278], ["poor PK", "PROBLEM", 62, 69], ["odanacatib", "TEST", 108, 118], ["a F atom in the Ile residue", "TREATMENT", 166, 193], ["block hydroxylation", "TREATMENT", 197, 216], ["the cyclopropyl moiety", "TREATMENT", 223, 245], ["amide hydrolysis", "TREATMENT", 273, 289]]], ["While odanacatib (170) has been quite successful clinically, with the phase 3 trial halted early due to the observation of good efficacy and safety, the pharmaceutical properties of this molecule are less than ideal [257] [258] [259] [260] .", [["odanacatib", "CHEMICAL", 6, 16], ["odanacatib", "CHEMICAL", 6, 16], ["odanacatib", "SIMPLE_CHEMICAL", 6, 16]]], ["Odanacatib (170) is highly crystalline and exhibits low aqueous solubility, properties that contribute to the 10% bioavailability across preclinical species after dosing the drug as a suspension in methocel.", [["Odanacatib", "CHEMICAL", 0, 10], ["Odanacatib", "CHEMICAL", 0, 10], ["Odanacatib", "SIMPLE_CHEMICAL", 0, 10], ["Odanacatib", "TREATMENT", 0, 10], ["low aqueous solubility", "PROBLEM", 52, 74], ["the 10% bioavailability across preclinical species", "PROBLEM", 106, 156], ["the drug", "TREATMENT", 170, 178], ["a suspension in methocel", "TREATMENT", 182, 206], ["highly crystalline", "OBSERVATION_MODIFIER", 20, 38], ["low", "OBSERVATION_MODIFIER", 52, 55], ["aqueous solubility", "OBSERVATION", 56, 74]]], ["In an effort to overcome the dissolution-limited bioavailability, modification of the CF 3 moiety to a CHF 2 was explored as a means of improving the physical properties by increasing the pK a of the amine [260] .", [["CHF", "DISEASE", 103, 106], ["amine", "CHEMICAL", 200, 205], ["CF 3", "CHEMICAL", 86, 90], ["CHF 2", "CHEMICAL", 103, 108], ["amine", "CHEMICAL", 200, 205], ["a CHF 2", "PROBLEM", 101, 108], ["CHF", "OBSERVATION", 103, 106]]], ["This modification afforded 171 which preserved cathepsin K inhibitory potency and selectivity while decreasing log D by 3 units, attributed to the increased basicity, with the result that bioavailability from a 1% methocel suspension was improved fourfold from 6% with odanacatib (170) to 23% with 171 in the dog and 8-22% in the rat.", [["K", "CHEMICAL", 57, 58], ["methocel", "CHEMICAL", 214, 222], ["odanacatib", "CHEMICAL", 269, 279], ["odanacatib", "CHEMICAL", 269, 279], ["cathepsin K", "GENE_OR_GENE_PRODUCT", 47, 58], ["dog", "ORGANISM", 309, 312], ["rat", "ORGANISM", 330, 333], ["cathepsin K", "PROTEIN", 47, 58], ["rat", "SPECIES", 330, 333], ["rat", "SPECIES", 330, 333], ["the increased basicity", "PROBLEM", 143, 165], ["a 1% methocel suspension", "TREATMENT", 209, 233], ["odanacatib", "TEST", 269, 279], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["basicity", "OBSERVATION", 157, 165]]], ["The increase in basicity with 171 facilitated salt formation with strong acids like HCl although, interestingly, salts offered no advantage over the neutral form in rat PK studies [260] .", [["HCl", "CHEMICAL", 84, 87], ["HCl", "CHEMICAL", 84, 87], ["salt", "SIMPLE_CHEMICAL", 46, 50], ["HCl", "SIMPLE_CHEMICAL", 84, 87], ["salts", "SIMPLE_CHEMICAL", 113, 118], ["rat", "ORGANISM", 165, 168], ["PK", "GENE_OR_GENE_PRODUCT", 169, 171], ["rat", "SPECIES", 165, 168], ["The increase in basicity", "PROBLEM", 0, 24], ["salt formation", "TREATMENT", 46, 60], ["strong acids like HCl", "TREATMENT", 66, 87], ["PK studies", "TEST", 169, 179], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["basicity", "OBSERVATION_MODIFIER", 16, 24]]], ["In a series of tetrahydroisoquinoline-based inhibitors of phenylethanolamine N-methyltransferase (PNMT), the enzyme that catalyzes the final step in epinephrine biosynthesis by methylating norepinephrine using S-adenosyl L-methionine as the cofactor, binding of these compounds to the \u03b1 2 adrenoreceptor was a significant issue.", [["tetrahydroisoquinoline", "CHEMICAL", 15, 37], ["phenylethanolamine", "CHEMICAL", 58, 76], ["epinephrine", "CHEMICAL", 149, 160], ["norepinephrine", "CHEMICAL", 189, 203], ["S-adenosyl L-methionine", "CHEMICAL", 210, 233], ["tetrahydroisoquinoline", "CHEMICAL", 15, 37], ["phenylethanolamine", "CHEMICAL", 58, 76], ["epinephrine", "CHEMICAL", 149, 160], ["norepinephrine", "CHEMICAL", 189, 203], ["S-adenosyl L-methionine", "CHEMICAL", 210, 233], ["tetrahydroisoquinoline", "SIMPLE_CHEMICAL", 15, 37], ["phenylethanolamine N-methyltransferase", "GENE_OR_GENE_PRODUCT", 58, 96], ["PNMT", "GENE_OR_GENE_PRODUCT", 98, 102], ["epinephrine", "SIMPLE_CHEMICAL", 149, 160], ["norepinephrine", "SIMPLE_CHEMICAL", 189, 203], ["S-adenosyl L-methionine", "SIMPLE_CHEMICAL", 210, 233], ["\u03b1 2 adrenoreceptor", "GENE_OR_GENE_PRODUCT", 285, 303], ["phenylethanolamine N-methyltransferase", "PROTEIN", 58, 96], ["PNMT", "PROTEIN", 98, 102], ["\u03b1 2 adrenoreceptor", "PROTEIN", 285, 303], ["tetrahydroisoquinoline-based inhibitors", "TREATMENT", 15, 54], ["phenylethanolamine N-methyltransferase (PNMT)", "TREATMENT", 58, 103], ["the enzyme", "TEST", 105, 115], ["epinephrine biosynthesis", "TREATMENT", 149, 173], ["methylating norepinephrine", "TREATMENT", 177, 203], ["S-adenosyl L-methionine", "TREATMENT", 210, 233]]], ["The prototypical 3-methyl derivative 172 is only modestly selective (Table 20 ) [261] .", [["3-methyl derivative 172", "CHEMICAL", 17, 40], ["3-methyl", "CHEMICAL", 17, 25], ["3-methyl derivative 172", "SIMPLE_CHEMICAL", 17, 40], ["The prototypical 3-methyl derivative", "TREATMENT", 0, 36]]], ["In an effort to address this problem, the effect of modulating the basicity of the amine by the successive introduction of F atoms into the 334 N.A. Meanwell 3-methyl group was explored, an approach that proved to be both productive and informative.", [["amine", "CHEMICAL", 83, 88], ["F atoms", "CHEMICAL", 123, 130], ["Meanwell 3-methyl", "CHEMICAL", 149, 166], ["amine", "CHEMICAL", 83, 88], ["F", "CHEMICAL", 123, 124], ["3-methyl", "CHEMICAL", 158, 166], ["amine", "SIMPLE_CHEMICAL", 83, 88], ["F atoms", "SIMPLE_CHEMICAL", 123, 130], ["3-methyl", "SIMPLE_CHEMICAL", 158, 166], ["this problem", "PROBLEM", 24, 36]]], ["The monofluoro analogue 173 exhibited similar affinity for the enzyme as 172 while \u03b1 2 binding declined only modestly and this molecule was calculated to be less basic than the prototype by 1.5 pK a units.", [["monofluoro analogue 173", "CHEMICAL", 4, 27], ["monofluoro", "CHEMICAL", 4, 14], ["monofluoro analogue 173", "SIMPLE_CHEMICAL", 4, 27], ["\u03b1 2", "GENE_OR_GENE_PRODUCT", 83, 86], ["The monofluoro analogue", "TEST", 0, 23], ["the enzyme", "TEST", 59, 69]]], ["The trifluoromethyl homologue 175 exhibited poor potency in both assays and is poorly basic; however, the difluoromethylated compound 174 provided the optimal balance of properties, retaining good affinity for PNMT while reducing \u03b1 2 adrenoreceptor binding b\u1ef9 200-fold and providing the first example of fluorination of an amine modulating target selectivity [261] .Isosteres to Modulate Basicity/Acidity and SolubilityA detailed analysis of the properties of 3-substituted oxetane rings and applications in the context of broader functionality have established this heterocycle as an advantageous structural element when utilized in a fashion that takes advantage of its electron-withdrawing properties and topographical isosterism with the carbonyl functionality [262] [263] [264] [265] .", [["trifluoromethyl", "CHEMICAL", 4, 19], ["amine", "CHEMICAL", 323, 328], ["3-substituted oxetane", "CHEMICAL", 460, 481], ["carbonyl", "CHEMICAL", 742, 750], ["trifluoromethyl", "CHEMICAL", 4, 19], ["amine", "CHEMICAL", 323, 328], ["3-substituted oxetane", "CHEMICAL", 460, 481], ["carbonyl", "CHEMICAL", 742, 750], ["trifluoromethyl homologue 175", "SIMPLE_CHEMICAL", 4, 33], ["PNMT", "SIMPLE_CHEMICAL", 210, 214], ["\u03b1 2 adrenoreceptor", "GENE_OR_GENE_PRODUCT", 230, 248], ["amine", "SIMPLE_CHEMICAL", 323, 328], ["3-substituted oxetane rings", "SIMPLE_CHEMICAL", 460, 487], ["electron", "SIMPLE_CHEMICAL", 672, 680], ["carbonyl", "SIMPLE_CHEMICAL", 742, 750], ["[262] [263] [264] [265]", "SIMPLE_CHEMICAL", 765, 788], ["PNMT", "PROTEIN", 210, 214], ["\u03b1 2 adrenoreceptor", "PROTEIN", 230, 248], ["The trifluoromethyl homologue", "TEST", 0, 29], ["poor potency in both assays", "PROBLEM", 44, 71], ["PNMT", "PROBLEM", 210, 214], ["Isosteres", "TREATMENT", 366, 375], ["Modulate Basicity/Acidity", "TREATMENT", 379, 404], ["substituted oxetane rings", "TREATMENT", 462, 487], ["applications", "TREATMENT", 492, 504], ["this heterocycle", "TREATMENT", 562, 578], ["poor potency", "OBSERVATION_MODIFIER", 44, 56], ["Basicity", "OBSERVATION_MODIFIER", 388, 396], ["Acidity", "OBSERVATION_MODIFIER", 397, 404]]], ["These properties allow the oxetane ring to be deployed as a ketone or amide mimetic depending on the structural context with the electronwithdrawing effects reducing the basicity of an amine in a fashion that is strictly dependent on proximity [262] .", [["oxetane", "CHEMICAL", 27, 34], ["ketone", "CHEMICAL", 60, 66], ["amine", "CHEMICAL", 185, 190], ["oxetane", "CHEMICAL", 27, 34], ["ketone", "CHEMICAL", 60, 66], ["amide", "CHEMICAL", 70, 75], ["amine", "CHEMICAL", 185, 190], ["oxetane", "SIMPLE_CHEMICAL", 27, 34], ["ketone", "SIMPLE_CHEMICAL", 60, 66], ["amine", "SIMPLE_CHEMICAL", 185, 190], ["the oxetane ring", "TREATMENT", 23, 39], ["a ketone or amide mimetic", "TREATMENT", 58, 83]]], ["As is evident from the homologous series presented in Table 21 , the amino oxetane 177 is the weakest base while the aminomethyl and aminoethyl homologues 178 and 179, respectively, exhibit progressively increased basicity which shows a correlation with solubility, with the exception of the parent molecule 176 which is poorly soluble despite being the most basic [262] .", [["amino oxetane", "CHEMICAL", 69, 82], ["aminomethyl", "CHEMICAL", 117, 128], ["aminoethyl", "CHEMICAL", 133, 143], ["amino oxetane", "CHEMICAL", 69, 82], ["aminomethyl", "CHEMICAL", 117, 128], ["aminoethyl", "CHEMICAL", 133, 143], ["amino oxetane 177", "SIMPLE_CHEMICAL", 69, 86], ["aminomethyl", "SIMPLE_CHEMICAL", 117, 128], ["the amino oxetane", "TREATMENT", 65, 82], ["the aminomethyl and aminoethyl homologues", "TEST", 113, 154], ["progressively increased basicity", "PROBLEM", 190, 222], ["aminomethyl", "ANATOMY_MODIFIER", 117, 128], ["progressively", "OBSERVATION_MODIFIER", 190, 203], ["increased", "OBSERVATION_MODIFIER", 204, 213], ["basicity", "OBSERVATION_MODIFIER", 214, 222], ["poorly soluble", "OBSERVATION_MODIFIER", 321, 335]]], ["It is the weak basicity associated with 177 coupled with the structural mimicry of the carbonyl moiety by the oxetane ring which adopts a planar topography that has led to this motif being considered as a useful isostere of an amide functionality (Fig. 30 ).Isosteres to Modulate Lipophilicity and sp 2 Atom CountThe oxetane ring has also been proposed as a useful replacement for the gem-dimethyl moiety that provides a similar vectorial presentation of the 2 substituents (Thorpe-Ingold effect) and a similar size while reducing the lipophilic burden [121, [262] [263] [264] [265] [266] .", [["carbonyl", "CHEMICAL", 87, 95], ["oxetane", "CHEMICAL", 110, 117], ["oxetane", "CHEMICAL", 317, 324], ["gem-dimethyl", "CHEMICAL", 385, 397], ["carbonyl", "CHEMICAL", 87, 95], ["oxetane", "CHEMICAL", 110, 117], ["amide", "CHEMICAL", 227, 232], ["oxetane", "CHEMICAL", 317, 324], ["gem-dimethyl", "CHEMICAL", 385, 397], ["Thorpe-Ingold", "CHEMICAL", 475, 488], ["carbonyl moiety", "SIMPLE_CHEMICAL", 87, 102], ["oxetane ring", "SIMPLE_CHEMICAL", 110, 122], ["oxetane ring", "SIMPLE_CHEMICAL", 317, 329], ["gem-dimethyl moiety", "SIMPLE_CHEMICAL", 385, 404], ["2 substituents", "SIMPLE_CHEMICAL", 459, 473], ["Thorpe-Ingold", "SIMPLE_CHEMICAL", 475, 488], ["the weak basicity", "PROBLEM", 6, 23], ["the carbonyl moiety", "TREATMENT", 83, 102], ["the oxetane ring", "TREATMENT", 106, 122], ["an amide functionality", "TREATMENT", 224, 246], ["Isosteres", "TREATMENT", 258, 267], ["Modulate Lipophilicity", "PROBLEM", 271, 293], ["sp 2 Atom CountThe oxetane ring", "TREATMENT", 298, 329], ["a useful replacement", "TREATMENT", 356, 376], ["the gem-dimethyl moiety", "TREATMENT", 381, 404], ["the lipophilic burden", "TEST", 531, 552], ["weak", "OBSERVATION_MODIFIER", 10, 14], ["basicity", "OBSERVATION", 15, 23], ["Lipophilicity", "OBSERVATION_MODIFIER", 280, 293], ["size", "OBSERVATION_MODIFIER", 511, 515], ["lipophilic burden", "OBSERVATION", 535, 552]]], ["This concept is particularly useful in an era where there is a considerable focus on the role of physical properties in drug design that has fostered the belief that contemporary practices relies far too heavily on lipophilicity to derive potency, a strategy that is based on taking advantage of entropic rather than enthalpic contributions to binding affinity [121, 177, [267] [268] [269] [270] .", [["a strategy", "TREATMENT", 248, 258], ["considerable", "OBSERVATION_MODIFIER", 63, 75]]], ["The rising appreciation of the potential problems associated with this approach to drug design, referred to as molecular obesity, is beginning to be manifested in the description of strategies and tactics to identify scaffolds that replace sp 2 carbon centers by sp 3 -based motifs [121, 181, 182, 238, [271] [272] [273] [274] [275] .", [["obesity", "DISEASE", 121, 128], ["carbon", "CHEMICAL", 245, 251], ["molecular obesity", "PROBLEM", 111, 128], ["scaffolds", "TREATMENT", 217, 226], ["obesity", "OBSERVATION", 121, 128]]], ["One example of this is provided by studies of oxytocin antagonists of which 180 was the prototype, a compound potent receptor affinity, K i \u00bc 6 nM, but poor aqueous solubility of 6 \u03bcg/mL and a low Fsp 3 of 0.18 [276] .", [["oxytocin", "CHEMICAL", 46, 54], ["K", "CHEMICAL", 136, 137], ["oxytocin", "CHEMICAL", 46, 54], ["oxytocin", "SIMPLE_CHEMICAL", 46, 54], ["oxytocin antagonists", "TREATMENT", 46, 66], ["a compound potent receptor affinity", "PROBLEM", 99, 134], ["K i", "TEST", 136, 139], ["poor aqueous solubility", "PROBLEM", 152, 175], ["a low Fsp", "TEST", 191, 200]]], ["The effect of replacing the pyrazine ring with piperidine, pyrrolidine, and azetidine was examined from which the azetidine 181 emerged as a preferred compound that bound to the oxytocin receptor with a K i of 9.5 nM but which exhibited tenfold improved aqueous solubility of 59 \u03bcg/mL and a much increased Fsp 3 of 0.46 [276] .", [["pyrazine", "CHEMICAL", 28, 36], ["piperidine", "CHEMICAL", 47, 57], ["pyrrolidine", "CHEMICAL", 59, 70], ["azetidine", "CHEMICAL", 76, 85], ["azetidine 181", "CHEMICAL", 114, 127], ["oxytocin", "CHEMICAL", 178, 186], ["K", "CHEMICAL", 203, 204], ["pyrazine", "CHEMICAL", 28, 36], ["piperidine", "CHEMICAL", 47, 57], ["pyrrolidine", "CHEMICAL", 59, 70], ["azetidine", "CHEMICAL", 76, 85], ["azetidine 181", "CHEMICAL", 114, 127], ["oxytocin", "CHEMICAL", 178, 186], ["pyrazine ring", "SIMPLE_CHEMICAL", 28, 41], ["piperidine", "SIMPLE_CHEMICAL", 47, 57], ["pyrrolidine", "SIMPLE_CHEMICAL", 59, 70], ["azetidine", "SIMPLE_CHEMICAL", 76, 85], ["azetidine 181", "SIMPLE_CHEMICAL", 114, 127], ["oxytocin receptor", "GENE_OR_GENE_PRODUCT", 178, 195], ["oxytocin receptor", "PROTEIN", 178, 195], ["the pyrazine ring", "TREATMENT", 24, 41], ["piperidine", "TREATMENT", 47, 57], ["pyrrolidine", "TREATMENT", 59, 70], ["azetidine", "TREATMENT", 76, 85], ["the azetidine", "TREATMENT", 110, 123], ["the oxytocin receptor", "TREATMENT", 174, 195], ["a K i", "TEST", 201, 206], ["aqueous solubility", "TEST", 254, 272], ["a much increased Fsp", "TEST", 289, 309]]], ["The establishment of an intramolecular H-bonding interaction can mimic the topology of an aromatic or heterocyclic ring in a fashion that reduces the dependence on sp 2 carbon centers, and this isosterism-based concept has found application in kinase inhibitor design.", [["H", "CHEMICAL", 39, 40], ["H", "CHEMICAL", 39, 40], ["carbon", "CHEMICAL", 169, 175], ["an aromatic or heterocyclic ring", "TREATMENT", 87, 119], ["the dependence", "PROBLEM", 146, 160], ["sp 2 carbon centers", "TREATMENT", 164, 183], ["this isosterism", "TREATMENT", 189, 204], ["kinase inhibitor design", "TREATMENT", 244, 267], ["heterocyclic ring", "OBSERVATION", 102, 119], ["dependence", "OBSERVATION_MODIFIER", 150, 160]]], ["The Cdk4 inhibitor 182 (Fig. 31 ) was identified as a weak lead inhibitor, IC 50 \u00bc 44 \u03bcM, derived by structure-based scaffold generation using a model of Cdk4 and a proprietary modeling program [277] .", [["Cdk4", "GENE_OR_GENE_PRODUCT", 4, 8], ["Fig. 31", "SIMPLE_CHEMICAL", 24, 31], ["Cdk4", "GENE_OR_GENE_PRODUCT", 154, 158], ["Cdk4", "PROTEIN", 4, 8], ["Cdk4", "PROTEIN", 154, 158], ["The Cdk4 inhibitor", "TEST", 0, 18], ["a weak lead inhibitor", "TREATMENT", 52, 73], ["IC", "TREATMENT", 75, 77], ["scaffold generation", "OBSERVATION", 117, 136]]], ["The SAR associated with the homologous series of pyridine derivatives 183-185 is summarized in Table 22 and clearly reveals the importance of the topological deployment of the N atom, attributed to the formation of an intramolecular H-bond between the 2-pyridyl N atom of 185 and the distal urea NH that favors a cis amide topology.", [["pyridine", "CHEMICAL", 49, 57], ["183-185", "CHEMICAL", 70, 77], ["H", "CHEMICAL", 233, 234], ["2-pyridyl", "CHEMICAL", 252, 261], ["urea", "CHEMICAL", 291, 295], ["pyridine", "CHEMICAL", 49, 57], ["N", "CHEMICAL", 176, 177], ["H", "CHEMICAL", 233, 234], ["2-pyridyl N", "CHEMICAL", 252, 263], ["urea", "CHEMICAL", 291, 295], ["NH", "CHEMICAL", 296, 298], ["cis amide", "CHEMICAL", 313, 322], ["pyridine derivatives 183-185", "SIMPLE_CHEMICAL", 49, 77], ["2-pyridyl N atom", "SIMPLE_CHEMICAL", 252, 268], ["urea NH", "SIMPLE_CHEMICAL", 291, 298], ["pyridine derivatives", "TEST", 49, 69], ["the topological deployment of the N atom", "TREATMENT", 142, 182], ["the distal urea NH", "PROBLEM", 280, 298], ["a cis amide topology", "TREATMENT", 311, 331], ["distal", "ANATOMY_MODIFIER", 284, 290]]], ["This hypothesis was subsequently confirmed by a co-crystal of the inhibitor with Cdk2 (Fig. 31 ) and the effect could be recapitulated with the thiazole 186 although this compound is threefold less potent than 185 [277] .Isosteres to Modulate Lipophilicity and sp 2 Atom CountPD-166285 (187) is a broad-acting kinase inhibitor that was used as a vehicle to explore the concept of replacing the pyridone ring with a mimic based on an intramolecular H-bond to favor the preferred topology [278, 279] .", [["thiazole 186", "CHEMICAL", 144, 156], ["CountPD-166285", "CHEMICAL", 271, 285], ["pyridone", "CHEMICAL", 394, 402], ["thiazole", "CHEMICAL", 144, 152], ["CountPD-166285", "CHEMICAL", 271, 285], ["pyridone", "CHEMICAL", 394, 402], ["H", "CHEMICAL", 448, 449], ["Cdk2", "GENE_OR_GENE_PRODUCT", 81, 85], ["thiazole 186", "SIMPLE_CHEMICAL", 144, 156], ["pyridone", "SIMPLE_CHEMICAL", 394, 402], ["Cdk2", "PROTEIN", 81, 85], ["Cdk2 (Fig.", "TEST", 81, 91], ["the thiazole", "TREATMENT", 140, 152], ["Isosteres", "TREATMENT", 221, 230], ["Modulate Lipophilicity", "TEST", 234, 256], ["Atom CountPD", "TEST", 266, 278], ["a broad-acting kinase inhibitor", "TREATMENT", 295, 326], ["the pyridone ring", "TREATMENT", 390, 407], ["Lipophilicity", "OBSERVATION_MODIFIER", 243, 256]]], ["Ab initio calculations predicted that the cis urea is favored by 0.5 kcal/mol in H 2 O and 3.2 kcal/mol in the gas phase, a contention supported by a search of the pyrimidinyl urea substructure in the CSD where seven molecules were found, all of which The Influence of Bioisosteres in Drug Design: Tactical Applications to. . .", [["urea", "CHEMICAL", 46, 50], ["H", "CHEMICAL", 81, 82], ["pyrimidinyl urea", "CHEMICAL", 164, 180], ["Bioisosteres", "CHEMICAL", 269, 281], ["urea", "CHEMICAL", 46, 50], ["H 2 O", "CHEMICAL", 81, 86], ["pyrimidinyl urea", "CHEMICAL", 164, 180], ["cis urea", "SIMPLE_CHEMICAL", 42, 50], ["H 2 O", "SIMPLE_CHEMICAL", 81, 86], ["pyrimidinyl urea", "SIMPLE_CHEMICAL", 164, 180], ["Ab initio calculations", "TEST", 0, 22], ["the cis urea", "TEST", 38, 50], ["the gas phase", "TEST", 107, 120], ["the pyrimidinyl urea substructure", "PROBLEM", 160, 193], ["Tactical Applications", "TREATMENT", 298, 319]]], ["337 exhibited an intramolecular H-bond (Fig. 32) .", [["H", "CHEMICAL", 32, 33], ["intramolecular", "OBSERVATION", 17, 31]]], ["The urea 188 demonstrated broadbased kinase inhibitory activity with potency comparable to 187 and the derivative NVP-BGJ398 (189) was advanced into phase 1 clinical trials [278, 279] .", [["urea 188", "CHEMICAL", 4, 12], ["NVP-BGJ398", "CHEMICAL", 114, 124], ["urea 188", "CHEMICAL", 4, 12], ["NVP-BGJ398", "CHEMICAL", 114, 124], ["urea 188", "SIMPLE_CHEMICAL", 4, 12], ["NVP-BGJ398", "SIMPLE_CHEMICAL", 114, 124], ["The urea", "TEST", 0, 8], ["broadbased kinase inhibitory activity", "PROBLEM", 26, 63], ["the derivative NVP", "TEST", 99, 117]]], ["Another successful example of the application of this concept is provided by the anthranilamide 190 which mimics the phthalazine 191, discovered as an inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinases by highthroughput screening [280] .", [["anthranilamide 190", "CHEMICAL", 81, 99], ["phthalazine 191", "CHEMICAL", 117, 132], ["tyrosine", "CHEMICAL", 221, 229], ["anthranilamide 190", "CHEMICAL", 81, 99], ["phthalazine 191", "CHEMICAL", 117, 132], ["tyrosine", "CHEMICAL", 221, 229], ["anthranilamide 190", "SIMPLE_CHEMICAL", 81, 99], ["phthalazine 191", "SIMPLE_CHEMICAL", 117, 132], ["fibroblast growth factor receptor", "GENE_OR_GENE_PRODUCT", 168, 201], ["receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 212, 237], ["fibroblast growth factor receptor family", "PROTEIN", 168, 208], ["receptor tyrosine kinases", "PROTEIN", 212, 237], ["the phthalazine", "TREATMENT", 113, 128], ["receptor tyrosine kinases", "TREATMENT", 212, 237]]], ["The anti topology of the para-chlorophenyl ring depicted is calculated by ab initio methods to be 3.1 kcal/mol more stable than the cis conformer.", [["para-chlorophenyl", "CHEMICAL", 25, 42], ["para-chlorophenyl", "CHEMICAL", 25, 42], ["para-chlorophenyl ring", "SIMPLE_CHEMICAL", 25, 47], ["the para-chlorophenyl ring", "TREATMENT", 21, 47], ["ab initio methods", "TREATMENT", 74, 91]]], ["This facilitated the design concept of replacing the pyridazine ring by an intramolecularly H-bonded moiety which led to compounds with potent kinase inhibitory properties [280] .", [["pyridazine", "CHEMICAL", 53, 63], ["H", "CHEMICAL", 92, 93], ["pyridazine", "CHEMICAL", 53, 63], ["H", "CHEMICAL", 92, 93], ["pyridazine ring", "SIMPLE_CHEMICAL", 53, 68], ["the pyridazine ring", "TREATMENT", 49, 68], ["an intramolecularly H-bonded moiety", "TREATMENT", 72, 107], ["potent kinase inhibitory properties", "TREATMENT", 136, 171]]], ["Other examples from the kinase inhibitor arena where this concept is well represented include the dual PI3K\u03b1/mTOR inhibitor 193 which is derived from 192, Lck inhibitors 194, and the p38\u03b1 MAP kinase inhibitor 195 [281] [282] [283] .", [["195 [281] [282", "CHEMICAL", 209, 223], ["PI3K\u03b1", "GENE_OR_GENE_PRODUCT", 103, 108], ["mTOR", "GENE_OR_GENE_PRODUCT", 109, 113], ["Lck", "GENE_OR_GENE_PRODUCT", 155, 158], ["p38", "GENE_OR_GENE_PRODUCT", 183, 186], ["MAP kinase", "GENE_OR_GENE_PRODUCT", 188, 198], ["PI3K\u03b1", "PROTEIN", 103, 108], ["mTOR", "PROTEIN", 109, 113], ["Lck", "PROTEIN", 155, 158], ["p38\u03b1", "PROTEIN", 183, 187], ["MAP kinase", "PROTEIN", 188, 198], ["the kinase inhibitor arena", "TREATMENT", 20, 46], ["the dual PI3K\u03b1/mTOR inhibitor", "TREATMENT", 94, 123], ["Lck inhibitors", "TEST", 155, 169], ["the p38", "TEST", 179, 186], ["MAP kinase inhibitor", "TEST", 188, 208]]], ["The presence of intramolecular H-bonds in molecules of this type in an aqueous environment has recently been verified by NMR [284, 285] .", [["H", "CHEMICAL", 31, 32], ["H", "CHEMICAL", 31, 32], ["intramolecular H-bonds in molecules", "PROBLEM", 16, 51], ["intramolecular H", "OBSERVATION", 16, 32]]], ["An interesting application of the isosteric interplay between rings and H-bonded surrogates is provided by the design of the B-Raf V600E kinase inhibitor 200 which has its origins in the benzamide derivative 196 [286] .", [["H", "CHEMICAL", 72, 73], ["benzamide", "CHEMICAL", 187, 196], ["H", "CHEMICAL", 72, 73], ["benzamide", "CHEMICAL", 187, 196], ["B-Raf", "GENE_OR_GENE_PRODUCT", 125, 130], ["B-Raf V600E kinase", "PROTEIN", 125, 143], ["the isosteric interplay between rings and H-bonded surrogates", "TREATMENT", 30, 91], ["the B-Raf V600E kinase inhibitor", "TREATMENT", 121, 153], ["the benzamide derivative", "TREATMENT", 183, 207]]], ["The lead amide 196 exhibits poor solubility, 3-9 \u03bcg/mL, and a high melting point of 226 C and offers only a very weakly basic aminopyridine moiety, pK a \u00bc 0.7, as a vehicle for salt formation, leading to a dependence on an amorphous dispersion-based formulation to deliver adequate oral exposure.", [["oral", "ANATOMY", 282, 286], ["lead amide 196", "CHEMICAL", 4, 18], ["aminopyridine", "CHEMICAL", 126, 139], ["amide 196", "CHEMICAL", 9, 18], ["aminopyridine", "CHEMICAL", 126, 139], ["lead amide 196", "SIMPLE_CHEMICAL", 4, 18], ["aminopyridine", "SIMPLE_CHEMICAL", 126, 139], ["salt", "SIMPLE_CHEMICAL", 177, 181], ["oral", "ORGANISM_SUBDIVISION", 282, 286], ["The lead amide", "TEST", 0, 14], ["poor solubility", "PROBLEM", 28, 43], ["pK", "TEST", 148, 150], ["salt formation", "PROBLEM", 177, 191], ["a dependence", "PROBLEM", 204, 216], ["an amorphous dispersion", "TREATMENT", 220, 243], ["poor solubility", "OBSERVATION_MODIFIER", 28, 43]]], ["The potency of 196 was improved markedly by modifying the aminopyridine moiety to the pyrazolopyridine found in 198 and both compounds were used as vehicles to explore the design of urea-based inhibitors that relied upon intramolecular H-bonding to correctly orient the pharmacophoric elements.", [["aminopyridine", "CHEMICAL", 58, 71], ["pyrazolopyridine", "CHEMICAL", 86, 102], ["urea", "CHEMICAL", 182, 186], ["H", "CHEMICAL", 236, 237], ["aminopyridine", "CHEMICAL", 58, 71], ["pyrazolopyridine", "CHEMICAL", 86, 102], ["urea", "CHEMICAL", 182, 186], ["H", "CHEMICAL", 236, 237], ["aminopyridine", "SIMPLE_CHEMICAL", 58, 71], ["pyrazolopyridine", "SIMPLE_CHEMICAL", 86, 102], ["urea", "SIMPLE_CHEMICAL", 182, 186], ["the aminopyridine moiety", "TREATMENT", 54, 78], ["the pyrazolopyridine", "TREATMENT", 82, 102], ["urea-based inhibitors", "TREATMENT", 182, 203], ["potency", "OBSERVATION_MODIFIER", 4, 11], ["pharmacophoric elements", "OBSERVATION", 270, 293]]], ["This was successful in the context of the ureas 198 and 199, but chemical instability led to further structural refinement with optimization ultimately focusing on the reverse amide series represented by 200, a series with improved physical properties and robust antitumor activity in a B-Raf V600E mouse xenograft model [286] .", [["antitumor", "ANATOMY", 263, 272], ["xenograft", "ANATOMY", 305, 314], ["ureas 198 and 199", "CHEMICAL", 42, 59], ["amide", "CHEMICAL", 176, 181], ["antitumor", "CANCER", 263, 272], ["B-Raf", "GENE_OR_GENE_PRODUCT", 287, 292], ["Raf", "PROTEIN", 289, 292], ["mouse", "SPECIES", 299, 304], ["mouse", "SPECIES", 299, 304], ["the ureas", "TEST", 38, 47], ["chemical instability", "PROBLEM", 65, 85], ["the reverse amide series", "TEST", 164, 188]]], ["The sulfonamide moiety was developed as a useful phenol isostere in the context of \u03b2-adrenergic antagonists with advantage since the high polar surface area and H-bonding properties of this moiety frequently restrict blood-brain barrier penetration as a consequence of reduced permeability and recognition by P-gp [1-10, 196, 197, 287-292] .", [["surface area", "ANATOMY", 144, 156], ["blood-brain barrier", "ANATOMY", 217, 236], ["sulfonamide", "CHEMICAL", 4, 15], ["phenol", "CHEMICAL", 49, 55], ["H", "CHEMICAL", 161, 162], ["sulfonamide", "CHEMICAL", 4, 15], ["phenol", "CHEMICAL", 49, 55], ["H", "CHEMICAL", 161, 162], ["sulfonamide moiety", "SIMPLE_CHEMICAL", 4, 22], ["phenol", "SIMPLE_CHEMICAL", 49, 55], ["\u03b2-adrenergic antagonists", "SIMPLE_CHEMICAL", 83, 107], ["blood", "ORGANISM_SUBSTANCE", 217, 222], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 223, 236], ["The sulfonamide moiety", "TREATMENT", 0, 22], ["a useful phenol isostere", "TREATMENT", 40, 64], ["\u03b2-adrenergic antagonists", "TREATMENT", 83, 107], ["the high polar surface area", "TREATMENT", 129, 156], ["this moiety", "PROBLEM", 185, 196], ["blood-brain barrier penetration", "TREATMENT", 217, 248], ["reduced permeability", "PROBLEM", 269, 289], ["polar", "OBSERVATION_MODIFIER", 138, 143], ["surface", "OBSERVATION_MODIFIER", 144, 151], ["brain", "ANATOMY", 223, 228], ["barrier penetration", "OBSERVATION", 229, 248]]], ["These physical properties have been exploited in restricting drug molecules to peripheral tissues, but the increased polarity may also reduce oral bioavailability due to poor membrane permeability and there are occasions where more lipophilic moieties are desirable [293, 294] .", [["peripheral tissues", "ANATOMY", 79, 97], ["oral", "ANATOMY", 142, 146], ["membrane", "ANATOMY", 175, 183], ["peripheral tissues", "TISSUE", 79, 97], ["oral", "ORGANISM_SUBDIVISION", 142, 146], ["membrane", "CELLULAR_COMPONENT", 175, 183], ["the increased polarity", "PROBLEM", 103, 125], ["oral bioavailability", "PROBLEM", 142, 162], ["poor membrane permeability", "PROBLEM", 170, 196], ["peripheral tissues", "ANATOMY", 79, 97]]], ["Although the 2,2-difluoro-2-(pyridin-2-yl)ethanamine moiety in the thrombin inhibitor 202 was introduced to interfere with benzylic oxidation by cyctochrome P450 (CYP 450), this moiety may, in essence, be functioning as a sulfonamide isostere based on analogy with the prototype 201 [216] [217] [218] [295] [296] [297] .", [["2,2-difluoro-2-(pyridin-2-yl)ethanamine", "CHEMICAL", 13, 52], ["inhibitor 202", "CHEMICAL", 76, 89], ["CYP 450", "CHEMICAL", 163, 170], ["sulfonamide", "CHEMICAL", 222, 233], ["2,2-difluoro-2-(pyridin-2-yl)ethanamine", "CHEMICAL", 13, 52], ["sulfonamide", "CHEMICAL", 222, 233], ["2,2-difluoro-2-(pyridin-2-yl)ethanamine moiety", "SIMPLE_CHEMICAL", 13, 59], ["thrombin inhibitor 202", "SIMPLE_CHEMICAL", 67, 89], ["cyctochrome P450", "GENE_OR_GENE_PRODUCT", 145, 161], ["CYP 450", "GENE_OR_GENE_PRODUCT", 163, 170], ["thrombin", "PROTEIN", 67, 75], ["cyctochrome P450", "PROTEIN", 145, 161], ["difluoro", "TEST", 17, 25], ["pyridin-2-yl)ethanamine moiety", "TREATMENT", 29, 59], ["the thrombin inhibitor", "TREATMENT", 63, 85], ["benzylic oxidation", "TREATMENT", 123, 141], ["a sulfonamide isostere", "TREATMENT", 220, 242]]], ["In this context, not recognized in the design process, the two electronegative F atoms may be viewed as nonpolar mimics of the sulfone oxygen atoms that also reduce the basicity of the nitrogen atom and enhance the H-bonding donating properties of the NH to more effectively mimic the sulfonamide.", [["oxygen", "CHEMICAL", 135, 141], ["H", "CHEMICAL", 215, 216], ["NH", "CHEMICAL", 252, 254], ["sulfonamide", "CHEMICAL", 285, 296], ["F", "CHEMICAL", 79, 80], ["sulfone", "CHEMICAL", 127, 134], ["oxygen", "CHEMICAL", 135, 141], ["nitrogen", "CHEMICAL", 185, 193], ["H", "CHEMICAL", 215, 216], ["NH", "CHEMICAL", 252, 254], ["sulfonamide", "CHEMICAL", 285, 296], ["F atoms", "SIMPLE_CHEMICAL", 79, 86], ["sulfone oxygen atoms", "SIMPLE_CHEMICAL", 127, 147], ["nitrogen atom", "SIMPLE_CHEMICAL", 185, 198], ["NH", "SIMPLE_CHEMICAL", 252, 254], ["sulfonamide", "SIMPLE_CHEMICAL", 285, 296], ["the sulfone oxygen atoms", "TREATMENT", 123, 147], ["the nitrogen atom", "TREATMENT", 181, 198], ["the sulfonamide", "TREATMENT", 281, 296]]], ["The extra atom introduced with the phenethyl moiety may 340 N.A. Meanwell compensate to some extent for the longer bonds associated with the C-S bonds in a sulfonamide.", [["phenethyl", "CHEMICAL", 35, 44], ["sulfonamide", "CHEMICAL", 156, 167], ["phenethyl", "CHEMICAL", 35, 44], ["C-S", "CHEMICAL", 141, 144], ["sulfonamide", "CHEMICAL", 156, 167], ["phenethyl", "SIMPLE_CHEMICAL", 35, 44], ["C-S bonds", "SIMPLE_CHEMICAL", 141, 150], ["sulfonamide", "SIMPLE_CHEMICAL", 156, 167], ["The extra atom", "TREATMENT", 0, 14], ["the phenethyl moiety", "TREATMENT", 31, 51], ["the longer bonds", "PROBLEM", 104, 120], ["a sulfonamide", "TREATMENT", 154, 167]]], ["However, the difluoroalkyl moiety has also been invoked as a heteroaryl ether isostere with the caveat that the geometry and topology of this moiety differs from that of an oxygen-based substituent; indeed, the difluoroalkyl substituent may more effectively mimic a fluoroalkyl ether which adopts an orthogonal disposition to the phenyl ring [298] .", [["difluoroalkyl", "CHEMICAL", 13, 26], ["heteroaryl ether", "CHEMICAL", 61, 77], ["oxygen", "CHEMICAL", 173, 179], ["difluoroalkyl", "CHEMICAL", 211, 224], ["fluoroalkyl ether", "CHEMICAL", 266, 283], ["difluoroalkyl", "CHEMICAL", 13, 26], ["heteroaryl ether", "CHEMICAL", 61, 77], ["oxygen", "CHEMICAL", 173, 179], ["difluoroalkyl", "CHEMICAL", 211, 224], ["fluoroalkyl ether", "CHEMICAL", 266, 283], ["phenyl", "CHEMICAL", 330, 336], ["difluoroalkyl moiety", "SIMPLE_CHEMICAL", 13, 33], ["heteroaryl ether isostere", "SIMPLE_CHEMICAL", 61, 86], ["oxygen", "SIMPLE_CHEMICAL", 173, 179], ["difluoroalkyl substituent", "SIMPLE_CHEMICAL", 211, 236], ["fluoroalkyl ether", "SIMPLE_CHEMICAL", 266, 283], ["a heteroaryl ether isostere", "TREATMENT", 59, 86], ["an oxygen-based substituent", "TREATMENT", 170, 197], ["the difluoroalkyl substituent", "TREATMENT", 207, 236], ["a fluoroalkyl ether", "TREATMENT", 264, 283]]], ["Interestingly, 202 also incorporates a fluorobenzene moiety to mimic the pyridone with a close interaction between the F atom and the thrombin peptide backbone NH observed in the co-crystal, indicative of isosterism between C-F and C\u00bcO bonds.", [["fluorobenzene", "CHEMICAL", 39, 52], ["pyridone", "CHEMICAL", 73, 81], ["fluorobenzene", "CHEMICAL", 39, 52], ["pyridone", "CHEMICAL", 73, 81], ["F", "CHEMICAL", 119, 120], ["NH", "CHEMICAL", 160, 162], ["C-F", "CHEMICAL", 224, 227], ["C\u00bcO", "CHEMICAL", 232, 235], ["fluorobenzene", "SIMPLE_CHEMICAL", 39, 52], ["pyridone", "SIMPLE_CHEMICAL", 73, 81], ["F atom", "SIMPLE_CHEMICAL", 119, 125], ["thrombin", "GENE_OR_GENE_PRODUCT", 134, 142], ["isosterism", "SIMPLE_CHEMICAL", 205, 215], ["C-F", "SIMPLE_CHEMICAL", 224, 227], ["C\u00bcO bonds", "SIMPLE_CHEMICAL", 232, 241], ["thrombin", "PROTEIN", 134, 142], ["a fluorobenzene moiety", "TREATMENT", 37, 59], ["the pyridone", "TREATMENT", 69, 81], ["the thrombin peptide backbone NH", "TREATMENT", 130, 162], ["isosterism", "PROBLEM", 205, 215]]], ["The affinity of 203 and 204 for the \u03b22-adrenergic receptor and the intrinsic agonistic properties are very similar, but the log D 7.4 and pK a of the nitrogen atom for the 2 molecules differ, with the difluoromethyl analogue 204 more lipophilic but more basic.", [["nitrogen", "CHEMICAL", 150, 158], ["difluoromethyl", "CHEMICAL", 201, 215], ["nitrogen", "CHEMICAL", 150, 158], ["difluoromethyl", "CHEMICAL", 201, 215], ["\u03b22-adrenergic receptor", "GENE_OR_GENE_PRODUCT", 36, 58], ["nitrogen atom", "SIMPLE_CHEMICAL", 150, 163], ["\u03b22-adrenergic receptor", "PROTEIN", 36, 58], ["The affinity", "TEST", 0, 12], ["the \u03b22-adrenergic receptor", "TREATMENT", 32, 58], ["the nitrogen atom", "TREATMENT", 146, 163], ["the difluoromethyl analogue", "TREATMENT", 197, 224]]], ["The design of 204 was based on the development of a model that identified secondary amines with a pK a > 8.0 and a log D 7.4 > 2 as molecules possessing an ultra-long duration of action [299] .", [["amines", "CHEMICAL", 84, 90], ["secondary amines", "CHEMICAL", 74, 90], ["a pK", "TEST", 96, 100], ["a log D", "TEST", 113, 120], ["an ultra", "TEST", 153, 161]]], ["The Influence of Bioisosteres in Drug Design: Tactical Applications to. . .Substitution of Hydrogen by DeuteriumThe substitution of H by D is the most conservative form of bioisosteric replacement and this tactic has attracted considerable attention recently as a practical approach to drug design.", [["Hydrogen", "CHEMICAL", 91, 99], ["Deuterium", "CHEMICAL", 103, 112], ["H", "CHEMICAL", 132, 133], ["Hydrogen", "CHEMICAL", 91, 99], ["Deuterium", "CHEMICAL", 103, 112], ["H", "CHEMICAL", 132, 133], ["Hydrogen", "SIMPLE_CHEMICAL", 91, 99], ["Deuterium", "SIMPLE_CHEMICAL", 103, 112], ["D", "SIMPLE_CHEMICAL", 137, 138], ["Tactical Applications", "TREATMENT", 46, 67], ["Hydrogen", "TREATMENT", 91, 99], ["bioisosteric replacement", "TREATMENT", 172, 196], ["a practical approach", "TREATMENT", 262, 282], ["bioisosteric replacement", "OBSERVATION", 172, 196]]], ["The underlying premise relies upon the effect of deuterium substitution to influence pharmacokinetic properties when deployed in a strategic fashion that takes advantage of the kinetic isotope effect (KIE) associated with the heavier atom [300] [301] [302] [303] [304] .", [["deuterium", "CHEMICAL", 49, 58], ["[300] [301] [302] [303] [304]", "CHEMICAL", 239, 268], ["deuterium", "SIMPLE_CHEMICAL", 49, 58], ["deuterium substitution", "TREATMENT", 49, 71], ["influence pharmacokinetic properties", "TREATMENT", 75, 111]]], ["The differences between the isotopes are small but measurable, with deuterium 0.140 cm 3 /mol per atom smaller than hydrogen, the C-D bond is 0.005 \u00c5 shorter than a C-H bond, and the log P oct of D is 0.006 units less lipophilic, an effect that can be measured in per-deuterated alkanes and which has facilitated the chromatographic separation of enantiomers that are based solely on H/D isotopic substitution [305] [306] [307] .", [["deuterium", "CHEMICAL", 68, 77], ["hydrogen", "CHEMICAL", 116, 124], ["H", "CHEMICAL", 384, 385], ["deuterium", "CHEMICAL", 68, 77], ["hydrogen", "CHEMICAL", 116, 124], ["C-D", "CHEMICAL", 130, 133], ["C-H", "CHEMICAL", 165, 168], ["alkanes", "CHEMICAL", 279, 286], ["H", "CHEMICAL", 384, 385], ["D", "CHEMICAL", 386, 387], ["hydrogen", "SIMPLE_CHEMICAL", 116, 124], ["C-D", "SIMPLE_CHEMICAL", 130, 133], ["C-H", "SIMPLE_CHEMICAL", 165, 168], ["D", "SIMPLE_CHEMICAL", 196, 197], ["per-deuterated alkanes", "SIMPLE_CHEMICAL", 264, 286], ["H/D", "SIMPLE_CHEMICAL", 384, 387], ["deuterium", "TEST", 68, 77], ["the C-D bond", "TEST", 126, 138], ["the chromatographic separation of enantiomers", "TREATMENT", 313, 358], ["isotopes", "OBSERVATION", 28, 36], ["small", "OBSERVATION_MODIFIER", 41, 46], ["measurable", "OBSERVATION_MODIFIER", 51, 61], ["smaller", "OBSERVATION_MODIFIER", 103, 110]]], ["Deuteration slightly increases the basicity of proximal amines and reduces the acidity of phenols and carboxylic acid derivatives [308] [309] [310] [311] .", [["Deuteration", "CHEMICAL", 0, 11], ["amines", "CHEMICAL", 56, 62], ["phenols", "CHEMICAL", 90, 97], ["carboxylic acid", "CHEMICAL", 102, 117], ["amines", "CHEMICAL", 56, 62], ["phenols", "CHEMICAL", 90, 97], ["carboxylic acid", "CHEMICAL", 102, 117], ["phenols", "SIMPLE_CHEMICAL", 90, 97], ["carboxylic acid", "SIMPLE_CHEMICAL", 102, 117], ["the acidity of phenols", "TREATMENT", 75, 97], ["carboxylic acid derivatives", "TREATMENT", 102, 129], ["slightly", "OBSERVATION_MODIFIER", 12, 20], ["increases", "OBSERVATION_MODIFIER", 21, 30], ["basicity", "OBSERVATION_MODIFIER", 35, 43], ["proximal", "ANATOMY_MODIFIER", 47, 55]]], ["Following the discovery of the isotope, deuteration of drug molecules was quickly adopted as a useful structural modification for the study of metabolic pathways and the origins of toxicity, with the KIE playing the key role in this application [300, [312] [313] [314] .", [["toxicity", "DISEASE", 181, 189], ["the isotope", "PROBLEM", 27, 38], ["drug molecules", "PROBLEM", 55, 69], ["the study", "TEST", 130, 139], ["toxicity", "PROBLEM", 181, 189]]], ["However, the study of the deuteration of drug candidates as an approach to improving pharmacokinetic properties by reducing the rate of metabolic modification at sites where H atom abstraction determines the rate of reaction has been adopted only recently, although the first demonstration of the practicality of the approach was described in 1961 [315] .", [["H", "CHEMICAL", 174, 175], ["H", "CHEMICAL", 174, 175], ["H atom", "SIMPLE_CHEMICAL", 174, 180], ["the study", "TEST", 9, 18], ["drug candidates", "TREATMENT", 41, 56], ["metabolic modification", "PROBLEM", 136, 158], ["H atom abstraction", "PROBLEM", 174, 192], ["metabolic modification", "OBSERVATION", 136, 158]]], ["The KIE for a D for H substitution is dependent on the circumstances but usually ranges from one-to sevenfold with calculations suggesting a seven-to tenfold difference; however, in specific cases, much higher isotope effects have been measured [316, 317] .", [["H", "CHEMICAL", 20, 21], ["H", "CHEMICAL", 20, 21], ["a D for H substitution", "TREATMENT", 12, 34], ["much higher isotope effects", "PROBLEM", 198, 225]]], ["D for H substitution has been shown to translate into meaningful changes in the clinical pharmacokinetic profiles of drugs, exemplified most effectively by CTP-347 (205) , a dideuterated analogue of the antidepressant paroxetine, and SD-254 (206) , a per-deuterated derivative of the dual serotonin/norepinephrine reuptake inhibitor venlafaxine that also finds utility for its antidepressant properties [303, 318, 319] .", [["H", "CHEMICAL", 6, 7], ["CTP-347", "CHEMICAL", 156, 163], ["antidepressant", "CHEMICAL", 203, 217], ["paroxetine", "CHEMICAL", 218, 228], ["SD-254", "CHEMICAL", 234, 240], ["serotonin", "CHEMICAL", 289, 298], ["norepinephrine", "CHEMICAL", 299, 313], ["venlafaxine", "CHEMICAL", 333, 344], ["antidepressant", "CHEMICAL", 377, 391], ["H", "CHEMICAL", 6, 7], ["CTP-347", "CHEMICAL", 156, 163], ["paroxetine", "CHEMICAL", 218, 228], ["SD-254", "CHEMICAL", 234, 240], ["serotonin", "CHEMICAL", 289, 298], ["norepinephrine", "CHEMICAL", 299, 313], ["venlafaxine", "CHEMICAL", 333, 344], ["D", "SIMPLE_CHEMICAL", 0, 1], ["CTP-347", "SIMPLE_CHEMICAL", 156, 163], ["paroxetine", "SIMPLE_CHEMICAL", 218, 228], ["SD-254", "SIMPLE_CHEMICAL", 234, 240], ["serotonin", "SIMPLE_CHEMICAL", 289, 298], ["norepinephrine", "SIMPLE_CHEMICAL", 299, 313], ["venlafaxine", "SIMPLE_CHEMICAL", 333, 344], ["drugs", "TREATMENT", 117, 122], ["CTP", "TEST", 156, 159], ["the antidepressant paroxetine", "TREATMENT", 199, 228], ["the dual serotonin/norepinephrine reuptake inhibitor venlafaxine", "TREATMENT", 280, 344]]], ["In CPT-347 (205) , deuterium is introduced at the methylenedioxy moiety, the site of metabolic modification by CYP 2D6, which leads to mechanism-based inhibition of the enzyme through the intermediacy of a carbene-based metabolite, resulting in drug accumulation on repeat dosing due to autoinhibition and precipitating drug-drug interactions [303, [320] [321] [322] .", [["CPT-347", "CHEMICAL", 3, 10], ["deuterium", "CHEMICAL", 19, 28], ["carbene", "CHEMICAL", 206, 213], ["CPT-347", "CHEMICAL", 3, 10], ["deuterium", "CHEMICAL", 19, 28], ["methylenedioxy", "CHEMICAL", 50, 64], ["carbene", "CHEMICAL", 206, 213], ["CPT-347", "SIMPLE_CHEMICAL", 3, 10], ["deuterium", "SIMPLE_CHEMICAL", 19, 28], ["methylenedioxy moiety", "SIMPLE_CHEMICAL", 50, 71], ["CYP 2D6", "GENE_OR_GENE_PRODUCT", 111, 118], ["CYP 2D6", "PROTEIN", 111, 118], ["CPT", "TEST", 3, 6], ["the methylenedioxy moiety", "TREATMENT", 46, 71], ["the enzyme", "TEST", 165, 175], ["a carbene", "TREATMENT", 204, 213], ["drug accumulation", "PROBLEM", 245, 262], ["repeat dosing", "TREATMENT", 266, 279], ["autoinhibition", "PROBLEM", 287, 301], ["metabolic modification", "OBSERVATION", 85, 107], ["drug accumulation", "OBSERVATION", 245, 262]]], ["CPT-347 (205) does not exhibit significant mechanism-based inhibition of CYP 2D6 in vitro and a phase 1 clinical study demonstrated that subjects dosed with the deuterated drug were able to metabolize the CYP 2D6 substrate dextromethorphan more effectively when compared to historical data for paroxetine [303] .", [["CPT-347", "CHEMICAL", 0, 7], ["dextromethorphan", "CHEMICAL", 223, 239], ["paroxetine", "CHEMICAL", 294, 304], ["CPT-347", "CHEMICAL", 0, 7], ["dextromethorphan", "CHEMICAL", 223, 239], ["paroxetine", "CHEMICAL", 294, 304], ["CPT-347", "SIMPLE_CHEMICAL", 0, 7], ["CYP 2D6", "GENE_OR_GENE_PRODUCT", 73, 80], ["CYP 2D6", "GENE_OR_GENE_PRODUCT", 205, 212], ["dextromethorphan", "SIMPLE_CHEMICAL", 223, 239], ["paroxetine", "SIMPLE_CHEMICAL", 294, 304], ["CYP 2D6", "PROTEIN", 73, 80], ["CPT", "TEST", 0, 3], ["clinical study", "TEST", 104, 118], ["the deuterated drug", "TREATMENT", 157, 176], ["the CYP 2D6 substrate dextromethorphan", "TREATMENT", 201, 239], ["paroxetine", "TREATMENT", 294, 304]]], ["In a phase 1 clinical trial in normal healthy volunteers, SD-254 (206) was reported to be metabolized more slowly than venlafaxine which is O-demethylated by CYP 2D6 [303] .", [["SD-254", "CHEMICAL", 58, 64], ["venlafaxine", "CHEMICAL", 119, 130], ["SD-254", "CHEMICAL", 58, 64], ["venlafaxine", "CHEMICAL", 119, 130], ["O", "CHEMICAL", 140, 141], ["volunteers", "ORGANISM", 46, 56], ["SD-254", "SIMPLE_CHEMICAL", 58, 64], ["venlafaxine", "SIMPLE_CHEMICAL", 119, 130], ["CYP 2D6", "GENE_OR_GENE_PRODUCT", 158, 165], ["CYP 2D6", "PROTEIN", 158, 165], ["SD", "TEST", 58, 60], ["venlafaxine", "TREATMENT", 119, 130]]], ["However, selective deuteration at a site of metabolism does not always lead to enhanced pharmacokinetic properties, illustrated by a study of the tyrosine kinase inhibitor imatinib (207) for which N-demethylation to the less active piperazine 208 is a major metabolic pathway [323] [324] [325] .", [["tyrosine", "CHEMICAL", 146, 154], ["imatinib", "CHEMICAL", 172, 180], ["piperazine", "CHEMICAL", 232, 242], ["tyrosine", "CHEMICAL", 146, 154], ["imatinib", "CHEMICAL", 172, 180], ["N", "CHEMICAL", 197, 198], ["piperazine 208", "CHEMICAL", 232, 246], ["imatinib", "SIMPLE_CHEMICAL", 172, 180], ["piperazine 208", "SIMPLE_CHEMICAL", 232, 246], ["tyrosine kinase", "PROTEIN", 146, 161], ["selective deuteration", "PROBLEM", 9, 30], ["a study", "TEST", 131, 138], ["the tyrosine kinase inhibitor imatinib", "TREATMENT", 142, 180], ["N-demethylation to the less active piperazine", "TREATMENT", 197, 242], ["selective", "OBSERVATION_MODIFIER", 9, 18], ["deuteration", "OBSERVATION", 19, 30]]], ["The tri-deuterio analogue 209 exhibited increased stability toward N-demethylation in rat and human liver microsomes, as anticipated, but intravenous administration of the compound to rats was not associated with increased exposure and the rate of demethylation of 209 was similar to 207, attributed to a relatively low rate of demethylation of the parent in rat liver microsomes and the low rate clearance of both compounds in rats [323] .", [["liver microsomes", "ANATOMY", 100, 116], ["intravenous", "ANATOMY", 138, 149], ["liver microsomes", "ANATOMY", 363, 379], ["tri-deuterio analogue 209", "CHEMICAL", 4, 29], ["N-demethylation", "CHEMICAL", 67, 82], ["tri-deuterio", "CHEMICAL", 4, 16], ["N", "CHEMICAL", 67, 68], ["tri-deuterio analogue 209", "SIMPLE_CHEMICAL", 4, 29], ["rat", "ORGANISM", 86, 89], ["human", "ORGANISM", 94, 99], ["liver microsomes", "TISSUE", 100, 116], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 138, 149], ["rats", "ORGANISM", 184, 188], ["rat", "ORGANISM", 359, 362], ["liver microsomes", "TISSUE", 363, 379], ["rats", "ORGANISM", 428, 432], ["rat liver microsomes", "CELL_TYPE", 359, 379], ["rat", "SPECIES", 86, 89], ["human", "SPECIES", 94, 99], ["rats", "SPECIES", 184, 188], ["rat", "SPECIES", 359, 362], ["rats", "SPECIES", 428, 432], ["rat", "SPECIES", 86, 89], ["human", "SPECIES", 94, 99], ["rat", "SPECIES", 359, 362], ["The tri-deuterio analogue", "TEST", 0, 25], ["increased stability", "PROBLEM", 40, 59], ["intravenous administration", "TREATMENT", 138, 164], ["increased exposure", "PROBLEM", 213, 231], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["stability", "OBSERVATION_MODIFIER", 50, 59], ["liver", "ANATOMY", 100, 105], ["liver", "ANATOMY", 363, 368]]], ["An alternative application of deuterium incorporation that led to improved pharmacokinetic properties is illustrated by the HCV NS3 protease inhibitor telaprevir (210) which suffers facile racemization at the P1 residue at higher pH and in human plasma [326] .", [["plasma", "ANATOMY", 246, 252], ["deuterium", "CHEMICAL", 30, 39], ["telaprevir", "CHEMICAL", 151, 161], ["deuterium", "CHEMICAL", 30, 39], ["telaprevir", "CHEMICAL", 151, 161], ["deuterium", "SIMPLE_CHEMICAL", 30, 39], ["telaprevir", "SIMPLE_CHEMICAL", 151, 161], ["human", "ORGANISM", 240, 245], ["plasma", "ORGANISM_SUBSTANCE", 246, 252], ["human", "SPECIES", 240, 245], ["HCV", "SPECIES", 124, 127], ["human", "SPECIES", 240, 245], ["deuterium incorporation", "TREATMENT", 30, 53], ["the HCV NS3 protease inhibitor telaprevir", "TREATMENT", 120, 161], ["facile racemization", "PROBLEM", 182, 201], ["deuterium incorporation", "OBSERVATION", 30, 53]]], ["The (R)-diastereomer is the major metabolite of telaprevir in vivo but is 30-fold weaker than the (S)-isomer which contributes to the need for this drug to be dosed on a TID schedule.", [["telaprevir", "CHEMICAL", 48, 58], ["(R)-diastereomer", "CHEMICAL", 4, 20], ["telaprevir", "CHEMICAL", 48, 58], ["(R)-diastereomer", "SIMPLE_CHEMICAL", 4, 20], ["telaprevir", "SIMPLE_CHEMICAL", 48, 58], ["(S)-isomer", "SIMPLE_CHEMICAL", 98, 108], ["telaprevir", "TREATMENT", 48, 58], ["this drug", "TREATMENT", 143, 152], ["a TID schedule", "TREATMENT", 168, 182]]], ["Installing a deuterium atom at the configurationally labile carbon atom gave a compound that inhibited HCV NS3 protease with a K i \u00bc 20 nM, approximately twofold more potent than the telaprevir (210) , and reduced the propensity for racemization in human plasma: the deuterated compound produced only 10% of the epimer over 1 h of incubation compared to 35% with the protio homologue.", [["plasma", "ANATOMY", 255, 261], ["deuterium atom", "CHEMICAL", 13, 27], ["K", "CHEMICAL", 127, 128], ["telaprevir", "CHEMICAL", 183, 193], ["deuterium", "CHEMICAL", 13, 22], ["carbon", "CHEMICAL", 60, 66], ["telaprevir", "CHEMICAL", 183, 193], ["deuterium atom", "SIMPLE_CHEMICAL", 13, 27], ["carbon atom", "SIMPLE_CHEMICAL", 60, 71], ["HCV", "ORGANISM", 103, 106], ["human", "ORGANISM", 249, 254], ["plasma", "ORGANISM_SUBSTANCE", 255, 261], ["HCV NS3 protease", "PROTEIN", 103, 119], ["human plasma", "CELL_TYPE", 249, 261], ["protio homologue", "PROTEIN", 367, 383], ["human", "SPECIES", 249, 254], ["HCV", "SPECIES", 103, 106], ["human", "SPECIES", 249, 254], ["a deuterium atom", "TREATMENT", 11, 27], ["the configurationally labile carbon atom", "PROBLEM", 31, 71], ["HCV NS3 protease", "TREATMENT", 103, 119], ["a K i", "TEST", 125, 130], ["the telaprevir", "TREATMENT", 179, 193]]], ["Although the stability of the deuterio derivative in rat plasma was lower, this compound exhibited a 13% increased AUC following oral administration to rats when compared to telaprevir (210) [326] .", [["plasma", "ANATOMY", 57, 63], ["oral", "ANATOMY", 129, 133], ["deuterio", "CHEMICAL", 30, 38], ["telaprevir", "CHEMICAL", 174, 184], ["deuterio", "CHEMICAL", 30, 38], ["telaprevir", "CHEMICAL", 174, 184], ["deuterio derivative", "SIMPLE_CHEMICAL", 30, 49], ["rat", "ORGANISM", 53, 56], ["plasma", "ORGANISM_SUBSTANCE", 57, 63], ["oral", "ORGANISM_SUBDIVISION", 129, 133], ["rats", "ORGANISM", 152, 156], ["rat", "SPECIES", 53, 56], ["rats", "SPECIES", 152, 156], ["rat", "SPECIES", 53, 56], ["the deuterio derivative in rat plasma", "TEST", 26, 63], ["a 13% increased AUC", "PROBLEM", 99, 118], ["oral administration", "TREATMENT", 129, 148], ["telaprevir", "TREATMENT", 174, 184], ["stability", "OBSERVATION_MODIFIER", 13, 22]]], ["Deuteration at metabolically labile sites can redirect metabolism away from a toxic species, as in the case of the HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz (211) , or enhance bioactivation of prodrugs, as illustrated by the platelet aggregation inhibitor clopidogrel (214) [327, 328] .", [["platelet", "ANATOMY", 246, 254], ["nucleoside", "CHEMICAL", 125, 135], ["efavirenz", "CHEMICAL", 168, 177], ["platelet aggregation", "DISEASE", 246, 266], ["clopidogrel", "CHEMICAL", 277, 288], ["nucleoside", "CHEMICAL", 125, 135], ["efavirenz (211)", "CHEMICAL", 168, 183], ["clopidogrel", "CHEMICAL", 277, 288], ["HIV-1", "ORGANISM", 115, 120], ["nucleoside reverse transcriptase", "GENE_OR_GENE_PRODUCT", 125, 157], ["efavirenz", "SIMPLE_CHEMICAL", 168, 177], ["prodrugs", "SIMPLE_CHEMICAL", 214, 222], ["platelet", "CELL", 246, 254], ["clopidogrel", "SIMPLE_CHEMICAL", 277, 288], ["nucleoside reverse transcriptase", "PROTEIN", 125, 157], ["HIV-1", "SPECIES", 115, 120], ["HIV-1", "SPECIES", 115, 120], ["Deuteration at metabolically labile sites", "PROBLEM", 0, 41], ["a toxic species", "PROBLEM", 76, 91], ["the HIV", "TEST", 111, 118], ["nucleoside reverse transcriptase inhibitor efavirenz", "TREATMENT", 125, 177], ["prodrugs", "TREATMENT", 214, 222], ["the platelet aggregation inhibitor clopidogrel", "TREATMENT", 242, 288], ["toxic", "OBSERVATION_MODIFIER", 78, 83]]], ["In rats, the metabolism of efavirenz (211) is complex, with the initial step hydroxylation of the aromatic ring to afford a phenol that is a substrate for sulfation.", [["efavirenz", "CHEMICAL", 27, 36], ["phenol", "CHEMICAL", 124, 130], ["efavirenz", "CHEMICAL", 27, 36], ["phenol", "CHEMICAL", 124, 130], ["rats", "ORGANISM", 3, 7], ["efavirenz", "SIMPLE_CHEMICAL", 27, 36], ["phenol", "SIMPLE_CHEMICAL", 124, 130], ["rats", "SPECIES", 3, 7], ["efavirenz", "TREATMENT", 27, 36], ["the initial step hydroxylation", "TREATMENT", 60, 90], ["a phenol", "TREATMENT", 122, 130]]], ["Subsequent hydroxylation at the propargylic position affords a cyclopropylcarbinol that facilitates the addition of glutathione to the alkyne to afford an adduct from which the glutamate is subsequently cleaved, a process blocked by acivicin, to afford 213, which was determined to be the source of kidney toxicity seen uniquely in rats.", [["kidney", "ANATOMY", 299, 305], ["cyclopropylcarbinol", "CHEMICAL", 63, 82], ["glutathione", "CHEMICAL", 116, 127], ["glutamate", "CHEMICAL", 177, 186], ["acivicin", "CHEMICAL", 233, 241], ["kidney toxicity", "DISEASE", 299, 314], ["cyclopropylcarbinol", "CHEMICAL", 63, 82], ["glutathione", "CHEMICAL", 116, 127], ["alkyne", "CHEMICAL", 135, 141], ["glutamate", "CHEMICAL", 177, 186], ["acivicin", "CHEMICAL", 233, 241], ["cyclopropylcarbinol", "SIMPLE_CHEMICAL", 63, 82], ["glutathione", "SIMPLE_CHEMICAL", 116, 127], ["alkyne", "SIMPLE_CHEMICAL", 135, 141], ["glutamate", "SIMPLE_CHEMICAL", 177, 186], ["acivicin", "SIMPLE_CHEMICAL", 233, 241], ["kidney", "ORGAN", 299, 305], ["rats", "ORGANISM", 332, 336], ["rats", "SPECIES", 332, 336], ["Subsequent hydroxylation at the propargylic position", "TREATMENT", 0, 52], ["a cyclopropylcarbinol", "TREATMENT", 61, 82], ["glutathione to the alkyne", "TREATMENT", 116, 141], ["an adduct", "PROBLEM", 152, 161], ["acivicin", "TREATMENT", 233, 241], ["kidney toxicity", "PROBLEM", 299, 314], ["kidney", "ANATOMY", 299, 305], ["toxicity", "OBSERVATION", 306, 314]]], ["As part of this investigation, deuteration at the propargylic position was designed to slow the hydroxylation step and reduce the amount of 213 produced, a successful enterprise since 212 exhibits less severe nephrotoxicity of lower frequency [327] .", [["nephrotoxicity", "DISEASE", 209, 223], ["this investigation", "TEST", 11, 29], ["deuteration at the propargylic position", "TREATMENT", 31, 70], ["the hydroxylation step", "TREATMENT", 92, 114], ["less severe nephrotoxicity of lower frequency", "PROBLEM", 197, 242], ["less severe", "OBSERVATION_MODIFIER", 197, 208], ["nephrotoxicity", "OBSERVATION", 209, 223], ["lower frequency", "OBSERVATION_MODIFIER", 227, 242]]], ["Clopidogrel (214) requires metabolic activation in order to express its antithrombotic effects, a process that is initiated by oxidation of the thiophene ring by CYP 450 enzymes to produce the thiolactone 215 [328, 329] .", [["Clopidogrel", "CHEMICAL", 0, 11], ["thiolactone", "CHEMICAL", 193, 204], ["Clopidogrel", "CHEMICAL", 0, 11], ["thiophene", "CHEMICAL", 144, 153], ["thiolactone", "CHEMICAL", 193, 204], ["Clopidogrel", "SIMPLE_CHEMICAL", 0, 11], ["CYP 450", "GENE_OR_GENE_PRODUCT", 162, 169], ["CYP 450 enzymes", "PROTEIN", 162, 177], ["Clopidogrel", "TREATMENT", 0, 11], ["metabolic activation", "TREATMENT", 27, 47], ["the thiophene ring", "TREATMENT", 140, 158], ["the thiolactone", "TEST", 189, 204]]], ["Thiolactone 215 is further oxidized to the acylated sulfoxide 216, a species that is readily hydrolyzed to the highly reactive sulfenic acid 217, considered to be the ultimate active principle of the drug that reacts covalently with and blocks the P2Y 12 receptor that is activated by adenosine diphosphate (ADP) [328, 329] .", [["Thiolactone 215", "CHEMICAL", 0, 15], ["acylated sulfoxide", "CHEMICAL", 43, 61], ["sulfenic acid 217", "CHEMICAL", 127, 144], ["adenosine diphosphate", "CHEMICAL", 285, 306], ["ADP", "CHEMICAL", 308, 311], ["Thiolactone 215", "CHEMICAL", 0, 15], ["acylated sulfoxide", "CHEMICAL", 43, 61], ["sulfenic acid", "CHEMICAL", 127, 140], ["adenosine diphosphate", "CHEMICAL", 285, 306], ["ADP", "CHEMICAL", 308, 311], ["Thiolactone 215", "SIMPLE_CHEMICAL", 0, 15], ["acylated sulfoxide 216", "SIMPLE_CHEMICAL", 43, 65], ["sulfenic acid 217", "SIMPLE_CHEMICAL", 127, 144], ["P2Y 12 receptor", "GENE_OR_GENE_PRODUCT", 248, 263], ["adenosine diphosphate", "SIMPLE_CHEMICAL", 285, 306], ["ADP", "SIMPLE_CHEMICAL", 308, 311], ["P2Y 12 receptor", "PROTEIN", 248, 263], ["Thiolactone", "TREATMENT", 0, 11], ["the acylated sulfoxide", "TEST", 39, 61], ["reactive sulfenic acid", "TEST", 118, 140], ["adenosine diphosphate (ADP", "TREATMENT", 285, 311]]], ["However, the metabolism of clopidogrel (214) into the active species is limited, complicated by alternative pathways that involve cleavage of the ester moiety to afford an inactive acid and CYP-mediated oxidation of the piperidine ring [328] .", [["clopidogrel", "CHEMICAL", 27, 38], ["ester", "CHEMICAL", 146, 151], ["piperidine", "CHEMICAL", 220, 230], ["clopidogrel", "CHEMICAL", 27, 38], ["ester", "CHEMICAL", 146, 151], ["piperidine", "CHEMICAL", 220, 230], ["clopidogrel", "SIMPLE_CHEMICAL", 27, 38], ["ester", "SIMPLE_CHEMICAL", 146, 151], ["CYP", "SIMPLE_CHEMICAL", 190, 193], ["CYP", "PROTEIN", 190, 193], ["clopidogrel", "TREATMENT", 27, 38], ["the ester moiety", "TREATMENT", 142, 158], ["an inactive acid", "TREATMENT", 169, 185], ["CYP-mediated oxidation of the piperidine ring", "TREATMENT", 190, 235], ["active", "OBSERVATION_MODIFIER", 54, 60], ["species", "OBSERVATION", 61, 68]]], ["In an effort to direct metabolic activation toward the thiophene ring and enhance the antiplatelet activity of clopidogrel (214) in vivo, the effect of deuteration of the piperidine was examined.", [["antiplatelet", "ANATOMY", 86, 98], ["thiophene", "CHEMICAL", 55, 64], ["clopidogrel", "CHEMICAL", 111, 122], ["piperidine", "CHEMICAL", 171, 181], ["thiophene", "CHEMICAL", 55, 64], ["clopidogrel", "CHEMICAL", 111, 122], ["piperidine", "CHEMICAL", 171, 181], ["clopidogrel", "SIMPLE_CHEMICAL", 111, 122], ["piperidine", "SIMPLE_CHEMICAL", 171, 181], ["the thiophene ring", "TREATMENT", 51, 69], ["clopidogrel", "TREATMENT", 111, 122], ["the piperidine", "TREATMENT", 167, 181]]], ["The d 6 derivative 218 exhibited similar metabolic 344 N.A. Meanwell stability to clopidogrel (214) in rat and human liver microsomes but improved conversion to the thiolactone 215, an effect that manifested in vivo in rats as enhanced ex vivo inhibition of ADP-induced platelet aggregation following oral administration of 218 [328] .Substitution of Carbon by SiliconThe replacement of carbon atoms by silicon has attracted attention as a drug design principle that may offer advantage in specific circumstances where the unique properties of silicon can be exploited [330, 331] .", [["liver microsomes", "ANATOMY", 117, 133], ["platelet", "ANATOMY", 270, 278], ["oral", "ANATOMY", 301, 305], ["d 6 derivative 218", "CHEMICAL", 4, 22], ["clopidogrel", "CHEMICAL", 82, 93], ["thiolactone 215", "CHEMICAL", 165, 180], ["ADP", "CHEMICAL", 258, 261], ["platelet aggregation", "DISEASE", 270, 290], ["Carbon", "CHEMICAL", 351, 357], ["Silicon", "CHEMICAL", 361, 368], ["carbon atoms", "CHEMICAL", 387, 399], ["silicon", "CHEMICAL", 403, 410], ["silicon", "CHEMICAL", 544, 551], ["clopidogrel", "CHEMICAL", 82, 93], ["thiolactone 215", "CHEMICAL", 165, 180], ["ADP", "CHEMICAL", 258, 261], ["Carbon", "CHEMICAL", 351, 357], ["Silicon", "CHEMICAL", 361, 368], ["carbon", "CHEMICAL", 387, 393], ["silicon", "CHEMICAL", 403, 410], ["silicon", "CHEMICAL", 544, 551], ["clopidogrel", "SIMPLE_CHEMICAL", 82, 93], ["rat", "ORGANISM", 103, 106], ["human", "ORGANISM", 111, 116], ["liver microsomes", "TISSUE", 117, 133], ["thiolactone 215", "SIMPLE_CHEMICAL", 165, 180], ["rats", "ORGANISM", 219, 223], ["ADP", "SIMPLE_CHEMICAL", 258, 261], ["platelet", "CELL", 270, 278], ["oral", "ORGANISM_SUBDIVISION", 301, 305], ["carbon atoms", "SIMPLE_CHEMICAL", 387, 399], ["silicon", "SIMPLE_CHEMICAL", 403, 410], ["silicon", "SIMPLE_CHEMICAL", 544, 551], ["platelet", "CELL_TYPE", 270, 278], ["rat", "SPECIES", 103, 106], ["human", "SPECIES", 111, 116], ["rats", "SPECIES", 219, 223], ["rat", "SPECIES", 103, 106], ["human", "SPECIES", 111, 116], ["clopidogrel", "TREATMENT", 82, 93], ["human liver microsomes", "TREATMENT", 111, 133], ["the thiolactone", "TREATMENT", 161, 176], ["ADP", "PROBLEM", 258, 261], ["platelet aggregation", "PROBLEM", 270, 290], ["oral administration", "TREATMENT", 301, 320], ["Carbon by SiliconThe replacement of carbon atoms", "TREATMENT", 351, 399], ["a drug design principle", "TREATMENT", 438, 461], ["liver", "ANATOMY", 117, 122], ["platelet aggregation", "OBSERVATION", 270, 290]]], ["A particularly compelling example of the application of deploying silicon in a tactical sense is provided by studies with the antipsychotic agent haloperidol (219), a dopamine D 2 antagonist, in which the replacement of the carbinol carbon by silicon was examined as a means of eliminating a problematic metabolic pathway [332, 333] .", [["silicon", "CHEMICAL", 66, 73], ["haloperidol", "CHEMICAL", 146, 157], ["dopamine", "CHEMICAL", 167, 175], ["carbinol carbon", "CHEMICAL", 224, 239], ["silicon", "CHEMICAL", 243, 250], ["silicon", "CHEMICAL", 66, 73], ["haloperidol", "CHEMICAL", 146, 157], ["dopamine", "CHEMICAL", 167, 175], ["carbinol carbon", "CHEMICAL", 224, 239], ["silicon", "CHEMICAL", 243, 250], ["haloperidol", "SIMPLE_CHEMICAL", 146, 157], ["dopamine D 2 antagonist", "SIMPLE_CHEMICAL", 167, 190], ["carbinol carbon", "SIMPLE_CHEMICAL", 224, 239], ["silicon", "SIMPLE_CHEMICAL", 243, 250], ["deploying silicon", "TREATMENT", 56, 73], ["the antipsychotic agent haloperidol", "TREATMENT", 122, 157], ["a dopamine D 2 antagonist", "TREATMENT", 165, 190], ["the replacement of the carbinol carbon by silicon", "TREATMENT", 201, 250]]], ["Haloperidol (219) is metabolized, in part, by dehydration of the piperidinol which affords the tetrahydropiperidine 221, a precursor to the pyridinium 222 which is neurotoxic, as summarized in Fig. 33 .", [["Haloperidol", "CHEMICAL", 0, 11], ["dehydration", "DISEASE", 46, 57], ["piperidinol", "CHEMICAL", 65, 76], ["tetrahydropiperidine 221", "CHEMICAL", 95, 119], ["pyridinium 222", "CHEMICAL", 140, 154], ["neurotoxic", "DISEASE", 164, 174], ["Haloperidol", "CHEMICAL", 0, 11], ["piperidinol", "CHEMICAL", 65, 76], ["tetrahydropiperidine 221", "CHEMICAL", 95, 119], ["pyridinium 222", "CHEMICAL", 140, 154], ["Haloperidol", "SIMPLE_CHEMICAL", 0, 11], ["piperidinol", "SIMPLE_CHEMICAL", 65, 76], ["tetrahydropiperidine 221", "SIMPLE_CHEMICAL", 95, 119], ["pyridinium 222", "SIMPLE_CHEMICAL", 140, 154], ["Haloperidol", "TREATMENT", 0, 11], ["the piperidinol", "TREATMENT", 61, 76], ["the tetrahydropiperidine", "TREATMENT", 91, 115]]], ["Sila-haloperidol (220) exhibits biological properties that are quite similar to the progenitor 219, but this compound cannot be metabolized by dehydration to 223 and further oxidized to 224 due to the inherent instability of carbon-silicon double bonds [332] .", [["progenitor 219", "ANATOMY", 84, 98], ["Sila-", "CHEMICAL", 0, 5], ["haloperidol", "CHEMICAL", 5, 16], ["dehydration", "DISEASE", 143, 154], ["carbon-silicon", "CHEMICAL", 225, 239], ["Sila-haloperidol", "CHEMICAL", 0, 16], ["carbon", "CHEMICAL", 225, 231], ["silicon", "CHEMICAL", 232, 239], ["Sila-haloperidol (220)", "SIMPLE_CHEMICAL", 0, 22], ["progenitor 219", "CELL", 84, 98], ["carbon-silicon double bonds", "SIMPLE_CHEMICAL", 225, 252], ["Sila-haloperidol", "TREATMENT", 0, 16], ["dehydration", "PROBLEM", 143, 154], ["the inherent instability", "PROBLEM", 197, 221], ["carbon-silicon double bonds", "TREATMENT", 225, 252]]], ["Indeed, the metabolism of sila-haloperidol (220) follows more conventional pathways associated with the piperidine moiety in which oxidative metabolism occurs adjacent to the N atom leading to dealkylation of the fluorophenyl-containing side chain to afford 225 and ring hydroxylation that produces 228 and 230 (Fig. 34 ) [334] .", [["sila-haloperidol", "CHEMICAL", 26, 42], ["piperidine", "CHEMICAL", 104, 114], ["fluorophenyl", "CHEMICAL", 213, 225], ["sila-haloperidol", "CHEMICAL", 26, 42], ["piperidine", "CHEMICAL", 104, 114], ["N", "CHEMICAL", 175, 176], ["fluorophenyl", "CHEMICAL", 213, 225], ["sila-haloperidol (220)", "SIMPLE_CHEMICAL", 26, 48], ["piperidine moiety", "SIMPLE_CHEMICAL", 104, 121], ["fluorophenyl-containing side chain", "SIMPLE_CHEMICAL", 213, 247], ["fluorophenyl-containing side chain", "PROTEIN", 213, 247], ["sila-haloperidol", "TREATMENT", 26, 42], ["the piperidine moiety", "TREATMENT", 100, 121], ["the N atom", "PROBLEM", 171, 181], ["dealkylation", "TREATMENT", 193, 205], ["the fluorophenyl-containing side chain", "TREATMENT", 209, 247]]], ["(219)Isosteres of Alkyl Groups and Alkylene Moietiestert-Butyl moieties are susceptible to metabolic oxidation of the methyl groups and this pathway can be a source of poor pharmacokinetic properties.", [["Alkyl", "CHEMICAL", 18, 23], ["Alkylene", "CHEMICAL", 35, 43], ["methyl", "CHEMICAL", 118, 124], ["(219)Isosteres", "CHEMICAL", 0, 14], ["Alkyl", "CHEMICAL", 18, 23], ["Alkylene Moietiestert-Butyl", "CHEMICAL", 35, 62], ["methyl", "CHEMICAL", 118, 124], ["Alkyl Groups", "SIMPLE_CHEMICAL", 18, 30], ["Alkylene Moietiestert-Butyl moieties", "SIMPLE_CHEMICAL", 35, 71], ["methyl groups", "SIMPLE_CHEMICAL", 118, 131], ["Isosteres of Alkyl Groups", "TREATMENT", 5, 30], ["Alkylene Moietiestert", "TREATMENT", 35, 56], ["Butyl moieties", "TREATMENT", 57, 71], ["the methyl groups", "TREATMENT", 114, 131], ["poor pharmacokinetic properties", "PROBLEM", 168, 199], ["metabolic oxidation", "OBSERVATION", 91, 110]]], ["Replacing a single methyl group with CF 3 in the context of the NK1 receptor antagonist 231 and the vanilloid receptor antagonist 233 afforded 232 and 234, respectively, as compounds that demonstrate enhanced metabolic stability in human liver microsomes compared to the prototypes [335] .", [["liver microsomes", "ANATOMY", 238, 254], ["methyl", "CHEMICAL", 19, 25], ["methyl", "CHEMICAL", 19, 25], ["CF 3", "CHEMICAL", 37, 41], ["human", "ORGANISM", 232, 237], ["liver microsomes", "MULTI-TISSUE_STRUCTURE", 238, 254], ["human liver microsomes", "CELL_TYPE", 232, 254], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 232, 237], ["a single methyl group with CF", "TREATMENT", 10, 39], ["the NK1 receptor antagonist", "TREATMENT", 60, 87], ["the vanilloid receptor antagonist", "TREATMENT", 96, 129], ["enhanced metabolic stability in human liver microsomes", "PROBLEM", 200, 254], ["metabolic stability", "OBSERVATION", 209, 228], ["liver", "ANATOMY", 238, 243]]], ["A further refinement of this approach identified the trifluoromethylcyclopropyl as a metabolically more stable tert-butyl isostere, exemplified in the type II 5\u03b1-reductase inhibitor finasteride (235) where this substitution provided 236 which exhibits a half-life in human liver microsomes of 114 min, a substantial improvement on the 63-min half-life measured for the progenitor [336] .", [["liver microsomes", "ANATOMY", 273, 289], ["progenitor", "ANATOMY", 369, 379], ["trifluoromethylcyclopropyl", "CHEMICAL", 53, 79], ["tert-butyl isostere", "CHEMICAL", 111, 130], ["finasteride", "CHEMICAL", 182, 193], ["trifluoromethylcyclopropyl", "CHEMICAL", 53, 79], ["tert-butyl", "CHEMICAL", 111, 121], ["finasteride", "CHEMICAL", 182, 193], ["trifluoromethylcyclopropyl", "SIMPLE_CHEMICAL", 53, 79], ["tert-butyl isostere", "SIMPLE_CHEMICAL", 111, 130], ["type II 5\u03b1-reductase", "GENE_OR_GENE_PRODUCT", 151, 171], ["finasteride", "SIMPLE_CHEMICAL", 182, 193], ["human", "ORGANISM", 267, 272], ["liver microsomes", "MULTI-TISSUE_STRUCTURE", 273, 289], ["type II 5\u03b1-reductase", "PROTEIN", 151, 171], ["human", "SPECIES", 267, 272], ["human", "SPECIES", 267, 272], ["this approach", "TREATMENT", 24, 37], ["the type II 5\u03b1-reductase inhibitor finasteride", "TREATMENT", 147, 193], ["liver", "ANATOMY", 273, 278], ["substantial", "OBSERVATION_MODIFIER", 304, 315], ["improvement", "OBSERVATION_MODIFIER", 316, 327]]], ["The potent respiratory syncytial virus fusion inhibitor 237 exhibits poor stability in human liver microsomes with a t 1/2 of just 4 min, similar to the isopropyl-and cyclobutyl-substituted homologues while the cyclopropyl derivative 238 uniquely addressed this deficiency exhibiting a tenfold improved t 1/2 of 39 min [337] .", [["liver microsomes", "ANATOMY", 93, 109], ["inhibitor 237", "CHEMICAL", 46, 59], ["isopropyl-and cyclobutyl-substituted", "CHEMICAL", 153, 189], ["cyclopropyl derivative 238", "CHEMICAL", 211, 237], ["isopropyl", "CHEMICAL", 153, 162], ["cyclobutyl", "CHEMICAL", 167, 177], ["cyclopropyl", "CHEMICAL", 211, 222], ["respiratory syncytial virus", "ORGANISM", 11, 38], ["human", "ORGANISM", 87, 92], ["liver microsomes", "MULTI-TISSUE_STRUCTURE", 93, 109], ["isopropyl", "SIMPLE_CHEMICAL", 153, 162], ["cyclobutyl-substituted homologues", "SIMPLE_CHEMICAL", 167, 200], ["cyclopropyl derivative 238", "SIMPLE_CHEMICAL", 211, 237], ["human", "SPECIES", 87, 92], ["respiratory syncytial virus", "SPECIES", 11, 38], ["human", "SPECIES", 87, 92], ["The potent respiratory syncytial virus fusion inhibitor", "TREATMENT", 0, 55], ["poor stability in human liver microsomes", "PROBLEM", 69, 109], ["the isopropyl", "TREATMENT", 149, 162], ["cyclobutyl", "TREATMENT", 167, 177], ["the cyclopropyl derivative", "TREATMENT", 207, 233], ["this deficiency", "PROBLEM", 257, 272], ["potent", "OBSERVATION_MODIFIER", 4, 10], ["respiratory", "OBSERVATION", 11, 22], ["syncytial virus", "OBSERVATION", 23, 38], ["stability", "OBSERVATION", 74, 83], ["liver", "ANATOMY", 93, 98]]], ["Alkanoic acid derivatives can be metabolized by \u03b2-oxidation that can lead to poor pharmacokinetic properties in vivo, a problem encountered with iloprost (240) , an analogue of prostacyclin (239) in which the chemically labile bicyclic enol ether oxygen atom is replaced with a CH 2 isostere [338] . \u03b2-Oxidation of fatty acids is a degradative pathway that proceeds mechanistically as depicted in Fig. 35 The Influence of Bioisosteres in Drug Design: Tactical Applications to. . . and involves the initial formation of a CoA ester as a substrate for oxidation to an \u03b1,\u03b2-unsaturated CoA ester that is further metabolized to a CoA ester with two fewer carbon atoms [339, 340] .", [["Alkanoic acid", "CHEMICAL", 0, 13], ["iloprost", "CHEMICAL", 145, 153], ["prostacyclin", "CHEMICAL", 177, 189], ["bicyclic enol", "CHEMICAL", 227, 240], ["oxygen", "CHEMICAL", 247, 253], ["CH 2 isostere", "CHEMICAL", 278, 291], ["fatty acids", "CHEMICAL", 315, 326], ["CoA ester", "CHEMICAL", 521, 530], ["\u03b1,\u03b2-unsaturated CoA ester", "CHEMICAL", 566, 591], ["CoA ester", "CHEMICAL", 625, 634], ["Alkanoic acid", "CHEMICAL", 0, 13], ["iloprost", "CHEMICAL", 145, 153], ["prostacyclin", "CHEMICAL", 177, 189], ["bicyclic enol ether", "CHEMICAL", 227, 246], ["oxygen", "CHEMICAL", 247, 253], ["CH", "CHEMICAL", 278, 280], ["fatty acids", "CHEMICAL", 315, 326], ["CoA ester", "CHEMICAL", 521, 530], ["\u03b1,\u03b2-unsaturated CoA ester", "CHEMICAL", 566, 591], ["CoA ester", "CHEMICAL", 625, 634], ["carbon", "CHEMICAL", 650, 656], ["Alkanoic acid derivatives", "SIMPLE_CHEMICAL", 0, 25], ["iloprost", "SIMPLE_CHEMICAL", 145, 153], ["prostacyclin", "SIMPLE_CHEMICAL", 177, 189], ["bicyclic enol ether oxygen atom", "SIMPLE_CHEMICAL", 227, 258], ["fatty acids", "SIMPLE_CHEMICAL", 315, 326], ["CoA ester", "SIMPLE_CHEMICAL", 521, 530], ["\u03b1,\u03b2-unsaturated CoA ester", "SIMPLE_CHEMICAL", 566, 591], ["CoA ester", "SIMPLE_CHEMICAL", 625, 634], ["Alkanoic acid derivatives", "TREATMENT", 0, 25], ["poor pharmacokinetic properties", "PROBLEM", 77, 108], ["iloprost", "TREATMENT", 145, 153], ["an analogue of prostacyclin", "TREATMENT", 162, 189], ["the chemically labile bicyclic enol ether oxygen atom", "TREATMENT", 205, 258], ["a CH 2 isostere", "TREATMENT", 276, 291], ["fatty acids", "PROBLEM", 315, 326], ["Tactical Applications", "TREATMENT", 451, 472], ["acid derivatives", "OBSERVATION", 9, 25], ["fatty acids", "OBSERVATION", 315, 326]]], ["The essential formation of the \u03b1,\u03b2-unsaturated CoA ester provides opportunity for rational structural modification of xenobiotic carboxylic acids to block this pathway.", [["\u03b1,\u03b2-unsaturated CoA ester", "CHEMICAL", 31, 56], ["xenobiotic carboxylic acids", "CHEMICAL", 118, 145], ["\u03b1,\u03b2-unsaturated CoA ester", "CHEMICAL", 31, 56], ["carboxylic acids", "CHEMICAL", 129, 145], ["\u03b1,\u03b2-unsaturated CoA ester", "SIMPLE_CHEMICAL", 31, 56], ["xenobiotic carboxylic acids", "SIMPLE_CHEMICAL", 118, 145], ["rational structural modification", "TREATMENT", 82, 114], ["xenobiotic carboxylic acids", "TREATMENT", 118, 145], ["essential", "OBSERVATION_MODIFIER", 4, 13], ["formation", "OBSERVATION", 14, 23]]], ["The introduction of germinal substitution at the \u03b1or \u03b2-positions and replacing the \u03b2-carbon with a heteroatom are effective tactics that prevent olefin formation and it was the latter that was successfully applied to iloprost (240) leading to the design of cicaprost (241), a compound with longerlasting hypotensive effects in rats following oral administration [338] .Isosteres of Carboxylic Acids to Reduce Reactive Metabolite FormationAcyl-CoA esters have been shown to be inherently electrophilic acylating agents, providing further impetus to replace the carboxylic acid moiety with an isostere that cannot engage in this metabolic pathway [10, [341] [342] [343] [344] [345] .", [["oral", "ANATOMY", 342, 346], ["\u03b2-carbon", "CHEMICAL", 83, 91], ["olefin", "CHEMICAL", 145, 151], ["iloprost", "CHEMICAL", 217, 225], ["cicaprost", "CHEMICAL", 257, 266], ["hypotensive", "DISEASE", 304, 315], ["Carboxylic Acids", "CHEMICAL", 382, 398], ["FormationAcyl-CoA esters", "CHEMICAL", 429, 453], ["carboxylic acid", "CHEMICAL", 560, 575], ["\u03b2-carbon", "CHEMICAL", 83, 91], ["olefin", "CHEMICAL", 145, 151], ["iloprost", "CHEMICAL", 217, 225], ["cicaprost", "CHEMICAL", 257, 266], ["Carboxylic Acids", "CHEMICAL", 382, 398], ["FormationAcyl-CoA esters", "CHEMICAL", 429, 453], ["carboxylic acid", "CHEMICAL", 560, 575], ["\u03b2-carbon", "SIMPLE_CHEMICAL", 83, 91], ["heteroatom", "SIMPLE_CHEMICAL", 99, 109], ["olefin", "SIMPLE_CHEMICAL", 145, 151], ["iloprost", "SIMPLE_CHEMICAL", 217, 225], ["cicaprost (241)", "SIMPLE_CHEMICAL", 257, 272], ["rats", "ORGANISM", 327, 331], ["oral", "ORGANISM_SUBDIVISION", 342, 346], ["Carboxylic Acids", "SIMPLE_CHEMICAL", 382, 398], ["Reactive Metabolite FormationAcyl-CoA esters", "SIMPLE_CHEMICAL", 409, 453], ["carboxylic acid", "SIMPLE_CHEMICAL", 560, 575], ["isostere", "SIMPLE_CHEMICAL", 591, 599], ["\u03b1or \u03b2-positions", "PROTEIN", 49, 64], ["rats", "SPECIES", 327, 331], ["germinal substitution", "TREATMENT", 20, 41], ["a heteroatom", "TREATMENT", 97, 109], ["olefin formation", "PROBLEM", 145, 161], ["iloprost", "TREATMENT", 217, 225], ["longerlasting hypotensive effects", "TREATMENT", 290, 323], ["oral administration", "TREATMENT", 342, 361], ["Isosteres of Carboxylic Acids", "TREATMENT", 369, 398], ["Reactive Metabolite", "TEST", 409, 428], ["electrophilic acylating agents", "TREATMENT", 487, 517], ["the carboxylic acid moiety", "TREATMENT", 556, 582], ["an isostere", "TREATMENT", 588, 599], ["germinal substitution", "OBSERVATION", 20, 41], ["olefin formation", "OBSERVATION", 145, 161], ["Reactive", "OBSERVATION_MODIFIER", 409, 417]]], ["Carboxylic acids are also readily conjugated with glucuronic acid in vivo to afford acyl glucuronides that can undergo sequential rearrangement of the acyl moiety to the adjacent hydroxyl substituents on the pyranose ring, a process summarized in Fig. 36 .", [["Carboxylic acids", "CHEMICAL", 0, 16], ["glucuronic acid", "CHEMICAL", 50, 65], ["acyl glucuronides", "CHEMICAL", 84, 101], ["acyl", "CHEMICAL", 151, 155], ["hydroxyl", "CHEMICAL", 179, 187], ["pyranose", "CHEMICAL", 208, 216], ["Carboxylic acids", "CHEMICAL", 0, 16], ["glucuronic acid", "CHEMICAL", 50, 65], ["acyl glucuronides", "CHEMICAL", 84, 101], ["acyl", "CHEMICAL", 151, 155], ["hydroxyl", "CHEMICAL", 179, 187], ["pyranose", "CHEMICAL", 208, 216], ["Carboxylic acids", "SIMPLE_CHEMICAL", 0, 16], ["glucuronic acid", "SIMPLE_CHEMICAL", 50, 65], ["acyl glucuronides", "SIMPLE_CHEMICAL", 84, 101], ["acyl moiety", "SIMPLE_CHEMICAL", 151, 162], ["hydroxyl substituents", "SIMPLE_CHEMICAL", 179, 200], ["pyranose", "SIMPLE_CHEMICAL", 208, 216], ["Carboxylic acids", "TREATMENT", 0, 16], ["glucuronic acid", "TREATMENT", 50, 65], ["acyl glucuronides", "TREATMENT", 84, 101], ["sequential rearrangement of the acyl moiety", "TREATMENT", 119, 162], ["the adjacent hydroxyl substituents", "TREATMENT", 166, 200], ["the pyranose ring", "TREATMENT", 204, 221], ["hydroxyl substituents", "OBSERVATION", 179, 200], ["pyranose ring", "OBSERVATION", 208, 221]]], ["This becomes problematic when the pyran ring opens to reveal an unnatural aldehyde which can react with amine moieties of proteins, lysine, for example, to generate an imine 4 , but this functionality can also undergo an Amadori rearrangement to afford the corresponding aminomethyl ketone, resulting in an irreversible protein modification that may create a hapten.", [["pyran", "CHEMICAL", 34, 39], ["aldehyde", "CHEMICAL", 74, 82], ["amine", "CHEMICAL", 104, 109], ["lysine", "CHEMICAL", 132, 138], ["aminomethyl ketone", "CHEMICAL", 271, 289], ["pyran", "CHEMICAL", 34, 39], ["aldehyde", "CHEMICAL", 74, 82], ["amine", "CHEMICAL", 104, 109], ["lysine", "CHEMICAL", 132, 138], ["imine", "CHEMICAL", 168, 173], ["aminomethyl ketone", "CHEMICAL", 271, 289], ["pyran ring", "SIMPLE_CHEMICAL", 34, 44], ["aldehyde", "SIMPLE_CHEMICAL", 74, 82], ["amine moieties", "SIMPLE_CHEMICAL", 104, 118], ["lysine", "AMINO_ACID", 132, 138], ["imine 4", "SIMPLE_CHEMICAL", 168, 175], ["Amadori", "SIMPLE_CHEMICAL", 221, 228], ["aminomethyl ketone", "SIMPLE_CHEMICAL", 271, 289], ["the pyran ring", "TREATMENT", 30, 44], ["an unnatural aldehyde", "PROBLEM", 61, 82], ["lysine", "TREATMENT", 132, 138], ["an Amadori rearrangement", "PROBLEM", 218, 242], ["the corresponding aminomethyl ketone", "TREATMENT", 253, 289], ["an irreversible protein modification", "PROBLEM", 304, 340], ["unnatural aldehyde", "OBSERVATION", 64, 82], ["Amadori rearrangement", "OBSERVATION", 221, 242], ["irreversible protein modification", "OBSERVATION", 307, 340]]], ["Insights have been gleaned into the properties of a carboxylic acid that promote this rearrangement which has been shown to be more facile for electron-deficient acids but slowed by bulky substituents at the \u03b1-carbon atom [348] [349] [350] .", [["carboxylic acid", "CHEMICAL", 52, 67], ["carboxylic acid", "CHEMICAL", 52, 67], ["\u03b1-carbon", "CHEMICAL", 208, 216], ["carboxylic acid", "SIMPLE_CHEMICAL", 52, 67], ["electron-deficient acids", "SIMPLE_CHEMICAL", 143, 167], ["bulky substituents", "SIMPLE_CHEMICAL", 182, 200], ["a carboxylic acid", "TREATMENT", 50, 67], ["electron-deficient acids", "TEST", 143, 167], ["bulky substituents", "PROBLEM", 182, 200], ["bulky substituents", "OBSERVATION", 182, 200]]], ["Guidelines have been developed that attempt to equate the propensity of rearrangement with the potential for idiosyncratic toxicity, with the half-life of the acyl glucuronide in buffer that separated safe from problematic acids estimated to be 3.6 h [351] .", [["toxicity", "DISEASE", 123, 131], ["acyl glucuronide", "CHEMICAL", 159, 175], ["acyl glucuronide", "CHEMICAL", 159, 175], ["acyl glucuronide", "SIMPLE_CHEMICAL", 159, 175], ["idiosyncratic toxicity", "PROBLEM", 109, 131], ["the acyl glucuronide in buffer", "TREATMENT", 155, 185], ["problematic acids", "TEST", 211, 228]]], ["The level of mechanistic understanding underlying the potential toxicity of carboxylic acid provides a rationale for structural modification to avoid this metabolic pathway by deploying an acid isostere incapable of undergoing rearrangement after glucuronidation.", [["toxicity", "DISEASE", 64, 72], ["carboxylic acid", "CHEMICAL", 76, 91], ["carboxylic acid", "CHEMICAL", 76, 91], ["carboxylic acid", "SIMPLE_CHEMICAL", 76, 91], ["carboxylic acid", "TREATMENT", 76, 91], ["structural modification", "TREATMENT", 117, 140], ["an acid isostere", "TREATMENT", 186, 202], ["glucuronidation", "TREATMENT", 247, 262]]], ["Figure 37 captures the range of acidic functionality that has been examined to address problems across a wide variety of medicinal chemistry campaigns [10, 344, 345, 352, 353] .Isosteres of Thiols and AlcoholsThe thiol moiety is relatively uncommon in drugs and drug candidates due to potential problems arising from metabolic lability or chemical reactivity, with the angiotensin-converting enzyme inhibitor captopril (243) and penicillamine (244), a chelator used to promote heavy metal excretion, the most prominent exceptions [354, 355] .", [["Thiols", "CHEMICAL", 190, 196], ["Alcohols", "CHEMICAL", 201, 209], ["thiol", "CHEMICAL", 213, 218], ["angiotensin", "CHEMICAL", 369, 380], ["captopril", "CHEMICAL", 409, 418], ["penicillamine", "CHEMICAL", 429, 442], ["Thiols", "CHEMICAL", 190, 196], ["Alcohols", "CHEMICAL", 201, 209], ["thiol", "CHEMICAL", 213, 218], ["captopril", "CHEMICAL", 409, 418], ["penicillamine", "CHEMICAL", 429, 442], ["Thiols", "SIMPLE_CHEMICAL", 190, 196], ["Alcohols", "SIMPLE_CHEMICAL", 201, 209], ["thiol moiety", "SIMPLE_CHEMICAL", 213, 225], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 369, 398], ["captopril", "SIMPLE_CHEMICAL", 409, 418], ["243)", "SIMPLE_CHEMICAL", 420, 424], ["penicillamine", "SIMPLE_CHEMICAL", 429, 442], ["chelator", "SIMPLE_CHEMICAL", 452, 460], ["Isosteres of Thiols and AlcoholsThe thiol moiety", "TREATMENT", 177, 225], ["potential problems", "PROBLEM", 285, 303], ["metabolic lability", "PROBLEM", 317, 335], ["chemical reactivity", "PROBLEM", 339, 358], ["the angiotensin-converting enzyme inhibitor captopril", "TREATMENT", 365, 418], ["penicillamine", "TREATMENT", 429, 442], ["a chelator", "TREATMENT", 450, 460], ["acidic functionality", "OBSERVATION", 32, 52], ["chemical reactivity", "OBSERVATION", 339, 358], ["most prominent", "OBSERVATION_MODIFIER", 504, 518]]], ["A useful although somewhat underutilized isostere of a thiol is the CHF 2 moiety which has been applied in an elegant fashion to the design of HCV NS3 protease inhibitors where the P1 cysteine moiety of hexapeptide, substrate-based inhibitors, was considered to be a liability [356] .", [["thiol", "CHEMICAL", 55, 60], ["CHF", "DISEASE", 68, 71], ["thiol", "CHEMICAL", 55, 60], ["cysteine", "CHEMICAL", 184, 192], ["isostere", "SIMPLE_CHEMICAL", 41, 49], ["thiol", "SIMPLE_CHEMICAL", 55, 60], ["HCV", "ORGANISM", 143, 146], ["HCV NS3 protease", "PROTEIN", 143, 159], ["HCV", "SPECIES", 143, 146], ["the CHF 2 moiety", "PROBLEM", 64, 80], ["HCV NS3 protease inhibitors", "TREATMENT", 143, 170], ["the P1 cysteine moiety of hexapeptide", "TREATMENT", 177, 214], ["substrate-based inhibitors", "TREATMENT", 216, 242], ["CHF", "OBSERVATION", 68, 71]]], ["Capitalizing on earlier observations of the intramolecular H-bonding properties of the CHF 2 moiety in 248, this element was examined as a thiol surrogate in the context of the potent NS3 inhibitor 245 which exhibited a K i \u00bc 40 nM [356, 357] .", [["H", "CHEMICAL", 59, 60], ["CHF", "DISEASE", 87, 90], ["thiol", "CHEMICAL", 139, 144], ["K", "CHEMICAL", 220, 221], ["H", "CHEMICAL", 59, 60], ["thiol", "CHEMICAL", 139, 144], ["CHF 2 moiety", "SIMPLE_CHEMICAL", 87, 99], ["the CHF", "PROBLEM", 83, 90], ["a thiol surrogate", "TREATMENT", 137, 154], ["the potent NS3 inhibitor", "TREATMENT", 173, 197], ["a K i", "TEST", 218, 223], ["CHF", "OBSERVATION", 87, 90]]], ["Replacing the P1 SH with CH 3 led to an almost 20-fold erosion of potency and 246 inhibited the enzyme with a K i \u00bc 700 nM.", [["CH 3", "CHEMICAL", 25, 29], ["K", "CHEMICAL", 110, 111], ["SH", "CHEMICAL", 17, 19], ["CH 3", "CHEMICAL", 25, 29], ["the enzyme", "TEST", 92, 102], ["a K i", "TEST", 108, 113], ["-fold", "OBSERVATION_MODIFIER", 49, 54], ["erosion", "OBSERVATION", 55, 62]]], ["However, a CHF 2 terminus at P1 proved to be very effective, fully restoring the potency of 247 to that of the cysteine progenitor, with a K i \u00bc 30 nM [356] .", [["CHF", "DISEASE", 11, 14], ["K", "CHEMICAL", 139, 140], ["cysteine", "CHEMICAL", 111, 119], ["CHF 2 terminus", "PROTEIN", 11, 25], ["a CHF 2 terminus at P1", "PROBLEM", 9, 31], ["the cysteine progenitor", "TREATMENT", 107, 130], ["a K i", "TEST", 137, 142], ["CHF", "OBSERVATION", 11, 14], ["very", "OBSERVATION_MODIFIER", 45, 49], ["effective", "OBSERVATION", 50, 59]]], ["This amino acid, referred to as difluoro-Abu, was conceived to be suitable for this context after an insightful analysis of its properties which suggested considerable potential to mimic the cysteine.", [["amino acid", "CHEMICAL", 5, 15], ["difluoro-Abu", "CHEMICAL", 32, 44], ["cysteine", "CHEMICAL", 191, 199], ["amino acid", "CHEMICAL", 5, 15], ["difluoro-Abu", "CHEMICAL", 32, 44], ["cysteine", "CHEMICAL", 191, 199], ["amino acid", "AMINO_ACID", 5, 15], ["difluoro-Abu", "SIMPLE_CHEMICAL", 32, 44], ["cysteine", "AMINO_ACID", 191, 199], ["This amino acid", "TEST", 0, 15], ["an insightful analysis", "TEST", 98, 120]]], ["Mimicry between a SH and a CHF 2 was based on The Influence of Bioisosteres in Drug Design: Tactical Applications to. . .", [["CHF", "DISEASE", 27, 30], ["a CHF 2", "PROBLEM", 25, 32], ["Tactical Applications", "TREATMENT", 92, 113], ["CHF", "OBSERVATION", 27, 30]]], ["(249) is a mitogen that has been shown to interact with four G protein-coupled receptors designated LPA 1-4 in addition to being an agonist at the peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3), a nuclear hormone receptor, and antagonists offer potential in a range of clinical conditions including the treatment of liver and lung fibrosis, several cancers, and neuropathic pain [358, 359] .", [["nuclear", "ANATOMY", 203, 210], ["liver", "ANATOMY", 322, 327], ["lung", "ANATOMY", 332, 336], ["cancers", "ANATOMY", 355, 362], ["LPA 1-4", "CHEMICAL", 100, 107], ["liver and lung fibrosis", "DISEASE", 322, 345], ["cancers", "DISEASE", 355, 362], ["neuropathic pain", "DISEASE", 368, 384], ["LPA 1-4", "CHEMICAL", 100, 107], ["G protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 61, 88], ["LPA 1-4", "GENE_OR_GENE_PRODUCT", 100, 107], ["peroxisome proliferator-activated receptor \u03b3", "GENE_OR_GENE_PRODUCT", 147, 191], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 193, 198], ["liver", "ORGAN", 322, 327], ["lung", "ORGAN", 332, 336], ["cancers", "CANCER", 355, 362], ["mitogen", "PROTEIN", 11, 18], ["G protein-coupled receptors", "PROTEIN", 61, 88], ["LPA 1-4", "PROTEIN", 100, 107], ["peroxisome proliferator-activated receptor \u03b3", "PROTEIN", 147, 191], ["PPAR\u03b3", "PROTEIN", 193, 198], ["nuclear hormone receptor", "PROTEIN", 203, 227], ["LPA", "TEST", 100, 103], ["activated receptor \u03b3 (PPAR\u03b3", "TREATMENT", 171, 198], ["a nuclear hormone receptor", "TREATMENT", 201, 227], ["antagonists", "TREATMENT", 233, 244], ["the treatment", "TREATMENT", 305, 318], ["liver and lung fibrosis", "PROBLEM", 322, 345], ["several cancers", "PROBLEM", 347, 362], ["neuropathic pain", "PROBLEM", 368, 384], ["liver", "ANATOMY", 322, 327], ["lung", "ANATOMY", 332, 336], ["fibrosis", "OBSERVATION", 337, 345], ["several", "OBSERVATION_MODIFIER", 347, 354], ["cancers", "OBSERVATION", 355, 362], ["neuropathic", "OBSERVATION_MODIFIER", 368, 379]]], ["The acyl moiety in lysophosphatidic acid (249) can migrate to the primary alcohol, stimulating the design of analogues that are functionally incapable of entering this rearrangement pathway [360, 361] .", [["acyl", "CHEMICAL", 4, 8], ["lysophosphatidic acid", "CHEMICAL", 19, 40], ["alcohol", "CHEMICAL", 74, 81], ["acyl", "CHEMICAL", 4, 8], ["lysophosphatidic acid", "CHEMICAL", 19, 40], ["primary alcohol", "CHEMICAL", 66, 81], ["acyl moiety", "SIMPLE_CHEMICAL", 4, 15], ["lysophosphatidic acid", "SIMPLE_CHEMICAL", 19, 40], ["alcohol", "SIMPLE_CHEMICAL", 74, 81], ["The acyl moiety in lysophosphatidic acid", "TREATMENT", 0, 40], ["acyl moiety", "OBSERVATION", 4, 15]]], ["In this context the CHF 2 moieties of 250 and 251 were conceived as potential mimics of the OH moiety of 249 that would be chemically stable.", [["CHF", "DISEASE", 20, 23], ["OH", "CHEMICAL", 92, 94], ["OH", "SIMPLE_CHEMICAL", 92, 94], ["the CHF", "PROBLEM", 16, 23], ["the OH moiety", "TEST", 88, 101], ["CHF", "OBSERVATION", 20, 23], ["chemically", "OBSERVATION_MODIFIER", 123, 133], ["stable", "OBSERVATION_MODIFIER", 134, 140]]], ["Neither compound was recognized by LPA receptors 1, 2, or 3, with both agonistic and antagonistic properties evaluated, but 250 was found to stimulate luciferase production in CV-1 cells transfected with luciferase under the control of a PPAR\u03b3-responsive element [360, 361] .Substitution of C-H by N in Phenyl Rings and C by N in DihydropyridinesThe substitution of the C-H moiety of a phenyl ring by nitrogen is a useful and wellestablished tactic for mitigating metabolic activation to chemically reactive and potentially toxic species that has found broad-based application and is captured in synoptic form by several illustrative examples [362] [363] [364] [365] [366] [367] .", [["CV-1 cells", "ANATOMY", 176, 186], ["C-H", "CHEMICAL", 291, 294], ["Dihydropyridines", "CHEMICAL", 330, 346], ["C-H", "CHEMICAL", 370, 373], ["phenyl ring", "CHEMICAL", 386, 397], ["nitrogen", "CHEMICAL", 401, 409], ["LPA", "CHEMICAL", 35, 38], ["C-H", "CHEMICAL", 291, 294], ["N", "CHEMICAL", 298, 299], ["Phenyl", "CHEMICAL", 303, 309], ["Dihydropyridines", "CHEMICAL", 330, 346], ["C-H", "CHEMICAL", 370, 373], ["phenyl", "CHEMICAL", 386, 392], ["nitrogen", "CHEMICAL", 401, 409], ["LPA receptors 1", "GENE_OR_GENE_PRODUCT", 35, 50], ["2", "GENE_OR_GENE_PRODUCT", 52, 53], ["3", "GENE_OR_GENE_PRODUCT", 58, 59], ["luciferase", "GENE_OR_GENE_PRODUCT", 151, 161], ["CV-1 cells", "CELL", 176, 186], ["luciferase", "GENE_OR_GENE_PRODUCT", 204, 214], ["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 238, 243], ["C-H", "SIMPLE_CHEMICAL", 291, 294], ["Phenyl Rings", "SIMPLE_CHEMICAL", 303, 315], ["C", "SIMPLE_CHEMICAL", 320, 321], ["Dihydropyridines", "SIMPLE_CHEMICAL", 330, 346], ["C-H", "SIMPLE_CHEMICAL", 370, 373], ["phenyl ring", "SIMPLE_CHEMICAL", 386, 397], ["nitrogen", "SIMPLE_CHEMICAL", 401, 409], ["LPA receptors 1, 2, or 3", "PROTEIN", 35, 59], ["luciferase", "PROTEIN", 151, 161], ["CV-1 cells", "CELL_LINE", 176, 186], ["luciferase", "PROTEIN", 204, 214], ["PPAR\u03b3-responsive element", "DNA", 238, 262], ["CV-1", "SPECIES", 176, 180], ["LPA receptors", "TEST", 35, 48], ["luciferase", "TREATMENT", 204, 214], ["Substitution of C-H by N in Phenyl Rings", "TREATMENT", 275, 315], ["Dihydropyridines", "TREATMENT", 330, 346], ["a phenyl ring", "TREATMENT", 384, 397], ["mitigating metabolic activation", "PROBLEM", 453, 484], ["chemically reactive", "PROBLEM", 488, 507], ["toxic species", "PROBLEM", 524, 537], ["toxic species", "OBSERVATION", 524, 537]]], ["The 4,7-dimethoxy indole derivative 252 is a potent HIV-1 attachment inhibitor, but the observation of O-demethylation as a metabolic pathway in HLM gave rise to the concern that the chemically electrophilic quinone 253 could be formed in vivo [362] .", [["4,7-dimethoxy indole", "CHEMICAL", 4, 24], ["HLM", "CHEMICAL", 145, 148], ["quinone 253", "CHEMICAL", 208, 219], ["4,7-dimethoxy indole", "CHEMICAL", 4, 24], ["O", "CHEMICAL", 103, 104], ["quinone", "CHEMICAL", 208, 215], ["4,7-dimethoxy indole derivative 252", "SIMPLE_CHEMICAL", 4, 39], ["HIV-1", "ORGANISM", 52, 57], ["HLM", "SIMPLE_CHEMICAL", 145, 148], ["electrophilic quinone 253", "SIMPLE_CHEMICAL", 194, 219], ["HIV-1", "SPECIES", 52, 57], ["HIV-1", "SPECIES", 52, 57], ["The 4,7-dimethoxy indole derivative", "TREATMENT", 0, 35], ["a potent HIV-1 attachment inhibitor", "TREATMENT", 43, 78], ["the chemically electrophilic quinone", "PROBLEM", 179, 215]]], ["The 4,7-dimethoxy-6-azaindole 254 analogue largely preserved the antiviral activity of 252 but, in contrast, would afford the far less electrophilic 255 upon dealkylative metabolism, and it was this compound, designated BMS-488043, that was advanced into proof-of-concept clinical studies [362] .", [["4,7-dimethoxy-6-azaindole 254", "CHEMICAL", 4, 33], ["BMS-488043", "CHEMICAL", 220, 230], ["4,7-dimethoxy-6-azaindole 254", "CHEMICAL", 4, 33], ["BMS-488043", "CHEMICAL", 220, 230], ["4,7-dimethoxy-6-azaindole 254", "SIMPLE_CHEMICAL", 4, 33], ["dealkylative", "SIMPLE_CHEMICAL", 158, 170], ["BMS-488043", "SIMPLE_CHEMICAL", 220, 230], ["dimethoxy", "TEST", 8, 17], ["azaindole", "TREATMENT", 20, 29], ["BMS", "TEST", 220, 223], ["antiviral activity", "OBSERVATION_MODIFIER", 65, 83]]], ["In addition, the mild basicity associated with the azaindole ring of 254 led to improved aqueous solubility.", [["azaindole ring of 254", "CHEMICAL", 51, 72], ["azaindole", "CHEMICAL", 51, 60], ["azaindole", "SIMPLE_CHEMICAL", 51, 60], ["aqueous", "ORGANISM_SUBSTANCE", 89, 96], ["the mild basicity", "PROBLEM", 13, 30], ["the azaindole ring", "TREATMENT", 47, 65], ["mild", "OBSERVATION_MODIFIER", 17, 21], ["basicity", "OBSERVATION", 22, 30], ["improved", "OBSERVATION_MODIFIER", 80, 88], ["aqueous solubility", "OBSERVATION", 89, 107]]], ["The phenol 256 is a short-acting calcium-sensing receptor antagonist that was examined for its potential as a treatment for osteoporosis [363, 364] .", [["phenol 256", "CHEMICAL", 4, 14], ["calcium", "CHEMICAL", 33, 40], ["osteoporosis", "DISEASE", 124, 136], ["phenol 256", "CHEMICAL", 4, 14], ["calcium", "CHEMICAL", 33, 40], ["phenol 256", "SIMPLE_CHEMICAL", 4, 14], ["calcium", "SIMPLE_CHEMICAL", 33, 40], ["The phenol", "TREATMENT", 0, 10], ["a short-acting calcium-sensing receptor antagonist", "TREATMENT", 18, 68], ["osteoporosis", "PROBLEM", 124, 136]]], ["However, CYP 3A4-mediated oxidation of the phenol ring of 256 afforded the catechol 257 which underwent further oxidation to the corresponding ortho quinone, a metabolite identified as the source of GSH adducts in both human and rat liver microsomes.", [["liver microsomes", "ANATOMY", 233, 249], ["phenol ring of 256", "CHEMICAL", 43, 61], ["catechol 257", "CHEMICAL", 75, 87], ["ortho quinone", "CHEMICAL", 143, 156], ["GSH", "CHEMICAL", 199, 202], ["phenol", "CHEMICAL", 43, 49], ["catechol", "CHEMICAL", 75, 83], ["ortho quinone", "CHEMICAL", 143, 156], ["GSH", "CHEMICAL", 199, 202], ["CYP 3A4", "GENE_OR_GENE_PRODUCT", 9, 16], ["phenol ring", "SIMPLE_CHEMICAL", 43, 54], ["catechol 257", "SIMPLE_CHEMICAL", 75, 87], ["ortho quinone", "SIMPLE_CHEMICAL", 143, 156], ["GSH", "SIMPLE_CHEMICAL", 199, 202], ["human", "ORGANISM", 219, 224], ["rat", "ORGANISM", 229, 232], ["liver microsomes", "TISSUE", 233, 249], ["CYP 3A4", "PROTEIN", 9, 16], ["human and rat liver microsomes", "CELL_TYPE", 219, 249], ["human", "SPECIES", 219, 224], ["rat", "SPECIES", 229, 232], ["human", "SPECIES", 219, 224], ["rat", "SPECIES", 229, 232], ["CYP 3A4", "TEST", 9, 16], ["the phenol ring", "TEST", 39, 54], ["the catechol", "TEST", 71, 83], ["further oxidation", "TREATMENT", 104, 121], ["the corresponding ortho quinone", "TEST", 125, 156], ["GSH adducts in both human and rat liver microsomes", "PROBLEM", 199, 249], ["GSH adducts", "OBSERVATION", 199, 210], ["both", "ANATOMY_MODIFIER", 214, 218], ["human", "ANATOMY", 219, 224], ["liver", "ANATOMY", 233, 238], ["microsomes", "ANATOMY_MODIFIER", 239, 249]]], ["The strategic introduction of a nitrogen atom into the phenol ring of 256 to give 258 was anticipated to reduce the rate of metabolic activation of the catechol based on quantum chemistry calculations which indicated that oxidation of the aza-catechol derived from 258 to the corresponding quinone was energetically less favorable than for 257.", [["nitrogen atom", "CHEMICAL", 32, 45], ["phenol", "CHEMICAL", 55, 61], ["catechol", "CHEMICAL", 152, 160], ["aza-catechol", "CHEMICAL", 239, 251], ["quinone", "CHEMICAL", 290, 297], ["nitrogen", "CHEMICAL", 32, 40], ["phenol", "CHEMICAL", 55, 61], ["catechol", "CHEMICAL", 152, 160], ["aza-catechol", "CHEMICAL", 239, 251], ["quinone", "CHEMICAL", 290, 297], ["phenol", "SIMPLE_CHEMICAL", 55, 61], ["catechol", "SIMPLE_CHEMICAL", 152, 160], ["aza-catechol", "SIMPLE_CHEMICAL", 239, 251], ["quinone", "SIMPLE_CHEMICAL", 290, 297], ["a nitrogen atom", "TREATMENT", 30, 45], ["the phenol ring", "TREATMENT", 51, 66], ["the catechol", "TREATMENT", 148, 160], ["quantum chemistry calculations", "TEST", 170, 200], ["the aza-catechol", "TEST", 235, 251]]], ["This was confirmed experimentally with a 50-fold reduction in the formation of GSH adducts compared to 256 when 258 was incubated in liver microsomes [363, 364] .", [["liver microsomes", "ANATOMY", 133, 149], ["GSH", "CHEMICAL", 79, 82], ["GSH", "CHEMICAL", 79, 82], ["GSH", "SIMPLE_CHEMICAL", 79, 82], ["liver microsomes", "CANCER", 133, 149], ["a 50-fold reduction", "TREATMENT", 39, 58], ["GSH adducts", "PROBLEM", 79, 90], ["GSH adducts", "OBSERVATION", 79, 90], ["liver", "ANATOMY", 133, 138]]], ["The CRF antagonist 259 was found to undergo metabolic activation following dosing to rats followed by trapping of the reactive species by GSH which afforded adducts amounting to 25% of the dose, with 260 identified as the major species produced in vivo [365] [366] [367] .", [["CRF", "DISEASE", 4, 7], ["GSH", "CHEMICAL", 138, 141], ["GSH", "CHEMICAL", 138, 141], ["CRF antagonist", "GENE_OR_GENE_PRODUCT", 4, 18], ["rats", "ORGANISM", 85, 89], ["GSH", "SIMPLE_CHEMICAL", 138, 141], ["rats", "SPECIES", 85, 89], ["The CRF antagonist", "TEST", 0, 18], ["the reactive species", "PROBLEM", 114, 134], ["metabolic activation", "OBSERVATION", 44, 64], ["reactive species", "OBSERVATION", 118, 134]]], ["This metabolic process was postulated to proceed via iminoquinone formation, providing a rationale for studying the effect of replacing the electron-rich phenyl ring with a pyridine, an approach that, after additional optimization, led to the identification of 261 as a compound with targeted biological and pharmacokinetic properties.", [["iminoquinone", "CHEMICAL", 53, 65], ["pyridine", "CHEMICAL", 173, 181], ["iminoquinone", "CHEMICAL", 53, 65], ["phenyl", "CHEMICAL", 154, 160], ["pyridine", "CHEMICAL", 173, 181], ["iminoquinone", "SIMPLE_CHEMICAL", 53, 65], ["electron", "SIMPLE_CHEMICAL", 140, 148], ["phenyl ring", "SIMPLE_CHEMICAL", 154, 165], ["pyridine", "SIMPLE_CHEMICAL", 173, 181], ["the electron-rich phenyl ring", "TREATMENT", 136, 165], ["a pyridine", "TREATMENT", 171, 181]]], ["As part of the structural refinement of 259, the pyrazinone chlorine substituent was replaced with an electron-withdrawing nitrile moiety in order to reduce metabolic activation of the olefin while the methoxy was introduced into the side chain to redirect metabolism to an alternative site that would provide benign products [365] [366] [367] .", [["pyrazinone chlorine", "CHEMICAL", 49, 68], ["olefin", "CHEMICAL", 185, 191], ["methoxy", "CHEMICAL", 202, 209], ["pyrazinone chlorine", "CHEMICAL", 49, 68], ["nitrile", "CHEMICAL", 123, 130], ["olefin", "CHEMICAL", 185, 191], ["methoxy", "CHEMICAL", 202, 209], ["pyrazinone chlorine substituent", "SIMPLE_CHEMICAL", 49, 80], ["electron", "SIMPLE_CHEMICAL", 102, 110], ["olefin", "SIMPLE_CHEMICAL", 185, 191], ["methoxy", "SIMPLE_CHEMICAL", 202, 209], ["the structural refinement", "TEST", 11, 36], ["the pyrazinone chlorine substituent", "TREATMENT", 45, 80], ["an electron-withdrawing nitrile moiety", "TREATMENT", 99, 137], ["metabolic activation of the olefin", "TREATMENT", 157, 191], ["the methoxy", "TREATMENT", 198, 209]]], ["Another example of the beneficial effect of replacing a C atom with N to interfere with metabolism is provided by the bioisosteric replacement of the dihydropyridine (DHP) ring of the Ca 2+ channel blocker class of smooth muscle relaxant exemplified by nifedipine (262, R\u00bcortho-NO 2 ) with a pyrimidinone heterocycle [368] [369] [370] [371] .", [["muscle", "ANATOMY", 222, 228], ["dihydropyridine", "CHEMICAL", 150, 165], ["DHP", "CHEMICAL", 167, 170], ["Ca", "CHEMICAL", 184, 186], ["nifedipine", "CHEMICAL", 253, 263], ["262, R\u00bcortho-NO", "CHEMICAL", 265, 280], ["pyrimidinone", "CHEMICAL", 292, 304], ["C", "CHEMICAL", 56, 57], ["N", "CHEMICAL", 68, 69], ["dihydropyridine", "CHEMICAL", 150, 165], ["DHP", "CHEMICAL", 167, 170], ["Ca 2+", "CHEMICAL", 184, 189], ["nifedipine", "CHEMICAL", 253, 263], ["R\u00bcortho-NO 2", "CHEMICAL", 270, 282], ["pyrimidinone", "CHEMICAL", 292, 304], ["C atom", "SIMPLE_CHEMICAL", 56, 62], ["dihydropyridine", "SIMPLE_CHEMICAL", 150, 165], ["DHP", "SIMPLE_CHEMICAL", 167, 170], ["Ca 2+", "SIMPLE_CHEMICAL", 184, 189], ["smooth muscle", "TISSUE", 215, 228], ["nifedipine", "SIMPLE_CHEMICAL", 253, 263], ["R\u00bcortho-NO 2", "SIMPLE_CHEMICAL", 270, 282], ["pyrimidinone heterocycle [368] [369] [370] [371]", "SIMPLE_CHEMICAL", 292, 340], ["a C atom with N", "TREATMENT", 54, 69], ["the bioisosteric replacement", "TREATMENT", 114, 142], ["the dihydropyridine (DHP)", "TREATMENT", 146, 171], ["the Ca 2+ channel blocker", "TREATMENT", 180, 205], ["smooth muscle relaxant", "TREATMENT", 215, 237], ["nifedipine", "TREATMENT", 253, 263], ["a pyrimidinone heterocycle", "TREATMENT", 290, 316], ["smooth muscle", "ANATOMY", 215, 228]]], ["The dihydropyridine ring is subject to rapid first-pass oxidative metabolism in vivo to give the corresponding pyridine 263 which is an inactive metabolite.", [["dihydropyridine", "CHEMICAL", 4, 19], ["pyridine 263", "CHEMICAL", 111, 123], ["dihydropyridine", "CHEMICAL", 4, 19], ["pyridine 263", "CHEMICAL", 111, 123], ["dihydropyridine ring", "SIMPLE_CHEMICAL", 4, 24], ["pyridine 263", "SIMPLE_CHEMICAL", 111, 123], ["The dihydropyridine ring", "TREATMENT", 0, 24], ["the corresponding pyridine", "TREATMENT", 93, 119], ["dihydropyridine ring", "OBSERVATION", 4, 24], ["inactive metabolite", "OBSERVATION", 136, 155]]], ["This led to the design of the pyrimidinone 264 as a probe of the idea that this ring system would be an effective substitute of the DHP ring.", [["pyrimidinone 264", "CHEMICAL", 30, 46], ["DHP", "CHEMICAL", 132, 135], ["pyrimidinone 264", "CHEMICAL", 30, 46], ["DHP", "CHEMICAL", 132, 135], ["pyrimidinone 264", "SIMPLE_CHEMICAL", 30, 46], ["DHP", "SIMPLE_CHEMICAL", 132, 135], ["the pyrimidinone", "TREATMENT", 26, 42], ["the DHP ring", "TREATMENT", 128, 140], ["DHP ring", "OBSERVATION", 132, 140]]], ["The design concept was based on the premise that the amide NH of 264 would mimic the H-bond donor properties of the dihydropyridine NH of 262 while the second nitrogen atom of the ring would provide a site for the introduction of the important carbonyl moiety, initially examined in the context of the methoxycarbonyl derivative 264, as well as providing resistance toward facile oxidation of the heterocycle.", [["amide NH", "CHEMICAL", 53, 61], ["dihydropyridine", "CHEMICAL", 116, 131], ["methoxycarbonyl", "CHEMICAL", 302, 317], ["amide", "CHEMICAL", 53, 58], ["NH", "CHEMICAL", 59, 61], ["H", "CHEMICAL", 85, 86], ["dihydropyridine", "CHEMICAL", 116, 131], ["NH", "CHEMICAL", 132, 134], ["nitrogen", "CHEMICAL", 159, 167], ["carbonyl", "CHEMICAL", 244, 252], ["methoxycarbonyl", "CHEMICAL", 302, 317], ["dihydropyridine NH", "SIMPLE_CHEMICAL", 116, 134], ["carbonyl moiety", "SIMPLE_CHEMICAL", 244, 259], ["methoxycarbonyl derivative 264", "SIMPLE_CHEMICAL", 302, 332], ["the amide NH", "TEST", 49, 61], ["the dihydropyridine NH", "TREATMENT", 112, 134], ["the second nitrogen atom of the ring", "TREATMENT", 148, 184], ["the important carbonyl moiety", "TREATMENT", 230, 259], ["the methoxycarbonyl derivative", "TREATMENT", 298, 328], ["resistance toward facile oxidation of the heterocycle", "TREATMENT", 355, 408]]], ["However, as an acylated urea derivative, 264 suffered from chemical instability, necessitating replacement by the more robust ureido moiety found in 265.", [["acylated urea", "CHEMICAL", 15, 28], ["ureido", "CHEMICAL", 126, 132], ["urea", "CHEMICAL", 24, 28], ["ureido", "CHEMICAL", 126, 132], ["urea derivative", "SIMPLE_CHEMICAL", 24, 39], ["ureido moiety", "SIMPLE_CHEMICAL", 126, 139], ["an acylated urea derivative", "PROBLEM", 12, 39], ["chemical instability", "PROBLEM", 59, 79], ["replacement", "TREATMENT", 95, 106], ["chemical instability", "OBSERVATION", 59, 79]]], ["In this analogue, the orientation of the exocyclic carbonyl group is as depicted in 265, favored by both dipole-dipole interactions and an intramolecular H-bond that projects the R substituent in a vector compatible with vasodilatory activity [368] [369] [370] [371] .Isosteres of Heterocycles to Reduce Metabolic ActivationThe potent bradykinin B 1 antagonist 266, K i \u00bc 11.8 nM, developed as a potential treatment for pain, was found to produce glutathione adducts when incubated in rat and human liver microsomal preparations, a metabolic pathway also observed 354 N.A. Meanwell in vivo following oral administration of the drug to rats with GSH adducts derived from the drug identified in bile [372] .", [["liver microsomal", "ANATOMY", 499, 515], ["oral", "ANATOMY", 600, 604], ["bile", "ANATOMY", 693, 697], ["carbonyl", "CHEMICAL", 51, 59], ["Heterocycles", "CHEMICAL", 281, 293], ["bradykinin B", "CHEMICAL", 335, 347], ["K", "CHEMICAL", 366, 367], ["pain", "DISEASE", 420, 424], ["glutathione", "CHEMICAL", 447, 458], ["GSH", "CHEMICAL", 645, 648], ["carbonyl", "CHEMICAL", 51, 59], ["H", "CHEMICAL", 154, 155], ["Heterocycles", "CHEMICAL", 281, 293], ["bradykinin B", "CHEMICAL", 335, 347], ["glutathione", "CHEMICAL", 447, 458], ["GSH", "CHEMICAL", 645, 648], ["R substituent", "SIMPLE_CHEMICAL", 179, 192], ["Heterocycles", "SIMPLE_CHEMICAL", 281, 293], ["bradykinin B 1", "GENE_OR_GENE_PRODUCT", 335, 349], ["K i", "SIMPLE_CHEMICAL", 366, 369], ["glutathione", "SIMPLE_CHEMICAL", 447, 458], ["rat", "ORGANISM", 485, 488], ["human", "ORGANISM", 493, 498], ["liver", "ORGAN", 499, 504], ["oral", "ORGANISM_SUBDIVISION", 600, 604], ["rats", "ORGANISM", 635, 639], ["GSH", "SIMPLE_CHEMICAL", 645, 648], ["rat", "SPECIES", 485, 488], ["human", "SPECIES", 493, 498], ["rats", "SPECIES", 635, 639], ["rat", "SPECIES", 485, 488], ["human", "SPECIES", 493, 498], ["Isosteres of Heterocycles", "TREATMENT", 268, 293], ["Metabolic Activation", "PROBLEM", 304, 324], ["The potent bradykinin B", "TEST", 324, 347], ["antagonist", "TEST", 350, 360], ["K i", "TEST", 366, 369], ["a potential treatment", "TREATMENT", 394, 415], ["pain", "PROBLEM", 420, 424], ["glutathione adducts", "PROBLEM", 447, 466], ["human liver microsomal preparations", "TREATMENT", 493, 528], ["oral administration", "TREATMENT", 600, 619], ["GSH adducts", "PROBLEM", 645, 656], ["R", "ANATOMY_MODIFIER", 179, 180], ["substituent", "ANATOMY_MODIFIER", 181, 192], ["glutathione adducts", "OBSERVATION", 447, 466], ["liver", "ANATOMY", 499, 504], ["bile", "ANATOMY", 693, 697]]], ["The site of GSH adduction was determined to be the pyridine ring, characterized as 268 and hypothesized to arise either from the diiminoquinone 267 or the epoxide 270, while the pyridine N-oxide 269 was determined to be a minor contributory pathway.", [["GSH", "CHEMICAL", 12, 15], ["pyridine", "CHEMICAL", 51, 59], ["diiminoquinone 267", "CHEMICAL", 129, 147], ["pyridine N-oxide 269", "CHEMICAL", 178, 198], ["GSH", "CHEMICAL", 12, 15], ["pyridine", "CHEMICAL", 51, 59], ["diiminoquinone", "CHEMICAL", 129, 143], ["epoxide", "CHEMICAL", 155, 162], ["pyridine N-oxide", "CHEMICAL", 178, 194], ["GSH", "SIMPLE_CHEMICAL", 12, 15], ["pyridine ring", "SIMPLE_CHEMICAL", 51, 64], ["diiminoquinone 267", "SIMPLE_CHEMICAL", 129, 147], ["epoxide 270", "SIMPLE_CHEMICAL", 155, 166], ["pyridine N-oxide 269", "SIMPLE_CHEMICAL", 178, 198], ["GSH adduction", "PROBLEM", 12, 25], ["the pyridine ring", "TREATMENT", 47, 64], ["the pyridine N-oxide", "TREATMENT", 174, 194], ["GSH adduction", "OBSERVATION", 12, 25]]], ["The design of a suitable isostere of the diaminopyridine ring was based upon the assumption that both NHs were of importance while the pyridine N atom was considered to function as a H-bond acceptor, an analysis that anticipated the simple glycine derivative 271 as the most rudimentary mimic.", [["diaminopyridine", "CHEMICAL", 41, 56], ["pyridine", "CHEMICAL", 135, 143], ["glycine", "CHEMICAL", 240, 247], ["diaminopyridine", "CHEMICAL", 41, 56], ["NHs", "CHEMICAL", 102, 105], ["pyridine", "CHEMICAL", 135, 143], ["N", "CHEMICAL", 144, 145], ["H", "CHEMICAL", 183, 184], ["glycine", "CHEMICAL", 240, 247], ["diaminopyridine ring", "SIMPLE_CHEMICAL", 41, 61], ["NHs", "SIMPLE_CHEMICAL", 102, 105], ["pyridine N atom", "SIMPLE_CHEMICAL", 135, 150], ["a suitable isostere of the diaminopyridine ring", "TREATMENT", 14, 61], ["the pyridine N atom", "TREATMENT", 131, 150], ["an analysis", "TEST", 200, 211], ["the simple glycine derivative", "TREATMENT", 229, 258]]], ["In order to influence the conformation of 271 in a fashion that allowed mimicry of the topology of the orthodisposed substituents of 266, the gem-dimethyl derivative 272 was prepared, but this compound expressed only modest affinity for the bradykinin B 1 receptor, K i \u00bc 3.5 \u03bcM [372] .", [["gem-dimethyl derivative 272", "CHEMICAL", 142, 169], ["bradykinin", "CHEMICAL", 241, 251], ["K", "CHEMICAL", 266, 267], ["gem-dimethyl", "CHEMICAL", 142, 154], ["bradykinin B", "CHEMICAL", 241, 253], ["gem-dimethyl derivative 272", "SIMPLE_CHEMICAL", 142, 169], ["bradykinin B 1 receptor", "GENE_OR_GENE_PRODUCT", 241, 264], ["bradykinin B 1 receptor", "PROTEIN", 241, 264], ["the orthodisposed substituents", "TREATMENT", 99, 129], ["the gem-dimethyl derivative", "TREATMENT", 138, 165], ["the bradykinin B", "TEST", 237, 253], ["K i", "TEST", 266, 269]]], ["Further refinement to the cyclopropyl analogue 273 led to a more than 50-fold increase in potency, attributed to conformational constraint due to \u03c0-\u03c0 hyperconjugation between the cyclopropyl C-C bond and the amide C\u00bcO that favors the two conformations depicted in Fig. 38 , with that represented by A mimicking the topology associated with 266.", [["cyclopropyl analogue 273", "CHEMICAL", 26, 50], ["cyclopropyl C-C", "CHEMICAL", 179, 194], ["cyclopropyl", "CHEMICAL", 26, 37], ["cyclopropyl C-C", "CHEMICAL", 179, 194], ["amide C\u00bcO", "CHEMICAL", 208, 217], ["cyclopropyl analogue 273", "SIMPLE_CHEMICAL", 26, 50], ["\u03c0-\u03c0", "SIMPLE_CHEMICAL", 146, 149], ["cyclopropyl C-C", "SIMPLE_CHEMICAL", 179, 194], ["amide C\u00bcO", "SIMPLE_CHEMICAL", 208, 217], ["cyclopropyl C-C bond", "PROTEIN", 179, 199], ["amide C\u00bcO", "PROTEIN", 208, 217], ["the cyclopropyl analogue", "TREATMENT", 22, 46], ["conformational constraint", "PROBLEM", 113, 138], ["\u03c0-\u03c0 hyperconjugation", "PROBLEM", 146, 166], ["the cyclopropyl C-C bond", "TREATMENT", 175, 199]]], ["In addition, it was noted that the 116 bond angle associate with the cyclopropane ring substituents more closely matches the 120 vectors projected by the pyridine ring.", [["cyclopropane", "CHEMICAL", 69, 81], ["pyridine", "CHEMICAL", 154, 162], ["cyclopropane", "CHEMICAL", 69, 81], ["pyridine", "CHEMICAL", 154, 162], ["cyclopropane ring substituents", "SIMPLE_CHEMICAL", 69, 99], ["pyridine ring", "SIMPLE_CHEMICAL", 154, 167], ["the cyclopropane ring substituents", "TREATMENT", 65, 99], ["the pyridine ring", "TREATMENT", 150, 167], ["cyclopropane ring", "OBSERVATION", 69, 86], ["pyridine ring", "OBSERVATION", 154, 167]]], ["Amide and ester isosteres are susceptible to protease and/or esterase-mediated degradation in vivo while alkyl esters can be degraded by oxidative dealkylation by CYP 450 enzymes to afford the corresponding carboxylic acids, providing an impetus to identify surrogates with resistance to metabolic modification [373] [374] [375] [376] [377] .", [["Amide", "CHEMICAL", 0, 5], ["ester", "CHEMICAL", 10, 15], ["alkyl esters", "CHEMICAL", 105, 117], ["carboxylic acids", "CHEMICAL", 207, 223], ["Amide", "CHEMICAL", 0, 5], ["ester", "CHEMICAL", 10, 15], ["alkyl esters", "CHEMICAL", 105, 117], ["carboxylic acids", "CHEMICAL", 207, 223], ["Amide", "SIMPLE_CHEMICAL", 0, 5], ["ester isosteres", "SIMPLE_CHEMICAL", 10, 25], ["esterase", "SIMPLE_CHEMICAL", 61, 69], ["alkyl esters", "SIMPLE_CHEMICAL", 105, 117], ["CYP 450", "GENE_OR_GENE_PRODUCT", 163, 170], ["carboxylic acids", "SIMPLE_CHEMICAL", 207, 223], ["protease", "PROTEIN", 45, 53], ["esterase", "PROTEIN", 61, 69], ["CYP 450 enzymes", "PROTEIN", 163, 178], ["Amide and ester isosteres", "TREATMENT", 0, 25], ["protease", "TREATMENT", 45, 53], ["esterase", "TREATMENT", 61, 69], ["oxidative dealkylation", "TREATMENT", 137, 159], ["the corresponding carboxylic acids", "TREATMENT", 189, 223]]], ["Pioneering studies in this area were focused on the design of heterocycles as ester replacements in the context of benzodiazepine derivatives of general The Influence of Bioisosteres in Drug Design: Tactical Applications to. . . structure 274 and 275 and muscarinic agonists based on the naturally occurring arecoline (276) [378] [379] [380] .", [["ester", "CHEMICAL", 78, 83], ["benzodiazepine", "CHEMICAL", 115, 129], ["arecoline", "CHEMICAL", 308, 317], ["heterocycles", "CHEMICAL", 62, 74], ["ester", "CHEMICAL", 78, 83], ["benzodiazepine", "CHEMICAL", 115, 129], ["arecoline", "CHEMICAL", 308, 317], ["ester", "SIMPLE_CHEMICAL", 78, 83], ["benzodiazepine derivatives", "SIMPLE_CHEMICAL", 115, 141], ["arecoline", "SIMPLE_CHEMICAL", 308, 317], ["Pioneering studies", "TEST", 0, 18], ["heterocycles as ester replacements", "TREATMENT", 62, 96], ["benzodiazepine derivatives", "TREATMENT", 115, 141], ["Tactical Applications", "TREATMENT", 199, 220], ["structure", "TEST", 229, 238], ["muscarinic agonists", "TEST", 255, 274]]], ["Azole heterocycles are the most common amide and ester replacements that have been explored, captured in synoptic fashion in Fig. 39 .", [["Azole heterocycles", "CHEMICAL", 0, 18], ["ester", "CHEMICAL", 49, 54], ["Azole heterocycles", "CHEMICAL", 0, 18], ["amide", "CHEMICAL", 39, 44], ["ester", "CHEMICAL", 49, 54], ["Azole heterocycles", "SIMPLE_CHEMICAL", 0, 18], ["amide", "SIMPLE_CHEMICAL", 39, 44], ["ester", "SIMPLE_CHEMICAL", 49, 54], ["Azole heterocycles", "TREATMENT", 0, 18], ["ester replacements", "TREATMENT", 49, 67]]], ["This tactic remains an approach of contemporary interest although there can be marked differences between heterocycles in the ability to emulate carbonyl-based functionality dependent on context that may be attributed to subtle effects associated with the underlying electronic properties of a heterocycle that are not always understood [2, 3, 9, 10, 71, [381] [382] [383] [384] [385] [386] [387] .Isosteres of the NO 2 MoietyThe unique properties of the nitro group have often made this a difficult structural motif to emulate by isosteric replacement [388, 389] .", [["carbonyl", "CHEMICAL", 145, 153], ["NO", "CHEMICAL", 415, 417], ["nitro", "CHEMICAL", 455, 460], ["heterocycles", "CHEMICAL", 106, 118], ["carbonyl", "CHEMICAL", 145, 153], ["NO 2", "CHEMICAL", 415, 419], ["nitro", "CHEMICAL", 455, 460], ["carbonyl", "SIMPLE_CHEMICAL", 145, 153], ["heterocycles", "TREATMENT", 106, 118], ["subtle effects", "PROBLEM", 221, 235], ["a heterocycle", "TREATMENT", 292, 305], ["the nitro group", "TREATMENT", 451, 466], ["a difficult structural motif", "PROBLEM", 488, 516], ["isosteric replacement", "TREATMENT", 531, 552], ["marked", "OBSERVATION_MODIFIER", 79, 85], ["NO", "UNCERTAINTY", 415, 417]]], ["For example, the nitrophenyl moiety of 277, an inhibitor of the protein-protein interaction between murine double minute 2 (MDM2) and p53, offers the optimal potency from an extensive survey of potential substitutes [389] .", [["nitrophenyl", "CHEMICAL", 17, 28], ["nitrophenyl", "CHEMICAL", 17, 28], ["nitrophenyl", "SIMPLE_CHEMICAL", 17, 28], ["murine double minute 2", "GENE_OR_GENE_PRODUCT", 100, 122], ["MDM2", "GENE_OR_GENE_PRODUCT", 124, 128], ["p53", "GENE_OR_GENE_PRODUCT", 134, 137], ["murine double minute 2", "PROTEIN", 100, 122], ["MDM2", "PROTEIN", 124, 128], ["p53", "PROTEIN", 134, 137], ["murine", "SPECIES", 100, 106], ["the nitrophenyl moiety", "TREATMENT", 13, 35], ["an inhibitor", "TREATMENT", 44, 56], ["the protein", "TEST", 60, 71]]], ["These observations were suggested to be a function of a lipophilic and strongly directional interaction between the nitro group and the MDM2 protein that is also dependent on the electron-withdrawing properties.", [["nitro", "CHEMICAL", 116, 121], ["nitro", "CHEMICAL", 116, 121], ["MDM2", "GENE_OR_GENE_PRODUCT", 136, 140], ["electron", "SIMPLE_CHEMICAL", 179, 187], ["MDM2 protein", "PROTEIN", 136, 148], ["a lipophilic", "PROBLEM", 54, 66], ["the nitro group", "TREATMENT", 112, 127], ["the MDM2 protein", "TREATMENT", 132, 148]]], ["Where the latter effect is of importance for drug-target interactions, several electron-withdrawing functional groups can substitute for the nitro, including pyridine, pyridine N-oxide, sulfonyl, trifluoromethyl, amide, and a carboxylic acid moiety that is considered to be an exact isostere [104, [390] [391] [392] [393] [394] [395] .", [["nitro", "CHEMICAL", 141, 146], ["pyridine", "CHEMICAL", 158, 166], ["pyridine N-oxide", "CHEMICAL", 168, 184], ["sulfonyl, trifluoromethyl, amide", "CHEMICAL", 186, 218], ["carboxylic acid", "CHEMICAL", 226, 241], ["nitro", "CHEMICAL", 141, 146], ["pyridine", "CHEMICAL", 158, 166], ["pyridine N-oxide", "CHEMICAL", 168, 184], ["sulfonyl", "CHEMICAL", 186, 194], ["trifluoromethyl", "CHEMICAL", 196, 211], ["amide", "CHEMICAL", 213, 218], ["carboxylic acid", "CHEMICAL", 226, 241], ["electron", "SIMPLE_CHEMICAL", 79, 87], ["nitro", "SIMPLE_CHEMICAL", 141, 146], ["pyridine", "SIMPLE_CHEMICAL", 158, 166], ["pyridine N-oxide", "SIMPLE_CHEMICAL", 168, 184], ["sulfonyl, trifluoromethyl, amide", "SIMPLE_CHEMICAL", 186, 218], ["a carboxylic acid", "SIMPLE_CHEMICAL", 224, 241], ["the nitro", "TREATMENT", 137, 146], ["pyridine", "TREATMENT", 158, 166], ["pyridine N-oxide", "TREATMENT", 168, 184], ["sulfonyl, trifluoromethyl, amide", "TREATMENT", 186, 218], ["a carboxylic acid moiety", "TREATMENT", 224, 248]]], ["Intermolecular interactions for the nitro moiety as collected from the Cambridge Structural Database of small molecules are summarized in Fig. 40 [387] .EpilogueThe design of bioisosteres is a powerful and effective concept in drug design that has been applied to solve a wide range of problems encountered in drug discovery campaigns.", [["nitro", "CHEMICAL", 36, 41], ["nitro", "CHEMICAL", 36, 41], ["nitro moiety", "SIMPLE_CHEMICAL", 36, 48], ["the nitro moiety", "TREATMENT", 32, 48], ["small molecules", "OBSERVATION", 104, 119]]], ["This chapter has focused on the practical utility of applying bioisosteric substitution to solve contemporary developability challenges that are encountered almost routinely by the practicing medicinal chemistry.", [["bioisosteric substitution", "TREATMENT", 62, 87], ["contemporary developability challenges", "TREATMENT", 97, 135], ["bioisosteric substitution", "OBSERVATION", 62, 87]]], ["The creativity and ingenuity of medicinal chemists is quite clear from this synopsis which captures many insightful and elegant examples of drug design.", [["creativity", "OBSERVATION_MODIFIER", 4, 14], ["medicinal chemists", "OBSERVATION", 32, 50]]], ["The most successful and creative designs are frequently based on a careful analysis of not only the chemistry underlying a particular problem but also a deep and detailed understanding of the physicochemical properties of the atoms and structural elements that are selected to address an issue.", [["a careful analysis", "TEST", 65, 83]]], ["While medicinal chemists have developed a broad toolbox of useful structural elements to draw upon to emulate a range of commonly encountered functionalities, it is anticipated that the challenges in drug design that lie ahead will continue to provide a stimulus for creativity that will expand the range of bioisosteric replacements.", [["bioisosteric replacements", "TREATMENT", 308, 333], ["bioisosteric replacements", "OBSERVATION", 308, 333]]]], "PMC7392886": [["BackgroundThe Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) is a zoonotic \u03b2-coronavirus that is closely related to SARS-CoV, which also entered the human population from an animal host [1,2].", [["Acute Respiratory Syndrome CoronaVirus", "DISEASE", 21, 59], ["zoonotic \u03b2-coronavirus", "DISEASE", 80, 102], ["SARS", "DISEASE", 130, 134], ["SARS-CoV-2", "ORGANISM", 63, 73], ["\u03b2-coronavirus", "CANCER", 89, 102], ["SARS-CoV", "ORGANISM", 130, 138], ["human", "ORGANISM", 163, 168], ["human", "SPECIES", 163, 168], ["Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2", "SPECIES", 14, 73], ["SARS-CoV", "SPECIES", 130, 138], ["human", "SPECIES", 163, 168], ["The Severe Acute Respiratory Syndrome CoronaVirus", "PROBLEM", 10, 59], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["a zoonotic \u03b2-coronavirus", "PROBLEM", 78, 102], ["SARS", "PROBLEM", 130, 134], ["Severe", "OBSERVATION_MODIFIER", 14, 20], ["Acute", "OBSERVATION_MODIFIER", 21, 26], ["Respiratory Syndrome", "OBSERVATION", 27, 47]]], ["SARS-CoV-2 is the cause of COVID-19.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["COVID-19", "DNA", 27, 35], ["SARS-CoV", "SPECIES", 0, 8], ["COVID", "TEST", 27, 32]]], ["This is an illness that appears to lead to mild symptoms in the majority of people and indeed, many infected individuals remain asymptomatic throughout the course of the infection [3].", [["infection", "DISEASE", 170, 179], ["people", "ORGANISM", 76, 82], ["individuals", "ORGANISM", 109, 120], ["people", "SPECIES", 76, 82], ["an illness", "PROBLEM", 8, 18], ["mild symptoms", "PROBLEM", 43, 56], ["many infected individuals", "PROBLEM", 95, 120], ["asymptomatic", "PROBLEM", 128, 140], ["the infection", "PROBLEM", 166, 179], ["illness", "OBSERVATION", 11, 18], ["mild", "OBSERVATION_MODIFIER", 43, 47], ["symptoms", "OBSERVATION", 48, 56], ["infected", "OBSERVATION", 100, 108], ["infection", "OBSERVATION", 170, 179]]], ["However, the illness often develops to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to considerable morbidity and mortality.", [["respiratory", "ANATOMY", 66, 77], ["illness", "DISEASE", 13, 20], ["pneumonia", "DISEASE", 46, 55], ["acute respiratory distress syndrome", "DISEASE", 60, 95], ["ARDS", "DISEASE", 97, 101], ["the illness", "PROBLEM", 9, 20], ["severe pneumonia", "PROBLEM", 39, 55], ["acute respiratory distress syndrome", "PROBLEM", 60, 95], ["ARDS", "PROBLEM", 97, 101], ["considerable morbidity", "PROBLEM", 115, 137], ["mortality", "PROBLEM", 142, 151], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["pneumonia", "OBSERVATION", 46, 55], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory distress syndrome", "OBSERVATION", 66, 95], ["considerable", "OBSERVATION_MODIFIER", 115, 127], ["morbidity", "OBSERVATION", 128, 137]]], ["While the CFR attributed to SARS-CoV induced SARS was considerably higher and according to the World Health Organisation (WHO) may have exceeded 15% [7].", [["SARS", "DISEASE", 28, 32], ["SARS", "DISEASE", 45, 49], ["SARS-CoV", "ORGANISM", 28, 36], ["SARS-CoV", "SPECIES", 28, 36], ["the CFR", "TEST", 6, 13], ["SARS", "PROBLEM", 28, 32], ["CoV induced SARS", "PROBLEM", 33, 49], ["SARS", "OBSERVATION", 28, 32]]], ["However, the absolute number of people killed by/with SARS-CoV-2, to date, is greater than both SARS and middle east respiratory syndrome (MERS) combined [8].", [["SARS", "DISEASE", 54, 58], ["SARS", "DISEASE", 96, 100], ["middle east respiratory syndrome", "DISEASE", 105, 137], ["people", "ORGANISM", 32, 38], ["SARS-CoV-2", "ORGANISM", 54, 64], ["people", "SPECIES", 32, 38], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "PROBLEM", 54, 58], ["both SARS and middle east respiratory syndrome", "PROBLEM", 91, 137], ["middle", "ANATOMY_MODIFIER", 105, 111], ["respiratory syndrome", "OBSERVATION", 117, 137]]], ["This is largely owing to a much higher rate of transmission, different tissue tropism and due to significant changes in its genome and protein structure compared to the other viruses (reviewed by [9]).BackgroundSARS-CoV-2 enters permissive cells as a result of S spike protein high affinity engagement with angiotensin converting enzyme (ACE)-2 receptors and subsequent cleavage by the adjacent protease TMPRSS2 in a similar manner to SARS-CoV [10,11].", [["tissue", "ANATOMY", 71, 77], ["cells", "ANATOMY", 240, 245], ["angiotensin", "CHEMICAL", 307, 318], ["SARS", "DISEASE", 435, 439], ["tissue", "TISSUE", 71, 77], ["BackgroundSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 201, 221], ["cells", "CELL", 240, 245], ["angiotensin converting enzyme (ACE)-2", "GENE_OR_GENE_PRODUCT", 307, 344], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 404, 411], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 435, 443], ["permissive cells", "CELL_TYPE", 229, 245], ["S spike protein", "PROTEIN", 261, 276], ["angiotensin converting enzyme (ACE)-2 receptors", "PROTEIN", 307, 354], ["protease TMPRSS2", "PROTEIN", 395, 411], ["SARS-CoV", "SPECIES", 435, 443], ["different tissue tropism", "PROBLEM", 61, 85], ["significant changes in its genome and protein structure", "PROBLEM", 97, 152], ["BackgroundSARS", "TEST", 201, 215], ["CoV", "TEST", 216, 219], ["permissive cells", "PROBLEM", 229, 245], ["angiotensin converting enzyme (ACE)", "TREATMENT", 307, 342], ["subsequent cleavage", "TREATMENT", 359, 378], ["the adjacent protease TMPRSS2", "TREATMENT", 382, 411], ["different tissue tropism", "OBSERVATION", 61, 85], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["changes", "OBSERVATION", 109, 116]]], ["However, SARS-CoV-2 initially enters and replicates in epithelial cells of the upper respiratory tract [12,13].", [["epithelial cells", "ANATOMY", 55, 71], ["upper respiratory tract", "ANATOMY", 79, 102], ["SARS", "DISEASE", 9, 13], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 9, 19], ["epithelial cells", "CELL", 55, 71], ["upper respiratory", "ORGANISM_SUBDIVISION", 79, 96], ["tract", "ORGANISM_SUBDIVISION", 97, 102], ["epithelial cells", "CELL_TYPE", 55, 71], ["SARS-CoV", "SPECIES", 9, 17], ["SARS", "PROBLEM", 9, 13], ["CoV", "TEST", 14, 17], ["epithelial cells", "OBSERVATION", 55, 71], ["upper", "ANATOMY_MODIFIER", 79, 84], ["respiratory tract", "ANATOMY", 85, 102]]], ["This phenomenon is not observed in SARS-CoV to any significant extent [14,15].", [["SARS", "DISEASE", 35, 39], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 35, 43], ["SARS-CoV", "SPECIES", 35, 43], ["This phenomenon", "PROBLEM", 0, 15], ["SARS", "PROBLEM", 35, 39], ["not observed", "UNCERTAINTY", 19, 31], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["extent", "OBSERVATION_MODIFIER", 63, 69]]], ["This process likely explains the relatively high viral load in the upper respiratory tract [16], increased levels of viral shedding [13] and significantly higher transmissibility [17].BackgroundThis difference in tropism may be explained in part by an increased affinity towards ACE-2 receptors, which appears to be between 10 and twenty times higher than that displayed by SARS-CoV [18,19].", [["upper respiratory tract", "ANATOMY", 67, 90], ["upper respiratory", "ORGANISM_SUBDIVISION", 67, 84], ["tract", "ORGANISM_SUBDIVISION", 85, 90], ["ACE-2", "GENE_OR_GENE_PRODUCT", 279, 284], ["ACE-2 receptors", "PROTEIN", 279, 294], ["SARS-CoV", "SPECIES", 374, 382], ["the relatively high viral load in the upper respiratory tract", "PROBLEM", 29, 90], ["viral shedding", "PROBLEM", 117, 131], ["significantly higher transmissibility", "PROBLEM", 141, 178], ["an increased affinity", "PROBLEM", 249, 270], ["ACE", "TEST", 279, 282], ["high", "OBSERVATION_MODIFIER", 44, 48], ["viral load", "OBSERVATION", 49, 59], ["upper", "ANATOMY_MODIFIER", 67, 72], ["respiratory tract", "ANATOMY", 73, 90], ["increased", "OBSERVATION", 252, 261]]], ["This allows SARS-CoV-2 to readily replicate in the upper respiratory tract despite a relative paucity of ACE-2 bearing cells in that region [20,21].BackgroundIn addition, the SARS-CoV-2 spike protein contains a Furin cleavage site in the spike protein that does not exist in SARS-CoV [[22], [23], [24]], allowing cleavage by cellular polyprotein convertases, such as furin and capthesin and potentially enhancing the efficiency of entry by endocytosis [12,25].", [["upper respiratory tract", "ANATOMY", 51, 74], ["cells", "ANATOMY", 119, 124], ["cellular", "ANATOMY", 325, 333], ["capthesin", "CHEMICAL", 377, 386], ["upper respiratory", "ORGANISM_SUBDIVISION", 51, 68], ["tract", "ORGANISM_SUBDIVISION", 69, 74], ["ACE-2", "GENE_OR_GENE_PRODUCT", 105, 110], ["cells", "CELL", 119, 124], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 175, 185], ["Furin", "GENE_OR_GENE_PRODUCT", 211, 216], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 275, 283], ["[22], [23], [24]]", "SIMPLE_CHEMICAL", 285, 302], ["cellular", "CELL", 325, 333], ["furin", "GENE_OR_GENE_PRODUCT", 367, 372], ["capthesin", "SIMPLE_CHEMICAL", 377, 386], ["ACE", "PROTEIN", 105, 108], ["SARS-CoV-2 spike protein", "PROTEIN", 175, 199], ["Furin cleavage site", "PROTEIN", 211, 230], ["spike protein", "PROTEIN", 238, 251], ["cellular polyprotein convertases", "PROTEIN", 325, 357], ["furin", "PROTEIN", 367, 372], ["capthesin", "PROTEIN", 377, 386], ["SARS-CoV", "SPECIES", 12, 20], ["SARS-CoV", "SPECIES", 175, 183], ["SARS-CoV", "SPECIES", 275, 283], ["SARS", "TEST", 12, 16], ["the SARS", "TEST", 171, 179], ["CoV", "TEST", 180, 183], ["spike protein", "PROBLEM", 186, 199], ["a Furin cleavage site", "PROBLEM", 209, 230], ["the spike protein", "PROBLEM", 234, 251], ["CoV", "TEST", 280, 283], ["cleavage", "TREATMENT", 313, 321], ["cellular polyprotein convertases", "TREATMENT", 325, 357], ["furin and capthesin", "TREATMENT", 367, 386], ["upper", "ANATOMY_MODIFIER", 51, 56], ["respiratory tract", "ANATOMY", 57, 74], ["paucity", "OBSERVATION_MODIFIER", 94, 101]]], ["In this context, it is noteworthy that the Furin cleavage site is also seen in spike proteins of pandemic strains of influenza, including the strain responsible for the so called \u201cSpanish flu\u201d of the early 20th century [22,26].", [["influenza", "DISEASE", 117, 126], ["Furin", "GENE_OR_GENE_PRODUCT", 43, 48], ["Furin cleavage site", "DNA", 43, 62], ["spike proteins", "PROTEIN", 79, 93], ["the Furin cleavage site", "PROBLEM", 39, 62], ["pandemic strains", "PROBLEM", 97, 113], ["influenza", "PROBLEM", 117, 126]]], ["The benefit to those viruses in possession of the cleavage site is increased tropism, it is conceivable that SARS-CoV-2 might be able to infect and replicate in otherwise non-permissive cells in the upper respiratory tract.", [["cells", "ANATOMY", 186, 191], ["upper respiratory tract", "ANATOMY", 199, 222], ["SARS-CoV-2", "ORGANISM", 109, 119], ["cells", "CELL", 186, 191], ["upper respiratory", "ORGANISM_SUBDIVISION", 199, 216], ["tract", "ORGANISM_SUBDIVISION", 217, 222], ["non-permissive cells", "CELL_TYPE", 171, 191], ["those viruses", "PROBLEM", 15, 28], ["the cleavage site", "PROBLEM", 46, 63], ["increased tropism", "PROBLEM", 67, 84], ["SARS-CoV-2", "PROBLEM", 109, 119], ["increased tropism", "OBSERVATION", 67, 84], ["non-permissive cells", "OBSERVATION", 171, 191], ["upper", "ANATOMY_MODIFIER", 199, 204], ["respiratory tract", "ANATOMY", 205, 222]]], ["There is also some evidence to suggest that cathepsin may be an alternative spike cleavage protease in cells expressing ACE-2 receptors but lacking Transmembrane protease, serine 2 (TMPRSS2) which normally plays an indispensable role in the cleavage of the spike protein thereby enabling the fusion of the viral and host membrane [25].BackgroundWhile changes in tissue tropism and increased cell internalisation play a role in the high transmissibility of the virus, another factor is the initially muted immune response following infection [27].", [["cells", "ANATOMY", 103, 108], ["membrane", "ANATOMY", 321, 329], ["tissue", "ANATOMY", 362, 368], ["cell", "ANATOMY", 391, 395], ["infection", "DISEASE", 531, 540], ["serine", "CHEMICAL", 172, 178], ["cathepsin", "GENE_OR_GENE_PRODUCT", 44, 53], ["cells", "CELL", 103, 108], ["ACE-2 receptors", "GENE_OR_GENE_PRODUCT", 120, 135], ["Transmembrane protease, serine 2", "GENE_OR_GENE_PRODUCT", 148, 180], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 182, 189], ["tissue", "TISSUE", 362, 368], ["cell", "CELL", 391, 395], ["cathepsin", "PROTEIN", 44, 53], ["alternative spike cleavage protease", "PROTEIN", 64, 99], ["ACE-2 receptors", "PROTEIN", 120, 135], ["Transmembrane protease", "PROTEIN", 148, 170], ["serine 2", "PROTEIN", 172, 180], ["TMPRSS2", "PROTEIN", 182, 189], ["spike protein", "PROTEIN", 257, 270], ["cathepsin", "TREATMENT", 44, 53], ["an alternative spike cleavage protease in cells", "PROBLEM", 61, 108], ["ACE-2 receptors", "TREATMENT", 120, 135], ["Transmembrane protease", "TREATMENT", 148, 170], ["the spike protein", "PROBLEM", 253, 270], ["tissue tropism", "PROBLEM", 362, 376], ["increased cell internalisation", "PROBLEM", 381, 411], ["the virus", "PROBLEM", 456, 465], ["infection", "PROBLEM", 531, 540], ["cathepsin", "OBSERVATION", 44, 53], ["host membrane", "OBSERVATION", 316, 329], ["tissue tropism", "OBSERVATION", 362, 376], ["increased cell internalisation", "OBSERVATION", 381, 411], ["virus", "OBSERVATION", 460, 465]]], ["Mechanistically, this is due to significant changes in the structure of the orf3a protein in SARS-CoV-2 compared to SARS-CoV, which allows a greater capacity to inhibit the production of interferons I, II and III [[28], [29], [30]].", [["SARS", "DISEASE", 116, 120], ["orf3a", "GENE_OR_GENE_PRODUCT", 76, 81], ["SARS-CoV-2", "ORGANISM", 93, 103], ["SARS-CoV", "ORGANISM", 116, 124], ["interferons I", "GENE_OR_GENE_PRODUCT", 187, 200], ["II", "GENE_OR_GENE_PRODUCT", 202, 204], ["[28], [29], [30]", "SIMPLE_CHEMICAL", 214, 230], ["orf3a protein", "PROTEIN", 76, 89], ["interferons I, II and III", "PROTEIN", 187, 212], ["SARS-CoV", "SPECIES", 93, 101], ["SARS-CoV", "SPECIES", 116, 124], ["significant changes in the structure", "PROBLEM", 32, 68], ["the orf3a protein", "TEST", 72, 89], ["SARS", "PROBLEM", 93, 97], ["CoV", "TEST", 98, 101], ["SARS-CoV", "TEST", 116, 124], ["a greater capacity", "PROBLEM", 139, 157], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["changes", "OBSERVATION", 44, 51]]], ["The inhibition of the interferon response in infected cells in the upper respiratory tract allows for relatively unhindered replication of the virus, which in combination, makes an additional contribution to a high viral load in the upper respiratory tract (URT).", [["cells", "ANATOMY", 54, 59], ["upper respiratory tract", "ANATOMY", 67, 90], ["upper respiratory tract", "ANATOMY", 233, 256], ["URT", "ANATOMY", 258, 261], ["cells", "CELL", 54, 59], ["upper respiratory", "ORGANISM_SUBDIVISION", 67, 84], ["tract", "ORGANISM_SUBDIVISION", 85, 90], ["upper respiratory", "ORGANISM_SUBDIVISION", 233, 250], ["tract", "ORGANISM_SUBDIVISION", 251, 256], ["interferon", "PROTEIN", 22, 32], ["infected cells", "CELL_TYPE", 45, 59], ["the interferon response", "TREATMENT", 18, 41], ["infected cells in the upper respiratory tract", "PROBLEM", 45, 90], ["the virus", "PROBLEM", 139, 148], ["a high viral load in the upper respiratory tract", "PROBLEM", 208, 256], ["interferon response", "OBSERVATION", 22, 41], ["infected cells", "OBSERVATION", 45, 59], ["upper", "ANATOMY_MODIFIER", 67, 72], ["respiratory tract", "ANATOMY", 73, 90], ["virus", "OBSERVATION", 143, 148], ["high viral load", "OBSERVATION", 210, 225], ["upper", "ANATOMY_MODIFIER", 233, 238], ["respiratory tract", "ANATOMY", 239, 256]]], ["Importantly, these factors also explain the high levels of the virus in the URT and goes some way to explaining the high transmission rates by pre and asymptomatic people which according to some studies may account for as many as half of all transmissions) [31].", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["the virus", "PROBLEM", 59, 68], ["some studies", "TEST", 190, 202]]], ["This may further explain why the spread of this virus has been so difficult to control [3,13,16,32].BackgroundEvidence accrued from the initial epidemic of COVID-19 in the Wuhan province of China suggests that approximately 20% of patients infected with COVID-19 develop severe disease that require hospitalisation.", [["COVID-19", "CHEMICAL", 156, 164], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["this virus", "PROBLEM", 43, 53], ["COVID", "TEST", 156, 161], ["COVID", "TEST", 254, 259], ["severe disease", "PROBLEM", 271, 285], ["severe", "OBSERVATION_MODIFIER", 271, 277], ["disease", "OBSERVATION", 278, 285]]], ["In addition, 20% of admitted patients develop pneumonia and ARDS thereafter, requiring protracted ventilation [33,34].", [["pneumonia", "DISEASE", 46, 55], ["ARDS", "DISEASE", 60, 64], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["pneumonia", "PROBLEM", 46, 55], ["ARDS", "PROBLEM", 60, 64], ["protracted ventilation", "TREATMENT", 87, 109], ["pneumonia", "OBSERVATION", 46, 55], ["ARDS", "OBSERVATION", 60, 64]]], ["In almost 50% of cases death occurred from respiratory failure [33,34].BackgroundThe presence of invading RNA viruses is detected by a family of Toll like receptors (TLRs) RIG like receptors and NOD-like receptors.", [["respiratory", "ANATOMY", 43, 54], ["death", "DISEASE", 23, 28], ["respiratory failure", "DISEASE", 43, 62], ["Toll like receptors", "GENE_OR_GENE_PRODUCT", 145, 164], ["RIG like receptors", "GENE_OR_GENE_PRODUCT", 172, 190], ["NOD-like receptors", "GENE_OR_GENE_PRODUCT", 195, 213], ["Toll like receptors (TLRs) RIG like receptors", "PROTEIN", 145, 190], ["NOD-like receptors", "PROTEIN", 195, 213], ["cases death", "PROBLEM", 17, 28], ["respiratory failure", "PROBLEM", 43, 62], ["invading RNA viruses", "PROBLEM", 97, 117], ["respiratory failure", "OBSERVATION", 43, 62], ["invading", "OBSERVATION_MODIFIER", 97, 105], ["RNA viruses", "OBSERVATION", 106, 117]]], ["From the perspective of coronavirus recognition, the important TLRs are TLR-7 and 3 which recognise single stranded RN and the dimers of positive and negative sense RNA formed during coronavirus replication.", [["coronavirus", "ORGANISM", 24, 35], ["TLRs", "GENE_OR_GENE_PRODUCT", 63, 67], ["TLR-7", "GENE_OR_GENE_PRODUCT", 72, 77], ["3", "GENE_OR_GENE_PRODUCT", 82, 83], ["coronavirus", "ORGANISM", 183, 194], ["TLRs", "PROTEIN", 63, 67], ["TLR-7 and 3", "PROTEIN", 72, 83], ["positive and negative sense RNA", "RNA", 137, 168], ["coronavirus recognition", "PROBLEM", 24, 47], ["coronavirus replication", "TREATMENT", 183, 206], ["coronavirus", "OBSERVATION", 24, 35]]], ["TLR 3 and 7 are located in late endosomes which maximises viral interaction while denying the pathogen's access to the cytoplasm and nucleus.", [["late endosomes", "ANATOMY", 27, 41], ["cytoplasm", "ANATOMY", 119, 128], ["nucleus", "ANATOMY", 133, 140], ["TLR 3", "GENE_OR_GENE_PRODUCT", 0, 5], ["7", "GENE_OR_GENE_PRODUCT", 10, 11], ["late endosomes", "CELLULAR_COMPONENT", 27, 41], ["cytoplasm", "ORGANISM_SUBSTANCE", 119, 128], ["nucleus", "CELLULAR_COMPONENT", 133, 140], ["TLR 3 and 7", "PROTEIN", 0, 11], ["viral interaction", "PROBLEM", 58, 75], ["nucleus", "ANATOMY", 133, 140]]], ["Activation of these pattern recognition receptors results in the transcription of NF-\u03baB and INF5 leading to the production of PICs inducible nitric oxide prostaglandins and a large number of chemokines.", [["nitric oxide", "CHEMICAL", 141, 153], ["nitric oxide", "CHEMICAL", 141, 153], ["prostaglandins", "CHEMICAL", 154, 168], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 20, 49], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 82, 87], ["INF5", "GENE_OR_GENE_PRODUCT", 92, 96], ["nitric oxide prostaglandins", "SIMPLE_CHEMICAL", 141, 168], ["pattern recognition receptors", "PROTEIN", 20, 49], ["NF-\u03baB", "PROTEIN", 82, 87], ["INF5", "PROTEIN", 92, 96], ["PICs", "PROTEIN", 126, 130], ["chemokines", "PROTEIN", 191, 201], ["INF5", "TREATMENT", 92, 96], ["PICs inducible nitric oxide prostaglandins", "TREATMENT", 126, 168], ["nitric oxide prostaglandins", "OBSERVATION", 141, 168], ["large", "OBSERVATION_MODIFIER", 175, 180], ["number", "OBSERVATION_MODIFIER", 181, 187], ["chemokines", "OBSERVATION", 191, 201]]], ["The presence of coronavirus RNA is also recognised by the retinoic acid-inducible gene I (RIG-)-like receptors RIG-1 and MDA5 which are located in the cytoplasm.", [["cytoplasm", "ANATOMY", 151, 160], ["coronavirus", "ORGANISM", 16, 27], ["retinoic acid-inducible gene I (RIG-)-like receptors", "GENE_OR_GENE_PRODUCT", 58, 110], ["RIG-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["MDA5", "GENE_OR_GENE_PRODUCT", 121, 125], ["cytoplasm", "ORGANISM_SUBSTANCE", 151, 160], ["coronavirus RNA", "RNA", 16, 31], ["retinoic acid-inducible gene I (RIG-)-like receptors", "PROTEIN", 58, 110], ["RIG-1", "PROTEIN", 111, 116], ["MDA5", "PROTEIN", 121, 125], ["coronavirus", "SPECIES", 16, 27], ["coronavirus RNA", "PROBLEM", 16, 31], ["the retinoic acid-", "TEST", 54, 72], ["MDA5", "PROBLEM", 121, 125], ["coronavirus RNA", "OBSERVATION", 16, 31], ["MDA5", "ANATOMY", 121, 125], ["cytoplasm", "OBSERVATION_MODIFIER", 151, 160]]], ["The activation of either PPR results in the assembly of a protein complex known as MAVS which acts as a signal relay to trigger the activation of INF3 and INF-7 leading to the production of type 1 II and III interferons.", [["PPR", "GENE_OR_GENE_PRODUCT", 25, 28], ["MAVS", "GENE_OR_GENE_PRODUCT", 83, 87], ["INF3", "GENE_OR_GENE_PRODUCT", 146, 150], ["INF-7", "GENE_OR_GENE_PRODUCT", 155, 160], ["type 1 II", "GENE_OR_GENE_PRODUCT", 190, 199], ["III interferons", "GENE_OR_GENE_PRODUCT", 204, 219], ["PPR", "PROTEIN", 25, 28], ["protein complex", "PROTEIN", 58, 73], ["MAVS", "PROTEIN", 83, 87], ["INF3", "PROTEIN", 146, 150], ["INF-7", "PROTEIN", 155, 160], ["type 1 II and III interferons", "PROTEIN", 190, 219], ["a protein complex", "PROBLEM", 56, 73], ["MAVS", "PROBLEM", 83, 87]]], ["There is also evidence to suggest that coronavirus activate nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) leading to the assembly of the NLRP3 inflammasome and the resultant production of IL-18 and IL-1.There is evidence that SARSCoV-2 inhibits interferon via the production of the non-structural proteins ORF3a and nsp-3 leading to a muted immune response and enhanced viral replication.BackgroundCOVID-19 ARDS is typified by the presence of diffuse alveolar damage, fibrin-rich hyaline membranes, increased epithelial and endothelial cell permeability, fluid leakage into the pulmonary interstitium, gross disruption of gas exchange, hypoxia and respiratory failure [33,[35], [36], [37]] reviewed in [38].", [["alveolar", "ANATOMY", 475, 483], ["hyaline membranes", "ANATOMY", 504, 521], ["epithelial", "ANATOMY", 533, 543], ["endothelial cell", "ANATOMY", 548, 564], ["fluid", "ANATOMY", 579, 584], ["pulmonary interstitium", "ANATOMY", 602, 624], ["respiratory", "ANATOMY", 672, 683], ["nucleotide", "CHEMICAL", 60, 70], ["ARDS", "DISEASE", 431, 435], ["alveolar damage", "DISEASE", 475, 490], ["hypoxia", "DISEASE", 660, 667], ["respiratory failure", "DISEASE", 672, 691], ["nucleotide", "CHEMICAL", 60, 70], ["SARSCoV-2", "CHEMICAL", 250, 259], ["coronavirus", "ORGANISM", 39, 50], ["nucleotide-binding oligomerization domain (NOD)-like receptors", "GENE_OR_GENE_PRODUCT", 60, 122], ["NLRs", "GENE_OR_GENE_PRODUCT", 124, 128], ["NLRP3", "GENE_OR_GENE_PRODUCT", 161, 166], ["IL-18", "GENE_OR_GENE_PRODUCT", 212, 217], ["IL-1", "GENE_OR_GENE_PRODUCT", 222, 226], ["SARSCoV-2", "GENE_OR_GENE_PRODUCT", 250, 259], ["interferon", "GENE_OR_GENE_PRODUCT", 269, 279], ["ORF3a", "GENE_OR_GENE_PRODUCT", 330, 335], ["nsp-3", "GENE_OR_GENE_PRODUCT", 340, 345], ["alveolar", "TISSUE", 475, 483], ["fibrin", "GENE_OR_GENE_PRODUCT", 492, 498], ["hyaline membranes", "CELLULAR_COMPONENT", 504, 521], ["epithelial", "TISSUE", 533, 543], ["endothelial cell", "TISSUE", 548, 564], ["pulmonary interstitium", "MULTI-TISSUE_STRUCTURE", 602, 624], ["nucleotide-binding oligomerization domain (NOD)-like receptors", "PROTEIN", 60, 122], ["NLRs", "PROTEIN", 124, 128], ["NLRP3 inflammasome", "PROTEIN", 161, 179], ["IL-18", "PROTEIN", 212, 217], ["IL-1", "PROTEIN", 222, 226], ["interferon", "PROTEIN", 269, 279], ["non-structural proteins", "PROTEIN", 306, 329], ["ORF3a", "PROTEIN", 330, 335], ["nsp-3", "PROTEIN", 340, 345], ["fibrin", "PROTEIN", 492, 498], ["coronavirus activate nucleotide-binding oligomerization domain", "PROBLEM", 39, 101], ["the NLRP3 inflammasome", "PROBLEM", 157, 179], ["IL", "TEST", 212, 214], ["SARSCoV", "TEST", 250, 257], ["interferon", "TREATMENT", 269, 279], ["the non-structural proteins", "TEST", 302, 329], ["nsp", "TEST", 340, 343], ["a muted immune response", "PROBLEM", 357, 380], ["enhanced viral replication", "TREATMENT", 385, 411], ["BackgroundCOVID", "TEST", 412, 427], ["ARDS", "PROBLEM", 431, 435], ["diffuse alveolar damage", "PROBLEM", 467, 490], ["fibrin-rich hyaline membranes", "PROBLEM", 492, 521], ["increased epithelial and endothelial cell permeability", "PROBLEM", 523, 577], ["fluid leakage into the pulmonary interstitium", "PROBLEM", 579, 624], ["gross disruption of gas exchange", "PROBLEM", 626, 658], ["hypoxia", "PROBLEM", 660, 667], ["respiratory failure", "PROBLEM", 672, 691], ["evidence to suggest", "UNCERTAINTY", 14, 33], ["coronavirus", "OBSERVATION", 39, 50], ["viral replication", "OBSERVATION", 394, 411], ["ARDS", "OBSERVATION", 431, 435], ["diffuse", "OBSERVATION_MODIFIER", 467, 474], ["alveolar damage", "OBSERVATION", 475, 490], ["fibrin", "OBSERVATION", 492, 498], ["rich", "OBSERVATION_MODIFIER", 499, 503], ["hyaline membranes", "OBSERVATION", 504, 521], ["increased", "OBSERVATION_MODIFIER", 523, 532], ["epithelial", "ANATOMY_MODIFIER", 533, 543], ["endothelial cell permeability", "OBSERVATION", 548, 577], ["fluid leakage", "OBSERVATION", 579, 592], ["pulmonary", "ANATOMY", 602, 611], ["interstitium", "ANATOMY_MODIFIER", 612, 624], ["gross", "OBSERVATION_MODIFIER", 626, 631], ["disruption", "OBSERVATION", 632, 642], ["gas exchange", "OBSERVATION", 646, 658], ["hypoxia", "OBSERVATION_MODIFIER", 660, 667], ["respiratory failure", "OBSERVATION", 672, 691]]], ["These features are characteristic of ARDS secondary to sepsis, viral infections or many other triggers and in this respect, COVID-19 ARDS is unremarkable [39].BackgroundHowever, in another respect COVID-19 ARDS appears to be distinct from the ARDS associated with other respiratory viruses (e.g. H1N1 influenza Virus) due to evidence of hypercoagulation and an exhausted fibrinolytic system [38,[40], [41], [42]].", [["ARDS", "DISEASE", 37, 41], ["sepsis", "DISEASE", 55, 61], ["viral infections", "DISEASE", 63, 79], ["ARDS", "DISEASE", 133, 137], ["ARDS", "DISEASE", 206, 210], ["ARDS", "DISEASE", 243, 247], ["respiratory viruses", "DISEASE", 270, 289], ["influenza Virus", "DISEASE", 301, 316], ["hypercoagulation", "DISEASE", 337, 353], ["H1N1 influenza Virus", "ORGANISM", 296, 316], ["H1N1 influenza Virus", "SPECIES", 296, 316], ["H1N1 influenza Virus", "SPECIES", 296, 316], ["ARDS", "PROBLEM", 37, 41], ["sepsis", "PROBLEM", 55, 61], ["viral infections", "PROBLEM", 63, 79], ["many other triggers", "PROBLEM", 83, 102], ["COVID", "TEST", 124, 129], ["ARDS", "PROBLEM", 133, 137], ["ARDS", "PROBLEM", 206, 210], ["the ARDS", "PROBLEM", 239, 247], ["other respiratory viruses", "PROBLEM", 264, 289], ["H1N1 influenza Virus", "PROBLEM", 296, 316], ["hypercoagulation", "PROBLEM", 337, 353], ["an exhausted fibrinolytic system", "PROBLEM", 358, 390], ["characteristic of", "UNCERTAINTY", 19, 36], ["ARDS", "OBSERVATION", 37, 41], ["sepsis", "OBSERVATION", 55, 61], ["viral", "OBSERVATION_MODIFIER", 63, 68], ["infections", "OBSERVATION", 69, 79], ["ARDS", "OBSERVATION", 206, 210], ["ARDS", "OBSERVATION", 243, 247], ["respiratory", "ANATOMY", 270, 281], ["viruses", "OBSERVATION", 282, 289], ["hypercoagulation", "OBSERVATION", 337, 353]]], ["The importance of hypercoagulation in the pathogenesis of severe COVID-19 is further emphasised by an analysis which revealed that 70% of fatal cases satisfied a diagnosis for disseminated intravascular coagulation (DIC), while that was true in only 1% of survivors [43].BackgroundSeveral research teams have reported the presence of gross immune dysregulation in the lungs of patients with severe disease.", [["intravascular", "ANATOMY", 189, 202], ["lungs", "ANATOMY", 368, 373], ["hypercoagulation", "DISEASE", 18, 34], ["COVID", "DISEASE", 65, 70], ["intravascular coagulation", "DISEASE", 189, 214], ["DIC", "DISEASE", 216, 219], ["COVID-19", "CHEMICAL", 65, 73], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 202], ["lungs", "ORGAN", 368, 373], ["patients", "ORGANISM", 377, 385], ["patients", "SPECIES", 377, 385], ["hypercoagulation", "PROBLEM", 18, 34], ["severe COVID", "PROBLEM", 58, 70], ["an analysis", "TEST", 99, 110], ["disseminated intravascular coagulation", "PROBLEM", 176, 214], ["gross immune dysregulation in the lungs", "PROBLEM", 334, 373], ["severe disease", "PROBLEM", 391, 405], ["hypercoagulation", "OBSERVATION", 18, 34], ["gross immune dysregulation", "OBSERVATION", 334, 360], ["lungs", "ANATOMY", 368, 373], ["severe", "OBSERVATION_MODIFIER", 391, 397], ["disease", "OBSERVATION", 398, 405]]], ["For example, there is extensive evidence of activated alveolar macrophages [5,14,35,44] and a depletion in the absolute numbers of these immune cells due to excessive levels of pyroptosis [[44], [45], [46]].", [["alveolar macrophages", "ANATOMY", 54, 74], ["immune cells", "ANATOMY", 137, 149], ["pyroptosis", "DISEASE", 177, 187], ["alveolar macrophages", "CELL", 54, 74], ["immune cells", "CELL", 137, 149], ["activated alveolar macrophages", "CELL_TYPE", 44, 74], ["immune cells", "CELL_TYPE", 137, 149], ["activated alveolar macrophages", "PROBLEM", 44, 74], ["a depletion", "PROBLEM", 92, 103], ["excessive levels of pyroptosis", "PROBLEM", 157, 187], ["extensive", "OBSERVATION_MODIFIER", 22, 31], ["evidence of", "UNCERTAINTY", 32, 43], ["activated", "OBSERVATION_MODIFIER", 44, 53], ["alveolar macrophages", "OBSERVATION", 54, 74], ["depletion", "OBSERVATION_MODIFIER", 94, 103], ["absolute numbers", "OBSERVATION_MODIFIER", 111, 127], ["immune cells", "OBSERVATION", 137, 149]]], ["Excessive infiltration of activated neutrophils into alveoli and lung interstitial tissue is another common finding in severe COVID-19 [36,47] review [48].", [["neutrophils", "ANATOMY", 36, 47], ["alveoli", "ANATOMY", 53, 60], ["lung interstitial tissue", "ANATOMY", 65, 89], ["COVID-19", "CHEMICAL", 126, 134], ["neutrophils", "CELL", 36, 47], ["alveoli", "TISSUE", 53, 60], ["lung interstitial tissue", "TISSUE", 65, 89], ["activated neutrophils", "CELL_TYPE", 26, 47], ["Excessive infiltration", "PROBLEM", 0, 22], ["activated neutrophils into alveoli and lung interstitial tissue", "PROBLEM", 26, 89], ["severe COVID", "TEST", 119, 131], ["infiltration", "OBSERVATION", 10, 22], ["activated neutrophils", "OBSERVATION", 26, 47], ["alveoli", "ANATOMY_MODIFIER", 53, 60], ["lung", "ANATOMY", 65, 69], ["interstitial", "ANATOMY_MODIFIER", 70, 82]]], ["Importantly, evidence suggests that these neutrophils are a source of highly toxic neutrophil extracellular traps (NETs) [36,49].", [["neutrophils", "ANATOMY", 42, 53], ["neutrophil extracellular", "ANATOMY", 83, 107], ["neutrophils", "CELL", 42, 53], ["neutrophil", "CELL", 83, 93], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 94, 107], ["neutrophils", "CELL_TYPE", 42, 53], ["these neutrophils", "PROBLEM", 36, 53], ["highly toxic neutrophil extracellular traps", "PROBLEM", 70, 113], ["evidence suggests", "UNCERTAINTY", 13, 30], ["neutrophils", "OBSERVATION", 42, 53], ["highly", "OBSERVATION_MODIFIER", 70, 76], ["toxic", "OBSERVATION_MODIFIER", 77, 82]]], ["Influx of interleukin (IL)-1 and tumor necrosis factor (TNF) secreting bone marrow derived monocytes is also a finding in such individuals [50].", [["bone marrow", "ANATOMY", 71, 82], ["monocytes", "ANATOMY", 91, 100], ["necrosis", "DISEASE", 39, 47], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 10, 28], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 33, 54], ["TNF", "GENE_OR_GENE_PRODUCT", 56, 59], ["bone marrow derived monocytes", "CELL", 71, 100], ["interleukin (IL)-1", "PROTEIN", 10, 28], ["tumor necrosis factor (TNF) secreting bone marrow derived monocytes", "CELL_TYPE", 33, 100], ["Influx of interleukin (IL)", "TEST", 0, 26], ["tumor necrosis factor", "PROBLEM", 33, 54], ["secreting bone marrow derived monocytes", "PROBLEM", 61, 100], ["tumor", "OBSERVATION_MODIFIER", 33, 38], ["necrosis", "OBSERVATION", 39, 47], ["bone", "ANATOMY", 71, 75]]], ["Interestingly, these monocytes also secrete lactate dehydrogenase indicating that these immune cells are also undergoing cell death via pyroptosis [50].", [["monocytes", "ANATOMY", 21, 30], ["immune cells", "ANATOMY", 88, 100], ["cell", "ANATOMY", 121, 125], ["lactate", "CHEMICAL", 44, 51], ["death", "DISEASE", 126, 131], ["pyroptosis", "DISEASE", 136, 146], ["lactate", "CHEMICAL", 44, 51], ["monocytes", "CELL", 21, 30], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 44, 65], ["immune cells", "CELL", 88, 100], ["cell", "CELL", 121, 125], ["monocytes", "CELL_TYPE", 21, 30], ["lactate dehydrogenase", "PROTEIN", 44, 65], ["immune cells", "CELL_TYPE", 88, 100], ["these monocytes", "TEST", 15, 30], ["lactate dehydrogenase", "TEST", 44, 65], ["these immune cells", "PROBLEM", 82, 100], ["cell death", "PROBLEM", 121, 131], ["pyroptosis", "PROBLEM", 136, 146], ["monocytes", "ANATOMY", 21, 30], ["immune cells", "OBSERVATION", 88, 100]]], ["The presence of excessive levels of inflammation in patients with COVID-19 ARDS is further reinforced by evidence of hypercytokinemia [44,51,52].BackgroundThere is also an accumulating body of evidence suggesting excessive systemic immune activation and inflammation in patients suffering from COVID-19, with increased levels of TNF-alpha, IL-1 beta, IL-6, IL-10, monocyte chemoattractant protein-1 (MCP-1) and C-X-C motif chemokine 10 (CXCL10), being commonly reported in patients with severe symptoms and pneumonia [44,48,[53], [54], [55], [56]].", [["inflammation", "DISEASE", 36, 48], ["ARDS", "DISEASE", 75, 79], ["hypercytokinemia", "DISEASE", 117, 133], ["inflammation", "DISEASE", 254, 266], ["pneumonia", "DISEASE", 507, 516], ["COVID-19", "CHEMICAL", 294, 302], ["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 270, 278], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 329, 338], ["IL-1 beta", "GENE_OR_GENE_PRODUCT", 340, 349], ["IL-6", "GENE_OR_GENE_PRODUCT", 351, 355], ["IL-10", "GENE_OR_GENE_PRODUCT", 357, 362], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 364, 398], ["MCP-1", "GENE_OR_GENE_PRODUCT", 400, 405], ["C-X-C motif chemokine 10", "GENE_OR_GENE_PRODUCT", 411, 435], ["CXCL10", "GENE_OR_GENE_PRODUCT", 437, 443], ["patients", "ORGANISM", 473, 481], ["TNF", "PROTEIN", 329, 332], ["monocyte chemoattractant protein-1 (MCP-1", "PROTEIN", 364, 405], ["C-X-C motif chemokine 10", "PROTEIN", 411, 435], ["CXCL10", "PROTEIN", 437, 443], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 270, 278], ["patients", "SPECIES", 473, 481], ["excessive levels of inflammation", "PROBLEM", 16, 48], ["COVID", "TEST", 66, 71], ["ARDS", "PROBLEM", 75, 79], ["hypercytokinemia", "PROBLEM", 117, 133], ["excessive systemic immune activation", "PROBLEM", 213, 249], ["inflammation", "PROBLEM", 254, 266], ["COVID", "TEST", 294, 299], ["increased levels", "PROBLEM", 309, 325], ["TNF", "TEST", 329, 332], ["alpha", "TEST", 333, 338], ["IL", "TEST", 340, 342], ["IL", "TEST", 351, 353], ["IL", "TEST", 357, 359], ["monocyte chemoattractant protein", "TEST", 364, 396], ["MCP", "TEST", 400, 403], ["C", "TEST", 411, 412], ["C motif chemokine", "TREATMENT", 415, 432], ["CXCL10", "TEST", 437, 443], ["severe symptoms", "PROBLEM", 487, 502], ["pneumonia", "PROBLEM", 507, 516], ["excessive", "OBSERVATION_MODIFIER", 16, 25], ["levels", "OBSERVATION_MODIFIER", 26, 32], ["inflammation", "OBSERVATION", 36, 48], ["evidence suggesting", "UNCERTAINTY", 193, 212], ["excessive", "OBSERVATION_MODIFIER", 213, 222], ["systemic", "OBSERVATION_MODIFIER", 223, 231], ["immune activation", "OBSERVATION", 232, 249], ["inflammation", "OBSERVATION_MODIFIER", 254, 266], ["TNF", "ANATOMY", 329, 332], ["pneumonia", "OBSERVATION", 507, 516]]], ["Furthermore, the extent of immune activation and inflammation increases with severity of disease and is some cases ten-fold higher in critically ill patients compared to those with mild disease [57].BackgroundThe importance of peripheral immune activation in the pathogenesis of severe COVID-19 is further emphasised by replicated data demonstrating that the plasma neutrophil: lymphocyte ratio is predictive of both disease severity [58] and mortality [59].", [["plasma neutrophil", "ANATOMY", 359, 376], ["lymphocyte", "ANATOMY", 378, 388], ["inflammation", "DISEASE", 49, 61], ["critically ill", "DISEASE", 134, 148], ["COVID", "DISEASE", 286, 291], ["COVID-19", "CHEMICAL", 286, 294], ["patients", "ORGANISM", 149, 157], ["plasma", "ORGANISM_SUBSTANCE", 359, 365], ["neutrophil", "CELL", 366, 376], ["lymphocyte", "CELL", 378, 388], ["plasma neutrophil", "CELL_TYPE", 359, 376], ["patients", "SPECIES", 149, 157], ["immune activation", "PROBLEM", 27, 44], ["inflammation", "PROBLEM", 49, 61], ["severity of disease", "PROBLEM", 77, 96], ["some cases ten-fold", "PROBLEM", 104, 123], ["mild disease", "PROBLEM", 181, 193], ["peripheral immune activation", "TREATMENT", 227, 255], ["severe COVID", "PROBLEM", 279, 291], ["the plasma neutrophil", "TEST", 355, 376], ["lymphocyte ratio", "TEST", 378, 394], ["both disease severity", "PROBLEM", 412, 433], ["mortality", "TEST", 443, 452], ["immune activation", "OBSERVATION", 27, 44], ["inflammation", "OBSERVATION", 49, 61], ["disease", "OBSERVATION", 89, 96], ["mild", "OBSERVATION_MODIFIER", 181, 185], ["disease", "OBSERVATION", 186, 193], ["peripheral immune activation", "OBSERVATION", 227, 255], ["severe", "OBSERVATION_MODIFIER", 279, 285]]], ["This concept is further supported by data suggesting that levels of IL-6 in the bloodstream correlate with symptom severity and morbidity, as well as being predictive of mortality [51,57,60,61].BackgroundIn addition, lymphopenia is common in an environment of severe inflammation [62,63].", [["bloodstream", "ANATOMY", 80, 91], ["lymphopenia", "DISEASE", 217, 228], ["inflammation", "DISEASE", 267, 279], ["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["IL-6", "PROTEIN", 68, 72], ["IL", "TEST", 68, 70], ["symptom severity", "PROBLEM", 107, 123], ["morbidity", "PROBLEM", 128, 137], ["lymphopenia", "PROBLEM", 217, 228], ["severe inflammation", "PROBLEM", 260, 279], ["lymphopenia", "OBSERVATION", 217, 228], ["severe", "OBSERVATION_MODIFIER", 260, 266], ["inflammation", "OBSERVATION", 267, 279]]], ["It is commonly observed in patients suffering severe disease [48,54,[64], [65], [66]].", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["severe disease", "PROBLEM", 46, 60]]], ["The weight of evidence suggests that drastically reduced numbers of CD4+ T cells, CD8+ T cells, B cells and natural killer (NK) cells are characteristic of COVID-19 [48,54,[64], [65], [66]].", [["CD4+ T cells", "ANATOMY", 68, 80], ["CD8+ T cells", "ANATOMY", 82, 94], ["B cells", "ANATOMY", 96, 103], ["natural killer (NK) cells", "ANATOMY", 108, 133], ["COVID-19", "CHEMICAL", 156, 164], ["CD4", "GENE_OR_GENE_PRODUCT", 68, 71], ["CD8", "GENE_OR_GENE_PRODUCT", 82, 85], ["B cells", "CELL", 96, 103], ["natural killer (NK) cells", "CELL", 108, 133], ["CD4+ T cells", "CELL_TYPE", 68, 80], ["CD8+ T cells", "CELL_TYPE", 82, 94], ["B cells", "CELL_TYPE", 96, 103], ["natural killer (NK) cells", "CELL_TYPE", 108, 133], ["The weight", "TEST", 0, 10], ["CD4", "TEST", 68, 71], ["T cells", "PROBLEM", 73, 80], ["CD8", "TEST", 82, 85], ["B cells", "TEST", 96, 103], ["COVID", "TEST", 156, 161], ["drastically", "OBSERVATION_MODIFIER", 37, 48], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["natural killer", "OBSERVATION", 108, 122]]], ["In addition, the degree of lymphopenia correlates with symptom severity [4,67] and inversely with inflammatory markers such as TNF-alpha and IL-6,[50].", [["lymphopenia", "DISEASE", 27, 38], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 127, 136], ["IL-6", "GENE_OR_GENE_PRODUCT", 141, 145], ["inflammatory markers", "PROTEIN", 98, 118], ["TNF", "PROTEIN", 127, 130], ["IL", "PROTEIN", 141, 143], ["lymphopenia", "PROBLEM", 27, 38], ["symptom severity", "PROBLEM", 55, 71], ["inflammatory markers", "TEST", 98, 118], ["TNF", "TEST", 127, 130], ["alpha and IL", "TREATMENT", 131, 143], ["degree", "OBSERVATION_MODIFIER", 17, 23], ["lymphopenia", "OBSERVATION", 27, 38], ["inflammatory", "OBSERVATION_MODIFIER", 98, 110]]], ["Furthermore, remaining CD4 and CD8 T lymphocytes display signs of exhaustion and dysfunction as evidenced by increased expression of PD-1, Tim-3 and NKG2A receptors [64,[68], [69], [70]].", [["CD4", "ANATOMY", 23, 26], ["CD8 T lymphocytes", "ANATOMY", 31, 48], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD8", "GENE_OR_GENE_PRODUCT", 31, 34], ["PD-1", "GENE_OR_GENE_PRODUCT", 133, 137], ["Tim-3", "GENE_OR_GENE_PRODUCT", 139, 144], ["NKG2A", "GENE_OR_GENE_PRODUCT", 149, 154], ["CD4 and CD8 T lymphocytes", "CELL_TYPE", 23, 48], ["PD-1", "PROTEIN", 133, 137], ["Tim-3", "PROTEIN", 139, 144], ["NKG2A receptors", "PROTEIN", 149, 164], ["remaining CD4", "TEST", 13, 26], ["exhaustion", "PROBLEM", 66, 76], ["dysfunction", "PROBLEM", 81, 92], ["PD", "TEST", 133, 135], ["Tim", "TEST", 139, 142], ["NKG2A receptors", "TEST", 149, 164], ["CD4", "OBSERVATION", 23, 26], ["exhaustion", "OBSERVATION", 66, 76], ["increased", "OBSERVATION_MODIFIER", 109, 118]]], ["It should be noted that the extent of T cell exhaustion is predictive of greater disease severity [69].BackgroundSeveral research teams have also reported the presence of TH17 polarised CD4 T cells in the lungs and periphery of COVID-19 patients with severe ARDS [66,71,72].", [["T cell", "ANATOMY", 38, 44], ["CD4 T cells", "ANATOMY", 186, 197], ["lungs", "ANATOMY", 205, 210], ["ARDS", "DISEASE", 258, 262], ["T cell", "CELL", 38, 44], ["TH17", "CELL", 171, 175], ["CD4 T cells", "CELL", 186, 197], ["lungs", "ORGAN", 205, 210], ["patients", "ORGANISM", 237, 245], ["TH17 polarised CD4 T cells", "CELL_TYPE", 171, 197], ["patients", "SPECIES", 237, 245], ["T cell exhaustion", "PROBLEM", 38, 55], ["greater disease severity", "PROBLEM", 73, 97], ["COVID", "TEST", 228, 233], ["severe ARDS", "PROBLEM", 251, 262], ["T cell exhaustion", "OBSERVATION", 38, 55], ["greater", "OBSERVATION_MODIFIER", 73, 80], ["CD4 T cells", "OBSERVATION", 186, 197], ["lungs", "ANATOMY", 205, 210], ["periphery", "ANATOMY_MODIFIER", 215, 224], ["severe", "OBSERVATION_MODIFIER", 251, 257], ["ARDS", "OBSERVATION", 258, 262]]], ["Moreover, these T cells secrete relatively large amounts of the highly cytotoxic cytokine IL-17 [66,71,72].BackgroundThe patterns and extent of immune disturbance seen in the lungs and periphery of patients suffering from severe COVID-19 are characteristic of a cytokine storm and are commonly observed in cytokine release syndromes [48,51,53,[73], [74], [75]].", [["T cells", "ANATOMY", 16, 23], ["lungs", "ANATOMY", 175, 180], ["COVID-19", "CHEMICAL", 229, 237], ["T cells", "CELL", 16, 23], ["IL-17", "GENE_OR_GENE_PRODUCT", 90, 95], ["lungs", "ORGAN", 175, 180], ["patients", "ORGANISM", 198, 206], ["T cells", "CELL_TYPE", 16, 23], ["cytokine", "PROTEIN", 81, 89], ["cytokine", "PROTEIN", 262, 270], ["cytokine", "PROTEIN", 306, 314], ["patients", "SPECIES", 198, 206], ["the highly cytotoxic cytokine IL", "TEST", 60, 92], ["immune disturbance", "PROBLEM", 144, 162], ["severe COVID", "PROBLEM", 222, 234], ["a cytokine storm", "PROBLEM", 260, 276], ["cytokine release syndromes", "TEST", 306, 332], ["large", "OBSERVATION_MODIFIER", 43, 48], ["amounts", "OBSERVATION_MODIFIER", 49, 56], ["highly", "OBSERVATION_MODIFIER", 64, 70], ["cytotoxic", "OBSERVATION_MODIFIER", 71, 80], ["extent", "OBSERVATION_MODIFIER", 134, 140], ["immune disturbance", "OBSERVATION", 144, 162], ["lungs", "ANATOMY", 175, 180], ["periphery", "OBSERVATION_MODIFIER", 185, 194], ["severe", "OBSERVATION_MODIFIER", 222, 228], ["cytokine storm", "OBSERVATION", 262, 276]]], ["In addition, many patients with severe disease qualify for a diagnosis of \u201cSepsis\u201d under the Sepsis 3 guidelines and many authors have proposed that severe COVID-19 is a virally induced sepsis [76,77].BackgroundThus far there are no published models of the pathophysiology of the condition from the point of viral entry and how the disease might progress.", [["Sepsis", "DISEASE", 75, 81], ["Sepsis", "DISEASE", 93, 99], ["COVID", "DISEASE", 156, 161], ["sepsis", "DISEASE", 186, 192], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["severe disease", "PROBLEM", 32, 46], ["Sepsis", "PROBLEM", 75, 81], ["severe COVID", "PROBLEM", 149, 161], ["a virally induced sepsis", "PROBLEM", 168, 192], ["viral entry", "PROBLEM", 308, 319], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["disease", "OBSERVATION", 39, 46], ["Sepsis", "OBSERVATION", 75, 81], ["sepsis", "OBSERVATION", 186, 192]]], ["This paper aims to propose such a model We will initially focus on the engagement of the virus with type 2 alveolar cells and subsequent activation of alveolar macrophages.Activation of alveolar epithelial cells and macrophagesThere is ample evidence that SARS infects type 2 alveolar epithelial cells leading to their death by apoptosis and pyroptosis via the activation of NLP-3 through mechanisms described above [78,79] reviewed [80].", [["type 2 alveolar cells", "ANATOMY", 100, 121], ["alveolar macrophages", "ANATOMY", 151, 171], ["alveolar epithelial cells", "ANATOMY", 186, 211], ["macrophages", "ANATOMY", 216, 227], ["type 2 alveolar epithelial cells", "ANATOMY", 269, 301], ["SARS", "DISEASE", 256, 260], ["death", "DISEASE", 319, 324], ["pyroptosis", "DISEASE", 342, 352], ["type 2 alveolar cells", "CELL", 100, 121], ["alveolar macrophages", "CELL", 151, 171], ["alveolar epithelial cells", "CELL", 186, 211], ["macrophages", "CELL", 216, 227], ["type 2 alveolar epithelial cells", "CELL", 269, 301], ["NLP-3", "GENE_OR_GENE_PRODUCT", 375, 380], ["type 2 alveolar cells", "CELL_TYPE", 100, 121], ["alveolar macrophages", "CELL_TYPE", 151, 171], ["alveolar epithelial cells", "CELL_TYPE", 186, 211], ["macrophages", "CELL_TYPE", 216, 227], ["type 2 alveolar epithelial cells", "CELL_TYPE", 269, 301], ["NLP", "PROTEIN", 375, 378], ["the virus", "PROBLEM", 85, 94], ["type 2 alveolar cells", "PROBLEM", 100, 121], ["alveolar macrophages", "PROBLEM", 151, 171], ["alveolar epithelial cells", "PROBLEM", 186, 211], ["macrophages", "PROBLEM", 216, 227], ["SARS infects type 2 alveolar epithelial cells", "PROBLEM", 256, 301], ["their death", "PROBLEM", 313, 324], ["apoptosis", "PROBLEM", 328, 337], ["pyroptosis", "PROBLEM", 342, 352], ["NLP", "TEST", 375, 378], ["alveolar cells", "ANATOMY", 107, 121], ["alveolar macrophages", "OBSERVATION", 151, 171], ["alveolar epithelial cells", "OBSERVATION", 186, 211], ["macrophages", "OBSERVATION", 216, 227], ["SARS", "OBSERVATION_MODIFIER", 256, 260], ["alveolar epithelial cells", "OBSERVATION", 276, 301], ["pyroptosis", "OBSERVATION", 342, 352]]], ["This is also clearly true of SARS-CoV-2 [14,36,37,46,47,81,82].", [["SARS-CoV", "SPECIES", 29, 37], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37]]], ["Furthermore, the weight of evidence suggests that SARS-COV [83,84] and SARS-CoV-2 [5,14,35,44] result in the activation of alveolar macrophages (AM).", [["alveolar macrophages", "ANATOMY", 123, 143], ["AM", "ANATOMY", 145, 147], ["SARS", "DISEASE", 50, 54], ["SARS-COV", "GENE_OR_GENE_PRODUCT", 50, 58], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 71, 81], ["5,14,35,44", "SIMPLE_CHEMICAL", 83, 93], ["alveolar macrophages", "CELL", 123, 143], ["AM", "CELL", 145, 147], ["alveolar macrophages", "CELL_TYPE", 123, 143], ["AM", "CELL_TYPE", 145, 147], ["SARS-CoV", "SPECIES", 71, 79], ["SARS", "TEST", 50, 54], ["COV", "TEST", 55, 58], ["SARS", "TEST", 71, 75], ["CoV", "TEST", 76, 79], ["alveolar", "ANATOMY", 123, 131]]], ["This is unsurprising, given the close proximity of these immune cells to type II pneumocytes and their expression of ACE-2 receptors [11,85,86].Activation of alveolar epithelial cells and macrophagesThe loss of type II alveolar cells and AM activation has considerable pathophysiological importance resulting in the loss of immune homeostasis in the lung [39,[86], [87], [88]].", [["immune cells", "ANATOMY", 57, 69], ["type II pneumocytes", "ANATOMY", 73, 92], ["alveolar epithelial cells", "ANATOMY", 158, 183], ["macrophages", "ANATOMY", 188, 199], ["type II alveolar cells", "ANATOMY", 211, 233], ["AM", "ANATOMY", 238, 240], ["lung", "ANATOMY", 350, 354], ["immune cells", "CELL", 57, 69], ["type II pneumocytes", "CELL", 73, 92], ["ACE-2", "GENE_OR_GENE_PRODUCT", 117, 122], ["alveolar epithelial cells", "CELL", 158, 183], ["macrophages", "CELL", 188, 199], ["type II alveolar cells", "CELL", 211, 233], ["AM", "GENE_OR_GENE_PRODUCT", 238, 240], ["lung", "ORGAN", 350, 354], ["immune cells", "CELL_TYPE", 57, 69], ["type II pneumocytes", "CELL_TYPE", 73, 92], ["ACE-2 receptors", "PROTEIN", 117, 132], ["alveolar epithelial cells", "CELL_TYPE", 158, 183], ["macrophages", "CELL_TYPE", 188, 199], ["type II alveolar cells", "CELL_TYPE", 211, 233], ["type II pneumocytes", "PROBLEM", 73, 92], ["ACE", "TEST", 117, 120], ["alveolar epithelial cells", "PROBLEM", 158, 183], ["macrophages", "PROBLEM", 188, 199], ["The loss of type II alveolar cells", "PROBLEM", 199, 233], ["AM activation", "PROBLEM", 238, 251], ["the loss of immune homeostasis in the lung", "PROBLEM", 312, 354], ["immune cells", "OBSERVATION", 57, 69], ["alveolar epithelial cells", "OBSERVATION", 158, 183], ["macrophages", "OBSERVATION", 188, 199], ["loss", "OBSERVATION_MODIFIER", 203, 207], ["type II", "OBSERVATION_MODIFIER", 211, 218], ["alveolar cells", "OBSERVATION", 219, 233], ["loss", "OBSERVATION_MODIFIER", 316, 320], ["immune homeostasis", "OBSERVATION", 324, 342], ["lung", "ANATOMY", 350, 354]]], ["This dyshomeostasis in turn is an essential element in the development of severe pneumonia and the acute respiratory distress syndrome, which occurs as a consequence of virally induced sepsis or indeed, several other inflammatory insults [39,[86], [87], [88]].Activation of alveolar epithelial cells and macrophagesPyroptosis and necroptosis of alveolar epithelial and endothelial cells are major elements in development and progression of ARDS in part by releasing high mobility group box 1 (HMBG1) and other inflammatory damage-associated molecular patterns (DAMPS) [[89], [90], [91]].", [["respiratory", "ANATOMY", 105, 116], ["alveolar epithelial cells", "ANATOMY", 274, 299], ["macrophages", "ANATOMY", 304, 315], ["alveolar epithelial", "ANATOMY", 345, 364], ["endothelial cells", "ANATOMY", 369, 386], ["pneumonia", "DISEASE", 81, 90], ["acute respiratory distress syndrome", "DISEASE", 99, 134], ["sepsis", "DISEASE", 185, 191], ["Pyroptosis", "DISEASE", 315, 325], ["ARDS", "DISEASE", 440, 444], ["alveolar epithelial cells", "CELL", 274, 299], ["macrophages", "CELL", 304, 315], ["alveolar epithelial", "CELL", 345, 364], ["endothelial cells", "CELL", 369, 386], ["high mobility group box 1", "GENE_OR_GENE_PRODUCT", 466, 491], ["HMBG1", "GENE_OR_GENE_PRODUCT", 493, 498], ["alveolar epithelial cells", "CELL_TYPE", 274, 299], ["macrophages", "CELL_TYPE", 304, 315], ["alveolar epithelial", "CELL_TYPE", 345, 364], ["endothelial cells", "CELL_TYPE", 369, 386], ["high mobility group box 1", "PROTEIN", 466, 491], ["HMBG1", "PROTEIN", 493, 498], ["This dyshomeostasis", "PROBLEM", 0, 19], ["severe pneumonia", "PROBLEM", 74, 90], ["the acute respiratory distress syndrome", "PROBLEM", 95, 134], ["virally induced sepsis", "PROBLEM", 169, 191], ["several other inflammatory insults", "PROBLEM", 203, 237], ["alveolar epithelial cells", "PROBLEM", 274, 299], ["macrophages", "PROBLEM", 304, 315], ["Pyroptosis", "PROBLEM", 315, 325], ["necroptosis", "PROBLEM", 330, 341], ["alveolar epithelial and endothelial cells", "PROBLEM", 345, 386], ["ARDS", "PROBLEM", 440, 444], ["releasing high mobility group box", "PROBLEM", 456, 489], ["HMBG1", "TEST", 493, 498], ["other inflammatory damage", "PROBLEM", 504, 529], ["essential", "OBSERVATION_MODIFIER", 34, 43], ["element", "OBSERVATION_MODIFIER", 44, 51], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["pneumonia", "OBSERVATION", 81, 90], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["respiratory distress syndrome", "OBSERVATION", 105, 134], ["sepsis", "OBSERVATION", 185, 191], ["inflammatory", "OBSERVATION_MODIFIER", 217, 229], ["alveolar epithelial cells", "OBSERVATION", 274, 299], ["macrophages", "OBSERVATION", 304, 315], ["necroptosis", "OBSERVATION", 330, 341], ["alveolar", "ANATOMY_MODIFIER", 345, 353], ["epithelial", "ANATOMY_MODIFIER", 354, 364], ["endothelial cells", "OBSERVATION", 369, 386], ["progression", "OBSERVATION_MODIFIER", 425, 436], ["ARDS", "OBSERVATION", 440, 444], ["high", "OBSERVATION_MODIFIER", 466, 470], ["inflammatory", "OBSERVATION_MODIFIER", 510, 522]]], ["Hence, the pyroptotic death of type 2 alveolar cells following SARS-Cov2 infection may also be of pathophysiological significance in the development of COVID-19 and a major source of inflammation [85,86].Activation of alveolar epithelial cells and macrophagesActivated macrophages (AMs) play a major role in maintaining immune homeostasis in the lung in the face of pathogen invasion and a myriad of inflammatory insults.", [["type 2 alveolar cells", "ANATOMY", 31, 52], ["alveolar epithelial cells", "ANATOMY", 218, 243], ["macrophages", "ANATOMY", 248, 259], ["macrophages", "ANATOMY", 269, 280], ["AMs", "ANATOMY", 282, 285], ["lung", "ANATOMY", 346, 350], ["death", "DISEASE", 22, 27], ["infection", "DISEASE", 73, 82], ["COVID-19", "CHEMICAL", 152, 160], ["inflammation", "DISEASE", 183, 195], ["type 2 alveolar cells", "CELL", 31, 52], ["SARS-Cov2", "GENE_OR_GENE_PRODUCT", 63, 72], ["COVID-19", "CELL", 152, 160], ["alveolar epithelial cells", "CELL", 218, 243], ["macrophages", "CELL", 248, 259], ["macrophages", "CELL", 269, 280], ["AMs", "CELL", 282, 285], ["lung", "ORGAN", 346, 350], ["type 2 alveolar cells", "CELL_TYPE", 31, 52], ["alveolar epithelial cells", "CELL_TYPE", 218, 243], ["macrophages", "CELL_TYPE", 248, 259], ["Activated macrophages", "CELL_TYPE", 259, 280], ["AMs", "CELL_TYPE", 282, 285], ["the pyroptotic death", "PROBLEM", 7, 27], ["type 2 alveolar cells", "PROBLEM", 31, 52], ["SARS", "PROBLEM", 63, 67], ["Cov2 infection", "PROBLEM", 68, 82], ["COVID", "TEST", 152, 157], ["inflammation", "PROBLEM", 183, 195], ["alveolar epithelial cells", "PROBLEM", 218, 243], ["macrophages", "PROBLEM", 248, 259], ["Activated macrophages (AMs)", "TREATMENT", 259, 286], ["pathogen invasion", "PROBLEM", 366, 383], ["inflammatory insults", "PROBLEM", 400, 420], ["alveolar cells", "OBSERVATION", 38, 52], ["may also be of", "UNCERTAINTY", 83, 97], ["inflammation", "OBSERVATION", 183, 195], ["alveolar epithelial cells", "OBSERVATION", 218, 243], ["macrophages", "OBSERVATION", 248, 259], ["macrophages", "OBSERVATION", 269, 280], ["immune homeostasis", "OBSERVATION", 320, 338], ["lung", "ANATOMY", 346, 350], ["pathogen", "OBSERVATION_MODIFIER", 366, 374], ["invasion", "OBSERVATION", 375, 383], ["myriad", "OBSERVATION_MODIFIER", 390, 396], ["inflammatory", "OBSERVATION_MODIFIER", 400, 412]]], ["The main mechanisms involved phagocytosis of dying cells, secretion of anti-inflammatory mediators such as transforming growth factor (TGF) beta, Prostaglandin E2 (PGE2) and polyenoic fatty acids (PFA), and inhibiting the activation of circulating T cells (reviewed in [85,86]).", [["cells", "ANATOMY", 51, 56], ["T cells", "ANATOMY", 248, 255], ["Prostaglandin E2", "CHEMICAL", 146, 162], ["PGE2", "CHEMICAL", 164, 168], ["polyenoic fatty acids", "CHEMICAL", 174, 195], ["Prostaglandin E2", "CHEMICAL", 146, 162], ["PGE2", "CHEMICAL", 164, 168], ["polyenoic fatty acids", "CHEMICAL", 174, 195], ["PFA", "CHEMICAL", 197, 200], ["cells", "CELL", 51, 56], ["transforming growth factor (TGF) beta", "GENE_OR_GENE_PRODUCT", 107, 144], ["Prostaglandin E2", "SIMPLE_CHEMICAL", 146, 162], ["PGE2", "SIMPLE_CHEMICAL", 164, 168], ["polyenoic fatty acids", "SIMPLE_CHEMICAL", 174, 195], ["PFA", "SIMPLE_CHEMICAL", 197, 200], ["T cells", "CELL", 248, 255], ["dying cells", "CELL_TYPE", 45, 56], ["anti-inflammatory mediators", "PROTEIN", 71, 98], ["transforming growth factor (TGF) beta", "PROTEIN", 107, 144], ["PGE2", "PROTEIN", 164, 168], ["circulating T cells", "CELL_TYPE", 236, 255], ["phagocytosis of dying cells", "PROBLEM", 29, 56], ["anti-inflammatory mediators", "TREATMENT", 71, 98], ["transforming growth factor", "PROBLEM", 107, 133], ["beta, Prostaglandin E2 (PGE2)", "TEST", 140, 169], ["polyenoic fatty acids (PFA)", "PROBLEM", 174, 201], ["main", "OBSERVATION_MODIFIER", 4, 8], ["phagocytosis", "OBSERVATION_MODIFIER", 29, 41], ["dying cells", "OBSERVATION", 45, 56]]], ["However, once activated, these AMs secrete a range of proinflammatory cytokines (PICs) and chemokines such as TNF-alpha IL-1 beta, IL-6, and IL-8 [[92], [93], [94]] [[92], [93], [94]].", [["AMs", "ANATOMY", 31, 34], ["AMs", "CELL", 31, 34], ["PICs", "GENE_OR_GENE_PRODUCT", 81, 85], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 110, 119], ["IL-1 beta", "GENE_OR_GENE_PRODUCT", 120, 129], ["IL-6", "GENE_OR_GENE_PRODUCT", 131, 135], ["IL-8", "SIMPLE_CHEMICAL", 141, 145], ["[92], [93], [94]]", "SIMPLE_CHEMICAL", 147, 164], ["[92], [93], [94]]", "SIMPLE_CHEMICAL", 166, 183], ["AMs", "CELL_TYPE", 31, 34], ["proinflammatory cytokines", "PROTEIN", 54, 79], ["PICs", "PROTEIN", 81, 85], ["chemokines", "PROTEIN", 91, 101], ["TNF", "PROTEIN", 110, 113], ["IL-6", "PROTEIN", 131, 135], ["proinflammatory cytokines", "TEST", 54, 79], ["chemokines", "TEST", 91, 101], ["TNF", "TEST", 110, 113], ["alpha IL", "TEST", 114, 122], ["IL", "TEST", 131, 133], ["IL", "TEST", 141, 143]]], ["In addition, AM's also secrete microvesicles, containing massive levels of TNF-alpha [95].", [["microvesicles", "ANATOMY", 31, 44], ["AM", "GENE_OR_GENE_PRODUCT", 13, 15], ["microvesicles", "CELL", 31, 44], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 75, 84], ["TNF", "PROTEIN", 75, 78], ["secrete microvesicles", "PROBLEM", 23, 44], ["massive levels of TNF", "PROBLEM", 57, 78], ["massive", "OBSERVATION_MODIFIER", 57, 64], ["TNF", "ANATOMY", 75, 78]]], ["This increase in the secretion of inflammatory mediators is also accompanied by an increase in the number of AMs polarised into a highly inflammatory or M1 phenotype rather than the anti-inflammatory tolerogenic M2 phenotype prevalent in physiological conditions [96,97].", [["AMs", "ANATOMY", 109, 112], ["AMs", "CELL", 109, 112], ["M2", "GENE_OR_GENE_PRODUCT", 212, 214], ["inflammatory mediators", "PROTEIN", 34, 56], ["AMs", "CELL_TYPE", 109, 112], ["the secretion of inflammatory mediators", "PROBLEM", 17, 56], ["a highly inflammatory or M1 phenotype", "PROBLEM", 128, 165], ["increase", "OBSERVATION_MODIFIER", 5, 13], ["inflammatory", "OBSERVATION_MODIFIER", 34, 46], ["increase", "OBSERVATION_MODIFIER", 83, 91], ["highly", "OBSERVATION_MODIFIER", 130, 136], ["inflammatory", "OBSERVATION_MODIFIER", 137, 149], ["M1 phenotype", "OBSERVATION", 153, 165], ["anti-inflammatory", "OBSERVATION_MODIFIER", 182, 199], ["tolerogenic M2", "OBSERVATION", 200, 214]]], ["This is of considerable pathophysiological importance as a progressively increased population of M1 polarised alveolar macrophages over time results in excessive secretion of PICs and chemokines, and is highly predictive of mortality in ARDS patients, while an increased population of M2 polarised cells is predictive of survival [96,97].", [["alveolar macrophages", "ANATOMY", 110, 130], ["cells", "ANATOMY", 298, 303], ["ARDS", "DISEASE", 237, 241], ["M1", "CELL", 97, 99], ["alveolar macrophages", "CELL", 110, 130], ["PICs", "GENE_OR_GENE_PRODUCT", 175, 179], ["patients", "ORGANISM", 242, 250], ["M2 polarised cells", "CELL", 285, 303], ["M1 polarised alveolar macrophages", "CELL_TYPE", 97, 130], ["PICs", "PROTEIN", 175, 179], ["chemokines", "PROTEIN", 184, 194], ["M2 polarised cells", "CELL_LINE", 285, 303], ["patients", "SPECIES", 242, 250], ["excessive secretion of PICs", "PROBLEM", 152, 179], ["ARDS", "PROBLEM", 237, 241], ["progressively", "OBSERVATION_MODIFIER", 59, 72], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["population", "OBSERVATION_MODIFIER", 83, 93], ["M1", "OBSERVATION_MODIFIER", 97, 99], ["polarised", "OBSERVATION_MODIFIER", 100, 109], ["alveolar macrophages", "OBSERVATION", 110, 130], ["ARDS", "OBSERVATION", 237, 241], ["increased", "OBSERVATION_MODIFIER", 261, 270], ["population", "OBSERVATION_MODIFIER", 271, 281], ["M2 polarised", "OBSERVATION_MODIFIER", 285, 297]]], ["Importantly, the subsequent release of these cytokines and chemokines into the pulmonary vasculature plays an important role in the development of ARDS by initiating a series of events which results in the activation of vascular endothelial cells (EC) [86,88,98].", [["pulmonary vasculature", "ANATOMY", 79, 100], ["vascular endothelial cells", "ANATOMY", 220, 246], ["EC", "ANATOMY", 248, 250], ["ARDS", "DISEASE", 147, 151], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 79, 100], ["vascular endothelial cells", "CELL", 220, 246], ["EC", "CELL", 248, 250], ["cytokines", "PROTEIN", 45, 54], ["chemokines", "PROTEIN", 59, 69], ["vascular endothelial cells", "CELL_TYPE", 220, 246], ["EC", "CELL_TYPE", 248, 250], ["these cytokines", "TREATMENT", 39, 54], ["chemokines", "TREATMENT", 59, 69], ["ARDS", "PROBLEM", 147, 151], ["pulmonary vasculature", "ANATOMY", 79, 100], ["ARDS", "OBSERVATION", 147, 151], ["vascular endothelial", "ANATOMY", 220, 240]]], ["This in turn leads to the recruitment of highly cytotoxic neutrophils and inflammatory activated platelets into the alveolar space, resulting in a host of pathogenic consequences, as discussed below [86,88,98].Endothelial cell activation ::: Activation of vascular endothelial cells, platelets and neutrophilsIncreased levels of PICs such as TNF-alpha and IL-1 induce endothelial cell activation via the upregulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) [99,100], leading to a significant increase in the permeability of the pulmonary vascular endothelium [101].", [["neutrophils", "ANATOMY", 58, 69], ["platelets", "ANATOMY", 97, 106], ["alveolar space", "ANATOMY", 116, 130], ["Endothelial cell", "ANATOMY", 210, 226], ["vascular endothelial cells", "ANATOMY", 256, 282], ["platelets", "ANATOMY", 284, 293], ["neutrophils", "ANATOMY", 298, 309], ["endothelial cell", "ANATOMY", 368, 384], ["B cells", "ANATOMY", 475, 482], ["pulmonary vascular endothelium", "ANATOMY", 562, 592], ["neutrophils", "CELL", 58, 69], ["platelets", "CELL", 97, 106], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 116, 130], ["Endothelial cell", "CELL", 210, 226], ["vascular endothelial cells", "CELL", 256, 282], ["platelets", "CELL", 284, 293], ["neutrophils", "CELL", 298, 309], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 342, 351], ["IL-1", "GENE_OR_GENE_PRODUCT", 356, 360], ["endothelial cell", "CELL", 368, 384], ["kappa-light-chain-enhancer of activated B cells", "GENE_OR_GENE_PRODUCT", 435, 482], ["NF-kB", "GENE_OR_GENE_PRODUCT", 484, 489], ["pulmonary vascular endothelium", "TISSUE", 562, 592], ["cytotoxic neutrophils", "CELL_TYPE", 48, 69], ["inflammatory activated platelets", "CELL_TYPE", 74, 106], ["vascular endothelial cells", "CELL_TYPE", 256, 282], ["platelets", "CELL_TYPE", 284, 293], ["neutrophils", "CELL_TYPE", 298, 309], ["PICs", "PROTEIN", 329, 333], ["TNF-alpha", "PROTEIN", 342, 351], ["IL-1", "PROTEIN", 356, 360], ["nuclear factor kappa-light-chain-enhancer of activated B cells", "PROTEIN", 420, 482], ["NF-kB", "PROTEIN", 484, 489], ["highly cytotoxic neutrophils", "PROBLEM", 41, 69], ["inflammatory activated platelets into the alveolar space", "PROBLEM", 74, 130], ["vascular endothelial cells", "TEST", 256, 282], ["platelets", "TEST", 284, 293], ["neutrophils", "TEST", 298, 309], ["PICs", "PROBLEM", 329, 333], ["TNF", "TEST", 342, 345], ["alpha", "TEST", 346, 351], ["IL", "TEST", 356, 358], ["endothelial cell activation", "PROBLEM", 368, 395], ["nuclear factor kappa-light", "TEST", 420, 446], ["activated B cells", "PROBLEM", 465, 482], ["a significant increase", "PROBLEM", 512, 534], ["highly", "OBSERVATION_MODIFIER", 41, 47], ["cytotoxic neutrophils", "OBSERVATION", 48, 69], ["inflammatory", "OBSERVATION_MODIFIER", 74, 86], ["alveolar space", "ANATOMY", 116, 130], ["cell activation", "OBSERVATION", 222, 237], ["vascular endothelial", "ANATOMY", 256, 276], ["endothelial cell", "OBSERVATION", 368, 384], ["significant", "OBSERVATION_MODIFIER", 514, 525], ["increase", "OBSERVATION_MODIFIER", 526, 534], ["pulmonary", "ANATOMY_MODIFIER", 562, 571], ["vascular endothelium", "ANATOMY", 572, 592]]], ["The activation of pulmonary vascular endothelial cell (ECs) also promotes the recruitment of circulating neutrophils via the upregulation of surface membrane chemokines, most notably CCL5, CXCL1, MCP-1 and IL-8, the surface adherence proteins P-selectin, VCAM-1, ICAM-1 and an array of glycosaminoglycans, which play an essential role in neutrophil tethering and migration [[102], [103], [104]].Endothelial cell activation ::: Activation of vascular endothelial cells, platelets and neutrophilsOnce activated, vascular ECs behave in a similar manner to immune cells and become a source of PICs and reactive oxygen species (ROS) and also stimulate the activity of immune cells in the vascular environment, reviewed [105].", [["pulmonary vascular endothelial cell", "ANATOMY", 18, 53], ["ECs", "ANATOMY", 55, 58], ["neutrophils", "ANATOMY", 105, 116], ["surface membrane", "ANATOMY", 141, 157], ["surface", "ANATOMY", 216, 223], ["neutrophil", "ANATOMY", 338, 348], ["Endothelial cell", "ANATOMY", 395, 411], ["vascular endothelial cells", "ANATOMY", 441, 467], ["platelets", "ANATOMY", 469, 478], ["neutrophils", "ANATOMY", 483, 494], ["vascular ECs", "ANATOMY", 510, 522], ["immune cells", "ANATOMY", 553, 565], ["immune cells", "ANATOMY", 663, 675], ["vascular", "ANATOMY", 683, 691], ["oxygen", "CHEMICAL", 607, 613], ["ROS", "CHEMICAL", 623, 626], ["oxygen", "CHEMICAL", 607, 613], ["pulmonary vascular endothelial cell", "CELL", 18, 53], ["ECs", "CELL", 55, 58], ["neutrophils", "CELL", 105, 116], ["CCL5", "GENE_OR_GENE_PRODUCT", 183, 187], ["CXCL1", "GENE_OR_GENE_PRODUCT", 189, 194], ["MCP-1", "GENE_OR_GENE_PRODUCT", 196, 201], ["IL-8", "GENE_OR_GENE_PRODUCT", 206, 210], ["P-selectin", "GENE_OR_GENE_PRODUCT", 243, 253], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 255, 261], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 263, 269], ["glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 286, 304], ["neutrophil", "CELL", 338, 348], ["Endothelial cell", "CELL", 395, 411], ["vascular endothelial cells", "CELL", 441, 467], ["platelets", "CELL", 469, 478], ["neutrophils", "CELL", 483, 494], ["vascular ECs", "CELL", 510, 522], ["immune cells", "CELL", 553, 565], ["reactive oxygen species", "SIMPLE_CHEMICAL", 598, 621], ["ROS", "SIMPLE_CHEMICAL", 623, 626], ["immune cells", "CELL", 663, 675], ["vascular environment", "MULTI-TISSUE_STRUCTURE", 683, 703], ["pulmonary vascular endothelial cell", "CELL_TYPE", 18, 53], ["ECs", "CELL_TYPE", 55, 58], ["circulating neutrophils", "CELL_TYPE", 93, 116], ["surface membrane chemokines", "PROTEIN", 141, 168], ["CCL5", "PROTEIN", 183, 187], ["CXCL1", "PROTEIN", 189, 194], ["MCP-1", "PROTEIN", 196, 201], ["IL-8", "PROTEIN", 206, 210], ["surface adherence proteins", "PROTEIN", 216, 242], ["P", "PROTEIN", 243, 244], ["selectin", "PROTEIN", 245, 253], ["VCAM-1", "PROTEIN", 255, 261], ["ICAM-1", "PROTEIN", 263, 269], ["vascular endothelial cells", "CELL_TYPE", 441, 467], ["platelets", "CELL_TYPE", 469, 478], ["neutrophils", "CELL_TYPE", 483, 494], ["vascular ECs", "CELL_TYPE", 510, 522], ["immune cells", "CELL_TYPE", 553, 565], ["immune cells", "CELL_TYPE", 663, 675], ["circulating neutrophils", "TEST", 93, 116], ["surface membrane chemokines", "TEST", 141, 168], ["CCL5", "TEST", 183, 187], ["CXCL1", "TEST", 189, 194], ["MCP", "TEST", 196, 199], ["IL", "TEST", 206, 208], ["the surface adherence proteins", "TEST", 212, 242], ["P", "TEST", 243, 244], ["selectin", "TEST", 245, 253], ["VCAM", "TEST", 255, 259], ["ICAM", "TEST", 263, 267], ["an array of glycosaminoglycans", "TREATMENT", 274, 304], ["vascular endothelial cells", "TEST", 441, 467], ["platelets", "TEST", 469, 478], ["neutrophils", "TEST", 483, 494], ["vascular ECs", "TEST", 510, 522], ["PICs", "PROBLEM", 589, 593], ["reactive oxygen species", "PROBLEM", 598, 621], ["pulmonary vascular", "ANATOMY", 18, 36], ["endothelial cell", "OBSERVATION", 37, 53], ["neutrophil tethering", "OBSERVATION", 338, 358], ["cell activation", "OBSERVATION", 407, 422], ["vascular endothelial", "ANATOMY", 441, 461], ["neutrophils", "OBSERVATION", 483, 494], ["reactive", "OBSERVATION_MODIFIER", 598, 606], ["oxygen species", "OBSERVATION", 607, 621], ["vascular", "ANATOMY", 683, 691]]], ["Activated ECs also contribute to the development of coagulopathy via several mechanisms including the recruitment of platelets, independently secreting tissue factor and VWF, decreasing the activity of thrombomodulin and protein C while stimulating the activity of PAR-1, (reviewed by [106,107]).", [["ECs", "ANATOMY", 10, 13], ["platelets", "ANATOMY", 117, 126], ["coagulopathy", "DISEASE", 52, 64], ["ECs", "CELL", 10, 13], ["platelets", "CELL", 117, 126], ["tissue factor", "GENE_OR_GENE_PRODUCT", 152, 165], ["VWF", "GENE_OR_GENE_PRODUCT", 170, 173], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 202, 216], ["protein C", "GENE_OR_GENE_PRODUCT", 221, 230], ["PAR-1", "GENE_OR_GENE_PRODUCT", 265, 270], ["ECs", "CELL_TYPE", 10, 13], ["platelets", "CELL_TYPE", 117, 126], ["tissue factor", "PROTEIN", 152, 165], ["VWF", "PROTEIN", 170, 173], ["thrombomodulin", "PROTEIN", 202, 216], ["protein C", "PROTEIN", 221, 230], ["PAR-1", "PROTEIN", 265, 270], ["coagulopathy", "PROBLEM", 52, 64], ["the recruitment of platelets", "TREATMENT", 98, 126], ["independently secreting tissue factor", "PROBLEM", 128, 165], ["VWF", "PROBLEM", 170, 173], ["thrombomodulin and protein C", "TREATMENT", 202, 230], ["coagulopathy", "OBSERVATION", 52, 64]]], ["The development of endotheliopathy is a major factor in the pathogenesis of systemic sepsis and a major player in the development and exacerbation of the underlying cytokine storm [108,109].", [["endotheliopathy", "DISEASE", 19, 34], ["sepsis", "DISEASE", 85, 91], ["cytokine", "PROTEIN", 165, 173], ["endotheliopathy", "PROBLEM", 19, 34], ["systemic sepsis", "PROBLEM", 76, 91], ["the underlying cytokine storm", "PROBLEM", 150, 179], ["endotheliopathy", "OBSERVATION", 19, 34], ["systemic", "OBSERVATION_MODIFIER", 76, 84], ["sepsis", "OBSERVATION", 85, 91], ["cytokine storm", "OBSERVATION", 165, 179]]], ["Crucially, the development of endotheliopathy is also a pivotal factor in the pathogenesis of ARDS [110,111] as we discuss below.Endothelial cell activation ::: Activation of vascular endothelial cells, platelets and neutrophilsIn addition, as the mechanics of the coagulation cascade play a large part in the forthcoming discussion, a diagram of the processes involved is provided in Fig. 2.Endothelial cell activation ::: Activation of vascular endothelial cells, platelets and neutrophilsPlatelets activated by thrombin and or PICs initiate (PAR)\u2013mediated signalling further increasing levels of PICs VWF and TF coupled with suppression of suppression of thrombomodulin.", [["Endothelial cell", "ANATOMY", 129, 145], ["vascular endothelial cells", "ANATOMY", 175, 201], ["platelets", "ANATOMY", 203, 212], ["neutrophils", "ANATOMY", 217, 228], ["Endothelial cell", "ANATOMY", 392, 408], ["vascular endothelial cells", "ANATOMY", 438, 464], ["platelets", "ANATOMY", 466, 475], ["neutrophils", "ANATOMY", 480, 491], ["Platelets", "ANATOMY", 491, 500], ["endotheliopathy", "DISEASE", 30, 45], ["ARDS", "DISEASE", 94, 98], ["endotheliopathy", "CANCER", 30, 45], ["Endothelial cell", "CELL", 129, 145], ["vascular endothelial cells", "CELL", 175, 201], ["platelets", "CELL", 203, 212], ["neutrophils", "CELL", 217, 228], ["Endothelial cell", "CELL", 392, 408], ["vascular endothelial cells", "CELL", 438, 464], ["platelets", "CELL", 466, 475], ["neutrophils", "CELL", 480, 491], ["Platelets", "CELL", 491, 500], ["thrombin", "GENE_OR_GENE_PRODUCT", 514, 522], ["PICs", "GENE_OR_GENE_PRODUCT", 530, 534], ["PAR", "GENE_OR_GENE_PRODUCT", 545, 548], ["VWF", "GENE_OR_GENE_PRODUCT", 604, 607], ["TF", "GENE_OR_GENE_PRODUCT", 612, 614], ["thrombomodulin", "GENE_OR_GENE_PRODUCT", 658, 672], ["vascular endothelial cells", "CELL_TYPE", 175, 201], ["platelets", "CELL_TYPE", 203, 212], ["neutrophils", "CELL_TYPE", 217, 228], ["vascular endothelial cells", "CELL_TYPE", 438, 464], ["platelets", "CELL_TYPE", 466, 475], ["neutrophils", "CELL_TYPE", 480, 491], ["Platelets", "CELL_TYPE", 491, 500], ["thrombin", "PROTEIN", 514, 522], ["PICs", "PROTEIN", 530, 534], ["PAR", "PROTEIN", 545, 548], ["PICs", "PROTEIN", 599, 603], ["VWF", "PROTEIN", 604, 607], ["TF", "PROTEIN", 612, 614], ["thrombomodulin", "PROTEIN", 658, 672], ["endotheliopathy", "PROBLEM", 30, 45], ["a pivotal factor", "PROBLEM", 54, 70], ["ARDS", "PROBLEM", 94, 98], ["vascular endothelial cells", "TEST", 175, 201], ["platelets", "TEST", 203, 212], ["neutrophils", "TEST", 217, 228], ["the coagulation cascade", "TREATMENT", 261, 284], ["vascular endothelial cells", "TEST", 438, 464], ["platelets", "TEST", 466, 475], ["neutrophils", "TEST", 480, 491], ["Platelets", "TEST", 491, 500], ["thrombin", "TREATMENT", 514, 522], ["PICs", "TREATMENT", 530, 534], ["PICs VWF", "TREATMENT", 599, 607], ["TF", "TREATMENT", 612, 614], ["suppression of thrombomodulin", "TREATMENT", 643, 672], ["endotheliopathy", "OBSERVATION", 30, 45], ["ARDS", "OBSERVATION", 94, 98], ["cell activation", "OBSERVATION", 141, 156], ["vascular endothelial", "ANATOMY", 175, 195], ["neutrophils", "OBSERVATION", 217, 228], ["large", "OBSERVATION_MODIFIER", 292, 297], ["cell activation", "OBSERVATION", 404, 419], ["vascular endothelial", "ANATOMY", 438, 458], ["neutrophils", "OBSERVATION", 480, 491], ["PICs VWF", "OBSERVATION", 599, 607], ["thrombomodulin", "OBSERVATION", 658, 672]]], ["Platelet activation also results in increased expression of P-selectin, CD40 PF4 and a range of surface adhesion receptors ultimately recruiting neutrophils to form platelet neutrophil complexes.", [["Platelet", "ANATOMY", 0, 8], ["surface", "ANATOMY", 96, 103], ["neutrophils", "ANATOMY", 145, 156], ["platelet neutrophil complexes", "ANATOMY", 165, 194], ["Platelet", "CELL", 0, 8], ["P-selectin", "GENE_OR_GENE_PRODUCT", 60, 70], ["CD40 PF4", "GENE_OR_GENE_PRODUCT", 72, 80], ["surface adhesion receptors", "GENE_OR_GENE_PRODUCT", 96, 122], ["neutrophils", "CELL", 145, 156], ["platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 165, 194], ["P-selectin", "PROTEIN", 60, 70], ["CD40", "PROTEIN", 72, 76], ["PF4", "PROTEIN", 77, 80], ["surface adhesion receptors", "PROTEIN", 96, 122], ["neutrophils", "CELL_TYPE", 145, 156], ["platelet neutrophil complexes", "PROTEIN", 165, 194], ["Platelet activation", "TEST", 0, 19], ["P", "TEST", 60, 61], ["CD40 PF4", "TEST", 72, 80], ["a range of surface adhesion receptors", "TREATMENT", 85, 122], ["neutrophils", "TEST", 145, 156], ["platelet neutrophil complexes", "TEST", 165, 194], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["platelet neutrophil complexes", "OBSERVATION", 165, 194]]], ["NET secretion by neutrophils contributes to an increased coagulation stimulate increased levels of platelet activation, aggregation and TF mediated activation of thrombin.", [["neutrophils", "ANATOMY", 17, 28], ["platelet", "ANATOMY", 99, 107], ["NET", "GENE_OR_GENE_PRODUCT", 0, 3], ["neutrophils", "CELL", 17, 28], ["platelet", "CELL", 99, 107], ["TF", "GENE_OR_GENE_PRODUCT", 136, 138], ["thrombin", "GENE_OR_GENE_PRODUCT", 162, 170], ["neutrophils", "CELL_TYPE", 17, 28], ["TF", "PROTEIN", 136, 138], ["thrombin", "PROTEIN", 162, 170], ["NET secretion by neutrophils", "PROBLEM", 0, 28], ["an increased coagulation stimulate", "PROBLEM", 44, 78], ["platelet activation", "PROBLEM", 99, 118], ["aggregation", "PROBLEM", 120, 131], ["TF mediated activation of thrombin", "TREATMENT", 136, 170], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["coagulation", "OBSERVATION", 57, 68], ["platelet activation", "OBSERVATION", 99, 118]]], ["In addition, histones play an important role in promoting thrombin generation and inhibiting protein C-mediated anticoagulant responses.", [["histones", "GENE_OR_GENE_PRODUCT", 13, 21], ["thrombin", "GENE_OR_GENE_PRODUCT", 58, 66], ["protein C", "GENE_OR_GENE_PRODUCT", 93, 102], ["histones", "PROTEIN", 13, 21], ["thrombin", "PROTEIN", 58, 66], ["protein C", "PROTEIN", 93, 102], ["thrombin generation", "TREATMENT", 58, 77], ["protein C-mediated anticoagulant responses", "TREATMENT", 93, 135]]], ["PICs also play a role in the development of coagulopathy by inhibiting the protein C-protein S-thrombomodulin pathway and increasing the production of PAI-1.", [["coagulopathy", "DISEASE", 44, 56], ["S-thrombomodulin", "GENE_OR_GENE_PRODUCT", 93, 109], ["PAI-1", "GENE_OR_GENE_PRODUCT", 151, 156], ["protein C-protein S", "PROTEIN", 75, 94], ["thrombomodulin", "PROTEIN", 95, 109], ["PAI-1", "PROTEIN", 151, 156], ["coagulopathy", "PROBLEM", 44, 56], ["the protein C", "TEST", 71, 84], ["thrombomodulin pathway", "TREATMENT", 95, 117], ["PAI", "PROBLEM", 151, 154], ["coagulopathy", "OBSERVATION", 44, 56]]], ["The combination of a hyperactivated coagulation cascade and the inhibition of anti-coagulant pathways, such as the protein C-protein S-thrombomodulin pathway and inhibition of the fibrinolytic system is characteristic of DIC.", [["DIC", "DISEASE", 221, 224], ["S-thrombomodulin", "GENE_OR_GENE_PRODUCT", 133, 149], ["protein C-protein S", "PROTEIN", 115, 134], ["thrombomodulin", "PROTEIN", 135, 149], ["a hyperactivated coagulation cascade", "PROBLEM", 19, 55], ["anti-coagulant pathways", "TREATMENT", 78, 101], ["the protein C", "TEST", 111, 124], ["protein S", "TEST", 125, 134], ["thrombomodulin pathway", "TEST", 135, 157], ["inhibition of the fibrinolytic system", "PROBLEM", 162, 199], ["DIC", "PROBLEM", 221, 224], ["DIC", "OBSERVATION", 221, 224]]], ["This state is also the source of micro emboli and excessive alveolar fibrin deposition in ARDS.Activation of platelets ::: Activation of vascular endothelial cells, platelets and neutrophilsPlatelets in the pulmonary vasculature are also targets for activation by the high levels of PICs and ROS secreted by alveolar macrophages and activated type II epithelial cells [112]; (reviewed by [113]).", [["micro emboli", "ANATOMY", 33, 45], ["alveolar", "ANATOMY", 60, 68], ["platelets", "ANATOMY", 109, 118], ["vascular endothelial cells", "ANATOMY", 137, 163], ["platelets", "ANATOMY", 165, 174], ["neutrophils", "ANATOMY", 179, 190], ["Platelets", "ANATOMY", 190, 199], ["pulmonary vasculature", "ANATOMY", 207, 228], ["alveolar macrophages", "ANATOMY", 308, 328], ["type II epithelial cells", "ANATOMY", 343, 367], ["emboli", "DISEASE", 39, 45], ["ARDS", "DISEASE", 90, 94], ["alveolar", "IMMATERIAL_ANATOMICAL_ENTITY", 60, 68], ["fibrin", "GENE_OR_GENE_PRODUCT", 69, 75], ["platelets", "CELL", 109, 118], ["vascular endothelial cells", "CELL", 137, 163], ["platelets", "CELL", 165, 174], ["neutrophils", "CELL", 179, 190], ["Platelets", "CELL", 190, 199], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 207, 228], ["PICs", "GENE_OR_GENE_PRODUCT", 283, 287], ["ROS", "SIMPLE_CHEMICAL", 292, 295], ["alveolar macrophages", "CELL", 308, 328], ["type II epithelial cells", "CELL", 343, 367], ["platelets", "CELL_TYPE", 109, 118], ["vascular endothelial cells", "CELL_TYPE", 137, 163], ["platelets", "CELL_TYPE", 165, 174], ["neutrophils", "CELL_TYPE", 179, 190], ["Platelets", "CELL_TYPE", 190, 199], ["PICs", "PROTEIN", 283, 287], ["alveolar macrophages", "CELL_TYPE", 308, 328], ["activated type II epithelial cells", "CELL_TYPE", 333, 367], ["micro emboli", "PROBLEM", 33, 45], ["excessive alveolar fibrin deposition", "PROBLEM", 50, 86], ["ARDS", "PROBLEM", 90, 94], ["vascular endothelial cells", "TEST", 137, 163], ["platelets", "TEST", 165, 174], ["neutrophils", "TEST", 179, 190], ["Platelets", "TEST", 190, 199], ["activated type II epithelial cells", "PROBLEM", 333, 367], ["micro emboli", "OBSERVATION", 33, 45], ["excessive", "OBSERVATION_MODIFIER", 50, 59], ["alveolar", "ANATOMY_MODIFIER", 60, 68], ["fibrin deposition", "OBSERVATION", 69, 86], ["ARDS", "OBSERVATION", 90, 94], ["vascular endothelial", "ANATOMY", 137, 157], ["neutrophils", "OBSERVATION", 179, 190], ["pulmonary vasculature", "ANATOMY", 207, 228], ["alveolar macrophages", "OBSERVATION", 308, 328], ["epithelial cells", "OBSERVATION", 351, 367]]], ["Activated platelets (AP) also become a significant source of PICs and ROS [[114], [115], [116]] reviewed in [117].", [["platelets", "ANATOMY", 10, 19], ["ROS", "CHEMICAL", 70, 73], ["platelets", "CELL", 10, 19], ["AP", "CELLULAR_COMPONENT", 21, 23], ["PICs", "CELLULAR_COMPONENT", 61, 65], ["ROS", "SIMPLE_CHEMICAL", 70, 73], ["[116]", "SIMPLE_CHEMICAL", 89, 94], ["[117]", "SIMPLE_CHEMICAL", 108, 113], ["Activated platelets", "CELL_TYPE", 0, 19], ["Activated platelets (AP)", "TEST", 0, 24], ["PICs and ROS", "TEST", 61, 73], ["significant", "OBSERVATION_MODIFIER", 39, 50]]], ["Importantly, APs also secrete several chemokines, most notably RANTES, and CCL4, also known as platelet factor 4 (PF4), which increase neutrophil activation, survival, recruitment to the endothelium and subsequent tethering to EC [118,119].", [["neutrophil", "ANATOMY", 135, 145], ["endothelium", "ANATOMY", 187, 198], ["EC", "ANATOMY", 227, 229], ["APs", "SIMPLE_CHEMICAL", 13, 16], ["RANTES", "GENE_OR_GENE_PRODUCT", 63, 69], ["CCL4", "GENE_OR_GENE_PRODUCT", 75, 79], ["platelet factor 4", "GENE_OR_GENE_PRODUCT", 95, 112], ["PF4", "GENE_OR_GENE_PRODUCT", 114, 117], ["neutrophil", "CELL", 135, 145], ["endothelium", "TISSUE", 187, 198], ["EC", "CELL", 227, 229], ["chemokines", "PROTEIN", 38, 48], ["RANTES", "PROTEIN", 63, 69], ["CCL4", "PROTEIN", 75, 79], ["platelet factor 4", "PROTEIN", 95, 112], ["PF4", "PROTEIN", 114, 117], ["EC", "CELL_TYPE", 227, 229], ["CCL4", "TEST", 75, 79], ["platelet factor", "TEST", 95, 110], ["PF4", "TEST", 114, 117], ["neutrophil activation", "PROBLEM", 135, 156], ["increase", "OBSERVATION_MODIFIER", 126, 134], ["neutrophil activation", "OBSERVATION", 135, 156], ["endothelium", "ANATOMY", 187, 198]]], ["Finally, AP also play a crucial role in mediating and exacerbating neutrophil mediated inflammatory responses in acute lung injury and systemic sepsis by binding directly to neutrophils, resulting in the formation of platelet neutrophil complexes (PNC) [[120], [121], [122]].Formation of platelet neutrophil complexes ::: Activation of vascular endothelial cells, platelets and neutrophilsThe formation of PNCs complexes in inflammatory conditions is initiated by the binding of P-selectin expressed on the surface of APs and P-selectin glycoprotein ligand-1 (PSGL-1) expressed on neutrophils followed by the binding between platelet glycoprotein Ib\u03b1 and the neutrophil beta integrin, macrophage-1 antigen (MAC-1) [121,123] (reviewed by [124]).", [["neutrophil", "ANATOMY", 67, 77], ["lung", "ANATOMY", 119, 123], ["neutrophils", "ANATOMY", 174, 185], ["platelet", "ANATOMY", 217, 225], ["platelet neutrophil", "ANATOMY", 288, 307], ["vascular endothelial cells", "ANATOMY", 336, 362], ["platelets", "ANATOMY", 364, 373], ["neutrophils", "ANATOMY", 378, 389], ["surface", "ANATOMY", 507, 514], ["neutrophils", "ANATOMY", 581, 592], ["acute lung injury", "DISEASE", 113, 130], ["sepsis", "DISEASE", 144, 150], ["AP", "GENE_OR_GENE_PRODUCT", 9, 11], ["neutrophil", "CELL", 67, 77], ["lung", "ORGAN", 119, 123], ["neutrophils", "CELL", 174, 185], ["platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 217, 246], ["PNC", "SIMPLE_CHEMICAL", 248, 251], ["platelet", "CELL", 288, 296], ["neutrophil", "CELL", 297, 307], ["vascular endothelial cells", "CELL", 336, 362], ["platelets", "CELL", 364, 373], ["neutrophils", "CELL", 378, 389], ["PNCs", "GENE_OR_GENE_PRODUCT", 406, 410], ["P-selectin", "GENE_OR_GENE_PRODUCT", 479, 489], ["surface", "CELLULAR_COMPONENT", 507, 514], ["APs", "SIMPLE_CHEMICAL", 518, 521], ["P-selectin glycoprotein ligand-1", "GENE_OR_GENE_PRODUCT", 526, 558], ["PSGL-1", "GENE_OR_GENE_PRODUCT", 560, 566], ["neutrophils", "CELL", 581, 592], ["platelet glycoprotein Ib\u03b1", "GENE_OR_GENE_PRODUCT", 625, 650], ["neutrophil beta integrin", "GENE_OR_GENE_PRODUCT", 659, 683], ["macrophage-1 antigen", "GENE_OR_GENE_PRODUCT", 685, 705], ["MAC-1", "GENE_OR_GENE_PRODUCT", 707, 712], ["AP", "PROTEIN", 9, 11], ["neutrophils", "CELL_TYPE", 174, 185], ["platelet neutrophil complexes", "PROTEIN", 217, 246], ["platelet neutrophil complexes", "PROTEIN", 288, 317], ["vascular endothelial cells", "CELL_TYPE", 336, 362], ["platelets", "CELL_TYPE", 364, 373], ["neutrophils", "CELL_TYPE", 378, 389], ["PNCs complexes", "PROTEIN", 406, 420], ["P", "PROTEIN", 479, 480], ["selectin", "PROTEIN", 481, 489], ["APs", "PROTEIN", 518, 521], ["P-selectin glycoprotein ligand-1 (PSGL-1", "PROTEIN", 526, 566], ["neutrophils", "CELL_TYPE", 581, 592], ["platelet glycoprotein Ib\u03b1", "PROTEIN", 625, 650], ["neutrophil beta integrin", "PROTEIN", 659, 683], ["macrophage-1 antigen", "PROTEIN", 685, 705], ["MAC", "PROTEIN", 707, 710], ["exacerbating neutrophil mediated inflammatory responses", "PROBLEM", 54, 109], ["acute lung injury", "PROBLEM", 113, 130], ["systemic sepsis", "PROBLEM", 135, 150], ["neutrophils", "TEST", 174, 185], ["platelet neutrophil complexes", "TEST", 217, 246], ["PNC", "TEST", 248, 251], ["platelet neutrophil complexes", "TEST", 288, 317], ["vascular endothelial cells", "TEST", 336, 362], ["platelets", "TEST", 364, 373], ["neutrophils", "TEST", 378, 389], ["PNCs complexes", "PROBLEM", 406, 420], ["inflammatory conditions", "PROBLEM", 424, 447], ["APs", "TEST", 518, 521], ["P-selectin glycoprotein ligand", "TEST", 526, 556], ["PSGL", "TEST", 560, 564], ["neutrophils", "TEST", 581, 592], ["platelet glycoprotein Ib\u03b1", "TEST", 625, 650], ["the neutrophil beta integrin", "TEST", 655, 683], ["macrophage", "TEST", 685, 695], ["MAC", "TEST", 707, 710], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["lung", "ANATOMY", 119, 123], ["injury", "OBSERVATION", 124, 130], ["systemic", "OBSERVATION_MODIFIER", 135, 143], ["sepsis", "OBSERVATION", 144, 150], ["platelet neutrophil complexes", "OBSERVATION", 217, 246], ["platelet neutrophil complexes", "OBSERVATION", 288, 317], ["vascular endothelial", "ANATOMY", 336, 356], ["neutrophils", "OBSERVATION", 378, 389], ["PNCs complexes", "OBSERVATION", 406, 420], ["inflammatory conditions", "OBSERVATION", 424, 447]]], ["P-selectin also plays an important role in increasing neutrophil binding to ECs, thereby increasing neutrophil rolling while increasing expression of MAC-1 in PNCs, which increases neutrophil tethering and subsequent crawling [125,126].", [["neutrophil", "ANATOMY", 54, 64], ["ECs", "ANATOMY", 76, 79], ["neutrophil", "ANATOMY", 100, 110], ["PNCs", "ANATOMY", 159, 163], ["neutrophil", "ANATOMY", 181, 191], ["P-selectin", "GENE_OR_GENE_PRODUCT", 0, 10], ["neutrophil", "CELL", 54, 64], ["ECs", "CELL", 76, 79], ["neutrophil", "CELL", 100, 110], ["MAC-1", "GENE_OR_GENE_PRODUCT", 150, 155], ["PNCs", "PATHOLOGICAL_FORMATION", 159, 163], ["neutrophil", "CELL", 181, 191], ["P-selectin", "PROTEIN", 0, 10], ["ECs", "CELL_TYPE", 76, 79], ["MAC", "PROTEIN", 150, 153], ["PNCs", "CELL_TYPE", 159, 163], ["increasing neutrophil binding", "PROBLEM", 43, 72], ["increasing neutrophil rolling", "TREATMENT", 89, 118], ["neutrophil tethering", "PROBLEM", 181, 201], ["increasing", "OBSERVATION_MODIFIER", 89, 99], ["neutrophil rolling", "OBSERVATION", 100, 118], ["neutrophil tethering", "OBSERVATION", 181, 201]]], ["There are other receptors involved in the process and readers interested in a more detailed consideration of this topic are referred to excellent reviews by [127,128].Consequences of platelet neutrophil complex formation ::: Activation of vascular endothelial cells, platelets and neutrophilsEvidence suggests that the formation of PNCs increases neutrophil recruitment, activation priming and the ultimate extraversion of these immune cells in an activated and primed state into inflamed lung tissue [126,[129], [130], [131], [132]].", [["platelet neutrophil", "ANATOMY", 183, 202], ["vascular endothelial cells", "ANATOMY", 239, 265], ["platelets", "ANATOMY", 267, 276], ["neutrophils", "ANATOMY", 281, 292], ["PNCs", "ANATOMY", 332, 336], ["neutrophil", "ANATOMY", 347, 357], ["immune cells", "ANATOMY", 429, 441], ["lung tissue", "ANATOMY", 489, 500], ["platelet neutrophil complex", "GENE_OR_GENE_PRODUCT", 183, 210], ["vascular endothelial cells", "CELL", 239, 265], ["platelets", "CELL", 267, 276], ["neutrophils", "CELL", 281, 292], ["PNCs", "GENE_OR_GENE_PRODUCT", 332, 336], ["neutrophil", "CELL", 347, 357], ["immune cells", "CELL", 429, 441], ["lung tissue", "TISSUE", 489, 500], ["platelet neutrophil complex", "PROTEIN", 183, 210], ["vascular endothelial cells", "CELL_TYPE", 239, 265], ["platelets", "CELL_TYPE", 267, 276], ["neutrophils", "CELL_TYPE", 281, 292], ["PNCs", "CELL_TYPE", 332, 336], ["immune cells", "CELL_TYPE", 429, 441], ["platelet neutrophil complex", "TEST", 183, 210], ["vascular endothelial cells", "TEST", 239, 265], ["platelets", "TEST", 267, 276], ["neutrophils", "TEST", 281, 292], ["PNCs", "PROBLEM", 332, 336], ["neutrophil recruitment", "TREATMENT", 347, 369], ["activation priming", "TREATMENT", 371, 389], ["these immune cells", "TREATMENT", 423, 441], ["platelet neutrophil complex", "OBSERVATION", 183, 210], ["vascular endothelial", "ANATOMY", 239, 259], ["neutrophils", "OBSERVATION", 281, 292], ["increases", "OBSERVATION_MODIFIER", 337, 346], ["neutrophil recruitment", "OBSERVATION", 347, 369], ["immune cells", "OBSERVATION", 429, 441], ["inflamed", "ANATOMY_MODIFIER", 480, 488], ["lung", "ANATOMY", 489, 493]]], ["As previously discussed, this is a crucial element in the pathophysiology of ARDS [86,88,98], and understanding the mechanisms involved may identify therapeutic opportunities.Consequences of platelet neutrophil complex formation ::: Activation of vascular endothelial cells, platelets and neutrophilsBriefly, PNCs have a reduced velocity compared to platelets and neutrophils alone and this property combined with increased endothelial adhesion increases the sequestration of neutrophils and platelets in the microvascular beds of the lung [[133], [134], [135]].", [["platelet neutrophil", "ANATOMY", 191, 210], ["vascular endothelial cells", "ANATOMY", 247, 273], ["platelets", "ANATOMY", 275, 284], ["neutrophils", "ANATOMY", 289, 300], ["PNCs", "ANATOMY", 309, 313], ["platelets", "ANATOMY", 350, 359], ["neutrophils", "ANATOMY", 364, 375], ["endothelial", "ANATOMY", 424, 435], ["neutrophils", "ANATOMY", 476, 487], ["platelets", "ANATOMY", 492, 501], ["microvascular beds", "ANATOMY", 509, 527], ["lung", "ANATOMY", 535, 539], ["ARDS", "DISEASE", 77, 81], ["platelet neutrophil complex", "GENE_OR_GENE_PRODUCT", 191, 218], ["vascular endothelial cells", "CELL", 247, 273], ["platelets", "CELL", 275, 284], ["neutrophils", "CELL", 289, 300], ["PNCs", "CELL", 309, 313], ["platelets", "CELL", 350, 359], ["neutrophils", "CELL", 364, 375], ["endothelial", "CELL", 424, 435], ["neutrophils", "CELL", 476, 487], ["platelets", "CELL", 492, 501], ["microvascular beds", "TISSUE", 509, 527], ["lung", "ORGAN", 535, 539], ["platelet neutrophil complex", "PROTEIN", 191, 218], ["vascular endothelial cells", "CELL_TYPE", 247, 273], ["platelets", "CELL_TYPE", 275, 284], ["neutrophils", "CELL_TYPE", 289, 300], ["PNCs", "CELL_TYPE", 309, 313], ["platelets", "CELL_TYPE", 350, 359], ["neutrophils", "CELL_TYPE", 364, 375], ["neutrophils", "CELL_TYPE", 476, 487], ["platelets", "CELL_TYPE", 492, 501], ["ARDS", "PROBLEM", 77, 81], ["platelet neutrophil complex", "TEST", 191, 218], ["vascular endothelial cells", "TEST", 247, 273], ["platelets", "TEST", 275, 284], ["neutrophils", "TEST", 289, 300], ["PNCs", "TEST", 309, 313], ["a reduced velocity", "PROBLEM", 319, 337], ["platelets", "TEST", 350, 359], ["neutrophils", "TEST", 364, 375], ["increased endothelial adhesion", "PROBLEM", 414, 444], ["the sequestration of neutrophils", "PROBLEM", 455, 487], ["platelets", "TEST", 492, 501], ["ARDS", "OBSERVATION", 77, 81], ["platelet neutrophil complex", "OBSERVATION", 191, 218], ["vascular endothelial", "ANATOMY", 247, 267], ["reduced", "OBSERVATION_MODIFIER", 321, 328], ["velocity", "OBSERVATION_MODIFIER", 329, 337], ["increased", "OBSERVATION_MODIFIER", 414, 423], ["endothelial adhesion", "OBSERVATION", 424, 444], ["sequestration", "OBSERVATION_MODIFIER", 459, 472], ["neutrophils", "OBSERVATION", 476, 487], ["microvascular", "ANATOMY", 509, 522], ["beds", "ANATOMY_MODIFIER", 523, 527], ["lung", "ANATOMY", 535, 539]]], ["In addition, activated platelets and neutrophils engage in mutual amplification of PIC and ROS production, leading to an increased level of inflammation than would be achieved by either alone [126,[129], [130], [131], [132]].", [["platelets", "ANATOMY", 23, 32], ["neutrophils", "ANATOMY", 37, 48], ["ROS", "CHEMICAL", 91, 94], ["inflammation", "DISEASE", 140, 152], ["platelets", "CELL", 23, 32], ["neutrophils", "CELL", 37, 48], ["PIC", "GENE_OR_GENE_PRODUCT", 83, 86], ["ROS", "SIMPLE_CHEMICAL", 91, 94], ["activated platelets", "CELL_TYPE", 13, 32], ["neutrophils", "CELL_TYPE", 37, 48], ["activated platelets", "TEST", 13, 32], ["neutrophils", "TEST", 37, 48], ["PIC and ROS production", "PROBLEM", 83, 105], ["an increased level of inflammation", "PROBLEM", 118, 152], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["inflammation", "OBSERVATION", 140, 152]]], ["Sequestrated PNCs become a source of excessive PIC, ROS and chemokine production in the pulmonary vasculature in addition to the PICs, ROS and chemokines secreted by alveolar macrophages and type II epithelial cells and vascular ECs as discussed above.", [["PNCs", "ANATOMY", 13, 17], ["pulmonary vasculature", "ANATOMY", 88, 109], ["alveolar macrophages", "ANATOMY", 166, 186], ["type II epithelial cells", "ANATOMY", 191, 215], ["vascular ECs", "ANATOMY", 220, 232], ["PNCs", "CELL", 13, 17], ["PIC", "GENE_OR_GENE_PRODUCT", 47, 50], ["ROS", "SIMPLE_CHEMICAL", 52, 55], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 88, 109], ["ROS", "SIMPLE_CHEMICAL", 135, 138], ["alveolar macrophages", "CELL", 166, 186], ["type II epithelial cells", "CELL", 191, 215], ["vascular ECs", "CELL", 220, 232], ["PNCs", "CELL_TYPE", 13, 17], ["chemokine", "PROTEIN", 60, 69], ["PICs", "PROTEIN", 129, 133], ["chemokines", "PROTEIN", 143, 153], ["alveolar macrophages", "CELL_TYPE", 166, 186], ["type II epithelial cells", "CELL_TYPE", 191, 215], ["vascular ECs", "CELL_TYPE", 220, 232], ["Sequestrated PNCs", "PROBLEM", 0, 17], ["excessive PIC", "PROBLEM", 37, 50], ["chemokine production in the pulmonary vasculature", "PROBLEM", 60, 109], ["the PICs", "TEST", 125, 133], ["chemokines", "TEST", 143, 153], ["alveolar macrophages", "PROBLEM", 166, 186], ["type II epithelial cells", "PROBLEM", 191, 215], ["vascular ECs", "PROBLEM", 220, 232], ["excessive", "OBSERVATION_MODIFIER", 37, 46], ["PIC", "OBSERVATION", 47, 50], ["chemokine production", "OBSERVATION", 60, 80], ["pulmonary vasculature", "ANATOMY", 88, 109], ["PICs", "OBSERVATION", 129, 133], ["alveolar macrophages", "OBSERVATION", 166, 186], ["epithelial cells", "OBSERVATION", 199, 215], ["vascular ECs", "OBSERVATION", 220, 232]]], ["This facilitates neutrophil priming.Consequences of platelet neutrophil complex formation ::: Activation of vascular endothelial cells, platelets and neutrophilsPriming may be induced by a range of cytokines, chemokines and growth factors such as TNF-alpha, IL-1 beta, IL-8 and granulocyte-macrophage colony-stimulating factor (GM-CSF), or engagement with activated endothelial cells [136].", [["neutrophil", "ANATOMY", 17, 27], ["platelet neutrophil", "ANATOMY", 52, 71], ["vascular endothelial cells", "ANATOMY", 108, 134], ["platelets", "ANATOMY", 136, 145], ["neutrophils", "ANATOMY", 150, 161], ["endothelial cells", "ANATOMY", 366, 383], ["neutrophil", "CELL", 17, 27], ["platelet neutrophil complex", "GENE_OR_GENE_PRODUCT", 52, 79], ["vascular endothelial cells", "CELL", 108, 134], ["platelets", "CELL", 136, 145], ["neutrophils", "CELL", 150, 161], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 247, 256], ["IL-1 beta", "GENE_OR_GENE_PRODUCT", 258, 267], ["IL-8", "GENE_OR_GENE_PRODUCT", 269, 273], ["granulocyte-macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 278, 326], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 328, 334], ["endothelial cells", "CELL", 366, 383], ["neutrophil", "CELL_TYPE", 17, 27], ["platelet neutrophil complex", "PROTEIN", 52, 79], ["vascular endothelial cells", "CELL_TYPE", 108, 134], ["platelets", "CELL_TYPE", 136, 145], ["neutrophils", "CELL_TYPE", 150, 161], ["cytokines", "PROTEIN", 198, 207], ["chemokines", "PROTEIN", 209, 219], ["growth factors", "PROTEIN", 224, 238], ["TNF", "PROTEIN", 247, 250], ["IL-8", "PROTEIN", 269, 273], ["granulocyte-macrophage colony-stimulating factor", "PROTEIN", 278, 326], ["GM", "PROTEIN", 328, 330], ["CSF", "PROTEIN", 331, 334], ["endothelial cells", "CELL_TYPE", 366, 383], ["neutrophil priming", "TREATMENT", 17, 35], ["platelet neutrophil complex", "TEST", 52, 79], ["vascular endothelial cells", "TEST", 108, 134], ["platelets", "TEST", 136, 145], ["neutrophils", "TEST", 150, 161], ["growth factors", "PROBLEM", 224, 238], ["TNF", "TEST", 247, 250], ["alpha", "TEST", 251, 256], ["IL", "TEST", 258, 260], ["IL", "TEST", 269, 271], ["granulocyte", "TEST", 278, 289], ["macrophage colony", "TEST", 290, 307], ["stimulating factor", "TEST", 308, 326], ["activated endothelial cells", "PROBLEM", 356, 383], ["neutrophil priming", "OBSERVATION", 17, 35], ["platelet neutrophil complex", "OBSERVATION", 52, 79], ["vascular endothelial", "ANATOMY", 108, 128], ["neutrophils", "OBSERVATION", 150, 161], ["granulocyte", "ANATOMY", 278, 289], ["macrophage colony", "OBSERVATION", 290, 307]]], ["The mechanisms involved include major changes in phosphoinositide 3-kinase (PI3K) mitogen-activated protein kinases (MAPKs), phospholipase D and calcium level instigated signalling pathways [137,138].", [["calcium", "CHEMICAL", 145, 152], ["calcium", "CHEMICAL", 145, 152], ["phosphoinositide 3-kinase", "GENE_OR_GENE_PRODUCT", 49, 74], ["PI3K", "GENE_OR_GENE_PRODUCT", 76, 80], ["mitogen-activated protein kinases", "GENE_OR_GENE_PRODUCT", 82, 115], ["MAPKs", "GENE_OR_GENE_PRODUCT", 117, 122], ["phospholipase D", "GENE_OR_GENE_PRODUCT", 125, 140], ["calcium", "SIMPLE_CHEMICAL", 145, 152], ["phosphoinositide 3-kinase (PI3K) mitogen-activated protein kinases", "PROTEIN", 49, 115], ["MAPKs", "PROTEIN", 117, 122], ["phospholipase D", "PROTEIN", 125, 140], ["phosphoinositide", "TEST", 49, 65], ["mitogen", "TEST", 82, 89], ["activated protein kinases", "TEST", 90, 115], ["MAPKs", "TEST", 117, 122], ["phospholipase D and calcium level", "TEST", 125, 158], ["signalling pathways", "TEST", 170, 189]]], ["Priming results in profound cytoskeletal reorganisation and a significant reduction in deformability and increased retention in pulmonary capillary beds [139,140].", [["cytoskeletal", "ANATOMY", 28, 40], ["pulmonary capillary beds", "ANATOMY", 128, 152], ["pulmonary capillary", "TISSUE", 128, 147], ["profound cytoskeletal reorganisation", "PROBLEM", 19, 55], ["a significant reduction in deformability", "PROBLEM", 60, 100], ["increased retention in pulmonary capillary beds", "PROBLEM", 105, 152], ["profound", "OBSERVATION_MODIFIER", 19, 27], ["cytoskeletal reorganisation", "OBSERVATION", 28, 55], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["reduction", "OBSERVATION_MODIFIER", 74, 83], ["deformability", "OBSERVATION_MODIFIER", 87, 100], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["retention", "OBSERVATION_MODIFIER", 115, 124], ["pulmonary capillary", "ANATOMY", 128, 147]]], ["These are resistant to apoptosis and secrete massive levels of cytotoxic products including PICs, chemokines, proteases and NETs [139,141].", [["PICs", "GENE_OR_GENE_PRODUCT", 92, 96], ["NETs", "GENE_OR_GENE_PRODUCT", 124, 128], ["cytotoxic products", "PROTEIN", 63, 81], ["PICs", "PROTEIN", 92, 96], ["chemokines", "PROTEIN", 98, 108], ["proteases", "PROTEIN", 110, 119], ["NETs", "PROTEIN", 124, 128], ["apoptosis", "PROBLEM", 23, 32], ["cytotoxic products", "TREATMENT", 63, 81], ["PICs", "TREATMENT", 92, 96], ["resistant", "OBSERVATION_MODIFIER", 10, 19], ["massive", "OBSERVATION_MODIFIER", 45, 52], ["cytotoxic products", "OBSERVATION", 63, 81]]], ["The association of platelets and neutrophils has pathological consequences other than increased sequestration of neutrophils into the lung.", [["platelets", "ANATOMY", 19, 28], ["neutrophils", "ANATOMY", 33, 44], ["neutrophils", "ANATOMY", 113, 124], ["lung", "ANATOMY", 134, 138], ["platelets", "CELL", 19, 28], ["neutrophils", "CELL", 33, 44], ["neutrophils", "CELL", 113, 124], ["lung", "ORGAN", 134, 138], ["platelets", "CELL_TYPE", 19, 28], ["neutrophils", "CELL_TYPE", 33, 44], ["neutrophils", "CELL_TYPE", 113, 124], ["platelets", "TEST", 19, 28], ["neutrophils", "TEST", 33, 44], ["pathological consequences", "PROBLEM", 49, 74], ["increased sequestration of neutrophils into the lung", "PROBLEM", 86, 138], ["platelets", "OBSERVATION", 19, 28], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["sequestration", "OBSERVATION", 96, 109], ["neutrophils", "OBSERVATION", 113, 124], ["lung", "ANATOMY", 134, 138]]], ["In particular, there is ample evidence to confirm that increased sequestration of platelets and neutrophils in lung microvascular beds leads to the development of a pro-coagulant and proinflammatory environment [[133], [134], [135]].", [["platelets", "ANATOMY", 82, 91], ["neutrophils", "ANATOMY", 96, 107], ["lung microvascular beds", "ANATOMY", 111, 134], ["platelets", "CELL", 82, 91], ["neutrophils", "CELL", 96, 107], ["lung microvascular", "TISSUE", 111, 129], ["platelets", "CELL_TYPE", 82, 91], ["neutrophils", "CELL_TYPE", 96, 107], ["increased sequestration of platelets", "PROBLEM", 55, 91], ["neutrophils in lung microvascular beds", "PROBLEM", 96, 134], ["a pro-coagulant and proinflammatory environment", "PROBLEM", 163, 210], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["sequestration", "OBSERVATION", 65, 78], ["platelets", "OBSERVATION", 82, 91], ["neutrophils", "OBSERVATION_MODIFIER", 96, 107], ["lung", "ANATOMY", 111, 115], ["microvascular beds", "OBSERVATION", 116, 134]]], ["The mechanisms involved are discussed below.Platelet neutrophil complexes and the development of hypercoagulability ::: Activation of vascular endothelial cells, platelets and neutrophilsPlatelets complexed with neutrophils enhance their phagocytic capacity and their release of ROS and other cytotoxic molecules such as myeloperoxidase (MPO) [142,143].", [["Platelet neutrophil", "ANATOMY", 44, 63], ["vascular endothelial cells", "ANATOMY", 134, 160], ["platelets", "ANATOMY", 162, 171], ["neutrophils", "ANATOMY", 176, 187], ["Platelets", "ANATOMY", 187, 196], ["neutrophils", "ANATOMY", 212, 223], ["hypercoagulability", "DISEASE", 97, 115], ["ROS", "CHEMICAL", 279, 282], ["Platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 44, 73], ["vascular endothelial cells", "CELL", 134, 160], ["platelets", "CELL", 162, 171], ["neutrophils", "CELL", 176, 187], ["Platelets", "CELL", 187, 196], ["neutrophils", "CELL", 212, 223], ["ROS", "SIMPLE_CHEMICAL", 279, 282], ["myeloperoxidase", "SIMPLE_CHEMICAL", 321, 336], ["MPO", "SIMPLE_CHEMICAL", 338, 341], ["Platelet neutrophil complexes", "PROTEIN", 44, 73], ["vascular endothelial cells", "CELL_TYPE", 134, 160], ["platelets", "CELL_TYPE", 162, 171], ["neutrophils", "CELL_TYPE", 176, 187], ["Platelets", "CELL_TYPE", 187, 196], ["neutrophils", "CELL_TYPE", 212, 223], ["cytotoxic molecules", "PROTEIN", 293, 312], ["myeloperoxidase", "PROTEIN", 321, 336], ["MPO", "PROTEIN", 338, 341], ["Platelet neutrophil complexes", "TEST", 44, 73], ["vascular endothelial cells", "TEST", 134, 160], ["platelets", "TEST", 162, 171], ["neutrophils", "TEST", 176, 187], ["Platelets", "TEST", 187, 196], ["neutrophils", "TEST", 212, 223], ["their phagocytic capacity", "TEST", 232, 257], ["other cytotoxic molecules", "PROBLEM", 287, 312], ["myeloperoxidase (MPO)", "TEST", 321, 342], ["neutrophil complexes", "OBSERVATION", 53, 73], ["hypercoagulability", "OBSERVATION", 97, 115], ["vascular endothelial", "ANATOMY", 134, 154], ["neutrophils", "OBSERVATION", 176, 187]]], ["Platelets also stimulate neutrophil production of NETs [144,145] via a mechanism which involves inducing NETosis [125,146,147].", [["Platelets", "ANATOMY", 0, 9], ["neutrophil", "ANATOMY", 25, 35], ["Platelets", "CELL", 0, 9], ["neutrophil", "CELL", 25, 35], ["NETs", "GENE_OR_GENE_PRODUCT", 50, 54], ["Platelets", "CELL_TYPE", 0, 9], ["Platelets", "TEST", 0, 9], ["neutrophil production", "TEST", 25, 46], ["NETosis", "PROBLEM", 105, 112], ["neutrophil production", "OBSERVATION", 25, 46]]], ["Mechanistically, this involves the secretion of high mobility group box 1 (HGMB1), which stimulates NET production via increasing receptor for advanced glycation endproducts (RAGE) mediated autophagy [[147], [148], [149]].", [["high mobility group box 1", "GENE_OR_GENE_PRODUCT", 48, 73], ["HGMB1", "GENE_OR_GENE_PRODUCT", 75, 80], ["NET", "GENE_OR_GENE_PRODUCT", 100, 103], ["receptor for advanced glycation endproducts", "SIMPLE_CHEMICAL", 130, 173], ["RAGE", "GENE_OR_GENE_PRODUCT", 175, 179], ["[147], [148]", "SIMPLE_CHEMICAL", 201, 213], ["high mobility group box 1", "PROTEIN", 48, 73], ["HGMB1", "PROTEIN", 75, 80], ["RAGE", "PROTEIN", 175, 179], ["advanced glycation endproducts", "TREATMENT", 143, 173]]], ["This DAMP also plays a major role in increasing NET production by increasing platelet activation via engagement with Toll-like receptor (TLR)-4, resulting in the formation of a positive feedback loop [122,150].", [["platelet", "ANATOMY", 77, 85], ["DAMP", "CHEMICAL", 5, 9], ["DAMP", "GENE_OR_GENE_PRODUCT", 5, 9], ["NET", "GENE_OR_GENE_PRODUCT", 48, 51], ["platelet", "CELL", 77, 85], ["Toll-like receptor (TLR)-4", "GENE_OR_GENE_PRODUCT", 117, 143], ["DAMP", "PROTEIN", 5, 9], ["Toll-like receptor (TLR)-4", "PROTEIN", 117, 143], ["increasing NET production", "PROBLEM", 37, 62], ["increasing platelet activation", "TREATMENT", 66, 96], ["Toll-like receptor (TLR)", "TREATMENT", 117, 141], ["a positive feedback loop", "PROBLEM", 175, 199], ["platelet activation", "OBSERVATION", 77, 96]]], ["HMBG1 also enhances neutrophil survival, neutrophil mediated tissue damage, and contributes to the creation of a self-amplifying pattern of platelet activation and NET production [122,149,150].Platelet neutrophil complexes and the development of hypercoagulability ::: Activation of vascular endothelial cells, platelets and neutrophilsIn turn, NETs stimulate increased levels of platelet activation, aggregation and tissue factor (TF) mediated activation of thrombin, resulting in enhanced intravascular coagulation [124,151,152].", [["neutrophil", "ANATOMY", 20, 30], ["neutrophil", "ANATOMY", 41, 51], ["tissue", "ANATOMY", 61, 67], ["platelet", "ANATOMY", 140, 148], ["Platelet neutrophil", "ANATOMY", 193, 212], ["vascular endothelial cells", "ANATOMY", 283, 309], ["platelets", "ANATOMY", 311, 320], ["neutrophils", "ANATOMY", 325, 336], ["NETs", "ANATOMY", 345, 349], ["platelet", "ANATOMY", 380, 388], ["intravascular", "ANATOMY", 491, 504], ["HMBG1", "CHEMICAL", 0, 5], ["hypercoagulability", "DISEASE", 246, 264], ["intravascular coagulation", "DISEASE", 491, 516], ["HMBG1", "SIMPLE_CHEMICAL", 0, 5], ["neutrophil", "CELL", 20, 30], ["neutrophil", "CELL", 41, 51], ["tissue", "TISSUE", 61, 67], ["platelet", "CELL", 140, 148], ["NET", "GENE_OR_GENE_PRODUCT", 164, 167], ["Platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 193, 222], ["vascular endothelial cells", "CELL", 283, 309], ["platelets", "CELL", 311, 320], ["neutrophils", "CELL", 325, 336], ["NETs", "GENE_OR_GENE_PRODUCT", 345, 349], ["platelet", "CELL", 380, 388], ["tissue factor", "GENE_OR_GENE_PRODUCT", 417, 430], ["TF", "GENE_OR_GENE_PRODUCT", 432, 434], ["thrombin", "GENE_OR_GENE_PRODUCT", 459, 467], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 491, 504], ["HMBG1", "PROTEIN", 0, 5], ["Platelet neutrophil complexes", "PROTEIN", 193, 222], ["vascular endothelial cells", "CELL_TYPE", 283, 309], ["platelets", "CELL_TYPE", 311, 320], ["neutrophils", "CELL_TYPE", 325, 336], ["tissue factor", "PROTEIN", 417, 430], ["TF", "PROTEIN", 432, 434], ["thrombin", "PROTEIN", 459, 467], ["neutrophil survival", "PROBLEM", 20, 39], ["neutrophil mediated tissue damage", "PROBLEM", 41, 74], ["platelet activation", "PROBLEM", 140, 159], ["Platelet neutrophil complexes", "TEST", 193, 222], ["vascular endothelial cells", "TEST", 283, 309], ["platelets", "TEST", 311, 320], ["neutrophils", "TEST", 325, 336], ["platelet activation", "PROBLEM", 380, 399], ["aggregation", "PROBLEM", 401, 412], ["tissue factor (TF)", "TREATMENT", 417, 435], ["activation of thrombin", "TREATMENT", 445, 467], ["enhanced intravascular coagulation", "TEST", 482, 516], ["neutrophil survival", "OBSERVATION", 20, 39], ["neutrophil mediated tissue damage", "OBSERVATION", 41, 74], ["platelet activation", "OBSERVATION", 140, 159], ["neutrophil complexes", "OBSERVATION", 202, 222], ["hypercoagulability", "OBSERVATION", 246, 264], ["vascular endothelial", "ANATOMY", 283, 303], ["neutrophils", "OBSERVATION", 325, 336], ["platelet activation", "OBSERVATION", 380, 399]]], ["Several mechanisms appear to underpin the contribution of NETs to thrombus formation including TF- and FXII-mediated initiation of the coagulation cascade, increasing the recruitment and adhesion of additional platelets, inhibition of fibrinolysis and recruitment of VWF and other platelet adhesion proteins [153,154].", [["NETs", "ANATOMY", 58, 62], ["thrombus", "ANATOMY", 66, 74], ["platelets", "ANATOMY", 210, 219], ["platelet", "ANATOMY", 281, 289], ["NETs", "DISEASE", 58, 62], ["thrombus", "DISEASE", 66, 74], ["NETs", "GENE_OR_GENE_PRODUCT", 58, 62], ["thrombus", "PATHOLOGICAL_FORMATION", 66, 74], ["TF", "GENE_OR_GENE_PRODUCT", 95, 97], ["FXII", "GENE_OR_GENE_PRODUCT", 103, 107], ["platelets", "CELL", 210, 219], ["VWF", "GENE_OR_GENE_PRODUCT", 267, 270], ["platelet adhesion proteins", "GENE_OR_GENE_PRODUCT", 281, 307], ["TF", "PROTEIN", 95, 97], ["FXII", "PROTEIN", 103, 107], ["platelets", "CELL_TYPE", 210, 219], ["VWF", "PROTEIN", 267, 270], ["platelet adhesion proteins", "PROTEIN", 281, 307], ["NETs to thrombus formation", "PROBLEM", 58, 84], ["TF", "TEST", 95, 97], ["FXII", "PROBLEM", 103, 107], ["the coagulation cascade", "TREATMENT", 131, 154], ["additional platelets", "TREATMENT", 199, 219], ["fibrinolysis", "TREATMENT", 235, 247], ["recruitment of VWF", "TREATMENT", 252, 270], ["other platelet adhesion proteins", "TEST", 275, 307], ["thrombus", "OBSERVATION", 66, 74], ["recruitment", "OBSERVATION_MODIFIER", 171, 182]]], ["In addition, histones play a major role in driving thrombin generation and inhibiting protein C-mediated anticoagulant responses [155].", [["histones", "GENE_OR_GENE_PRODUCT", 13, 21], ["thrombin", "GENE_OR_GENE_PRODUCT", 51, 59], ["protein C", "GENE_OR_GENE_PRODUCT", 86, 95], ["histones", "PROTEIN", 13, 21], ["thrombin", "PROTEIN", 51, 59], ["protein C", "PROTEIN", 86, 95], ["driving thrombin generation", "TREATMENT", 43, 70], ["protein C-mediated anticoagulant responses", "TREATMENT", 86, 128]]], ["The importance of NETS in the development of coagulopathy is emphasised by their involvement in the pathophysiology of sepsis in numerous thrombotic diseases [156,157].Platelet neutrophil complexes and the development of hypercoagulability ::: Activation of vascular endothelial cells, platelets and neutrophilsOver time, the combined effects of activated ECs, neutrophils and platelets, NETs and activated endothelial cells in the pulmonary alveo-capillary vasculature lead to the development of a highly inflammatory and pro-coagulant state typified by hyperactivation of the coagulation cascade and relative exhaustion of the fibrinolytic system with excessive production of PICs, DAMPS and fibrin deposition.", [["Platelet neutrophil", "ANATOMY", 168, 187], ["vascular endothelial cells", "ANATOMY", 258, 284], ["platelets", "ANATOMY", 286, 295], ["neutrophils", "ANATOMY", 300, 311], ["ECs", "ANATOMY", 356, 359], ["neutrophils", "ANATOMY", 361, 372], ["platelets", "ANATOMY", 377, 386], ["NETs", "ANATOMY", 388, 392], ["endothelial cells", "ANATOMY", 407, 424], ["pulmonary alveo-capillary vasculature", "ANATOMY", 432, 469], ["coagulopathy", "DISEASE", 45, 57], ["sepsis", "DISEASE", 119, 125], ["thrombotic diseases", "DISEASE", 138, 157], ["hypercoagulability", "DISEASE", 221, 239], ["NETS", "GENE_OR_GENE_PRODUCT", 18, 22], ["Platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 168, 197], ["vascular endothelial cells", "CELL", 258, 284], ["platelets", "CELL", 286, 295], ["neutrophils", "CELL", 300, 311], ["ECs", "CELL", 356, 359], ["neutrophils", "CELL", 361, 372], ["platelets", "CELL", 377, 386], ["NETs", "CELL", 388, 392], ["endothelial cells", "CELL", 407, 424], ["pulmonary alveo-capillary vasculature", "MULTI-TISSUE_STRUCTURE", 432, 469], ["PICs", "GENE_OR_GENE_PRODUCT", 678, 682], ["DAMPS", "GENE_OR_GENE_PRODUCT", 684, 689], ["fibrin", "GENE_OR_GENE_PRODUCT", 694, 700], ["Platelet neutrophil complexes", "PROTEIN", 168, 197], ["vascular endothelial cells", "CELL_TYPE", 258, 284], ["platelets", "CELL_TYPE", 286, 295], ["neutrophils", "CELL_TYPE", 300, 311], ["ECs", "CELL_TYPE", 356, 359], ["neutrophils", "CELL_TYPE", 361, 372], ["platelets", "CELL_TYPE", 377, 386], ["NETs", "CELL_TYPE", 388, 392], ["activated endothelial cells", "CELL_TYPE", 397, 424], ["PICs", "PROTEIN", 678, 682], ["DAMPS", "PROTEIN", 684, 689], ["fibrin", "PROTEIN", 694, 700], ["NETS", "TREATMENT", 18, 22], ["coagulopathy", "PROBLEM", 45, 57], ["sepsis", "PROBLEM", 119, 125], ["numerous thrombotic diseases", "PROBLEM", 129, 157], ["Platelet neutrophil complexes", "TEST", 168, 197], ["hypercoagulability", "PROBLEM", 221, 239], ["vascular endothelial cells", "TEST", 258, 284], ["platelets", "TEST", 286, 295], ["neutrophils", "TEST", 300, 311], ["activated ECs", "TEST", 346, 359], ["neutrophils", "TEST", 361, 372], ["platelets", "TEST", 377, 386], ["NETs", "TEST", 388, 392], ["activated endothelial cells", "PROBLEM", 397, 424], ["a highly inflammatory and pro-coagulant state", "PROBLEM", 497, 542], ["hyperactivation of the coagulation cascade", "PROBLEM", 555, 597], ["relative exhaustion of the fibrinolytic system", "PROBLEM", 602, 648], ["excessive production of PICs", "PROBLEM", 654, 682], ["DAMPS", "PROBLEM", 684, 689], ["fibrin deposition", "PROBLEM", 694, 711], ["coagulopathy", "OBSERVATION", 45, 57], ["sepsis", "OBSERVATION", 119, 125], ["numerous", "OBSERVATION_MODIFIER", 129, 137], ["thrombotic", "OBSERVATION", 138, 148], ["neutrophil complexes", "OBSERVATION", 177, 197], ["hypercoagulability", "OBSERVATION", 221, 239], ["vascular endothelial", "ANATOMY", 258, 278], ["neutrophils", "OBSERVATION", 300, 311], ["activated endothelial cells", "OBSERVATION", 397, 424], ["pulmonary", "ANATOMY", 432, 441], ["alveo", "ANATOMY_MODIFIER", 442, 447], ["capillary", "ANATOMY_MODIFIER", 448, 457], ["vasculature", "ANATOMY", 458, 469], ["highly", "OBSERVATION_MODIFIER", 499, 505], ["inflammatory", "OBSERVATION", 506, 518], ["coagulation cascade", "OBSERVATION", 578, 597], ["fibrinolytic system", "ANATOMY", 629, 648], ["excessive", "OBSERVATION_MODIFIER", 654, 663], ["production", "OBSERVATION_MODIFIER", 664, 674], ["PICs", "OBSERVATION_MODIFIER", 678, 682], ["fibrin deposition", "OBSERVATION", 694, 711]]], ["This is described as immuno-thrombosis [98,158,159].", [["thrombosis", "DISEASE", 28, 38], ["immuno-thrombosis", "PROBLEM", 21, 38], ["thrombosis", "OBSERVATION", 28, 38]]], ["This state has a major pathophysiological role in the development and exacerbation of systemic sepsis as it generates the formation of vascular microthrombi, the development of DIC and subsequent multi-organ damage or failure [109,160,161].Platelet neutrophil complexes and the development of hypercoagulability ::: Activation of vascular endothelial cells, platelets and neutrophilsThe sequestration of PNCs in the pulmonary vasculature and the subsequent development of immunothrombosis is also the ultimate cause of micro-thrombi and micro-emboli in the alveocapillary circulation [162,163] and intra alveolar fibrin deposits [98,[164], [165], [166], [167]].", [["vascular", "ANATOMY", 135, 143], ["multi-organ", "ANATOMY", 196, 207], ["Platelet neutrophil", "ANATOMY", 240, 259], ["vascular endothelial cells", "ANATOMY", 330, 356], ["platelets", "ANATOMY", 358, 367], ["neutrophils", "ANATOMY", 372, 383], ["PNCs", "ANATOMY", 404, 408], ["pulmonary vasculature", "ANATOMY", 416, 437], ["alveocapillary", "ANATOMY", 557, 571], ["sepsis", "DISEASE", 95, 101], ["vascular microthrombi", "DISEASE", 135, 156], ["DIC", "DISEASE", 177, 180], ["multi-organ damage", "DISEASE", 196, 214], ["hypercoagulability", "DISEASE", 293, 311], ["immunothrombosis", "DISEASE", 472, 488], ["vascular", "MULTI-TISSUE_STRUCTURE", 135, 143], ["multi-organ", "ORGAN", 196, 207], ["Platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 240, 269], ["vascular endothelial cells", "CELL", 330, 356], ["platelets", "CELL", 358, 367], ["neutrophils", "CELL", 372, 383], ["PNCs", "GENE_OR_GENE_PRODUCT", 404, 408], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 416, 437], ["fibrin", "GENE_OR_GENE_PRODUCT", 613, 619], ["Platelet neutrophil complexes", "PROTEIN", 240, 269], ["vascular endothelial cells", "CELL_TYPE", 330, 356], ["platelets", "CELL_TYPE", 358, 367], ["neutrophils", "CELL_TYPE", 372, 383], ["PNCs", "PROTEIN", 404, 408], ["systemic sepsis", "PROBLEM", 86, 101], ["vascular microthrombi", "PROBLEM", 135, 156], ["DIC", "PROBLEM", 177, 180], ["subsequent multi-organ damage", "PROBLEM", 185, 214], ["failure", "PROBLEM", 218, 225], ["Platelet neutrophil complexes", "TEST", 240, 269], ["hypercoagulability", "PROBLEM", 293, 311], ["vascular endothelial cells", "TEST", 330, 356], ["platelets", "TEST", 358, 367], ["neutrophils", "TEST", 372, 383], ["PNCs in the pulmonary vasculature", "PROBLEM", 404, 437], ["immunothrombosis", "PROBLEM", 472, 488], ["micro-thrombi", "PROBLEM", 519, 532], ["micro-emboli in the alveocapillary circulation", "PROBLEM", 537, 583], ["intra alveolar fibrin deposits", "PROBLEM", 598, 628], ["systemic", "OBSERVATION_MODIFIER", 86, 94], ["sepsis", "OBSERVATION", 95, 101], ["vascular", "ANATOMY", 135, 143], ["microthrombi", "OBSERVATION", 144, 156], ["multi-organ", "ANATOMY", 196, 207], ["damage", "OBSERVATION", 208, 214], ["failure", "OBSERVATION", 218, 225], ["neutrophil complexes", "OBSERVATION", 249, 269], ["hypercoagulability", "OBSERVATION", 293, 311], ["vascular endothelial", "ANATOMY", 330, 350], ["neutrophils", "OBSERVATION", 372, 383], ["sequestration", "OBSERVATION_MODIFIER", 387, 400], ["PNCs", "OBSERVATION", 404, 408], ["pulmonary vasculature", "ANATOMY", 416, 437], ["immunothrombosis", "OBSERVATION", 472, 488], ["micro-thrombi", "OBSERVATION", 519, 532], ["alveocapillary circulation", "ANATOMY", 557, 583], ["intra", "ANATOMY_MODIFIER", 598, 603], ["alveolar", "ANATOMY_MODIFIER", 604, 612], ["fibrin deposits", "OBSERVATION", 613, 628]]], ["This subsequently increases both dead-space ventilation and intra-pulmonary shunting, both characteristic features of ARDS [168] [[169], [170], [171]].", [["intra-pulmonary", "ANATOMY", 60, 75], ["ARDS", "DISEASE", 118, 122], ["space ventilation", "TREATMENT", 38, 55], ["intra-pulmonary shunting", "PROBLEM", 60, 84], ["ARDS", "PROBLEM", 118, 122], ["increases", "OBSERVATION_MODIFIER", 18, 27], ["both", "OBSERVATION_MODIFIER", 28, 32], ["dead", "OBSERVATION_MODIFIER", 33, 37], ["space ventilation", "OBSERVATION", 38, 55], ["intra-pulmonary shunting", "OBSERVATION", 60, 84], ["ARDS", "OBSERVATION", 118, 122]]], ["The development of exaggerated immunothrombosis and the failure of mechanisms required to anchor thrombi in the local environment also drive the development of DIC and readers interested in further details are referred to [172,173].Platelet neutrophil complexes and the development of hypercoagulability ::: Activation of vascular endothelial cells, platelets and neutrophilsThe activity of PNCs and the high levels of NET producing neutrophils resulting in immunothrombosis appears to be a plausible mechanism underpinning the development of grossly enhanced coagulation seen in COVID-19 ARDS.", [["thrombi", "ANATOMY", 97, 104], ["Platelet neutrophil", "ANATOMY", 232, 251], ["vascular endothelial cells", "ANATOMY", 322, 348], ["platelets", "ANATOMY", 350, 359], ["neutrophils", "ANATOMY", 364, 375], ["PNCs", "ANATOMY", 391, 395], ["neutrophils", "ANATOMY", 433, 444], ["immunothrombosis", "DISEASE", 31, 47], ["thrombi", "DISEASE", 97, 104], ["DIC", "DISEASE", 160, 163], ["hypercoagulability", "DISEASE", 285, 303], ["immunothrombosis", "DISEASE", 458, 474], ["ARDS", "DISEASE", 589, 593], ["Platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 232, 261], ["vascular endothelial cells", "CELL", 322, 348], ["platelets", "CELL", 350, 359], ["neutrophils", "CELL", 364, 375], ["PNCs", "GENE_OR_GENE_PRODUCT", 391, 395], ["NET", "GENE_OR_GENE_PRODUCT", 419, 422], ["neutrophils", "CELL", 433, 444], ["Platelet neutrophil complexes", "PROTEIN", 232, 261], ["vascular endothelial cells", "CELL_TYPE", 322, 348], ["platelets", "CELL_TYPE", 350, 359], ["neutrophils", "CELL_TYPE", 364, 375], ["PNCs", "PROTEIN", 391, 395], ["neutrophils", "CELL_TYPE", 433, 444], ["exaggerated immunothrombosis", "PROBLEM", 19, 47], ["the failure of mechanisms", "PROBLEM", 52, 77], ["anchor thrombi", "PROBLEM", 90, 104], ["DIC", "PROBLEM", 160, 163], ["Platelet neutrophil complexes", "TEST", 232, 261], ["hypercoagulability", "PROBLEM", 285, 303], ["vascular endothelial cells", "TEST", 322, 348], ["platelets", "TEST", 350, 359], ["neutrophils", "TEST", 364, 375], ["PNCs", "TEST", 391, 395], ["NET producing neutrophils", "PROBLEM", 419, 444], ["immunothrombosis", "PROBLEM", 458, 474], ["grossly enhanced coagulation", "PROBLEM", 543, 571], ["COVID", "TEST", 580, 585], ["ARDS", "PROBLEM", 589, 593], ["exaggerated", "OBSERVATION_MODIFIER", 19, 30], ["immunothrombosis", "OBSERVATION", 31, 47], ["thrombi", "OBSERVATION", 97, 104], ["neutrophil complexes", "OBSERVATION", 241, 261], ["hypercoagulability", "OBSERVATION", 285, 303], ["vascular endothelial", "ANATOMY", 322, 342], ["neutrophils", "OBSERVATION", 364, 375], ["activity", "OBSERVATION_MODIFIER", 379, 387], ["appears to be", "UNCERTAINTY", 475, 488], ["grossly", "OBSERVATION_MODIFIER", 543, 550], ["enhanced", "OBSERVATION_MODIFIER", 551, 559], ["coagulation", "OBSERVATION", 560, 571], ["ARDS", "OBSERVATION", 589, 593]]], ["We now turn our attention to the development of hypercytokinemia and high rates of AM death and inflammatory lung tissue damage seen in such patients.", [["lung tissue", "ANATOMY", 109, 120], ["hypercytokinemia", "DISEASE", 48, 64], ["death", "DISEASE", 86, 91], ["lung tissue damage", "DISEASE", 109, 127], ["AM", "CELL", 83, 85], ["lung tissue", "TISSUE", 109, 120], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["hypercytokinemia", "PROBLEM", 48, 64], ["AM death", "PROBLEM", 83, 91], ["inflammatory lung tissue damage", "PROBLEM", 96, 127], ["hypercytokinemia", "OBSERVATION", 48, 64], ["high", "OBSERVATION_MODIFIER", 69, 73], ["inflammatory", "OBSERVATION_MODIFIER", 96, 108], ["lung", "ANATOMY", 109, 113], ["tissue", "OBSERVATION", 114, 120]]], ["We begin with the pathological consequences stemming from a high population of NET secreting neutrophils.", [["neutrophils", "ANATOMY", 93, 104], ["NET", "CELL", 79, 82], ["neutrophils", "CELL", 93, 104], ["NET secreting neutrophils", "CELL_TYPE", 79, 104], ["the pathological consequences stemming", "PROBLEM", 14, 52], ["NET secreting neutrophils", "PROBLEM", 79, 104], ["high", "OBSERVATION_MODIFIER", 60, 64], ["NET", "OBSERVATION_MODIFIER", 79, 82], ["secreting neutrophils", "OBSERVATION", 83, 104]]], ["These processes are depicted in Fig. 3.Platelet neutrophil complexes and the development of hypercoagulability ::: Activation of vascular endothelial cells, platelets and neutrophilsInitial infection and activation of type 2 alveolar cells and alveolar macrophages results in the secretion of IL-6, PICs and a wide range of chemokines which activate vascular endothelial cells and recruit peripheral activated NET producing neutrophils.", [["Platelet neutrophil", "ANATOMY", 39, 58], ["vascular endothelial cells", "ANATOMY", 129, 155], ["platelets", "ANATOMY", 157, 166], ["neutrophils", "ANATOMY", 171, 182], ["type 2 alveolar cells", "ANATOMY", 218, 239], ["alveolar macrophages", "ANATOMY", 244, 264], ["vascular endothelial cells", "ANATOMY", 350, 376], ["NET", "ANATOMY", 410, 413], ["neutrophils", "ANATOMY", 424, 435], ["hypercoagulability", "DISEASE", 92, 110], ["infection", "DISEASE", 190, 199], ["Platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 39, 68], ["vascular endothelial cells", "CELL", 129, 155], ["platelets", "CELL", 157, 166], ["neutrophils", "CELL", 171, 182], ["type 2 alveolar cells", "CELL", 218, 239], ["alveolar macrophages", "CELL", 244, 264], ["IL-6", "GENE_OR_GENE_PRODUCT", 293, 297], ["PICs", "GENE_OR_GENE_PRODUCT", 299, 303], ["vascular endothelial cells", "CELL", 350, 376], ["NET", "GENE_OR_GENE_PRODUCT", 410, 413], ["neutrophils", "CELL", 424, 435], ["Platelet neutrophil complexes", "PROTEIN", 39, 68], ["vascular endothelial cells", "CELL_TYPE", 129, 155], ["platelets", "CELL_TYPE", 157, 166], ["neutrophils", "CELL_TYPE", 171, 182], ["type 2 alveolar cells", "CELL_TYPE", 218, 239], ["alveolar macrophages", "CELL_TYPE", 244, 264], ["IL-6", "PROTEIN", 293, 297], ["PICs", "PROTEIN", 299, 303], ["chemokines", "PROTEIN", 324, 334], ["vascular endothelial cells", "CELL_TYPE", 350, 376], ["peripheral activated NET producing neutrophils", "CELL_TYPE", 389, 435], ["Platelet neutrophil complexes", "TEST", 39, 68], ["vascular endothelial cells", "TEST", 129, 155], ["platelets", "TEST", 157, 166], ["neutrophils", "TEST", 171, 182], ["Initial infection", "PROBLEM", 182, 199], ["type 2 alveolar cells", "PROBLEM", 218, 239], ["alveolar macrophages", "PROBLEM", 244, 264], ["the secretion of IL", "PROBLEM", 276, 295], ["PICs", "PROBLEM", 299, 303], ["a wide range of chemokines", "TREATMENT", 308, 334], ["vascular endothelial cells", "PROBLEM", 350, 376], ["peripheral activated NET producing neutrophils", "PROBLEM", 389, 435], ["Fig", "OBSERVATION_MODIFIER", 32, 35], ["neutrophil complexes", "OBSERVATION", 48, 68], ["hypercoagulability", "OBSERVATION", 92, 110], ["vascular endothelial", "ANATOMY", 129, 149], ["neutrophils", "OBSERVATION", 171, 182], ["infection", "OBSERVATION", 190, 199], ["alveolar cells", "OBSERVATION", 225, 239], ["alveolar macrophages", "OBSERVATION", 244, 264], ["wide range", "OBSERVATION_MODIFIER", 310, 320], ["vascular endothelial cells", "OBSERVATION", 350, 376]]], ["Mechanistically this is achieved via the formation of platelet neutrophil complexes which become sequestrated in the lung microcapillaries creating a hyper coagulant and highly inflammatory environment within these blood vessels and the wider pulmonary circulation.", [["platelet neutrophil complexes", "ANATOMY", 54, 83], ["lung microcapillaries", "ANATOMY", 117, 138], ["blood vessels", "ANATOMY", 215, 228], ["pulmonary", "ANATOMY", 243, 252], ["platelet neutrophil complexes", "GENE_OR_GENE_PRODUCT", 54, 83], ["lung", "ORGAN", 117, 121], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 215, 228], ["pulmonary", "ORGAN", 243, 252], ["platelet neutrophil complexes", "PROTEIN", 54, 83], ["platelet neutrophil complexes", "TEST", 54, 83], ["a hyper coagulant", "PROBLEM", 148, 165], ["highly inflammatory environment", "PROBLEM", 170, 201], ["platelet neutrophil complexes", "OBSERVATION", 54, 83], ["lung", "ANATOMY", 117, 121], ["microcapillaries", "ANATOMY_MODIFIER", 122, 138], ["hyper coagulant", "OBSERVATION", 150, 165], ["highly", "OBSERVATION_MODIFIER", 170, 176], ["inflammatory", "OBSERVATION", 177, 189], ["blood vessels", "ANATOMY", 215, 228], ["wider", "OBSERVATION_MODIFIER", 237, 242], ["pulmonary circulation", "ANATOMY", 243, 264]]], ["The entry of neutrophils into the lung coupled with their prolonged survival results in the development of a cytokine storm with extreme tissue damage and lung dysfunction fuelled by an interplay between PICS DAMPS ROS, NLRPS activation, macrophage pyroptosis, influx of inflammatory monocytes and necroptosis.NETS and ARDS severity ::: The recruitment of activated neutrophils into alveolae and interstitial tissueAs previously discussed, NETS are highly toxic to epithelial and endothelial cells and high levels in the alveolar space in patients suffering from ARDS correlate with the severity of the condition [174].", [["neutrophils", "ANATOMY", 13, 24], ["lung", "ANATOMY", 34, 38], ["tissue", "ANATOMY", 137, 143], ["lung", "ANATOMY", 155, 159], ["macrophage", "ANATOMY", 238, 248], ["monocytes", "ANATOMY", 284, 293], ["neutrophils", "ANATOMY", 366, 377], ["alveolae", "ANATOMY", 383, 391], ["interstitial tissue", "ANATOMY", 396, 415], ["epithelial", "ANATOMY", 465, 475], ["endothelial cells", "ANATOMY", 480, 497], ["alveolar space", "ANATOMY", 521, 535], ["tissue damage", "DISEASE", 137, 150], ["lung dysfunction", "DISEASE", 155, 171], ["ARDS", "DISEASE", 319, 323], ["ARDS", "DISEASE", 563, 567], ["neutrophils", "CELL", 13, 24], ["lung", "ORGAN", 34, 38], ["tissue", "TISSUE", 137, 143], ["lung", "ORGAN", 155, 159], ["PICS", "GENE_OR_GENE_PRODUCT", 204, 208], ["DAMPS", "GENE_OR_GENE_PRODUCT", 209, 214], ["ROS", "SIMPLE_CHEMICAL", 215, 218], ["NLRPS", "GENE_OR_GENE_PRODUCT", 220, 225], ["macrophage", "CELL", 238, 248], ["monocytes", "CELL", 284, 293], ["neutrophils", "CELL", 366, 377], ["alveolae", "CELL", 383, 391], ["interstitial tissue", "TISSUE", 396, 415], ["NETS", "SIMPLE_CHEMICAL", 440, 444], ["epithelial", "CELL", 465, 475], ["endothelial cells", "CELL", 480, 497], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 521, 535], ["patients", "ORGANISM", 539, 547], ["neutrophils", "CELL_TYPE", 13, 24], ["cytokine", "PROTEIN", 109, 117], ["NLRPS", "PROTEIN", 220, 225], ["inflammatory monocytes", "CELL_TYPE", 271, 293], ["activated neutrophils", "CELL_TYPE", 356, 377], ["alveolae", "CELL_TYPE", 383, 391], ["epithelial and endothelial cells", "CELL_TYPE", 465, 497], ["patients", "SPECIES", 539, 547], ["a cytokine storm", "PROBLEM", 107, 123], ["extreme tissue damage", "PROBLEM", 129, 150], ["lung dysfunction", "PROBLEM", 155, 171], ["PICS DAMPS ROS", "TEST", 204, 218], ["NLRPS activation", "PROBLEM", 220, 236], ["macrophage pyroptosis", "PROBLEM", 238, 259], ["inflammatory monocytes", "PROBLEM", 271, 293], ["necroptosis", "PROBLEM", 298, 309], ["ARDS severity", "PROBLEM", 319, 332], ["activated neutrophils into alveolae", "PROBLEM", 356, 391], ["interstitial tissue", "PROBLEM", 396, 415], ["epithelial and endothelial cells", "PROBLEM", 465, 497], ["high levels in the alveolar space", "PROBLEM", 502, 535], ["ARDS", "PROBLEM", 563, 567], ["lung", "ANATOMY", 34, 38], ["cytokine storm", "OBSERVATION", 109, 123], ["extreme tissue", "OBSERVATION_MODIFIER", 129, 143], ["damage", "OBSERVATION", 144, 150], ["lung", "ANATOMY", 155, 159], ["dysfunction", "OBSERVATION", 160, 171], ["macrophage pyroptosis", "OBSERVATION", 238, 259], ["inflammatory monocytes", "OBSERVATION", 271, 293], ["necroptosis", "OBSERVATION", 298, 309], ["ARDS", "OBSERVATION", 319, 323], ["activated neutrophils", "OBSERVATION", 356, 377], ["interstitial tissue", "ANATOMY", 396, 415], ["endothelial cells", "OBSERVATION", 480, 497], ["high", "OBSERVATION_MODIFIER", 502, 506], ["levels", "OBSERVATION_MODIFIER", 507, 513], ["alveolar", "ANATOMY_MODIFIER", 521, 529], ["ARDS", "OBSERVATION", 563, 567]]], ["In addition, NET activity, as determined by levels of double stranded DNA, citrullinated histones, HMBG1 and MPO, is associated with almost four times the level of mortality in patients with severe pneumonia [175].", [["pneumonia", "DISEASE", 198, 207], ["NET", "GENE_OR_GENE_PRODUCT", 13, 16], ["DNA", "CELLULAR_COMPONENT", 70, 73], ["citrullinated histones", "GENE_OR_GENE_PRODUCT", 75, 97], ["HMBG1", "GENE_OR_GENE_PRODUCT", 99, 104], ["MPO", "SIMPLE_CHEMICAL", 109, 112], ["patients", "ORGANISM", 177, 185], ["NET", "PROTEIN", 13, 16], ["citrullinated histones", "PROTEIN", 75, 97], ["HMBG1", "PROTEIN", 99, 104], ["MPO", "PROTEIN", 109, 112], ["patients", "SPECIES", 177, 185], ["double stranded DNA", "PROBLEM", 54, 73], ["citrullinated histones", "PROBLEM", 75, 97], ["HMBG1", "TREATMENT", 99, 104], ["severe pneumonia", "PROBLEM", 191, 207], ["NET activity", "OBSERVATION", 13, 25], ["severe", "OBSERVATION_MODIFIER", 191, 197], ["pneumonia", "OBSERVATION", 198, 207]]], ["There are very high levels of NETS and neutrophils in the alveolar space of ventilated ARDS patients, with the latter secreting excessive levels of IL-6, IL-8 and CCL2, each playing a major role in increasing tissue damage either directly or via the recruitment of more neutrophils from the periphery [176].", [["neutrophils", "ANATOMY", 39, 50], ["alveolar space", "ANATOMY", 58, 72], ["tissue", "ANATOMY", 209, 215], ["neutrophils", "ANATOMY", 270, 281], ["ARDS", "DISEASE", 87, 91], ["NETS", "GENE_OR_GENE_PRODUCT", 30, 34], ["neutrophils", "CELL", 39, 50], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 58, 72], ["patients", "ORGANISM", 92, 100], ["IL-6", "GENE_OR_GENE_PRODUCT", 148, 152], ["IL-8", "GENE_OR_GENE_PRODUCT", 154, 158], ["CCL2", "GENE_OR_GENE_PRODUCT", 163, 167], ["tissue", "TISSUE", 209, 215], ["neutrophils", "CELL", 270, 281], ["NETS", "PROTEIN", 30, 34], ["neutrophils", "CELL_TYPE", 39, 50], ["IL-6", "PROTEIN", 148, 152], ["IL-8", "PROTEIN", 154, 158], ["CCL2", "PROTEIN", 163, 167], ["neutrophils", "CELL_TYPE", 270, 281], ["patients", "SPECIES", 92, 100], ["very high levels of NETS", "PROBLEM", 10, 34], ["neutrophils", "TEST", 39, 50], ["ventilated ARDS", "PROBLEM", 76, 91], ["IL", "TEST", 148, 150], ["IL", "TEST", 154, 156], ["increasing tissue damage", "PROBLEM", 198, 222], ["very", "OBSERVATION_MODIFIER", 10, 14], ["high", "OBSERVATION_MODIFIER", 15, 19], ["levels", "OBSERVATION_MODIFIER", 20, 26], ["alveolar", "ANATOMY_MODIFIER", 58, 66], ["ventilated ARDS", "OBSERVATION", 76, 91], ["increasing tissue", "OBSERVATION_MODIFIER", 198, 215], ["damage", "OBSERVATION", 216, 222], ["periphery", "ANATOMY_MODIFIER", 291, 300]]], ["It is, however, important to note that while the release of PICs and enzymes such as elastase and MPO from activated neutrophils makes a significant contribution to increasing inflammation and lung damage, the dominant players in this regard are the contents of NETs, most notably mtDNA, HGMB1 and histones [177,178].", [["neutrophils", "ANATOMY", 117, 128], ["lung", "ANATOMY", 193, 197], ["NETs", "ANATOMY", 262, 266], ["inflammation", "DISEASE", 176, 188], ["lung damage", "DISEASE", 193, 204], ["PICs", "CELLULAR_COMPONENT", 60, 64], ["elastase", "GENE_OR_GENE_PRODUCT", 85, 93], ["MPO", "SIMPLE_CHEMICAL", 98, 101], ["neutrophils", "CELL", 117, 128], ["lung", "ORGAN", 193, 197], ["NETs", "GENE_OR_GENE_PRODUCT", 262, 266], ["mtDNA", "CELLULAR_COMPONENT", 281, 286], ["HGMB1", "GENE_OR_GENE_PRODUCT", 288, 293], ["histones", "CELLULAR_COMPONENT", 298, 306], ["PICs", "PROTEIN", 60, 64], ["elastase", "PROTEIN", 85, 93], ["MPO", "PROTEIN", 98, 101], ["activated neutrophils", "CELL_TYPE", 107, 128], ["HGMB1", "PROTEIN", 288, 293], ["histones", "PROTEIN", 298, 306], ["enzymes", "TEST", 69, 76], ["elastase", "TEST", 85, 93], ["MPO", "TEST", 98, 101], ["activated neutrophils", "PROBLEM", 107, 128], ["increasing inflammation", "PROBLEM", 165, 188], ["lung damage", "PROBLEM", 193, 204], ["significant contribution to", "UNCERTAINTY", 137, 164], ["increasing", "OBSERVATION_MODIFIER", 165, 175], ["inflammation", "OBSERVATION", 176, 188], ["lung", "ANATOMY", 193, 197], ["damage", "OBSERVATION", 198, 204], ["dominant", "OBSERVATION_MODIFIER", 210, 218]]], ["Given their importance, the role of each in the pathophysiology of ARDS is briefly considered below.Role of histones in the pathophysiology of ARDS: Increased levels of histones ::: The recruitment of activated neutrophils into alveolae and interstitial tissueLevels of extracellular histones are substantially higher in the bronchoalveolar lavage fluids (BALF) and plasma of ARDS patients, correlate with symptom severity and are predictive of mortality [[179], [180], [181]].", [["neutrophils", "ANATOMY", 211, 222], ["alveolae", "ANATOMY", 228, 236], ["interstitial tissueLevels", "ANATOMY", 241, 266], ["extracellular", "ANATOMY", 270, 283], ["bronchoalveolar lavage fluids", "ANATOMY", 325, 354], ["BALF", "ANATOMY", 356, 360], ["plasma", "ANATOMY", 366, 372], ["ARDS", "DISEASE", 67, 71], ["ARDS", "DISEASE", 143, 147], ["ARDS", "DISEASE", 376, 380], ["histones", "GENE_OR_GENE_PRODUCT", 108, 116], ["neutrophils", "CELL", 211, 222], ["alveolae", "CELL", 228, 236], ["extracellular histones", "CELLULAR_COMPONENT", 270, 292], ["bronchoalveolar lavage fluids", "ORGANISM_SUBSTANCE", 325, 354], ["BALF", "ORGANISM_SUBSTANCE", 356, 360], ["plasma", "ORGANISM_SUBSTANCE", 366, 372], ["patients", "ORGANISM", 381, 389], ["histones", "PROTEIN", 108, 116], ["histones", "PROTEIN", 169, 177], ["activated neutrophils", "CELL_TYPE", 201, 222], ["alveolae", "CELL_TYPE", 228, 236], ["extracellular histones", "PROTEIN", 270, 292], ["patients", "SPECIES", 381, 389], ["ARDS", "PROBLEM", 67, 71], ["ARDS", "PROBLEM", 143, 147], ["Increased levels of histones", "PROBLEM", 149, 177], ["activated neutrophils into alveolae", "PROBLEM", 201, 236], ["interstitial tissueLevels of extracellular histones", "PROBLEM", 241, 292], ["the bronchoalveolar lavage fluids", "TEST", 321, 354], ["ARDS patients", "PROBLEM", 376, 389], ["symptom severity", "TEST", 406, 422], ["ARDS", "OBSERVATION", 67, 71], ["histones", "OBSERVATION", 108, 116], ["ARDS", "OBSERVATION", 143, 147], ["Increased", "OBSERVATION_MODIFIER", 149, 158], ["recruitment", "OBSERVATION_MODIFIER", 186, 197], ["activated neutrophils", "OBSERVATION", 201, 222], ["interstitial", "ANATOMY_MODIFIER", 241, 253], ["extracellular histones", "OBSERVATION", 270, 292], ["substantially", "OBSERVATION_MODIFIER", 297, 310], ["higher", "OBSERVATION_MODIFIER", 311, 317], ["bronchoalveolar lavage", "OBSERVATION", 325, 347], ["ARDS", "OBSERVATION", 376, 380]]], ["Histones function as a DAMP capable of activating membrane bound and cytosolic PPRs leading to the release of inflammatory mediators such as TNF-alpha, IL-1 and iNOS [182,183].", [["membrane", "ANATOMY", 50, 58], ["cytosolic", "ANATOMY", 69, 78], ["Histones", "CELLULAR_COMPONENT", 0, 8], ["DAMP", "SIMPLE_CHEMICAL", 23, 27], ["membrane", "CELLULAR_COMPONENT", 50, 58], ["PPRs", "GENE_OR_GENE_PRODUCT", 79, 83], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 141, 150], ["IL-1", "GENE_OR_GENE_PRODUCT", 152, 156], ["iNOS", "GENE_OR_GENE_PRODUCT", 161, 165], ["DAMP", "PROTEIN", 23, 27], ["cytosolic PPRs", "PROTEIN", 69, 83], ["inflammatory mediators", "PROTEIN", 110, 132], ["TNF", "PROTEIN", 141, 144], ["IL-1", "PROTEIN", 152, 156], ["iNOS", "PROTEIN", 161, 165], ["Histones function", "PROBLEM", 0, 17], ["activating membrane bound", "PROBLEM", 39, 64], ["cytosolic PPRs", "TREATMENT", 69, 83], ["inflammatory mediators", "PROBLEM", 110, 132], ["TNF", "TEST", 141, 144], ["IL", "TEST", 152, 154], ["inflammatory", "OBSERVATION", 110, 122]]], ["These molecules are also efficient activators of the NLP3 inflammasome and inducers of immune and epithelial cell pyroptosis [184].", [["epithelial cell", "ANATOMY", 98, 113], ["NLP3", "GENE_OR_GENE_PRODUCT", 53, 57], ["immune", "CELL", 87, 93], ["epithelial cell", "CELL", 98, 113], ["NLP3 inflammasome", "PROTEIN", 53, 70], ["the NLP3 inflammasome", "PROBLEM", 49, 70], ["epithelial cell pyroptosis", "PROBLEM", 98, 124], ["epithelial cell pyroptosis", "OBSERVATION", 98, 124]]], ["This latter point is important as one mechanism underpinning the effects of histones in the development and exacerbation of ARDS involves NLRP3 activation and subsequent pyroptosis of peripheral macrophages resulting in significant increases in peripheral inflammation [179,180].", [["peripheral macrophages", "ANATOMY", 184, 206], ["ARDS", "DISEASE", 124, 128], ["peripheral inflammation", "DISEASE", 245, 268], ["histones", "GENE_OR_GENE_PRODUCT", 76, 84], ["NLRP3", "GENE_OR_GENE_PRODUCT", 138, 143], ["peripheral macrophages", "CELL", 184, 206], ["histones", "PROTEIN", 76, 84], ["NLRP3", "PROTEIN", 138, 143], ["peripheral macrophages", "CELL_TYPE", 184, 206], ["histones", "TREATMENT", 76, 84], ["ARDS", "PROBLEM", 124, 128], ["NLRP3 activation", "PROBLEM", 138, 154], ["subsequent pyroptosis of peripheral macrophages", "PROBLEM", 159, 206], ["significant increases in peripheral inflammation", "PROBLEM", 220, 268], ["ARDS", "OBSERVATION", 124, 128], ["peripheral macrophages", "OBSERVATION", 184, 206], ["significant", "OBSERVATION_MODIFIER", 220, 231], ["increases", "OBSERVATION_MODIFIER", 232, 241], ["peripheral", "ANATOMY_MODIFIER", 245, 255], ["inflammation", "OBSERVATION", 256, 268]]], ["Unsurprisingly, high levels of histones in the alveoli and the interstitial tissue of the lung also increases the activation of resident immune cells, epithelial cells and endothelial cells, and induces their death by pyroptosis and necrosis.", [["alveoli", "ANATOMY", 47, 54], ["interstitial tissue", "ANATOMY", 63, 82], ["lung", "ANATOMY", 90, 94], ["immune cells", "ANATOMY", 137, 149], ["epithelial cells", "ANATOMY", 151, 167], ["endothelial cells", "ANATOMY", 172, 189], ["death", "DISEASE", 209, 214], ["pyroptosis", "DISEASE", 218, 228], ["necrosis", "DISEASE", 233, 241], ["histones", "GENE_OR_GENE_PRODUCT", 31, 39], ["alveoli", "MULTI-TISSUE_STRUCTURE", 47, 54], ["interstitial tissue", "TISSUE", 63, 82], ["lung", "ORGAN", 90, 94], ["immune cells", "CELL", 137, 149], ["epithelial cells", "CELL", 151, 167], ["endothelial cells", "CELL", 172, 189], ["histones", "PROTEIN", 31, 39], ["resident immune cells", "CELL_TYPE", 128, 149], ["epithelial cells", "CELL_TYPE", 151, 167], ["endothelial cells", "CELL_TYPE", 172, 189], ["high levels of histones", "PROBLEM", 16, 39], ["epithelial cells and endothelial cells", "PROBLEM", 151, 189], ["their death", "PROBLEM", 203, 214], ["pyroptosis", "PROBLEM", 218, 228], ["necrosis", "PROBLEM", 233, 241], ["high", "OBSERVATION_MODIFIER", 16, 20], ["histones", "OBSERVATION", 31, 39], ["alveoli", "ANATOMY_MODIFIER", 47, 54], ["interstitial", "ANATOMY_MODIFIER", 63, 75], ["tissue", "ANATOMY_MODIFIER", 76, 82], ["lung", "ANATOMY", 90, 94], ["immune cells", "OBSERVATION", 137, 149], ["epithelial cells", "OBSERVATION", 151, 167], ["endothelial cells", "OBSERVATION", 172, 189], ["pyroptosis", "OBSERVATION", 218, 228], ["necrosis", "OBSERVATION", 233, 241]]], ["This results in further damage to the alveolar epithelium, vascular endothelium and enhances barrier dysfunction [185].", [["alveolar epithelium", "ANATOMY", 38, 57], ["vascular endothelium", "ANATOMY", 59, 79], ["barrier", "ANATOMY", 93, 100], ["alveolar epithelium", "TISSUE", 38, 57], ["vascular endothelium", "TISSUE", 59, 79], ["barrier", "TISSUE", 93, 100], ["further damage to the alveolar epithelium", "PROBLEM", 16, 57], ["barrier dysfunction", "PROBLEM", 93, 112], ["damage", "OBSERVATION", 24, 30], ["alveolar", "ANATOMY_MODIFIER", 38, 46], ["epithelium", "ANATOMY_MODIFIER", 47, 57], ["vascular endothelium", "ANATOMY", 59, 79], ["barrier dysfunction", "OBSERVATION", 93, 112]]], ["Histones released from NETs or activated but otherwise viable immune cells also contribute to the pathophysiology of ARDS other than by directly inducing severe pulmonary tissue damage and increasing levels of peripheral inflammation such as activation of the complement and coagulation cascades [185,186].Role of mitochondrial DNA in the pathophysiology of ARDS ::: The recruitment of activated neutrophils into alveolae and interstitial tissueThe presence of mtDNA in the circulation is a marker of mortality in sepsis patients in the intensive care unit [187,188].", [["NETs", "ANATOMY", 23, 27], ["immune cells", "ANATOMY", 62, 74], ["pulmonary tissue", "ANATOMY", 161, 177], ["mitochondrial", "ANATOMY", 314, 327], ["neutrophils", "ANATOMY", 396, 407], ["alveolae", "ANATOMY", 413, 421], ["interstitial tissue", "ANATOMY", 426, 445], ["ARDS", "DISEASE", 117, 121], ["pulmonary tissue damage", "DISEASE", 161, 184], ["peripheral inflammation", "DISEASE", 210, 233], ["ARDS", "DISEASE", 358, 362], ["sepsis", "DISEASE", 514, 520], ["Histones", "CELLULAR_COMPONENT", 0, 8], ["NETs", "GENE_OR_GENE_PRODUCT", 23, 27], ["immune cells", "CELL", 62, 74], ["pulmonary tissue", "TISSUE", 161, 177], ["mitochondrial", "CELLULAR_COMPONENT", 314, 327], ["DNA", "CELLULAR_COMPONENT", 328, 331], ["neutrophils", "CELL", 396, 407], ["alveolae", "CELL", 413, 421], ["interstitial tissue", "TISSUE", 426, 445], ["mtDNA", "CELLULAR_COMPONENT", 461, 466], ["patients", "ORGANISM", 521, 529], ["immune cells", "CELL_TYPE", 62, 74], ["activated neutrophils", "CELL_TYPE", 386, 407], ["alveolae", "CELL_TYPE", 413, 421], ["patients", "SPECIES", 521, 529], ["Histones", "PROBLEM", 0, 8], ["ARDS", "PROBLEM", 117, 121], ["severe pulmonary tissue damage", "PROBLEM", 154, 184], ["peripheral inflammation", "PROBLEM", 210, 233], ["coagulation cascades", "TEST", 275, 295], ["mitochondrial DNA", "PROBLEM", 314, 331], ["ARDS", "PROBLEM", 358, 362], ["activated neutrophils into alveolae", "PROBLEM", 386, 421], ["interstitial tissue", "PROBLEM", 426, 445], ["sepsis", "PROBLEM", 514, 520], ["ARDS", "OBSERVATION", 117, 121], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["pulmonary tissue", "ANATOMY", 161, 177], ["damage", "OBSERVATION", 178, 184], ["increasing", "OBSERVATION_MODIFIER", 189, 199], ["peripheral", "ANATOMY_MODIFIER", 210, 220], ["inflammation", "OBSERVATION", 221, 233], ["mitochondrial DNA", "OBSERVATION", 314, 331], ["ARDS", "OBSERVATION", 358, 362], ["activated neutrophils", "OBSERVATION", 386, 407], ["interstitial tissue", "ANATOMY", 426, 445], ["mtDNA", "OBSERVATION", 461, 466], ["circulation", "ANATOMY", 474, 485], ["sepsis", "OBSERVATION", 514, 520]]], ["In addition, levels of plasma mtDNA is predictive of the transition to ARDS [189] and need for ventilation in this population [190].", [["plasma", "ANATOMY", 23, 29], ["ARDS", "DISEASE", 71, 75], ["plasma", "ORGANISM_SUBSTANCE", 23, 29], ["mtDNA", "CELLULAR_COMPONENT", 30, 35], ["plasma mtDNA", "TEST", 23, 35], ["ARDS", "PROBLEM", 71, 75], ["ventilation", "TREATMENT", 95, 106]]], ["Mechanistically, the role of mtDNA in the pathophysiology of sepsis and ARDS also stems from its activity as a DAMP capable of activating cytosolic TLR-9 receptors, stimulating the activation of the NLRP 3 inflammasome following release from mitochondria within stressed cells or when released into the extracellular environment by apoptosis, necrosis, pyroptosis and NETosis (reviewed by [191]).Role of HGMB1 in the pathophysiology of ARDS ::: The recruitment of activated neutrophils into alveolae and interstitial tissueHigh-mobility group protein 1 (HMBG-1) is another major player in the pathogenesis and pathophysiology of ARDS, and levels of this molecule in the blood are predictive of mortality in virally induced ARDS and severe pneumonia [[192], [193], [194], [195]].", [["cytosolic", "ANATOMY", 138, 147], ["mitochondria", "ANATOMY", 242, 254], ["cells", "ANATOMY", 271, 276], ["extracellular", "ANATOMY", 303, 316], ["neutrophils", "ANATOMY", 474, 485], ["alveolae", "ANATOMY", 491, 499], ["interstitial", "ANATOMY", 504, 516], ["blood", "ANATOMY", 670, 675], ["sepsis", "DISEASE", 61, 67], ["ARDS", "DISEASE", 72, 76], ["necrosis", "DISEASE", 343, 351], ["pyroptosis", "DISEASE", 353, 363], ["NETosis", "DISEASE", 368, 375], ["ARDS", "DISEASE", 436, 440], ["ARDS", "DISEASE", 629, 633], ["ARDS", "DISEASE", 723, 727], ["pneumonia", "DISEASE", 739, 748], ["mtDNA", "CELLULAR_COMPONENT", 29, 34], ["DAMP", "SIMPLE_CHEMICAL", 111, 115], ["TLR-9 receptors", "GENE_OR_GENE_PRODUCT", 148, 163], ["NLRP 3", "GENE_OR_GENE_PRODUCT", 199, 205], ["mitochondria", "CELLULAR_COMPONENT", 242, 254], ["cells", "CELL", 271, 276], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 303, 316], ["HGMB1", "GENE_OR_GENE_PRODUCT", 404, 409], ["neutrophils", "CELL", 474, 485], ["alveolae", "CELL", 491, 499], ["interstitial tissueHigh-mobility group protein 1", "GENE_OR_GENE_PRODUCT", 504, 552], ["HMBG-1", "GENE_OR_GENE_PRODUCT", 554, 560], ["blood", "ORGANISM_SUBSTANCE", 670, 675], ["cytosolic TLR-9 receptors", "PROTEIN", 138, 163], ["NLRP 3", "PROTEIN", 199, 205], ["stressed cells", "CELL_TYPE", 262, 276], ["HGMB1", "PROTEIN", 404, 409], ["activated neutrophils", "CELL_TYPE", 464, 485], ["alveolae and interstitial tissueHigh-mobility group protein 1", "PROTEIN", 491, 552], ["HMBG", "PROTEIN", 554, 558], ["sepsis", "PROBLEM", 61, 67], ["ARDS also stems", "PROBLEM", 72, 87], ["activating cytosolic TLR", "TREATMENT", 127, 151], ["necrosis", "PROBLEM", 343, 351], ["pyroptosis", "PROBLEM", 353, 363], ["NETosis", "PROBLEM", 368, 375], ["ARDS", "PROBLEM", 436, 440], ["activated neutrophils", "TEST", 464, 485], ["alveolae", "TEST", 491, 499], ["interstitial tissueHigh", "TEST", 504, 527], ["mobility group protein", "TEST", 528, 550], ["HMBG", "TEST", 554, 558], ["ARDS", "PROBLEM", 629, 633], ["levels", "TEST", 639, 645], ["this molecule", "PROBLEM", 649, 662], ["the blood", "TEST", 666, 675], ["virally induced ARDS", "PROBLEM", 707, 727], ["severe pneumonia", "PROBLEM", 732, 748], ["sepsis", "OBSERVATION", 61, 67], ["ARDS", "OBSERVATION", 72, 76], ["necrosis", "OBSERVATION", 343, 351], ["pyroptosis", "OBSERVATION", 353, 363], ["ARDS", "OBSERVATION", 436, 440], ["interstitial", "ANATOMY_MODIFIER", 504, 516], ["ARDS", "OBSERVATION", 629, 633], ["blood", "ANATOMY", 670, 675], ["ARDS", "OBSERVATION", 723, 727], ["severe", "OBSERVATION_MODIFIER", 732, 738], ["pneumonia", "OBSERVATION", 739, 748]]], ["This heat shock protein also functions as a DAMP and plays a major role in the propagation and exacerbation of sterile inflammation and in the development of sepsis [196].", [["inflammation", "DISEASE", 119, 131], ["sepsis", "DISEASE", 158, 164], ["heat shock protein", "GENE_OR_GENE_PRODUCT", 5, 23], ["DAMP", "GENE_OR_GENE_PRODUCT", 44, 48], ["heat shock protein", "PROTEIN", 5, 23], ["DAMP", "PROTEIN", 44, 48], ["This heat shock protein", "PROBLEM", 0, 23], ["a DAMP", "PROBLEM", 42, 48], ["sterile inflammation", "PROBLEM", 111, 131], ["sepsis", "PROBLEM", 158, 164], ["shock", "OBSERVATION", 10, 15], ["inflammation", "OBSERVATION", 119, 131], ["sepsis", "OBSERVATION", 158, 164]]], ["In addition, HMBG1 appears to be the dominant driver of inflammation resulting from cell necrosis and proptosis, and there is evidence to suggest that its role in the development of ARDS may be multidimensional.", [["cell", "ANATOMY", 84, 88], ["inflammation", "DISEASE", 56, 68], ["necrosis", "DISEASE", 89, 97], ["proptosis", "DISEASE", 102, 111], ["ARDS", "DISEASE", 182, 186], ["HMBG1", "GENE_OR_GENE_PRODUCT", 13, 18], ["cell", "CELL", 84, 88], ["HMBG1", "PROTEIN", 13, 18], ["HMBG1", "TREATMENT", 13, 18], ["inflammation", "PROBLEM", 56, 68], ["cell necrosis", "PROBLEM", 84, 97], ["proptosis", "PROBLEM", 102, 111], ["ARDS", "PROBLEM", 182, 186], ["appears to be", "UNCERTAINTY", 19, 32], ["dominant", "OBSERVATION_MODIFIER", 37, 45], ["driver", "OBSERVATION", 46, 52], ["inflammation", "OBSERVATION", 56, 68], ["cell necrosis", "OBSERVATION", 84, 97], ["proptosis", "OBSERVATION", 102, 111], ["ARDS", "OBSERVATION", 182, 186]]], ["The association between increased HGMB1 levels and accelerated NET production by neutrophils has been discussed.", [["neutrophils", "ANATOMY", 81, 92], ["HGMB1", "GENE_OR_GENE_PRODUCT", 34, 39], ["NET", "GENE_OR_GENE_PRODUCT", 63, 66], ["neutrophils", "CELL", 81, 92], ["HGMB1", "PROTEIN", 34, 39], ["neutrophils", "CELL_TYPE", 81, 92], ["increased HGMB1 levels", "PROBLEM", 24, 46], ["accelerated NET production", "PROBLEM", 51, 77], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["HGMB1 levels", "OBSERVATION", 34, 46], ["NET production", "OBSERVATION", 63, 77]]], ["This cytokine also exerts a pathological effect in the development of ARDS by aiding in delayed NET clearance, which is a distinctive element driving the development and acceleration of the condition [197,198].", [["ARDS", "DISEASE", 70, 74], ["NET", "SIMPLE_CHEMICAL", 96, 99], ["cytokine", "PROTEIN", 5, 13], ["a pathological effect", "PROBLEM", 26, 47], ["ARDS", "PROBLEM", 70, 74], ["delayed NET clearance", "PROBLEM", 88, 109], ["ARDS", "OBSERVATION", 70, 74], ["distinctive element", "OBSERVATION", 122, 141]]], ["Ultimately, the decreased clearance of NETs is a consequence of delayed neutrophil apoptosis [197,198] which is discussed below.The role of decreased neutrophil apoptosis in the pathophysiology of ARDS ::: The recruitment of activated neutrophils into alveolae and interstitial tissueSeveral research teams have reported delayed neutrophil apoptosis and clearance of NETS in patients with sepsis related ARDS [[199], [200], [201], [202]].", [["NETs", "ANATOMY", 39, 43], ["neutrophil", "ANATOMY", 72, 82], ["neutrophil", "ANATOMY", 150, 160], ["neutrophils", "ANATOMY", 235, 246], ["alveolae", "ANATOMY", 252, 260], ["interstitial tissueSeveral", "ANATOMY", 265, 291], ["neutrophil", "ANATOMY", 329, 339], ["NETs", "DISEASE", 39, 43], ["ARDS", "DISEASE", 197, 201], ["sepsis", "DISEASE", 389, 395], ["ARDS", "DISEASE", 404, 408], ["NETs", "CANCER", 39, 43], ["neutrophil", "CELL", 72, 82], ["neutrophil", "CELL", 150, 160], ["neutrophils", "CELL", 235, 246], ["alveolae", "CELL", 252, 260], ["neutrophil", "CELL", 329, 339], ["NETS", "SIMPLE_CHEMICAL", 367, 371], ["patients", "ORGANISM", 375, 383], ["neutrophil", "CELL_TYPE", 150, 160], ["activated neutrophils", "CELL_TYPE", 225, 246], ["patients", "SPECIES", 375, 383], ["the decreased clearance of NETs", "PROBLEM", 12, 43], ["delayed neutrophil apoptosis", "PROBLEM", 64, 92], ["decreased neutrophil apoptosis", "PROBLEM", 140, 170], ["ARDS", "PROBLEM", 197, 201], ["delayed neutrophil apoptosis", "PROBLEM", 321, 349], ["clearance of NETS", "TREATMENT", 354, 371], ["sepsis related ARDS", "PROBLEM", 389, 408], ["decreased", "OBSERVATION_MODIFIER", 16, 25], ["clearance", "OBSERVATION_MODIFIER", 26, 35], ["neutrophil apoptosis", "OBSERVATION", 72, 92], ["decreased", "OBSERVATION_MODIFIER", 140, 149], ["neutrophil apoptosis", "OBSERVATION", 150, 170], ["ARDS", "OBSERVATION", 197, 201], ["interstitial", "ANATOMY_MODIFIER", 265, 277], ["neutrophil apoptosis", "OBSERVATION", 329, 349]]], ["In addition, the percentage of the neutrophil population displaying markers of delayed apoptosis correlates with the severity of symptoms and several objective measures of tissue damage [[199], [200], [201], [202]] and survival [90].", [["neutrophil", "ANATOMY", 35, 45], ["tissue", "ANATOMY", 172, 178], ["neutrophil", "CELL", 35, 45], ["tissue", "TISSUE", 172, 178], ["neutrophil population", "CELL_TYPE", 35, 56], ["the neutrophil population", "PROBLEM", 31, 56], ["delayed apoptosis", "PROBLEM", 79, 96], ["the severity of symptoms", "PROBLEM", 113, 137], ["tissue damage", "PROBLEM", 172, 185], ["percentage", "OBSERVATION_MODIFIER", 17, 27], ["neutrophil population", "OBSERVATION", 35, 56], ["delayed apoptosis", "OBSERVATION", 79, 96]]], ["Delayed apoptosis is also accompanied by serious pathological consequences as the phenomenon may lead to neutrophil pyroptosis [203,204] or, in some instances, necroptosis [205,206] with increases in highly oxidised mtDNA, histones, HMBG1, PICs and a swathe of other inflammatory molecules [205,207,208].", [["neutrophil", "ANATOMY", 105, 115], ["necroptosis", "DISEASE", 160, 171], ["neutrophil", "CELL", 105, 115], ["mtDNA", "CELLULAR_COMPONENT", 216, 221], ["histones", "CELLULAR_COMPONENT", 223, 231], ["HMBG1", "GENE_OR_GENE_PRODUCT", 233, 238], ["neutrophil", "CELL_TYPE", 105, 115], ["histones", "PROTEIN", 223, 231], ["HMBG1", "PROTEIN", 233, 238], ["PICs", "PROTEIN", 240, 244], ["inflammatory molecules", "PROTEIN", 267, 289], ["Delayed apoptosis", "PROBLEM", 0, 17], ["serious pathological consequences", "PROBLEM", 41, 74], ["the phenomenon", "PROBLEM", 78, 92], ["neutrophil pyroptosis", "PROBLEM", 105, 126], ["necroptosis", "PROBLEM", 160, 171], ["highly oxidised mtDNA", "PROBLEM", 200, 221], ["histones", "PROBLEM", 223, 231], ["HMBG1", "TEST", 233, 238], ["PICs", "PROBLEM", 240, 244], ["other inflammatory molecules", "PROBLEM", 261, 289], ["apoptosis", "OBSERVATION", 8, 17], ["neutrophil pyroptosis", "OBSERVATION", 105, 126], ["necroptosis", "OBSERVATION", 160, 171], ["highly", "OBSERVATION_MODIFIER", 200, 206], ["oxidised mtDNA", "OBSERVATION", 207, 221]]], ["Importantly, delayed neutrophil apoptosis acts as an additional source of increasing inflammation further exacerbating cell death and tissue damage [209]; review [177].Causes of delayed neutrophil apoptosis ::: The recruitment of activated neutrophils into alveolae and interstitial tissueSpirally increasing levels of HMBG1 may contribute to decreased neutrophil clearance in ARDS patients by inhibiting neutrophil apoptosis [[210], [211], [212]].", [["neutrophil", "ANATOMY", 21, 31], ["cell", "ANATOMY", 119, 123], ["tissue", "ANATOMY", 134, 140], ["neutrophil", "ANATOMY", 186, 196], ["neutrophils", "ANATOMY", 240, 251], ["alveolae", "ANATOMY", 257, 265], ["interstitial", "ANATOMY", 270, 282], ["neutrophil", "ANATOMY", 353, 363], ["neutrophil", "ANATOMY", 405, 415], ["inflammation", "DISEASE", 85, 97], ["death", "DISEASE", 124, 129], ["HMBG1", "CHEMICAL", 319, 324], ["ARDS", "DISEASE", 377, 381], ["neutrophil", "CELL", 21, 31], ["cell", "CELL", 119, 123], ["tissue", "TISSUE", 134, 140], ["neutrophil", "CELL", 186, 196], ["neutrophils", "CELL", 240, 251], ["alveolae", "CELL", 257, 265], ["HMBG1", "GENE_OR_GENE_PRODUCT", 319, 324], ["neutrophil", "CELL", 353, 363], ["patients", "ORGANISM", 382, 390], ["neutrophil", "CELL", 405, 415], ["neutrophil", "CELL_TYPE", 21, 31], ["neutrophil", "CELL_TYPE", 186, 196], ["activated neutrophils", "CELL_TYPE", 230, 251], ["HMBG1", "PROTEIN", 319, 324], ["neutrophil", "CELL_TYPE", 405, 415], ["patients", "SPECIES", 382, 390], ["delayed neutrophil apoptosis acts", "PROBLEM", 13, 46], ["increasing inflammation", "PROBLEM", 74, 97], ["cell death", "PROBLEM", 119, 129], ["tissue damage", "PROBLEM", 134, 147], ["delayed neutrophil apoptosis", "PROBLEM", 178, 206], ["activated neutrophils into alveolae", "PROBLEM", 230, 265], ["interstitial tissueSpirally increasing levels of HMBG1", "PROBLEM", 270, 324], ["decreased neutrophil clearance", "PROBLEM", 343, 373], ["ARDS", "PROBLEM", 377, 381], ["neutrophil apoptosis", "TEST", 405, 425], ["neutrophil apoptosis", "OBSERVATION", 21, 41], ["increasing", "OBSERVATION_MODIFIER", 74, 84], ["inflammation", "OBSERVATION", 85, 97], ["delayed", "OBSERVATION_MODIFIER", 178, 185], ["neutrophil apoptosis", "OBSERVATION", 186, 206], ["interstitial", "ANATOMY_MODIFIER", 270, 282], ["may contribute to", "UNCERTAINTY", 325, 342], ["decreased", "OBSERVATION_MODIFIER", 343, 352], ["neutrophil clearance", "OBSERVATION", 353, 373]]], ["In addition, increased levels of HMGB1 produced by the activity of NETS stimulates the release of NETS by other neutrophils increasing the population of neutrophils resistant to apoptosis in the lung.", [["neutrophils", "ANATOMY", 112, 123], ["neutrophils", "ANATOMY", 153, 164], ["lung", "ANATOMY", 195, 199], ["HMGB1", "GENE_OR_GENE_PRODUCT", 33, 38], ["NETS", "GENE_OR_GENE_PRODUCT", 67, 71], ["NETS", "GENE_OR_GENE_PRODUCT", 98, 102], ["neutrophils", "CELL", 112, 123], ["neutrophils", "CELL", 153, 164], ["lung", "ORGAN", 195, 199], ["HMGB1", "PROTEIN", 33, 38], ["NETS", "PROTEIN", 67, 71], ["NETS", "PROTEIN", 98, 102], ["neutrophils", "CELL_TYPE", 112, 123], ["neutrophils", "CELL_TYPE", 153, 164], ["increased levels of HMGB1", "PROBLEM", 13, 38], ["NETS", "TREATMENT", 98, 102], ["neutrophils", "PROBLEM", 153, 164], ["apoptosis in the lung", "PROBLEM", 178, 199], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["levels", "OBSERVATION_MODIFIER", 23, 29], ["neutrophils resistant", "OBSERVATION", 153, 174], ["apoptosis", "OBSERVATION", 178, 187], ["lung", "ANATOMY", 195, 199]]], ["This results in a significant increase in inflammation and tissue damage, creating one of many feedforward loops involved in the progression of ARDS [148,150].Causes of delayed neutrophil apoptosis ::: The recruitment of activated neutrophils into alveolae and interstitial tissueAnother, and perhaps predominant cause of prolonged neutrophil survival and sub-optimal NET clearance in many patients suffering from ARDS would appear to be impaired alveolar macrophage phagocytic clearance of dying cells or efferocytosis [86,197,[213], [214], [215]].", [["tissue", "ANATOMY", 59, 65], ["neutrophil", "ANATOMY", 177, 187], ["neutrophils", "ANATOMY", 231, 242], ["alveolae", "ANATOMY", 248, 256], ["interstitial tissueAnother", "ANATOMY", 261, 287], ["neutrophil", "ANATOMY", 332, 342], ["alveolar macrophage", "ANATOMY", 447, 466], ["cells", "ANATOMY", 497, 502], ["inflammation", "DISEASE", 42, 54], ["ARDS", "DISEASE", 144, 148], ["ARDS", "DISEASE", 414, 418], ["tissue", "TISSUE", 59, 65], ["neutrophil", "CELL", 177, 187], ["neutrophils", "CELL", 231, 242], ["alveolae", "CELL", 248, 256], ["interstitial tissueAnother", "TISSUE", 261, 287], ["neutrophil", "CELL", 332, 342], ["NET", "SIMPLE_CHEMICAL", 368, 371], ["patients", "ORGANISM", 390, 398], ["alveolar macrophage", "CELL", 447, 466], ["cells", "CELL", 497, 502], ["neutrophil", "CELL_TYPE", 177, 187], ["activated neutrophils", "CELL_TYPE", 221, 242], ["dying cells", "CELL_TYPE", 491, 502], ["patients", "SPECIES", 390, 398], ["a significant increase in inflammation", "PROBLEM", 16, 54], ["tissue damage", "PROBLEM", 59, 72], ["ARDS", "PROBLEM", 144, 148], ["delayed neutrophil apoptosis", "PROBLEM", 169, 197], ["activated neutrophils into alveolae and interstitial tissueAnother", "PROBLEM", 221, 287], ["prolonged neutrophil survival", "TREATMENT", 322, 351], ["sub-optimal NET clearance", "PROBLEM", 356, 381], ["ARDS", "PROBLEM", 414, 418], ["impaired alveolar macrophage phagocytic clearance of dying cells", "PROBLEM", 438, 502], ["efferocytosis", "PROBLEM", 506, 519], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["inflammation", "OBSERVATION", 42, 54], ["tissue damage", "OBSERVATION", 59, 72], ["many", "OBSERVATION_MODIFIER", 90, 94], ["feedforward loops", "OBSERVATION", 95, 112], ["progression", "OBSERVATION_MODIFIER", 129, 140], ["ARDS", "OBSERVATION", 144, 148], ["delayed", "OBSERVATION_MODIFIER", 169, 176], ["neutrophil apoptosis", "OBSERVATION", 177, 197], ["activated neutrophils", "OBSERVATION", 221, 242], ["interstitial tissueAnother", "ANATOMY", 261, 287], ["prolonged", "OBSERVATION_MODIFIER", 322, 331], ["neutrophil survival", "OBSERVATION", 332, 351], ["ARDS", "OBSERVATION", 414, 418], ["appear to be", "UNCERTAINTY", 425, 437], ["impaired", "OBSERVATION_MODIFIER", 438, 446], ["alveolar macrophage phagocytic", "OBSERVATION", 447, 477]]], ["This phenomenon has serious pathological consequences since in physiological conditions, alveolar macrophages play an indispensable role in the immunologically silent removal of neutrophils and the adoption of an anti-inflammatory profile by macrophages [[216], [217], [218]].", [["alveolar macrophages", "ANATOMY", 89, 109], ["neutrophils", "ANATOMY", 178, 189], ["macrophages", "ANATOMY", 242, 253], ["alveolar macrophages", "CELL", 89, 109], ["neutrophils", "CELL", 178, 189], ["macrophages", "CELL", 242, 253], ["alveolar macrophages", "CELL_TYPE", 89, 109], ["neutrophils", "CELL_TYPE", 178, 189], ["macrophages", "CELL_TYPE", 242, 253], ["serious pathological consequences", "PROBLEM", 20, 53], ["alveolar macrophages", "PROBLEM", 89, 109], ["the immunologically silent removal of neutrophils", "TREATMENT", 140, 189], ["an anti-inflammatory profile", "TEST", 210, 238], ["serious", "OBSERVATION_MODIFIER", 20, 27], ["alveolar macrophages", "OBSERVATION", 89, 109]]], ["In addition, macrophage efferocytosis plays a major role in the clearance of NETs [219,220].Causes of impaired macrophage efferocytosis ::: The recruitment of activated neutrophils into alveolae and interstitial tissueThe weight of evidence suggests that high levels of HGMB1 is an important if not predominant driver of impaired alveolar macrophage efferocytosis seen in several lung disease including ARDS [[210], [211], [212]].", [["macrophage", "ANATOMY", 13, 23], ["NETs", "ANATOMY", 77, 81], ["macrophage", "ANATOMY", 111, 121], ["neutrophils", "ANATOMY", 169, 180], ["alveolae", "ANATOMY", 186, 194], ["interstitial tissue", "ANATOMY", 199, 218], ["alveolar macrophage", "ANATOMY", 330, 349], ["lung", "ANATOMY", 380, 384], ["lung disease", "DISEASE", 380, 392], ["ARDS", "DISEASE", 403, 407], ["macrophage", "CELL", 13, 23], ["NETs", "GENE_OR_GENE_PRODUCT", 77, 81], ["macrophage", "CELL", 111, 121], ["neutrophils", "CELL", 169, 180], ["alveolae", "CELL", 186, 194], ["interstitial tissue", "TISSUE", 199, 218], ["HGMB1", "GENE_OR_GENE_PRODUCT", 270, 275], ["alveolar macrophage", "CELL", 330, 349], ["lung", "ORGAN", 380, 384], ["activated neutrophils", "CELL_TYPE", 159, 180], ["alveolae", "CELL_TYPE", 186, 194], ["HGMB1", "PROTEIN", 270, 275], ["macrophage efferocytosis", "PROBLEM", 13, 37], ["impaired macrophage efferocytosis", "PROBLEM", 102, 135], ["activated neutrophils into alveolae", "PROBLEM", 159, 194], ["interstitial tissue", "PROBLEM", 199, 218], ["The weight", "TEST", 218, 228], ["high levels of HGMB1", "PROBLEM", 255, 275], ["impaired alveolar macrophage efferocytosis", "PROBLEM", 321, 363], ["several lung disease", "PROBLEM", 372, 392], ["ARDS", "PROBLEM", 403, 407], ["macrophage efferocytosis", "OBSERVATION", 13, 37], ["impaired", "OBSERVATION_MODIFIER", 102, 110], ["macrophage efferocytosis", "OBSERVATION", 111, 135], ["activated neutrophils", "OBSERVATION", 159, 180], ["interstitial tissue", "ANATOMY", 199, 218], ["high", "OBSERVATION_MODIFIER", 255, 259], ["impaired", "OBSERVATION_MODIFIER", 321, 329], ["alveolar macrophage efferocytosis", "OBSERVATION", 330, 363], ["several", "OBSERVATION_MODIFIER", 372, 379], ["lung", "ANATOMY", 380, 384], ["disease", "OBSERVATION", 385, 392], ["ARDS", "OBSERVATION", 403, 407]]], ["Clearly, increased NET generation is a major source of HGMB1, but it should be noted that there are also other sources of this molecule in ARDS patients which is relevant in the COVID-19 model proposed here.", [["ARDS", "DISEASE", 139, 143], ["NET", "GENE_OR_GENE_PRODUCT", 19, 22], ["HGMB1", "GENE_OR_GENE_PRODUCT", 55, 60], ["patients", "ORGANISM", 144, 152], ["HGMB1", "PROTEIN", 55, 60], ["patients", "SPECIES", 144, 152], ["increased NET generation", "PROBLEM", 9, 33], ["HGMB1", "PROBLEM", 55, 60], ["this molecule in ARDS", "PROBLEM", 122, 143], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["NET generation", "OBSERVATION", 19, 33], ["ARDS", "OBSERVATION", 139, 143]]], ["Such sources include alveolar macrophages, dendritic cells, alveolar epithelial cells and alveolar endothelial cells activated in response to viral activation or high levels of TNF-alpha [[221], [222], [223], [224]].Causes of impaired macrophage efferocytosis ::: The recruitment of activated neutrophils into alveolae and interstitial tissueHigh levels of TNF-alpha may also contribute to delayed neutrophil apoptosis and impaired alveolar macrophage efferocytosis in ARDS patients.", [["alveolar macrophages", "ANATOMY", 21, 41], ["dendritic cells", "ANATOMY", 43, 58], ["alveolar epithelial cells", "ANATOMY", 60, 85], ["alveolar endothelial cells", "ANATOMY", 90, 116], ["macrophage", "ANATOMY", 235, 245], ["neutrophils", "ANATOMY", 293, 304], ["alveolae", "ANATOMY", 310, 318], ["interstitial tissueHigh", "ANATOMY", 323, 346], ["neutrophil", "ANATOMY", 398, 408], ["alveolar macrophage", "ANATOMY", 432, 451], ["ARDS", "DISEASE", 469, 473], ["alveolar macrophages", "CELL", 21, 41], ["dendritic cells", "CELL", 43, 58], ["alveolar epithelial cells", "CELL", 60, 85], ["alveolar endothelial cells", "CELL", 90, 116], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 177, 186], ["macrophage", "CELL", 235, 245], ["neutrophils", "CELL", 293, 304], ["alveolae", "CELL", 310, 318], ["interstitial tissueHigh", "TISSUE", 323, 346], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 357, 366], ["neutrophil", "CELL", 398, 408], ["alveolar macrophage", "CELL", 432, 451], ["patients", "ORGANISM", 474, 482], ["alveolar macrophages", "CELL_TYPE", 21, 41], ["dendritic cells", "CELL_TYPE", 43, 58], ["alveolar epithelial cells", "CELL_TYPE", 60, 85], ["alveolar endothelial cells", "CELL_TYPE", 90, 116], ["TNF", "PROTEIN", 177, 180], ["activated neutrophils", "CELL_TYPE", 283, 304], ["alveolae", "CELL_TYPE", 310, 318], ["TNF-alpha", "PROTEIN", 357, 366], ["patients", "SPECIES", 474, 482], ["alveolar macrophages", "PROBLEM", 21, 41], ["dendritic cells", "PROBLEM", 43, 58], ["alveolar epithelial cells", "PROBLEM", 60, 85], ["alveolar endothelial cells", "PROBLEM", 90, 116], ["viral activation", "TEST", 142, 158], ["high levels of TNF", "PROBLEM", 162, 180], ["impaired macrophage efferocytosis", "PROBLEM", 226, 259], ["activated neutrophils into alveolae", "PROBLEM", 283, 318], ["interstitial tissueHigh levels", "TEST", 323, 353], ["TNF", "TEST", 357, 360], ["delayed neutrophil apoptosis", "PROBLEM", 390, 418], ["impaired alveolar macrophage efferocytosis", "PROBLEM", 423, 465], ["ARDS patients", "PROBLEM", 469, 482], ["alveolar macrophages", "OBSERVATION", 21, 41], ["dendritic cells", "OBSERVATION", 43, 58], ["alveolar", "ANATOMY_MODIFIER", 60, 68], ["epithelial cells", "OBSERVATION", 69, 85], ["alveolar endothelial cells", "OBSERVATION", 90, 116], ["viral activation", "OBSERVATION", 142, 158], ["impaired", "OBSERVATION_MODIFIER", 226, 234], ["macrophage efferocytosis", "OBSERVATION", 235, 259], ["interstitial", "ANATOMY_MODIFIER", 323, 335], ["may also contribute to", "UNCERTAINTY", 367, 389], ["delayed", "OBSERVATION_MODIFIER", 390, 397], ["neutrophil apoptosis", "OBSERVATION", 398, 418], ["impaired", "OBSERVATION_MODIFIER", 423, 431], ["alveolar macrophage efferocytosis", "OBSERVATION", 432, 465], ["ARDS", "OBSERVATION", 469, 473]]], ["Excessive levels of environmental TNF-alpha is a well-documented cause of compromised phagocytosis in these immune cells [225,226].", [["immune cells", "ANATOMY", 108, 120], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 34, 43], ["immune cells", "CELL", 108, 120], ["TNF-alpha", "PROTEIN", 34, 43], ["immune cells", "CELL_TYPE", 108, 120], ["Excessive levels of environmental TNF", "PROBLEM", 0, 37], ["compromised phagocytosis", "PROBLEM", 74, 98], ["compromised phagocytosis", "OBSERVATION", 74, 98]]], ["In addition, high levels of HMBG1 may increase the population of M1 polarised macrophages via a mechanism involving TLR-4 and RAGE activation [212,[227], [228], [229]].", [["macrophages", "ANATOMY", 78, 89], ["HMBG1", "CHEMICAL", 28, 33], ["HMBG1", "GENE_OR_GENE_PRODUCT", 28, 33], ["M1 polarised macrophages", "CELL", 65, 89], ["TLR-4", "GENE_OR_GENE_PRODUCT", 116, 121], ["RAGE", "GENE_OR_GENE_PRODUCT", 126, 130], ["HMBG1", "PROTEIN", 28, 33], ["M1 polarised macrophages", "CELL_TYPE", 65, 89], ["TLR", "PROTEIN", 116, 119], ["RAGE", "PROTEIN", 126, 130], ["high levels of HMBG1", "PROBLEM", 13, 33], ["TLR", "TEST", 116, 119], ["population", "OBSERVATION_MODIFIER", 51, 61], ["M1 polarised macrophages", "OBSERVATION", 65, 89]]], ["This is of importance from the perspective of impaired efferocytosis, as macrophages polarised in such a manner display inhibited phagocytosis compared to their M2 polarised counterparts [230].", [["macrophages", "ANATOMY", 73, 84], ["impaired efferocytosis", "DISEASE", 46, 68], ["macrophages", "CELL", 73, 84], ["macrophages", "CELL_TYPE", 73, 84], ["impaired efferocytosis", "PROBLEM", 46, 68], ["inhibited phagocytosis", "PROBLEM", 120, 142], ["impaired", "OBSERVATION_MODIFIER", 46, 54], ["efferocytosis", "OBSERVATION", 55, 68]]], ["Increased polarisation of M1 polarisation is also driven by increased levels of TNF-alpha [231,232] and IL-6 [233,234].Causes of impaired macrophage efferocytosis ::: The recruitment of activated neutrophils into alveolae and interstitial tissueClearly an increasing interplay between DAMPS, cytokines and ROS secreted by epithelial cells, neutrophils and alveolar macrophages can explain high levels of inflammation and lung tissue damage seen in ARDS secondary to sepsis and COVID-19.", [["macrophage", "ANATOMY", 138, 148], ["neutrophils", "ANATOMY", 196, 207], ["alveolae", "ANATOMY", 213, 221], ["interstitial", "ANATOMY", 226, 238], ["epithelial cells", "ANATOMY", 322, 338], ["neutrophils", "ANATOMY", 340, 351], ["alveolar macrophages", "ANATOMY", 356, 376], ["lung tissue", "ANATOMY", 421, 432], ["inflammation", "DISEASE", 404, 416], ["lung tissue damage", "DISEASE", 421, 439], ["ARDS", "DISEASE", 448, 452], ["sepsis", "DISEASE", 466, 472], ["M1", "CELL", 26, 28], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 80, 89], ["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["macrophage", "CELL", 138, 148], ["neutrophils", "CELL", 196, 207], ["alveolae", "CELL", 213, 221], ["DAMPS", "GENE_OR_GENE_PRODUCT", 285, 290], ["ROS", "SIMPLE_CHEMICAL", 306, 309], ["epithelial cells", "CELL", 322, 338], ["neutrophils", "CELL", 340, 351], ["alveolar macrophages", "CELL", 356, 376], ["lung tissue", "TISSUE", 421, 432], ["TNF", "PROTEIN", 80, 83], ["activated neutrophils", "CELL_TYPE", 186, 207], ["DAMPS", "PROTEIN", 285, 290], ["cytokines", "PROTEIN", 292, 301], ["epithelial cells", "CELL_TYPE", 322, 338], ["neutrophils", "CELL_TYPE", 340, 351], ["alveolar macrophages", "CELL_TYPE", 356, 376], ["Increased polarisation of M1 polarisation", "PROBLEM", 0, 41], ["TNF", "TEST", 80, 83], ["alpha", "TEST", 84, 89], ["IL", "TEST", 104, 106], ["impaired macrophage efferocytosis", "PROBLEM", 129, 162], ["activated neutrophils into alveolae", "PROBLEM", 186, 221], ["interstitial tissueClearly", "PROBLEM", 226, 252], ["cytokines and ROS", "TEST", 292, 309], ["epithelial cells", "TEST", 322, 338], ["neutrophils", "TEST", 340, 351], ["alveolar macrophages", "PROBLEM", 356, 376], ["high levels of inflammation", "PROBLEM", 389, 416], ["lung tissue damage", "PROBLEM", 421, 439], ["ARDS", "PROBLEM", 448, 452], ["sepsis", "PROBLEM", 466, 472], ["COVID", "TEST", 477, 482], ["polarisation", "OBSERVATION_MODIFIER", 10, 22], ["M1 polarisation", "OBSERVATION", 26, 41], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["impaired", "OBSERVATION_MODIFIER", 129, 137], ["macrophage efferocytosis", "OBSERVATION", 138, 162], ["interstitial", "ANATOMY_MODIFIER", 226, 238], ["increasing", "OBSERVATION_MODIFIER", 256, 266], ["epithelial cells", "OBSERVATION", 322, 338], ["alveolar macrophages", "OBSERVATION", 356, 376], ["inflammation", "OBSERVATION", 404, 416], ["lung", "ANATOMY", 421, 425], ["tissue", "OBSERVATION", 426, 432], ["ARDS", "OBSERVATION", 448, 452], ["sepsis", "OBSERVATION", 466, 472]]], ["This theme will continue to be explored in the following section which focuses on the interplay between DAMPS, TLRs, NOD-like receptors (NLRs), PIC and ROS and various forms of necrotic cell death in the development of a cytokine storm.", [["cell", "ANATOMY", 186, 190], ["necrotic", "DISEASE", 177, 185], ["death", "DISEASE", 191, 196], ["DAMPS", "GENE_OR_GENE_PRODUCT", 104, 109], ["TLRs", "GENE_OR_GENE_PRODUCT", 111, 115], ["NOD-like receptors", "GENE_OR_GENE_PRODUCT", 117, 135], ["NLRs", "GENE_OR_GENE_PRODUCT", 137, 141], ["PIC", "GENE_OR_GENE_PRODUCT", 144, 147], ["ROS", "SIMPLE_CHEMICAL", 152, 155], ["necrotic cell", "CELL", 177, 190], ["DAMPS", "PROTEIN", 104, 109], ["TLRs", "PROTEIN", 111, 115], ["NOD-like receptors", "PROTEIN", 117, 135], ["NLRs", "PROTEIN", 137, 141], ["PIC", "PROTEIN", 144, 147], ["cytokine", "PROTEIN", 221, 229], ["TLRs", "TREATMENT", 111, 115], ["PIC", "PROBLEM", 144, 147], ["necrotic cell death", "PROBLEM", 177, 196], ["a cytokine storm", "PROBLEM", 219, 235], ["necrotic cell death", "OBSERVATION", 177, 196], ["cytokine storm", "OBSERVATION", 221, 235]]], ["The interplay between DAMPS and pattern recognition receptors plays a pivotal role in this process.The development of the cytokine storm and irreversible tissue damage ::: The recruitment of activated neutrophils into alveolae and interstitial tissueHMGM1, often described as the prototypical DAMP, may contribute to the development of acute or chronic lung injury by activating TLR-4, TLR-2 and RAGE receptors resulting in the activation of MAP Kinases and ERK, and culminating in the nuclear translocation of NF-kB resulting in increased production of PICs and ROS [[235], [236], [237], [238]].", [["tissue", "ANATOMY", 154, 160], ["neutrophils", "ANATOMY", 201, 212], ["alveolae", "ANATOMY", 218, 226], ["interstitial tissueHMGM1", "ANATOMY", 231, 255], ["lung", "ANATOMY", 353, 357], ["nuclear", "ANATOMY", 486, 493], ["tissue damage", "DISEASE", 154, 167], ["lung injury", "DISEASE", 353, 364], ["ROS", "CHEMICAL", 563, 566], ["DAMPS", "GENE_OR_GENE_PRODUCT", 22, 27], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 32, 61], ["tissue", "TISSUE", 154, 160], ["neutrophils", "CELL", 201, 212], ["alveolae", "CELL", 218, 226], ["interstitial tissueHMGM1", "TISSUE", 231, 255], ["DAMP", "GENE_OR_GENE_PRODUCT", 293, 297], ["lung", "ORGAN", 353, 357], ["TLR-4", "GENE_OR_GENE_PRODUCT", 379, 384], ["TLR-2", "GENE_OR_GENE_PRODUCT", 386, 391], ["RAGE", "GENE_OR_GENE_PRODUCT", 396, 400], ["MAP Kinases", "GENE_OR_GENE_PRODUCT", 442, 453], ["ERK", "GENE_OR_GENE_PRODUCT", 458, 461], ["nuclear", "CELLULAR_COMPONENT", 486, 493], ["NF-kB", "GENE_OR_GENE_PRODUCT", 511, 516], ["ROS", "SIMPLE_CHEMICAL", 563, 566], ["DAMPS", "PROTEIN", 22, 27], ["pattern recognition receptors", "PROTEIN", 32, 61], ["cytokine", "PROTEIN", 122, 130], ["activated neutrophils", "CELL_TYPE", 191, 212], ["alveolae", "CELL_TYPE", 218, 226], ["DAMP", "PROTEIN", 293, 297], ["TLR-4", "PROTEIN", 379, 384], ["TLR-2 and RAGE receptors", "PROTEIN", 386, 410], ["MAP Kinases", "PROTEIN", 442, 453], ["ERK", "PROTEIN", 458, 461], ["NF-kB", "PROTEIN", 511, 516], ["PICs", "PROTEIN", 554, 558], ["DAMPS", "TREATMENT", 22, 27], ["the cytokine storm", "PROBLEM", 118, 136], ["irreversible tissue damage", "PROBLEM", 141, 167], ["interstitial tissueHMGM1", "PROBLEM", 231, 255], ["the prototypical DAMP", "PROBLEM", 276, 297], ["acute or chronic lung injury", "PROBLEM", 336, 364], ["activating TLR", "TEST", 368, 382], ["TLR", "TEST", 386, 389], ["MAP Kinases", "TEST", 442, 453], ["ERK", "TEST", 458, 461], ["increased production of PICs", "PROBLEM", 530, 558], ["cytokine storm", "OBSERVATION", 122, 136], ["irreversible tissue damage", "OBSERVATION", 141, 167], ["interstitial", "ANATOMY_MODIFIER", 231, 243], ["acute", "OBSERVATION_MODIFIER", 336, 341], ["chronic", "OBSERVATION_MODIFIER", 345, 352], ["lung", "ANATOMY", 353, 357], ["injury", "OBSERVATION", 358, 364], ["increased", "OBSERVATION_MODIFIER", 530, 539], ["production", "OBSERVATION_MODIFIER", 540, 550], ["PICs", "OBSERVATION_MODIFIER", 554, 558]]], ["Increased levels of PICs in turn induce the release of HMBG1 from immune and epithelial cells and directly cause a self-amplifying cascade of inflammation, oxidative stress and lung tissue damage [[239], [240], [241]]; (reviewed by [242]).", [["epithelial cells", "ANATOMY", 77, 93], ["lung tissue", "ANATOMY", 177, 188], ["inflammation", "DISEASE", 142, 154], ["lung tissue damage", "DISEASE", 177, 195], ["PICs", "GENE_OR_GENE_PRODUCT", 20, 24], ["HMBG1", "GENE_OR_GENE_PRODUCT", 55, 60], ["immune", "CELL", 66, 72], ["epithelial cells", "CELL", 77, 93], ["lung tissue", "TISSUE", 177, 188], ["PICs", "PROTEIN", 20, 24], ["HMBG1", "PROTEIN", 55, 60], ["immune and epithelial cells", "CELL_TYPE", 66, 93], ["Increased levels of PICs", "PROBLEM", 0, 24], ["epithelial cells", "PROBLEM", 77, 93], ["inflammation", "PROBLEM", 142, 154], ["oxidative stress and lung tissue damage", "PROBLEM", 156, 195], ["PICs", "OBSERVATION_MODIFIER", 20, 24], ["epithelial cells", "OBSERVATION", 77, 93], ["inflammation", "OBSERVATION", 142, 154], ["lung", "ANATOMY", 177, 181]]], ["This process is likely central to the development of chronic, escalating inflammation and tissue damage in many illnesses such as multiple sclerosis, rheumatoid arthritis and major depression and has been described as the Toll-like Receptor Radical Cycle [243].The development of the cytokine storm and irreversible tissue damage ::: The recruitment of activated neutrophils into alveolae and interstitial tissueIn the context of ARDS, the weight of evidence suggests that excessive PIC and ROS damage to cellular proteins and DNA also results in massively increased intracellular mtROS production and the subsequent activation of the NLPR 3 inflammasome [244,245].", [["tissue", "ANATOMY", 90, 96], ["tissue", "ANATOMY", 316, 322], ["neutrophils", "ANATOMY", 363, 374], ["alveolae", "ANATOMY", 380, 388], ["interstitial tissueIn", "ANATOMY", 393, 414], ["cellular", "ANATOMY", 505, 513], ["intracellular", "ANATOMY", 567, 580], ["inflammation", "DISEASE", 73, 85], ["tissue damage", "DISEASE", 90, 103], ["multiple sclerosis", "DISEASE", 130, 148], ["rheumatoid arthritis", "DISEASE", 150, 170], ["major depression", "DISEASE", 175, 191], ["tissue damage", "DISEASE", 316, 329], ["ARDS", "DISEASE", 430, 434], ["ROS", "CHEMICAL", 491, 494], ["PIC", "CHEMICAL", 483, 486], ["tissue", "TISSUE", 90, 96], ["tissue", "TISSUE", 316, 322], ["neutrophils", "CELL", 363, 374], ["alveolae", "CELL", 380, 388], ["interstitial tissueIn", "TISSUE", 393, 414], ["PIC", "GENE_OR_GENE_PRODUCT", 483, 486], ["ROS", "SIMPLE_CHEMICAL", 491, 494], ["cellular", "CELL", 505, 513], ["DNA", "CELLULAR_COMPONENT", 527, 530], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 567, 580], ["mtROS", "GENE_OR_GENE_PRODUCT", 581, 586], ["NLPR 3", "GENE_OR_GENE_PRODUCT", 635, 641], ["Toll", "PROTEIN", 222, 226], ["cytokine", "PROTEIN", 284, 292], ["activated neutrophils", "CELL_TYPE", 353, 374], ["alveolae", "CELL_TYPE", 380, 388], ["cellular proteins", "PROTEIN", 505, 522], ["mtROS", "PROTEIN", 581, 586], ["NLPR 3", "PROTEIN", 635, 641], ["chronic, escalating inflammation", "PROBLEM", 53, 85], ["tissue damage", "PROBLEM", 90, 103], ["many illnesses", "PROBLEM", 107, 121], ["multiple sclerosis", "PROBLEM", 130, 148], ["rheumatoid arthritis", "PROBLEM", 150, 170], ["major depression", "PROBLEM", 175, 191], ["the cytokine storm", "PROBLEM", 280, 298], ["irreversible tissue damage", "PROBLEM", 303, 329], ["activated neutrophils into alveolae", "PROBLEM", 353, 388], ["interstitial tissueIn", "PROBLEM", 393, 414], ["ARDS", "PROBLEM", 430, 434], ["excessive PIC", "PROBLEM", 473, 486], ["ROS damage", "PROBLEM", 491, 501], ["cellular proteins", "TEST", 505, 522], ["massively increased intracellular mtROS production", "PROBLEM", 547, 597], ["is likely", "UNCERTAINTY", 13, 22], ["central", "OBSERVATION_MODIFIER", 23, 30], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["escalating", "OBSERVATION_MODIFIER", 62, 72], ["inflammation", "OBSERVATION", 73, 85], ["tissue", "OBSERVATION_MODIFIER", 90, 96], ["damage", "OBSERVATION_MODIFIER", 97, 103], ["multiple", "OBSERVATION_MODIFIER", 130, 138], ["sclerosis", "OBSERVATION", 139, 148], ["rheumatoid arthritis", "OBSERVATION", 150, 170], ["cytokine storm", "OBSERVATION", 284, 298], ["irreversible tissue damage", "OBSERVATION", 303, 329], ["recruitment", "OBSERVATION_MODIFIER", 338, 349], ["interstitial", "ANATOMY_MODIFIER", 393, 405], ["ARDS", "OBSERVATION", 430, 434], ["excessive", "OBSERVATION_MODIFIER", 473, 482], ["massively", "OBSERVATION_MODIFIER", 547, 556], ["increased", "OBSERVATION_MODIFIER", 557, 566], ["intracellular mtROS", "OBSERVATION", 567, 586]]], ["This is an important point as inflammasome activation and the release of IL-1 and IL-18 appear to make a significant contribution to the development and progression of ARDS in the later stages of disease and high levels of the latter cytokine is associated with an extremely poor prognosis [[246], [247], [248]].", [["ARDS", "DISEASE", 168, 172], ["IL-1", "GENE_OR_GENE_PRODUCT", 73, 77], ["IL-18", "GENE_OR_GENE_PRODUCT", 82, 87], ["IL-1 and IL-18", "PROTEIN", 73, 87], ["cytokine", "PROTEIN", 234, 242], ["the release of IL", "TREATMENT", 58, 75], ["IL", "TREATMENT", 82, 84], ["ARDS", "PROBLEM", 168, 172], ["disease", "PROBLEM", 196, 203], ["an extremely poor prognosis", "PROBLEM", 262, 289], ["progression", "OBSERVATION_MODIFIER", 153, 164], ["ARDS", "OBSERVATION", 168, 172], ["high levels", "OBSERVATION_MODIFIER", 208, 219]]], ["This is perhaps unsurprising given data highlighting the indispensable role of NLRP-3 activation in the progression of ARDS [247] and sepsis [249].", [["ARDS", "DISEASE", 119, 123], ["sepsis", "DISEASE", 134, 140], ["NLRP-3", "GENE_OR_GENE_PRODUCT", 79, 85], ["NLRP-3", "PROTEIN", 79, 85], ["ARDS", "PROBLEM", 119, 123], ["sepsis", "PROBLEM", 134, 140], ["progression", "OBSERVATION_MODIFIER", 104, 115], ["ARDS", "OBSERVATION", 119, 123]]], ["In addition information gleaned from animal studies suggests that the inhibition of this inflammasome is associated with increased rates of survival [250,251] (reviewed by [252]).", [["animal studies", "TEST", 37, 51], ["this inflammasome", "PROBLEM", 84, 101], ["increased rates of survival", "PROBLEM", 121, 148]]], ["There would appear to be many elements underpinning the association between increased inflammasome activity and mortality in ARDS patients.", [["ARDS", "DISEASE", 125, 129], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["increased inflammasome activity", "PROBLEM", 76, 107], ["ARDS", "PROBLEM", 125, 129], ["appear to be", "UNCERTAINTY", 12, 24], ["increased", "OBSERVATION_MODIFIER", 76, 85], ["inflammasome activity", "OBSERVATION", 86, 107], ["ARDS", "OBSERVATION", 125, 129]]], ["Perhaps the most important is spirally increasing cell death by pyroptosis and necrosis, most notably in macrophages and epithelial cells [244,245].The role of pyroptosis in the pathophysiology of ARDS ::: The recruitment of activated neutrophils into alveolae and interstitial tissueAs previously discussed, pyroptosis and necroptosis of alveolar epithelial and endothelial cells are major elements in the development and progression of ARDS [[89], [90], [91]].", [["cell", "ANATOMY", 50, 54], ["macrophages", "ANATOMY", 105, 116], ["epithelial cells", "ANATOMY", 121, 137], ["neutrophils", "ANATOMY", 235, 246], ["alveolae", "ANATOMY", 252, 260], ["interstitial tissueAs", "ANATOMY", 265, 286], ["alveolar epithelial", "ANATOMY", 339, 358], ["endothelial cells", "ANATOMY", 363, 380], ["death", "DISEASE", 55, 60], ["pyroptosis", "DISEASE", 64, 74], ["necrosis", "DISEASE", 79, 87], ["pyroptosis", "DISEASE", 160, 170], ["ARDS", "DISEASE", 197, 201], ["ARDS", "DISEASE", 438, 442], ["cell", "CELL", 50, 54], ["macrophages", "CELL", 105, 116], ["epithelial cells", "CELL", 121, 137], ["neutrophils", "CELL", 235, 246], ["alveolae", "CELL", 252, 260], ["interstitial tissueAs", "CANCER", 265, 286], ["alveolar epithelial", "CELL", 339, 358], ["endothelial cells", "CELL", 363, 380], ["macrophages", "CELL_TYPE", 105, 116], ["epithelial cells", "CELL_TYPE", 121, 137], ["activated neutrophils", "CELL_TYPE", 225, 246], ["alveolae", "CELL_TYPE", 252, 260], ["alveolar epithelial and endothelial cells", "CELL_TYPE", 339, 380], ["spirally increasing cell death", "PROBLEM", 30, 60], ["pyroptosis", "PROBLEM", 64, 74], ["necrosis", "PROBLEM", 79, 87], ["epithelial cells", "TEST", 121, 137], ["pyroptosis", "PROBLEM", 160, 170], ["ARDS", "PROBLEM", 197, 201], ["activated neutrophils into alveolae", "PROBLEM", 225, 260], ["interstitial tissueAs", "PROBLEM", 265, 286], ["pyroptosis", "PROBLEM", 309, 319], ["necroptosis", "PROBLEM", 324, 335], ["alveolar epithelial and endothelial cells", "PROBLEM", 339, 380], ["ARDS", "PROBLEM", 438, 442], ["most important", "UNCERTAINTY", 12, 26], ["increasing", "OBSERVATION_MODIFIER", 39, 49], ["cell death", "OBSERVATION", 50, 60], ["pyroptosis", "OBSERVATION", 64, 74], ["necrosis", "OBSERVATION", 79, 87], ["macrophages", "OBSERVATION", 105, 116], ["epithelial cells", "OBSERVATION", 121, 137], ["pyroptosis", "OBSERVATION", 160, 170], ["ARDS", "OBSERVATION", 197, 201], ["recruitment", "OBSERVATION_MODIFIER", 210, 221], ["interstitial tissueAs", "ANATOMY", 265, 286], ["necroptosis", "OBSERVATION_MODIFIER", 324, 335], ["alveolar", "ANATOMY_MODIFIER", 339, 347], ["epithelial", "ANATOMY_MODIFIER", 348, 358], ["endothelial cells", "OBSERVATION", 363, 380], ["progression", "OBSERVATION_MODIFIER", 423, 434], ["ARDS", "OBSERVATION", 438, 442]]], ["There is also evidence to suggest that the pyroptotic death of neutrophils makes an independent contribution to the exacerbation of inflammation in more advanced stages of the condition [203].", [["neutrophils", "ANATOMY", 63, 74], ["death", "DISEASE", 54, 59], ["inflammation", "DISEASE", 132, 144], ["neutrophils", "CELL", 63, 74], ["neutrophils", "CELL_TYPE", 63, 74], ["the pyroptotic death of neutrophils", "PROBLEM", 39, 74], ["the exacerbation of inflammation", "PROBLEM", 112, 144], ["evidence to suggest", "UNCERTAINTY", 14, 33], ["inflammation", "OBSERVATION", 132, 144]]], ["However, from the perspective of ARDS related mortality, perhaps the most important element is the pyroptosis of alveolar macrophages [85,[253], [254], [255]].", [["alveolar macrophages", "ANATOMY", 113, 133], ["ARDS", "DISEASE", 33, 37], ["alveolar macrophages", "CELL", 113, 133], ["alveolar macrophages", "CELL_TYPE", 113, 133], ["ARDS", "PROBLEM", 33, 37], ["the pyroptosis of alveolar macrophages", "PROBLEM", 95, 133], ["ARDS", "OBSERVATION", 33, 37], ["pyroptosis", "OBSERVATION", 99, 109], ["alveolar macrophages", "OBSERVATION", 113, 133]]], ["Indeed, high levels of AM pyroptosis is another marker of mortality in patients with ARDS [256].The role of pyroptosis in the pathophysiology of ARDS ::: The recruitment of activated neutrophils into alveolae and interstitial tissueThere is ample evidence to suggest that excessive loss of AMs as result of death via pyroptosis, or necrosis, plays an important role in the development and acceleration of lung damage by contribution to auto-inflammatory pathways [[257], [258], [259], [260]].", [["neutrophils", "ANATOMY", 183, 194], ["alveolae", "ANATOMY", 200, 208], ["interstitial tissue", "ANATOMY", 213, 232], ["AMs", "ANATOMY", 290, 293], ["lung", "ANATOMY", 405, 409], ["pyroptosis", "DISEASE", 26, 36], ["ARDS", "DISEASE", 85, 89], ["pyroptosis", "DISEASE", 108, 118], ["ARDS", "DISEASE", 145, 149], ["death", "DISEASE", 307, 312], ["pyroptosis", "DISEASE", 317, 327], ["necrosis", "DISEASE", 332, 340], ["lung damage", "DISEASE", 405, 416], ["AM", "GENE_OR_GENE_PRODUCT", 23, 25], ["patients", "ORGANISM", 71, 79], ["neutrophils", "CELL", 183, 194], ["alveolae", "CELL", 200, 208], ["interstitial tissue", "TISSUE", 213, 232], ["AMs", "CELL", 290, 293], ["lung", "ORGAN", 405, 409], ["activated neutrophils", "CELL_TYPE", 173, 194], ["alveolae", "CELL_TYPE", 200, 208], ["AMs", "CELL_TYPE", 290, 293], ["patients", "SPECIES", 71, 79], ["AM pyroptosis", "PROBLEM", 23, 36], ["ARDS", "PROBLEM", 85, 89], ["pyroptosis", "PROBLEM", 108, 118], ["ARDS", "PROBLEM", 145, 149], ["activated neutrophils into alveolae", "PROBLEM", 173, 208], ["interstitial tissue", "PROBLEM", 213, 232], ["excessive loss of AMs", "PROBLEM", 272, 293], ["death", "PROBLEM", 307, 312], ["pyroptosis", "PROBLEM", 317, 327], ["necrosis", "PROBLEM", 332, 340], ["lung damage", "PROBLEM", 405, 416], ["high", "OBSERVATION_MODIFIER", 8, 12], ["pyroptosis", "OBSERVATION", 108, 118], ["ARDS", "OBSERVATION", 145, 149], ["activated neutrophils", "OBSERVATION", 173, 194], ["interstitial tissue", "ANATOMY", 213, 232], ["ample evidence to suggest", "UNCERTAINTY", 241, 266], ["excessive", "OBSERVATION_MODIFIER", 272, 281], ["pyroptosis", "OBSERVATION", 317, 327], ["necrosis", "OBSERVATION", 332, 340], ["lung", "ANATOMY", 405, 409], ["damage", "OBSERVATION", 410, 416]]], ["Firstly, the loss of resident AMs results in a repopulation of AMs derived from highly inflammatory peripheral monocytes which display grossly reduced phagocytic capacity, increased production of inflammatory mediators and susceptibility to pyroptosis and other forms of cell death [261,262] (reviewed by [263]).", [["AMs", "ANATOMY", 30, 33], ["AMs", "ANATOMY", 63, 66], ["peripheral monocytes", "ANATOMY", 100, 120], ["cell", "ANATOMY", 271, 275], ["pyroptosis", "DISEASE", 241, 251], ["death", "DISEASE", 276, 281], ["AMs", "CELL", 30, 33], ["AMs", "CELL", 63, 66], ["peripheral monocytes", "CELL", 100, 120], ["cell", "CELL", 271, 275], ["resident AMs", "CELL_TYPE", 21, 33], ["AMs", "CELL_TYPE", 63, 66], ["inflammatory peripheral monocytes", "CELL_TYPE", 87, 120], ["inflammatory mediators", "PROTEIN", 196, 218], ["AMs", "PROBLEM", 63, 66], ["highly inflammatory peripheral monocytes", "PROBLEM", 80, 120], ["grossly reduced phagocytic capacity", "PROBLEM", 135, 170], ["inflammatory mediators", "PROBLEM", 196, 218], ["pyroptosis", "PROBLEM", 241, 251], ["cell death", "PROBLEM", 271, 281], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99], ["peripheral monocytes", "OBSERVATION", 100, 120], ["grossly", "OBSERVATION_MODIFIER", 135, 142], ["reduced", "OBSERVATION_MODIFIER", 143, 150], ["phagocytic capacity", "OBSERVATION", 151, 170], ["increased", "OBSERVATION_MODIFIER", 172, 181], ["production", "OBSERVATION_MODIFIER", 182, 192], ["inflammatory", "OBSERVATION_MODIFIER", 196, 208], ["pyroptosis", "OBSERVATION", 241, 251]]], ["Secondly, accelerated pyroptosis of the AM population, results in ever increasing levels of DAMPS, PIC and ROS in turn resulting in spirally increasing tissue damage [259,264,265]; (reviewed by [85]).", [["tissue", "ANATOMY", 152, 158], ["ROS", "CHEMICAL", 107, 110], ["PIC", "CHEMICAL", 99, 102], ["DAMPS", "GENE_OR_GENE_PRODUCT", 92, 97], ["PIC", "SIMPLE_CHEMICAL", 99, 102], ["ROS", "SIMPLE_CHEMICAL", 107, 110], ["tissue", "TISSUE", 152, 158], ["DAMPS", "PROTEIN", 92, 97], ["accelerated pyroptosis", "PROBLEM", 10, 32], ["increasing levels of DAMPS", "PROBLEM", 71, 97], ["PIC", "TREATMENT", 99, 102], ["spirally increasing tissue damage", "PROBLEM", 132, 165], ["accelerated", "OBSERVATION_MODIFIER", 10, 21], ["pyroptosis", "OBSERVATION", 22, 32], ["DAMPS", "OBSERVATION", 92, 97]]], ["The weight of evidence suggests that HMBG1 may well be the dominant driver of the inflammatory responses following pyroptotic cell death, as inhibition of this molecule significantly decreases such responses [266].", [["cell", "ANATOMY", 126, 130], ["HMBG1", "CHEMICAL", 37, 42], ["death", "DISEASE", 131, 136], ["HMBG1", "GENE_OR_GENE_PRODUCT", 37, 42], ["cell", "CELL", 126, 130], ["HMBG1", "PROTEIN", 37, 42], ["The weight", "TEST", 0, 10], ["HMBG1", "PROBLEM", 37, 42], ["the inflammatory responses", "PROBLEM", 78, 104], ["pyroptotic cell death", "PROBLEM", 115, 136], ["this molecule", "PROBLEM", 155, 168], ["inflammatory", "OBSERVATION_MODIFIER", 82, 94]]], ["Given this and the other information discussed above, it seems reasonable to conclude that interventions capable of decreasing the activity and or production of this heat shock protein may well have importance in the prevention and potentially the resolution of ARDS.The advent of necroinflammation in the pathophysiology of ARDS ::: The recruitment of activated neutrophils into alveolae and interstitial tissueThere is now accumulating evidence to suggest that the escalating increases in levels of IL-6, TNF-alpha, nitric oxide (NO) and ROS secreted by macrophages [[92], [93], [94]] also make a significant contributions to mortality by stimulating widespread cellular RIPK mediated necroptosis [89,94].", [["neutrophils", "ANATOMY", 363, 374], ["alveolae", "ANATOMY", 380, 388], ["interstitial tissue", "ANATOMY", 393, 412], ["macrophages", "ANATOMY", 556, 567], ["cellular", "ANATOMY", 664, 672], ["shock", "DISEASE", 171, 176], ["ARDS", "DISEASE", 262, 266], ["ARDS", "DISEASE", 325, 329], ["nitric oxide", "CHEMICAL", 518, 530], ["NO", "CHEMICAL", 532, 534], ["ROS", "CHEMICAL", 540, 543], ["nitric oxide", "CHEMICAL", 518, 530], ["NO", "CHEMICAL", 532, 534], ["heat shock protein", "GENE_OR_GENE_PRODUCT", 166, 184], ["neutrophils", "CELL", 363, 374], ["alveolae", "CELL", 380, 388], ["interstitial tissue", "TISSUE", 393, 412], ["IL-6", "GENE_OR_GENE_PRODUCT", 501, 505], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 507, 516], ["nitric oxide", "SIMPLE_CHEMICAL", 518, 530], ["NO", "SIMPLE_CHEMICAL", 532, 534], ["ROS", "SIMPLE_CHEMICAL", 540, 543], ["macrophages", "CELL", 556, 567], ["cellular", "CELL", 664, 672], ["RIPK", "GENE_OR_GENE_PRODUCT", 673, 677], ["heat shock protein", "PROTEIN", 166, 184], ["activated neutrophils", "CELL_TYPE", 353, 374], ["alveolae", "CELL_TYPE", 380, 388], ["IL-6", "PROTEIN", 501, 505], ["TNF-alpha", "PROTEIN", 507, 516], ["macrophages", "CELL_TYPE", 556, 567], ["RIPK", "PROTEIN", 673, 677], ["interventions", "TREATMENT", 91, 104], ["this heat shock protein", "PROBLEM", 161, 184], ["ARDS", "PROBLEM", 262, 266], ["necroinflammation", "PROBLEM", 281, 298], ["ARDS", "PROBLEM", 325, 329], ["activated neutrophils into alveolae", "PROBLEM", 353, 388], ["interstitial tissue", "PROBLEM", 393, 412], ["the escalating increases", "PROBLEM", 463, 487], ["IL", "TEST", 501, 503], ["TNF", "TEST", 507, 510], ["nitric oxide", "TREATMENT", 518, 530], ["stimulating widespread cellular RIPK mediated necroptosis", "PROBLEM", 641, 698], ["ARDS", "OBSERVATION", 262, 266], ["necroinflammation", "OBSERVATION", 281, 298], ["ARDS", "OBSERVATION", 325, 329], ["activated neutrophils", "OBSERVATION", 353, 374], ["interstitial tissue", "ANATOMY", 393, 412], ["evidence to suggest", "UNCERTAINTY", 438, 457], ["escalating", "OBSERVATION_MODIFIER", 467, 477], ["increases", "OBSERVATION_MODIFIER", 478, 487]]], ["This form of cell death is associated with massive increases in levels of HGMB1, mtDNA, PICs, chemokines and ROS with ever amplifying levels of tissue damage, described as necroinflammation [267,268], leading to irreversible lung failure [269].", [["cell", "ANATOMY", 13, 17], ["tissue", "ANATOMY", 144, 150], ["lung", "ANATOMY", 225, 229], ["death", "DISEASE", 18, 23], ["tissue damage", "DISEASE", 144, 157], ["lung failure", "DISEASE", 225, 237], ["cell", "CELL", 13, 17], ["HGMB1", "GENE_OR_GENE_PRODUCT", 74, 79], ["mtDNA", "CELLULAR_COMPONENT", 81, 86], ["PICs", "GENE_OR_GENE_PRODUCT", 88, 92], ["ROS", "SIMPLE_CHEMICAL", 109, 112], ["tissue", "TISSUE", 144, 150], ["lung", "ORGAN", 225, 229], ["HGMB1", "PROTEIN", 74, 79], ["PICs", "PROTEIN", 88, 92], ["chemokines", "PROTEIN", 94, 104], ["cell death", "PROBLEM", 13, 23], ["massive increases in levels of HGMB1", "PROBLEM", 43, 79], ["mtDNA", "PROBLEM", 81, 86], ["PICs", "TREATMENT", 88, 92], ["tissue damage", "PROBLEM", 144, 157], ["necroinflammation", "PROBLEM", 172, 189], ["irreversible lung failure", "PROBLEM", 212, 237], ["cell death", "OBSERVATION", 13, 23], ["massive", "OBSERVATION_MODIFIER", 43, 50], ["increases", "OBSERVATION_MODIFIER", 51, 60], ["irreversible", "OBSERVATION_MODIFIER", 212, 224], ["lung", "ANATOMY", 225, 229], ["failure", "OBSERVATION", 230, 237]]], ["Necroptosis is predictive of non-resolving ARDS and mortality in patients on mechanical ventilation [89,94].", [["Necroptosis", "DISEASE", 0, 11], ["ARDS", "DISEASE", 43, 47], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["Necroptosis", "PROBLEM", 0, 11], ["non-resolving ARDS", "PROBLEM", 29, 47], ["mechanical ventilation", "TREATMENT", 77, 99], ["non-resolving", "OBSERVATION_MODIFIER", 29, 42], ["ARDS", "OBSERVATION", 43, 47]]], ["The pathological consequences of programmed cell death are difficult to overstate as studies have reported a causative association between the advent of widespread RIP Kinase-dependent necroptosis and the development of multiple organ failure and death in systemic inflammatory response syndrome and sepsis [270].", [["cell", "ANATOMY", 44, 48], ["organ", "ANATOMY", 229, 234], ["death", "DISEASE", 49, 54], ["necroptosis", "DISEASE", 185, 196], ["multiple organ failure", "DISEASE", 220, 242], ["death", "DISEASE", 247, 252], ["systemic inflammatory response syndrome", "DISEASE", 256, 295], ["sepsis", "DISEASE", 300, 306], ["cell", "CELL", 44, 48], ["RIP Kinase", "GENE_OR_GENE_PRODUCT", 164, 174], ["organ", "ORGAN", 229, 234], ["RIP Kinase", "PROTEIN", 164, 174], ["programmed cell death", "PROBLEM", 33, 54], ["widespread RIP Kinase", "PROBLEM", 153, 174], ["dependent necroptosis", "PROBLEM", 175, 196], ["multiple organ failure", "PROBLEM", 220, 242], ["death", "PROBLEM", 247, 252], ["systemic inflammatory response syndrome", "PROBLEM", 256, 295], ["sepsis", "PROBLEM", 300, 306], ["programmed cell death", "OBSERVATION", 33, 54], ["widespread", "OBSERVATION_MODIFIER", 153, 163], ["RIP Kinase", "OBSERVATION", 164, 174], ["dependent", "OBSERVATION_MODIFIER", 175, 184], ["necroptosis", "OBSERVATION", 185, 196], ["multiple", "OBSERVATION_MODIFIER", 220, 228], ["organ", "ANATOMY", 229, 234], ["failure", "OBSERVATION", 235, 242], ["systemic", "OBSERVATION_MODIFIER", 256, 264], ["inflammatory response syndrome", "OBSERVATION", 265, 295], ["sepsis", "OBSERVATION", 300, 306]]], ["Elevated levels of RIP-3 in the blood is an almost invariant marker of a cytokine storm and is predictive of multiple organ failure and death.", [["blood", "ANATOMY", 32, 37], ["organ", "ANATOMY", 118, 123], ["organ failure", "DISEASE", 118, 131], ["death", "DISEASE", 136, 141], ["RIP-3", "GENE_OR_GENE_PRODUCT", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["organ", "ORGAN", 118, 123], ["RIP-3", "PROTEIN", 19, 24], ["cytokine", "PROTEIN", 73, 81], ["Elevated levels of RIP", "PROBLEM", 0, 22], ["a cytokine storm", "PROBLEM", 71, 87], ["multiple organ failure", "PROBLEM", 109, 131], ["death", "PROBLEM", 136, 141], ["levels", "OBSERVATION_MODIFIER", 9, 15], ["RIP", "OBSERVATION_MODIFIER", 19, 22], ["blood", "ANATOMY", 32, 37], ["almost", "OBSERVATION_MODIFIER", 44, 50], ["invariant", "OBSERVATION_MODIFIER", 51, 60], ["cytokine storm", "OBSERVATION", 73, 87], ["multiple", "OBSERVATION_MODIFIER", 109, 117], ["organ", "ANATOMY", 118, 123], ["failure", "OBSERVATION", 124, 131]]], ["The mechanisms underpinning the development of necroptosis are relatively complex and readers interested in the biochemistry involved are referred to comprehensive reviews by [274,275] and the matter will not be considered further here.", [["necroptosis", "DISEASE", 47, 58], ["necroptosis", "PROBLEM", 47, 58], ["necroptosis", "OBSERVATION", 47, 58]]], ["However of note a recent study has revealed the existence of a positive feedback loop between pyroptosis and necroptosis which leads to even higher levels of tissue damage and dysfunction [276].", [["tissue", "ANATOMY", 158, 164], ["pyroptosis", "DISEASE", 94, 104], ["tissue damage", "DISEASE", 158, 171], ["tissue", "TISSUE", 158, 164], ["a recent study", "TEST", 16, 30], ["a positive feedback loop between pyroptosis", "PROBLEM", 61, 104], ["necroptosis", "PROBLEM", 109, 120], ["tissue damage", "PROBLEM", 158, 171], ["dysfunction", "PROBLEM", 176, 187], ["positive", "OBSERVATION_MODIFIER", 63, 71], ["feedback loop", "OBSERVATION", 72, 85], ["pyroptosis", "OBSERVATION", 94, 104], ["necroptosis", "OBSERVATION", 109, 120], ["tissue", "ANATOMY", 158, 164], ["damage", "OBSERVATION", 165, 171]]], ["This data further emphasises the importance of NLRP3 activation in the pathophysiology of ARDS and highlights the widespread inhibition of this inflammasome as a highly desirable therapeutic target.The role of T cells in the pathophysiology of ARDSAn environment of severe chronic inflammation and oxidative stress seen in patients in advanced ARDS can lead to lymphopenia, compromised leucocyte function and a high Th17:regulatory T cell (T reg) ratio [[277], [278], [279], [280], [281], [282]] contributing to the pathophysiology of the condition.The role of T cells in the pathophysiology of ARDST regs play an important role in the prevention and resolution of ARDS via several routes such as promoting neutrophil clearance, inhibiting the effects of IL-6 and promoting the M2 polarisation of alveolar macrophages [283].", [["T cells", "ANATOMY", 210, 217], ["leucocyte", "ANATOMY", 386, 395], ["T cell", "ANATOMY", 432, 438], ["T cells", "ANATOMY", 561, 568], ["ARDST regs", "ANATOMY", 595, 605], ["neutrophil", "ANATOMY", 707, 717], ["alveolar macrophages", "ANATOMY", 797, 817], ["ARDS", "DISEASE", 90, 94], ["inflammation", "DISEASE", 281, 293], ["ARDS", "DISEASE", 344, 348], ["lymphopenia", "DISEASE", 361, 372], ["ARDS", "DISEASE", 665, 669], ["NLRP3", "GENE_OR_GENE_PRODUCT", 47, 52], ["T cells", "CELL", 210, 217], ["patients", "ORGANISM", 323, 331], ["leucocyte", "CELL", 386, 395], ["T cell", "CELL", 432, 438], ["T reg", "GENE_OR_GENE_PRODUCT", 440, 445], ["T cells", "CELL", 561, 568], ["ARDST regs", "CELL", 595, 605], ["neutrophil", "CELL", 707, 717], ["IL-6", "GENE_OR_GENE_PRODUCT", 755, 759], ["M2", "GENE_OR_GENE_PRODUCT", 778, 780], ["alveolar macrophages", "CELL", 797, 817], ["NLRP3", "PROTEIN", 47, 52], ["T cells", "CELL_TYPE", 210, 217], ["Th17:regulatory T cell", "CELL_TYPE", 416, 438], ["T reg", "CELL_TYPE", 440, 445], ["T cells", "CELL_TYPE", 561, 568], ["IL-6", "PROTEIN", 755, 759], ["alveolar macrophages", "CELL_TYPE", 797, 817], ["patients", "SPECIES", 323, 331], ["NLRP3 activation", "TREATMENT", 47, 63], ["ARDS", "PROBLEM", 90, 94], ["this inflammasome", "PROBLEM", 139, 156], ["severe chronic inflammation", "PROBLEM", 266, 293], ["oxidative stress", "PROBLEM", 298, 314], ["advanced ARDS", "PROBLEM", 335, 348], ["lymphopenia", "PROBLEM", 361, 372], ["compromised leucocyte function", "PROBLEM", 374, 404], ["ARDS", "PROBLEM", 665, 669], ["promoting neutrophil clearance", "TREATMENT", 697, 727], ["IL", "TREATMENT", 755, 757], ["alveolar macrophages", "PROBLEM", 797, 817], ["ARDS", "OBSERVATION", 90, 94], ["severe", "OBSERVATION_MODIFIER", 266, 272], ["chronic", "OBSERVATION_MODIFIER", 273, 280], ["inflammation", "OBSERVATION", 281, 293], ["lymphopenia", "OBSERVATION", 361, 372], ["ARDS", "OBSERVATION", 665, 669], ["M2", "OBSERVATION_MODIFIER", 778, 780], ["alveolar macrophages", "OBSERVATION", 797, 817]]], ["T regs also act as a cytokine sink and ameliorates otherwise uncontrolled inflammation via the secretion of IL-10 and TGF beta with a resultant downregulation in the production of TNF-alpha and IL-1 beta by resident and infiltrating macrophages [283,284].The role of T cells in the pathophysiology of ARDSTH17 polarised T cells also play a pathological role in the development and exacerbation of ARDS [284].", [["infiltrating macrophages", "ANATOMY", 220, 244], ["T cells", "ANATOMY", 267, 274], ["ARDSTH17 polarised T cells", "ANATOMY", 301, 327], ["inflammation", "DISEASE", 74, 86], ["ARDS", "DISEASE", 397, 401], ["T regs", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-10", "GENE_OR_GENE_PRODUCT", 108, 113], ["TGF beta", "GENE_OR_GENE_PRODUCT", 118, 126], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 180, 189], ["IL-1 beta", "GENE_OR_GENE_PRODUCT", 194, 203], ["macrophages", "CELL", 233, 244], ["T cells", "CELL", 267, 274], ["ARDSTH17 polarised T cells", "CELL", 301, 327], ["IL-10", "PROTEIN", 108, 113], ["TGF beta", "PROTEIN", 118, 126], ["TNF", "PROTEIN", 180, 183], ["IL-1 beta", "PROTEIN", 194, 203], ["resident and infiltrating macrophages", "CELL_TYPE", 207, 244], ["T cells", "CELL_TYPE", 267, 274], ["ARDSTH17 polarised T cells", "CELL_LINE", 301, 327], ["a cytokine sink", "PROBLEM", 19, 34], ["uncontrolled inflammation", "PROBLEM", 61, 86], ["the secretion of IL", "TEST", 91, 110], ["a resultant downregulation", "PROBLEM", 132, 158], ["TNF", "TEST", 180, 183], ["alpha and IL", "TREATMENT", 184, 196], ["infiltrating macrophages", "PROBLEM", 220, 244], ["T cells", "PROBLEM", 267, 274], ["ARDSTH17 polarised T cells", "PROBLEM", 301, 327], ["ARDS", "PROBLEM", 397, 401], ["uncontrolled", "OBSERVATION_MODIFIER", 61, 73], ["inflammation", "OBSERVATION", 74, 86], ["resultant", "OBSERVATION_MODIFIER", 134, 143], ["downregulation", "OBSERVATION", 144, 158], ["infiltrating macrophages", "OBSERVATION", 220, 244], ["ARDS", "OBSERVATION", 397, 401]]], ["The main mechanism underpinning this association is increased production of IL-17 [66,71,72].", [["IL-17", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL", "PROTEIN", 76, 78], ["increased production of IL", "PROBLEM", 52, 78], ["main", "OBSERVATION_MODIFIER", 4, 8], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["production", "OBSERVATION_MODIFIER", 62, 72]]], ["This is a highly cytotoxic molecule capable of causing significant levels of tissue damage and plays a major role in the recruitment of neutrophils from the periphery [285].", [["tissue", "ANATOMY", 77, 83], ["neutrophils", "ANATOMY", 136, 147], ["tissue damage", "DISEASE", 77, 90], ["tissue", "TISSUE", 77, 83], ["neutrophils", "CELL", 136, 147], ["neutrophils", "CELL_TYPE", 136, 147], ["tissue damage", "PROBLEM", 77, 90], ["highly", "OBSERVATION_MODIFIER", 10, 16], ["cytotoxic molecule", "OBSERVATION", 17, 35], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["levels", "OBSERVATION_MODIFIER", 67, 73], ["of tissue", "OBSERVATION_MODIFIER", 74, 83], ["damage", "OBSERVATION", 84, 90]]], ["High levels of IL-17 is a marker for a poor prognosis in patients with ARDS [285].", [["ARDS", "DISEASE", 71, 75], ["IL-17", "GENE_OR_GENE_PRODUCT", 15, 20], ["patients", "ORGANISM", 57, 65], ["IL-17", "PROTEIN", 15, 20], ["patients", "SPECIES", 57, 65], ["ARDS", "PROBLEM", 71, 75]]], ["The importance of Th17 and T regs in the pathophysiology of ARDS is emphasised by data suggesting that the TH17:T reg ratio is predictive of 28 day mortality in ventilated ARDS patients [285].A suggested therapeutic approach to treatmentMany of the elements involved in the pathophysiology of ARDS are dependent on the chronic or long-term activation of NF-\u03baB.", [["Th17", "ANATOMY", 18, 22], ["T regs", "ANATOMY", 27, 33], ["ARDS", "DISEASE", 60, 64], ["ARDS", "DISEASE", 172, 176], ["ARDS", "DISEASE", 293, 297], ["Th17", "CELL", 18, 22], ["T regs", "GENE_OR_GENE_PRODUCT", 27, 33], ["TH17", "CELL", 107, 111], ["T reg", "GENE_OR_GENE_PRODUCT", 112, 117], ["patients", "ORGANISM", 177, 185], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 354, 358], ["Th17 and T regs", "CELL_TYPE", 18, 33], ["NF-\u03baB.", "PROTEIN", 354, 360], ["patients", "SPECIES", 177, 185], ["Th17 and T regs", "TREATMENT", 18, 33], ["ARDS", "PROBLEM", 60, 64], ["T reg ratio", "TEST", 112, 123], ["therapeutic approach", "TREATMENT", 204, 224], ["treatment", "TREATMENT", 228, 237], ["ARDS", "PROBLEM", 293, 297], ["long-term activation of NF", "TREATMENT", 330, 356], ["ARDS", "OBSERVATION", 60, 64], ["ARDS", "OBSERVATION", 293, 297], ["dependent", "OBSERVATION_MODIFIER", 302, 311], ["chronic", "OBSERVATION_MODIFIER", 319, 326], ["long-term", "OBSERVATION_MODIFIER", 330, 339]]], ["For example there is copious evidence that activated NF-\u03baB plays an important if not indispensable role in the initiation of platelet activation and maintaining such platelets in that state [[286], [287], [288], [289], [290]].", [["platelet", "ANATOMY", 125, 133], ["platelets", "ANATOMY", 166, 175], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 53, 58], ["platelet", "CELL", 125, 133], ["platelets", "CELL", 166, 175], ["NF-\u03baB", "PROTEIN", 53, 58], ["platelets", "CELL_TYPE", 166, 175], ["platelet activation", "TEST", 125, 144], ["such platelets", "TEST", 161, 175], ["copious", "OBSERVATION_MODIFIER", 21, 28]]], ["Activated NF-\u03baB plays an indispensable role in the production, survival, and activation of neutrophils [291,292] and their release of NETs [293,294].", [["neutrophils", "ANATOMY", 91, 102], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 10, 15], ["neutrophils", "CELL", 91, 102], ["NETs", "GENE_OR_GENE_PRODUCT", 134, 138], ["NF-\u03baB", "PROTEIN", 10, 15], ["neutrophils", "CELL_TYPE", 91, 102], ["neutrophils", "TEST", 91, 102]]], ["Chronically upregulated NF-\u03baB is also an essential element enabling the activation of alveolar macrophages [295,296].", [["alveolar macrophages", "ANATOMY", 86, 106], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 24, 29], ["alveolar macrophages", "CELL", 86, 106], ["NF-\u03baB", "PROTEIN", 24, 29], ["alveolar macrophages", "CELL_TYPE", 86, 106], ["Chronically upregulated NF", "PROBLEM", 0, 26], ["alveolar macrophages", "PROBLEM", 86, 106], ["essential element", "OBSERVATION", 41, 58], ["alveolar macrophages", "OBSERVATION", 86, 106]]], ["This is also true of monocyte activation and their subsequent differentiation into macrophages [297,298].", [["monocyte", "ANATOMY", 21, 29], ["macrophages", "ANATOMY", 83, 94], ["monocyte", "CELL", 21, 29], ["macrophages", "CELL", 83, 94], ["macrophages", "CELL_TYPE", 83, 94], ["monocyte activation", "PROBLEM", 21, 40], ["monocyte activation", "OBSERVATION", 21, 40]]], ["Inflammasome activation is also dependent on the upregulation of NF-\u03baB [297,299].", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 65, 70], ["NF-\u03baB", "PROTEIN", 65, 70], ["Inflammasome activation", "PROBLEM", 0, 23], ["dependent", "OBSERVATION_MODIFIER", 32, 41]]], ["Importantly there is an accumulating body of evidence implicating elevated NF-\u03baB in the pathogenesis and progression of ARDS [[300], [301], [302], [303]].A suggested therapeutic approach to treatmentIn addition there is a wealth of evidence to suggest that the maintenance and progression of ARDS also requires the presence of systemic sepsis or at the least excessive levels of systemic inflammation [85,88,304].", [["ARDS", "DISEASE", 120, 124], ["ARDS", "DISEASE", 292, 296], ["sepsis", "DISEASE", 336, 342], ["inflammation", "DISEASE", 388, 400], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 75, 80], ["NF-\u03baB", "PROTEIN", 75, 80], ["elevated NF", "PROBLEM", 66, 77], ["ARDS", "PROBLEM", 120, 124], ["therapeutic approach", "TREATMENT", 166, 186], ["treatment", "TREATMENT", 190, 199], ["ARDS", "PROBLEM", 292, 296], ["systemic sepsis", "PROBLEM", 327, 342], ["systemic inflammation", "PROBLEM", 379, 400], ["accumulating", "OBSERVATION_MODIFIER", 24, 36], ["body", "OBSERVATION_MODIFIER", 37, 41], ["elevated", "OBSERVATION_MODIFIER", 66, 74], ["NF", "OBSERVATION_MODIFIER", 75, 77], ["-\u03baB", "OBSERVATION_MODIFIER", 77, 80], ["progression", "OBSERVATION_MODIFIER", 105, 116], ["ARDS", "OBSERVATION", 120, 124], ["ARDS", "OBSERVATION", 292, 296], ["systemic", "OBSERVATION_MODIFIER", 327, 335], ["sepsis", "OBSERVATION", 336, 342], ["systemic", "OBSERVATION_MODIFIER", 379, 387], ["inflammation", "OBSERVATION", 388, 400]]], ["This is important as there is considerable evidence of sepsis in patients with severe COVID-19 and that chronic activation of NF-\u03baB in the development and progression of systemic sepsis (reviewed by [305]).", [["sepsis", "DISEASE", 55, 61], ["systemic sepsis", "DISEASE", 170, 185], ["COVID-19", "CHEMICAL", 86, 94], ["patients", "ORGANISM", 65, 73], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 126, 131], ["NF-\u03baB", "PROTEIN", 126, 131], ["patients", "SPECIES", 65, 73], ["sepsis", "PROBLEM", 55, 61], ["severe COVID", "PROBLEM", 79, 91], ["chronic activation of NF", "PROBLEM", 104, 128], ["systemic sepsis", "PROBLEM", 170, 185], ["considerable evidence of", "UNCERTAINTY", 30, 54], ["sepsis", "OBSERVATION", 55, 61], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["progression", "OBSERVATION_MODIFIER", 155, 166], ["systemic", "OBSERVATION_MODIFIER", 170, 178], ["sepsis", "OBSERVATION", 179, 185]]], ["Hence the localised suppression of NF-\u03baB would seem to be an attractive option and [306] (reviewed by [109]).Suggestions for therapeutic interventionThe weight of evidence suggests that Zinc (Zn) is a highly effective NF-\u03baB inhibitor in vivo [[307], [308], [309]].", [["Zinc", "CHEMICAL", 186, 190], ["Zn", "CHEMICAL", 192, 194], ["Zinc", "CHEMICAL", 186, 190], ["Zn", "CHEMICAL", 192, 194], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 35, 40], ["Zinc (Zn", "SIMPLE_CHEMICAL", 186, 194], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 218, 223], ["NF-\u03baB", "PROTEIN", 35, 40], ["NF-\u03baB", "PROTEIN", 218, 223], ["the localised suppression of NF", "PROBLEM", 6, 37], ["therapeutic intervention", "TREATMENT", 125, 149], ["Zinc (Zn)", "TREATMENT", 186, 195]]], ["This is of particular interest as several authors have reported grossly depleted Zn levels in patients with severe infections, sepsis and ARDS hence there is a case for Zn supplementation in COVID-19 [[310], [311], [312], [313]].", [["Zn", "CHEMICAL", 81, 83], ["infections", "DISEASE", 115, 125], ["sepsis", "DISEASE", 127, 133], ["ARDS", "DISEASE", 138, 142], ["Zn", "CHEMICAL", 169, 171], ["Zn", "CHEMICAL", 81, 83], ["Zn", "CHEMICAL", 169, 171], ["COVID-19", "CHEMICAL", 191, 199], ["Zn", "SIMPLE_CHEMICAL", 81, 83], ["patients", "ORGANISM", 94, 102], ["Zn", "SIMPLE_CHEMICAL", 169, 171], ["patients", "SPECIES", 94, 102], ["grossly depleted Zn levels", "PROBLEM", 64, 90], ["severe infections", "PROBLEM", 108, 125], ["sepsis", "PROBLEM", 127, 133], ["ARDS", "PROBLEM", 138, 142], ["Zn supplementation", "TREATMENT", 169, 187], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["infections", "OBSERVATION", 115, 125], ["sepsis", "OBSERVATION", 127, 133], ["ARDS", "OBSERVATION", 138, 142]]], ["It is also noteworthy that vitamin C levels are also commonly depleted in patients with sepsis and ARDS [314,315] and several authors have reported downregulation of NF-\u03baB following its administration [316,317].", [["vitamin C", "CHEMICAL", 27, 36], ["sepsis", "DISEASE", 88, 94], ["ARDS", "DISEASE", 99, 103], ["vitamin C", "CHEMICAL", 27, 36], ["vitamin C", "SIMPLE_CHEMICAL", 27, 36], ["patients", "ORGANISM", 74, 82], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 166, 171], ["NF-\u03baB", "PROTEIN", 166, 171], ["patients", "SPECIES", 74, 82], ["vitamin C levels", "TEST", 27, 43], ["sepsis", "PROBLEM", 88, 94], ["ARDS", "PROBLEM", 99, 103], ["downregulation of NF", "PROBLEM", 148, 168], ["sepsis", "OBSERVATION", 88, 94], ["ARDS", "OBSERVATION", 99, 103]]], ["Vitamin D is also severely depleted in many patients with sepsis and ARDS [318,319] and dietary supplementation with this molecule also results in significant inhibition of NF-\u03baB [[320], [321], [322], [323], [324]].", [["Vitamin D", "CHEMICAL", 0, 9], ["sepsis", "DISEASE", 58, 64], ["ARDS", "DISEASE", 69, 73], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["patients", "ORGANISM", 44, 52], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 173, 178], ["NF-\u03baB", "PROTEIN", 173, 178], ["patients", "SPECIES", 44, 52], ["Vitamin D", "TREATMENT", 0, 9], ["severely depleted", "PROBLEM", 18, 35], ["sepsis", "PROBLEM", 58, 64], ["ARDS", "PROBLEM", 69, 73], ["dietary supplementation", "TREATMENT", 88, 111], ["this molecule", "TEST", 117, 130], ["significant inhibition of NF", "PROBLEM", 147, 175], ["sepsis", "OBSERVATION", 58, 64], ["ARDS", "OBSERVATION", 69, 73]]], ["There is also growing interest in vitamin D supplementation in treating COVID-19 following the publication of a paper reporting severely depleted levels of this vitamin in patients with COVID-19 pneumonia and COVID-19 ARDS [325].Suggestions for therapeutic interventionThere are several other molecules with a proven pedigree as NF-\u03baB inhibitors such as azithromycin (AZM) [326,327], curcumin, melatonin and coenzyme Q10 [[328], [329], [330]].This is also true of N-acetyl-cysteine [[331], [332], [333]].", [["vitamin D", "CHEMICAL", 34, 43], ["vitamin", "CHEMICAL", 161, 168], ["pneumonia", "DISEASE", 195, 204], ["ARDS", "DISEASE", 218, 222], ["azithromycin", "CHEMICAL", 354, 366], ["AZM", "CHEMICAL", 368, 371], ["curcumin", "CHEMICAL", 384, 392], ["melatonin", "CHEMICAL", 394, 403], ["coenzyme Q10", "CHEMICAL", 408, 420], ["N-acetyl-cysteine", "CHEMICAL", 464, 481], ["vitamin D", "CHEMICAL", 34, 43], ["vitamin", "CHEMICAL", 161, 168], ["azithromycin", "CHEMICAL", 354, 366], ["AZM", "CHEMICAL", 368, 371], ["curcumin", "CHEMICAL", 384, 392], ["melatonin", "CHEMICAL", 394, 403], ["coenzyme Q10", "CHEMICAL", 408, 420], ["N-acetyl-cysteine", "CHEMICAL", 464, 481], ["vitamin D", "SIMPLE_CHEMICAL", 34, 43], ["vitamin", "SIMPLE_CHEMICAL", 161, 168], ["patients", "ORGANISM", 172, 180], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 329, 334], ["azithromycin", "SIMPLE_CHEMICAL", 354, 366], ["AZM", "SIMPLE_CHEMICAL", 368, 371], ["curcumin", "SIMPLE_CHEMICAL", 384, 392], ["melatonin", "SIMPLE_CHEMICAL", 394, 403], ["coenzyme Q10", "SIMPLE_CHEMICAL", 408, 420], ["[328], [329]", "SIMPLE_CHEMICAL", 422, 434], ["N-acetyl-cysteine", "SIMPLE_CHEMICAL", 464, 481], ["NF-\u03baB", "PROTEIN", 329, 334], ["patients", "SPECIES", 172, 180], ["vitamin D supplementation", "TREATMENT", 34, 59], ["COVID", "TREATMENT", 72, 77], ["severely depleted levels", "PROBLEM", 128, 152], ["this vitamin", "TREATMENT", 156, 168], ["COVID", "TEST", 186, 191], ["pneumonia", "PROBLEM", 195, 204], ["COVID", "TEST", 209, 214], ["ARDS", "PROBLEM", 218, 222], ["therapeutic intervention", "TREATMENT", 245, 269], ["NF-\u03baB inhibitors", "TREATMENT", 329, 345], ["azithromycin (AZM)", "TREATMENT", 354, 372], ["curcumin", "TREATMENT", 384, 392], ["melatonin and coenzyme Q10", "TREATMENT", 394, 420], ["growing", "OBSERVATION_MODIFIER", 14, 21], ["interest", "OBSERVATION_MODIFIER", 22, 30], ["depleted", "OBSERVATION", 137, 145], ["pneumonia", "OBSERVATION", 195, 204]]], ["There is also evidence that aspirin is an effective NF-\u03baB inhibitor [[334], [335], [336]] although it should be emphasised that doses in excess of 300 mg/day are needed to exert this effect in vivo [337,338].ConclusionA detailed and highly plausible model has been put forward in this paper demonstrating the pathophysiological steps of COVID-19 from the initial infection of type II alveolar epithelial cells by SARS-CoV-2 to the development of ARDS.", [["type II alveolar epithelial cells", "ANATOMY", 376, 409], ["aspirin", "CHEMICAL", 28, 35], ["COVID-19", "CHEMICAL", 337, 345], ["infection", "DISEASE", 363, 372], ["ARDS", "DISEASE", 446, 450], ["aspirin", "CHEMICAL", 28, 35], ["COVID-19", "CHEMICAL", 337, 345], ["aspirin", "SIMPLE_CHEMICAL", 28, 35], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 52, 57], ["type II alveolar epithelial cells", "CELL", 376, 409], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 413, 423], ["type II alveolar epithelial cells", "CELL_TYPE", 376, 409], ["aspirin", "TREATMENT", 28, 35], ["COVID", "TEST", 337, 342], ["type II alveolar epithelial cells", "PROBLEM", 376, 409], ["SARS", "PROBLEM", 413, 417], ["CoV", "TEST", 418, 421], ["ARDS", "PROBLEM", 446, 450], ["infection", "OBSERVATION", 363, 372], ["alveolar epithelial cells", "OBSERVATION", 384, 409], ["ARDS", "OBSERVATION", 446, 450]]], ["There are various control points in this model at which interventions might be of therapeutic value.", [["various", "OBSERVATION_MODIFIER", 10, 17], ["control points", "OBSERVATION", 18, 32]]], ["These include inhibition of EC platelet and neutrophil activation, inhibition of neutrophil migration and NET production, stimulation of AM phagocytosis, and inhibition of the NLRP3 inflammasome.", [["EC platelet", "ANATOMY", 28, 39], ["neutrophil", "ANATOMY", 44, 54], ["neutrophil", "ANATOMY", 81, 91], ["EC", "CELL", 28, 30], ["platelet", "CELL", 31, 39], ["neutrophil", "CELL", 44, 54], ["neutrophil", "CELL", 81, 91], ["NET", "GENE_OR_GENE_PRODUCT", 106, 109], ["AM", "GENE_OR_GENE_PRODUCT", 137, 139], ["NLRP3", "GENE_OR_GENE_PRODUCT", 176, 181], ["EC platelet", "CELL_TYPE", 28, 39], ["NLRP3", "PROTEIN", 176, 181], ["EC platelet", "TREATMENT", 28, 39], ["neutrophil activation", "TREATMENT", 44, 65], ["neutrophil migration", "PROBLEM", 81, 101], ["NET production", "TREATMENT", 106, 120], ["stimulation of AM phagocytosis", "TREATMENT", 122, 152], ["the NLRP3 inflammasome", "TREATMENT", 172, 194], ["neutrophil activation", "OBSERVATION", 44, 65], ["neutrophil migration", "OBSERVATION", 81, 101]]], ["These objectives might all be achieved via the concomitant use of one or more NF-\u03baB inhibitors.", [["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 78, 83], ["NF-\u03baB", "PROTEIN", 78, 83], ["NF-\u03baB inhibitors", "TREATMENT", 78, 94]]], ["A trial investigating the combined use of Zinc, vitamin C and vitamin D would seem to be a rational option given their depleted levels in patients with sepsis and ARDS and their potential as inhibitors of NF-\u03baB.", [["Zinc", "CHEMICAL", 42, 46], ["vitamin C", "CHEMICAL", 48, 57], ["vitamin D", "CHEMICAL", 62, 71], ["sepsis", "DISEASE", 152, 158], ["ARDS", "DISEASE", 163, 167], ["Zinc", "CHEMICAL", 42, 46], ["vitamin C", "CHEMICAL", 48, 57], ["vitamin D", "CHEMICAL", 62, 71], ["Zinc", "SIMPLE_CHEMICAL", 42, 46], ["vitamin C", "SIMPLE_CHEMICAL", 48, 57], ["vitamin D", "SIMPLE_CHEMICAL", 62, 71], ["patients", "ORGANISM", 138, 146], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 205, 209], ["patients", "SPECIES", 138, 146], ["Zinc", "TREATMENT", 42, 46], ["vitamin C", "TREATMENT", 48, 57], ["vitamin D", "TREATMENT", 62, 71], ["a rational option", "TREATMENT", 89, 106], ["their depleted levels", "PROBLEM", 113, 134], ["sepsis", "PROBLEM", 152, 158], ["ARDS", "PROBLEM", 163, 167], ["inhibitors of NF", "TREATMENT", 191, 207], ["sepsis", "OBSERVATION", 152, 158], ["ARDS", "OBSERVATION", 163, 167]]], ["In addition, one or more of the NF-\u03baB inhibitors discussed above might also be considered given their benign side effect profile and the difficulty of treating ARDS once the condition has arisen.Ethics approval and consent to participateNot applicable.Consent for publicationNot applicable.Authors' contributionsGM conceptualized the work and was a major contributor in writing the manuscript.", [["ARDS", "DISEASE", 160, 164], ["GM", "CHEMICAL", 312, 314], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 32, 37], ["the NF-\u03baB inhibitors", "TREATMENT", 28, 48], ["their benign side effect profile", "PROBLEM", 96, 128], ["ARDS", "PROBLEM", 160, 164]]], ["CCB created the figures.", [["CCB", "CHEMICAL", 0, 3], ["CCB", "SIMPLE_CHEMICAL", 0, 3], ["CCB", "TREATMENT", 0, 3], ["figures", "OBSERVATION", 16, 23]]], ["MB has received Grant/Research Support from the 10.13039/100000002NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, 10.13039/501100000925National Health and Medical Research Council, 10.13039/100012505Medical Research Futures Fund, 10.13039/501100001166Beyond Blue, 10.13039/501100001036Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier \u2013 all unrelated to this work.", [["MB", "CHEMICAL", 0, 2], ["Autism", "DISEASE", 107, 113], ["Cancer", "DISEASE", 126, 132], ["Allergan", "CHEMICAL", 587, 595], ["Allergan", "TREATMENT", 587, 595], ["Astra Zeneca", "TREATMENT", 597, 609], ["Bioadvantex", "TREATMENT", 611, 622]]], ["WM is currently funded by an Alfred Deakin Postdoctoral Research Fellowship and a 10.13039/501100000924Multiple Sclerosis Research Australia early-career fellowship.", [["Sclerosis", "DISEASE", 112, 121], ["Multiple Sclerosis", "PROBLEM", 103, 121], ["Sclerosis", "OBSERVATION", 112, 121]]], ["WM has previously received funding from the 10.13039/501100001168Cancer Council Queensland and university grants/fellowships from La Trobe University, Deakin University, University of Queensland, and Bond University.", [["Cancer", "ANATOMY", 65, 71], ["Cancer", "DISEASE", 65, 71]]], ["WM has received speaker honoraria from The Cancer Council Queensland and the Princess Alexandra Research Foundation.", [["Cancer", "DISEASE", 43, 49], ["Cancer", "OBSERVATION", 43, 49]]], ["AO is supported by a Future Leader Fellowship (#101160) from the Heart Foundation Australia and Wilson Foundation.", [["Heart", "ANATOMY", 65, 70]]]], "PMC7150342": [], "PMC7113905": [["IntroductionThe ER is an important cellular organelle that controls several critical aspects of cellular processes such as cellular proteins folding and post-translational modifications.", [["cellular organelle", "ANATOMY", 35, 53], ["cellular", "ANATOMY", 96, 104], ["cellular", "ANATOMY", 123, 131], ["ER", "GENE_OR_GENE_PRODUCT", 16, 18], ["cellular", "CELL", 35, 43], ["cellular", "CELL", 96, 104], ["cellular", "CELL", 123, 131], ["ER", "PROTEIN", 16, 18], ["cellular proteins", "PROTEIN", 123, 140], ["cellular processes", "PROBLEM", 96, 114], ["cellular proteins folding", "PROBLEM", 123, 148], ["post-translational modifications", "TREATMENT", 153, 185], ["several", "OBSERVATION_MODIFIER", 68, 75], ["critical aspects", "OBSERVATION_MODIFIER", 76, 92], ["cellular processes", "OBSERVATION", 96, 114], ["cellular proteins folding", "OBSERVATION", 123, 148], ["post-translational modifications", "OBSERVATION", 153, 185]]], ["It also plays pivotal roles in viral infection processes.", [["viral infection", "DISEASE", 31, 46], ["viral infection processes", "PROBLEM", 31, 56], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 37, 46]]], ["As intracellular parasites, viruses must utilize the ER to complete some of their life cycles including virus entry, viral protein synthesis and modifications, genome replication and virus assembly (He, 2006; Inoue & Tsai, 2013).", [["intracellular", "ANATOMY", 3, 16], ["ER", "ANATOMY", 53, 55], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 3, 16], ["ER", "GENE_OR_GENE_PRODUCT", 53, 55], ["genome", "CELLULAR_COMPONENT", 160, 166], ["ER", "PROTEIN", 53, 55], ["viral protein", "PROTEIN", 117, 130], ["intracellular parasites", "PROBLEM", 3, 26], ["viruses", "PROBLEM", 28, 35], ["their life cycles", "TREATMENT", 76, 93], ["virus entry", "TREATMENT", 104, 115], ["viral protein synthesis", "TREATMENT", 117, 140], ["genome replication", "TREATMENT", 160, 178], ["parasites", "OBSERVATION", 17, 26]]], ["During productive viral infection, viruses hijack the host translation apparatus to produce a large amount of viral proteins accumulated in the ER lumen.", [["ER lumen", "ANATOMY", 144, 152], ["viral infection", "DISEASE", 18, 33], ["ER lumen", "CELLULAR_COMPONENT", 144, 152], ["viral proteins", "PROTEIN", 110, 124], ["productive viral infection", "PROBLEM", 7, 33], ["viral proteins", "PROBLEM", 110, 124], ["productive", "OBSERVATION_MODIFIER", 7, 17], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33], ["large", "OBSERVATION_MODIFIER", 94, 99], ["amount", "OBSERVATION_MODIFIER", 100, 106], ["viral proteins accumulated", "OBSERVATION", 110, 136], ["lumen", "ANATOMY_MODIFIER", 147, 152]]], ["Some viruses even utilize the ER as their replication sites such as Hepatitis C virus (HCV) (Moradpour et al., 2007) and African swine fever virus (ASFV) (Galindo et al., 2012).", [["ER", "ANATOMY", 30, 32], ["Hepatitis C", "DISEASE", 68, 79], ["swine fever", "DISEASE", 129, 140], ["ER", "GENE_OR_GENE_PRODUCT", 30, 32], ["Hepatitis C virus", "ORGANISM", 68, 85], ["HCV", "ORGANISM", 87, 90], ["African swine fever virus", "ORGANISM", 121, 146], ["ASFV", "ORGANISM", 148, 152], ["ER", "PROTEIN", 30, 32], ["Hepatitis C virus", "SPECIES", 68, 85], ["African swine fever virus", "SPECIES", 121, 146], ["Hepatitis C virus", "SPECIES", 68, 85], ["HCV", "SPECIES", 87, 90], ["African swine fever virus", "SPECIES", 121, 146], ["ASFV", "SPECIES", 148, 152], ["Some viruses", "PROBLEM", 0, 12], ["Hepatitis C virus (HCV)", "PROBLEM", 68, 91], ["African swine fever virus", "PROBLEM", 121, 146], ["viruses", "OBSERVATION", 5, 12]]], ["These activities of alien pathogens may disrupt the homeostasis of the ER and lead to a rapid accumulation of malfolded and unfolded proteins inside the ER lumen.", [["ER", "ANATOMY", 71, 73], ["ER lumen", "ANATOMY", 153, 161], ["ER", "GENE_OR_GENE_PRODUCT", 71, 73], ["ER lumen", "CELLULAR_COMPONENT", 153, 161], ["ER", "PROTEIN", 71, 73], ["malfolded and unfolded proteins", "PROTEIN", 110, 141], ["alien pathogens", "PROBLEM", 20, 35], ["a rapid accumulation of malfolded", "PROBLEM", 86, 119], ["lumen", "ANATOMY_MODIFIER", 156, 161]]], ["Consequently, cells face great challenges and stress, so called ER stress, which may cause a wide variety of prevalent diseases such as neurodegenerative diseases, renal disease, liver disease and cancer (Hetz, 2012).", [["cells", "ANATOMY", 14, 19], ["renal", "ANATOMY", 164, 169], ["liver", "ANATOMY", 179, 184], ["cancer", "ANATOMY", 197, 203], ["neurodegenerative diseases", "DISEASE", 136, 162], ["renal disease", "DISEASE", 164, 177], ["liver disease", "DISEASE", 179, 192], ["cancer", "DISEASE", 197, 203], ["cells", "CELL", 14, 19], ["ER", "GENE_OR_GENE_PRODUCT", 64, 66], ["renal", "ORGAN", 164, 169], ["liver", "ORGAN", 179, 184], ["cancer", "CANCER", 197, 203], ["ER", "PROTEIN", 64, 66], ["stress", "PROBLEM", 46, 52], ["prevalent diseases", "PROBLEM", 109, 127], ["neurodegenerative diseases", "PROBLEM", 136, 162], ["renal disease", "PROBLEM", 164, 177], ["liver disease", "PROBLEM", 179, 192], ["cancer", "PROBLEM", 197, 203], ["neurodegenerative", "OBSERVATION_MODIFIER", 136, 153], ["diseases", "OBSERVATION", 154, 162], ["renal", "ANATOMY", 164, 169], ["disease", "OBSERVATION", 170, 177], ["liver", "ANATOMY", 179, 184], ["disease", "OBSERVATION", 185, 192], ["cancer", "OBSERVATION", 197, 203]]], ["To alleviate the detrimental effects of ER stress, cells evolved an ER-to-nucleus signaling pathway termed the unfolded protein response (UPR), which functions to restore the ER homeostasis (Bernales et al., 2006; Schroder & Kaufman, 2005).", [["cells", "ANATOMY", 51, 56], ["ER", "ANATOMY", 68, 70], ["nucleus", "ANATOMY", 74, 81], ["ER", "ANATOMY", 175, 177], ["ER", "GENE_OR_GENE_PRODUCT", 40, 42], ["cells", "CELL", 51, 56], ["ER", "GENE_OR_GENE_PRODUCT", 68, 70], ["nucleus", "CELLULAR_COMPONENT", 74, 81], ["unfolded protein response", "GENE_OR_GENE_PRODUCT", 111, 136], ["UPR", "GENE_OR_GENE_PRODUCT", 138, 141], ["ER", "GENE_OR_GENE_PRODUCT", 175, 177], ["ER", "PROTEIN", 40, 42], ["ER", "PROTEIN", 68, 70], ["UPR", "PROTEIN", 138, 141], ["ER", "PROTEIN", 175, 177], ["ER stress, cells", "PROBLEM", 40, 56], ["the unfolded protein response", "PROBLEM", 107, 136], ["unfolded", "OBSERVATION_MODIFIER", 111, 119], ["protein response", "OBSERVATION", 120, 136]]], ["However, if under unsolved or intense ER stress, cells would fail to regain the ER homeostasis and instead, initiate the intrinsic apoptotic cascades, which have been thought to primarily associate with virus pathogenesis (Galluzzi et al., 2008).", [["cells", "ANATOMY", 49, 54], ["ER", "ANATOMY", 80, 82], ["ER", "GENE_OR_GENE_PRODUCT", 38, 40], ["cells", "CELL", 49, 54], ["ER", "GENE_OR_GENE_PRODUCT", 80, 82], ["ER", "PROTEIN", 38, 40], ["ER", "PROTEIN", 80, 82], ["the intrinsic apoptotic cascades", "PROBLEM", 117, 149], ["virus pathogenesis", "PROBLEM", 203, 221], ["apoptotic cascades", "OBSERVATION", 131, 149], ["virus", "OBSERVATION", 203, 208]]], ["Here, we give a comprehensive description about the dynamic relationship between ER stress and virus infection with emphasis on how UPR and apoptosis influence viral replication and pathogenesis as well as the strategies employed by viruses to cope with ER stress.", [["infection", "DISEASE", 101, 110], ["ER", "GENE_OR_GENE_PRODUCT", 81, 83], ["UPR", "GENE_OR_GENE_PRODUCT", 132, 135], ["ER", "GENE_OR_GENE_PRODUCT", 254, 256], ["ER", "PROTEIN", 81, 83], ["ER", "PROTEIN", 254, 256], ["ER stress and virus infection", "PROBLEM", 81, 110], ["viral replication", "TREATMENT", 160, 177], ["pathogenesis", "PROBLEM", 182, 194]]], ["In particular, we discuss the current developed ER stress-related antivirals including broad-spectrum therapy by targeting ER stress signaling pathways and specifically targeted antiviral therapy by disturbing the functions of ER stress-triggering viral proteins.PERK-eIF2\u03b1 pathway ::: Overview of ER stress-mediated UPR ::: Virus, ER stress and the UPRPERK is a type I ER-resident transmembrane kinase (Bernales et al., 2006; Lin et al., 2008).", [["ER", "GENE_OR_GENE_PRODUCT", 48, 50], ["ER", "GENE_OR_GENE_PRODUCT", 123, 125], ["ER", "GENE_OR_GENE_PRODUCT", 227, 229], ["PERK", "GENE_OR_GENE_PRODUCT", 263, 267], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 268, 273], ["ER", "GENE_OR_GENE_PRODUCT", 298, 300], ["Virus", "ORGANISM", 325, 330], ["ER", "GENE_OR_GENE_PRODUCT", 332, 334], ["UPRPERK", "GENE_OR_GENE_PRODUCT", 350, 357], ["type I ER", "GENE_OR_GENE_PRODUCT", 363, 372], ["ER", "PROTEIN", 48, 50], ["ER", "PROTEIN", 123, 125], ["ER", "PROTEIN", 227, 229], ["viral proteins", "PROTEIN", 248, 262], ["PERK", "PROTEIN", 263, 267], ["eIF2\u03b1", "PROTEIN", 268, 273], ["ER", "PROTEIN", 298, 300], ["UPR", "PROTEIN", 317, 320], ["ER", "PROTEIN", 332, 334], ["UPRPERK", "PROTEIN", 350, 357], ["type I ER-resident transmembrane kinase", "PROTEIN", 363, 402], ["ER stress", "TREATMENT", 48, 57], ["related antivirals", "TREATMENT", 58, 76], ["broad-spectrum therapy", "TREATMENT", 87, 109], ["targeting ER stress signaling pathways", "TREATMENT", 113, 151], ["targeted antiviral therapy", "TREATMENT", 169, 195], ["ER stress", "TEST", 227, 236], ["viral proteins", "PROBLEM", 248, 262], ["Virus", "PROBLEM", 325, 330], ["transmembrane kinase", "TEST", 382, 402]]], ["When it senses ER stress, PERK undergoes oligomerization and autophosphorylation to form active PERK, which then phosphorylates the \u03b1 subunit of the eukaryotic translation initiation factor-2 (eIF2\u03b1) to reduce global protein synthesis and thus relieve the ER stress (Harding et al., 2000).", [["ER", "GENE_OR_GENE_PRODUCT", 15, 17], ["PERK", "GENE_OR_GENE_PRODUCT", 26, 30], ["PERK", "GENE_OR_GENE_PRODUCT", 96, 100], ["eukaryotic translation initiation factor-2", "GENE_OR_GENE_PRODUCT", 149, 191], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 193, 198], ["ER", "GENE_OR_GENE_PRODUCT", 256, 258], ["ER", "PROTEIN", 15, 17], ["PERK", "PROTEIN", 26, 30], ["PERK", "PROTEIN", 96, 100], ["\u03b1 subunit", "PROTEIN", 132, 141], ["eukaryotic translation initiation factor-2 (eIF2\u03b1", "PROTEIN", 149, 198], ["ER", "PROTEIN", 256, 258], ["PERK undergoes oligomerization", "PROBLEM", 26, 56], ["autophosphorylation", "PROBLEM", 61, 80], ["active PERK", "PROBLEM", 89, 100], ["global protein synthesis", "PROBLEM", 210, 234], ["the ER stress", "PROBLEM", 252, 265], ["protein synthesis", "OBSERVATION", 217, 234]]], ["However, this limited amount of active eIF2\u03b1 selectively increases the translation of activating transcription factor-4 (ATF4), a pro-survival transcription factor that facilitates cell survival through activating genes involved in amino acids biosynthesis and transport, stress response, redox reactions and protein secretion (Harding et al., 2000).", [["cell", "ANATOMY", 181, 185], ["amino acids", "CHEMICAL", 232, 243], ["amino acids", "CHEMICAL", 232, 243], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 39, 44], ["activating transcription factor-4", "GENE_OR_GENE_PRODUCT", 86, 119], ["ATF4", "GENE_OR_GENE_PRODUCT", 121, 125], ["cell", "CELL", 181, 185], ["amino acids", "AMINO_ACID", 232, 243], ["eIF2\u03b1", "PROTEIN", 39, 44], ["activating transcription factor-4", "PROTEIN", 86, 119], ["ATF4", "PROTEIN", 121, 125], ["pro-survival transcription factor", "PROTEIN", 130, 163], ["active eIF2", "TREATMENT", 32, 43], ["activating transcription factor", "PROBLEM", 86, 117], ["a pro-survival transcription factor", "TREATMENT", 128, 163], ["cell survival", "TREATMENT", 181, 194], ["amino acids biosynthesis", "TREATMENT", 232, 256], ["stress response", "TEST", 272, 287], ["redox reactions", "PROBLEM", 289, 304], ["protein secretion", "PROBLEM", 309, 326], ["active", "OBSERVATION_MODIFIER", 32, 38], ["eIF2", "OBSERVATION", 39, 43], ["cell survival", "OBSERVATION", 181, 194]]], ["One target gene of ATF4 is growth arrest and DNA damage-inducible 34 (GADD34), a protein phosphatase 1 (PP1) regulatory subunit that recruits PP1 to dephosphorylate eIF2\u03b1 and derepresses PERK-eIF2\u03b1-mediated translation attenuation, thereby constituting a negative feedback loop in the UPR (Novoa et al., 2001).IRE1-XBP1 pathway ::: Overview of ER stress-mediated UPR ::: Virus, ER stress and the UPRThe IRE1-XBP1 pathway is a highly conserved UPR branch in eukaryotic cells, which starts with activation of IRE1, a dual-activity enzyme harboring a serine-threoine kinase domain and an endoribonuclease domain (Sidrauski & Walter, 1997; Szegezdi et al., 2006).", [["cells", "ANATOMY", 468, 473], ["serine", "CHEMICAL", 548, 554], ["ATF4", "GENE_OR_GENE_PRODUCT", 19, 23], ["DNA damage-inducible 34", "GENE_OR_GENE_PRODUCT", 45, 68], ["GADD34", "GENE_OR_GENE_PRODUCT", 70, 76], ["protein phosphatase 1", "GENE_OR_GENE_PRODUCT", 81, 102], ["PP1", "GENE_OR_GENE_PRODUCT", 104, 107], ["PP1", "GENE_OR_GENE_PRODUCT", 142, 145], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 165, 170], ["PERK", "GENE_OR_GENE_PRODUCT", 187, 191], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 192, 197], ["IRE1", "GENE_OR_GENE_PRODUCT", 310, 314], ["XBP1", "GENE_OR_GENE_PRODUCT", 315, 319], ["ER", "GENE_OR_GENE_PRODUCT", 344, 346], ["Virus", "ORGANISM", 371, 376], ["ER", "GENE_OR_GENE_PRODUCT", 378, 380], ["IRE1", "GENE_OR_GENE_PRODUCT", 403, 407], ["XBP1", "GENE_OR_GENE_PRODUCT", 408, 412], ["eukaryotic cells", "CELL", 457, 473], ["IRE1", "GENE_OR_GENE_PRODUCT", 507, 511], ["ATF4", "PROTEIN", 19, 23], ["DNA damage-inducible 34", "PROTEIN", 45, 68], ["GADD34", "PROTEIN", 70, 76], ["protein phosphatase 1 (PP1) regulatory subunit", "PROTEIN", 81, 127], ["PP1", "PROTEIN", 142, 145], ["eIF2\u03b1", "PROTEIN", 165, 170], ["PERK", "PROTEIN", 187, 191], ["eIF2\u03b1", "PROTEIN", 192, 197], ["IRE1", "PROTEIN", 310, 314], ["XBP1", "PROTEIN", 315, 319], ["ER", "PROTEIN", 344, 346], ["UPR", "PROTEIN", 363, 366], ["ER", "PROTEIN", 378, 380], ["IRE1", "PROTEIN", 403, 407], ["XBP1", "PROTEIN", 408, 412], ["eukaryotic cells", "CELL_TYPE", 457, 473], ["IRE1", "PROTEIN", 507, 511], ["dual-activity enzyme", "PROTEIN", 515, 535], ["serine-threoine kinase domain", "PROTEIN", 548, 577], ["endoribonuclease domain", "PROTEIN", 585, 608], ["growth arrest", "PROBLEM", 27, 40], ["DNA damage", "PROBLEM", 45, 55], ["a protein phosphatase", "TEST", 79, 100], ["dephosphorylate eIF2", "TREATMENT", 149, 169], ["PERK", "TEST", 187, 191], ["Virus", "PROBLEM", 371, 376], ["ER stress", "TEST", 378, 387], ["the UPRThe IRE1", "TEST", 392, 407], ["activation of IRE1", "PROBLEM", 493, 511], ["growth arrest", "OBSERVATION", 27, 40], ["UPR", "OBSERVATION_MODIFIER", 443, 446], ["branch", "OBSERVATION_MODIFIER", 447, 453], ["eukaryotic cells", "OBSERVATION", 457, 473]]], ["When IRE1 dissociates from GRP78, it undergoes oligomerization, which in turn activates its kinase and endonuclease activities.", [["IRE1", "GENE_OR_GENE_PRODUCT", 5, 9], ["GRP78", "GENE_OR_GENE_PRODUCT", 27, 32], ["IRE1", "PROTEIN", 5, 9], ["GRP78", "PROTEIN", 27, 32], ["kinase", "PROTEIN", 92, 98], ["endonuclease", "PROTEIN", 103, 115], ["IRE1 dissociates", "PROBLEM", 5, 21], ["oligomerization", "PROBLEM", 47, 62], ["oligomerization", "OBSERVATION", 47, 62]]], ["Activated IRE1 removes a 26-nucleotide intron from X box-binding protein 1 (XBP1) mRNA to form a spliced XBP1 (XBP1(s)), which is subsequently translated into a basic-zipper (bZIP) transcription factor that activates the transcription of genes that enhance the ER protein-folding capacity, phospholipid biosynthesis and ER-associated protein degradation (ERAD) (Lee et al., 2003; Shaffer et al., 2004).", [["IRE1", "GENE_OR_GENE_PRODUCT", 10, 14], ["X box-binding protein 1", "GENE_OR_GENE_PRODUCT", 51, 74], ["XBP1", "GENE_OR_GENE_PRODUCT", 76, 80], ["XBP1", "GENE_OR_GENE_PRODUCT", 105, 109], ["XBP1(s)", "GENE_OR_GENE_PRODUCT", 111, 118], ["bZIP", "GENE_OR_GENE_PRODUCT", 175, 179], ["ER", "GENE_OR_GENE_PRODUCT", 261, 263], ["phospholipid", "SIMPLE_CHEMICAL", 290, 302], ["ER", "GENE_OR_GENE_PRODUCT", 320, 322], ["IRE1", "PROTEIN", 10, 14], ["26-nucleotide intron", "DNA", 25, 45], ["X box-binding protein 1 (XBP1) mRNA", "RNA", 51, 86], ["XBP1", "PROTEIN", 105, 109], ["XBP1", "PROTEIN", 111, 115], ["basic-zipper (bZIP) transcription factor", "PROTEIN", 161, 201], ["ER", "PROTEIN", 261, 263], ["ER", "PROTEIN", 320, 322], ["ERAD", "PROTEIN", 355, 359], ["Activated IRE1 removes", "TREATMENT", 0, 22], ["nucleotide intron from X box", "TREATMENT", 28, 56], ["binding protein", "TEST", 57, 72], ["a spliced XBP1", "TEST", 95, 109], ["a basic-zipper (bZIP) transcription factor", "TREATMENT", 159, 201], ["the ER protein", "TEST", 257, 271], ["phospholipid biosynthesis", "TEST", 290, 315], ["protein degradation", "PROBLEM", 334, 353], ["spliced XBP1", "OBSERVATION", 97, 109]]], ["XBP1(s) is also able to activate the HSP40 family member P58IPK, which can bind PERK and inhibit its activity to phoshporylate eIF2\u03b1 (Yan et al., 2002).", [["XBP1", "GENE_OR_GENE_PRODUCT", 0, 4], ["HSP40", "GENE_OR_GENE_PRODUCT", 37, 42], ["P58IPK", "GENE_OR_GENE_PRODUCT", 57, 63], ["PERK", "GENE_OR_GENE_PRODUCT", 80, 84], ["eIF2", "GENE_OR_GENE_PRODUCT", 127, 131], ["XBP1", "PROTEIN", 0, 4], ["HSP40 family member", "PROTEIN", 37, 56], ["P58IPK", "PROTEIN", 57, 63], ["PERK", "PROTEIN", 80, 84], ["eIF2", "PROTEIN", 127, 131]]], ["IRE1, by itself, can degrade ER-bound mRNAs through the regulated IRE1-dependent decay (RIDD) pathway to reduce protein translation and limit unfolded protein load in the ER lumen (Hollien et al., 2009).ATF6 pathway ::: Overview of ER stress-mediated UPR ::: Virus, ER stress and the UPRATF6 is a bZIP transcription factor but is initially synthesized as a type II transmembrane protein having an ER stress-sensing luminal domain, transmembrane domain and a cytosolic N-terminal domain (Walter & Ron, 2011).", [["ER lumen", "ANATOMY", 171, 179], ["ER", "ANATOMY", 397, 399], ["transmembrane", "ANATOMY", 431, 444], ["cytosolic", "ANATOMY", 458, 467], ["N", "CHEMICAL", 468, 469], ["IRE1", "GENE_OR_GENE_PRODUCT", 0, 4], ["ER", "GENE_OR_GENE_PRODUCT", 29, 31], ["IRE1", "GENE_OR_GENE_PRODUCT", 66, 70], ["ER", "GENE_OR_GENE_PRODUCT", 171, 173], ["ATF6", "GENE_OR_GENE_PRODUCT", 203, 207], ["ER", "GENE_OR_GENE_PRODUCT", 232, 234], ["Virus", "ORGANISM", 259, 264], ["ER", "GENE_OR_GENE_PRODUCT", 266, 268], ["UPRATF6", "GENE_OR_GENE_PRODUCT", 284, 291], ["bZIP", "GENE_OR_GENE_PRODUCT", 297, 301], ["ER", "GENE_OR_GENE_PRODUCT", 397, 399], ["transmembrane", "CELLULAR_COMPONENT", 431, 444], ["IRE1", "PROTEIN", 0, 4], ["ER", "PROTEIN", 29, 31], ["mRNAs", "RNA", 38, 43], ["IRE1", "PROTEIN", 66, 70], ["ATF6", "PROTEIN", 203, 207], ["ER", "PROTEIN", 232, 234], ["UPR", "PROTEIN", 251, 254], ["ER", "PROTEIN", 266, 268], ["UPRATF6", "PROTEIN", 284, 291], ["bZIP transcription factor", "PROTEIN", 297, 322], ["type II transmembrane protein", "PROTEIN", 357, 386], ["ER", "PROTEIN", 397, 399], ["luminal domain", "PROTEIN", 415, 429], ["transmembrane domain", "PROTEIN", 431, 451], ["cytosolic N-terminal domain", "PROTEIN", 458, 485], ["Ron", "PROTEIN", 496, 499], ["2011", "PROTEIN", 501, 505], ["dependent decay (RIDD) pathway", "TREATMENT", 71, 101], ["protein translation", "PROBLEM", 112, 131], ["unfolded protein load", "PROBLEM", 142, 163], ["Virus", "PROBLEM", 259, 264], ["ER stress", "PROBLEM", 266, 275], ["a bZIP transcription factor", "PROBLEM", 295, 322], ["a type II transmembrane protein", "PROBLEM", 355, 386], ["transmembrane domain", "PROBLEM", 431, 451], ["protein load", "OBSERVATION", 151, 163], ["lumen", "ANATOMY_MODIFIER", 174, 179]]], ["In response to ER stress, ATF6 is packaged in ER-derived transport vesicles and translocates into the Golgi complex, where two specific proteases cleave its transmembrane domain and liberate its active N-terminal DNA binding domain, ATF6 (N) (Ye et al., 2000).", [["ER", "ANATOMY", 46, 48], ["vesicles", "ANATOMY", 67, 75], ["Golgi complex", "ANATOMY", 102, 115], ["transmembrane", "ANATOMY", 157, 170], ["N", "CHEMICAL", 202, 203], ["ER", "GENE_OR_GENE_PRODUCT", 15, 17], ["ATF6", "GENE_OR_GENE_PRODUCT", 26, 30], ["ER", "GENE_OR_GENE_PRODUCT", 46, 48], ["vesicles", "CELLULAR_COMPONENT", 67, 75], ["Golgi", "CELLULAR_COMPONENT", 102, 107], ["DNA", "CELLULAR_COMPONENT", 213, 216], ["ATF6", "GENE_OR_GENE_PRODUCT", 233, 237], ["ER", "PROTEIN", 15, 17], ["ATF6", "PROTEIN", 26, 30], ["ER", "PROTEIN", 46, 48], ["Golgi complex", "PROTEIN", 102, 115], ["proteases", "PROTEIN", 136, 145], ["transmembrane domain", "PROTEIN", 157, 177], ["N-terminal DNA binding domain", "PROTEIN", 202, 231], ["ATF6", "PROTEIN", 233, 237], ["ER stress", "TEST", 15, 24], ["terminal DNA binding domain", "PROBLEM", 204, 231]]], ["ATF6 (N) then translocates into the nucleus and activates genes that improve the ER folding capacity such as ER chaperones, protein disulphide isomerase (PDI) as well as XBP1 (Yoshida et al., 2001).", [["nucleus", "ANATOMY", 36, 43], ["ER", "ANATOMY", 81, 83], ["disulphide", "CHEMICAL", 132, 142], ["ATF6 (N)", "GENE_OR_GENE_PRODUCT", 0, 8], ["nucleus", "CELLULAR_COMPONENT", 36, 43], ["ER", "GENE_OR_GENE_PRODUCT", 81, 83], ["ER", "GENE_OR_GENE_PRODUCT", 109, 111], ["protein disulphide isomerase", "GENE_OR_GENE_PRODUCT", 124, 152], ["PDI", "GENE_OR_GENE_PRODUCT", 154, 157], ["XBP1", "GENE_OR_GENE_PRODUCT", 170, 174], ["ATF6 (N)", "PROTEIN", 0, 8], ["ER", "PROTEIN", 81, 83], ["ER chaperones", "PROTEIN", 109, 122], ["protein disulphide isomerase", "PROTEIN", 124, 152], ["PDI", "PROTEIN", 154, 157], ["XBP1", "PROTEIN", 170, 174], ["the ER folding capacity", "PROBLEM", 77, 100], ["ER chaperones", "TREATMENT", 109, 122], ["protein disulphide isomerase", "TREATMENT", 124, 152], ["nucleus", "ANATOMY", 36, 43]]], ["Overall, these three branches function to remedy ER stress by reducing the flux of newly synthesized polypeptides into the ER, degrading ER-localized proteins and expanding the ER folding capacity.Induction of ER stress and UPR by virus infection ::: Virus, ER stress and the UPREmerging evidence indicates that a large number of viruses are capable of eliciting ER stress during their infection, which is summarized in Table 1.", [["ER", "ANATOMY", 123, 125], ["ER", "ANATOMY", 177, 179], ["infection", "DISEASE", 237, 246], ["infection", "DISEASE", 386, 395], ["ER", "GENE_OR_GENE_PRODUCT", 49, 51], ["ER", "GENE_OR_GENE_PRODUCT", 123, 125], ["ER", "GENE_OR_GENE_PRODUCT", 137, 139], ["ER", "GENE_OR_GENE_PRODUCT", 177, 179], ["ER", "GENE_OR_GENE_PRODUCT", 210, 212], ["UPR", "GENE_OR_GENE_PRODUCT", 224, 227], ["Virus", "ORGANISM", 251, 256], ["ER", "GENE_OR_GENE_PRODUCT", 258, 260], ["ER", "GENE_OR_GENE_PRODUCT", 363, 365], ["ER", "PROTEIN", 49, 51], ["ER", "PROTEIN", 123, 125], ["ER", "PROTEIN", 137, 139], ["localized proteins", "PROTEIN", 140, 158], ["ER", "PROTEIN", 177, 179], ["ER", "PROTEIN", 210, 212], ["UPR", "PROTEIN", 224, 227], ["ER", "PROTEIN", 258, 260], ["ER", "PROTEIN", 363, 365], ["ER stress", "PROBLEM", 49, 58], ["ER stress", "TEST", 210, 219], ["Virus", "PROBLEM", 251, 256], ["ER stress", "TEST", 258, 267], ["a large number of viruses", "PROBLEM", 312, 337], ["eliciting ER stress", "PROBLEM", 353, 372], ["their infection", "PROBLEM", 380, 395], ["branches", "OBSERVATION_MODIFIER", 21, 29], ["folding capacity", "OBSERVATION", 180, 196], ["large", "OBSERVATION_MODIFIER", 314, 319], ["number", "OBSERVATION_MODIFIER", 320, 326], ["viruses", "OBSERVATION", 330, 337], ["infection", "OBSERVATION", 386, 395]]], ["Currently, 35 animal and 1 plant viruses, which belong to 18 virus families with the majority being RNA viruses, have been reported to trigger ER stress indicators including inducing ER chaperones and activating three UPR sensors.", [["ER", "GENE_OR_GENE_PRODUCT", 143, 145], ["ER", "GENE_OR_GENE_PRODUCT", 183, 185], ["ER", "PROTEIN", 143, 145], ["ER chaperones", "PROTEIN", 183, 196], ["1 plant viruses", "PROBLEM", 25, 40], ["RNA viruses", "PROBLEM", 100, 111], ["viruses", "OBSERVATION", 33, 40], ["RNA viruses", "OBSERVATION", 100, 111]]], ["19 viruses have been reported to induce the expression of ER chaperone proteins (Bip, GRP78, GRP94, calnexin, calreticulin), which might be caused by accumulation of malfolded and unfolded viral proteins inside the ER lumen.", [["ER lumen", "ANATOMY", 215, 223], ["ER", "GENE_OR_GENE_PRODUCT", 58, 60], ["Bip", "GENE_OR_GENE_PRODUCT", 81, 84], ["GRP78", "GENE_OR_GENE_PRODUCT", 86, 91], ["GRP94", "GENE_OR_GENE_PRODUCT", 93, 98], ["calnexin", "GENE_OR_GENE_PRODUCT", 100, 108], ["calreticulin", "GENE_OR_GENE_PRODUCT", 110, 122], ["ER", "GENE_OR_GENE_PRODUCT", 215, 217], ["lumen", "CELLULAR_COMPONENT", 218, 223], ["ER chaperone proteins", "PROTEIN", 58, 79], ["Bip", "PROTEIN", 81, 84], ["GRP78", "PROTEIN", 86, 91], ["GRP94", "PROTEIN", 93, 98], ["calnexin", "PROTEIN", 100, 108], ["calreticulin", "PROTEIN", 110, 122], ["malfolded and unfolded viral proteins", "PROTEIN", 166, 203], ["19 viruses", "PROBLEM", 0, 10], ["GRP78", "TEST", 86, 91], ["GRP94", "TEST", 93, 98], ["calnexin", "TREATMENT", 100, 108], ["accumulation of malfolded", "PROBLEM", 150, 175], ["unfolded viral proteins", "PROBLEM", 180, 203], ["viruses", "OBSERVATION", 3, 10], ["unfolded", "OBSERVATION_MODIFIER", 180, 188], ["viral proteins", "OBSERVATION", 189, 203], ["lumen", "ANATOMY_MODIFIER", 218, 223]]], ["These viruses include Potato virus X (PVX), Chikungunya virus (CHIKV), ASFV, Infectious pancreatic necrosis virus (IPNV), Tula virus (TULV), Porcine epidemic diarrhea virus (PEDV), Bovine viral diarrhea virus (BVDV), Dengue virus (DENV), Japanese encephalitis virus (JEV), Hepatitis B virus (HBV), Hepatitis E virus (HEV), Herpes simplex virus type 1 (HSV-1), Canine distemper virus (CDV), Human respiratory syncytial virus (RSV), Simian virus 5 (SV5), Coxsackievirus B3 (CVB3), Human immunodeficiency virus (HIV), Moloney murine leukemia virus-TB (MoMuLV), and Neurovirulent mouse retrovirus (FrCasE) (Table 1).", [["Chikungunya virus", "DISEASE", 44, 61], ["Infectious pancreatic necrosis", "DISEASE", 77, 107], ["IPNV", "DISEASE", 115, 119], ["Porcine epidemic diarrhea virus", "DISEASE", 141, 172], ["Bovine viral diarrhea virus (BVDV), Dengue virus (DENV)", "DISEASE", 181, 236], ["Japanese encephalitis virus", "DISEASE", 238, 265], ["JEV", "DISEASE", 267, 270], ["Hepatitis B", "DISEASE", 273, 284], ["Hepatitis E", "DISEASE", 298, 309], ["Herpes simplex virus", "DISEASE", 323, 343], ["Canine distemper virus", "DISEASE", 360, 382], ["respiratory syncytial virus", "DISEASE", 396, 423], ["Human immunodeficiency virus (HIV), Moloney murine leukemia virus-TB", "DISEASE", 479, 547], ["Potato virus X", "ORGANISM", 22, 36], ["PVX", "ORGANISM", 38, 41], ["Chikungunya virus", "ORGANISM", 44, 61], ["CHIKV", "ORGANISM", 63, 68], ["ASFV", "ORGANISM", 71, 75], ["Infectious pancreatic necrosis virus", "ORGANISM", 77, 113], ["IPNV", "ORGANISM", 115, 119], ["Tula virus", "ORGANISM", 122, 132], ["Porcine epidemic diarrhea virus", "ORGANISM", 141, 172], ["Bovine viral diarrhea virus", "ORGANISM", 181, 208], ["BVDV", "ORGANISM", 210, 214], ["Dengue virus", "ORGANISM", 217, 229], ["DENV", "ORGANISM", 231, 235], ["Japanese encephalitis virus", "ORGANISM", 238, 265], ["JEV", "ORGANISM", 267, 270], ["Hepatitis B virus", "ORGANISM", 273, 290], ["HBV", "ORGANISM", 292, 295], ["Hepatitis E virus (HEV", "ORGANISM", 298, 320], ["Herpes simplex virus type 1", "ORGANISM", 323, 350], ["HSV-1", "ORGANISM", 352, 357], ["Canine distemper virus", "ORGANISM", 360, 382], ["CDV", "ORGANISM", 384, 387], ["Human respiratory syncytial virus", "ORGANISM", 390, 423], ["RSV", "ORGANISM", 425, 428], ["Simian virus 5", "ORGANISM", 431, 445], ["SV5", "ORGANISM", 447, 450], ["Coxsackievirus B3", "ORGANISM", 453, 470], ["CVB3", "ORGANISM", 472, 476], ["Human immunodeficiency virus", "ORGANISM", 479, 507], ["HIV", "ORGANISM", 509, 512], ["Moloney murine leukemia virus-TB", "ORGANISM", 515, 547], ["MoMuLV", "ORGANISM", 549, 555], ["mouse retrovirus", "ORGANISM", 576, 592], ["Potato virus", "SPECIES", 22, 34], ["Chikungunya virus", "SPECIES", 44, 61], ["Infectious pancreatic necrosis virus", "SPECIES", 77, 113], ["Tula virus", "SPECIES", 122, 132], ["Porcine epidemic diarrhea virus", "SPECIES", 141, 172], ["Bovine viral diarrhea virus", "SPECIES", 181, 208], ["BVDV", "SPECIES", 210, 214], ["Dengue virus", "SPECIES", 217, 229], ["Japanese encephalitis virus", "SPECIES", 238, 265], ["Hepatitis B virus", "SPECIES", 273, 290], ["Hepatitis E virus", "SPECIES", 298, 315], ["Herpes simplex virus type 1", "SPECIES", 323, 350], ["HSV-1", "SPECIES", 352, 357], ["Canine distemper virus", "SPECIES", 360, 382], ["Human", "SPECIES", 390, 395], ["respiratory syncytial virus", "SPECIES", 396, 423], ["RSV", "SPECIES", 425, 428], ["Simian virus", "SPECIES", 431, 443], ["Coxsackievirus B3", "SPECIES", 453, 470], ["CVB3", "SPECIES", 472, 476], ["Human immunodeficiency virus", "SPECIES", 479, 507], ["HIV", "SPECIES", 509, 512], ["Moloney", "SPECIES", 515, 522], ["murine", "SPECIES", 523, 529], ["leukemia virus", "SPECIES", 530, 544], ["mouse", "SPECIES", 576, 581], ["Potato virus", "SPECIES", 22, 34], ["PVX", "SPECIES", 38, 41], ["Chikungunya virus", "SPECIES", 44, 61], ["CHIKV", "SPECIES", 63, 68], ["ASFV", "SPECIES", 71, 75], ["Infectious pancreatic necrosis virus", "SPECIES", 77, 113], ["IPNV", "SPECIES", 115, 119], ["Tula virus", "SPECIES", 122, 132], ["TULV", "SPECIES", 134, 138], ["Porcine epidemic diarrhea virus", "SPECIES", 141, 172], ["PEDV", "SPECIES", 174, 178], ["Bovine viral diarrhea virus", "SPECIES", 181, 208], ["BVDV", "SPECIES", 210, 214], ["Dengue virus", "SPECIES", 217, 229], ["DENV", "SPECIES", 231, 235], ["Japanese encephalitis virus", "SPECIES", 238, 265], ["JEV", "SPECIES", 267, 270], ["Hepatitis B virus", "SPECIES", 273, 290], ["HBV", "SPECIES", 292, 295], ["Hepatitis E virus", "SPECIES", 298, 315], ["HEV", "SPECIES", 317, 320], ["Herpes simplex virus type 1", "SPECIES", 323, 350], ["HSV-1", "SPECIES", 352, 357], ["Canine distemper virus", "SPECIES", 360, 382], ["CDV", "SPECIES", 384, 387], ["Human respiratory syncytial virus", "SPECIES", 390, 423], ["RSV", "SPECIES", 425, 428], ["Simian virus 5", "SPECIES", 431, 445], ["SV5", "SPECIES", 447, 450], ["Coxsackievirus B3", "SPECIES", 453, 470], ["CVB3", "SPECIES", 472, 476], ["Human immunodeficiency virus", "SPECIES", 479, 507], ["HIV", "SPECIES", 509, 512], ["Moloney murine leukemia virus", "SPECIES", 515, 544], ["MoMuLV", "SPECIES", 549, 555], ["mouse", "SPECIES", 576, 581], ["These viruses", "PROBLEM", 0, 13], ["Potato virus", "PROBLEM", 22, 34], ["PVX", "PROBLEM", 38, 41], ["Chikungunya virus (CHIKV)", "PROBLEM", 44, 69], ["ASFV", "PROBLEM", 71, 75], ["Infectious pancreatic necrosis virus", "PROBLEM", 77, 113], ["IPNV", "PROBLEM", 115, 119], ["Tula virus (TULV)", "PROBLEM", 122, 139], ["Porcine epidemic diarrhea virus (PEDV", "PROBLEM", 141, 178], ["Bovine viral diarrhea virus", "PROBLEM", 181, 208], ["BVDV", "PROBLEM", 210, 214], ["Dengue virus (DENV)", "PROBLEM", 217, 236], ["Japanese encephalitis virus (JEV", "PROBLEM", 238, 270], ["Hepatitis B virus", "PROBLEM", 273, 290], ["HBV", "TEST", 292, 295], ["Hepatitis E virus", "PROBLEM", 298, 315], ["HEV)", "TEST", 317, 321], ["Herpes simplex virus type", "TEST", 323, 348], ["HSV", "TEST", 352, 355], ["Canine distemper virus", "PROBLEM", 360, 382], ["CDV", "TEST", 384, 387], ["Human respiratory syncytial virus (RSV)", "PROBLEM", 390, 429], ["Simian virus", "PROBLEM", 431, 443], ["Coxsackievirus B3 (CVB3)", "PROBLEM", 453, 477], ["Human immunodeficiency virus (HIV)", "PROBLEM", 479, 513], ["Moloney murine leukemia virus", "PROBLEM", 515, 544], ["TB (MoMuLV)", "TREATMENT", 545, 556], ["Neurovirulent mouse retrovirus", "TREATMENT", 562, 592], ["viruses", "OBSERVATION", 6, 13], ["Potato virus", "OBSERVATION", 22, 34], ["Infectious", "OBSERVATION_MODIFIER", 77, 87], ["pancreatic", "ANATOMY", 88, 98], ["necrosis", "OBSERVATION", 99, 107], ["distemper virus", "OBSERVATION", 367, 382], ["respiratory syncytial", "ANATOMY", 396, 417], ["Moloney murine leukemia virus", "OBSERVATION", 515, 544]]], ["Intriguingly, upon virus-triggered ER stress, the three UPR transmembrane sensors are differentially activated: 19, 17 and 14 viruses have been reported to activate the PERK-eIF2\u03b1, IRE1-XBP1 and ATF6 branches, respectively (Table 1 and Figure 1), implying that cells prefer to initiate the PERK-eIF2\u03b1 pathway in response to virus infection, presumably because the PERK-eIF2\u03b1-mediated global translational attenuation can efficiently restrict virus replication by preventing the synthesis of viral and cellular proteins crucial for virus life cycle (Baltzis et al., 2004; Pena & Harris, 2011).", [["cells", "ANATOMY", 261, 266], ["cellular", "ANATOMY", 501, 509], ["infection", "DISEASE", 330, 339], ["ER", "GENE_OR_GENE_PRODUCT", 35, 37], ["UPR", "GENE_OR_GENE_PRODUCT", 56, 59], ["PERK", "GENE_OR_GENE_PRODUCT", 169, 173], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 174, 179], ["IRE1", "GENE_OR_GENE_PRODUCT", 181, 185], ["XBP1", "GENE_OR_GENE_PRODUCT", 186, 190], ["ATF6", "GENE_OR_GENE_PRODUCT", 195, 199], ["Table 1", "GENE_OR_GENE_PRODUCT", 224, 231], ["Figure 1", "GENE_OR_GENE_PRODUCT", 236, 244], ["cells", "CELL", 261, 266], ["PERK", "GENE_OR_GENE_PRODUCT", 290, 294], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 295, 300], ["PERK", "GENE_OR_GENE_PRODUCT", 364, 368], ["eIF2\u03b1", "GENE_OR_GENE_PRODUCT", 369, 374], ["cellular", "CELL", 501, 509], ["ER", "PROTEIN", 35, 37], ["UPR transmembrane sensors", "PROTEIN", 56, 81], ["PERK", "PROTEIN", 169, 173], ["eIF2\u03b1", "PROTEIN", 174, 179], ["IRE1", "PROTEIN", 181, 185], ["XBP1", "PROTEIN", 186, 190], ["ATF6", "PROTEIN", 195, 199], ["PERK", "PROTEIN", 290, 294], ["eIF2\u03b1", "PROTEIN", 295, 300], ["PERK", "PROTEIN", 364, 368], ["eIF2\u03b1", "PROTEIN", 369, 374], ["viral and cellular proteins", "PROTEIN", 491, 518], ["ER stress", "PROBLEM", 35, 44], ["the three UPR transmembrane sensors", "TEST", 46, 81], ["IRE1", "TEST", 181, 185], ["the PERK", "TEST", 286, 294], ["eIF2\u03b1 pathway", "TREATMENT", 295, 308], ["virus infection", "PROBLEM", 324, 339], ["the PERK", "TEST", 360, 368], ["global translational attenuation", "PROBLEM", 384, 416], ["virus replication", "TREATMENT", 442, 459], ["viral and cellular proteins", "TREATMENT", 491, 518], ["virus life cycle", "TREATMENT", 531, 547], ["branches", "ANATOMY_MODIFIER", 200, 208]]], ["Nonetheless, it should be noted that at least two other eIF2\u03b1 kinases, double-stranded RNA-dependent protein kinase (PKR) and general control non-derepressible-2 (GCN2) could be activated upon virus infection to restrict virus replication by preventing protein translation (Berlanga et al., 2006; Garcia et al., 2007).", [["infection", "DISEASE", 199, 208], ["eIF2\u03b1 kinases", "GENE_OR_GENE_PRODUCT", 56, 69], ["double-stranded RNA-dependent protein kinase", "GENE_OR_GENE_PRODUCT", 71, 115], ["PKR", "GENE_OR_GENE_PRODUCT", 117, 120], ["non-derepressible-2", "GENE_OR_GENE_PRODUCT", 142, 161], ["GCN2", "GENE_OR_GENE_PRODUCT", 163, 167], ["eIF2\u03b1 kinases", "PROTEIN", 56, 69], ["double-stranded RNA-dependent protein kinase", "PROTEIN", 71, 115], ["PKR", "PROTEIN", 117, 120], ["non-derepressible-2", "PROTEIN", 142, 161], ["GCN2", "PROTEIN", 163, 167], ["eIF2\u03b1 kinases", "TEST", 56, 69], ["double-stranded RNA-dependent protein kinase", "TREATMENT", 71, 115], ["PKR", "TEST", 117, 120], ["general control non-derepressible", "TEST", 126, 159], ["virus infection", "PROBLEM", 193, 208], ["virus replication", "TREATMENT", 221, 238]]], ["Hence, the role of PERK in translational attenuation could change depending on the virus.", [["PERK", "GENE_OR_GENE_PRODUCT", 19, 23], ["PERK", "PROTEIN", 19, 23], ["PERK in translational attenuation", "PROBLEM", 19, 52], ["the virus", "PROBLEM", 79, 88], ["translational attenuation", "OBSERVATION", 27, 52]]]], "6e069fa44337631ccf85a8f11c85b51e82585acb": [["In Peru, as of June 3, 2020, there have been 17 8914 confirmed cases; 4894 reported deaths; and the mortality rate was 2.74% (Gobierno del Per\u00fa 2020).", [["deaths", "DISEASE", 84, 90], ["the mortality rate", "TEST", 96, 114]]], ["One psychological aspect of the COVID-19 pandemic is fear, which is defined as an unpleasant emotional state that is triggered by the perception of threatening stimuli .", [["threatening stimuli", "TEST", 148, 167]]], ["The relationship between infectious disease and fear is directly related to its form of transmission (rapid and invisible) and mortality rate (Ahorsu et al. 2020) .", [["infectious disease", "DISEASE", 25, 43], ["infectious disease", "PROBLEM", 25, 43], ["mortality rate", "TEST", 127, 141], ["infectious", "OBSERVATION", 25, 35]]], ["Due to the high communicability of COVID-19 and the increasing number of confirmed cases and deaths worldwide, negative emotions and thoughts have become more frequent (Duan and Zhu 2020) .", [["deaths", "DISEASE", 93, 99], ["COVID", "TEST", 35, 40]]], ["This fear experience can evolve into a range of mental health problems, including distress reactions (insomnia, anger, irritability), health risk behaviors (increased alcohol and tobacco use), and mental disorders (posttraumatic stress disorder, anxiety, and depression disorders), among others (Shigemura et al. 2020) .", [["distress reactions", "DISEASE", 82, 100], ["insomnia", "DISEASE", 102, 110], ["anger", "DISEASE", 112, 117], ["irritability", "DISEASE", 119, 131], ["alcohol", "CHEMICAL", 167, 174], ["mental disorders", "DISEASE", 197, 213], ["posttraumatic stress disorder", "DISEASE", 215, 244], ["anxiety", "DISEASE", 246, 253], ["depression disorders", "DISEASE", 259, 279], ["tobacco", "ORGANISM_SUBDIVISION", 179, 186], ["mental health problems", "PROBLEM", 48, 70], ["distress reactions", "PROBLEM", 82, 100], ["insomnia", "PROBLEM", 102, 110], ["irritability", "PROBLEM", 119, 131], ["mental disorders", "PROBLEM", 197, 213], ["posttraumatic stress disorder", "PROBLEM", 215, 244], ["anxiety", "PROBLEM", 246, 253], ["depression disorders", "PROBLEM", 259, 279]]], ["The proliferation of fear generates erratic behaviors among people during infectious outbreaks, which is an expected phenomenon .", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66], ["The proliferation of fear", "PROBLEM", 0, 25], ["erratic behaviors", "PROBLEM", 36, 53], ["an expected phenomenon", "PROBLEM", 105, 127], ["proliferation", "OBSERVATION_MODIFIER", 4, 17], ["infectious", "OBSERVATION_MODIFIER", 74, 84], ["expected phenomenon", "OBSERVATION", 108, 127]]]], "PMC7390460": [["IntroductionRadiopharmaceutical therapy (RPT) is defined by the delivery of radioactive atoms to tumour-associated targets.", [["tumour", "ANATOMY", 97, 103], ["tumour", "DISEASE", 97, 103], ["tumour", "CANCER", 97, 103], ["IntroductionRadiopharmaceutical therapy", "TREATMENT", 0, 39], ["radioactive atoms", "TREATMENT", 76, 93]]], ["RPT is a novel therapeutic modality for the treatment of cancer, providing several advantages over existing therapeutic approaches.", [["cancer", "ANATOMY", 57, 63], ["cancer", "DISEASE", 57, 63], ["cancer", "CANCER", 57, 63], ["a novel therapeutic modality", "TREATMENT", 7, 35], ["cancer", "PROBLEM", 57, 63], ["existing therapeutic approaches", "TREATMENT", 99, 130], ["cancer", "OBSERVATION", 57, 63]]], ["Unlike radiotherapy, the radiation is not administered from outside the body, but instead is delivered systemically or locoregionally, akin to chemotherapy or biologically targeted therapy.", [["body", "ANATOMY", 72, 76], ["body", "ORGANISM_SUBDIVISION", 72, 76], ["radiotherapy", "TREATMENT", 7, 19], ["the radiation", "TREATMENT", 21, 34], ["chemotherapy", "TREATMENT", 143, 155], ["biologically targeted therapy", "TREATMENT", 159, 188], ["radiotherapy", "OBSERVATION", 7, 19], ["body", "ANATOMY", 72, 76]]], ["The cytotoxic radiation is delivered to cancer cells or to their microenvironment either directly or, more typically, using delivery vehicles that either bind specifically to endogenous targets or accumulate by a wide variety of physiological mechanisms characteristic of neoplasia, enabling a targeted therapeutic approach.", [["cancer cells", "ANATOMY", 40, 52], ["neoplasia", "ANATOMY", 272, 281], ["cancer", "DISEASE", 40, 46], ["neoplasia", "DISEASE", 272, 281], ["cancer cells", "CELL", 40, 52], ["neoplasia", "CANCER", 272, 281], ["cancer cells", "CELL_TYPE", 40, 52], ["The cytotoxic radiation", "TREATMENT", 0, 23], ["cancer cells", "PROBLEM", 40, 52], ["delivery vehicles", "TREATMENT", 124, 141], ["neoplasia", "PROBLEM", 272, 281], ["a targeted therapeutic approach", "TREATMENT", 292, 323], ["cytotoxic", "OBSERVATION_MODIFIER", 4, 13], ["radiation", "OBSERVATION", 14, 23], ["neoplasia", "OBSERVATION", 272, 281]]], ["Unlike biologic therapy, it is far less dependent on an understanding of signalling pathways and on identifying agents that interrupt the putative cancer phenotype-driving pathway (or pathways).", [["cancer", "ANATOMY", 147, 153], ["cancer", "DISEASE", 147, 153], ["cancer", "CANCER", 147, 153], ["biologic therapy", "TREATMENT", 7, 23], ["agents", "TREATMENT", 112, 118], ["biologic therapy", "OBSERVATION", 7, 23]]], ["Notably, the clinical trial failure rate of \u2018targeted\u2019 (that is, biologic) cancer therapies is 97% (ref.1), which is in part due to the drugs selected for clinical trial investigation targeting the wrong pathway2.IntroductionRadionuclides with different emission properties \u2014 primarily \u03b2-particles or highly potent \u03b1-particles \u2014 are used to deliver radiation.", [["cancer", "ANATOMY", 75, 81], ["cancer", "DISEASE", 75, 81], ["cancer", "CANCER", 75, 81], ["\u03b2-particles", "SIMPLE_CHEMICAL", 286, 297], ["the clinical trial failure rate", "PROBLEM", 9, 40], ["cancer therapies", "TREATMENT", 75, 91], ["the drugs", "TREATMENT", 132, 141], ["clinical trial investigation", "TEST", 155, 183], ["IntroductionRadionuclides", "TREATMENT", 213, 238], ["different emission properties", "TREATMENT", 244, 273], ["radiation", "TREATMENT", 349, 358]]], ["In almost all cases, the radionuclides may be visualized by nuclear medicine imaging techniques to assess targeting of the agent, which provides a substantial advantage over existing therapeutic approaches and enables a precision medicine approach to RPT delivery.IntroductionPatients with cancer with distant metastases continue to have a grim prognosis despite ongoing efforts with new chemotherapeutics, small-molecule inhibitors, biologics, immune checkpoint inhibitors and various combinations of these; novel therapeutic approaches are therefore vital.", [["nuclear", "ANATOMY", 60, 67], ["cancer", "ANATOMY", 290, 296], ["metastases", "ANATOMY", 310, 320], ["cancer", "DISEASE", 290, 296], ["RPT", "CANCER", 251, 254], ["cancer", "CANCER", 290, 296], ["nuclear medicine imaging techniques", "TEST", 60, 95], ["the agent", "TREATMENT", 119, 128], ["therapeutic approaches", "TREATMENT", 183, 205], ["a precision medicine approach", "TREATMENT", 218, 247], ["RPT delivery", "TREATMENT", 251, 263], ["cancer", "PROBLEM", 290, 296], ["distant metastases", "PROBLEM", 302, 320], ["a grim prognosis", "PROBLEM", 338, 354], ["new chemotherapeutics", "TREATMENT", 384, 405], ["small-molecule inhibitors", "TREATMENT", 407, 432], ["biologics", "TREATMENT", 434, 443], ["immune checkpoint inhibitors", "TREATMENT", 445, 473], ["novel therapeutic approaches", "TREATMENT", 509, 537], ["cancer", "OBSERVATION", 290, 296], ["distant", "OBSERVATION_MODIFIER", 302, 309], ["metastases", "OBSERVATION", 310, 320]]], ["Compared with almost all other systemic cancer treatment options, RPT has shown efficacy with minimal toxicity3.", [["cancer", "ANATOMY", 40, 46], ["cancer", "DISEASE", 40, 46], ["RPT", "CHEMICAL", 66, 69], ["cancer", "CANCER", 40, 46], ["systemic cancer treatment options", "TREATMENT", 31, 64], ["RPT", "TEST", 66, 69], ["minimal toxicity3", "PROBLEM", 94, 111], ["systemic", "OBSERVATION_MODIFIER", 31, 39], ["cancer", "OBSERVATION", 40, 46], ["minimal", "OBSERVATION_MODIFIER", 94, 101], ["toxicity3", "OBSERVATION", 102, 111]]], ["In addition, unlike chemotherapy, responses with RPT agents typically do not require many months (or cycles) of therapy and are often observed after a single or at most five injections; side effects such as alopecia or peripheral neuropathy are generally less severe than with chemotherapy, if observed at all.IntroductionRPT development is a multidisciplinary endeavour, requiring expertise in radiochemistry, radiobiology, oncology, pharmacology, medical physics and radionuclide imaging and dosimetry \u2014 most pharmaceutical companies are not familiar with the radiation and radionuclide aspects of RPT and the deployment of RPT agents for cancer therapy is also unfamiliar to the oncology community.", [["cancer", "ANATOMY", 641, 647], ["alopecia", "DISEASE", 207, 215], ["peripheral neuropathy", "DISEASE", 219, 240], ["cancer", "DISEASE", 641, 647], ["RPT agents", "SIMPLE_CHEMICAL", 626, 636], ["cancer", "CANCER", 641, 647], ["unlike chemotherapy", "TREATMENT", 13, 32], ["RPT agents", "TREATMENT", 49, 59], ["therapy", "TREATMENT", 112, 119], ["side effects", "PROBLEM", 186, 198], ["alopecia", "PROBLEM", 207, 215], ["peripheral neuropathy", "PROBLEM", 219, 240], ["chemotherapy", "TREATMENT", 277, 289], ["radionuclide imaging", "TEST", 469, 489], ["RPT", "TEST", 600, 603], ["RPT agents", "TREATMENT", 626, 636], ["cancer therapy", "TREATMENT", 641, 655], ["chemotherapy", "OBSERVATION", 20, 32], ["peripheral", "ANATOMY", 219, 229], ["neuropathy", "OBSERVATION", 230, 240], ["less severe", "OBSERVATION_MODIFIER", 255, 266]]], ["For many decades RPT has been a treatment modality of last resort and available only in small clinical trials or as part of compassionate care from a small number of institutions in Europe and even fewer in the USA and the rest of the world.", [["RPT", "CANCER", 17, 20], ["a treatment modality", "TREATMENT", 30, 50], ["small", "OBSERVATION_MODIFIER", 150, 155]]], ["In the sense that RPT has no well-defined community of stakeholders it has been an \u2018orphan treatment\u2019 modality for many years.IntroductionHowever, the remarkable potential of RPT directed against primary cancers as well as distant metastases, is now being recognized as an effective, safe and economically and logistically viable treatment modality, receiving renewed attention from both small and large pharmaceutical companies4.", [["primary cancers", "ANATOMY", 196, 211], ["metastases", "ANATOMY", 231, 241], ["RPT", "CHEMICAL", 175, 178], ["primary cancers", "DISEASE", 196, 211], ["metastases", "DISEASE", 231, 241], ["RPT", "CANCER", 175, 178], ["primary cancers", "CANCER", 196, 211], ["RPT", "TEST", 18, 21], ["an \u2018orphan treatment", "TREATMENT", 80, 100], ["RPT", "TEST", 175, 178], ["primary cancers", "PROBLEM", 196, 211], ["distant metastases", "PROBLEM", 223, 241], ["logistically viable treatment modality", "TREATMENT", 310, 348], ["cancers", "OBSERVATION", 204, 211], ["distant", "OBSERVATION_MODIFIER", 223, 230], ["metastases", "OBSERVATION", 231, 241], ["small", "OBSERVATION_MODIFIER", 388, 393], ["large", "OBSERVATION_MODIFIER", 398, 403], ["pharmaceutical companies4", "OBSERVATION", 404, 429]]], ["The recent approval of \u03b2-particle-emitting RPT agents that act against neuroendocrine cancers and phaeochromocytomas, the approval of an \u03b1-emitter RPT for bone metastases of prostate cancer and the highly promising clinical and preclinical preliminary results with RPT agents using other \u03b1-particle-emitting radionuclides has reignited interest in RPT.IntroductionThis Review provides an overview of the radiochemistry and physics aspects needed to understand the fundamentals of RPT.", [["neuroendocrine cancers", "ANATOMY", 71, 93], ["phaeochromocytomas", "ANATOMY", 98, 116], ["bone metastases", "ANATOMY", 155, 170], ["prostate cancer", "ANATOMY", 174, 189], ["neuroendocrine cancers", "DISEASE", 71, 93], ["phaeochromocytomas", "DISEASE", 98, 116], ["bone metastases", "DISEASE", 155, 170], ["prostate cancer", "DISEASE", 174, 189], ["\u03b2-particle", "SIMPLE_CHEMICAL", 23, 33], ["neuroendocrine cancers", "CANCER", 71, 93], ["phaeochromocytomas", "CANCER", 98, 116], ["bone", "TISSUE", 155, 159], ["prostate cancer", "CANCER", 174, 189], ["RPT agents", "SIMPLE_CHEMICAL", 265, 275], ["RPT", "CANCER", 348, 351], ["RPT", "CANCER", 480, 483], ["\u03b2-particle-emitting RPT agents", "TREATMENT", 23, 53], ["neuroendocrine cancers", "PROBLEM", 71, 93], ["phaeochromocytomas", "PROBLEM", 98, 116], ["an \u03b1-emitter RPT", "TEST", 134, 150], ["bone metastases", "PROBLEM", 155, 170], ["prostate cancer", "PROBLEM", 174, 189], ["RPT agents", "TREATMENT", 265, 275], ["other \u03b1-particle", "TREATMENT", 282, 298], ["RPT", "TEST", 348, 351], ["RPT", "TEST", 480, 483], ["phaeochromocytomas", "OBSERVATION", 98, 116], ["bone", "ANATOMY", 155, 159], ["metastases", "OBSERVATION", 160, 170], ["prostate", "ANATOMY", 174, 182], ["cancer", "OBSERVATION", 183, 189]]], ["The different categories of RPT agents in use and in the clinic for the treatment of cancer and the challenges associated with their development and application are discussed.", [["cancer", "ANATOMY", 85, 91], ["cancer", "DISEASE", 85, 91], ["cancer", "CANCER", 85, 91], ["RPT agents", "TREATMENT", 28, 38], ["cancer", "PROBLEM", 85, 91], ["cancer", "OBSERVATION", 85, 91]]], ["Notably, many other RPT agents are in preclinical development, but their discussion is beyond the scope of this Review.", [["other RPT agents", "TREATMENT", 14, 30]]], ["Similarly, while RPT also has applications in non-oncological disorders, such as rheumatoid arthritis and polyarthritis, these will not be discussed here, and the reader is referred to recent reviews on these topics5,6.Mechanism and biological effects ::: Overview of RPTThe mechanism of action for RPT is radiation-induced killing of cells.", [["cells", "ANATOMY", 335, 340], ["non-oncological disorders", "DISEASE", 46, 71], ["rheumatoid arthritis", "DISEASE", 81, 101], ["polyarthritis", "DISEASE", 106, 119], ["RPT", "CHEMICAL", 299, 302], ["RPT", "SIMPLE_CHEMICAL", 299, 302], ["cells", "CELL", 335, 340], ["non-oncological disorders", "PROBLEM", 46, 71], ["rheumatoid arthritis", "PROBLEM", 81, 101], ["polyarthritis", "PROBLEM", 106, 119], ["RPT", "TEST", 299, 302], ["killing of cells", "PROBLEM", 324, 340], ["rheumatoid", "OBSERVATION_MODIFIER", 81, 91], ["arthritis", "OBSERVATION", 92, 101], ["polyarthritis", "OBSERVATION", 106, 119], ["biological effects", "OBSERVATION", 233, 251]]], ["Investigation into the effects of radiation on tissues and tumours began soon after the discovery of radiation and radioactivity.", [["tissues", "ANATOMY", 47, 54], ["tumours", "ANATOMY", 59, 66], ["tissues", "TISSUE", 47, 54], ["tumours", "CANCER", 59, 66], ["radiation on tissues", "TREATMENT", 34, 54], ["tumours", "PROBLEM", 59, 66], ["radiation and radioactivity", "TREATMENT", 101, 128], ["radiation", "OBSERVATION", 34, 43], ["radiation", "OBSERVATION", 101, 110]]], ["RPT has the benefit of drawing on the substantial knowledge base of radiotherapy7.", [["RPT", "CHEMICAL", 0, 3], ["radiotherapy7", "CHEMICAL", 68, 81], ["radiotherapy7", "CHEMICAL", 68, 81], ["radiotherapy7", "SIMPLE_CHEMICAL", 68, 81], ["radiotherapy7", "PROTEIN", 68, 81], ["radiotherapy7", "TREATMENT", 68, 81]]], ["However, RPT differs from radiotherapy, and it is important to understand how those elements unique to RPT influence therapy.Mechanism and biological effects ::: Overview of RPTThe essential questions for RPT are where does the agent localize and for how long?", [["RPT", "CANCER", 205, 208], ["radiotherapy", "TREATMENT", 26, 38], ["RPT influence therapy", "TREATMENT", 103, 124], ["RPT", "TEST", 174, 177], ["biological effects", "OBSERVATION", 139, 157]]], ["As noted in the section entitled \u2018Dosimetry\u2019, answers to these questions inform the tumour versus normal tissue absorbed dose and provide a measure of potential treatment success.Mechanism and biological effects ::: Overview of RPTThe biological effects of a given absorbed dose for a tumour depend on the rate at which the dose is delivered8\u201310.", [["tumour", "ANATOMY", 84, 90], ["tissue", "ANATOMY", 105, 111], ["tumour", "ANATOMY", 285, 291], ["tumour", "DISEASE", 84, 90], ["tumour", "DISEASE", 285, 291], ["tumour", "CANCER", 84, 90], ["tissue", "TISSUE", 105, 111], ["tumour", "CANCER", 285, 291], ["potential treatment success", "TREATMENT", 151, 178], ["RPT", "TEST", 228, 231], ["a tumour depend", "PROBLEM", 283, 298], ["biological effects", "OBSERVATION", 193, 211], ["tumour", "OBSERVATION", 285, 291]]], ["A dose of 30 Gy delivered to a tumour over a period of many weeks at a dose rate that is exponentially decreasing, as is typically the case with RPT, will have a very different effect from that of the same amount delivered at the much higher dose rates used in radiotherapy (for example, daily, 2-Gy fractions over 15 days).", [["tumour", "ANATOMY", 31, 37], ["tumour", "DISEASE", 31, 37], ["tumour", "CANCER", 31, 37], ["RPT", "TEST", 145, 148], ["radiotherapy", "TREATMENT", 261, 273], ["tumour", "OBSERVATION", 31, 37], ["exponentially", "OBSERVATION_MODIFIER", 89, 102], ["decreasing", "OBSERVATION_MODIFIER", 103, 113]]], ["The difference in biological outcome will depend on the biological repair and radiosensitivity properties of the tumour.", [["tumour", "ANATOMY", 113, 119], ["tumour", "DISEASE", 113, 119], ["tumour", "CANCER", 113, 119], ["The difference in biological outcome", "PROBLEM", 0, 36], ["the biological repair", "TREATMENT", 52, 73], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["repair", "OBSERVATION", 67, 73], ["tumour", "OBSERVATION", 113, 119]]], ["Dose-rate considerations also apply to normal organs11\u201313.Mechanism and biological effects ::: Overview of RPTAnother fundamental distinguishing feature important for understanding this treatment modality is the diminishing curative potential with reduced target cell number (Fig. 1).", [["organs", "ANATOMY", 46, 52], ["cell", "ANATOMY", 263, 267], ["organs", "ORGAN", 46, 52], ["cell", "CELL", 263, 267], ["this treatment modality", "TREATMENT", 181, 204], ["biological effects", "OBSERVATION", 72, 90]]], ["In radiotherapy the probability of killing all cells for a given absorbed dose increases as the number of target cells decreases \u2014 fewer cells to kill for a given radiation absorbed dose increases the chance that all of the cells will be killed.", [["cells", "ANATOMY", 47, 52], ["cells", "ANATOMY", 113, 118], ["cells", "ANATOMY", 137, 142], ["cells", "ANATOMY", 224, 229], ["cells", "CELL", 47, 52], ["cells", "CELL", 113, 118], ["cells", "CELL", 137, 142], ["cells", "CELL", 224, 229], ["target cells", "CELL_TYPE", 106, 118], ["radiotherapy", "TREATMENT", 3, 15], ["killing all cells", "TREATMENT", 35, 52], ["target cells", "PROBLEM", 106, 118], ["radiation absorbed dose", "TREATMENT", 163, 186], ["the cells", "TREATMENT", 220, 229]]], ["By contrast, fewer cells do not translate into a greater tumour control probability in RPT.", [["cells", "ANATOMY", 19, 24], ["tumour", "ANATOMY", 57, 63], ["tumour", "DISEASE", 57, 63], ["cells", "CELL", 19, 24], ["tumour", "CANCER", 57, 63], ["RPT", "CANCER", 87, 90], ["RPT", "CELL_TYPE", 87, 90], ["RPT", "TEST", 87, 90], ["greater", "OBSERVATION_MODIFIER", 49, 56], ["tumour", "OBSERVATION", 57, 63]]], ["This is because the radiation is not delivered uniformly to all cells.", [["cells", "ANATOMY", 64, 69], ["cells", "CELL", 64, 69], ["radiation", "OBSERVATION", 20, 29]]], ["If the emitted radiation originates from a radionuclide on the surface of tumour cells, fewer cells leads to a smaller fraction of the emitted energy being deposited into the targeted cells14.", [["surface", "ANATOMY", 63, 70], ["tumour cells", "ANATOMY", 74, 86], ["cells", "ANATOMY", 94, 99], ["cells", "ANATOMY", 184, 189], ["tumour", "DISEASE", 74, 80], ["surface", "CELLULAR_COMPONENT", 63, 70], ["tumour cells", "CELL", 74, 86], ["cells", "CELL", 94, 99], ["cells", "CELL", 184, 189], ["tumour cells", "CELL_TYPE", 74, 86], ["targeted cells14", "CELL_LINE", 175, 191], ["the emitted radiation", "PROBLEM", 3, 24], ["tumour cells", "PROBLEM", 74, 86], ["fewer cells", "PROBLEM", 88, 99], ["tumour cells", "OBSERVATION", 74, 86], ["smaller", "OBSERVATION_MODIFIER", 111, 118], ["emitted energy", "OBSERVATION", 135, 149]]], ["This is balanced, in part, by the greater concentration that may be achieved in smaller clusters of cells relative to large measurable tumours.Radionuclides used for RPT ::: Overview of RPTOne of the hallmarks of RPT is its ability to deliver highly potent forms of radiation directly to tumour cells.", [["cells", "ANATOMY", 100, 105], ["tumours", "ANATOMY", 135, 142], ["tumour cells", "ANATOMY", 288, 300], ["tumour", "DISEASE", 288, 294], ["cells", "CELL", 100, 105], ["tumours", "CANCER", 135, 142], ["RPT", "CANCER", 213, 216], ["tumour cells", "CELL", 288, 300], ["tumour cells", "CELL_TYPE", 288, 300], ["large measurable tumours", "PROBLEM", 118, 142], ["RPT", "TEST", 166, 169], ["RPT", "TEST", 213, 216], ["radiation", "TREATMENT", 266, 275], ["balanced", "OBSERVATION", 8, 16], ["may be", "UNCERTAINTY", 61, 67], ["smaller", "OBSERVATION_MODIFIER", 80, 87], ["large", "OBSERVATION_MODIFIER", 118, 123], ["measurable", "OBSERVATION_MODIFIER", 124, 134], ["tumours", "OBSERVATION", 135, 142], ["tumour cells", "OBSERVATION", 288, 300]]], ["Three different types of radiation are relevant to understanding RPT: photons, electrons and \u03b1-particles15.Radionuclides used for RPT ::: Overview of RPTPhotons come in two \u2018flavours\u2019 \u2014 X-rays and \u03b3-rays.", [["X", "PROTEIN", 186, 187], ["radiation", "TREATMENT", 25, 34], ["photons, electrons and \u03b1-particles", "TREATMENT", 70, 104], ["RPT", "TEST", 130, 133], ["radiation", "OBSERVATION", 25, 34]]], ["The former are derived from orbital electron transitions and are typically lower in energy than \u03b3-rays.", [["orbital", "ANATOMY", 28, 35], ["electron transitions", "OBSERVATION", 36, 56]]], ["Radionuclide photon emissions are useful for imaging the distribution of the RPT but not for localized delivery of cytotoxic radiation.", [["Radionuclide photon emissions", "TEST", 0, 29], ["imaging", "TEST", 45, 52], ["the RPT", "TEST", 73, 80], ["cytotoxic radiation", "TREATMENT", 115, 134], ["cytotoxic radiation", "OBSERVATION", 115, 134]]], ["Although a wide range of photon energies may be imaged (70\u2013400 keV), photon emission energies in the range from 100 to 200 keV are optimal for all nuclear medicine imaging cameras (\u03b3-cameras and single-photon emission computed tomography (SPECT) cameras).", [["a wide range of photon energies", "PROBLEM", 9, 40], ["photon emission energies", "TEST", 69, 93], ["all nuclear medicine imaging cameras", "TEST", 143, 179], ["single-photon emission computed tomography", "TEST", 195, 237], ["wide", "OBSERVATION_MODIFIER", 11, 15]]], ["A number of radionuclides also emit positrons which lead to the emission of 511-keV photons that are detected by positron emission tomography (PET) cameras.Radionuclides used for RPT ::: Overview of RPTElectron emissions are classified by energy and also by the type of decay.", [["511-keV photons", "TREATMENT", 76, 91], ["positron emission tomography", "TEST", 113, 141]]], ["Auger electrons, \u03b2-particles and monoenergetic electrons are relevant to RPT.", [["\u03b2-particles", "SIMPLE_CHEMICAL", 17, 28], ["Auger electrons, \u03b2-particles and monoenergetic electrons", "PROBLEM", 0, 56], ["RPT", "TEST", 73, 76]]], ["Auger electrons are generated from suborbital transitions.", [["suborbital transitions", "OBSERVATION", 35, 57]]], ["If the RPT drug localizes within the cell nucleus, these emissions could be highly cytotoxic13,16\u201320.", [["cell nucleus", "ANATOMY", 37, 49], ["RPT", "GENE_OR_GENE_PRODUCT", 7, 10], ["cell nucleus", "CELLULAR_COMPONENT", 37, 49], ["the RPT drug", "TEST", 3, 15], ["cell nucleus", "OBSERVATION", 37, 49]]], ["Although preclinical studies have shown substantial therapeutic efficacy, the small number of human investigations did not lead to clinical efficacy21\u201324.", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["preclinical studies", "TEST", 9, 28], ["human investigations", "TEST", 94, 114], ["substantial", "OBSERVATION_MODIFIER", 40, 51], ["therapeutic", "OBSERVATION_MODIFIER", 52, 63], ["small", "OBSERVATION_MODIFIER", 78, 83]]], ["Human studies using locoregional administration showed promise in terms of tumour cell incorporation of the Auger emitters17,20,25.", [["tumour cell", "ANATOMY", 75, 86], ["tumour", "DISEASE", 75, 81], ["Human", "ORGANISM", 0, 5], ["tumour cell", "CELL", 75, 86], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human studies", "TEST", 0, 13], ["locoregional administration", "TREATMENT", 20, 47], ["tumour cell incorporation", "TREATMENT", 75, 100], ["tumour cell incorporation", "OBSERVATION", 75, 100], ["Auger emitter", "OBSERVATION", 108, 121]]], ["The requirement that these agents be incorporated into the DNA and also their unfavourable pharmacokinetics are thought to be the reasons underlying the lack of efficacy.", [["DNA", "CELLULAR_COMPONENT", 59, 62], ["these agents", "TREATMENT", 21, 33], ["the DNA", "PROBLEM", 55, 62]]], ["Encouraged by ongoing technological developments that could overcome the factors listed above, these agents continue to be of interest to the RPT community26.Radionuclides used for RPT ::: Overview of RPT\u03b2-Particles are electrons emitted from the nucleus.", [["nucleus", "ANATOMY", 247, 254], ["nucleus", "CELLULAR_COMPONENT", 247, 254], ["these agents", "TREATMENT", 95, 107], ["RPT", "TEST", 181, 184], ["RPT", "TEST", 201, 204], ["nucleus", "ANATOMY", 247, 254]]], ["They typically have a longer range in tissue (of the order of 1\u20135 mm) and are the most frequently used emission type for RPT agents.", [["tissue", "ANATOMY", 38, 44], ["tissue", "TISSUE", 38, 44], ["RPT agents", "SIMPLE_CHEMICAL", 121, 131], ["RPT agents", "TREATMENT", 121, 131]]], ["This is in part because \u03b2-particle-emitting radionuclides are widely available, many of which also emit photons in an energy range that is easily imaged.", [["energy range", "OBSERVATION", 118, 130]]], ["The \u03b2-particle emitters samarium-153, lutetium-177, yttrium-90 and I-131 have been introduced and commonly used over the last 40 years (Fig. 2a; Tables 1,2).", [["samarium-153, lutetium-177", "CHEMICAL", 24, 50], ["yttrium-90 and I-131", "CHEMICAL", 52, 72], ["samarium-153", "CHEMICAL", 24, 36], ["lutetium-177", "CHEMICAL", 38, 50], ["yttrium", "CHEMICAL", 52, 59], ["samarium-153", "SIMPLE_CHEMICAL", 24, 36], ["lutetium-177", "SIMPLE_CHEMICAL", 38, 50], ["yttrium-90", "SIMPLE_CHEMICAL", 52, 62], ["I-131", "SIMPLE_CHEMICAL", 67, 72], ["The \u03b2-particle emitters samarium", "TEST", 0, 32], ["lutetium", "TEST", 38, 46], ["yttrium", "TREATMENT", 52, 59]]], ["The most familiar and frequently used of these is iodine-131, which is used to treat thyroid cancer.", [["thyroid cancer", "ANATOMY", 85, 99], ["iodine-131", "CHEMICAL", 50, 60], ["thyroid cancer", "DISEASE", 85, 99], ["iodine-131", "CHEMICAL", 50, 60], ["iodine-131", "SIMPLE_CHEMICAL", 50, 60], ["thyroid cancer", "CANCER", 85, 99], ["iodine", "TREATMENT", 50, 56], ["thyroid cancer", "PROBLEM", 85, 99], ["thyroid", "ANATOMY", 85, 92], ["cancer", "OBSERVATION", 93, 99]]], ["A number of other \u03b2-emitting radionuclides have been investigated or considered27\u201331 but for several reasons \u2014 including lack of availability, difficult radiochemistry or perhaps, most prominently, the absence of a commercial justification to overcome the regulatory and financial hurdles involved in their clinical translation \u2014 these agents have not been widely adopted32.Radionuclides used for RPT ::: Overview of RPTA variety of reasons for the progression and shift to different radionuclides may be invoked to explain the changes and additions of the different \u03b2-particle emitters used over time.", [["RPT", "TEST", 397, 400], ["the progression", "PROBLEM", 445, 460], ["the different \u03b2-particle emitters", "TREATMENT", 553, 586]]], ["For example, in an early theoretical evaluation of different radionuclides, yttrium-90 ranked second to rhenium-186 in a list of nine radionuclides considered12.", [["yttrium-90", "CHEMICAL", 76, 86], ["rhenium-186", "CHEMICAL", 104, 115], ["yttrium-90", "CHEMICAL", 76, 86], ["rhenium-186", "CHEMICAL", 104, 115], ["yttrium-90", "SIMPLE_CHEMICAL", 76, 86], ["rhenium-186", "SIMPLE_CHEMICAL", 104, 115], ["an early theoretical evaluation", "TEST", 16, 47], ["yttrium", "TEST", 76, 83], ["rhenium", "TEST", 104, 111], ["nine radionuclides", "TREATMENT", 129, 147]]], ["In that ranking, the main criterion was the tumour to non-tumour-absorbed dose ratio.", [["tumour", "ANATOMY", 44, 50], ["non-tumour", "ANATOMY", 54, 64], ["tumour", "DISEASE", 44, 50], ["tumour", "CANCER", 44, 50], ["main", "OBSERVATION_MODIFIER", 21, 25], ["tumour", "OBSERVATION", 44, 50]]], ["This was a theoretical calculation obtained for different radionuclides using typical radiolabelled antibody pharmacokinetics for tumour targeting and organ clearance.", [["tumour", "ANATOMY", 130, 136], ["organ", "ANATOMY", 151, 156], ["tumour", "DISEASE", 130, 136], ["tumour", "CANCER", 130, 136], ["organ", "ORGAN", 151, 156], ["a theoretical calculation", "TEST", 9, 34], ["different radionuclides", "TREATMENT", 48, 71], ["typical radiolabelled antibody pharmacokinetics", "TREATMENT", 78, 125], ["tumour targeting", "TREATMENT", 130, 146], ["organ clearance", "TEST", 151, 166]]], ["This optimum reflected the 64.2-hour half-life of yttrium-90 and its high-energy \u03b2-particle, which was deemed favourable for uniformly irradiating tumours.", [["tumours", "ANATOMY", 147, 154], ["yttrium-90", "CHEMICAL", 50, 60], ["yttrium-90", "CHEMICAL", 50, 60], ["yttrium-90", "SIMPLE_CHEMICAL", 50, 60], ["tumours", "CANCER", 147, 154], ["This optimum", "TEST", 0, 12], ["uniformly irradiating tumours", "PROBLEM", 125, 154], ["irradiating tumours", "OBSERVATION", 135, 154]]], ["Like iodine-131, the adoption of yttrium-90 for RPT is likely based on its history and widespread availability.", [["iodine-131", "CHEMICAL", 5, 15], ["yttrium-90", "CHEMICAL", 33, 43], ["iodine-131", "CHEMICAL", 5, 15], ["yttrium-90", "CHEMICAL", 33, 43], ["iodine-131", "SIMPLE_CHEMICAL", 5, 15], ["yttrium-90", "SIMPLE_CHEMICAL", 33, 43], ["iodine", "TREATMENT", 5, 11], ["yttrium", "TREATMENT", 33, 40], ["RPT", "TEST", 48, 51]]], ["In the 1970s it was used in colloidal form, primarily to treat rheumatoid conditions33,34.", [["rheumatoid conditions", "PROBLEM", 63, 84], ["rheumatoid", "OBSERVATION", 63, 73]]], ["Efforts to conjugate yttrium-90, a radiometal, were unsuccessful35 until a radiometal conjugation chemistry that retained stability in vivo was developed36,37.", [["yttrium-90", "CHEMICAL", 21, 31], ["yttrium-90", "CHEMICAL", 21, 31], ["yttrium-90", "SIMPLE_CHEMICAL", 21, 31], ["radiometal", "SIMPLE_CHEMICAL", 35, 45], ["conjugate yttrium", "TEST", 11, 28], ["a radiometal conjugation chemistry", "TEST", 73, 107], ["stability", "OBSERVATION_MODIFIER", 122, 131]]], ["Clinical trials using yttrium-90-labelled antibodies as RPT agents initially focused on ovarian cancer38,39 and subsequently on haematological cancers40\u201342, as well as radiopeptide therapy43.", [["ovarian cancer", "ANATOMY", 88, 102], ["haematological cancers", "ANATOMY", 128, 150], ["yttrium-90", "CHEMICAL", 22, 32], ["ovarian cancer", "DISEASE", 88, 102], ["haematological cancers", "DISEASE", 128, 150], ["yttrium-90", "CHEMICAL", 22, 32], ["yttrium-90", "SIMPLE_CHEMICAL", 22, 32], ["ovarian cancer", "CANCER", 88, 102], ["haematological cancers", "CANCER", 128, 150], ["yttrium-90-labelled antibodies", "PROTEIN", 22, 52], ["Clinical trials", "TEST", 0, 15], ["yttrium", "TEST", 22, 29], ["RPT agents", "TREATMENT", 56, 66], ["ovarian cancer", "PROBLEM", 88, 102], ["haematological cancers", "PROBLEM", 128, 150], ["radiopeptide therapy", "TREATMENT", 168, 188], ["ovarian", "ANATOMY", 88, 95], ["cancer", "OBSERVATION", 96, 102], ["haematological", "ANATOMY", 128, 142], ["cancers", "OBSERVATION", 143, 150]]], ["Yttrium-90 continues to be a popular radionuclide for RPT because of the clinical impact of yttrium-90-impregnated microspheres that are used for treatment of hepatic metastases44\u201348.", [["hepatic metastases", "ANATOMY", 159, 177], ["Yttrium-90", "CHEMICAL", 0, 10], ["yttrium-90-", "CHEMICAL", 92, 103], ["hepatic metastases", "DISEASE", 159, 177], ["Yttrium-90", "CHEMICAL", 0, 10], ["yttrium-90", "CHEMICAL", 92, 102], ["Yttrium-90", "SIMPLE_CHEMICAL", 0, 10], ["yttrium-90-impregnated microspheres", "SIMPLE_CHEMICAL", 92, 127], ["hepatic", "ORGAN", 159, 166], ["Yttrium", "TREATMENT", 0, 7], ["RPT", "TEST", 54, 57], ["yttrium", "TEST", 92, 99], ["impregnated microspheres", "TREATMENT", 103, 127], ["hepatic metastases", "PROBLEM", 159, 177], ["hepatic", "ANATOMY", 159, 166], ["metastases", "OBSERVATION", 167, 177]]], ["Although yttrium-90 has been imaged, imaging generally requires high activities (more than 300 MBq)49.", [["yttrium-90", "CHEMICAL", 9, 19], ["yttrium-90", "CHEMICAL", 9, 19], ["yttrium-90", "SIMPLE_CHEMICAL", 9, 19], ["yttrium", "TEST", 9, 16], ["imaging", "TEST", 37, 44]]], ["Such activities are typically achieved only in microsphere therapies.", [["microsphere therapies", "TREATMENT", 47, 68]]], ["Lutetium-177 gained popularity because it emits photons in the 100\u2013200-keV optimal imaging range and has a \u03b2-particle energy that is between that of iodine-131 and yttrium-90, which is appropriate for therapy.", [["Lutetium-177", "CHEMICAL", 0, 12], ["iodine-131", "CHEMICAL", 149, 159], ["yttrium-90", "CHEMICAL", 164, 174], ["Lutetium-177", "CHEMICAL", 0, 12], ["iodine-131", "CHEMICAL", 149, 159], ["yttrium-90", "CHEMICAL", 164, 174], ["Lutetium-177", "SIMPLE_CHEMICAL", 0, 12], ["iodine-131", "SIMPLE_CHEMICAL", 149, 159], ["yttrium-90", "SIMPLE_CHEMICAL", 164, 174], ["Lutetium", "TEST", 0, 8], ["a \u03b2-particle energy", "PROBLEM", 105, 124], ["iodine", "TREATMENT", 149, 155], ["therapy", "TREATMENT", 201, 208]]], ["These factors, along with a half-life that is compatible with the pharmacokinetics of both antibodies and peptides, make this radionuclide a theranostic in that the same radionuclide may be used to assess tumour uptake and the extent of cancer, and also as a treatment50.", [["tumour", "ANATOMY", 205, 211], ["cancer", "ANATOMY", 237, 243], ["tumour", "DISEASE", 205, 211], ["cancer", "DISEASE", 237, 243], ["tumour", "CANCER", 205, 211], ["cancer", "CANCER", 237, 243], ["antibodies", "PROTEIN", 91, 101], ["These factors", "PROBLEM", 0, 13], ["the pharmacokinetics of both antibodies and peptides", "PROBLEM", 62, 114], ["tumour uptake", "PROBLEM", 205, 218], ["cancer", "PROBLEM", 237, 243], ["compatible with", "UNCERTAINTY", 46, 61], ["cancer", "OBSERVATION", 237, 243]]], ["It is produced in a reactor and is therefore widely available51, with a relatively straightforward conjugation chemistry52.Radionuclides used for RPT ::: Overview of RPT\u03b1-Particles are helium nuclei (two protons and two neutrons) that are emitted from the nucleus of a radioactive atom.", [["nucleus", "ANATOMY", 256, 263], ["helium", "CHEMICAL", 185, 191], ["nucleus", "CELLULAR_COMPONENT", 256, 263], ["RPT", "TEST", 166, 169], ["nucleus", "ANATOMY_MODIFIER", 256, 263], ["radioactive atom", "OBSERVATION", 269, 285]]], ["Depending on their emission energy, they can travel 50\u2013100 \u00b5m in tissue.", [["tissue", "ANATOMY", 65, 71], ["tissue", "TISSUE", 65, 71]]], ["The amount of energy deposited per path length travelled (designated \u2018linear energy transfer\u2019) of \u03b1-particles is approximately 400 times greater than that of electrons.", [["amount", "OBSERVATION_MODIFIER", 4, 10], ["energy deposited", "OBSERVATION", 14, 30], ["path", "OBSERVATION_MODIFIER", 35, 39], ["length", "OBSERVATION_MODIFIER", 40, 46]]], ["This leads to substantially more damage along their path than that caused by electrons.", [["substantially", "OBSERVATION_MODIFIER", 14, 27], ["more", "OBSERVATION_MODIFIER", 28, 32], ["damage", "OBSERVATION", 33, 39]]], ["An \u03b1-particle track leads to a preponderance of complex and largely irreparable DNA double-strand breaks53,54.", [["DNA", "CELLULAR_COMPONENT", 80, 83], ["complex", "OBSERVATION_MODIFIER", 48, 55], ["irreparable", "OBSERVATION_MODIFIER", 68, 79], ["DNA", "OBSERVATION_MODIFIER", 80, 83], ["double", "OBSERVATION_MODIFIER", 84, 90]]], ["The absorbed dose required to achieve cytotoxicity relates to the number of \u03b1-particles traversing the cell nucleus.", [["cell nucleus", "ANATOMY", 103, 115], ["\u03b1-particles", "SIMPLE_CHEMICAL", 76, 87], ["cell nucleus", "CELLULAR_COMPONENT", 103, 115], ["\u03b1-particles", "PROTEIN", 76, 87], ["cytotoxicity", "PROBLEM", 38, 50], ["cell nucleus", "OBSERVATION", 103, 115]]], ["With use of this as a measure, cytotoxicity may be achieved with a range of 1 to 20 \u03b1-particle traversals of the cell nucleus53.", [["cell nucleus", "ANATOMY", 113, 125], ["cell", "CELL", 113, 117], ["cell nucleus", "ANATOMY", 113, 125]]], ["The resulting high potency, combined with the short range of \u03b1-particles (which reduces normal organ toxicity), has led to substantial commercial interest in developing \u03b1-particle-emitting RPT agents55.", [["organ", "ANATOMY", 95, 100], ["toxicity", "DISEASE", 101, 109], ["\u03b1-particles", "SIMPLE_CHEMICAL", 61, 72], ["organ", "ORGAN", 95, 100], ["\u03b1-particle", "SIMPLE_CHEMICAL", 169, 179], ["normal organ toxicity", "PROBLEM", 88, 109], ["\u03b1-particle-emitting RPT agents", "TREATMENT", 169, 199], ["high", "OBSERVATION_MODIFIER", 14, 18], ["potency", "OBSERVATION_MODIFIER", 19, 26], ["organ toxicity", "OBSERVATION", 95, 109], ["substantial", "OBSERVATION_MODIFIER", 123, 134]]], ["The \u03b1-particle emitters introduced and used for RPT over the last 40 years include astatine-211, bismuth-212, lead-212, bismuth-213, actinium-225, radium-223 and thorium-227 (Fig. 2b; Tables 1,2).Radionuclides used for RPT ::: Overview of RPTThe \u03b1-particle-emitting RPT agent radium-223 dichloride (Xofigo) was approved by the FDA in May 2013.", [["astatine-211", "CHEMICAL", 83, 95], ["bismuth-212, lead-212, bismuth-213, actinium-225, radium-223", "CHEMICAL", 97, 157], ["thorium-227", "CHEMICAL", 162, 173], ["radium-223 dichloride", "CHEMICAL", 276, 297], ["Xofigo", "CHEMICAL", 299, 305], ["astatine-211", "CHEMICAL", 83, 95], ["bismuth-212", "CHEMICAL", 97, 108], ["lead-212", "CHEMICAL", 110, 118], ["bismuth-213", "CHEMICAL", 120, 131], ["actinium-225", "CHEMICAL", 133, 145], ["radium-223", "CHEMICAL", 147, 157], ["thorium-227", "CHEMICAL", 162, 173], ["radium-223 dichloride", "CHEMICAL", 276, 297], ["Xofigo", "CHEMICAL", 299, 305], ["astatine-211", "SIMPLE_CHEMICAL", 83, 95], ["bismuth-212", "SIMPLE_CHEMICAL", 97, 108], ["lead-212", "SIMPLE_CHEMICAL", 110, 118], ["bismuth-213", "SIMPLE_CHEMICAL", 120, 131], ["actinium-225", "SIMPLE_CHEMICAL", 133, 145], ["radium-223", "SIMPLE_CHEMICAL", 147, 157], ["thorium-227", "SIMPLE_CHEMICAL", 162, 173], ["radium-223 dichloride", "SIMPLE_CHEMICAL", 276, 297], ["Xofigo", "SIMPLE_CHEMICAL", 299, 305], ["The \u03b1-particle emitters", "TREATMENT", 0, 23], ["RPT", "TEST", 48, 51], ["astatine", "TEST", 83, 91], ["bismuth", "TEST", 97, 104], ["lead", "TEST", 110, 114], ["bismuth", "TEST", 120, 127], ["actinium", "TEST", 133, 141], ["radium", "TEST", 147, 153], ["emitting RPT agent radium", "TREATMENT", 257, 282], ["dichloride (Xofigo)", "TREATMENT", 287, 306]]], ["At the time it was approved, effective therapies for patients with castration-resistant prostate cancer that had metastasized to bone did not exist.", [["prostate cancer", "ANATOMY", 88, 103], ["bone", "ANATOMY", 129, 133], ["prostate cancer", "DISEASE", 88, 103], ["patients", "ORGANISM", 53, 61], ["prostate cancer", "CANCER", 88, 103], ["bone", "TISSUE", 129, 133], ["patients", "SPECIES", 53, 61], ["effective therapies", "TREATMENT", 29, 48], ["castration", "TREATMENT", 67, 77], ["resistant prostate cancer", "PROBLEM", 78, 103], ["prostate", "ANATOMY", 88, 96], ["cancer", "OBSERVATION", 97, 103]]], ["The very encouraging clinical trial results56 and the subsequent FDA approval were instrumental in the renewed interest in RPT, in general, and \u03b1-emitter RPT, in particular.", [["RPT", "TEST", 123, 126]]], ["Subsequently, individual-patient demonstrations of \u03b1-emitter potency have reinforced the interest in \u03b1-particle-emitting RPT57,58.", [["patient", "ORGANISM", 25, 32], ["\u03b1-emitter", "SIMPLE_CHEMICAL", 51, 60], ["\u03b1-particle", "SIMPLE_CHEMICAL", 101, 111], ["patient", "SPECIES", 25, 32], ["\u03b1-emitter potency", "PROBLEM", 51, 68]]], ["Overall, there has been an almost sixfold increase in the number of studies related to \u03b1-emitters for RPT over the past 10 years.", [["studies", "TEST", 68, 75], ["RPT", "TEST", 102, 105], ["almost", "OBSERVATION_MODIFIER", 27, 33], ["sixfold", "OBSERVATION_MODIFIER", 34, 41], ["increase", "OBSERVATION_MODIFIER", 42, 50]]], ["Ongoing investigations of radium-223 in combination with other therapeutics59 that act against other bone-seeking cancers60\u201362 have led to the recent high prevalence of radium-223 RPT studies.Radionuclides used for RPT ::: Overview of RPTThere are more than 300 radionuclides that are potentially relevant to medicine and biology63.", [["bone", "ANATOMY", 101, 105], ["cancers", "ANATOMY", 114, 121], ["radium-223", "CHEMICAL", 26, 36], ["cancers", "DISEASE", 114, 121], ["radium-223", "CHEMICAL", 169, 179], ["radium-223", "CHEMICAL", 26, 36], ["radium-223", "CHEMICAL", 169, 179], ["radium-223", "SIMPLE_CHEMICAL", 26, 36], ["bone", "TISSUE", 101, 105], ["Ongoing investigations of radium", "TEST", 0, 32], ["RPT studies", "TEST", 180, 191], ["bone", "ANATOMY", 101, 105]]], ["Table 1 details the subset of these that are RPT agents of current interest, along with properties relevant to their use in RPT.Dosimetry ::: Overview of RPTResponse and toxicity prediction is essential for the rational implementation of cancer therapy.", [["cancer", "ANATOMY", 238, 244], ["toxicity", "DISEASE", 170, 178], ["cancer", "DISEASE", 238, 244], ["RPT", "CANCER", 124, 127], ["cancer", "CANCER", 238, 244], ["RPT agents", "TREATMENT", 45, 55], ["RPT", "TEST", 124, 127], ["toxicity prediction", "TEST", 170, 189], ["cancer therapy", "TREATMENT", 238, 252], ["cancer", "OBSERVATION", 238, 244]]], ["The biological effects of radionuclide therapy are mediated by a well-defined physical quantity, the absorbed dose (D), which is defined as the energy absorbed per unit mass of tissue.", [["tissue", "ANATOMY", 177, 183], ["tissue", "TISSUE", 177, 183], ["radionuclide therapy", "TREATMENT", 26, 46], ["mass", "OBSERVATION", 169, 173]]], ["The long and well-established cancer treatment experience in radiotherapy has provided ample evidence that absorbed dose may be used to predict biological response64.", [["cancer", "ANATOMY", 30, 36], ["cancer", "DISEASE", 30, 36], ["cancer", "CANCER", 30, 36], ["radiotherapy", "TREATMENT", 61, 73], ["cancer", "OBSERVATION", 30, 36]]], ["In chemotherapy, targeted biologic therapy and immunotherapy, there is no dosimetry analogue.", [["chemotherapy", "TREATMENT", 3, 15], ["targeted biologic therapy", "TREATMENT", 17, 42], ["immunotherapy", "TREATMENT", 47, 60], ["dosimetry analogue", "PROBLEM", 74, 92], ["no", "UNCERTAINTY", 71, 73]]], ["Dosimetry as implemented in RPT may be thought of as the ability to perform the equivalent of a pharmacodynamic study in treated patients in real time.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["RPT", "TEST", 28, 31], ["a pharmacodynamic study", "TEST", 94, 117]]], ["Dosimetry analysis may be performed as part of patient treatment to calculate tumour versus normal organ absorbed dose and therefore the likelihood of treatment success.", [["tumour", "ANATOMY", 78, 84], ["organ", "ANATOMY", 99, 104], ["tumour", "DISEASE", 78, 84], ["patient", "ORGANISM", 47, 54], ["tumour", "CANCER", 78, 84], ["organ", "ORGAN", 99, 104], ["patient", "SPECIES", 47, 54], ["Dosimetry analysis", "TEST", 0, 18], ["patient treatment", "TREATMENT", 47, 64], ["treatment success", "TREATMENT", 151, 168]]], ["The ability to rapidly assay genetic and epigenetic characteristics of tumour samples comes closest to providing the kind of information that RPT dosimetry provides regarding the potential efficacy and toxicity of a therapeutic agent in an individual patient.Dosimetry ::: Overview of RPTThe mathematical formalism and tools available to perform dosimetry have evolved over time.", [["tumour samples", "ANATOMY", 71, 85], ["tumour", "DISEASE", 71, 77], ["toxicity", "DISEASE", 202, 210], ["tumour samples", "CANCER", 71, 85], ["patient", "ORGANISM", 251, 258], ["patient", "SPECIES", 251, 258], ["tumour samples", "TEST", 71, 85], ["RPT dosimetry", "TREATMENT", 142, 155], ["a therapeutic agent", "TREATMENT", 214, 233], ["tumour", "OBSERVATION", 71, 77]]], ["The initial impetus for estimating absorbed dose was to assess the potential risks of nuclear medicine diagnostic imaging agents.", [["nuclear", "ANATOMY", 86, 93], ["diagnostic imaging agents", "TREATMENT", 103, 128]]], ["Dosimetry calculations intended to assess risk are performed for an anatomical geometry designed to represent the average patient population rather than any one particular patient.", [["patient", "ORGANISM", 122, 129], ["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 122, 129], ["patient", "SPECIES", 172, 179], ["Dosimetry calculations", "TEST", 0, 22]]], ["The scheme used to calculate these values is shown in Box 1.", [["Box 1", "PROTEIN", 54, 59]]], ["This scheme provides the foundation for RPT dosimetry but because the calculation is oriented towards assessing radiation-induced risks of diagnostic imaging, it is not appropriate for toxicity and antitumour efficacy evaluations relevant to RPT.", [["toxicity", "DISEASE", 185, 193], ["antitumour", "CANCER", 198, 208], ["RPT dosimetry", "TREATMENT", 40, 53], ["diagnostic imaging", "TEST", 139, 157], ["toxicity", "PROBLEM", 185, 193], ["antitumour efficacy evaluations", "TEST", 198, 229], ["RPT", "TEST", 242, 245]]], ["The dosimetry methods summarized in Box 2 describe a scheme appropriate to RPT.", [["The dosimetry methods", "TREATMENT", 0, 21], ["RPT", "TEST", 75, 78]]], ["The implications of adopting such a scheme and necessary extensions, not summarized in Box 2, are briefly described below.Dosimetry ::: Overview of RPTImage-based, patient-specific dosimetry allows the distribution of the agent in tumours and normal organs to be quantified65.", [["tumours", "ANATOMY", 231, 238], ["organs", "ANATOMY", 250, 256], ["patient", "ORGANISM", 164, 171], ["tumours", "CANCER", 231, 238], ["organs", "ORGAN", 250, 256], ["patient", "SPECIES", 164, 171], ["a scheme", "TREATMENT", 34, 42]]], ["The amount of RPT agent that concentrates in the tumour can be increased by increasing the administered activity, which also impacts the tumour-absorbed dose.", [["tumour", "ANATOMY", 49, 55], ["tumour", "ANATOMY", 137, 143], ["tumour", "DISEASE", 49, 55], ["tumour", "DISEASE", 137, 143], ["RPT", "SIMPLE_CHEMICAL", 14, 17], ["tumour", "CANCER", 49, 55], ["tumour", "CANCER", 137, 143], ["RPT agent", "TREATMENT", 14, 23], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["RPT agent", "OBSERVATION_MODIFIER", 14, 23], ["tumour", "OBSERVATION", 49, 55], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["Dosimetry analysis following a low-activity administration has the potential to inform the amount of activity to administer for subsequent therapy.", [["Dosimetry analysis", "TEST", 0, 18], ["a low-activity administration", "TREATMENT", 29, 58], ["subsequent therapy", "TREATMENT", 128, 146]]], ["For example, from radiotherapy experience, an absorbed dose of 60\u201370 Gy is required to achieve greater than 3-year tumour control for patients with osteosarcoma66,67.", [["tumour", "ANATOMY", 115, 121], ["tumour", "DISEASE", 115, 121], ["osteosarcom", "DISEASE", 148, 159], ["tumour", "CANCER", 115, 121], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["radiotherapy", "TREATMENT", 18, 30]]], ["Although such high average tumour-absorbed doses can be achieved with high administered activities, studies have indicated that intratumour variability can be large, with some portions of a tumour meeting and exceeding this dose range, but the overall average being well below therapeutic efficacy68.", [["tumour", "ANATOMY", 27, 33], ["tumour", "ANATOMY", 190, 196], ["tumour", "DISEASE", 27, 33], ["tumour", "DISEASE", 190, 196], ["tumour", "CANCER", 27, 33], ["tumour", "CANCER", 190, 196], ["studies", "TEST", 100, 107], ["intratumour variability", "PROBLEM", 128, 151], ["high", "OBSERVATION_MODIFIER", 14, 18], ["large", "OBSERVATION_MODIFIER", 159, 164], ["tumour", "OBSERVATION", 190, 196]]], ["These observations led to a rational, absorbed-dose driven approach for combining radiotherapy with RPT69.Dosimetry ::: Overview of RPTIn the context of RPT, organ toxicity is usually reflected not by a whole-organ absorbed dose but rather by absorbed dose \u2018hot spots\u2019.", [["organ", "ANATOMY", 158, 163], ["organ", "ANATOMY", 209, 214], ["RPT69", "CHEMICAL", 100, 105], ["organ toxicity", "DISEASE", 158, 172], ["RPT69", "CHEMICAL", 100, 105], ["RPT69", "SIMPLE_CHEMICAL", 100, 105], ["organ", "ORGAN", 158, 163], ["organ", "ORGAN", 209, 214], ["RPT69", "PROTEIN", 100, 105], ["a rational, absorbed-dose driven approach", "TREATMENT", 26, 67], ["combining radiotherapy", "TREATMENT", 72, 94], ["RPT69", "TREATMENT", 100, 105], ["RPT", "TEST", 153, 156], ["organ toxicity", "PROBLEM", 158, 172], ["hot spots\u2019", "PROBLEM", 258, 268], ["organ", "ANATOMY", 158, 163], ["toxicity", "OBSERVATION", 164, 172]]], ["This is particularly so if such regions of high absorbed dose correspond to organ subregions that are critical to organ function.", [["organ", "ANATOMY", 76, 81], ["organ", "ANATOMY", 114, 119], ["organ", "ORGAN", 76, 81], ["organ", "ORGAN", 114, 119], ["high absorbed dose", "PROBLEM", 43, 61], ["organ subregions", "PROBLEM", 76, 92]]], ["For example, some RPT agents (primarily peptides) concentrate and are retained in the renal cortex, so the absorbed dose in the renal cortex better predicts toxicity than the absorbed dose in the whole kidney volume70.", [["renal cortex", "ANATOMY", 86, 98], ["renal cortex", "ANATOMY", 128, 140], ["kidney", "ANATOMY", 202, 208], ["toxicity", "DISEASE", 157, 165], ["RPT agents", "SIMPLE_CHEMICAL", 18, 28], ["renal cortex", "MULTI-TISSUE_STRUCTURE", 86, 98], ["renal cortex", "MULTI-TISSUE_STRUCTURE", 128, 140], ["kidney", "ORGAN", 202, 208], ["some RPT agents", "TREATMENT", 13, 28], ["retained", "OBSERVATION", 70, 78], ["renal", "ANATOMY", 86, 91], ["cortex", "ANATOMY_MODIFIER", 92, 98], ["renal", "ANATOMY", 128, 133], ["cortex", "ANATOMY_MODIFIER", 134, 140], ["kidney", "ANATOMY", 202, 208]]], ["For certain RPT agents, the biologically relevant region can be microscopic (for example, the kidney nephron71 or the collecting ducts of the salivary glands72,73).", [["kidney nephron71", "ANATOMY", 94, 110], ["collecting ducts", "ANATOMY", 118, 134], ["salivary gland", "ANATOMY", 142, 156], ["kidney", "ORGAN", 94, 100], ["nephron71", "CANCER", 101, 110], ["collecting ducts", "MULTI-TISSUE_STRUCTURE", 118, 134], ["salivary gland", "ORGAN", 142, 156], ["certain RPT agents", "TREATMENT", 4, 22], ["kidney", "ANATOMY", 94, 100], ["ducts", "ANATOMY_MODIFIER", 129, 134], ["salivary gland", "ANATOMY", 142, 156]]], ["Estimates of the average absorbed dose in bone marrow do not predict the very low haematological toxicity of radium-223 dichloride (lower than that of almost all other RPT agents).", [["bone marrow", "ANATOMY", 42, 53], ["toxicity", "DISEASE", 97, 105], ["radium-223 dichloride", "CHEMICAL", 109, 130], ["radium-223 dichloride", "CHEMICAL", 109, 130], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 42, 53], ["radium-223 dichloride", "SIMPLE_CHEMICAL", 109, 130], ["the very low haematological toxicity of radium", "PROBLEM", 69, 115], ["dichloride", "TREATMENT", 120, 130], ["RPT agents", "TREATMENT", 168, 178]]], ["In a pivotal randomized clinical trial, the grade 3 or grade 4 haematological toxic effects observed in patients receiving radium-223 dichloride (Xofigo) included neutropenia (2%), thrombocytopenia (3%), leukopenia (3%) and pancytopenia (1%)56.", [["radium-223 dichloride", "CHEMICAL", 123, 144], ["Xofigo", "CHEMICAL", 146, 152], ["neutropenia", "DISEASE", 163, 174], ["thrombocytopenia", "DISEASE", 181, 197], ["leukopenia", "DISEASE", 204, 214], ["pancytopenia", "DISEASE", 224, 236], ["radium-223 dichloride", "CHEMICAL", 123, 144], ["Xofigo", "CHEMICAL", 146, 152], ["patients", "ORGANISM", 104, 112], ["radium-223 dichloride", "SIMPLE_CHEMICAL", 123, 144], ["Xofigo", "SIMPLE_CHEMICAL", 146, 152], ["patients", "SPECIES", 104, 112], ["the grade 3 or grade 4 haematological toxic effects", "PROBLEM", 40, 91], ["radium", "TREATMENT", 123, 129], ["dichloride (Xofigo)", "TREATMENT", 134, 153], ["neutropenia", "PROBLEM", 163, 174], ["thrombocytopenia", "PROBLEM", 181, 197], ["leukopenia", "PROBLEM", 204, 214], ["pancytopenia", "PROBLEM", 224, 236], ["toxic effects", "OBSERVATION", 78, 91], ["thrombocytopenia", "OBSERVATION", 181, 197], ["leukopenia", "OBSERVATION", 204, 214], ["pancytopenia", "OBSERVATION", 224, 236]]], ["This discrepancy could be resolved by a calculation that considered the microscale distribution of radium-223 in the bone marrow.", [["bone marrow", "ANATOMY", 117, 128], ["radium-223", "CHEMICAL", 99, 109], ["radium-223", "CHEMICAL", 99, 109], ["radium-223", "SIMPLE_CHEMICAL", 99, 109], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 117, 128], ["a calculation", "TEST", 38, 51], ["radium", "ANATOMY", 99, 105], ["bone marrow", "ANATOMY", 117, 128]]], ["Such an analysis demonstrated that because of the short range of \u03b1-particle emissions and the known localization of the RPT agent on the trabecular bone surface, only haematopoietic (bone marrow) cells within 80 \u00b5m of the bone surface were irradiated, meaning that most of the bone marrow space was not irradiated and, accordingly, the average bone marrow absorbed dose was not predictive of toxicity74.Dosimetry ::: Overview of RPTCurrent imaging techniques do not possess the resolution required to resolve activity distributions at the microscopic scale.", [["trabecular bone surface", "ANATOMY", 137, 160], ["haematopoietic", "ANATOMY", 167, 181], ["bone marrow) cells", "ANATOMY", 183, 201], ["bone surface", "ANATOMY", 222, 234], ["bone marrow space", "ANATOMY", 277, 294], ["bone marrow", "ANATOMY", 344, 355], ["toxicity", "DISEASE", 392, 400], ["\u03b1-particle", "SIMPLE_CHEMICAL", 65, 75], ["trabecular bone surface", "CELLULAR_COMPONENT", 137, 160], ["haematopoietic", "CELL", 167, 181], ["bone marrow) cells", "CELL", 183, 201], ["bone surface", "MULTI-TISSUE_STRUCTURE", 222, 234], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 277, 288], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 344, 355], ["haematopoietic (bone marrow) cells", "CELL_TYPE", 167, 201], ["an analysis", "TEST", 5, 16], ["the short range of \u03b1-particle emissions", "PROBLEM", 46, 85], ["the RPT agent", "TREATMENT", 116, 129], ["haematopoietic (bone marrow) cells", "TEST", 167, 201], ["the bone marrow space", "PROBLEM", 273, 294], ["toxicity", "PROBLEM", 392, 400], ["RPTCurrent imaging techniques", "TEST", 429, 458], ["the microscopic scale", "TEST", 535, 556], ["trabecular", "ANATOMY_MODIFIER", 137, 147], ["bone", "ANATOMY", 148, 152], ["surface", "ANATOMY_MODIFIER", 153, 160], ["haematopoietic", "ANATOMY", 167, 181], ["bone marrow", "ANATOMY", 183, 194], ["bone", "ANATOMY", 222, 226], ["surface", "ANATOMY_MODIFIER", 227, 234], ["irradiated", "OBSERVATION", 240, 250], ["bone", "ANATOMY", 277, 281], ["marrow space", "OBSERVATION", 282, 294]]], ["However, by pairing whole-organ macroscale measurements that can be performed in humans with microscale information that can be obtained from preclinical studies, it is possible to extract microscale information from macroscale measurements.", [["organ", "ANATOMY", 26, 31], ["organ", "ORGAN", 26, 31], ["humans", "ORGANISM", 81, 87], ["humans", "SPECIES", 81, 87], ["humans", "SPECIES", 81, 87], ["pairing whole-organ macroscale measurements", "TEST", 12, 55], ["preclinical studies", "TEST", 142, 161], ["macroscale measurements", "TEST", 217, 240]]], ["A contour may be drawn on an image obtained with a patient imaging modality such as PET/CT or SPECT/CT that encompasses the entire organ (for example, kidney) or macroscopic subcompartments within the organ (for example, renal cortex).", [["organ", "ANATOMY", 131, 136], ["kidney", "ANATOMY", 151, 157], ["organ", "ANATOMY", 201, 206], ["renal cortex", "ANATOMY", 221, 233], ["patient", "ORGANISM", 51, 58], ["organ", "ORGAN", 131, 136], ["kidney", "ORGAN", 151, 157], ["organ", "ORGAN", 201, 206], ["renal cortex", "MULTI-TISSUE_STRUCTURE", 221, 233], ["patient", "SPECIES", 51, 58], ["an image", "TEST", 26, 34], ["a patient imaging modality", "TEST", 49, 75], ["PET/CT", "TEST", 84, 90], ["SPECT/CT", "TEST", 94, 102], ["macroscopic subcompartments within the organ", "PROBLEM", 162, 206], ["kidney", "ANATOMY", 151, 157], ["organ", "ANATOMY", 201, 206], ["renal", "ANATOMY", 221, 226], ["cortex", "ANATOMY_MODIFIER", 227, 233]]], ["These macroscale contours may be used to obtain time-versus-activity curves (TACs) for the entire organ or macroscale subcompartments within the organ.", [["organ", "ANATOMY", 98, 103], ["organ", "ANATOMY", 145, 150], ["organ", "ORGAN", 98, 103], ["organ", "ORGAN", 145, 150], ["organ", "ANATOMY", 98, 103], ["macroscale subcompartments", "OBSERVATION", 107, 133], ["organ", "ANATOMY", 145, 150]]], ["Microscale structures within these macroscale contours may be obtained in preclinical models by tissue extraction and high-resolution imaging of tissue sections, for example75\u201377.", [["tissue", "ANATOMY", 96, 102], ["tissue sections", "ANATOMY", 145, 160], ["tissue", "TISSUE", 96, 102], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 145, 160], ["tissue extraction", "TEST", 96, 113], ["tissue sections", "TEST", 145, 160], ["macroscale contours", "OBSERVATION", 35, 54]]], ["These data may be used to obtain time-versus-activity curves for microstructures of interest (that is, those microstructures that govern the organ response to radiation).", [["organ", "ANATOMY", 141, 146], ["organ", "ORGAN", 141, 146]]], ["The integral of each curve gives the total number of radionuclide disintegrations for the whole organ and for each subcompartment.", [["organ", "ANATOMY", 96, 101], ["organ", "ORGAN", 96, 101], ["radionuclide disintegrations", "TREATMENT", 53, 81]]], ["With use of these measurements, a series of apportionment factors may be defined for each subcompartment.", [["apportionment factors", "PROTEIN", 44, 65], ["these measurements", "TEST", 12, 30]]], ["These preclinically derived apportionment factors may then be used to convert human whole-organ radionuclide disintegrations to the corresponding number of radionuclide disintegrations for each organ subcompartment in humans.Dosimetry ::: Overview of RPTBeyond the aspects highlighted above, there is an extensive literature on RPT dosimetry, including technical aspects53,54,78\u201386, dose\u2013response studies87\u201391 and the rationale for incorporating dosimetry in RPT92.Cancers targeted by RPT ::: Overview of RPTIn principle, RPT may be applied to any cancer that satisfies the targeting criteria needed for delivery of radionuclides.", [["organ", "ANATOMY", 90, 95], ["organ", "ANATOMY", 194, 199], ["Cancers", "ANATOMY", 465, 472], ["cancer", "ANATOMY", 548, 554], ["Cancers", "DISEASE", 465, 472], ["cancer", "DISEASE", 548, 554], ["human", "ORGANISM", 78, 83], ["organ", "ORGAN", 90, 95], ["organ", "ORGAN", 194, 199], ["humans", "ORGANISM", 218, 224], ["Cancers", "CANCER", 465, 472], ["cancer", "CANCER", 548, 554], ["RPT92", "DNA", 459, 464], ["human", "SPECIES", 78, 83], ["humans", "SPECIES", 218, 224], ["human", "SPECIES", 78, 83], ["humans", "SPECIES", 218, 224], ["human whole-organ radionuclide disintegrations", "TREATMENT", 78, 124], ["radionuclide disintegrations", "TREATMENT", 156, 184], ["RPT dosimetry", "TEST", 328, 341], ["technical aspects", "TEST", 353, 370], ["dose\u2013response studies", "TEST", 383, 404], ["incorporating dosimetry in RPT92", "TREATMENT", 432, 464], ["Cancers", "PROBLEM", 465, 472], ["RPT", "TREATMENT", 522, 525], ["any cancer", "PROBLEM", 544, 554], ["delivery of radionuclides", "TREATMENT", 604, 629], ["extensive", "OBSERVATION_MODIFIER", 304, 313], ["cancer", "OBSERVATION", 548, 554]]], ["However, RPT has been investigated for only selected cancers (Fig. 2c).", [["cancers", "ANATOMY", 53, 60], ["cancers", "DISEASE", 53, 60], ["RPT", "CANCER", 9, 12], ["cancers", "CANCER", 53, 60], ["RPT", "TEST", 9, 12], ["selected cancers", "PROBLEM", 44, 60], ["cancers", "OBSERVATION", 53, 60]]], ["The type of cancer investigated reflects developments related to the available targets, the availability of RPT agents against the targets, and the expertise and clinical investigators at academic institutions.Cancers targeted by RPT ::: Overview of RPTRPT has had the greatest historical impact for thyroid malignancies and this persists to the present day.", [["cancer", "ANATOMY", 12, 18], ["Cancers", "ANATOMY", 210, 217], ["thyroid malignancies", "ANATOMY", 300, 320], ["cancer", "DISEASE", 12, 18], ["Cancers", "DISEASE", 210, 217], ["thyroid malignancies", "DISEASE", 300, 320], ["cancer", "CANCER", 12, 18], ["Cancers", "CANCER", 210, 217], ["thyroid malignancies", "CANCER", 300, 320], ["cancer", "PROBLEM", 12, 18], ["RPT agents", "TREATMENT", 108, 118], ["Cancers", "PROBLEM", 210, 217], ["thyroid malignancies", "PROBLEM", 300, 320], ["cancer", "OBSERVATION", 12, 18], ["thyroid", "ANATOMY", 300, 307], ["malignancies", "OBSERVATION", 308, 320]]], ["Haematological malignancies were investigated starting in the early 1990s and continue to be a subject of interest.", [["Haematological malignancies", "ANATOMY", 0, 27], ["Haematological malignancies", "DISEASE", 0, 27], ["Haematological malignancies", "CANCER", 0, 27], ["Haematological malignancies", "PROBLEM", 0, 27], ["malignancies", "OBSERVATION", 15, 27]]], ["RPT for hepatic malignancies and prostate cancer has seen the greatest increase since the 1980s.", [["hepatic malignancies", "ANATOMY", 8, 28], ["prostate cancer", "ANATOMY", 33, 48], ["hepatic malignancies", "DISEASE", 8, 28], ["prostate cancer", "DISEASE", 33, 48], ["hepatic malignancies", "CANCER", 8, 28], ["prostate cancer", "CANCER", 33, 48], ["RPT", "TEST", 0, 3], ["hepatic malignancies", "PROBLEM", 8, 28], ["prostate cancer", "PROBLEM", 33, 48], ["hepatic", "ANATOMY", 8, 15], ["malignancies", "OBSERVATION", 16, 28], ["prostate", "ANATOMY", 33, 41], ["cancer", "OBSERVATION", 42, 48], ["greatest", "OBSERVATION_MODIFIER", 62, 70], ["increase", "OBSERVATION_MODIFIER", 71, 79]]], ["This increase is consistent with the development of new RPT agents, 90Y-loaded microspheres and \u03b2-emitter-labelled and \u03b1-emitter-labelled small-molecule prostate-specific membrane antigen (PSMA)-targeting constructs, respectively (see later).", [["RPT agents", "SIMPLE_CHEMICAL", 56, 66], ["90Y-loaded microspheres", "SIMPLE_CHEMICAL", 68, 91], ["\u03b2-emitter", "SIMPLE_CHEMICAL", 96, 105], ["\u03b1-emitter", "SIMPLE_CHEMICAL", 119, 128], ["prostate-specific membrane antigen", "GENE_OR_GENE_PRODUCT", 153, 187], ["PSMA", "GENE_OR_GENE_PRODUCT", 189, 193], ["\u03b2-emitter-labelled and \u03b1-emitter-labelled small-molecule prostate-specific membrane antigen (PSMA)-targeting constructs", "DNA", 96, 215], ["new RPT agents", "TREATMENT", 52, 66], ["90Y-loaded microspheres", "TREATMENT", 68, 91], ["\u03b2-emitter", "TEST", 96, 105], ["\u03b1-emitter", "TEST", 119, 128], ["consistent with", "UNCERTAINTY", 17, 32], ["new", "OBSERVATION_MODIFIER", 52, 55], ["prostate", "ANATOMY", 153, 161]]], ["The FDA-approved \u03b1-emitter 223Ra has also driven the substantial increase in interest in RPT for prostate cancer.", [["prostate cancer", "ANATOMY", 97, 112], ["\u03b1-emitter 223Ra", "CHEMICAL", 17, 32], ["prostate cancer", "DISEASE", 97, 112], ["\u03b1-emitter 223Ra", "SIMPLE_CHEMICAL", 17, 32], ["RPT", "CANCER", 89, 92], ["prostate cancer", "CANCER", 97, 112], ["prostate cancer", "PROBLEM", 97, 112], ["substantial", "OBSERVATION_MODIFIER", 53, 64], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["prostate", "ANATOMY", 97, 105], ["cancer", "OBSERVATION", 106, 112]]], ["Other solid cancers such as colorectal and breast cancer continue to be of interest but have not had the breakthrough construct development that has driven interest in RPT in hepatic and prostate cancer.", [["solid cancers", "ANATOMY", 6, 19], ["colorectal", "ANATOMY", 28, 38], ["breast cancer", "ANATOMY", 43, 56], ["hepatic", "ANATOMY", 175, 182], ["prostate cancer", "ANATOMY", 187, 202], ["cancers", "DISEASE", 12, 19], ["colorectal and breast cancer", "DISEASE", 28, 56], ["hepatic and prostate cancer", "DISEASE", 175, 202], ["solid cancers", "CANCER", 6, 19], ["colorectal", "CANCER", 28, 38], ["breast cancer", "CANCER", 43, 56], ["RPT", "CANCER", 168, 171], ["hepatic", "CANCER", 175, 182], ["prostate cancer", "CANCER", 187, 202], ["Other solid cancers", "PROBLEM", 0, 19], ["colorectal and breast cancer", "PROBLEM", 28, 56], ["the breakthrough construct development", "PROBLEM", 101, 139], ["RPT in hepatic and prostate cancer", "PROBLEM", 168, 202], ["solid", "OBSERVATION_MODIFIER", 6, 11], ["cancers", "OBSERVATION", 12, 19], ["colorectal", "ANATOMY", 28, 38], ["breast", "ANATOMY", 43, 49], ["cancer", "OBSERVATION", 50, 56], ["hepatic", "ANATOMY", 175, 182], ["prostate", "ANATOMY", 187, 195], ["cancer", "OBSERVATION", 196, 202]]], ["Neuroendocrine and somatostatin receptor cancers have been an ongoing subject of investigation, and the RPT agents targeting these cancers have probably reached maturity with the FDA approval of 177Lu-labelled DOTATATE.[131I]NaI (radioiodine) ::: Unconjugated or chelated radionuclide RPT ::: RPT agents in use and in clinical developmentThe prototypical example of RPT is radioiodine treatment of thyroid diseases93,117\u2013120.", [["Neuroendocrine", "ANATOMY", 0, 14], ["somatostatin receptor cancers", "ANATOMY", 19, 48], ["cancers", "ANATOMY", 131, 138], ["thyroid", "ANATOMY", 398, 405], ["cancers", "DISEASE", 41, 48], ["cancers", "DISEASE", 131, 138], ["177Lu", "CHEMICAL", 195, 200], ["RPT", "CHEMICAL", 366, 369], ["thyroid disease", "DISEASE", 398, 413], ["177Lu", "CHEMICAL", 195, 200], ["[131I]NaI", "CHEMICAL", 219, 228], ["radioiodine", "CHEMICAL", 230, 241], ["Neuroendocrine", "CANCER", 0, 14], ["somatostatin receptor", "GENE_OR_GENE_PRODUCT", 19, 40], ["cancers", "CANCER", 41, 48], ["cancers", "CANCER", 131, 138], ["177Lu-labelled DOTATATE", "SIMPLE_CHEMICAL", 195, 218], ["[131I]NaI", "SIMPLE_CHEMICAL", 219, 228], ["radioiodine", "SIMPLE_CHEMICAL", 230, 241], ["RPT agents", "SIMPLE_CHEMICAL", 293, 303], ["RPT", "CANCER", 366, 369], ["thyroid", "ORGAN", 398, 405], ["177Lu-labelled DOTATATE", "PROTEIN", 195, 218], ["Neuroendocrine and somatostatin receptor cancers", "PROBLEM", 0, 48], ["the RPT agents", "TREATMENT", 100, 114], ["these cancers", "PROBLEM", 125, 138], ["RPT agents", "TREATMENT", 293, 303], ["RPT", "TEST", 366, 369], ["radioiodine treatment", "TREATMENT", 373, 394], ["thyroid diseases", "PROBLEM", 398, 414], ["thyroid", "ANATOMY", 398, 405]]], ["Iodide-131, a \u03b2-particle-emitting radiohalogen with a half-life of 8.02 days, was discovered by John Livingood and Glenn Seaborg following cyclotron bombardment of tellurium121.", [["Iodide-131", "CHEMICAL", 0, 10], ["tellurium121", "CHEMICAL", 164, 176], ["Iodide-131", "CHEMICAL", 0, 10], ["radiohalogen", "CHEMICAL", 34, 46], ["tellurium", "CHEMICAL", 164, 173], ["Iodide-131", "SIMPLE_CHEMICAL", 0, 10], ["tellurium121", "SIMPLE_CHEMICAL", 164, 176], ["Iodide", "TREATMENT", 0, 6], ["a \u03b2-particle-emitting radiohalogen", "TREATMENT", 12, 46], ["Glenn Seaborg", "TREATMENT", 115, 128], ["cyclotron bombardment of tellurium", "TREATMENT", 139, 173]]], ["Currently, iodine-131 is produced for commercial use using a nuclear reactor by irradiating either tellurium-130 (130Te(n,\u03b3)131Te\u2192131I) or uranium-235 (235U(n,f)131I)122.", [["iodine-131", "CHEMICAL", 11, 21], ["tellurium-130", "CHEMICAL", 99, 112], ["uranium-235", "CHEMICAL", 139, 150], ["iodine-131", "CHEMICAL", 11, 21], ["tellurium-130", "CHEMICAL", 99, 112], ["130Te(n,\u03b3)131Te", "CHEMICAL", 114, 129], ["uranium-235", "CHEMICAL", 139, 150], ["235U(n,f)131I)122", "CHEMICAL", 152, 169], ["iodine-131", "SIMPLE_CHEMICAL", 11, 21], ["tellurium-130", "SIMPLE_CHEMICAL", 99, 112], ["130Te(n,\u03b3)131Te\u2192131I", "SIMPLE_CHEMICAL", 114, 134], ["uranium-235", "SIMPLE_CHEMICAL", 139, 150], ["iodine", "TREATMENT", 11, 17], ["a nuclear reactor", "TREATMENT", 59, 76], ["tellurium", "TEST", 99, 108], ["uranium", "TEST", 139, 146]]], ["Radioiodine was initially used to treat hyperthyroidism and thyroid carcinomas123.", [["thyroid carcinomas", "ANATOMY", 60, 78], ["Radioiodine", "CHEMICAL", 0, 11], ["hyperthyroidism", "DISEASE", 40, 55], ["thyroid carcinomas", "DISEASE", 60, 78], ["Radioiodine", "CHEMICAL", 0, 11], ["Radioiodine", "SIMPLE_CHEMICAL", 0, 11], ["thyroid carcinomas", "CANCER", 60, 78], ["Radioiodine", "TREATMENT", 0, 11], ["hyperthyroidism", "PROBLEM", 40, 55], ["thyroid carcinomas", "PROBLEM", 60, 78], ["hyperthyroidism", "OBSERVATION", 40, 55], ["thyroid", "ANATOMY", 60, 67], ["carcinomas", "OBSERVATION", 68, 78]]], ["Thyroid follicular cells and differentiated follicular thyroid cancer cells concentrate iodine via a sodium\u2013iodide symporter.", [["Thyroid follicular cells", "ANATOMY", 0, 24], ["follicular thyroid cancer cells", "ANATOMY", 44, 75], ["thyroid cancer", "DISEASE", 55, 69], ["iodine", "CHEMICAL", 88, 94], ["sodium\u2013iodide", "CHEMICAL", 101, 114], ["iodine", "CHEMICAL", 88, 94], ["sodium\u2013iodide", "CHEMICAL", 101, 114], ["Thyroid follicular cells", "CELL", 0, 24], ["follicular thyroid cancer cells", "CELL", 44, 75], ["iodine", "SIMPLE_CHEMICAL", 88, 94], ["sodium\u2013iodide", "SIMPLE_CHEMICAL", 101, 114], ["Thyroid follicular cells", "CELL_TYPE", 0, 24], ["differentiated follicular thyroid cancer cells", "CELL_TYPE", 29, 75], ["sodium\u2013iodide symporter", "PROTEIN", 101, 124], ["Thyroid follicular cells", "PROBLEM", 0, 24], ["differentiated follicular thyroid cancer cells", "PROBLEM", 29, 75], ["iodine", "TREATMENT", 88, 94], ["a sodium\u2013iodide symporter", "TREATMENT", 99, 124], ["follicular cells", "OBSERVATION", 8, 24], ["differentiated", "OBSERVATION_MODIFIER", 29, 43], ["follicular thyroid cancer", "OBSERVATION", 44, 69]]], ["The iodide is concentrated in iodine-rich thyroglobulin molecules that are cleaved to produce thyroid hormones.", [["iodide", "CHEMICAL", 4, 10], ["iodine", "CHEMICAL", 30, 36], ["iodide", "CHEMICAL", 4, 10], ["iodine", "CHEMICAL", 30, 36], ["iodide", "SIMPLE_CHEMICAL", 4, 10], ["iodine", "SIMPLE_CHEMICAL", 30, 36], ["thyroglobulin", "GENE_OR_GENE_PRODUCT", 42, 55], ["thyroid", "ORGAN", 94, 101], ["thyroglobulin molecules", "PROTEIN", 42, 65], ["The iodide", "TREATMENT", 0, 10], ["iodine-rich thyroglobulin molecules", "TREATMENT", 30, 65], ["thyroid hormones", "PROBLEM", 94, 110], ["concentrated", "OBSERVATION_MODIFIER", 14, 26], ["thyroglobulin molecules", "OBSERVATION", 42, 65], ["thyroid", "ANATOMY", 94, 101]]], ["These early discoveries led to the widespread and early use of radioiodine for the treatment of patients with thyroid malignancies.", [["thyroid malignancies", "ANATOMY", 110, 130], ["thyroid malignancies", "DISEASE", 110, 130], ["radioiodine", "SIMPLE_CHEMICAL", 63, 74], ["patients", "ORGANISM", 96, 104], ["thyroid malignancies", "CANCER", 110, 130], ["patients", "SPECIES", 96, 104], ["radioiodine", "TREATMENT", 63, 74], ["the treatment", "TREATMENT", 79, 92], ["thyroid malignancies", "PROBLEM", 110, 130], ["widespread", "OBSERVATION_MODIFIER", 35, 45], ["thyroid", "ANATOMY", 110, 117], ["malignancies", "OBSERVATION", 118, 130]]], ["Radioiodine therapy remains the recommended treatment for patients with metastatic differentiated thyroid cancer124.", [["metastatic differentiated thyroid cancer", "ANATOMY", 72, 112], ["Radioiodine", "CHEMICAL", 0, 11], ["thyroid cancer", "DISEASE", 98, 112], ["patients", "ORGANISM", 58, 66], ["thyroid cancer", "CANCER", 98, 112], ["patients", "SPECIES", 58, 66], ["Radioiodine therapy", "TREATMENT", 0, 19], ["treatment", "TREATMENT", 44, 53], ["metastatic differentiated thyroid cancer", "PROBLEM", 72, 112], ["metastatic", "OBSERVATION_MODIFIER", 72, 82], ["thyroid", "ANATOMY", 98, 105], ["cancer", "OBSERVATION", 106, 112]]], ["Patients with thyroid cancers that originate from cells not involved in concentrating iodine or that are undifferentiated and have lost the molecular machinery to concentrate iodine are not responsive to radioiodine therapy.", [["thyroid cancers", "ANATOMY", 14, 29], ["cells", "ANATOMY", 50, 55], ["thyroid cancers", "DISEASE", 14, 29], ["iodine", "CHEMICAL", 86, 92], ["iodine", "CHEMICAL", 175, 181], ["iodine", "CHEMICAL", 86, 92], ["iodine", "CHEMICAL", 175, 181], ["Patients", "ORGANISM", 0, 8], ["thyroid cancers", "CANCER", 14, 29], ["cells", "CELL", 50, 55], ["iodine", "SIMPLE_CHEMICAL", 86, 92], ["iodine", "SIMPLE_CHEMICAL", 175, 181], ["radioiodine", "SIMPLE_CHEMICAL", 204, 215], ["Patients", "SPECIES", 0, 8], ["thyroid cancers", "PROBLEM", 14, 29], ["iodine", "TREATMENT", 175, 181], ["radioiodine therapy", "TREATMENT", 204, 223], ["thyroid", "ANATOMY", 14, 21], ["cancers", "OBSERVATION", 22, 29]]], ["Patients in the latter category, however, can be successfully treated with radioiodine after differentiation therapy125.32P, 90Y ::: Unconjugated or chelated radionuclide RPT ::: RPT agents in use and in clinical developmentMany of unconjugated RPT agents were first developed for radiosynovectomy (note that none of the radiopharmaceuticals is explicitly approved for this scope, but it is an accepted (\u2018established\u2019) practice).", [["Patients", "ORGANISM", 0, 8], ["RPT agents", "SIMPLE_CHEMICAL", 179, 189], ["RPT agents", "SIMPLE_CHEMICAL", 245, 255], ["Patients", "SPECIES", 0, 8], ["radioiodine after differentiation therapy", "TREATMENT", 75, 116], ["RPT agents", "TREATMENT", 179, 189], ["unconjugated RPT agents", "TREATMENT", 232, 255], ["radiosynovectomy", "TREATMENT", 281, 297], ["this scope", "TEST", 369, 379]]], ["In Europe these agents continue to be used to treat patients with rheumatoid arthritis and polyarthritis owing to their advantageous faster therapeutic effect and reduced side effects and costs compared with surgical synovectomy5,6.", [["rheumatoid arthritis", "DISEASE", 66, 86], ["polyarthritis", "DISEASE", 91, 104], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["rheumatoid arthritis", "PROBLEM", 66, 86], ["polyarthritis", "PROBLEM", 91, 104], ["reduced side effects and costs", "PROBLEM", 163, 193], ["surgical synovectomy", "TREATMENT", 208, 228], ["rheumatoid arthritis", "OBSERVATION", 66, 86], ["polyarthritis", "OBSERVATION", 91, 104], ["reduced", "OBSERVATION_MODIFIER", 163, 170], ["side effects", "OBSERVATION_MODIFIER", 171, 183], ["synovectomy", "OBSERVATION", 217, 228]]], ["Beyond radiosynovectomy, colloidal chromic phosphate (and glass microspheres) containing phosphorus-32 have also been used to treat solid refractory cancers.", [["solid refractory cancers", "ANATOMY", 132, 156], ["chromic phosphate", "CHEMICAL", 35, 52], ["phosphorus-32", "CHEMICAL", 89, 102], ["cancers", "DISEASE", 149, 156], ["chromic phosphate", "CHEMICAL", 35, 52], ["phosphorus-32", "CHEMICAL", 89, 102], ["colloidal chromic phosphate", "SIMPLE_CHEMICAL", 25, 52], ["glass microspheres", "SIMPLE_CHEMICAL", 58, 76], ["phosphorus-32", "SIMPLE_CHEMICAL", 89, 102], ["solid refractory cancers", "CANCER", 132, 156], ["radiosynovectomy", "TREATMENT", 7, 23], ["colloidal chromic phosphate (and glass microspheres", "TREATMENT", 25, 76], ["phosphorus", "TREATMENT", 89, 99], ["solid refractory cancers", "PROBLEM", 132, 156], ["refractory", "OBSERVATION_MODIFIER", 138, 148], ["cancers", "OBSERVATION", 149, 156]]], ["These radiopharmaceuticals are used to irradiate and kill tumour cells and thus inhibit the growth of malignant disease.", [["tumour cells", "ANATOMY", 58, 70], ["malignant disease", "ANATOMY", 102, 119], ["tumour", "DISEASE", 58, 64], ["malignant disease", "DISEASE", 102, 119], ["tumour cells", "CELL", 58, 70], ["malignant disease", "CANCER", 102, 119], ["tumour cells", "CELL_TYPE", 58, 70], ["These radiopharmaceuticals", "TREATMENT", 0, 26], ["tumour cells", "PROBLEM", 58, 70], ["malignant disease", "PROBLEM", 102, 119], ["growth", "OBSERVATION_MODIFIER", 92, 98], ["malignant", "OBSERVATION", 102, 111]]], ["The major limitation in these applications is the reliance on radiological guidance for particle deposition (for example, CT, X-ray, ultrasonogram or direct inspection of the surgical field)126.223Ra ::: Unconjugated or chelated radionuclide RPT ::: RPT agents in use and in clinical developmentRadium-223 was the first \u03b1-emitter approved by the FDA and paved the way to the current development of other \u03b1-emitting radiopharmaceuticals.", [["developmentRadium-223", "CHEMICAL", 284, 305], ["developmentRadium-223", "CHEMICAL", 284, 305], ["developmentRadium-223", "SIMPLE_CHEMICAL", 284, 305], ["CT", "TEST", 122, 124], ["X-ray", "TEST", 126, 131], ["ultrasonogram", "TEST", 133, 146], ["RPT agents", "TREATMENT", 250, 260], ["clinical developmentRadium", "TEST", 275, 301], ["other \u03b1-emitting radiopharmaceuticals", "TREATMENT", 398, 435], ["major", "OBSERVATION_MODIFIER", 4, 9], ["limitation", "OBSERVATION_MODIFIER", 10, 20]]], ["Once absorbed into the newly formed bone matrix of osteoblastic metastases, the energetic \u03b1-particles emitted by radium-223 can generate irreparable DNA double-strand breaks in the adjacent osteoblasts and osteoclasts, which can lead to their death.", [["bone matrix", "ANATOMY", 36, 47], ["osteoblastic metastases", "ANATOMY", 51, 74], ["osteoblasts", "ANATOMY", 190, 201], ["osteoclasts", "ANATOMY", 206, 217], ["metastases", "DISEASE", 64, 74], ["radium-223", "CHEMICAL", 113, 123], ["death", "DISEASE", 243, 248], ["radium-223", "CHEMICAL", 113, 123], ["bone matrix", "MULTI-TISSUE_STRUCTURE", 36, 47], ["osteoblastic metastases", "CANCER", 51, 74], ["radium-223", "SIMPLE_CHEMICAL", 113, 123], ["DNA", "CELLULAR_COMPONENT", 149, 152], ["osteoblasts", "CELL", 190, 201], ["osteoclasts", "CELL", 206, 217], ["osteoblasts", "CELL_TYPE", 190, 201], ["osteoclasts", "CELL_TYPE", 206, 217], ["osteoblastic metastases", "PROBLEM", 51, 74], ["irreparable DNA double-strand breaks in the adjacent osteoblasts and osteoclasts", "PROBLEM", 137, 217], ["their death", "PROBLEM", 237, 248], ["bone", "ANATOMY", 36, 40], ["matrix", "OBSERVATION_MODIFIER", 41, 47], ["osteoblastic", "ANATOMY", 51, 63], ["metastases", "OBSERVATION", 64, 74], ["irreparable", "OBSERVATION_MODIFIER", 137, 148], ["DNA", "OBSERVATION_MODIFIER", 149, 152], ["double", "OBSERVATION_MODIFIER", 153, 159], ["strand breaks", "OBSERVATION", 160, 173], ["adjacent", "ANATOMY_MODIFIER", 181, 189], ["osteoblasts", "ANATOMY", 190, 201], ["osteoclasts", "OBSERVATION", 206, 217]]], ["This results in detrimental effects on the neighbouring cancer cells, which then lack their effector of abnormal bone formation, both at a cellular level and at a signalling level (growth factors and immunomodulators), and ultimately in a negative effect on tumour growth.", [["cancer cells", "ANATOMY", 56, 68], ["bone", "ANATOMY", 113, 117], ["cellular", "ANATOMY", 139, 147], ["tumour", "ANATOMY", 258, 264], ["cancer", "DISEASE", 56, 62], ["tumour", "DISEASE", 258, 264], ["cancer cells", "CELL", 56, 68], ["bone", "TISSUE", 113, 117], ["cellular", "CELL", 139, 147], ["tumour", "CANCER", 258, 264], ["neighbouring cancer cells", "CELL_TYPE", 43, 68], ["growth factors", "PROTEIN", 181, 195], ["detrimental effects", "PROBLEM", 16, 35], ["the neighbouring cancer cells", "PROBLEM", 39, 68], ["abnormal bone formation", "PROBLEM", 104, 127], ["immunomodulators", "TREATMENT", 200, 216], ["tumour growth", "PROBLEM", 258, 271], ["cancer cells", "OBSERVATION", 56, 68], ["abnormal", "OBSERVATION_MODIFIER", 104, 112], ["bone formation", "OBSERVATION", 113, 127]]], ["Mechanistic details of this complex interaction are still being evaluated127,128.223Ra ::: Unconjugated or chelated radionuclide RPT ::: RPT agents in use and in clinical developmentThe numerous clinical applications of radium-223 dichloride in men with metastatic castration-resistant prostate cancer culminated in the phase III placebo-controlled registration ALSYMCA trial, in which radium-223 treatment prolonged survival (14 months versus 11.2 months) when added to best standard of care in men with symptomatic bone metastases in the absence of visceral metastases56.", [["metastatic castration-resistant prostate cancer", "ANATOMY", 254, 301], ["bone metastases", "ANATOMY", 517, 532], ["visceral metastases", "ANATOMY", 551, 570], ["radium-223 dichloride", "CHEMICAL", 220, 241], ["prostate cancer", "DISEASE", 286, 301], ["radium-223", "CHEMICAL", 386, 396], ["bone metastases", "DISEASE", 517, 532], ["visceral metastases", "DISEASE", 551, 570], ["radium-223 dichloride", "CHEMICAL", 220, 241], ["radium-223", "CHEMICAL", 386, 396], ["Unconjugated", "SIMPLE_CHEMICAL", 91, 103], ["RPT agents", "SIMPLE_CHEMICAL", 137, 147], ["radium-223 dichloride", "SIMPLE_CHEMICAL", 220, 241], ["men", "ORGANISM", 245, 248], ["metastatic castration-resistant prostate cancer", "CANCER", 254, 301], ["radium-223", "SIMPLE_CHEMICAL", 386, 396], ["men", "ORGANISM", 496, 499], ["bone", "ORGAN", 517, 521], ["men", "SPECIES", 245, 248], ["men", "SPECIES", 496, 499], ["chelated radionuclide RPT", "TEST", 107, 132], ["RPT agents", "TREATMENT", 137, 147], ["radium-223 dichloride", "TREATMENT", 220, 241], ["metastatic castration", "TREATMENT", 254, 275], ["resistant prostate cancer", "PROBLEM", 276, 301], ["symptomatic bone metastases", "PROBLEM", 505, 532], ["visceral metastases", "PROBLEM", 551, 570], ["numerous", "OBSERVATION_MODIFIER", 186, 194], ["metastatic", "OBSERVATION_MODIFIER", 254, 264], ["castration", "OBSERVATION", 265, 275], ["resistant", "OBSERVATION_MODIFIER", 276, 285], ["prostate", "ANATOMY", 286, 294], ["cancer", "OBSERVATION", 295, 301], ["symptomatic", "OBSERVATION_MODIFIER", 505, 516], ["bone", "ANATOMY", 517, 521], ["metastases", "OBSERVATION", 522, 532], ["visceral", "ANATOMY", 551, 559], ["metastases", "OBSERVATION", 560, 570]]], ["To increase the significant but narrow margin of increased overall survival over standard of care, radium-223 is currently being explored in combination with other cytotoxic agents, such as docetaxel (DORA trial, NCT03574571), poly(ADP-ribose) polymerase inhibitors such as olaparib (NCT03317392) and new androgen axis inhibitors such as enzalutamide and abiraterone citrate (PEACE III trial, NCT02194842, and ERA223 trial, NCT02043678, respectively).", [["radium-223", "CHEMICAL", 99, 109], ["docetaxel", "CHEMICAL", 190, 199], ["DORA", "CHEMICAL", 201, 205], ["poly(ADP-ribose", "CHEMICAL", 227, 242], ["olaparib", "CHEMICAL", 274, 282], ["enzalutamide", "CHEMICAL", 338, 350], ["abiraterone citrate", "CHEMICAL", 355, 374], ["radium-223", "CHEMICAL", 99, 109], ["docetaxel", "CHEMICAL", 190, 199], ["DORA", "CHEMICAL", 201, 205], ["NCT03574571", "CHEMICAL", 213, 224], ["poly(ADP-ribose)", "CHEMICAL", 227, 243], ["olaparib", "CHEMICAL", 274, 282], ["NCT03317392", "CHEMICAL", 284, 295], ["androgen", "CHEMICAL", 305, 313], ["enzalutamide", "CHEMICAL", 338, 350], ["abiraterone citrate", "CHEMICAL", 355, 374], ["PEACE III", "CHEMICAL", 376, 385], ["radium-223", "SIMPLE_CHEMICAL", 99, 109], ["docetaxel", "SIMPLE_CHEMICAL", 190, 199], ["DORA", "SIMPLE_CHEMICAL", 201, 205], ["poly(ADP-ribose) polymerase", "GENE_OR_GENE_PRODUCT", 227, 254], ["olaparib", "SIMPLE_CHEMICAL", 274, 282], ["NCT03317392", "SIMPLE_CHEMICAL", 284, 295], ["androgen", "SIMPLE_CHEMICAL", 305, 313], ["enzalutamide", "SIMPLE_CHEMICAL", 338, 350], ["abiraterone citrate", "SIMPLE_CHEMICAL", 355, 374], ["other cytotoxic agents", "TREATMENT", 158, 180], ["docetaxel (DORA trial", "TREATMENT", 190, 211], ["poly(ADP-ribose) polymerase inhibitors", "TREATMENT", 227, 265], ["olaparib", "TREATMENT", 274, 282], ["new androgen axis inhibitors", "TREATMENT", 301, 329], ["enzalutamide", "TREATMENT", 338, 350], ["abiraterone citrate", "TREATMENT", 355, 374], ["PEACE III trial", "TREATMENT", 376, 391], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["narrow", "OBSERVATION_MODIFIER", 32, 38], ["margin", "OBSERVATION_MODIFIER", 39, 45], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["overall", "OBSERVATION_MODIFIER", 59, 66], ["survival", "OBSERVATION_MODIFIER", 67, 75]]], ["The first of these trials was recently modified to include bone-protective agents (bisphosphonate) in the treatment regimen129, which was found to reduce the incidence of bone fractures.", [["bone", "ANATOMY", 59, 63], ["bone", "ANATOMY", 171, 175], ["bisphosphonate", "CHEMICAL", 83, 97], ["bone fractures", "DISEASE", 171, 185], ["bisphosphonate", "CHEMICAL", 83, 97], ["bone", "TISSUE", 59, 63], ["bisphosphonate", "SIMPLE_CHEMICAL", 83, 97], ["bone", "TISSUE", 171, 175], ["bone-protective agents", "TREATMENT", 59, 81], ["bisphosphonate", "TREATMENT", 83, 97], ["bone fractures", "PROBLEM", 171, 185], ["bone", "ANATOMY", 59, 63], ["bone", "ANATOMY", 171, 175], ["fractures", "OBSERVATION", 176, 185]]], ["The recommendation was made owing to the observation of an unexpectedly high rate of bone fractures observed in the ERA 223 trial (radium-223 plus abiraterone)130, which may have been attributable to the inclusion of prednisone needed to ameliorate the glucocorticoid suppressive effects of abiraterone citrate131.", [["bone", "ANATOMY", 85, 89], ["bone fractures", "DISEASE", 85, 99], ["radium-223", "CHEMICAL", 131, 141], ["abiraterone", "CHEMICAL", 147, 158], ["prednisone", "CHEMICAL", 217, 227], ["abiraterone citrate", "CHEMICAL", 291, 310], ["radium-223", "CHEMICAL", 131, 141], ["abiraterone", "CHEMICAL", 147, 158], ["prednisone", "CHEMICAL", 217, 227], ["abiraterone citrate", "CHEMICAL", 291, 310], ["bone", "TISSUE", 85, 89], ["radium-223", "SIMPLE_CHEMICAL", 131, 141], ["abiraterone", "SIMPLE_CHEMICAL", 147, 158], ["prednisone", "SIMPLE_CHEMICAL", 217, 227], ["abiraterone citrate131", "SIMPLE_CHEMICAL", 291, 313], ["bone fractures", "PROBLEM", 85, 99], ["abiraterone", "TREATMENT", 147, 158], ["prednisone", "TREATMENT", 217, 227], ["the glucocorticoid suppressive effects", "TREATMENT", 249, 287], ["abiraterone citrate", "TREATMENT", 291, 310], ["bone", "ANATOMY", 85, 89], ["fractures", "OBSERVATION", 90, 99]]], ["Radium-223 is also being explored in combination with immuno-oncology agents such as pembrolizumab (NCT03093428) and in combination with external-beam radiotherapy (RAVENS trial, NCT04037358).153Sm ::: Unconjugated or chelated radionuclide RPT ::: RPT agents in use and in clinical developmentSamarium-153 (t1/2 = 46.3 hours) is a \u03b2-emitting radionuclide used for palliative treatment in patients with osteoblastic and mixed bone metastases in cancers, such as prostate, breast and other primary cancers132,133.", [["osteoblastic", "ANATOMY", 402, 414], ["bone metastases", "ANATOMY", 425, 440], ["cancers", "ANATOMY", 444, 451], ["prostate", "ANATOMY", 461, 469], ["breast", "ANATOMY", 471, 477], ["primary cancers", "ANATOMY", 488, 503], ["Radium-223", "CHEMICAL", 0, 10], ["pembrolizumab", "CHEMICAL", 85, 98], ["NCT03093428", "CHEMICAL", 100, 111], ["Samarium-153", "CHEMICAL", 293, 305], ["bone metastases", "DISEASE", 425, 440], ["cancers", "DISEASE", 444, 451], ["prostate, breast and other primary cancers", "DISEASE", 461, 503], ["Radium-223", "CHEMICAL", 0, 10], ["pembrolizumab", "CHEMICAL", 85, 98], ["NCT03093428", "CHEMICAL", 100, 111], ["Samarium-153", "CHEMICAL", 293, 305], ["Radium-223", "SIMPLE_CHEMICAL", 0, 10], ["pembrolizumab", "SIMPLE_CHEMICAL", 85, 98], ["chelated radionuclide RPT", "SIMPLE_CHEMICAL", 218, 243], ["RPT agents", "SIMPLE_CHEMICAL", 248, 258], ["Samarium-153", "SIMPLE_CHEMICAL", 293, 305], ["patients", "ORGANISM", 388, 396], ["osteoblastic", "CELL", 402, 414], ["bone", "ORGAN", 425, 429], ["cancers", "CANCER", 444, 451], ["prostate", "CANCER", 461, 469], ["breast", "CANCER", 471, 477], ["primary cancers", "CANCER", 488, 503], ["patients", "SPECIES", 388, 396], ["Samarium-153", "SPECIES", 293, 305], ["Radium", "TEST", 0, 6], ["immuno-oncology agents", "TREATMENT", 54, 76], ["pembrolizumab", "TREATMENT", 85, 98], ["external-beam radiotherapy", "TREATMENT", 137, 163], ["chelated radionuclide RPT", "TEST", 218, 243], ["RPT agents", "TREATMENT", 248, 258], ["Samarium", "TEST", 293, 301], ["a \u03b2-emitting radionuclide", "TREATMENT", 329, 354], ["palliative treatment", "TREATMENT", 364, 384], ["osteoblastic and mixed bone metastases in cancers", "PROBLEM", 402, 451], ["prostate, breast and other primary cancers", "PROBLEM", 461, 503], ["osteoblastic", "ANATOMY", 402, 414], ["mixed", "OBSERVATION_MODIFIER", 419, 424], ["bone", "ANATOMY", 425, 429], ["metastases", "OBSERVATION", 430, 440], ["cancers", "OBSERVATION", 444, 451], ["prostate", "ANATOMY", 461, 469], ["breast", "ANATOMY", 471, 477], ["primary", "OBSERVATION_MODIFIER", 488, 495], ["cancers", "OBSERVATION", 496, 503]]], ["153SmCl3 is produced by neutron bombardment of enriched 152Sm2O3, resulting in 153Sm2O3, which is dissolved in hydrochloric acid to yield 153SmCl3.", [["153SmCl3", "CHEMICAL", 0, 8], ["152Sm2O3", "CHEMICAL", 56, 64], ["153Sm2O3", "CHEMICAL", 79, 87], ["hydrochloric acid", "CHEMICAL", 111, 128], ["153SmCl3", "CHEMICAL", 138, 146], ["152Sm2O3", "CHEMICAL", 56, 64], ["153Sm2O3", "CHEMICAL", 79, 87], ["hydrochloric acid", "CHEMICAL", 111, 128], ["153SmCl3", "CHEMICAL", 138, 146], ["153SmCl3", "SIMPLE_CHEMICAL", 0, 8], ["152Sm2O3", "SIMPLE_CHEMICAL", 56, 64], ["153Sm2O3", "SIMPLE_CHEMICAL", 79, 87], ["hydrochloric acid", "SIMPLE_CHEMICAL", 111, 128], ["153SmCl3", "SIMPLE_CHEMICAL", 138, 146], ["153SmCl3", "PROTEIN", 138, 146], ["hydrochloric acid", "TEST", 111, 128]]], ["Alone, 153SmCl3 has poor uptake in bone; however, when chelated with multiple phosphate ligands, the complex accumulates in hydroxyapatite134.", [["bone", "ANATOMY", 35, 39], ["153SmCl3", "CHEMICAL", 7, 15], ["phosphate", "CHEMICAL", 78, 87], ["hydroxyapatite134", "CHEMICAL", 124, 141], ["153SmCl3", "CHEMICAL", 7, 15], ["phosphate", "CHEMICAL", 78, 87], ["hydroxyapatite134", "CHEMICAL", 124, 141], ["153SmCl3", "SIMPLE_CHEMICAL", 7, 15], ["bone", "TISSUE", 35, 39], ["hydroxyapatite134", "SIMPLE_CHEMICAL", 124, 141], ["poor uptake in bone", "PROBLEM", 20, 39], ["multiple phosphate ligands", "TREATMENT", 69, 95], ["hydroxyapatite", "TEST", 124, 138], ["poor", "OBSERVATION_MODIFIER", 20, 24], ["uptake", "OBSERVATION", 25, 31], ["bone", "ANATOMY", 35, 39]]], ["The affinity of phosphonate for calcium, which is found in rapidly growing bone, is attributed to the accumulation and adsorption of 153Sm in metastatic lesions over normal bone135\u2013137.", [["bone", "ANATOMY", 75, 79], ["metastatic lesions", "ANATOMY", 142, 160], ["phosphonate", "CHEMICAL", 16, 27], ["calcium", "CHEMICAL", 32, 39], ["phosphonate", "CHEMICAL", 16, 27], ["calcium", "CHEMICAL", 32, 39], ["phosphonate", "SIMPLE_CHEMICAL", 16, 27], ["calcium", "SIMPLE_CHEMICAL", 32, 39], ["bone", "TISSUE", 75, 79], ["153Sm", "SIMPLE_CHEMICAL", 133, 138], ["metastatic lesions", "CANCER", 142, 160], ["153Sm", "PROTEIN", 133, 138], ["phosphonate", "TREATMENT", 16, 27], ["calcium", "TEST", 32, 39], ["rapidly growing bone", "PROBLEM", 59, 79], ["the accumulation", "PROBLEM", 98, 114], ["metastatic lesions", "PROBLEM", 142, 160], ["rapidly", "OBSERVATION_MODIFIER", 59, 66], ["bone", "ANATOMY", 75, 79], ["metastatic", "OBSERVATION_MODIFIER", 142, 152], ["lesions", "OBSERVATION", 153, 160]]], ["Quadramet is an FDA-approved RPT agent that uses the ethylenediaminetetramethylenephosphonic acid (EDTMP) chelator, binding samarium-153 through six ligands (four phosphate groups and two amines) and forming a six-coordinate complex.", [["Quadramet", "CHEMICAL", 0, 9], ["ethylenediaminetetramethylenephosphonic acid", "CHEMICAL", 53, 97], ["EDTMP", "CHEMICAL", 99, 104], ["samarium-153", "CHEMICAL", 124, 136], ["phosphate", "CHEMICAL", 163, 172], ["amines", "CHEMICAL", 188, 194], ["ethylenediaminetetramethylenephosphonic acid", "CHEMICAL", 53, 97], ["EDTMP", "CHEMICAL", 99, 104], ["samarium-153", "CHEMICAL", 124, 136], ["phosphate", "CHEMICAL", 163, 172], ["amines", "CHEMICAL", 188, 194], ["Quadramet", "SIMPLE_CHEMICAL", 0, 9], ["RPT", "SIMPLE_CHEMICAL", 29, 32], ["ethylenediaminetetramethylenephosphonic acid", "SIMPLE_CHEMICAL", 53, 97], ["EDTMP", "SIMPLE_CHEMICAL", 99, 104], ["samarium-153", "SIMPLE_CHEMICAL", 124, 136], ["six-coordinate complex", "PROTEIN", 210, 232], ["RPT agent", "TREATMENT", 29, 38], ["the ethylenediaminetetramethylenephosphonic acid (EDTMP) chelator", "TREATMENT", 49, 114], ["binding samarium", "TEST", 116, 132], ["four phosphate groups", "TREATMENT", 158, 179]]], ["An alternative formulation of 153Sm has also been described, 153Sm-DOTMP (1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid), which is thought to have a more favourable chelant-to-metal ratio (1.5:1 versus 273:1)138,139.", [["153Sm", "CHEMICAL", 30, 35], ["153Sm-DOTMP", "CHEMICAL", 61, 72], ["1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid", "CHEMICAL", 74, 133], ["153Sm", "CHEMICAL", 30, 35], ["153Sm-DOTMP", "CHEMICAL", 61, 72], ["1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid", "CHEMICAL", 74, 133], ["153Sm", "SIMPLE_CHEMICAL", 30, 35], ["153Sm-DOTMP", "SIMPLE_CHEMICAL", 61, 72], ["1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid", "SIMPLE_CHEMICAL", 74, 133], ["chelant", "SIMPLE_CHEMICAL", 179, 186], ["An alternative formulation", "TEST", 0, 26], ["DOTMP", "TEST", 67, 72]]], ["A phase I trial of this agent against osteosarcoma has been listed (NCT03612466) but is not yet recruiting.[131I]mIBG ::: Small-molecule RPT ::: RPT agents in use and in clinical developmentThe success of iodide-131 in targeting and treating thyroid disorders and carcinomas encouraged the expansion of its use in a variety of cancers through its incorporation into targeting vectors.", [["osteosarcoma", "ANATOMY", 38, 50], ["thyroid", "ANATOMY", 242, 249], ["carcinomas", "ANATOMY", 264, 274], ["cancers", "ANATOMY", 327, 334], ["osteosarcoma", "DISEASE", 38, 50], ["iodide-131", "CHEMICAL", 205, 215], ["thyroid disorders", "DISEASE", 242, 259], ["carcinomas", "DISEASE", 264, 274], ["cancers", "DISEASE", 327, 334], ["[131I]mIBG", "CHEMICAL", 107, 117], ["iodide-131", "CHEMICAL", 205, 215], ["osteosarcoma", "CANCER", 38, 50], ["[131I]mIBG", "SIMPLE_CHEMICAL", 107, 117], ["Small-molecule RPT", "SIMPLE_CHEMICAL", 122, 140], ["RPT agents", "SIMPLE_CHEMICAL", 145, 155], ["iodide-131", "SIMPLE_CHEMICAL", 205, 215], ["thyroid", "ORGAN", 242, 249], ["carcinomas", "CANCER", 264, 274], ["cancers", "CANCER", 327, 334], ["this agent", "TREATMENT", 19, 29], ["osteosarcoma", "PROBLEM", 38, 50], ["mIBG", "TEST", 113, 117], ["Small-molecule RPT", "PROBLEM", 122, 140], ["RPT agents", "TREATMENT", 145, 155], ["iodide", "TREATMENT", 205, 211], ["thyroid disorders", "PROBLEM", 242, 259], ["carcinomas", "PROBLEM", 264, 274], ["cancers", "PROBLEM", 327, 334], ["osteosarcoma", "OBSERVATION", 38, 50], ["Small", "OBSERVATION_MODIFIER", 122, 127], ["thyroid", "ANATOMY", 242, 249], ["carcinomas", "OBSERVATION", 264, 274], ["expansion", "OBSERVATION_MODIFIER", 290, 299], ["cancers", "OBSERVATION", 327, 334]]], ["For example, iobenguane I-131 is the radioiodinated small-molecule meta-iodobenzylguanidine ([131I]mIBG), an analogue of the adrenergic neutrotransmitter noradrenaline that is used to treat patients with neuroblastomas140\u2013142.", [["neuroblastomas", "ANATOMY", 204, 218], ["iobenguane I-131", "CHEMICAL", 13, 29], ["meta-iodobenzylguanidine", "CHEMICAL", 67, 91], ["noradrenaline", "CHEMICAL", 154, 167], ["neuroblastomas140\u2013142", "CHEMICAL", 204, 225], ["iobenguane I-131", "CHEMICAL", 13, 29], ["meta-iodobenzylguanidine", "CHEMICAL", 67, 91], ["[131I]mIBG", "CHEMICAL", 93, 103], ["noradrenaline", "CHEMICAL", 154, 167], ["iobenguane I-131", "SIMPLE_CHEMICAL", 13, 29], ["small-molecule meta-iodobenzylguanidine", "SIMPLE_CHEMICAL", 52, 91], ["[131I]mIBG", "SIMPLE_CHEMICAL", 93, 103], ["noradrenaline", "SIMPLE_CHEMICAL", 154, 167], ["patients", "ORGANISM", 190, 198], ["neuroblastomas", "CANCER", 204, 218], ["patients", "SPECIES", 190, 198], ["iobenguane I", "TEST", 13, 25], ["the radioiodinated small-molecule meta-iodobenzylguanidine", "TREATMENT", 33, 91], ["the adrenergic neutrotransmitter noradrenaline", "TREATMENT", 121, 167], ["neuroblastomas", "PROBLEM", 204, 218]]], ["Iodide-131 can be introduced to targeting vectors as a highly reactive electrophilic iodine compound, allowing rapid iodination of molecules containing activated aromatic groups, or through displacement by nucleophilic attack of the radioiodide143. mIBG radiolabelled with high-specific-activity iodine-131 was recently approved by the FDA for the treatment of adult and paediatric patients aged 12 years or older with unresectable metastatic phaeochromocytoma or paraganglioma.", [["metastatic phaeochromocytoma", "ANATOMY", 432, 460], ["paraganglioma", "ANATOMY", 464, 477], ["Iodide-131", "CHEMICAL", 0, 10], ["radioiodide143", "CHEMICAL", 233, 247], ["mIBG", "CHEMICAL", 249, 253], ["iodine-131", "CHEMICAL", 296, 306], ["phaeochromocytoma", "DISEASE", 443, 460], ["paraganglioma", "DISEASE", 464, 477], ["Iodide-131", "CHEMICAL", 0, 10], ["iodine", "CHEMICAL", 85, 91], ["radioiodide", "CHEMICAL", 233, 244], ["iodine-131", "CHEMICAL", 296, 306], ["Iodide-131", "SIMPLE_CHEMICAL", 0, 10], ["iodine compound", "SIMPLE_CHEMICAL", 85, 100], ["radioiodide143", "SIMPLE_CHEMICAL", 233, 247], ["mIBG", "SIMPLE_CHEMICAL", 249, 253], ["iodine-131", "SIMPLE_CHEMICAL", 296, 306], ["patients", "ORGANISM", 382, 390], ["phaeochromocytoma", "CANCER", 443, 460], ["paraganglioma", "CANCER", 464, 477], ["patients", "SPECIES", 382, 390], ["Iodide", "TREATMENT", 0, 6], ["a highly reactive electrophilic iodine compound", "PROBLEM", 53, 100], ["rapid iodination of molecules", "TREATMENT", 111, 140], ["activated aromatic groups", "TREATMENT", 152, 177], ["the radioiodide", "TEST", 229, 244], ["mIBG radiolabelled", "TEST", 249, 267], ["activity iodine", "TREATMENT", 287, 302], ["unresectable metastatic phaeochromocytoma", "PROBLEM", 419, 460], ["paraganglioma", "PROBLEM", 464, 477], ["reactive", "OBSERVATION_MODIFIER", 62, 70], ["electrophilic iodine", "OBSERVATION", 71, 91], ["aromatic groups", "OBSERVATION", 162, 177], ["unresectable", "OBSERVATION_MODIFIER", 419, 431], ["metastatic phaeochromocytoma", "OBSERVATION", 432, 460], ["paraganglioma", "OBSERVATION", 464, 477]]], ["No FDA-approved therapy was available for these conditions before approval of this agent.", [["therapy", "TREATMENT", 16, 23], ["this agent", "TREATMENT", 78, 88]]], ["Use of this agent requires a positive mIBG imaging scan, standard, weight-based therapeutic dosing and the application of a process for individualized dosimetry using a pretreatment tracer study to calculate absorbed doses for normal organs.", [["organs", "ANATOMY", 234, 240], ["organs", "ORGAN", 234, 240], ["this agent", "TREATMENT", 7, 17], ["a positive mIBG imaging scan", "TEST", 27, 55], ["weight", "TEST", 67, 73], ["therapeutic dosing", "TREATMENT", 80, 98], ["individualized dosimetry", "TREATMENT", 136, 160], ["a pretreatment tracer study", "TEST", 167, 194], ["organs", "ANATOMY", 234, 240]]], ["Normal organ dosimetry is used to adjust the activity administered so that the organ doses are below specified threshold levels.", [["organ", "ANATOMY", 7, 12], ["organ", "ANATOMY", 79, 84], ["organ", "ORGAN", 7, 12], ["organ", "ORGAN", 79, 84], ["the activity administered", "TREATMENT", 41, 66], ["the organ doses", "TREATMENT", 75, 90], ["organ", "ANATOMY", 7, 12], ["dosimetry", "OBSERVATION", 13, 22]]], ["FDA approval of this agent was based on the substantial pre-existing experience with [131I]mIBG144\u2013151 and on a recent phase I study which yielded 1-year and 2-year overall survival of 85.7% and 61.9%, respectively, in 21 patients treated with the maximum tolerated dose152.", [["[131I]mIBG144\u2013151", "CHEMICAL", 85, 102], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 222, 230], ["this agent", "TREATMENT", 16, 26], ["a recent phase I study", "TEST", 110, 132], ["the maximum tolerated dose", "TREATMENT", 244, 270]]], ["Clinical trials using this agent are ongoing (NCT03561259 and NCT02378428).PSMA and folate receptor ligands ::: Small-molecule RPT ::: RPT agents in use and in clinical developmentThe past decade has seen increasing use of small-molecule radiotherapeutics targeting receptors such as PSMA receptor and folate receptor (FR).", [["folate", "CHEMICAL", 84, 90], ["folate", "CHEMICAL", 302, 308], ["folate", "CHEMICAL", 84, 90], ["folate", "CHEMICAL", 302, 308], ["PSMA", "GENE_OR_GENE_PRODUCT", 75, 79], ["folate", "SIMPLE_CHEMICAL", 84, 90], ["PSMA receptor", "GENE_OR_GENE_PRODUCT", 284, 297], ["folate receptor", "GENE_OR_GENE_PRODUCT", 302, 317], ["FR", "GENE_OR_GENE_PRODUCT", 319, 321], ["PSMA", "PROTEIN", 75, 79], ["PSMA receptor", "PROTEIN", 284, 297], ["folate receptor", "PROTEIN", 302, 317], ["FR", "PROTEIN", 319, 321], ["this agent", "TREATMENT", 22, 32], ["Small-molecule RPT", "PROBLEM", 112, 130], ["RPT agents", "TREATMENT", 135, 145], ["small-molecule radiotherapeutics targeting receptors", "TREATMENT", 223, 275], ["PSMA receptor and folate receptor (FR)", "TREATMENT", 284, 322], ["-molecule", "OBSERVATION_MODIFIER", 117, 126], ["increasing", "OBSERVATION_MODIFIER", 205, 215]]], ["Small-molecule PSMA inhibitors have been modified to deliver radiotherapeutic nuclides in prostate cancer as well as other cancers owing to the expression of PSMA on the neovasculature of tumours.", [["prostate cancer", "ANATOMY", 90, 105], ["cancers", "ANATOMY", 123, 130], ["neovasculature", "ANATOMY", 170, 184], ["tumours", "ANATOMY", 188, 195], ["prostate cancer", "DISEASE", 90, 105], ["cancers", "DISEASE", 123, 130], ["Small-molecule PSMA", "GENE_OR_GENE_PRODUCT", 0, 19], ["prostate cancer", "CANCER", 90, 105], ["cancers", "CANCER", 123, 130], ["PSMA", "GENE_OR_GENE_PRODUCT", 158, 162], ["tumours", "CANCER", 188, 195], ["PSMA", "PROTEIN", 158, 162], ["Small-molecule PSMA inhibitors", "TREATMENT", 0, 30], ["radiotherapeutic nuclides", "TREATMENT", 61, 86], ["prostate cancer", "PROBLEM", 90, 105], ["other cancers", "PROBLEM", 117, 130], ["-molecule", "OBSERVATION_MODIFIER", 5, 14], ["PSMA inhibitors", "OBSERVATION", 15, 30], ["prostate", "ANATOMY", 90, 98], ["cancer", "OBSERVATION", 99, 105], ["cancers", "OBSERVATION", 123, 130], ["neovasculature", "OBSERVATION", 170, 184], ["tumours", "OBSERVATION", 188, 195]]], ["PSMA inhibitors are designed to mimic its substrates, \u03b3-glutamyl folic acid derivatives and the neuropeptide N-acetylaspartylglutamate153,154.", [["\u03b3-glutamyl folic acid", "CHEMICAL", 54, 75], ["N-acetylaspartylglutamate153,154", "CHEMICAL", 109, 141], ["\u03b3-glutamyl folic acid", "CHEMICAL", 54, 75], ["PSMA", "GENE_OR_GENE_PRODUCT", 0, 4], ["\u03b3-glutamyl folic acid derivatives", "SIMPLE_CHEMICAL", 54, 87], ["neuropeptide N-acetylaspartylglutamate153,154", "GENE_OR_GENE_PRODUCT", 96, 141], ["PSMA inhibitors", "TREATMENT", 0, 15], ["its substrates", "TREATMENT", 38, 52], ["\u03b3-glutamyl folic acid derivatives", "TREATMENT", 54, 87], ["the neuropeptide N-acetylaspartylglutamate153,154", "TREATMENT", 92, 141]]], ["These small-molecule RPT agents are either urea-based inhibitors (for example, 177Lu-labelled PSMA-R2 and 177Lu-labelled PSMA-617)155\u2013162 or phosphoramidate-based inhibitors (for example, 177Lu-labelled CTT-1403) modified to deliver therapeutic radionuclides163\u2013165.", [["urea", "CHEMICAL", 43, 47], ["PSMA-617", "CHEMICAL", 121, 129], ["phosphoramidate", "CHEMICAL", 141, 156], ["177Lu-labelled CTT-1403", "CHEMICAL", 188, 211], ["urea", "CHEMICAL", 43, 47], ["phosphoramidate", "CHEMICAL", 141, 156], ["CTT-1403", "CHEMICAL", 203, 211], ["urea-based inhibitors", "SIMPLE_CHEMICAL", 43, 64], ["177Lu", "SIMPLE_CHEMICAL", 79, 84], ["PSMA-R2", "SIMPLE_CHEMICAL", 94, 101], ["177Lu", "SIMPLE_CHEMICAL", 106, 111], ["PSMA-617)155\u2013162", "SIMPLE_CHEMICAL", 121, 137], ["phosphoramidate-based inhibitors", "SIMPLE_CHEMICAL", 141, 173], ["177Lu", "SIMPLE_CHEMICAL", 188, 193], ["CTT-1403", "SIMPLE_CHEMICAL", 203, 211], ["PSMA", "PROTEIN", 94, 98], ["These small-molecule RPT agents", "TREATMENT", 0, 31], ["urea-based inhibitors", "TREATMENT", 43, 64], ["177Lu", "TEST", 79, 84], ["PSMA", "TEST", 94, 98], ["177Lu", "TEST", 106, 111], ["PSMA", "TEST", 121, 125], ["phosphoramidate", "TEST", 141, 156], ["177Lu", "TEST", 188, 193], ["CTT", "TEST", 203, 206], ["small", "OBSERVATION_MODIFIER", 6, 11]]], ["The urea and phosphoramidate functionalities interact with zinc(ii) located in the PSMA active site; in addition, these small molecules are designed to interact with the S1 glutamate pocket as well as the entrance funnel of PSMA (Fig.4a,b).", [["urea", "CHEMICAL", 4, 8], ["phosphoramidate", "CHEMICAL", 13, 28], ["zinc", "CHEMICAL", 59, 63], ["glutamate", "CHEMICAL", 173, 182], ["urea", "CHEMICAL", 4, 8], ["phosphoramidate", "CHEMICAL", 13, 28], ["zinc(ii)", "CHEMICAL", 59, 67], ["glutamate", "CHEMICAL", 173, 182], ["urea", "SIMPLE_CHEMICAL", 4, 8], ["phosphoramidate", "SIMPLE_CHEMICAL", 13, 28], ["zinc(ii)", "SIMPLE_CHEMICAL", 59, 67], ["PSMA", "GENE_OR_GENE_PRODUCT", 83, 87], ["PSMA", "GENE_OR_GENE_PRODUCT", 224, 228], ["Fig.4a,b", "GENE_OR_GENE_PRODUCT", 230, 238], ["PSMA active site", "PROTEIN", 83, 99], ["S1 glutamate pocket", "PROTEIN", 170, 189], ["PSMA", "PROTEIN", 224, 228], ["Fig.4a,b)", "PROTEIN", 230, 239], ["The urea and phosphoramidate functionalities", "TREATMENT", 0, 44], ["zinc(ii)", "TREATMENT", 59, 67], ["these small molecules", "PROBLEM", 114, 135], ["the S1 glutamate pocket", "TREATMENT", 166, 189], ["PSMA", "ANATOMY", 83, 87], ["active site", "OBSERVATION", 88, 99], ["small", "OBSERVATION_MODIFIER", 120, 125], ["molecules", "OBSERVATION", 126, 135]]], ["The entrance funnel allows a wide variation of modifications to present a pendant group or a chelator for radiolabelling with therapeutic and imaging radionuclides.", [["chelator", "SIMPLE_CHEMICAL", 93, 101], ["a chelator", "TREATMENT", 91, 101], ["radiolabelling", "TREATMENT", 106, 120], ["imaging radionuclides", "TEST", 142, 163], ["entrance funnel", "OBSERVATION", 4, 19]]], ["All three agents are currently in clinical trials: NCT03490838, NCT03511664 and NCT03822871, respectively (Table 2).PSMA and folate receptor ligands ::: Small-molecule RPT ::: RPT agents in use and in clinical development177Lu-labelled PSMA-617 is currently in a multicentre (84 sites), phase III randomized trial (VISION).", [["folate", "CHEMICAL", 125, 131], ["PSMA-617", "CHEMICAL", 236, 244], ["folate", "CHEMICAL", 125, 131], ["PSMA", "GENE_OR_GENE_PRODUCT", 116, 120], ["folate", "SIMPLE_CHEMICAL", 125, 131], ["177Lu", "SIMPLE_CHEMICAL", 221, 226], ["PSMA-617", "SIMPLE_CHEMICAL", 236, 244], ["PSMA", "PROTEIN", 116, 120], ["Small-molecule RPT", "PROBLEM", 153, 171], ["RPT agents", "TREATMENT", 176, 186], ["PSMA", "TEST", 236, 240], ["phase III randomized trial", "TREATMENT", 287, 313], ["-molecule", "OBSERVATION_MODIFIER", 158, 167]]], ["In a previous prospective single-centre phase II trial in men with metastatic castration-resistant prostate cancer in whom standard therapies had failed, patients who showed high expression of the PSMA target by (68Ga-labelled PSMA-11) PET yielded favourable responses; patients with high [18F]fluorodeoxyglucose (FDG) uptake in low-PSMA-uptake lesions were excluded.", [["metastatic castration-resistant prostate cancer", "ANATOMY", 67, 114], ["lesions", "ANATOMY", 345, 352], ["prostate cancer", "DISEASE", 99, 114], ["[18F]fluorodeoxyglucose", "CHEMICAL", 289, 312], ["men", "ORGANISM", 58, 61], ["castration-resistant prostate cancer", "CANCER", 78, 114], ["patients", "ORGANISM", 154, 162], ["PSMA", "GENE_OR_GENE_PRODUCT", 197, 201], ["patients", "ORGANISM", 270, 278], ["[18F]fluorodeoxyglucose", "SIMPLE_CHEMICAL", 289, 312], ["FDG", "SIMPLE_CHEMICAL", 314, 317], ["low-PSMA", "SIMPLE_CHEMICAL", 329, 337], ["lesions", "PATHOLOGICAL_FORMATION", 345, 352], ["PSMA", "PROTEIN", 197, 201], ["PSMA", "PROTEIN", 227, 231], ["PSMA", "PROTEIN", 333, 337], ["men", "SPECIES", 58, 61], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 270, 278], ["centre phase II trial", "TREATMENT", 33, 54], ["metastatic castration", "TREATMENT", 67, 88], ["resistant prostate cancer", "PROBLEM", 89, 114], ["standard therapies", "TREATMENT", 123, 141], ["68Ga", "TEST", 213, 217], ["PSMA", "TEST", 227, 231], ["PET", "TEST", 236, 239], ["18F]fluorodeoxyglucose (FDG) uptake", "TEST", 290, 325], ["uptake lesions", "PROBLEM", 338, 352], ["metastatic", "OBSERVATION_MODIFIER", 67, 77], ["castration", "OBSERVATION", 78, 88], ["resistant", "OBSERVATION_MODIFIER", 89, 98], ["prostate", "ANATOMY", 99, 107], ["cancer", "OBSERVATION", 108, 114], ["low", "OBSERVATION_MODIFIER", 329, 332], ["uptake lesions", "OBSERVATION", 338, 352]]], ["Of 43 enrolled patients, 30 met the PSMA and FDG imaging criteria to advance to therapy.", [["patients", "ORGANISM", 15, 23], ["FDG", "SIMPLE_CHEMICAL", 45, 48], ["patients", "SPECIES", 15, 23], ["the PSMA", "TEST", 32, 40], ["FDG imaging criteria", "TEST", 45, 65], ["therapy", "TREATMENT", 80, 87]]], ["At 3 months after therapy, reductions in tumour dimensions (by CT) and PSMA uptake and metabolic activity (by PET) were observed in approximately 40% of treated patients166.", [["tumour", "ANATOMY", 41, 47], ["tumour", "DISEASE", 41, 47], ["tumour", "CANCER", 41, 47], ["PSMA", "GENE_OR_GENE_PRODUCT", 71, 75], ["patients", "ORGANISM", 161, 169], ["PSMA", "PROTEIN", 71, 75], ["patients", "SPECIES", 161, 169], ["therapy", "TREATMENT", 18, 25], ["reductions in tumour dimensions", "TEST", 27, 58], ["CT", "TEST", 63, 65], ["PSMA uptake", "TEST", 71, 82], ["metabolic activity", "OBSERVATION", 87, 105]]], ["The imaging-based screening criteria used in this study highlighted the ability to image the distribution of the therapeutic target \u2014 a feature that is integral to RPT.", [["The imaging", "TEST", 0, 11], ["based screening criteria", "TEST", 12, 36], ["this study", "TEST", 45, 55], ["RPT", "TEST", 164, 167]]], ["Although the theranostic (that is, imaging-based patient selection) used in this trial has been discussed as providing a highly favourable patient population and potentially excluding patients who may have benefited from the treatment167,168, the percentage of screened patients who were treated was higher than for most genomics-based screening criteria that are typically used in trials of biologic agents169.PSMA and folate receptor ligands ::: Small-molecule RPT ::: RPT agents in use and in clinical developmentThe 177Lu-labelled PSMA-R2 ligand is in a phase I/II multicentre dose-escalation study.", [["folate", "CHEMICAL", 420, 426], ["folate", "CHEMICAL", 420, 426], ["177Lu", "CHEMICAL", 520, 525], ["patient", "ORGANISM", 49, 56], ["patient", "ORGANISM", 139, 146], ["patients", "ORGANISM", 184, 192], ["patients", "ORGANISM", 270, 278], ["PSMA", "GENE_OR_GENE_PRODUCT", 411, 415], ["folate", "SIMPLE_CHEMICAL", 420, 426], ["177Lu", "SIMPLE_CHEMICAL", 520, 525], ["PSMA-R2", "GENE_OR_GENE_PRODUCT", 535, 542], ["PSMA", "PROTEIN", 411, 415], ["177Lu-labelled PSMA-R2 ligand", "PROTEIN", 520, 549], ["patient", "SPECIES", 49, 56], ["patient", "SPECIES", 139, 146], ["patients", "SPECIES", 184, 192], ["patients", "SPECIES", 270, 278], ["imaging", "TEST", 35, 42], ["the treatment", "TREATMENT", 221, 234], ["screening criteria", "TEST", 336, 354], ["biologic agents", "TEST", 392, 407], ["Small-molecule RPT", "PROBLEM", 448, 466], ["RPT agents", "TREATMENT", 471, 481], ["The 177Lu", "TEST", 516, 525], ["multicentre dose-escalation study", "TEST", 569, 602], ["-molecule", "OBSERVATION_MODIFIER", 453, 462]]], ["The eligibility criteria for this study include a positive 68Ga-labelled PSMA-R2 PET scan; in contrast to PSMA-617, lesion metabolism by FDG PET is not a screening criterion.", [["lesion", "ANATOMY", 116, 122], ["PSMA-617", "CHEMICAL", 106, 114], ["PSMA", "GENE_OR_GENE_PRODUCT", 73, 77], ["PSMA-617", "SIMPLE_CHEMICAL", 106, 114], ["lesion", "PATHOLOGICAL_FORMATION", 116, 122], ["FDG", "SIMPLE_CHEMICAL", 137, 140], ["PSMA", "PROTEIN", 73, 77], ["PSMA", "PROTEIN", 106, 110], ["this study", "TEST", 29, 39], ["labelled PSMA", "TEST", 64, 77], ["R2 PET scan", "TEST", 78, 89], ["PSMA", "TEST", 106, 110], ["lesion metabolism", "PROBLEM", 116, 133], ["FDG PET", "TEST", 137, 144], ["a screening criterion", "TEST", 152, 173]]], ["Preclinical comparison of these two agents suggests similar efficacy170.PSMA and folate receptor ligands ::: Small-molecule RPT ::: RPT agents in use and in clinical developmentThe 177Lu-labelled CTT-1403 anti-PSMA ligand is an irreversible phosphoramidate-based PSMA inhibitor that includes an albumin-binding motif171,172.", [["folate", "CHEMICAL", 81, 87], ["177Lu", "CHEMICAL", 181, 186], ["CTT-1403", "CHEMICAL", 196, 204], ["phosphoramidate", "CHEMICAL", 241, 256], ["folate", "CHEMICAL", 81, 87], ["177Lu", "CHEMICAL", 181, 186], ["CTT-1403", "CHEMICAL", 196, 204], ["phosphoramidate", "CHEMICAL", 241, 256], ["PSMA", "GENE_OR_GENE_PRODUCT", 72, 76], ["folate", "SIMPLE_CHEMICAL", 81, 87], ["177Lu", "SIMPLE_CHEMICAL", 181, 186], ["CTT-1403", "SIMPLE_CHEMICAL", 196, 204], ["phosphoramidate", "SIMPLE_CHEMICAL", 241, 256], ["PSMA", "GENE_OR_GENE_PRODUCT", 263, 267], ["albumin", "GENE_OR_GENE_PRODUCT", 295, 302], ["PSMA", "PROTEIN", 72, 76], ["177Lu-labelled CTT-1403 anti-PSMA ligand", "PROTEIN", 181, 221], ["Small-molecule RPT", "PROBLEM", 109, 127], ["RPT agents", "TREATMENT", 132, 142], ["labelled CTT", "TEST", 187, 199], ["an irreversible phosphoramidate-based PSMA inhibitor", "PROBLEM", 225, 277], ["an albumin-binding motif", "TEST", 292, 316], ["-molecule", "OBSERVATION_MODIFIER", 114, 123], ["irreversible phosphoramidate", "OBSERVATION", 228, 256]]], ["This agent is in a first-in-human phase I dose-escalation trial.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33]]], ["As with the two urea-based agents described earlier, CTT-1403 also incorporates a theranostic paradigm using a companion diagnostic, CTT-1057, which is a 18F-labelled PET agent.PSMA and folate receptor ligands ::: Small-molecule RPT ::: RPT agents in use and in clinical developmentRecent reviews provide more background regarding PSMA-targeting ligands173,174.PSMA and folate receptor ligands ::: Small-molecule RPT ::: RPT agents in use and in clinical developmentFR is overexpressed in a variety of cancers with limited expression in normal tissue; expression on the luminal surface of the kidneys is the greatest concern for FR-targeted radiotherapeutics175,176.", [["cancers", "ANATOMY", 502, 509], ["tissue", "ANATOMY", 544, 550], ["luminal surface", "ANATOMY", 570, 585], ["kidneys", "ANATOMY", 593, 600], ["urea", "CHEMICAL", 16, 20], ["CTT-1403", "CHEMICAL", 53, 61], ["CTT-1057", "CHEMICAL", 133, 141], ["folate", "CHEMICAL", 186, 192], ["folate", "CHEMICAL", 370, 376], ["cancers", "DISEASE", 502, 509], ["luminal", "CHEMICAL", 570, 577], ["urea", "CHEMICAL", 16, 20], ["CTT-1403", "CHEMICAL", 53, 61], ["CTT-1057", "CHEMICAL", 133, 141], ["18F", "CHEMICAL", 154, 157], ["folate", "CHEMICAL", 186, 192], ["folate", "CHEMICAL", 370, 376], ["urea", "SIMPLE_CHEMICAL", 16, 20], ["CTT-1403", "SIMPLE_CHEMICAL", 53, 61], ["CTT-1057", "SIMPLE_CHEMICAL", 133, 141], ["PSMA", "GENE_OR_GENE_PRODUCT", 177, 181], ["folate", "SIMPLE_CHEMICAL", 186, 192], ["PSMA", "GENE_OR_GENE_PRODUCT", 331, 335], ["PSMA", "GENE_OR_GENE_PRODUCT", 361, 365], ["folate", "SIMPLE_CHEMICAL", 370, 376], ["cancers", "CANCER", 502, 509], ["normal tissue", "TISSUE", 537, 550], ["luminal surface", "CELLULAR_COMPONENT", 570, 585], ["kidneys", "ORGAN", 593, 600], ["PSMA", "PROTEIN", 177, 181], ["PSMA", "PROTEIN", 331, 335], ["PSMA", "PROTEIN", 361, 365], ["developmentFR", "PROTEIN", 455, 468], ["the two urea-based agents", "TREATMENT", 8, 33], ["CTT", "TEST", 53, 56], ["CTT", "TEST", 133, 136], ["a 18F-labelled PET agent", "TREATMENT", 152, 176], ["Small-molecule RPT", "PROBLEM", 214, 232], ["RPT agents", "TREATMENT", 237, 247], ["PSMA", "TEST", 331, 335], ["Small-molecule RPT", "PROBLEM", 398, 416], ["RPT agents", "TREATMENT", 421, 431], ["cancers", "PROBLEM", 502, 509], ["-molecule", "OBSERVATION_MODIFIER", 219, 228], ["-molecule", "OBSERVATION_MODIFIER", 403, 412], ["cancers", "OBSERVATION", 502, 509], ["normal tissue", "OBSERVATION_MODIFIER", 537, 550], ["luminal", "ANATOMY_MODIFIER", 570, 577], ["surface", "ANATOMY_MODIFIER", 578, 585], ["kidneys", "ANATOMY", 593, 600]]], ["Similarly to PSMA-targeted radiotherapy, FR-targeted radiotherapeutics have been developed based on the substrates of FR \u2014 specifically folate.", [["folate", "CHEMICAL", 136, 142], ["folate", "CHEMICAL", 136, 142], ["PSMA", "GENE_OR_GENE_PRODUCT", 13, 17], ["FR", "SIMPLE_CHEMICAL", 41, 43], ["FR", "SIMPLE_CHEMICAL", 118, 120], ["folate", "SIMPLE_CHEMICAL", 136, 142], ["PSMA", "PROTEIN", 13, 17], ["FR", "PROTEIN", 41, 43], ["FR", "PROTEIN", 118, 120], ["PSMA", "TEST", 13, 17], ["targeted radiotherapy", "TREATMENT", 18, 39], ["FR-targeted radiotherapeutics", "TREATMENT", 41, 70], ["folate", "TEST", 136, 142]]], ["Derivatives of folate have been developed for delivery of radionuclides for imaging and therapy (Fig. 4c); however, currently the FR-targeted radiotherapeutics have not been translated to clinical studies177\u2013181.Phospholipid ether analogues ::: Small-molecule RPT ::: RPT agents in use and in clinical developmentEarly observations of a difference in the membrane composition of neoplastic cells compared with normal cells182,183 led to the development of radioiodinated phospholipid ether constructs that showed rapid and persistent tumour accumulation184,185.", [["membrane", "ANATOMY", 355, 363], ["neoplastic cells", "ANATOMY", 379, 395], ["cells", "ANATOMY", 417, 422], ["tumour", "ANATOMY", 534, 540], ["folate", "CHEMICAL", 15, 21], ["Phospholipid ether", "CHEMICAL", 212, 230], ["phospholipid ether", "CHEMICAL", 471, 489], ["tumour", "DISEASE", 534, 540], ["folate", "CHEMICAL", 15, 21], ["Phospholipid ether", "CHEMICAL", 212, 230], ["ether", "CHEMICAL", 484, 489], ["folate", "SIMPLE_CHEMICAL", 15, 21], ["Phospholipid ether analogues", "SIMPLE_CHEMICAL", 212, 240], ["membrane", "CELLULAR_COMPONENT", 355, 363], ["neoplastic cells", "CELL", 379, 395], ["cells", "CELL", 417, 422], ["radioiodinated phospholipid ether", "SIMPLE_CHEMICAL", 456, 489], ["tumour", "CANCER", 534, 540], ["neoplastic cells", "CELL_TYPE", 379, 395], ["Derivatives of folate", "TREATMENT", 0, 21], ["delivery of radionuclides", "TREATMENT", 46, 71], ["imaging", "TEST", 76, 83], ["therapy", "TREATMENT", 88, 95], ["clinical studies", "TEST", 188, 204], ["Small-molecule RPT", "PROBLEM", 245, 263], ["RPT agents", "TREATMENT", 268, 278], ["a difference", "PROBLEM", 335, 347], ["neoplastic cells", "PROBLEM", 379, 395], ["radioiodinated phospholipid ether constructs", "TEST", 456, 500], ["rapid and persistent tumour accumulation", "PROBLEM", 513, 553], ["-molecule", "OBSERVATION_MODIFIER", 250, 259], ["neoplastic cells", "OBSERVATION", 379, 395], ["rapid", "OBSERVATION_MODIFIER", 513, 518], ["persistent", "OBSERVATION_MODIFIER", 523, 533], ["tumour accumulation", "OBSERVATION", 534, 553]]], ["The localization and clearance properties of these low-molecular-weight agents depend on the length of the alkyl chain and they localize to tumours not by a specific receptor but by an overabundance of lipid rafts present on cancer cell membranes186,187.", [["tumours", "ANATOMY", 140, 147], ["lipid rafts", "ANATOMY", 202, 213], ["cancer cell membranes", "ANATOMY", 225, 246], ["cancer", "DISEASE", 225, 231], ["tumours", "CANCER", 140, 147], ["lipid rafts", "CELLULAR_COMPONENT", 202, 213], ["cancer cell membranes", "CELLULAR_COMPONENT", 225, 246], ["alkyl chain", "PROTEIN", 107, 118], ["these low-molecular-weight agents", "TREATMENT", 45, 78], ["the alkyl chain", "TREATMENT", 103, 118], ["cancer cell membranes", "PROBLEM", 225, 246], ["lipid rafts", "OBSERVATION", 202, 213], ["cancer cell membranes", "OBSERVATION", 225, 246]]], ["These agents have been used for both cancer imaging and cancer therapy65,188\u2013191.", [["cancer", "ANATOMY", 37, 43], ["cancer", "ANATOMY", 56, 62], ["cancer", "DISEASE", 37, 43], ["cancer", "DISEASE", 56, 62], ["cancer", "CANCER", 37, 43], ["cancer", "CANCER", 56, 62], ["cancer imaging", "TEST", 37, 51], ["cancer therapy", "TREATMENT", 56, 70], ["cancer", "OBSERVATION", 37, 43]]], ["As pan-cancer RPT agents they are under clinical trial investigation for a wide spectrum of haematological malignancies and solid tumours (NCT03478462, NCT04105543, NCT02952508, NCT02952508 and NCT01495663).Bombesin analogue peptides ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentFollowing the success of the somatostatin receptor theranostics, other G protein-coupled receptors with similar binding properties have been explored, including the mammalian gastrin-releasing peptide (or amphibian bombesin) receptors, BB1 (NMBR), BB2 (GRPR) and BB3 (BRS3)202.", [["haematological malignancies", "ANATOMY", 92, 119], ["solid tumours", "ANATOMY", 124, 137], ["haematological malignancies", "DISEASE", 92, 119], ["Bombesin", "CHEMICAL", 207, 215], ["bombesin", "CHEMICAL", 527, 535], ["Bombesin", "CHEMICAL", 207, 215], ["somatostatin", "CHEMICAL", 341, 353], ["haematological malignancies", "CANCER", 92, 119], ["solid tumours", "CANCER", 124, 137], ["Bombesin", "SIMPLE_CHEMICAL", 207, 215], ["somatostatin receptor", "GENE_OR_GENE_PRODUCT", 341, 362], ["G protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 383, 410], ["gastrin-releasing peptide", "GENE_OR_GENE_PRODUCT", 487, 512], ["bombesin", "GENE_OR_GENE_PRODUCT", 527, 535], ["BB1", "GENE_OR_GENE_PRODUCT", 548, 551], ["NMBR", "GENE_OR_GENE_PRODUCT", 553, 557], ["BB2", "GENE_OR_GENE_PRODUCT", 560, 563], ["GRPR", "GENE_OR_GENE_PRODUCT", 565, 569], ["BB3", "GENE_OR_GENE_PRODUCT", 575, 578], ["somatostatin receptor", "PROTEIN", 341, 362], ["G protein-coupled receptors", "PROTEIN", 383, 410], ["mammalian gastrin-releasing peptide (or amphibian bombesin) receptors", "PROTEIN", 477, 546], ["BB1", "PROTEIN", 548, 551], ["NMBR", "PROTEIN", 553, 557], ["BB2", "PROTEIN", 560, 563], ["GRPR", "PROTEIN", 565, 569], ["BB3 (BRS3)202", "PROTEIN", 575, 588], ["pan-cancer RPT agents", "TREATMENT", 3, 24], ["clinical trial investigation", "TEST", 40, 68], ["haematological malignancies", "PROBLEM", 92, 119], ["solid tumours", "PROBLEM", 124, 137], ["NCT04105543", "TEST", 152, 163], ["NCT02952508", "TEST", 165, 176], ["Bombesin analogue peptides", "TREATMENT", 207, 233], ["RPT agents", "TREATMENT", 267, 277], ["the somatostatin receptor theranostics", "TREATMENT", 337, 375], ["other G protein-coupled receptors", "TREATMENT", 377, 410], ["the mammalian gastrin-releasing peptide", "TREATMENT", 473, 512], ["amphibian bombesin) receptors", "TEST", 517, 546], ["BB1", "TEST", 548, 551], ["NMBR", "TEST", 553, 557], ["BB2", "TEST", 560, 563], ["GRPR", "TEST", 565, 569], ["BB3", "TEST", 575, 578]]], ["These receptors are overexpressed in several cancers, mainly in prostate and breast cancers203\u2013208.Bombesin analogue peptides ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentAfter initial experiences with agonists, such as the 68Ga/177Lu-labelled AMBA theranostic pair, burdened by a multitude of symptoms related to receptor activation and by poor plasma stability209, clinical trials have proceeded with antagonists, owing to their superior targeting properties and their neutral pharmacologic action and resistance to peripheral peptidase degradation210.", [["cancers", "ANATOMY", 45, 52], ["prostate", "ANATOMY", 64, 72], ["breast cancers", "ANATOMY", 77, 91], ["plasma", "ANATOMY", 379, 385], ["cancers", "DISEASE", 45, 52], ["prostate and breast cancers", "DISEASE", 64, 91], ["Bombesin", "CHEMICAL", 99, 107], ["Bombesin", "CHEMICAL", 99, 107], ["AMBA", "CHEMICAL", 277, 281], ["cancers", "CANCER", 45, 52], ["prostate", "CANCER", 64, 72], ["breast cancers", "CANCER", 77, 91], ["Bombesin", "SIMPLE_CHEMICAL", 99, 107], ["AMBA", "SIMPLE_CHEMICAL", 277, 281], ["plasma", "ORGANISM_SUBSTANCE", 379, 385], ["several cancers", "PROBLEM", 37, 52], ["breast cancers", "PROBLEM", 77, 91], ["Bombesin analogue peptides", "TREATMENT", 99, 125], ["RPT agents", "TREATMENT", 159, 169], ["agonists", "TREATMENT", 235, 243], ["symptoms", "PROBLEM", 327, 335], ["receptor activation", "PROBLEM", 347, 366], ["poor plasma stability209", "PROBLEM", 374, 398], ["antagonists", "TREATMENT", 436, 447], ["peripheral peptidase degradation", "TEST", 551, 583], ["several", "OBSERVATION_MODIFIER", 37, 44], ["cancers", "OBSERVATION", 45, 52], ["prostate", "ANATOMY", 64, 72], ["breast", "ANATOMY", 77, 83], ["cancers", "OBSERVATION", 84, 91]]], ["Multiple antagonists have been developed for imaging, such as 68Ga-labelled RM2 (formerly BAY 867548), 68Ga-labelled RM26 and 68Ga-labelled NeoBOMB1 (ref.203).", [["BAY 867548", "CHEMICAL", 90, 100], ["BAY 867548", "CHEMICAL", 90, 100], ["68Ga", "CHEMICAL", 103, 107], ["RM26", "CHEMICAL", 117, 121], ["68Ga", "CHEMICAL", 126, 130], ["68Ga-labelled RM2", "SIMPLE_CHEMICAL", 62, 79], ["BAY 867548", "SIMPLE_CHEMICAL", 90, 100], ["68Ga-labelled RM26", "SIMPLE_CHEMICAL", 103, 121], ["68Ga", "SIMPLE_CHEMICAL", 126, 130], ["Multiple antagonists", "TREATMENT", 0, 20], ["imaging", "TEST", 45, 52], ["68Ga", "TEST", 62, 66], ["68Ga", "TEST", 103, 107], ["68Ga", "TEST", 126, 130]]], ["Therapeutic experience is, however, limited to 177Lu-labelled NeoBOMB1 and 177Lu-labelled RM2.", [["177Lu", "CHEMICAL", 75, 80], ["177Lu", "CHEMICAL", 47, 52], ["NeoBOMB1", "CHEMICAL", 62, 70], ["177Lu", "CHEMICAL", 75, 80], ["177Lu-labelled NeoBOMB1", "SIMPLE_CHEMICAL", 47, 70], ["177Lu-labelled RM2", "SIMPLE_CHEMICAL", 75, 93], ["177Lu", "PROTEIN", 75, 80], ["RM2", "PROTEIN", 90, 93], ["NeoBOMB1", "TEST", 62, 70], ["177Lu", "TEST", 75, 80]]], ["The former has been studied in PC-3 tumour-xenografted nude mice, demonstrating high tumour uptake and favourable pharmacokinetics, including limited pancreatic uptake, which makes it a suitable candidate for clinical applications211.Bombesin analogue peptides ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentThe dosimetry of the GRPR antagonist 177Lu-labelled RM2 was recently studied in individuals with metastatic castration-resistant prostate cancer.", [["PC-3 tumour", "ANATOMY", 31, 42], ["tumour", "ANATOMY", 85, 91], ["pancreatic", "ANATOMY", 150, 160], ["metastatic castration-resistant prostate cancer", "ANATOMY", 436, 483], ["tumour", "DISEASE", 36, 42], ["tumour", "DISEASE", 85, 91], ["Bombesin", "CHEMICAL", 234, 242], ["177Lu", "CHEMICAL", 376, 381], ["RM2", "CHEMICAL", 391, 394], ["prostate cancer", "DISEASE", 468, 483], ["Bombesin", "CHEMICAL", 234, 242], ["177Lu", "CHEMICAL", 376, 381], ["PC-3 tumour", "CANCER", 31, 42], ["nude mice", "ORGANISM", 55, 64], ["tumour", "CANCER", 85, 91], ["pancreatic", "ORGAN", 150, 160], ["Bombesin", "SIMPLE_CHEMICAL", 234, 242], ["GRPR", "GENE_OR_GENE_PRODUCT", 360, 364], ["177Lu", "SIMPLE_CHEMICAL", 376, 381], ["RM2", "SIMPLE_CHEMICAL", 391, 394], ["metastatic castration-resistant prostate cancer", "CANCER", 436, 483], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 60, 64], ["PC", "TEST", 31, 33], ["high tumour uptake", "PROBLEM", 80, 98], ["limited pancreatic uptake", "PROBLEM", 142, 167], ["Bombesin analogue peptides", "TREATMENT", 234, 260], ["RPT agents", "TREATMENT", 294, 304], ["the GRPR antagonist 177Lu", "TEST", 356, 381], ["metastatic castration", "PROBLEM", 436, 457], ["resistant prostate cancer", "PROBLEM", 458, 483], ["high", "OBSERVATION_MODIFIER", 80, 84], ["tumour uptake", "OBSERVATION", 85, 98], ["favourable pharmacokinetics", "OBSERVATION_MODIFIER", 103, 130], ["pancreatic", "ANATOMY", 150, 160], ["uptake", "OBSERVATION", 161, 167], ["metastatic", "OBSERVATION_MODIFIER", 436, 446], ["resistant", "OBSERVATION_MODIFIER", 458, 467], ["prostate", "ANATOMY", 468, 476], ["cancer", "OBSERVATION", 477, 483]]], ["The analysis showed high tumour doses (6.20 \u00b1 3.00 Gy/GBq), with rapid clearance from normal organs, including the pancreas, which are promising attributes for therapeutic applications212.Antibody-based RPT ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentThe IgG antibody class has been used almost exclusively for RPT.", [["tumour", "ANATOMY", 25, 31], ["organs", "ANATOMY", 93, 99], ["pancreas", "ANATOMY", 115, 123], ["tumour", "DISEASE", 25, 31], ["tumour", "CANCER", 25, 31], ["organs", "ORGAN", 93, 99], ["pancreas", "ORGAN", 115, 123], ["RPT", "CANCER", 345, 348], ["IgG antibody class", "PROTEIN", 289, 307], ["The analysis", "TEST", 0, 12], ["high tumour doses", "PROBLEM", 20, 37], ["Gy/GBq", "TEST", 51, 57], ["rapid clearance", "TEST", 65, 80], ["therapeutic applications", "TREATMENT", 160, 184], ["Antibody", "TEST", 188, 196], ["RPT agents", "TREATMENT", 240, 250], ["The IgG antibody class", "TEST", 285, 307], ["RPT", "TEST", 345, 348], ["high", "OBSERVATION_MODIFIER", 20, 24], ["tumour", "OBSERVATION", 25, 31], ["normal", "OBSERVATION", 86, 92], ["organs", "ANATOMY", 93, 99], ["pancreas", "ANATOMY", 115, 123]]], ["IgG antibodies are proteins with a molecular weight of 150,000 and which have a long biological half-life in the circulation (2\u20135 days, depending on their isotype and structure) and are eventually catabolized by the liver and elements of the reticuloendothelial system213,214.", [["liver", "ANATOMY", 216, 221], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 0, 14], ["liver", "ORGAN", 216, 221], ["reticuloendothelial", "ANATOMICAL_SYSTEM", 242, 261], ["IgG antibodies", "PROTEIN", 0, 14], ["IgG antibodies", "TEST", 0, 14], ["a molecular weight", "TEST", 33, 51], ["the reticuloendothelial system", "TEST", 238, 268], ["circulation", "ANATOMY", 113, 124], ["liver", "ANATOMY", 216, 221], ["reticuloendothelial system", "ANATOMY", 242, 268]]], ["The ability to generate antibodies possessing well-defined reactivity characteristics against selected antigens (that is, monoclonal antibodies215) was a precondition for the use of antibodies as viable radionuclide delivery vehicles.", [["antibodies", "PROTEIN", 24, 34], ["antigens", "PROTEIN", 103, 111], ["monoclonal antibodies215", "PROTEIN", 122, 146], ["antibodies", "PROTEIN", 182, 192], ["monoclonal antibodies", "TEST", 122, 143], ["antibodies", "TREATMENT", 182, 192]]], ["Haematological and lymphoid malignancies have dominated RPT investigations.", [["lymphoid malignancies", "ANATOMY", 19, 40], ["Haematological and lymphoid malignancies", "DISEASE", 0, 40], ["lymphoid malignancies", "CANCER", 19, 40], ["Haematological and lymphoid malignancies", "PROBLEM", 0, 40], ["RPT investigations", "TEST", 56, 74], ["lymphoid malignancies", "OBSERVATION", 19, 40]]], ["Antibodies to cell-surface differentiation antigens (for example, CD33, CD20, CD45 and CD37) were available for radiolabelling and clinical investigations (Fig. 6).", [["cell", "ANATOMY", 14, 18], ["surface", "ANATOMY", 19, 26], ["cell", "CELL", 14, 18], ["CD33", "GENE_OR_GENE_PRODUCT", 66, 70], ["CD20", "GENE_OR_GENE_PRODUCT", 72, 76], ["CD45", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD37", "GENE_OR_GENE_PRODUCT", 87, 91], ["cell-surface differentiation antigens", "PROTEIN", 14, 51], ["CD33", "PROTEIN", 66, 70], ["CD20", "PROTEIN", 72, 76], ["CD45", "PROTEIN", 78, 82], ["CD37", "PROTEIN", 87, 91], ["Antibodies", "TEST", 0, 10], ["cell-surface differentiation antigens", "TEST", 14, 51], ["CD33", "TEST", 66, 70], ["CD20", "TEST", 72, 76], ["CD45", "TEST", 78, 82], ["CD37", "TEST", 87, 91], ["radiolabelling", "TEST", 112, 126], ["clinical investigations", "TEST", 131, 154]]], ["These early studies used the readily available radionuclide 131I, which permitted (1) biodistribution of the radioiodinated antibodies to be imaged using SPECT216,217 and (2) therapy218\u2013220.", [["131I", "SIMPLE_CHEMICAL", 60, 64], ["radioiodinated antibodies", "PROTEIN", 109, 134], ["These early studies", "TEST", 0, 19], ["the radioiodinated antibodies", "TEST", 105, 134], ["SPECT216,217", "TEST", 154, 166]]], ["Radiolabelled antibodies in this class of targets were used either as molecularly targeted replacements for total-body irradiation in preparation for bone marrow transplantation (NCT02665065)221\u2013228 or for direct targeting of lineages that exhibit uncontrolled proliferation229\u2013231.", [["body", "ANATOMY", 114, 118], ["bone marrow", "ANATOMY", 150, 161], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 150, 161], ["\u2013231", "GENE_OR_GENE_PRODUCT", 277, 281], ["Radiolabelled antibodies", "PROTEIN", 0, 24], ["proliferation229\u2013231", "DNA", 261, 281], ["Radiolabelled antibodies", "TEST", 0, 24], ["molecularly targeted replacements", "TREATMENT", 70, 103], ["total-body irradiation", "TREATMENT", 108, 130], ["bone marrow transplantation", "TREATMENT", 150, 177], ["uncontrolled proliferation229", "PROBLEM", 248, 277], ["antibodies", "OBSERVATION", 14, 24], ["uncontrolled", "OBSERVATION_MODIFIER", 248, 260]]], ["More recently, the \u03b1-emitter astatine-211 is being investigated with anti-CD45 as a lower-toxicity alternative to iodine-131 or radiotherapy for bone marrow ablation in preparation for transplantation232,233.Antibody-based RPT ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentEscalating doses of the iodinated antibody M195 (anti-CD33) were used to treat ten patients with acute myelogenous leukaemia in a phase I clinical trial234.", [["bone marrow", "ANATOMY", 145, 156], ["acute myelogenous leukaemia", "ANATOMY", 402, 429], ["\u03b1-emitter", "CHEMICAL", 19, 28], ["astatine-211", "CHEMICAL", 29, 41], ["toxicity", "DISEASE", 90, 98], ["iodine-131", "CHEMICAL", 114, 124], ["acute myelogenous leukaemia", "DISEASE", 402, 429], ["astatine-211", "CHEMICAL", 29, 41], ["iodine-131", "CHEMICAL", 114, 124], ["\u03b1-emitter astatine-211", "SIMPLE_CHEMICAL", 19, 41], ["anti-CD45", "GENE_OR_GENE_PRODUCT", 69, 78], ["iodine-131", "SIMPLE_CHEMICAL", 114, 124], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 145, 156], ["anti-CD33", "GENE_OR_GENE_PRODUCT", 354, 363], ["patients", "ORGANISM", 388, 396], ["acute myelogenous leukaemia", "CANCER", 402, 429], ["anti-CD45", "PROTEIN", 69, 78], ["iodinated antibody M195", "PROTEIN", 329, 352], ["CD33", "PROTEIN", 359, 363], ["patients", "SPECIES", 388, 396], ["anti-CD45", "TREATMENT", 69, 78], ["a lower-toxicity", "PROBLEM", 82, 98], ["iodine", "TREATMENT", 114, 120], ["radiotherapy", "TREATMENT", 128, 140], ["bone marrow ablation", "TREATMENT", 145, 165], ["transplantation", "TREATMENT", 185, 200], ["Antibody", "TEST", 208, 216], ["Peptide and antibody RPT", "TEST", 231, 255], ["RPT agents", "TREATMENT", 260, 270], ["the iodinated antibody M195", "TEST", 325, 352], ["anti-CD33)", "TREATMENT", 354, 364], ["acute myelogenous leukaemia", "PROBLEM", 402, 429], ["bone", "ANATOMY", 145, 149], ["marrow ablation", "OBSERVATION", 150, 165], ["acute", "OBSERVATION_MODIFIER", 402, 407], ["myelogenous leukaemia", "OBSERVATION", 408, 429]]], ["The appending of iodine-131 to the M195 antibody allowed detailed pharmacokinetic and dosimetric studies to be performed as well as serial blood and bone marrow sampling and whole-body \u03b3-camera imaging.", [["blood", "ANATOMY", 139, 144], ["bone marrow", "ANATOMY", 149, 160], ["body", "ANATOMY", 180, 184], ["iodine-131", "CHEMICAL", 17, 27], ["iodine-131", "CHEMICAL", 17, 27], ["iodine-131", "SIMPLE_CHEMICAL", 17, 27], ["M195 antibody", "GENE_OR_GENE_PRODUCT", 35, 48], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 149, 160], ["M195 antibody", "PROTEIN", 35, 48], ["iodine", "TREATMENT", 17, 23], ["the M195 antibody", "TEST", 31, 48], ["dosimetric studies", "TEST", 86, 104], ["serial blood", "TEST", 132, 144], ["bone marrow sampling", "TEST", 149, 169], ["whole-body \u03b3-camera imaging", "TEST", 174, 201], ["bone", "ANATOMY", 149, 153]]], ["Disease in the bone marrow was specifically and clearly imaged starting within hours after injection.", [["bone marrow", "ANATOMY", 15, 26], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 15, 26], ["Disease in the bone marrow", "PROBLEM", 0, 26], ["bone", "ANATOMY", 15, 19], ["marrow", "OBSERVATION", 20, 26]]], ["The radioiodinated M195 was rapidly modulated and internalized into target cells in vivo.", [["cells", "ANATOMY", 75, 80], ["M195", "CHEMICAL", 19, 23], ["M195", "SIMPLE_CHEMICAL", 19, 23], ["cells", "CELL", 75, 80], ["radioiodinated M195", "PROTEIN", 4, 23], ["target cells", "CELL_TYPE", 68, 80], ["target cells", "OBSERVATION", 68, 80]]], ["Importantly, a rapid, specific and quantitative delivery to the bone marrow and the efficient internalization of M195 into target cells in vivo suggested that the delivery of \u03b2-emitting and \u03b1-emitting radionuclides was feasible.", [["bone marrow", "ANATOMY", 64, 75], ["cells", "ANATOMY", 130, 135], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 64, 75], ["M195", "SIMPLE_CHEMICAL", 113, 117], ["cells", "CELL", 130, 135], ["\u03b2-emitting", "SIMPLE_CHEMICAL", 175, 185], ["M195", "PROTEIN", 113, 117], ["target cells", "CELL_TYPE", 123, 135], ["the delivery of \u03b2-emitting and \u03b1-emitting radionuclides", "TREATMENT", 159, 214], ["rapid", "OBSERVATION_MODIFIER", 15, 20], ["bone marrow", "ANATOMY", 64, 75]]], ["Humanization of M195 (HuM195, lintuzumab) and access to \u03b1-particle-emitting bismuth-213 and actinium-225 and \u03b2-particle-emitting yttrium-90 radionuclides expanded the warheads available to the anti-CD33 armament235\u2013240.", [["M195", "CHEMICAL", 16, 20], ["HuM195", "CHEMICAL", 22, 28], ["lintuzumab", "CHEMICAL", 30, 40], ["bismuth-213", "CHEMICAL", 76, 87], ["actinium-225", "CHEMICAL", 92, 104], ["yttrium", "CHEMICAL", 129, 136], ["M195", "CHEMICAL", 16, 20], ["HuM195", "CHEMICAL", 22, 28], ["lintuzumab", "CHEMICAL", 30, 40], ["bismuth-213", "CHEMICAL", 76, 87], ["actinium-225", "CHEMICAL", 92, 104], ["yttrium-90", "CHEMICAL", 129, 139], ["M195", "SIMPLE_CHEMICAL", 16, 20], ["HuM195", "SIMPLE_CHEMICAL", 22, 28], ["lintuzumab", "SIMPLE_CHEMICAL", 30, 40], ["\u03b1-particle", "SIMPLE_CHEMICAL", 56, 66], ["bismuth-213", "SIMPLE_CHEMICAL", 76, 87], ["actinium-225", "SIMPLE_CHEMICAL", 92, 104], ["\u03b2-particle", "SIMPLE_CHEMICAL", 109, 119], ["yttrium-90 radionuclides", "SIMPLE_CHEMICAL", 129, 153], ["anti-CD33", "GENE_OR_GENE_PRODUCT", 193, 202], ["anti-CD33 armament235\u2013240", "PROTEIN", 193, 218], ["emitting bismuth", "TREATMENT", 67, 83], ["actinium", "TREATMENT", 92, 100], ["\u03b2-particle-emitting yttrium", "TREATMENT", 109, 136]]], ["The pioneering studies using iodine-131 advanced the utility of the humanized anti-CD33 with more potent and shorter-ranged energy emissions because the pharmacokinetics and biology of the system were well understood.", [["iodine-131", "CHEMICAL", 29, 39], ["iodine-131", "CHEMICAL", 29, 39], ["iodine-131", "SIMPLE_CHEMICAL", 29, 39], ["anti-CD33", "GENE_OR_GENE_PRODUCT", 78, 87], ["humanized anti-CD33", "PROTEIN", 68, 87], ["The pioneering studies", "TEST", 0, 22], ["iodine", "TREATMENT", 29, 35], ["the humanized anti-CD33", "TREATMENT", 64, 87]]], ["Potent antileukaemic responses have been observed with both of the \u03b1-particle-emitting lintuzumab drugs with minimal off-target toxic effects239,241\u2013243.", [["lintuzumab", "CHEMICAL", 87, 97], ["lintuzumab", "CHEMICAL", 87, 97], ["\u03b1-particle", "SIMPLE_CHEMICAL", 67, 77], ["lintuzumab", "SIMPLE_CHEMICAL", 87, 97], ["the \u03b1-particle-emitting lintuzumab drugs", "TREATMENT", 63, 103]]], ["Actinium-225-labelled anti-CD38 targeting multiple myeloma has also been studied244,245.", [["myeloma", "ANATOMY", 51, 58], ["Actinium-225", "CHEMICAL", 0, 12], ["anti-CD38", "CHEMICAL", 22, 31], ["multiple myeloma", "DISEASE", 42, 58], ["Actinium-225", "CHEMICAL", 0, 12], ["Actinium-225", "SIMPLE_CHEMICAL", 0, 12], ["anti-CD38", "SIMPLE_CHEMICAL", 22, 31], ["myeloma", "CANCER", 51, 58], ["anti-CD38", "PROTEIN", 22, 31], ["Actinium", "TEST", 0, 8], ["multiple myeloma", "PROBLEM", 42, 58], ["multiple", "OBSERVATION_MODIFIER", 42, 50], ["myeloma", "OBSERVATION", 51, 58]]], ["This \u03b1-emitter is also being investigated against solid tumours that express insulin-like growth factor receptor type 1 (NCT03746431)246.", [["solid tumours", "ANATOMY", 50, 63], ["\u03b1-emitter", "SIMPLE_CHEMICAL", 5, 14], ["solid tumours", "CANCER", 50, 63], ["insulin-like growth factor receptor type 1", "GENE_OR_GENE_PRODUCT", 77, 119], ["insulin", "PROTEIN", 77, 84], ["solid tumours", "PROBLEM", 50, 63], ["insulin", "TEST", 77, 84]]], ["Several antibodies for delivery of a low-dose-rate \u03b1-particle emitter, thorium-227, are being investigated247.", [["thorium-227", "CHEMICAL", 71, 82], ["thorium-227", "CHEMICAL", 71, 82], ["\u03b1-particle", "SIMPLE_CHEMICAL", 51, 61], ["thorium-227", "SIMPLE_CHEMICAL", 71, 82], ["antibodies", "PROTEIN", 8, 18], ["Several antibodies", "TEST", 0, 18], ["delivery", "TREATMENT", 23, 31], ["a low-dose-rate \u03b1-particle emitter", "TREATMENT", 35, 69]]], ["Thorium-227-conjugated antibodies targeting mesothelin248,249, PSMA250,251, and CD22 (ref.252) are currently in phase I clinical trials (NCT03507452, NCT03724747 and NCT02581878, respectively).", [["Thorium-227", "CHEMICAL", 0, 11], ["Thorium-227", "CHEMICAL", 0, 11], ["Thorium-227", "SIMPLE_CHEMICAL", 0, 11], ["mesothelin248,249", "GENE_OR_GENE_PRODUCT", 44, 61], ["PSMA250,251", "SIMPLE_CHEMICAL", 63, 74], ["CD22", "GENE_OR_GENE_PRODUCT", 80, 84], ["Thorium-227-conjugated antibodies", "PROTEIN", 0, 33], ["mesothelin248,249", "PROTEIN", 44, 61], ["PSMA250,251", "PROTEIN", 63, 74], ["CD22", "PROTEIN", 80, 84], ["Thorium", "TEST", 0, 7], ["conjugated antibodies", "TEST", 12, 33], ["mesothelin", "TEST", 44, 54], ["PSMA250,251", "TEST", 63, 74], ["CD22", "TEST", 80, 84]]], ["An anti-HER2/neu conjugate is under preclinical investigation.", [["anti-HER2", "GENE_OR_GENE_PRODUCT", 3, 12], ["neu", "GENE_OR_GENE_PRODUCT", 13, 16], ["anti-HER2/neu conjugate", "PROTEIN", 3, 26], ["An anti-HER2/neu conjugate", "TREATMENT", 0, 26], ["preclinical investigation", "TEST", 36, 61]]], ["This conjugate has demonstrated substantially greater antitumour efficacy compared with a toxin (T-DM1) anti-HER2/neu conjugate253\u2013255.", [["antitumour", "CANCER", 54, 64], ["T-DM1", "GENE_OR_GENE_PRODUCT", 97, 102], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 104, 113], ["neu", "GENE_OR_GENE_PRODUCT", 114, 117], ["toxin (T-DM1) anti-HER2/neu conjugate253\u2013255", "PROTEIN", 90, 134], ["substantially greater antitumour efficacy", "PROBLEM", 32, 73], ["a toxin", "TEST", 88, 95], ["anti-HER2/neu conjugate253\u2013255", "TREATMENT", 104, 134], ["substantially", "OBSERVATION_MODIFIER", 32, 45], ["greater", "OBSERVATION_MODIFIER", 46, 53], ["antitumour efficacy", "OBSERVATION", 54, 73]]], ["It has also demonstrated synergy in combination with olaparib in a BRCA2-deficient xenograft model256Antibody-based RPT ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentLymphoma radionuclide therapy followed a similar trajectory to that of acute myelogenous leukaemia described earlier.", [["xenograft", "ANATOMY", 83, 92], ["Lymphoma", "ANATOMY", 198, 206], ["acute myelogenous leukaemia", "ANATOMY", 269, 296], ["olaparib", "CHEMICAL", 53, 61], ["RPT agents", "CHEMICAL", 153, 163], ["Lymphoma", "DISEASE", 198, 206], ["acute myelogenous leukaemia", "DISEASE", 269, 296], ["olaparib", "CHEMICAL", 53, 61], ["olaparib", "SIMPLE_CHEMICAL", 53, 61], ["BRCA2", "GENE_OR_GENE_PRODUCT", 67, 72], ["xenograft", "CANCER", 83, 92], ["Lymphoma", "CANCER", 198, 206], ["acute myelogenous leukaemia", "CANCER", 269, 296], ["BRCA2", "DNA", 67, 72], ["synergy", "PROBLEM", 25, 32], ["olaparib", "TREATMENT", 53, 61], ["a BRCA2", "TREATMENT", 65, 72], ["RPT agents", "TREATMENT", 153, 163], ["Lymphoma radionuclide therapy", "TREATMENT", 198, 227], ["acute myelogenous leukaemia", "PROBLEM", 269, 296], ["synergy", "OBSERVATION_MODIFIER", 25, 32], ["olaparib", "OBSERVATION", 53, 61], ["BRCA2", "OBSERVATION", 67, 72], ["Lymphoma", "OBSERVATION", 198, 206], ["acute", "OBSERVATION_MODIFIER", 269, 274], ["myelogenous leukaemia", "OBSERVATION", 275, 296]]], ["Rituximab (anti-CD20) was developed to treat relapsed and refractory follicular low-grade non-Hodgkin lymphoma (NHL).", [["follicular low-grade non-Hodgkin lymphoma", "ANATOMY", 69, 110], ["NHL", "ANATOMY", 112, 115], ["Rituximab", "CHEMICAL", 0, 9], ["low-grade non-Hodgkin lymphoma", "DISEASE", 80, 110], ["NHL", "DISEASE", 112, 115], ["Rituximab", "SIMPLE_CHEMICAL", 0, 9], ["anti-CD20", "GENE_OR_GENE_PRODUCT", 11, 20], ["follicular low-grade non-Hodgkin lymphoma", "CANCER", 69, 110], ["NHL", "CANCER", 112, 115], ["CD20", "PROTEIN", 16, 20], ["Rituximab (anti-CD20)", "TREATMENT", 0, 21], ["relapsed and refractory follicular low-grade non-Hodgkin lymphoma", "PROBLEM", 45, 110], ["refractory", "OBSERVATION_MODIFIER", 58, 68], ["follicular", "OBSERVATION", 69, 79], ["low", "OBSERVATION_MODIFIER", 80, 83], ["-grade", "OBSERVATION_MODIFIER", 83, 89], ["non-Hodgkin lymphoma", "OBSERVATION", 90, 110]]], ["When it was used as a single agent, response rates of 50\u201370% in follicular lymphoma and 15\u201350% in small B cell lymphoma were reported.", [["follicular lymphoma", "ANATOMY", 64, 83], ["small B cell lymphoma", "ANATOMY", 98, 119], ["follicular lymphoma", "DISEASE", 64, 83], ["small B cell lymphoma", "DISEASE", 98, 119], ["follicular lymphoma", "CANCER", 64, 83], ["small B cell lymphoma", "CANCER", 98, 119], ["response rates", "TEST", 36, 50], ["follicular lymphoma", "PROBLEM", 64, 83], ["small B cell lymphoma", "PROBLEM", 98, 119], ["follicular lymphoma", "OBSERVATION", 64, 83], ["small", "OBSERVATION_MODIFIER", 98, 103], ["B cell lymphoma", "OBSERVATION", 104, 119]]], ["These indolent lymphomas are characteristically radiosensitive; however, external-beam radiation is limited by toxic effects on normal tissues.", [["indolent lymphomas", "ANATOMY", 6, 24], ["tissues", "ANATOMY", 135, 142], ["lymphomas", "DISEASE", 15, 24], ["indolent lymphomas", "CANCER", 6, 24], ["normal tissues", "TISSUE", 128, 142], ["These indolent lymphomas", "PROBLEM", 0, 24], ["external-beam radiation", "TREATMENT", 73, 96], ["indolent", "OBSERVATION_MODIFIER", 6, 14], ["lymphomas", "OBSERVATION", 15, 24], ["radiosensitive", "OBSERVATION_MODIFIER", 48, 62], ["toxic", "OBSERVATION_MODIFIER", 111, 116], ["normal tissues", "OBSERVATION", 128, 142]]], ["Delivery of the radioactive emission source specifically to cancer cells is accomplished via the monoclonal antibody delivery vehicle, providing a potent dose of targeted radiation therapy specifically to tumour cells that express the desired antigen257\u2013260.Antibody-based RPT ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentThere are two intact antibodies directed against the CD20 antigen which have been conjugated to radionuclides.", [["cancer cells", "ANATOMY", 60, 72], ["tumour cells", "ANATOMY", 205, 217], ["cancer", "DISEASE", 60, 66], ["tumour", "DISEASE", 205, 211], ["cancer cells", "CELL", 60, 72], ["tumour cells", "CELL", 205, 217], ["antigen257\u2013260", "GENE_OR_GENE_PRODUCT", 243, 257], ["CD20 antigen", "GENE_OR_GENE_PRODUCT", 408, 420], ["cancer cells", "CELL_TYPE", 60, 72], ["tumour cells", "CELL_TYPE", 205, 217], ["antigen257\u2013260", "PROTEIN", 243, 257], ["CD20 antigen", "PROTEIN", 408, 420], ["Delivery", "TREATMENT", 0, 8], ["the radioactive emission source", "PROBLEM", 12, 43], ["cancer cells", "PROBLEM", 60, 72], ["the monoclonal antibody delivery vehicle", "TREATMENT", 93, 133], ["targeted radiation therapy", "TREATMENT", 162, 188], ["tumour cells", "PROBLEM", 205, 217], ["Antibody", "TEST", 258, 266], ["RPT agents", "TREATMENT", 310, 320], ["two intact antibodies", "TREATMENT", 365, 386], ["the CD20 antigen", "TEST", 404, 420], ["intact", "OBSERVATION_MODIFIER", 369, 375], ["antibodies", "OBSERVATION", 376, 386]]], ["Ibritumomab tiuxetan conjugated to yttrium-90 yielded Zevalin (Schering AG, Berlin, Germany) and tositumomab conjugated to iodine-131 yielded Bexxar (Corixa Corp, Seattle, WA, USA).", [["Ibritumomab", "CHEMICAL", 0, 11], ["tiuxetan", "CHEMICAL", 12, 20], ["yttrium-90", "CHEMICAL", 35, 45], ["Zevalin", "CHEMICAL", 54, 61], ["Schering AG", "CHEMICAL", 63, 74], ["tositumomab", "CHEMICAL", 97, 108], ["iodine-131", "CHEMICAL", 123, 133], ["yttrium-90", "CHEMICAL", 35, 45], ["Zevalin", "CHEMICAL", 54, 61], ["tositumomab", "CHEMICAL", 97, 108], ["iodine-131", "CHEMICAL", 123, 133], ["Ibritumomab", "SIMPLE_CHEMICAL", 0, 11], ["tiuxetan", "SIMPLE_CHEMICAL", 12, 20], ["yttrium-90", "SIMPLE_CHEMICAL", 35, 45], ["Zevalin", "SIMPLE_CHEMICAL", 54, 61], ["Schering AG", "SIMPLE_CHEMICAL", 63, 74], ["tositumomab", "SIMPLE_CHEMICAL", 97, 108], ["iodine-131", "SIMPLE_CHEMICAL", 123, 133], ["Bexxar", "SIMPLE_CHEMICAL", 142, 148], ["Ibritumomab tiuxetan", "TREATMENT", 0, 20], ["Zevalin (Schering AG", "TREATMENT", 54, 74], ["tositumomab", "TREATMENT", 97, 108], ["iodine", "TREATMENT", 123, 129]]], ["Both 90Y-ibritumomab and 131I-tositumomab have been compared with their respective unlabelled antibody counterparts in randomized trials.Antibody-based RPT ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentIn a phase III study of patients with relapsed CD20-positive NHL, those who received 90Y-ibritumomab had a higher overall response rate than those who received the \u2018cold\u2019 unlabelled rituximab (response rate of 80% compared with 56%, respectively)261.", [["NHL", "ANATOMY", 295, 298], ["90Y-ibritumomab", "CHEMICAL", 5, 20], ["131I-tositumomab", "CHEMICAL", 25, 41], ["NHL", "DISEASE", 295, 298], ["90Y-ibritumomab", "CHEMICAL", 319, 334], ["rituximab", "CHEMICAL", 416, 425], ["90Y-ibritumomab", "CHEMICAL", 5, 20], ["131I-tositumomab", "CHEMICAL", 25, 41], ["90Y-ibritumomab", "SIMPLE_CHEMICAL", 5, 20], ["131I-tositumomab", "SIMPLE_CHEMICAL", 25, 41], ["patients", "ORGANISM", 258, 266], ["CD20", "GENE_OR_GENE_PRODUCT", 281, 285], ["NHL", "CANCER", 295, 298], ["90Y-ibritumomab", "SIMPLE_CHEMICAL", 319, 334], ["rituximab", "SIMPLE_CHEMICAL", 416, 425], ["CD20", "PROTEIN", 281, 285], ["patients", "SPECIES", 258, 266], ["131I-tositumomab", "TREATMENT", 25, 41], ["Antibody", "TEST", 137, 145], ["RPT agents", "TREATMENT", 189, 199], ["a phase III study", "TEST", 237, 254], ["relapsed CD20", "PROBLEM", 272, 285], ["positive NHL", "PROBLEM", 286, 298], ["90Y-ibritumomab", "TREATMENT", 319, 334], ["the \u2018cold\u2019 unlabelled rituximab", "TREATMENT", 394, 425], ["response rate", "TEST", 427, 440]]], ["Complete response rates of 30% and 16%, respectively, were reported.", [["Complete response rates", "TEST", 0, 23]]], ["Reversible myelosuppression was associated with 90Y-ibritumomab therapy.", [["myelosuppression", "DISEASE", 11, 27], ["90Y-ibritumomab", "CHEMICAL", 48, 63], ["90Y-ibritumomab", "SIMPLE_CHEMICAL", 48, 63], ["Reversible myelosuppression", "PROBLEM", 0, 27], ["90Y-ibritumomab therapy", "TREATMENT", 48, 71], ["myelosuppression", "OBSERVATION", 11, 27]]], ["In addition, in a randomized trial designed to treat relapsed low-grade or transformed indolent NHL, patients receiving the \u2018hot\u2019 131I-labelled tositumomab drug exhibited response rates of 55%, while those receiving \u2018cold\u2019 unlabelled tositumomab exhibited only a 33% response rate.", [["NHL", "ANATOMY", 96, 99], ["NHL", "DISEASE", 96, 99], ["tositumomab", "CHEMICAL", 144, 155], ["tositumomab", "CHEMICAL", 234, 245], ["NHL", "CANCER", 96, 99], ["patients", "ORGANISM", 101, 109], ["131I-labelled tositumomab", "SIMPLE_CHEMICAL", 130, 155], ["tositumomab", "SIMPLE_CHEMICAL", 234, 245], ["patients", "SPECIES", 101, 109], ["relapsed low-grade or transformed indolent NHL", "PROBLEM", 53, 99], ["response rates", "TEST", 171, 185], ["indolent NHL", "OBSERVATION", 87, 99]]], ["The complete response rates reported were 17% and 8%, respectively262.Antibody-based RPT ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentThe amount of 131I-tositumomab prescribed to patients was determined by assessing the whole-body clearance rate, so that the amount administered was adjusted to deliver the same whole-body absorbed dose in all treated patients263, making it the first RPT agent whose package insert specified an absorbed dose-based treatment planning procedure.", [["body", "ANATOMY", 259, 263], ["body", "ANATOMY", 351, 355], ["131I-tositumomab", "CHEMICAL", 181, 197], ["131I-tositumomab", "CHEMICAL", 181, 197], ["131I-tositumomab", "SIMPLE_CHEMICAL", 181, 197], ["patients", "ORGANISM", 212, 220], ["body", "ORGANISM_SUBDIVISION", 259, 263], ["body", "ORGANISM_SUBDIVISION", 351, 355], ["patients", "ORGANISM", 385, 393], ["patients", "SPECIES", 212, 220], ["patients", "SPECIES", 385, 393], ["The complete response rates", "TEST", 0, 27], ["Antibody", "TEST", 70, 78], ["RPT agents", "TREATMENT", 122, 132], ["131I-tositumomab", "TREATMENT", 181, 197], ["the same whole-body absorbed dose", "TREATMENT", 336, 369], ["the first RPT agent", "TREATMENT", 408, 427], ["package insert", "TREATMENT", 434, 448], ["an absorbed dose", "TREATMENT", 459, 475], ["based treatment planning procedure", "TREATMENT", 476, 510], ["amount", "OBSERVATION_MODIFIER", 171, 177]]], ["Such an approach was, in part, necessitated because the radioiodine in iodine-131-labelled antibodies is cleaved (due to dehalogenation) from the antibody if the radiolabelled antibody construct is internalized.Antibody-based RPT ::: Peptide and antibody RPT ::: RPT agents in use and in clinical developmentAs mentioned already, there are a number of antigenic targets for antibody-based RPT for solid tumours (Fig. 6).", [["solid tumours", "ANATOMY", 397, 410], ["iodine-131", "CHEMICAL", 71, 81], ["solid tumours", "DISEASE", 397, 410], ["radioiodine", "CHEMICAL", 56, 67], ["iodine-131", "CHEMICAL", 71, 81], ["radioiodine", "SIMPLE_CHEMICAL", 56, 67], ["iodine-131", "SIMPLE_CHEMICAL", 71, 81], ["solid tumours", "CANCER", 397, 410], ["iodine-131-labelled antibodies", "PROTEIN", 71, 101], ["the radioiodine in iodine", "TEST", 52, 77], ["dehalogenation", "TEST", 121, 135], ["the antibody", "TEST", 142, 154], ["the radiolabelled antibody construct", "PROBLEM", 158, 194], ["Antibody", "TEST", 211, 219], ["RPT agents", "TREATMENT", 263, 273], ["antibody", "TEST", 374, 382], ["solid tumours", "PROBLEM", 397, 410]]], ["However, antibody-mediated RPT for solid tumours has not provided the clinical impact of antibody-mediated RPT for haematological and lymphoid malignancies.", [["solid tumours", "ANATOMY", 35, 48], ["haematological", "ANATOMY", 115, 129], ["lymphoid malignancies", "ANATOMY", 134, 155], ["haematological and lymphoid malignancies", "DISEASE", 115, 155], ["solid tumours", "CANCER", 35, 48], ["RPT", "CELL", 107, 110], ["haematological", "CANCER", 115, 129], ["lymphoid malignancies", "CANCER", 134, 155], ["antibody", "TEST", 9, 17], ["solid tumours", "PROBLEM", 35, 48], ["antibody", "TEST", 89, 97], ["haematological and lymphoid malignancies", "PROBLEM", 115, 155], ["lymphoid malignancies", "OBSERVATION", 134, 155]]], ["This may be explained by the substantially greater absorbed dose required to effectively treat solid cancers \u2014 50\u201380 Gy compared with as low as 3 Gy for some lymphomas103.", [["solid cancers", "ANATOMY", 95, 108], ["lymphomas", "ANATOMY", 158, 167], ["cancers", "DISEASE", 101, 108], ["lymphomas", "DISEASE", 158, 167], ["solid cancers", "CANCER", 95, 108], ["lymphomas", "CANCER", 158, 167], ["solid cancers", "PROBLEM", 95, 108], ["some lymphomas", "PROBLEM", 153, 167], ["lymphomas", "OBSERVATION", 158, 167]]], ["Radiolabelled antibodies must overcome a number of barriers before they can effectively irradiate solid tumour targets.", [["solid tumour", "ANATOMY", 98, 110], ["tumour", "DISEASE", 104, 110], ["solid tumour", "CANCER", 98, 110], ["Radiolabelled antibodies", "PROTEIN", 0, 24], ["Radiolabelled antibodies", "TREATMENT", 0, 24]]], ["They must extravasate and diffuse across an interstitial fluid space that is characterized by pressure gradients opposing macromolecular transport264\u2013266 and penetrate throughout antigen-positive tumours, wherein a high antigen concentration itself presents a binding-site barrier267\u2013269.", [["interstitial fluid", "ANATOMY", 44, 62], ["tumours", "ANATOMY", 196, 203], ["antigen", "GENE_OR_GENE_PRODUCT", 179, 186], ["tumours", "CANCER", 196, 203], ["binding-site barrier267\u2013269", "DNA", 260, 287], ["diffuse across an interstitial fluid space", "PROBLEM", 26, 68], ["pressure gradients", "TEST", 94, 112], ["positive tumours", "PROBLEM", 187, 203], ["a high antigen concentration", "PROBLEM", 213, 241], ["diffuse", "OBSERVATION_MODIFIER", 26, 33], ["interstitial", "ANATOMY_MODIFIER", 44, 56], ["fluid space", "OBSERVATION", 57, 68], ["pressure", "OBSERVATION_MODIFIER", 94, 102], ["gradients", "OBSERVATION_MODIFIER", 103, 112], ["positive tumours", "OBSERVATION", 187, 203]]], ["These barriers, along with the long circulation half-life of antibodies, lead to high bone marrow absorbed doses and insufficient dose delivery to tumours.", [["bone marrow", "ANATOMY", 86, 97], ["tumours", "ANATOMY", 147, 154], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 86, 97], ["tumours", "CANCER", 147, 154], ["antibodies", "PROTEIN", 61, 71], ["antibodies", "TREATMENT", 61, 71], ["high bone marrow absorbed doses", "TREATMENT", 81, 112], ["insufficient dose delivery", "TREATMENT", 117, 143], ["tumours", "PROBLEM", 147, 154], ["bone", "ANATOMY", 86, 90]]], ["A number of strategies that retain the exquisite specificity and high binding affinity of antibodies have been examined to overcome these limitations270,271.", [["antibodies", "PROTEIN", 90, 100], ["high binding affinity of antibodies", "PROBLEM", 65, 100]]], ["The most widely investigated of these is \u2018pretargeting\u2019, in which delivery of the radionuclide is temporally dissociated from tumour targeting.", [["tumour", "ANATOMY", 126, 132], ["tumour", "DISEASE", 126, 132], ["tumour", "CANCER", 126, 132], ["most widely", "OBSERVATION_MODIFIER", 4, 15], ["tumour", "OBSERVATION", 126, 132]]], ["The original pretargeting paradigm involved administration of a radiolabel-free streptavidin-conjugated antibody.", [["streptavidin", "SIMPLE_CHEMICAL", 80, 92], ["streptavidin-conjugated antibody", "PROTEIN", 80, 112], ["a radiolabel-free streptavidin", "TEST", 62, 92]]], ["This was followed by administration of lower molecular weight biotin which is radiolabelled272.", [["biotin", "CHEMICAL", 62, 68], ["biotin", "CHEMICAL", 62, 68], ["biotin", "SIMPLE_CHEMICAL", 62, 68], ["lower molecular weight biotin", "TREATMENT", 39, 68]]], ["The initial construct localizes to tumours without irradiating the bone marrow.", [["tumours", "ANATOMY", 35, 42], ["bone marrow", "ANATOMY", 67, 78], ["tumours", "CANCER", 35, 42], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 67, 78], ["tumours", "OBSERVATION", 35, 42], ["bone marrow", "ANATOMY", 67, 78]]], ["The subsequent radiolabelled biotin has a lower molecular weight and is not susceptible to the pharmacokinetics and barriers of intact radiolabelled antibody delivery.", [["biotin", "CHEMICAL", 29, 35], ["biotin", "CHEMICAL", 29, 35], ["biotin", "SIMPLE_CHEMICAL", 29, 35], ["intact radiolabelled antibody delivery", "TREATMENT", 128, 166], ["lower molecular", "OBSERVATION_MODIFIER", 42, 57], ["radiolabelled antibody", "OBSERVATION", 135, 157]]], ["Antibody engineering has eliminated the requirement for bacterial-derived elements (with their attendant immunogenicity), and a large number of novel approaches have been developed that are founded on the basic concept of temporal dissociation273.Nanoconstruct and microsphere RPT ::: RPT agents in use and in clinical developmentYttrium-90 radioembolization is a technique that targets radiolabelled microspheres to liver tumours associated with unresectable hepatocellular carcinomas or metastatic liver tumours from primary colorectal cancer.", [["liver tumours", "ANATOMY", 417, 430], ["unresectable hepatocellular carcinomas", "ANATOMY", 447, 485], ["metastatic liver tumours", "ANATOMY", 489, 513], ["primary colorectal cancer", "ANATOMY", 519, 544], ["Yttrium-90 radioembolization", "CHEMICAL", 330, 358], ["liver tumours", "DISEASE", 417, 430], ["hepatocellular carcinomas", "DISEASE", 460, 485], ["liver tumours", "DISEASE", 500, 513], ["primary colorectal cancer", "DISEASE", 519, 544], ["Yttrium-90", "CHEMICAL", 330, 340], ["Yttrium-90", "SIMPLE_CHEMICAL", 330, 340], ["liver tumours", "CANCER", 417, 430], ["hepatocellular carcinomas", "CANCER", 460, 485], ["metastatic liver tumours", "CANCER", 489, 513], ["primary colorectal cancer", "CANCER", 519, 544], ["Antibody engineering", "TEST", 0, 20], ["bacterial-derived elements", "PROBLEM", 56, 82], ["temporal dissociation", "PROBLEM", 222, 243], ["RPT agents", "TREATMENT", 285, 295], ["Yttrium", "TREATMENT", 330, 337], ["radioembolization", "TREATMENT", 341, 358], ["a technique", "TREATMENT", 362, 373], ["targets radiolabelled microspheres", "TREATMENT", 379, 413], ["liver tumours", "PROBLEM", 417, 430], ["unresectable hepatocellular carcinomas", "PROBLEM", 447, 485], ["metastatic liver tumours", "PROBLEM", 489, 513], ["primary colorectal cancer", "PROBLEM", 519, 544], ["large", "OBSERVATION_MODIFIER", 128, 133], ["temporal", "OBSERVATION_MODIFIER", 222, 230], ["dissociation", "OBSERVATION", 231, 243], ["liver", "ANATOMY", 417, 422], ["tumours", "OBSERVATION", 423, 430], ["unresectable", "OBSERVATION_MODIFIER", 447, 459], ["hepatocellular", "ANATOMY", 460, 474], ["carcinomas", "OBSERVATION", 475, 485], ["metastatic", "OBSERVATION_MODIFIER", 489, 499], ["liver", "ANATOMY", 500, 505], ["tumours", "OBSERVATION", 506, 513], ["primary", "OBSERVATION_MODIFIER", 519, 526], ["colorectal cancer", "OBSERVATION", 527, 544]]], ["Liver tumours derive their blood supply from the hepatic artery, whereas the normal liver derives its blood supply from the portal vein, allowing targeted delivery of 90Y-loaded microspheres via intra-arterial injection274\u2013276.", [["Liver tumours", "ANATOMY", 0, 13], ["blood", "ANATOMY", 27, 32], ["hepatic artery", "ANATOMY", 49, 63], ["liver", "ANATOMY", 84, 89], ["blood", "ANATOMY", 102, 107], ["portal vein", "ANATOMY", 124, 135], ["Liver tumours", "CANCER", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["hepatic artery", "MULTI-TISSUE_STRUCTURE", 49, 63], ["liver", "ORGAN", 84, 89], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["portal vein", "MULTI-TISSUE_STRUCTURE", 124, 135], ["90Y-loaded microspheres", "SIMPLE_CHEMICAL", 167, 190], ["Liver tumours", "PROBLEM", 0, 13], ["targeted delivery of 90Y-loaded microspheres via intra-arterial injection274", "TREATMENT", 146, 222], ["tumours", "OBSERVATION", 6, 13], ["hepatic artery", "ANATOMY", 49, 63], ["normal", "OBSERVATION", 77, 83], ["liver", "ANATOMY", 84, 89], ["portal vein", "ANATOMY", 124, 135]]], ["The commercially available 90Y-loaded microspheres are either glass based (TheraSphere) or resin based (SIR-Spheres), differing in size, number of microspheres injected and activity per microsphere277,278.", [["90Y", "CHEMICAL", 27, 30], ["90Y", "SIMPLE_CHEMICAL", 27, 30], ["TheraSphere", "SIMPLE_CHEMICAL", 75, 86], ["90Y-loaded microspheres", "TREATMENT", 27, 50], ["activity per microsphere", "TEST", 173, 197], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["We include these as RPT agents because they better fit the broad definition of RPT agents provided earlier.", [["RPT agents", "TREATMENT", 20, 30], ["RPT agents", "TREATMENT", 79, 89]]], ["The findings of studies comparing 90Y-loaded glass-based and resin-based microspheres are conflicting and further investigation is needed.", [["90Y", "CHEMICAL", 34, 37], ["90Y", "SIMPLE_CHEMICAL", 34, 37], ["resin-based microspheres", "SIMPLE_CHEMICAL", 61, 85], ["studies", "TEST", 16, 23], ["90Y-loaded glass", "TREATMENT", 34, 50], ["resin-based microspheres", "TREATMENT", 61, 85], ["further investigation", "TEST", 106, 127]]], ["For example, while one study in patients with unresectable hepatocellular carcinomas found a significantly higher overall survival for treatment with 90Y-loaded glass microspheres compared with 90Y-loaded resin microspheres279, another study found a similar outcome in terms of progression-free survival and overall survival between patients treated with 90Y-loaded glass-based microspheres and patients treated with 90Y-loaded resin-based microspheres278.", [["unresectable hepatocellular carcinomas", "ANATOMY", 46, 84], ["hepatocellular carcinomas", "DISEASE", 59, 84], ["90Y", "CHEMICAL", 150, 153], ["patients", "ORGANISM", 32, 40], ["hepatocellular carcinomas", "CANCER", 59, 84], ["90Y-loaded glass microspheres", "SIMPLE_CHEMICAL", 150, 179], ["90Y", "SIMPLE_CHEMICAL", 194, 197], ["patients", "ORGANISM", 333, 341], ["90Y", "SIMPLE_CHEMICAL", 355, 358], ["glass-based microspheres", "SIMPLE_CHEMICAL", 366, 390], ["patients", "ORGANISM", 395, 403], ["90Y", "SIMPLE_CHEMICAL", 417, 420], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 333, 341], ["patients", "SPECIES", 395, 403], ["one study", "TEST", 19, 28], ["unresectable hepatocellular carcinomas", "PROBLEM", 46, 84], ["treatment", "TREATMENT", 135, 144], ["90Y-loaded glass microspheres", "TREATMENT", 150, 179], ["90Y-loaded resin microspheres", "TREATMENT", 194, 223], ["another study", "TEST", 228, 241], ["90Y-loaded glass-based microspheres", "TREATMENT", 355, 390], ["90Y-loaded resin-based microspheres", "TREATMENT", 417, 452], ["unresectable", "OBSERVATION_MODIFIER", 46, 58], ["hepatocellular", "ANATOMY", 59, 73], ["carcinomas", "OBSERVATION", 74, 84]]], ["Additional transarterial radiotherapeutics are being explored, including phosphorus-32 glass microspheres and holmium-166 microspheres (NCT02067988)280\u2013282, as well as 131I-labelled or 188Re-labelled iodized oil282\u2013284.", [["transarterial", "ANATOMY", 11, 24], ["phosphorus", "CHEMICAL", 73, 83], ["holmium-166 microspheres", "CHEMICAL", 110, 134], ["phosphorus", "CHEMICAL", 73, 83], ["holmium-166", "CHEMICAL", 110, 121], ["131I", "CHEMICAL", 168, 172], ["phosphorus-32 glass microspheres", "SIMPLE_CHEMICAL", 73, 105], ["holmium-166 microspheres", "SIMPLE_CHEMICAL", 110, 134], ["131I-labelled", "SIMPLE_CHEMICAL", 168, 181], ["188Re-labelled iodized oil282\u2013284", "SIMPLE_CHEMICAL", 185, 218], ["Additional transarterial radiotherapeutics", "TREATMENT", 0, 42], ["phosphorus", "TEST", 73, 83], ["holmium", "TEST", 110, 117]]], ["Initial clinical trials of 131I-labelled iodized oil (131I-labelled Lipiodol) were completed in the late 1980s/early 1990s285\u2013288, and clinical investigations of this treatment modality continued until 2013 (NCT00116454, NCT00870558 and NCT00027768).", [["Lipiodol", "CHEMICAL", 68, 76], ["131I", "CHEMICAL", 27, 31], ["131I", "CHEMICAL", 54, 58], ["Lipiodol", "CHEMICAL", 68, 76], ["131I-labelled iodized oil", "SIMPLE_CHEMICAL", 27, 52], ["131I-labelled Lipiodol", "SIMPLE_CHEMICAL", 54, 76], ["131I", "TEST", 27, 31], ["Lipiodol", "TREATMENT", 68, 76], ["this treatment modality", "TREATMENT", 162, 185]]], ["Administration of 131I-labelled Lipiodol in the adjuvant setting, after resection or radiofrequency ablation for hepatocellular carcinoma, yielded a 6-month increase in recurrence-free survival and a 24-month increase in median overall survival289.", [["hepatocellular carcinoma", "ANATOMY", 113, 137], ["Lipiodol", "CHEMICAL", 32, 40], ["hepatocellular carcinoma", "DISEASE", 113, 137], ["131I", "CHEMICAL", 18, 22], ["Lipiodol", "CHEMICAL", 32, 40], ["131I-labelled Lipiodol", "SIMPLE_CHEMICAL", 18, 40], ["hepatocellular carcinoma", "CANCER", 113, 137], ["131I-labelled Lipiodol", "TREATMENT", 18, 40], ["resection", "TREATMENT", 72, 81], ["radiofrequency ablation", "TREATMENT", 85, 108], ["hepatocellular carcinoma", "PROBLEM", 113, 137], ["recurrence", "PROBLEM", 169, 179], ["free survival", "TREATMENT", 180, 193], ["resection", "OBSERVATION", 72, 81], ["hepatocellular", "ANATOMY", 113, 127], ["carcinoma", "OBSERVATION", 128, 137]]], ["In a prospective randomized 43-patient trial, adjuvant treatment of patients with hepatocellular carcinoma led to a significant increase in overall survival at 3 years of 86.4% in the treated group versus 46.3% in the control group290.", [["hepatocellular carcinoma", "ANATOMY", 82, 106], ["hepatocellular carcinoma", "DISEASE", 82, 106], ["patient", "ORGANISM", 31, 38], ["patients", "ORGANISM", 68, 76], ["hepatocellular carcinoma", "CANCER", 82, 106], ["patient", "SPECIES", 31, 38], ["patients", "SPECIES", 68, 76], ["adjuvant treatment", "TREATMENT", 46, 64], ["hepatocellular carcinoma", "PROBLEM", 82, 106], ["hepatocellular", "ANATOMY", 82, 96], ["carcinoma", "OBSERVATION", 97, 106], ["significant", "OBSERVATION_MODIFIER", 116, 127], ["increase", "OBSERVATION_MODIFIER", 128, 136], ["overall", "OBSERVATION_MODIFIER", 140, 147], ["survival", "OBSERVATION_MODIFIER", 148, 156]]], ["At both the 5-year follow-up and the 10-year follow-up, actuarial overall survival in the treated group was statistically significantly greater than in the control group (66.7% versus 36.4%, respectively, and 52.4% versus 27.3%, respectively).", [["greater", "OBSERVATION_MODIFIER", 136, 143]]], ["The difference in overall survival lost statistical significance 8 years after randomization291.Challenges and considerations in RPTRPT has proven to be an effective cancer treatment when other standard therapeutic approaches have failed.", [["cancer", "ANATOMY", 166, 172], ["RPTRPT", "CHEMICAL", 129, 135], ["cancer", "DISEASE", 166, 172], ["cancer", "CANCER", 166, 172], ["randomization", "TEST", 79, 92], ["an effective cancer treatment", "TREATMENT", 153, 182], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["effective", "OBSERVATION_MODIFIER", 156, 165], ["cancer", "OBSERVATION", 166, 172]]], ["However, despite more than 40 years of clinical investigation, RPT has not become a part of the cancer treatment armamentarium in the same way as other therapies292.", [["cancer", "ANATOMY", 96, 102], ["cancer", "DISEASE", 96, 102], ["RPT", "CANCER", 63, 66], ["cancer", "CANCER", 96, 102], ["clinical investigation", "TEST", 39, 61], ["RPT", "TEST", 63, 66], ["the cancer treatment armamentarium", "TREATMENT", 92, 126], ["other therapies", "TREATMENT", 146, 161], ["cancer", "OBSERVATION", 96, 102]]], ["\u2018Targeted\u2019 cancer therapies are associated with clinical trial failure rates of 97% (ref.1), partly because the agents targeted a pathway that was not involved in promoting the cancer phenotype2.", [["cancer", "ANATOMY", 11, 17], ["cancer", "ANATOMY", 177, 183], ["cancer", "DISEASE", 11, 17], ["cancer", "DISEASE", 177, 183], ["cancer", "CANCER", 11, 17], ["cancer", "CANCER", 177, 183], ["Targeted\u2019 cancer therapies", "TREATMENT", 1, 27], ["clinical trial failure rates", "TEST", 48, 76], ["the cancer phenotype2", "PROBLEM", 173, 194], ["cancer", "OBSERVATION", 11, 17], ["cancer", "OBSERVATION", 177, 183]]], ["By contrast, RPT has been unsuccessful owing to a failure to adopt and rigorously evaluate this treatment modality, which may be explained in part by the multidisciplinary nature of the treatment.Challenges and considerations in RPTAdditional challenges facing the development and application of RPT include public perception and fear of radioactivity as well as the perceived complexity of the treatment.", [["RPT", "TEST", 13, 16], ["a failure", "PROBLEM", 48, 57], ["this treatment modality", "TREATMENT", 91, 114], ["the treatment", "TREATMENT", 182, 195], ["RPTAdditional challenges", "TREATMENT", 229, 253], ["RPT", "TREATMENT", 296, 299], ["public perception", "TREATMENT", 308, 325], ["fear of radioactivity", "PROBLEM", 330, 351], ["the treatment", "TREATMENT", 391, 404]]], ["A 2007 review of the management of painful bone metastases293 highlights this, implying that the efficacy, low toxicity, minimal side effects and non-addictiveness of RPT for bone pain palliation is trumped by the complexity and need for a multidisciplinary implementation.", [["bone metastases293", "ANATOMY", 43, 61], ["bone", "ANATOMY", 175, 179], ["bone metastases", "DISEASE", 43, 58], ["toxicity", "DISEASE", 111, 119], ["bone pain", "DISEASE", 175, 184], ["bone", "ORGAN", 43, 47], ["bone", "TISSUE", 175, 179], ["the management", "TREATMENT", 17, 31], ["painful bone metastases", "PROBLEM", 35, 58], ["low toxicity", "PROBLEM", 107, 119], ["minimal side effects", "PROBLEM", 121, 141], ["RPT", "TEST", 167, 170], ["bone pain", "PROBLEM", 175, 184], ["palliation", "TREATMENT", 185, 195], ["a multidisciplinary implementation", "TREATMENT", 238, 272], ["painful", "OBSERVATION_MODIFIER", 35, 42], ["bone", "ANATOMY", 43, 47], ["metastases", "OBSERVATION", 48, 58], ["low toxicity", "OBSERVATION_MODIFIER", 107, 119], ["bone", "ANATOMY", 175, 179]]], ["The lack of a medical constituency for RPT suggests the need for a new specialty or subspecialty to provide the multidisciplinary training needed to safely and effectively administer RPT agents to patients and subsequently manage them.", [["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["RPT", "TEST", 39, 42], ["the multidisciplinary training", "TREATMENT", 108, 138], ["RPT agents", "TREATMENT", 183, 193]]], ["As delivery of radiation is involved, the participation of medical physicists familiar with both imaging and radionuclide dosimetry is important.Challenges and considerations in RPTRadionuclide supply, in particular for \u03b1-particle-emitting radionuclides (such as actinium-225), is considered a potential obstacle for growth of the field.", [["RPTRadionuclide", "CHEMICAL", 178, 193], ["actinium-225", "CHEMICAL", 263, 275], ["actinium-225", "CHEMICAL", 263, 275], ["RPTRadionuclide", "SIMPLE_CHEMICAL", 178, 193], ["actinium-225", "SIMPLE_CHEMICAL", 263, 275], ["radiation", "TREATMENT", 15, 24], ["both imaging", "TEST", 92, 104], ["RPTRadionuclide supply", "TREATMENT", 178, 200], ["\u03b1-particle-emitting radionuclides", "PROBLEM", 220, 253], ["radiation", "OBSERVATION", 15, 24]]], ["These developments suggest that supply issues are transient technical issues that will be resolved with greater investment if RPT is adopted as a mainstream cancer therapy.Challenges and considerations in RPTAssuming that the early dramatic results obtained with \u03b1-particle RPT continue to be borne out in rigorous clinical trials, the growth of \u03b1-emitter RPT is likely to accelerate.", [["cancer", "ANATOMY", 157, 163], ["cancer", "DISEASE", 157, 163], ["cancer", "CANCER", 157, 163], ["transient technical issues", "PROBLEM", 50, 76], ["RPT", "TEST", 126, 129], ["a mainstream cancer therapy", "TREATMENT", 144, 171], ["\u03b1-particle RPT", "TREATMENT", 263, 277], ["the growth of \u03b1-emitter RPT", "PROBLEM", 332, 359], ["cancer", "OBSERVATION", 157, 163]]], ["However, the development of biological resistance to these agents \u2014 likely due to outgrowth of cancer cells with low or no target expression \u2014 must be considered.", [["cancer cells", "ANATOMY", 95, 107], ["cancer", "DISEASE", 95, 101], ["cancer cells", "CELL", 95, 107], ["cancer cells", "CELL_TYPE", 95, 107], ["these agents", "TREATMENT", 53, 65], ["outgrowth of cancer cells", "PROBLEM", 82, 107], ["biological resistance", "OBSERVATION", 28, 49], ["cancer", "OBSERVATION", 95, 101]]], ["Accordingly, combination treatment will be necessary.", [["combination treatment", "TREATMENT", 13, 34]]], ["Identifying the optimal combination cancer therapy is currently largely a trial-and-error effort.", [["cancer", "ANATOMY", 36, 42], ["cancer", "DISEASE", 36, 42], ["cancer", "CANCER", 36, 42], ["the optimal combination cancer therapy", "TREATMENT", 12, 50], ["cancer", "OBSERVATION", 36, 42]]], ["By incorporating molecular imaging to assess the impact of other therapeutics on RPT delivery and calculation of the target and normal tissue absorbed doses, the trial-and-error effort needed to optimize combination therapy for RPT agents can be substantially reduced.", [["tissue", "ANATOMY", 135, 141], ["RPT", "MULTI-TISSUE_STRUCTURE", 81, 84], ["tissue", "TISSUE", 135, 141], ["RPT agents", "SIMPLE_CHEMICAL", 228, 238], ["molecular imaging", "TEST", 17, 34], ["RPT delivery", "TREATMENT", 81, 93], ["the trial", "TEST", 158, 167], ["combination therapy", "TREATMENT", 204, 223], ["RPT agents", "TREATMENT", 228, 238], ["normal tissue", "OBSERVATION_MODIFIER", 128, 141]]], ["Furthermore, preclinical models to assess changes in radiosensitivity arising from combination therapy can also be used for optimization.", [["preclinical models", "TEST", 13, 31], ["changes in radiosensitivity", "PROBLEM", 42, 69], ["combination therapy", "TREATMENT", 83, 102]]], ["In contrast to biologics or chemotherapeutics, both radiation delivery and the biological response to radiation may be mathematically modelled and used to understand the parameters of a treatment that are most important in influencing efficacy and toxicity296.", [["toxicity", "DISEASE", 248, 256], ["biologics", "TREATMENT", 15, 24], ["chemotherapeutics", "TREATMENT", 28, 45], ["both radiation delivery", "TREATMENT", 47, 70], ["radiation", "TREATMENT", 102, 111], ["a treatment", "TREATMENT", 184, 195], ["toxicity", "PROBLEM", 248, 256]]], ["In this sense, the trial-and-error process can be further attenuated by modelling to reduce the \u2018parameter space\u2019 that needs to be clinically investigated.", [["the trial", "TEST", 15, 24], ["the \u2018parameter space", "TREATMENT", 92, 112]]], ["Finally, as a radiation delivery modality, one may envision widespread adoption of treatment planning that combines RPT with external-beam radiotherapy; the former to target disseminated cancer and the latter to target bulky disease that is less effectively treated by RPT.", [["disseminated cancer", "ANATOMY", 174, 193], ["cancer", "DISEASE", 187, 193], ["disseminated cancer", "CANCER", 174, 193], ["a radiation delivery modality", "TREATMENT", 12, 41], ["treatment planning", "TREATMENT", 83, 101], ["external-beam radiotherapy", "TREATMENT", 125, 151], ["target disseminated cancer", "PROBLEM", 167, 193], ["target bulky disease", "PROBLEM", 212, 232], ["RPT", "TEST", 269, 272], ["disseminated", "OBSERVATION_MODIFIER", 174, 186], ["cancer", "OBSERVATION", 187, 193], ["bulky disease", "OBSERVATION", 219, 232], ["less effectively", "OBSERVATION_MODIFIER", 241, 257]]], ["Such a combination strategy would expand patient eligibility for both RPT and external-beam radiotherapy.OutlookThe systemic delivery of short-ranged potent radiation is an effective approach to treating patients with cancer, exhibiting a number of advantages over current therapeutic strategies.", [["cancer", "ANATOMY", 218, 224], ["cancer", "DISEASE", 218, 224], ["patient", "ORGANISM", 41, 48], ["patients", "ORGANISM", 204, 212], ["cancer", "CANCER", 218, 224], ["patient", "SPECIES", 41, 48], ["patients", "SPECIES", 204, 212], ["both RPT", "TEST", 65, 73], ["external-beam radiotherapy", "TREATMENT", 78, 104], ["The systemic delivery", "TREATMENT", 112, 133], ["short-ranged potent radiation", "TREATMENT", 137, 166], ["cancer", "PROBLEM", 218, 224], ["current therapeutic strategies", "TREATMENT", 265, 295], ["cancer", "OBSERVATION", 218, 224]]], ["These advantages include the ability to image and calculate quantities that directly impact efficacy and potential toxicity such as absorbed dose, the ability to deliver radiation that is impervious to almost all conventional resistance mechanisms and the ability to combine RPT with radiotherapy in a rational and absorbed dose-driven manner so as to reduce the level of empiricism in clinical trials.", [["toxicity", "DISEASE", 115, 123], ["potential toxicity", "PROBLEM", 105, 123], ["radiation", "TREATMENT", 170, 179], ["radiotherapy", "TREATMENT", 284, 296], ["empiricism", "PROBLEM", 372, 382], ["empiricism", "OBSERVATION", 372, 382]]], ["The field of RPT has been active and growing for nearly 40 years, and is attracting a high level of recognition and commercial interest (Table 2).OutlookAside from establishing trained practitioners, the future growth of RPT will be fuelled by continued discovery of more-specific tumour-associated targets, improvements in radiochemistry, increased and low-cost availability of radionuclides (particularly \u03b1-particle emitters) and expanded preclinical and clinical investigation of combination therapy with agents and treatment modalities that are complementary to RPT.", [["tumour", "ANATOMY", 281, 287], ["tumour", "DISEASE", 281, 287], ["RPT", "CANCER", 13, 16], ["tumour", "CANCER", 281, 287], ["RPT", "TEST", 221, 224], ["radiochemistry", "TEST", 324, 338], ["combination therapy", "TREATMENT", 483, 502], ["agents", "TREATMENT", 508, 514], ["treatment modalities", "TREATMENT", 519, 539], ["RPT", "TEST", 566, 569], ["active", "OBSERVATION_MODIFIER", 26, 32], ["increased", "OBSERVATION_MODIFIER", 340, 349], ["low", "OBSERVATION_MODIFIER", 354, 357]]], ["The ability to image and quantitatively characterize the likely biological outcome of RPT through dosimetry and treatment planning is a major and unique strength of this treatment approach.OutlookThe question to be addressed is how does the field strike the right balance between using those features of RPT \u2014 imaging, dosimetry and treatment planning \u2014 that can help guide and optimize patient treatment and that provide an advantage over other cancer therapies versus the more expedient approach of adopting a chemotherapy dosing paradigm?", [["cancer", "ANATOMY", 446, 452], ["cancer", "DISEASE", 446, 452], ["RPT", "MULTI-TISSUE_STRUCTURE", 86, 89], ["patient", "ORGANISM", 387, 394], ["cancer", "CANCER", 446, 452], ["patient", "SPECIES", 387, 394], ["RPT through dosimetry", "TREATMENT", 86, 107], ["treatment planning", "TREATMENT", 112, 130], ["this treatment approach", "TREATMENT", 165, 188], ["RPT \u2014 imaging", "TEST", 304, 317], ["treatment planning", "TREATMENT", 333, 351], ["patient treatment", "TREATMENT", 387, 404], ["an advantage over other cancer therapies", "TREATMENT", 422, 462], ["a chemotherapy dosing paradigm", "TREATMENT", 510, 540], ["right", "ANATOMY_MODIFIER", 258, 263]]], ["The former is seen as too complicated, while the latter is already in use, is thought to work well enough and has already introduced commercially viable and beneficial agents to patients.", [["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["beneficial agents", "TREATMENT", 157, 174], ["too complicated", "OBSERVATION_MODIFIER", 22, 37]]], ["The answer lies in early-stage clinical trials that incorporate imaging and dosimetry so that the value of these unique aspects of RPT may be rigorously evaluated and compared with existing therapeutic approaches.", [["RPT", "MULTI-TISSUE_STRUCTURE", 131, 134], ["imaging", "TEST", 64, 71], ["RPT", "TEST", 131, 134]]]], "PMC4453553": [["LETTERIn a Letter to the Editor of mBio, Professor Ron Fouchier published a calculation (1) in which he finds a very low probability, P1, for a laboratory-acquired infection (LAI) for a single lab for a single year.", [["infection", "DISEASE", 164, 173], ["a very low probability, P1", "PROBLEM", 110, 136], ["a laboratory-acquired infection", "PROBLEM", 142, 173], ["infection", "OBSERVATION", 164, 173]]], ["Claiming numerous safety precautions in his biosafety level 3 (BSL3+) laboratory, Fouchier calculates P1 = 1 \u00d7 10\u20137 per person per year, and since there are 10 workers with access to his laboratory, P1 = 1 \u00d7 10\u20136 per lab per year.", [["person", "SPECIES", 120, 126], ["his biosafety level", "TEST", 40, 59], ["P1", "TEST", 199, 201]]], ["Compare this to P1 = 2 \u00d7 10\u20133 per lab per year for BSL3 laboratories calculated from CDC statistics for undetected or unreported LAIs (2, 3), here called \u201ccommunity LAIs,\u201d as it is assumed that an undetected or unreported LAI represents an infection that has traveled outside the lab and into the community.LETTERRecently reported escapes of LAIs from high-level biocontainment at CDC laboratories (4) and the long history of LAIs and other escapes from laboratories (5) also argue that Fouchier\u2019s value for P1 is too low.", [["LAIs", "DISEASE", 129, 133], ["infection", "DISEASE", 240, 249], ["LAIs", "DISEASE", 342, 346], ["P1", "TEST", 16, 18], ["BSL3 laboratories", "TEST", 51, 68], ["CDC statistics", "TEST", 85, 99], ["an infection", "PROBLEM", 237, 249], ["escapes of LAIs", "PROBLEM", 331, 346], ["LAIs", "PROBLEM", 426, 430], ["P1", "PROBLEM", 508, 510], ["infection", "OBSERVATION", 240, 249], ["escapes", "OBSERVATION_MODIFIER", 331, 338]]], ["Lipsitch and Inglesby (6) have supplied additional arguments as to why the Fouchier value for P1 is likely much too low.LETTERFouchier uses a simplistic formula, y = 1/P1, to calculate the elapsed time in years for an LAI to escape from his laboratory, y = 1/(1 \u00d7 10\u20136) = 1 \u00d7 106, that is, the million years stated in his Letter.", [["the Fouchier value", "TEST", 71, 89], ["P1", "PROBLEM", 94, 96], ["his laboratory", "TEST", 237, 251]]], ["It is not clear what this calculation tells us.", [["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15]]], ["In this regard, the elapsed time for a 100% chance is infinite, as we can never be absolutely certain that an LAI will occur.LETTERI suggest attaching little weight to this elapsed time calculation and instead concentrating on risk = likelihood \u00d7 consequences, starting with the P1 probability, specifically: potential pandemic fatalities = (probability of a community LAI) \u00d7 (probability that the community LAI leads to a pandemic) \u00d7 (estimated fatalities in a pandemic).LETTERMy risk calculation estimates the likelihood of a community LAI for both a single laboratory and n laboratories conducting this research over y years.", [["fatalities", "DISEASE", 328, 338], ["pandemic", "DISEASE", 423, 431], ["pandemic", "DISEASE", 462, 470]]], ["The total number of laboratories involved in this potential pandemic pathogen research is called here the \u201cresearch enterprise.\u201dLETTERA single, easily derived equation is used to determine the likelihood of a community LAI:(1)E=1\u2212(1\u2212P1)ynwhere E is the probability of at least one community LAI from n laboratories in y years.", [["E", "TEST", 226, 227], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Example results are presented in Table 1 for three values of P1.LETTERIn Table 1, the number of laboratories is either n = 1 for a single laboratory, such as Fouchier\u2019s, or n = 30, which is twice the 15 laboratories currently subject to the NIH funding pause.", [["P1", "DNA", 61, 63], ["Fouchier\u2019s", "TEST", 158, 168], ["funding pause", "OBSERVATION", 245, 258]]], ["Picking n = 30 is a reasonable guess since there are likely many other labs throughout the world conducting this research that are not funded by NIH. y = 10 years is a reasonable time frame for this research to be completed.LETTERThe rationale for picking the probabilities, P1, in Table 1 is as follows: P1 = 2 \u00d7 10\u20133 is calculated from the CDC statistics (2, 3).", [["many other labs", "PROBLEM", 60, 75]]], ["P1 = 2 \u00d7 10\u20134 is 10-fold less and is my \u201cguestimate\u201d for a BSL3+ lab with rigorous safety practices.", [["P1", "TEST", 0, 2], ["a BSL3", "TEST", 57, 63], ["rigorous safety practices", "TREATMENT", 74, 99]]], ["P1 = 1 \u00d7 10\u20136 is Fouchier\u2019s calculated value.LETTERThere are valuable observations to be gleaned from Table 1.", [["P1", "TEST", 0, 2], ["Fouchier", "TEST", 17, 25]]], ["For instance, taking into account the whole research enterprise, not just a single lab, is important.LETTERFurthermore, even for Fouchier\u2019s very low value for P1, there is an estimated probability of E = 0.0003 that there will be at least one community LAI over a 10-year period for 30 labs (likely exactly one LAI, as two is much less probable).", [["very low value for P1", "PROBLEM", 140, 161], ["30 labs", "TEST", 283, 290]]], ["This range is consistent with the 5 to 15% range found by Merler and coworkers (8) and with the 1 to 30% range found in a focused risk assessment (9) for infection spread beginning on crowded public transportation.", [["infection", "DISEASE", 154, 163], ["a focused risk assessment", "TEST", 120, 145], ["infection spread", "PROBLEM", 154, 170], ["consistent with", "UNCERTAINTY", 14, 29]]], ["As an illustration, using an intermediate value of 10% for pandemic probability, which is within the estimated ranges, the probability that a community LAI occurs and leads to a pandemic would be 0.0003 \u00d7 0.1 = 3 \u00d7 10\u20135.LETTERA pandemic could result in 140 million fatalities (world population of 7 billion, 20% infected, 10% fatality rate).", [["pandemic", "DISEASE", 178, 186], ["fatalities", "DISEASE", 265, 275], ["an intermediate value", "TEST", 26, 47], ["pandemic probability", "PROBLEM", 59, 79]]], ["Thus, in this example the estimated number of fatalities for the research enterprise could be 3 \u00d7 10\u20135 \u00d7 140 million = 4,200 fatalities, and the estimated \u201cfatality burden\u201d for each lab in the research enterprise could be 4,200/30 = 140 fatalities over 10 years or 14 fatalities per year.", [["fatalities", "DISEASE", 46, 56], ["fatalities", "DISEASE", 125, 135], ["fatalities", "DISEASE", 237, 247], ["the estimated \u201cfatality burden", "PROBLEM", 141, 171]]], ["To put this fatality burden number in perspective, no Institutional Review Board tasked with assessing human subject research would approve a proposed research project with 14 potential fatalities per year.LETTERIf instead P1 = 2 \u00d7 10\u20134 or P1 = 2 \u00d7 10\u20133 is more representative of the real probability, then the fatalities and fatality burden for each lab in the enterprise would be much higher.", [["fatalities", "DISEASE", 186, 196], ["fatalities", "DISEASE", 311, 321], ["fatality", "DISEASE", 326, 334], ["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["P1", "TEST", 223, 225], ["P1", "TEST", 240, 242]]], ["Over the assortment of BSL3 and BSL3+ labs that may be participating in the research enterprise, frighteningly high fatality burdens may not be unrealistic.LETTERTo try to understand the meaning of Fouchier\u2019s simplistic equation y = 1/P1, I substitute into equation 1 the values calculated by Fouchier (P1 = 1 \u00d7 10\u20136, y = 1 \u00d7 106 years, n = 1, for his single lab) to find E = 0.63.", [["BSL3", "GENE_OR_GENE_PRODUCT", 23, 27], ["BSL3", "GENE_OR_GENE_PRODUCT", 32, 36], ["BSL3", "PROTEIN", 32, 36], ["BSL3", "TEST", 23, 27], ["labs", "TEST", 38, 42], ["Fouchier", "TEST", 293, 301], ["his single lab", "TEST", 348, 362], ["E", "TEST", 372, 373], ["may not be", "UNCERTAINTY", 133, 143]]], ["As I suspected, the value is high.", [["the value", "TEST", 16, 25], ["high", "OBSERVATION_MODIFIER", 29, 33]]], ["Recall that the highest value of the probability E is 1.0, which implies absolute certainty of an escape, which would take infinite elapsed time, y.LETTEREven if every laboratory in the research enterprise is as safe as Fouchier claims his is, potential pandemic fatalities and fatality burden are still too great.", [["fatalities", "DISEASE", 263, 273], ["fatality burden", "PROBLEM", 278, 293], ["escape", "OBSERVATION", 98, 104]]], ["Until the research enterprise is restricted to only a few special BSL4+ labs, with extraordinary precautions (3) to reduce significantly the probability of community infections, the international community should agree to pause this research indefinitely.", [["infections", "DISEASE", 166, 176], ["BSL4", "GENE_OR_GENE_PRODUCT", 66, 70], ["BSL4", "PROTEIN", 66, 70], ["extraordinary precautions", "TREATMENT", 83, 108], ["community infections", "PROBLEM", 156, 176], ["infections", "OBSERVATION", 166, 176]]], ["Alternatively, the research should be redesigned to not require the development of live respiratory aerosol-transmissible potential pandemic pathogens (10).", [["live respiratory aerosol", "TREATMENT", 83, 107], ["transmissible potential pandemic pathogens", "PROBLEM", 108, 150]]]]}